<SEC-DOCUMENT>0001104659-26-028068.txt : 20260316
<SEC-HEADER>0001104659-26-028068.hdr.sgml : 20260316
<ACCEPTANCE-DATETIME>20260316083038
ACCESSION NUMBER:		0001104659-26-028068
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260316
DATE AS OF CHANGE:		20260316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aprea Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39069
		FILM NUMBER:		26754603

	BUSINESS ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
		BUSINESS PHONE:		215-948-4119

	MAIL ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>apre-20251231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/14/2026 1:08:24 AM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:apre="http://aprea.com/20251231" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>Aprea Therapeutics, Inc._December&#160;31,&#160;2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" xs:nil="true" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_9oFZihkkQECVl5y8JTh2kw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" xs:nil="true" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_qhPKQOZ9VEe6KfkyUEYQWA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_rkBjBNAGOE6odzFkepIi6w">6538722</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_2bIqUQ7Wo0WN9XrI5UPgUQ">5509921</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityCentralIndexKey" id="Tc_5jDj1vEUukmMZAgR8urGxQ_1_1">0001781983</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:CurrentFiscalYearEndDate" id="Tc_kJCYyi2-kUqsQAJR4mixjw_2_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentFiscalYearFocus" id="Tc_JOTNd_e--0qn9EYECguCJw_3_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentFiscalPeriodFocus" id="Tc_8y9pwbBXWU-0j5Gv6PNeaQ_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:AmendmentFlag" id="Tc_ML03aarikkO8ANbVPu4kXQ_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_7wfplDUgUEm3Te5ScBml_w" decimals="INF" name="apre:ClassOfWarrantOrRightNumberOfWarrantsExercised" id="Hidden_P05V6E5pREuHn9AeSp3VTQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_Pm5taDx8J0uJMmRJ6og-yg" decimals="INF" name="apre:ClassOfWarrantOrRightNumberOfWarrantsExercised" id="Hidden_kQnMjb4IG0CtJN1L8Njr2Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_f-pPCqIy8E-ac35O2X99gw">56227</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_Wt4Cqy-K_0eS7ycaDAWEUA">31194</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_T-uNdx4YOk20X25X5TdsLg">5481055</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_VO-coJ2sxUK7ihYecHFhqA">8192538</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" sign="-" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_UtaHMkDmT0ap2lFEPXUUqA">1.93</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" sign="-" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_rVAU4-Gn2EmhmVcPiU32CQ">2.35</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" xs:nil="true" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" id="Hidden_GAiVwh82eUmdKx4UoyCRCA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" id="Hidden_eE2fcbd4R0eebi4itMmEZg">http://xbrl.sec.gov/country/2025#US</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_qn32aboQakGIBXr3nC5CDw">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ" name="ecd:Rule10b51ArrTrmntdFlag" id="Hidden_cLaLWqpS3UqfFJPfyGBgqw">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ" name="ecd:NonRule10b51ArrAdoptedFlag" id="Hidden_qPJf3vDE6U6wN26nyYncQQ">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ" name="ecd:NonRule10b51ArrTrmntdFlag" id="Hidden_otCW9f-QjESf3tKfAs3j6w">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="apre-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UTwtKV-qkEOxVLKfaZVgbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IJ8zJ18I4EClq_KQWPYSqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_X9yxNCi1eUiwkdxf-fOimw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_tzboIpMCLE6jmiSEJoPsxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember__-_le6ti2UOYE_b8iPNg5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_0OTUY_lcakyo9dePfZ4fUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_ukSBibSsYkOC0ffd9tzE2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_3j5lWFF8JEWOa1ah--AL8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-QRsPFW0-E--PaKIJUY7Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAL2DshPD0OdJw_EpkpGGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J9HtUxOqeEaXcgWIs4717Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PilxZKpEyEi9WNFYDfCOhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F_cddC-SRkOjmWWwt-fqVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T49vl6RPsU-nKirVaTJE3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7S-nLeE1P0KWLPTOkK9J0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W8VMjZfm3kqAuG4zdxRBGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uxcYngPZ4Ueh1LhH_AOjNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HdVMa0DdwEmc14llqTxLvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtIejotXFUSQPrZvskRYfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K43Lpib1Z0SaiG-7BlUL6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8TENrsfRpEip6COKOMdc6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_EQUr4jqfV0eUSMk3W0IsWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_VhYbqu6uqEa_Z5RqOOudRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_svVivUO6SEy1bko-xpnpmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_vo0Rp1fMEEe6cXCjrjqRkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_uALQGM6dfkS0eVFcd0iIJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_RiL5VScdAUCDUTJd-n0MRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_evHTOe8x2keNSJoG80M35Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vI7qdqQk_0OgoyeWE7tHaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_S_ge6OQffkO1GwngF7q5dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_76awlW8Ih02pce5XsSRECw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_c5rmFiY3ek-6CbIN1sUk5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_KhoEA3ZPM0CBUJFvhI2tBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_K66RcqO0CUSYIecB3rtHQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_ObCThvYr3EuNhTdvZHWN5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnTwoYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_51RPXCrdCEOuPhYMJBeuWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnThreeYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_ppTWFla4xU-u0Ra-s34Jfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LrUkAv7nCEugy4KCFPIs0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_XAXHtIodGE2ofHLJnzdW0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnTwoYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_kvlb4D8nYUSyelfb-KCo2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnThreeYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LU7BJLvVE0iqW66H9_OrGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_CGXEBDoB80uMJgtwrAZVgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_OfficeFurnitureAndLaboratoryEquipmentMember_N7HQnrCgnk6dOXicETh-5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apre:OfficeFurnitureAndLaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ZLW0Hz7D7kWIA9AazR-fdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_sUM0Rd5XwUaQcZ4Pzaib0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apre:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajl5U0Fik0WBAVlJp8BOHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_uJ12jSW3IE2IlsnxHNVHYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apre:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-28</xbrli:startDate><xbrli:endDate>2026-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_28_2026_To_1_28_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_dtwms4JdkkCkrALAA9rEeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-28</xbrli:startDate><xbrli:endDate>2026-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rw7WXSTzPUS_r8Ou3XFKVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rfpje9runUCtL_Q69zMdAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_sq6NeJo7pkSi5n0W2_R52w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_-mt0Lba2K0O1my_pp5wpyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_ZoIolndLmUyXsd1mQPpAUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_OyQ7wp2wFUSYaMzly9YdTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_kq5Z_aQ4GkOW-yWNsb-P5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mRdeq00MTEmoRCUVaSWaIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_x2waWdI6y06iIcRFhALG5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_mZZT_4w8FUqzJrb9O-iaKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7BZm_z9xCkSv0FQpO74xqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_iTqHbEL2pkeKPob89U4UMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_gXVMK2ewSUubD_HBDBGCyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6EMQYsKTe06p12xtaqpj7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_PlacementAgentMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_nCqKvJ6VqEOdmrCe-eB1xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:PlacementAgentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JlhBUytMKkeo3cvNZE4vVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_12HariDjbkGdtP5EmFWGYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:January2026WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheBWarrantsMember_fQ1ml1hVHU6nU0Lh1uc_aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsMember_HnwiahFpV0Kqxh7uoQXQfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheaWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024PreFundedWarrantsMember_a-axkHFuHU6wmJ8RwuZaXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_IWhpmSyLkkquMghWrBhMLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025PreFundedWarrantsMember_-GQYBDW1ekGtGJann-TV6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JysbG2LVi0WviMI_bz_gpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_CJR1S7G5HUqhj3cWK_5B4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Pk_DcJsgPU6S0cEiZFfnSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_REODE2xYG0ygbK6Gt1iCwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oq3hsrqBykm0qXaMoCxjKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7byEi2lE20ibECXouEsanw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_hqbRhvOLLEi90FCZNRS2RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_05GUoR4aq0ubc6DwiLlP2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_yFpzhwTg9Ea949XNcHNkug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_kKVKD6hRDEiYuHXysXTBig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2026_c8x7vDEpiEe3RndPj6R4hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_0jPUe0y1K0OJ53mzIl5oew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BAoeaXQje0CtAvGY50doJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lqTYSTP7MUWrNQSGACl75w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:January2026WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-28</xbrli:startDate><xbrli:endDate>2026-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-08</xbrli:startDate><xbrli:endDate>2025-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_dYgdlu90I0-v-bYG_Tb6iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_X3e_9uk1uEKJQCgyQcQNiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Vm4iVeX890G-C4Gmcq830Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MGDWpqe1Kkq0c-y3kaCxwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zk8TLXVZiU-91j2mSRo40Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_jtkh2IFT8EeIdDld8qFq5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_lILoXMI7xUCZVU-gQHudoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_Pm5taDx8J0uJMmRJ6og-yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheaWarrantsAndTrancheBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_R5lNv0SMpkG5QNmfjLhHmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_7wfplDUgUEm3Te5ScBml_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheaWarrantsAndTrancheBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_1IwBxFQ5D06BZajC8QiMmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_wfZiBhJ28kKlJpaYLmFFOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:HCWainrightCoLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_e9RDxBm4kkmD7GckPR-Osw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:HCWainrightCoLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_xL2dOMznHEmc_uWBXbUEqA"><xbrli:measure>apre:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_QaFYmEckJU-MqyGJp97u6A"><xbrli:measure>apre:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e3db04ff_c333_47f9_83a6_6b171e8f364b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:3pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 2pt 0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentType" id="Narr_gwfw0YKNLkKIZKeLnXH1Hg"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentAnnualReport" id="Narr_FNF8hA31h0qGXAfVPPQP2w"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:bold;">&#9746;</b></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentPeriodEndDate" id="Narr_-Z9t7E250UWn-6ROqhOJYg"><b style="font-size:9pt;font-weight:bold;">December&#160;31,&#160;2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentTransitionReport" id="Narr_EJL1RSj9rk2FjUA2HFUd-g"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:bold;">&#9744;</b></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b style="font-weight:bold;">to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityFileNumber" id="Narr_kcBep-XPNESx2hmtOOej1A"><b style="font-size:8pt;font-weight:bold;">001-39069</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityRegistrantName" id="Narr_zYReueof-0mqF9FuC0Q3sw"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></ix:nonNumeric><span style="font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_d8ea9ac9_6d0c_48a3_938a_c6beae6ee446"></a><a id="Tc_nqUylQHbaUSquVNTDjyboA_2_0"></a><a id="Tc_rhLw40QND0aCpTMYppeDVA_2_1"></a><a id="Tc_JsCyigU-U0yUQ_d0j0bzkQ_5_0"></a><a id="Tc_06BsUO9INE2itzHrUTrIow_5_1"></a><a id="Tc_hPTe6n7on02LwhWxfg9Slw_6_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:2.35pt;padding-right:2.35pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityIncorporationStateCountryCode" id="Tc_LuH8CSiO80SoV6iGA22e1g_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityTaxIdentificationNumber" id="Tc_sNQSyn0GsUKFajCblGKUpg_1_1"><b style="font-size:8pt;font-weight:bold;">84-2246769</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityAddressAddressLine1" id="Tc_VGaKVaG_wUy5-b4Bx-UuGA_4_0"><b style="font-size:9pt;font-weight:bold;">3805 Old Easton Road</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityAddressPostalZipCode" id="Tc_Rv5-yM2C40yS9-KmCF-0Kw_4_1"><b style="font-size:9pt;font-weight:bold;">18902</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityAddressCityOrTown" id="Narr_xC0voTpWp0qgzJ1toNQlyQ"><b style="font-size:9pt;font-weight:bold;">Doylestown</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityAddressStateOrProvince" id="Narr_jN2XHmiatUCYu7-_6Ty8AQ"><b style="font-size:9pt;font-weight:bold;">Pennsylvania</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:CityAreaCode" id="Narr_3cpjoolZQkeDcRUCvptTLg"><b style="font-size:9pt;font-weight:bold;">215</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:LocalPhoneNumber" id="Narr_YfWyrKTPBUK65_0QgKflqQ"><b style="font-size:9pt;font-weight:bold;">948-4119</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant's telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_1a8ea614_a62c_4e67_a9df_bbdf30e4d04c"></a><a id="Tc_iZEKjDHtJ0qa0C7BAclX8A_1_4"></a><a id="Tc_5qXEIQWMX0aayX_NRHOdDA_2_0"></a><a id="Tc_AkkzBZxksEmxurXkmaG86Q_2_2"></a><a id="Tc_BUXa7rL3ck2UtzSl6NqeSQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:2.35pt;padding-right:2.35pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.27%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:28.78%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:28.7%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:37.27%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.78%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.7%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of exchange</b></p></td></tr><tr style=""><td style="vertical-align:top;width:37.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:28.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on which registered:</b></p></td></tr><tr style="height:10pt;"><td style="vertical-align:top;width:37.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:Security12bTitle" id="Tc_48JDFbcMq0yAG4cBGdjm2Q_3_0"><span style="font-size:8pt;">Common stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.78%;border-top:1px solid #000000;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:TradingSymbol" id="Tc_LUG_NkoiEUmMKgsdnE3JeA_3_2"><span style="font-size:8pt;">APRE</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.7%;border-top:1px solid #000000;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:SecurityExchangeName" id="Tc_Bs6ypfV8Z0OPXmvY_eh8OQ_3_4"><span style="font-size:8pt;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="white-space:pre-wrap;">Securities registered pursuant to Section 12(g) of the Act:  </span><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_yRG1u1oWok2FQkxlBNR6cg"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityVoluntaryFilers" id="Narr_8mAdtvcQN0ymcy5ALrcTzQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past </span><span style="font-size:7pt;background:#ffffff;">90</span><span style="font-size:7pt;"> days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityCurrentReportingStatus" id="Narr_k3RJfIWxlkCyDLFXIr-OAA"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;white-space:pre-wrap;">   No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityInteractiveDataCurrent" id="Narr_XqeL8TZ-8EmG4XsT_JTMDg"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Large accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityFilerCategory" id="Narr_hlO-eZ84AUCvOjNvAHqmDg"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntitySmallBusiness" id="Narr_q_Y4-JQ7wUGByCVj-0yJpA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityEmergingGrowthCompany" id="Narr_Ol5QUaxU4UiA9XLYSrbAIw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:IcfrAuditorAttestationFlag" id="Narr_sBQtnNgWO0S29YCVNtTYRQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_Qwn7avrb8EWPgtz9P4YRyQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:EntityShellCompany" id="Narr_dIz1Iry5IUOtb6YoBS4-gA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2025 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" format="ixt:num-dot-decimal" scale="6" contextRef="As_Of_6_30_2025_kKVKD6hRDEiYuHXysXTBig" decimals="-5" name="dei:EntityPublicFloat" id="Narr_UNj8PE1pGU-VNRF1nu9_bw">8.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_16_2026_c8x7vDEpiEe3RndPj6R4hA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_CggGJvZwYEGl3FiRIGW7zw">11,452,452</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value, outstanding as of March 16, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_M_fJjvH4Ck6ffjKitQWK4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed within 120 days of the registrant&#8217;s fiscal year ended December&#160;31,&#160;2025, are incorporated by reference in Part III of this Annual Report on Form 10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:14.4pt;border-bottom:3.0pt solid #000000;border-top:1px dashed #000000;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b667b645_b9c1_4b8e_aefe_fd9b4c5fa951"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;">A</span>prea Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Annual Report on Form 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">For the Year Ended December&#160;31,&#160;2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Table of Contents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:92.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:normal;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:4.5%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:100%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9pt;" href="#PARTI_588426"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1Business_988624"><span style="font-style:normal;font-weight:normal;">Item 1. Business</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">5</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_779731"><span style="font-style:normal;font-weight:normal;">Item 1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">48</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUnresolvedStaffComments_845403"><span style="font-style:normal;font-weight:normal;">Item 1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">110</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Item 1C. Cybersecurity</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">110</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Item 2. Properties</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">111</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item3LegalProceedings_459401"><span style="font-style:normal;font-weight:normal;">Item 3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">111</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MineSafetyDisclosures_10830"><span style="font-style:normal;font-weight:normal;">Item 4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">111</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:100%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9pt;" href="#PARTII_76010"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">112</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6SelectedFinancialData_571863"><span style="font-style:normal;font-weight:normal;">Item 6. [Reserved] </span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">113</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">114</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7aQuantitativeandqualitativedisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">F-1</p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">125</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsandProcedures_745095"><span style="font-style:normal;font-weight:normal;">Item 9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">125</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOtherInformation_252198"><span style="font-style:normal;font-weight:normal;">Item 9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:100%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9pt;" href="#PARTIII_178079"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item 10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11ExecutiveCompensation_421004"><span style="font-style:normal;font-weight:normal;">Item 11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13. Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item 14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:100%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="font-size:9pt;" href="#PARTIV_228969"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item 15. Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">126</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:92.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_288121"><span style="font-style:normal;font-weight:normal;">Item 16. Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">130</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ab46019f_f7d0_4689_97e6_6f945d5608b0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K includes statements that are, or may be deemed, &#8220;forward-looking statements.&#8221; In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;designed,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately&#8221; or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Annual Report on Form&#160;10-K and include statements regarding our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical trials, including for APR-1051 and ATRN-119, our ongoing and planned development, prospects for commercialization, and market uptake of our potential product candidates, the strength and breadth of our intellectual property, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the legal and regulatory landscape impacting our business, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our development and validation of manufacturing capabilities, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By their nature, forward-looking statements involve risks and uncertainties because they relate to future events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees, or predictive, of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Some of the factors that we believe could cause actual results to differ from those anticipated or predicted include</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of our expenses, capital requirements and our needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions, including delays in enrollment, patient follow-up and data collection of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prospects of our product candidates, all of which are still in development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outcomes and results of ongoing or future preclinical studies and clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our ability to identify, discover or acquire additional suitable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of our ongoing and planned clinical trials, including the sample size, trial duration, endpoint definition, event rate assumptions and eligibility criteria;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from clinical development programs&#160;and our ability to predict clinical outcomes based on such preclinical and early clinical results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll patients in clinical trials, to timely and successfully complete those trials and to receive necessary regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the timing of initiation of data readout from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance or commercial success of any product candidate we develop and the degree of acceptance among physicians, patients, patient advocacy groups, health care payors and the medical community;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding competition, potential market size, the size of the patient populations for our product candidates, if approved for commercial use, and market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain regulatory approval of our product candidates, and any restrictions, limitations and/or warnings in their labels, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential claims relating to our intellectual property and third-party intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of our intellectual property estate that will provide protection for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sales, marketing or distribution capabilities and our ability to commercialize our product candidates, if we obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current and future agreements with third parties in connection with conducting clinical trials, as well as the manufacturing of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the ability of our current contract manufacturing partners to produce our product candidates in the quantities and timeframe that we will require;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our future costs of goods;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract, retain and motivate key personnel and increase the size of our organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations in lieu of obtaining additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the time during which we will be a smaller reporting company under the Exchange Act.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Any forward-looking statements that we make in this Annual Report on Form&#160;10-K speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Annual Report on Form&#160;10-K. You should also read carefully the factors described in the &#8220;Risk Factors&#8221; included in Part&#160;I,&#160;Item&#160;<span style="white-space:pre-wrap;">1A of this Annual Report to better understand significant risks and uncertainties inherent in our business and underlying any forward-looking statements.  As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form&#160;10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">This Annual Report on Form&#160;10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Form&#160;10-K may include trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Form&#160;10-K may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_01fc1f6c_61e3_4a06_b5cd_c104ae1ce62a"></a><a id="PARTI_588426"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="_960308"></a><a id="Item1Business_988624"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1. Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. We have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aprea Therapeutics AB was originally incorporated in 2002 and commenced principal operations in 2006. On September 20, 2019, we consummated a reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB were exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB became a wholly-owned subsidiary of Aprea Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to our acquisition of Atrin Pharmaceuticals Inc. (&#8220;Atrin&#8221;) in May 2022, we were engaged in the clinical development of cancer therapeutics that related to the mutant p53 tumor suppressor protein. Following our acquisition of Atrin, we enhanced our pipeline and shifted the focus of our activities to the assets acquired from Atrin and those developed in house.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that precision medicine has the potential to impact patients&#8217; lives in a wide range of cancer types. Genomic instability is the hallmark or cancer. When a gene pathway is damaged or fails, related genes make up for its loss of function. Our approach is to inhibit these make up genes, thereby specifically killing cancer cells with defined mutations. This approach is called synthetic lethality. Using synthetic lethality, our product candidates are designed to selectively kill cancer cells while minimizing the effect on normal, unmutated cells, decreasing the toxicity usually associated with cancer treatment. We aspire to become a leader in this emerging field and are establishing a pipeline of clinical and preclinical programs that we believe may have broad applications to cancer treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WEE1 Inhibitor: APR-1051</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In this program, we are targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Our lead WEE1 inhibitor product candidate is APR-1051. In March 2024, our investigational new drug (&#8220;IND&#8221;) application for APR-1051 (IND 169359) went into effect and in the second quarter of 2024 we enrolled the first patient into ACESOT-1051, our Phase 1 dose escalation study. A total of 9 cohorts are planned for ACESOT-1051 that will evaluate doses of 10 mg to 300 mg once daily. As of March 2, 2026, we are enrolling cohort 8 for ACESOT-1051 to evaluate a dose of 220 mg once daily. Preliminary results provide early clinical proof-of-concept of APR-1051. A potential dose-response trend was observed, with increasing single-agent activity across the 70 mg, 100 mg, 150 mg and 220 mg cohorts. On January 29, 2026, we announced the first unconfirmed partial response (uPR) observed in a patient enrolled in the ongoing Phase 1 ACESOT-1051 dose-escalation study: a patient with PPP2R1A-mutated uterine serous carcinoma, a form of endometrial cancer, treated at the 150 mg dose level of APR-1051. At the protocol-defined 8-week first imaging assessment, the patient achieved a 50% reduction in target lesion size per RECIST v1.1 criteria, along with a marked reduction in cancer antigen 125 (CA-125) levels, from 732 to 70 U/mL. CA-125 is a well-recognized tumor marker in endometrial cancer. On February 18, 2026, we announced the second uPR observed in a patient with PPP2R1A-mutated endometrial cancer, treated at the 220 mg dose level: at the first imaging assessment the patient achieved a 50% reduction in target lesion size, along with a marked decline in CA-125 from 362 at baseline to 47 U/mL, further supporting the anti-tumor activity of APR-1051.In addition, preliminary results from the ACESOT-1051 study indicate that APR-1051 has been safe and well-tolerated to date, supporting our development strategy to differentiate WEE1 inhibition through a potentially improved therapeutic index. Low therapeutic index has been a major hurdle in the development of WEE1 inhibitors. Active enrollment is ongoing at three sites in the U.S. (NCT06260514) with additional </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">sites planned. We anticipate additional open-label safety/efficacy data to be available in the second quarter of 2026. We expect to complete dose-escalation in the third quarter of 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATR Inhibitor: ATRN-119 (Mosipasertib)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our second clinical-stage synthetic lethality product candidate is ATRN-119, an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR. The ATR kinase is a master regulator of the DNA damage response, with key roles in cell cycle control and DNA repair following replication stress. We have developed ATRN-119, the first oral macrocyclic ATR inhibitor to enter clinical trials. On October 15, 2025, we announced that we had determined the recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 in the ABOYA-119 Phase 1/2a dose-escalation study, in patients with advanced solid tumors. Building on the completion of dose escalation, we are considering further ATRN-119 development in combination approaches that could expand its therapeutic potential. We believe ATRN-119's mechanism of action, favorable safety profile, and pharmacologic characteristics make it an ideal candidate for combination with other anti-cancer therapies, including radiation therapy, antibody-drug conjugates (ADCs) and immune checkpoint inhibitors. We are currently in discussions with leading academic centers to explore combining ATRN-119 with radiation in patients with human papillomavirus&#8211;positive (HPV+) head and neck cancer. Additional investigator-led studies evaluating ATRN-119 in combination with an I/O agent and ADCs are also being explored. As part of this strategic focus, we have paused further enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and started an orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">P53 Reactivator: APR-246 (eprenetapopt) </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not currently have any ongoing clinical trials involving our reactivator of mutant p53, which we were previously engaged in prior to our acquisition of Atrin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DYRK1 Inhibitor: APR-1602</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also have an early-stage program, APR-1602, a macrocyclic DYRK1A/B inhibitor, that will be ready to enter IND-enabling studies in the fourth quarter of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are focused on delivering breakthrough therapies for cancers with high unmet medical need. Our two lead programs are APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor. Both compounds were discovered internally and are being developed by our experienced team of chemists, scientists, and clinicians. We believe our programs have the potential to advance innovative treatments for cancer patients with unmet medical needs and deliver meaningful impact to patients and generate long-term value for shareholders. In addition, our pipeline also includes a DYRK1 inhibitor, APR-1602, which is a preclinical program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k001.jpg" alt="Graphic" style="display:inline-block;height:205.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:462.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We aspire to be a leader in the emerging field of synthetic lethality-based precision oncology therapeutics. The key elements of our strategy are to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to efficiently develop our clinical-stage product candidate, APR-1051, an orally bioavailable small molecule inhibitor of WEE1.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are currently conducting a Phase 1 clinical trial evaluating APR-1051 in patients with biomarkers that may predict sensitivity to WEE1 inhibition. Cancers with those biomarkers represent a high unmet medical need. We are enrolling patients into part 1 of this clinical trial. The primary objectives of the Phase 1 study are&#160;to measure safety, dose-limiting toxicities (DLTs), maximum tolerated dose or maximum administered dose (MTD/MAD), and recommended Phase 2 dose (RP2D); secondary objectives are to evaluate pharmacokinetics, preliminary efficacy according to RECIST or PCWG3 criteria; pharmacodynamic parameters are exploratory objectives.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to efficiently develop our clinical-stage product candidate, ATRN-119, an orally bioavailable small molecule inhibitor of ATR.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have recently determined the RP2D of ATRN-119 monotherapy in a Phase 1/2a clinical trial evaluating ATRN-119 in patients with advanced solid tumors having mutations in defined DDR-related genes. Based on the completion of dose escalation, we are considering further ATRN-119 development in combination approaches that could expand its therapeutic potential. We are currently in discussions with leading academic centers to explore potential combinations of ATRN-119 with radiation, I/O agents or ADCs.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Identify opportunities for combination therapy regimens.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are also researching opportunities to combine product candidates in our pipeline with other therapies that may enhance synthetic lethality and potentially increase benefit to genetically defined populations of cancer patients.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Maximize the commercial opportunity of our product candidates across global markets.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">  We currently retain worldwide development and commercialization rights to all our product candidates. We may elect to selectively evaluate strategic partnership opportunities for our product candidates with partners whose development and commercial capabilities complement our own.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Approach</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our approach to the development of novel cancer therapies is based on a powerful biological phenomenon known as synthetic lethality. Synthetic lethality represents an emerging strategy to treat a broad spectrum of cancers that currently </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:221.18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lack effective treatments. Our focus is the application of synthetic lethality in the DDR pathway to effect selective killing of cancer cells while sparing normal cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Background on Synthetic Lethality</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">First described in 1922, the concept of synthetic lethality describes biological observations wherein mutations in a pair of genes result in cell death, but mutations in either gene alone do not. Cancer is a genetically driven collection of diseases in which mutations in the genome allow cells to bypass the normal checks and balances that control cell replication. Frequently, these mutations occur in genes that have critical roles in metabolism and DNA repair. While mutations in such genes may permit cells to survive, it is possible that mutation in a second gene, or loss of function resulting from pharmacologic inhibition, may trigger cancer cell death if the two genes are synthetically lethal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The first clinical validation of synthetic lethality for cancer treatment was with BRCA1/2 mutations and PARP inhibition. BRCA1 and BRCA2 are proteins with key roles in the repair of DNA double-strand breaks (DSBs), one of the most lethal DNA lesions. BRCA1/2 mediate homologous recombination (HR), the major mechanism of DSB repair. When there is a loss of function in BRCA1/2, then cells become more dependent on PARP to prevent the formation of DSBs. If in this context PARP function is inhibited, then BRCA1/2 mutated cancer cells die. In other words, BRCA1/2 mutation and PARP inhibition are synthetically lethal. In contrast, normal cells with functional BRCA1/2 are spared. There are currently multiple PARP inhibitors approved by FDA for the treatment of various solid tumors with BRCA1/2 dysfunction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k002.jpg" alt="Graphic" style="display:inline-block;height:221.18pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:457.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Background on DDR</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cells are continuously exposed to endogenous and exogenous stress that can lead to DNA damage. To counter this lethal threat, cells have mechanisms to detect DNA damage, activate the appropriate repair pathway or, if irreparable, induce cell cycle arrest or apoptosis. These DDR processes are vital for cell survival.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancer cells rely on various alternative pathways to repair and resist DNA damage and replication stress. Many of these DDR-related genes are mutated across cancers, as loss of the DDR pathway allows cancer cells to rapidly evolve and grow out of control. Notably, functional loss of these pathways also creates a vulnerability in these cancers because mutation or loss of some DDR genes increases reliance on other DDR genes to support continued cancer cell growth. When mutation or loss of function of two DDR genes leads to cell death, the interplay between these genes is synthetic lethality. Importantly, selective targeting of specific members of the DDR pathway represents an attractive potential therapeutic approach for the treatment of cancer. Furthermore, because genes that are mutated in cancers continue to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:115.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">function normally in healthy tissues, this treatment approach can potentially reduce drug-induced toxicity while maintaining anti-cancer activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Development of Highly Precise Cancer Therapies</b> <b style="font-weight:bold;">by Blocking DNA Repair, While Sparing Healthy Cells</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k003.jpg" alt="Graphic" style="display:inline-block;height:115.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:382.5pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">WEE1 Inhibitors in Advanced Solid Tumors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are advancing our clinical-stage WEE1 inhibitor, APR-1051, for patients having tumors with mutations in PPP2R1A, FBXW7 or with increased expression of Cyclin E1 (&#8220;CCNE1&#8221;), among other genetic and/or molecular signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WEE1 kinase is a key regulator of multiple phases of the cell cycle, most prominently in progression from G1 to S phase and from G2 to M phase through inhibitory phosphorylation of CDK2 and CDK1, respectively. Thus, when WEE1 is inhibited, both G1-S and G2-M checkpoints are abrogated, leading to premature S-phase and M-phase entry. Notably, the replication stress caused by CCNE1 overexpression is transformed into toxic levels of DSBs and cancer cell death when WEE1 is inhibited. These findings suggest CCNE1 overexpression is a cancer-associated vulnerability that may be used to sensitize these cancers to WEE1 inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">APR-1051 Potential Differentiation and Preclinical Data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Several WEE1 inhibitors in development by other companies have been and are currently being evaluated in clinical trials. WEE1 has been proven as a clinically validated target in various clinical studies. However, competitor WEE1 inhibitors have been associated with significant grade &#8805;3 hematological, gastrointestinal and cardiovascular toxicities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have developed a highly potent and selective inhibitor of WEE1, APR-1051, that has the potential to become the best-in-class WEE1 inhibitor. We believe that APR-1051 is potentially differentiated from other WEE1 inhibitors in its: 1) molecular structure; 2) selectivity for WEE1 versus off-target inhibition of the polo-like kinase, or PLK, family of kinases; and 3) potential absence of QT prolongation at doses that significantly inhibit WEE1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In preclinical biochemical studies, we have observed high potency of APR-1051 for inhibition of WEE1, with an IC50 of approximately 1.6 nM; however, even when tested at a very high relative concentration of 1 &#181;M, APR-1051 did not appreciably inhibit PLK1 (17%), PLK2 (33%) or PLK3 (12%). We believe that this high selectivity for WEE1 over PLK1, PLK2 and PLK3 is an important differentiating attribute of APR-1051 versus some of the other WEE1 inhibitors in development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Head-to-head studies of APR-1051 versus the oral WEE1 inhibitors ZN-c3 (Azenosertib, Zentalis) and AZD-1775 (Adavosertib, Astra Zeneca) have not been conducted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:183.62pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APR-1051 Does Not Substantially Off-target PLK1, PLK2 or PLK3 and Comparison to ZN-c3 </b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="apre-20251231x10k004.jpg" alt="Graphic" style="display:inline-block;height:149.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:370.5pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In vitro kinase IC50 determination of APR-1051 vs. ZN-c3: APR-1051 IC50 values show &gt;150-fold, &gt;50-fold, and &gt;600-fold IC50 values compared to ZN-c3 for PLK1, PLK2, and PLK3, respectively, potentially showing higher selectivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;">1  </sup>AACR-NCI-EORTC Meeting, Poster B323, 2024 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">In addition to the potential safety issues associated with PLK1 inhibition, in an in-vitro study we showed that PLK1 inhibition reduces the expected molecular effects of WEE1 inhibitor on phos-H2AX and phos-CDK1, hence we believe that minimal PLK1 co-inhibition enables full therapeutic potential of APR-1051.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PLK1 Inhibition Reduces the Molecular Effects of WEE1 Inhibitors in Cells</b><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k005.jpg" alt="Graphic" style="display:inline-block;height:183.62pt;width:459.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Dose range of a PLK inhibitor GSK-461364 in combination with a single dose of APR-1051 in OVCAR3 cells suggests interference with the genotoxic effects of WEE1 inhibition (pH2AX). Western blot suggests that the PLK inhibitors, GSK-461364 and BI-2536 interfere with APR- 1051&#8217;s ability to increase pH2AX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;">1  </sup>AACR-NCI-EORTC Meeting, Poster B323, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As part of our preclinical studies with APR-1051, we conducted a CDX mouse model study using the CCNE1-amplified ovarian cancer cell line OVCAR3. In this study we injected female mice (N=7 per group) with tumor cells and waited for tumor volume to reach approximately 150 mm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> before initiating daily administration over a period of 28 days with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:264pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">vehicle administered orally or an exploratory formulation of APR-1051 administered orally at 30 mg/kg/day. In this model we observed strong tumor growth inhibition when APR-1051 was administered at 30 mg/kg/day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APR-1051 Exhibits Strong Tumor Control in CCNE1-Overexpressing CDX Model </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k006.jpg" alt="Graphic" style="display:inline-block;height:263.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:383.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, pre-clinical results from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations in HPV+ head and neck squamous cell carcinoma (HNSCC). APR-1051 demonstrated robust antiproliferative single-agent effects across a broad panel of human and murine head and neck cancer cell lines, including HPV+ subtypes, with IC&#8325;&#8320; values ranging from 8.9 to 230 nM. Significant anti-tumor synergy was observed with APR-1051 in combination with anti&#8211;PD-1 therapies, as well as in combination with cisplatin in HPV+ HNSCC animal models, positioning APR-1051 as a potential candidate for combination-based clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APR-1051 Potentiates the Immune Response to Checkpoint Inhibitors in an HPV+ HNSCC Animal Model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"><img src="apre-20251231x10k007.jpg" alt="Graphic" style="display:inline-block;height:144.55pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:206.35pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APR-1051 Synergizes with Cisplatin</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> </span><b style="font-weight:bold;">in Another HPV+ HNSCC Animal Model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k008.jpg" alt="Graphic" style="display:inline-block;height:176.55pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:194.85pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In preclinical mice studies, APR-1051 has also demonstrated potentially favorable pharmacokinetic properties as assessed by the area under the curve, or AUC, a commonly used measure of drug exposure. Head-to-head studies of APR-1051 versus the oral ZN-c3 and AZD-1775 have not been conducted; however, data for the ZN-c3 and AZD-1775 have been previously disclosed by Zentalis and suggest that APR-1051 may have potentially advantageous drug exposure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:162.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APR-1051 Pre-Clinical Data Highlight Potentially Favorable Pharmacokinetic Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k009.jpg" alt="Graphic" style="display:inline-block;height:162.45pt;width:457.79pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, QT prolongation has been reported with competitor WEE1 inhibitors developed by other companies. APR-1051 showed negligible inhibition of hERG channels, which may indicate a lower likelihood of QT prolongation at doses expected to achieve meaningful WEE1 inhibition.</p><div style="clear:both;"></div><div style="clear:right;float:right;height:20.15pt;width:0pt;"></div><div style="clear:right;float:right;height:134.64pt;margin-left:9pt;margin-right:calc(50% - 238.68pt);margin-top:20.15pt;width:477.36pt;z-index:-9223372036603117568;"><div style="height:134.64pt;left:0pt;padding-bottom:0pt;position:relative;width:477.36pt;"><img src="apre-20251231x10k010.jpg" alt="Graphic" style="height:134.64pt;width:477.36pt;"/></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">APR-1051 Exhibits Substantially Lower Inhibition of hERG than of WEE1</b><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup>AACR-NCI-EORTC Meeting, Poster B323, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">APR-1051 Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In March 2024, our IND for APR-1051 (IND 169359) went into effect and in the second quarter of 2024 we enrolled the first patient into ACESOT-1051 (a Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051). The study is evaluating APR-1051 for monotherapy treatment of solid tumors harboring deleterious mutations in FBXW7 or PPP2R1A, overexpressing Cyclin E, colorectal cancer with KRAS GLY12 or GLY13 and TP53 co-mutation, patients with HPV+ oropharyngeal squamous cell carcinoma,<span style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> </span>or cervical, vaginal, or vulvar squamous cell carcinoma, as well as patients with uterine serous carcinoma, regardless of biomarker status. The primary objectives of this Phase 1 study are&#160;to measure safety, dose-limiting toxicities (DLTs), maximum tolerated dose or maximum administered dose (MTD/MAD), and recommended Phase 2 dose (RP2D); secondary objectives are to evaluate pharmacokinetics and preliminary efficacy according to RECIST Version 1.1 or PCWG3 criteria; exploratory objectives are to evaluate pharmacodynamic parameters. A total of 9 cohorts are planned for ACESOT-1051 that will evaluate doses of 10 mg to 300 mg once daily (higher doses are permitted if indicated). As of March 2, 2026, we are enrolling cohort 8 for ACESOT-1051 to evaluate a dose of 220 mg once daily. In addition, we intend to enroll additional patients as backfill cohorts, in order to obtain further safety, efficacy and PK data. Active enrollment is ongoing at three sites in the U.S. (NCT06260514) with additional sites planned. Up to 130 patients are planned to be enrolled in this Phase 1 study, including up to 50 patients in the dose-escalation Part 1 and up to additional 80 patients in the dose-optimization </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Part 2 of the study. We anticipate additional open-label safety/efficacy data to be available in the second quarter of 2026. We expect to complete the dose-escalation part of this study in the third quarter of 2026.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ACESOT-1051: Study Design</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k011.jpg" alt="Graphic" style="display:inline-block;height:226.5pt;width:461pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">* Higher doses permitted if indicated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preliminary results provide early clinical proof-of-concept of APR-1051. On January 29, 2026, we announced the first uPR observed in a patient enrolled in the ongoing Phase 1 ACESOT-1051 dose-escalation study: a patient with PPP2R1A-mutated uterine serous carcinoma, a form of endometrial cancer, treated at the 150 mg dose level of APR-1051. At the protocol-defined 8-week first imaging assessment, the patient achieved a 50% reduction in target lesion size per RECIST v1.1 criteria, along with a marked reduction in cancer antigen 125 (CA-125) levels, from 732 to 70 U/mL. CA-125 is a well-recognized tumor marker in endometrial cancer. On February 18, 2026, we announced the second uPR observed in a patient with PPP2R1A-mutated endometrial cancer, treated at the 220 mg dose level: at the first imaging assessment the patient achieved a 50% reduction in target lesion size, along with a marked decline in CA-125 from 362 at baseline to 47 U/mL, further supporting the anti-tumor activity of APR-1051.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Five more patients in ACESOT-1051 have achieved stable disease in earlier cohorts of the ACESOT-1051 study, including a 5% reduction in tumor burden at the 70 mg dose in a patient with HPV+ HNSCC and a 15% reduction in a patient with FBXW7-mutated colon cancer treated at the 100 mg dose level. Two additional patients at the 100 mg dose and another patient treated at the 150 mg dose level achieved stable disease at the first follow-up imaging assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Collectively, these findings suggest that APR-1051 may have therapeutic potential across a range of solid tumors, with a potential dose-response trend.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:232.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ACESOT-1051 Clinical Trial, Summary of Duration of Treatment (N=23) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k012.jpg" alt="Graphic" style="display:inline-block;height:232pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:437.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ACESOT-1051 Clinical Trial, Safety Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preliminary results indicate that APR-1051 is safe and well-tolerated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment Related AEs in Patients Treated With APR-1051, as of February 18, 2026 (N=23): </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k013.jpg" alt="Graphic" style="display:inline-block;height:226.6pt;width:410pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that the emerging clinical proof of concept responses, together with the potential dose-response trend that was observed with increasing single-agent activity across lower doses, and without class-limiting toxicity to date, support our development strategy of differentiated WEE1 inhibition through a potentially improved therapeutic index (TI), as low TI has been a major hurdle in the development of WEE1 inhibitors. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ATR Inhibitors in Advanced Solid Tumors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our second clinical-stage synthetic lethality product candidate is ATRN-119 <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib)</i>, an ATR inhibitor for patients with solid tumors having defined genetic mutations in DDR-related genes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ataxia Telangiectasia and Rad3-related (ATR) and Checkpoint Kinase 1 (CHK1) are critical DNA damage response kinases that prevent the collapse of replication forks into DSBs. ATR is one of several key regulators of the response to defective DNA replication and DNA damage, which occurs more commonly in cancer cells than in normal cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In response to these cancer-associated genomic insults, ATR is activated to inhibit progression to cellular division and prevent the assembly of the SLX1-SLX4, MUS81-EME1 and XPF-ERCC1 (SMX) endonuclease (DNA cutting) complex. When ATR is inhibited, the SMX complex is inappropriately activated, promoting the cutting of replication forks into DSBs. In association with ATR&#8217;s fundamental roles in these replication responses, cells with increased oncogenic stress, p53 mutations and deficiencies in DDR pathways are predicted to have increased sensitivity to ATR inhibition. Accordingly, ATR inhibition is also predicted to sensitize cells to DNA-damaging chemotherapy, radiotherapy, and PARP inhibitor treatments, making ATR inhibitors particularly attractive for the development of novel combination therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have developed a highly potent and selective macrocyclic inhibitor of ATR, ATRN-119, the first oral macrocyclic ATR inhibitor to enter clinical trials. On October 15, 2025, we announced that we had determined the recommended Phase 2 dose (RP2D) of ATRN-119 in the ABOYA-119 Phase 1/2a dose-escalation study, in patients with advanced solid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ATRN-119 </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib) </i><i style="font-style:italic;">Preclinical Data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ATRN-119 is a macrocycle and is structurally dissimilar to three oral ATR inhibitors for which chemical structures have been disclosed: AZD-6738 (AstraZeneca), BAY1895344 (Bayer), and RP-3500 (Repare). The macrocyclic structure of ATRN-119 was designed to restrict the conformational freedom of the molecule, or ability to rotate freely around certain chemical bonds, which may reduce its ability to bind off-target proteins, resulting in potentially increased tolerability, hence permitting higher efficacious drug dosing. Consistent with this hypothesis, ATRN-119 has demonstrated increased selectivity for ATR versus related members of the PIKK family of kinases, including ataxia-telangiectasia mutated (ATM), DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR). In preclinical studies, we have observed a high potency of ATRN-119 for inhibition of ATR, with an IC50 of approximately 4 nM, whereas the IC50 of ATRN-119 is significantly higher for off-target inhibition of ATM (&gt;600-fold), DNA-PK (&gt;2000-fold) and mTOR (&gt;2000-fold). Selectivity for ATR over other kinases, including PIKKs, may potentially limit toxicity from off-target inhibition. Comprehensive in-vitro head-to-head studies of ATRN-119 versus the oral ATR inhibitors AZD-6738, BAY1895344, and RP-3500 have not been conducted, but data for these other ATR inhibitors have been reported in peer-reviewed scientific publications.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:151.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ATRN-119 Displays High Selectivity for ATR Versus Related PIKK Kinases</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:26.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">On Target Cellular IC</b><sub style="font-size:7.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;vertical-align:sub;">50</sub><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> (nM)</b></p></td><td colspan="5" style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fold Difference in IC</b><sub style="font-size:7.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;vertical-align:sub;">50</sub><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> for Off-Target PIKK Inhibition</b></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:26.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ATR</b></p></td><td style="vertical-align:top;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ATM</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DNA-PK</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">mTOR</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.22%;background:#cceeff;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aprea: ATRN-119</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:top;width:23.41%;background:#cceeff;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 600x</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 2000x</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 2000x</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.22%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">AstraZeneca: AZD-6738</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:top;width:23.41%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">74</p></td><td style="vertical-align:top;width:14.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 400x</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 400x</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">70 &#8211; 310x</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.22%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Bayer: BAY1895344</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:top;width:23.41%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">36</p></td><td style="vertical-align:top;width:14.08%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">39x</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9x</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">61x</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.22%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Repare: RP-3500</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:top;width:23.41%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.33</p></td><td style="vertical-align:top;width:14.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 20000x</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt; 20000x</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">30x</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ATRN-119 data from HCT116 &#8211; Bcl/XL cell line</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Foote et al (2018), </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">J Med Chem</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">L&#252;cking et al (2020), </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">J Med Chem</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Roulston et al (2022), </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Mol Cancer Ther</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We observed ATRN-119 to have a potentially favorable tolerability profile across our preclinical studies and animal models. As part of our preclinical studies with ATRN-119, we conducted cell line-derived xenograft, or CDX, mouse model studies, using the colon cancer cell line HCT-116 (mutated KRAS, p53 null). In this study we injected female mice (N=4 per group) with tumor cells and waited for tumor volume to reach approximately 150 mm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> before initiating daily administration over a period of 17 days with vehicle administered orally; ATRN-119 administered orally at 100 mg/kg/day; ATRN-157 (an active metabolite of ATRN-119 with comparable potency and selectivity to the parent compound) was administered subcutaneously at 20 mg/kg/day; or a competitor ATR inhibitor administered orally at 25 mg/kg/day. In this study, both ATRN-119 and ATRN-157 demonstrated statistically significant tumor growth inhibition as compared to vehicle control and smaller tumor volume than measured in mice receiving the competitor ATR inhibitor. Body weight loss, as a measurement of tolerability, was negligible across all groups of mice in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ATRN-119 Halts Tumor Progression and Causes No Obvious Toxicity in KRAS-Mutant, p53-Null CDX Model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k014.jpg" alt="Graphic" style="display:inline-block;height:151.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:474.98pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Data from clinical trials testing the oral ATR inhibitors BAY1895344, ART0380 and RP-3500 have been presented and support preclinical observation of synthetic lethality between ATR inhibitors and ATM-deficient cancers. In addition, data from various clinical trials with oral ATR inhibitors demonstrated responses in patients with tumors having mutations in ARID1A, CDK12, RAD51C and BRCA1/2. We believe these data are encouraging and indicate that additional DDR-related mutations may be synthetic lethal with ATR inhibitors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ATRN-119</i> <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib) </i><i style="font-style:italic;">Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In our open-label Phase 1/2a clinical trial of ATRN-119 as monotherapy, we enrolled patients with advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. In the monotherapy dose escalation phase (Part 1) of our trial, the primary endpoint was evaluating the tolerability and pharmacokinetics of continuous daily oral dosing of ATRN-119 using a 3+3 trial design in up to approximately 72 patients (up to 54 patients dosed once-daily and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:220.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">up to 18 patients dosed twice-daily). A secondary endpoint was evaluating potential initial efficacy. An efficacy evaluation was performed every eight weeks. On October 15, 2025, we announced that we had determined the recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 monotherapy. Based on the completion of dose escalation, we are considering further ATRN-119 development in combination approaches that could expand its therapeutic potential. We believe that ATRN-119's mechanism of action, favorable safety profile, and pharmacological characteristics make it an ideal candidate for combination with DNA-damaging agents, including radiation therapy, antibody-drug conjugates and with immune checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of this strategic focus, we have paused further enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and started an orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Phase 1/2a Clinical Trial of ATRN-119 </b><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib)</span><b style="font-weight:bold;"> as Monotherapy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k015.jpg" alt="Graphic" style="display:inline-block;height:220.5pt;width:467.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the Phase 1 dose-escalation study, ATRN-119 demonstrated:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Favorable tolerability profile with manageable adverse events at the RP2D of 1,100 mg once daily</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preliminary signs of clinical activity in biomarker-selected populations &#8211; 8 stable disease cases</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Durable disease stabilization in heavily pretreated patients across multiple tumor types</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dose-proportional pharmacokinetics supporting once-daily dosing</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:206.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ATRN-119 </b><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib),</span><b style="font-weight:bold;"> Phase 1/2a Safety Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment Related AEs Reported in &#8805; 2 Patients and/or any Grade &#8805; 3 in Patients Treated With ATRN-119 QD as of February 26, 2026 (N=33):</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k016.jpg" alt="Graphic" style="display:inline-block;height:206.15pt;width:467pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ATRN-119 </b><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib)</span><b style="font-weight:bold;">, Phase 1/2a, Summary of Duration of Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A total of eight stable disease patients were observed in the dose escalation Phase 1 trial, four at the QD cohorts and 4 at the BID cohorts:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:232.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Duration Of Treatment for Patients Dosed QD (N=33)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="apre-20251231x10k017.jpg" alt="Graphic" style="display:inline-block;height:232.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:448.1pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Opportunities for Combination of ATRN-119 </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(Mosipasertib</i><i style="font-style:italic;">) with Other Therapies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Combinations of anti-cancer agents have the potential to interact synergistically. This synergy can potentially augment efficacy over monotherapy regimens and reduce the risk of drug resistance. We believe that our ATRN-119 could potentially interact synergistically with various anti-cancer agents, including PARP inhibitors, WEE1 inhibitors, radiopharmaceuticals, chemotherapies, ADCs and immunotherapies. In a preclinical study, we evaluated ATRN-119 and the PARP inhibitor olaparib as both monotherapies and a combination therapy in a patient-derived xenograft, or PDX, ovarian cancer mouse model. Mice were first transplanted with patient-derived BRCA2 deficient ovarian cancer tumor material. When tumors grew to approximately 100 mm<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> the mice were dosed (N=6-8 per group) with vehicle, olaparib at 50 mg/kg/day, ATRN-119 at 90 mg/kg twice daily, or the combination of the two agents at the same doses and schedules. In this study, ATRN-119 and olaparib monotherapies demonstrated comparable tumor growth inhibition. However, the combination of ATRN-119 + olaparib demonstrated statistically significant tumor growth inhibition compared to either single agent or vehicle control. Body weight loss, as a measurement of tolerability, was negligible in the mice receiving any of these regimens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are currently in discussions with leading academic centers to explore combining ATRN-119 with radiation in patients with HPV+ head and neck cancer. Additional investigator-led studies evaluating ATRN-119 in combination with an I/O agent and antibody-drug conjugates (ADCs) are also being explored. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:224.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ATRN-119 + Olaparib Combination Drives Regression and No Serious Toxicity in BRCA2-deficient PDX Model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="apre-20251231x10k018.jpg" alt="Graphic" style="display:inline-block;height:224.05pt;width:476.05pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">DYRK1A/B Inhibitor, APR-1602</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also have an early preclinical program, in which a first generation macrocyclic lead candidate was selected. We plan to have APR-1602 ready to enter IND-enabling studies during the fourth quarter of 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently contract with third parties for the manufacture of our product candidates for certain preclinical studies and clinical trial materials, including raw materials and consumables necessary for their manufacture, consistent with applicable cGMP requirements. We intend to continue to contract production of these materials and services in the future, including commercial manufacture if our product candidates receive marketing approval. We do not own or operate cGMP manufacturing facilities, nor do we currently plan to build our own cGMP manufacturing capabilities for production of our product candidates for clinical or commercial use. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we rely upon contract manufacturers for the manufacture of our product candidates for pre-clinical trials and clinical trials, we have personnel and consultants who oversee our contract manufacturers. In the future, we may also rely upon collaboration partners, in addition to contract manufacturers, for the manufacture of our product candidates or any products for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Currently, we have agreements with manufacturers for the production of APR-1051 and ATRN-119 active pharmaceutical ingredients, or APIs, and drug products. We believe that these third parties have sufficient capacity to meet our current demand and, in the event they fail to meet our demand, we believe that adequate alternative sources for the supply of materials for our product candidates exist. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that one or more of our current contract manufacturers will have capacity to support commercial scale production but we do not have any formal agreements in place at this time given our early stage of development. If needed, we believe we can identify and establish agreements with additional contract manufacturers to provide APIs as well as drug product. We intend to identify and qualify additional manufacturers to provide the APIs, drug product and other services pertaining to our clinical and potential future supply chains prior to seeking marketing approval for any of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates are small molecules and are manufactured synthetically from readily available starting materials. The chemistry underlying our product candidates appears amenable to scale-up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Manufacturing clinical products is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our contract manufacturers are required to comply with current good manufacturing practice (cGMP) regulations, which are regulatory requirements for the production of pharmaceuticals for use in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries generally, and the cancer drug sector specifically, are highly competitive and characterized by rapidly advancing technologies, evolving understanding of disease etiology and a strong emphasis on proprietary drugs. While we believe that our product candidates, development capabilities, experience and scientific knowledge provide us with competitive advantages, we face significant potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are a large number of companies developing or marketing treatments for cancer, including the indications for which we may develop product candidates. Many of the companies that we compete against or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The most common methods of treating patients with cancer are surgery, radiation and therapy with drugs or biologics. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently-approved drug therapies are branded and subject to patent protection and may be established as standard of care for the treatment of indications for which we may choose to seek regulatory approvals. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors, and even if our drug candidates were to be approved, there can be no assurance that our drugs would displace existing treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to currently marketed therapies, there are also a number of drugs in late-stage clinical development to treat cancer, including for the treatment of the indications for which we are developing product candidates. These clinical-stage drug candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently-marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With respect to our WEE1 inhibitor product candidate, APR-1051, several companies are developing WEE1 inhibitors, including Zentalis Pharmaceuticals, Debiopharm, IMPACT Therapeutics, Schrodinger and Acrivon Therapeutics. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Several of these companies are conducting clinical trials with their WEE1 inhibitors as monotherapy and/or in combination with other chemotherapies and targeted agents. AstraZeneca was previously developing a clinical-stage WEE1 inhibitor, AZD-1775 (Adavosertib), but reported discontinuation of further development in July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">With respect to our ATR inhibitor, ATRN-119, several companies are developing ATR inhibitors, including Artios Pharma, AstraZeneca, IMPACT Therapeutics, Merck KGaA and Xeno Therapeutics (formerly Repare Therapeutics&#8217; ATR inhibitor program). Several of these companies are conducting clinical trials with their ATR inhibitors as monotherapy and/or in combination with other chemotherapies and targeted agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent protection intended to cover claims directed to composition of matter, methods-of-use, formulations, and manufacturing processes for our product candidates, as well as other inventions that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable patents and other proprietary rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights, which are important or necessary to the development or commercialization of our product candidates. If it becomes necessary for us to use patented or proprietary technology of third parties to develop or commercialize our product candidates, we may need to seek a license from such third parties. Our business could be harmed, possibly materially, if we are unable to obtain such a license on terms that are commercially reasonable, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may seek to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment, diagnostics, and additional compounds and their derivatives. Specifically, we have sought and will continue to seek patent protection in the United States and internationally for novel compositions of matter covering the compounds of our product candidates, the chemistries and processes for manufacturing these compounds, and the use of these compounds in a variety of therapies. The chemical structure of eprenetapopt is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of eprenetapopt and will not in the future own or license any composition of matter patents claiming the chemical structure of eprenetapopt as described in the public domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&#160;months, and since publication of discoveries in the scientific or patent literature often lags actual discoveries, we cannot be certain of whether inventions covered by pending patent applications represent the first priority filings of those inventions. Moreover, we may have to participate in proceedings declared by the United States Patent and Trademark Office, or USPTO, in post-grant challenge proceedings at the USPTO or at a foreign patent office, such as inter partes review and post grant review proceedings at the USPTO and opposition proceedings at the European Patent Office, that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent portfolio </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, our exclusively owned patent portfolio is directed toward various aspects of our product candidates and research programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, the portion of our portfolio for DDR inhibitors, including our ATR and WEE1 programs, consists of 4 issued U.S. patents, 2 U.S. patent applications, 30 pending non-U.S. patent applications (including 1 International patent application), and 22 non-U.S. patents. The claims of these owned patents and patent applications are directed toward composition of matter, pharmaceutical compositions and methods of use. The granted patents and pending applications, if issued, in this family are expected to expire between 2035 and 2045, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, the portion of our portfolio for p53 reactivators, including eprenetapopt, consists of 3 issued U.S. patents, 1 pending U.S. application, and approximately 80 foreign issued patents. The claims of these owned patents and patent applications are directed toward drug product formulations and methods of use. The granted patents and pending applications, if issued, in this family are expected to expire between 2031 and 2040, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property protection </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the earliest date of filing a non-provisional patent application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Hatch-Waxman Act permits a patent holder to apply for patent term extension of a patent that covers an FDA-approved drug, which, if granted, can extend the patent term of such patent to compensate for part of the patent term lost during the FDA regulatory review process. This extension can be for up to five years beyond the original expiration date of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Similar provisions are available in Europe and other non-United States jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. While we intend to seek patent term extensions to any of our patents in any jurisdiction where such extensions are available, there is no guarantee that the applicable authorities, including the FDA and the USPTO in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition to our reliance on patent protection for our inventions, product candidates and research programs, we also rely on trade secrets and confidentiality agreements to protect our technology, know-how and other aspects our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information, are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government regulation and product approvals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of drug products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Review and approval of drugs in the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA approves drug products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The failure to comply with applicable requirements under the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, debarment, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with applicable FDA good laboratory practice, or GLP, regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must take effect before human clinical trials begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, or ethics committee, or EC, representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, and other applicable regulations to establish the safety and efficacy of the proposed drug product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of an NDA requesting marketing for one or more proposed indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">review by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees and securing FDA approval of the NDA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product candidate or disease. A clinical hold may occur at any time during the life of an IND and may affect one or more specific trials or all trials conducted under the IND. The testing and approval process requires substantial time, effort, and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preclinical studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before an applicant begins testing a compound with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as <i style="font-style:italic;">in vitro</i> and animal studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive AEs and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">The IND and IRB processes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug that is not the subject of an approved NDA. In support of a request for an IND, a sponsor must submit, among other things, a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The sponsor may be a company seeking to develop the drug or, as in the case of an investigator-initiated trial, the sponsor may be an investigator who is conducting the trial. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. If the FDA has neither commented on nor questioned the IND within this 30-day period, the IND is deemed to be in effect and the clinical trial proposed in the IND may begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval. Specifically, FDA has promulgated regulations governing the acceptance of foreign clinical trials not conducted under an IND, establishing that such studies will be accepted as support for an IND or application for marketing approval if the study was conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an on-site inspection if FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. If a marketing application is based solely on foreign clinical data, the FDA requires that the foreign data be applicable to the U.S. population and U.S. medical practice; the studies must have been performed by clinical investigators of recognized competence; and the FDA must be able to validate the data through an on-site inspection or other appropriate means, if the FDA deems such an inspection to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form, and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Human clinical trials in support of an NDA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in the following sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style=""><td style="vertical-align:bottom;width:12.91%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><i style="font-style:italic;">Phase&#160;1:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:84.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">Phase&#160;2:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">Phase&#160;3:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">Phase&#160;4:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">Post-approval studies, which are conducted following initial approval, are typically conducted to gain additional experience and data from treatment of patients in the intended therapeutic indication.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious AEs occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions for which there is evidence to suggest a causal relationship between the drug and the AE; findings from other studies or animal or <i style="font-style:italic;">in vitro</i> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#8217;s or the IRB&#8217;s requirements, or if the drug has been associated with unexpected serious harm to subjects. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Submission of an NDA to the FDA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from several alternative sources, including investigator-initiated trials that are not sponsored by company. Under federal law, the submission of NDAs requiring clinical data is additionally subject to an application user fee, which for federal fiscal year 2025 is $4,310,002. The sponsor of an approved NDA is also subject to annual program fees, which for fiscal year 2025 are $403,889 per eligible product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of an NDA within 60&#160;days of its receipt and informs the sponsor whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the filing date, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of the filing date. The review process and the Prescription Drug User Fee Act goal date may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including drug component manufacturing (such as APIs), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. In September 2025, FDA announced that it is considering ending advisory committee on new drugs because they take up significant resources and may not be needed.  It is currently unclear whether and to what extent FDA may implement such changes in its use of advisory committees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fast track, breakthrough therapy and priority review designations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation and priority review designation. In May 2014, the FDA published a final Guidance for Industry titled &#8220;Expedited Programs for Serious Conditions-Drugs and Biologics,&#8221; which provides guidance on the FDA programs that are intended to facilitate and expedite development and review of new product candidates as well as threshold criteria generally applicable to concluding that a product candidate is a candidate for these expedited development and review programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accelerated approval pathway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s decision on an NDA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#8217;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission during the review period that amends the original application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.&#160;The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Post-approval requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, including total or partial suspension of production, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning or untitled letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in a manner and for uses consistent with the approved </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription drug products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription drug product samples and impose requirements to ensure accountability in distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with any of the FDA&#8217;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with the FDA&#8217;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in adverse publicity, among other adverse consequences.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">U.S. Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme allowing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the API, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. An applicant may submit an ANDA suitability petition to request the FDA&#8217;s prior permission to submit an abbreviated application for a drug that differs from the RLD in route of administration, dosage form, or strength, or for a drug that has one different active ingredient in a fixed-combination drug product (i.e., a drug product with multiple active ingredients). At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists may consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years from the date the NDA is approved, unless the submission is accompanied by a Paragraph IV certification that a listed patent for the RLD is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">invalid or will not be infringed by the drug that is the subject of the ANDA, in which case the applicant may submit its application four years following the original product approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would only be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; it does, however, block the FDA from approving ANDAs during the period of exclusivity. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">505(b)(2) NDAs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on FDA&#8217;s previous findings of safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant. An RLD&#8217;s unexpired non-patent exclusivities would also block FDA from accepting or approving 505(b)(2) NDAs in the same way as they apply to ANDAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Hatch-Waxman patent certification and the 30-Month Stay</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods-of-use for which the ANDA applicant is not seeking approval. To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Specifically, the applicant must certify with respect to each patent that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required patent information has not been filed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has expired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the applicant is not seeking approval).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the ANDA or 505(b)(2) applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA or 505(b)(2) application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from granting final approval of the application until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Pediatric studies and exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act of 2012, sponsors must also submit pediatric study plans prior to the assessment data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. FDA may only grant pediatric exclusivity if existing patent or exclusivity protections for the drug would otherwise expire at least 9 months after the grant of the pediatric exclusivity; FDA has 180 days to make a pediatric exclusivity determination once the NDA sponsor submits study reports required under the written request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Orphan drug designation and exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Among the other benefits of orphan drug designation </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">are tax credits for certain research and an exemption from the NDA or BLA application fee. The FDA may revoke orphan drug designation, and if it does, it will publicize that the drug is no longer designated as an orphan drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the sponsor of a product with orphan designation receives the first FDA approval for that drug for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains orphan drug designation and FDA approval of the same therapeutic candidate for the same condition or disease as our orphan-designated drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, as the FDA has interpreted the Orphan Drug Act, even if a previously approved same drug does not have unexpired orphan exclusivity, a demonstration of clinical superiority is required for a subsequent marketing application for the same orphan-designated drug for the same disease or condition to be awarded a 7-year period of orphan exclusivity upon marketing approval. In recent years, there have been multiple legal challenges to this FDA interpretation, and in August 2017, Congress amended the orphan drug provisions of the FDCA through enactment of the FDA Reauthorization Act of 2017 to codify FDA&#8217;s longstanding interpretation. Section 527 of the FDCA now expressly provides that if a sponsor of an orphan-designated drug that is otherwise the same as an already approved drug for the same rare disease or condition is seeking orphan exclusivity, FDA shall require such sponsor, to demonstrate that such drug is clinically superior to any already approved or licensed drug that is the same drug in order to obtain orphan drug exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the United States Court of Appeals for the Eleventh Circuit decided in&#160;<i style="font-style:italic;">Catalyst Pharmaceuticals, Inc. v. FDA</i>&#160;that the FDA&#8217;s interpretation of orphan drug exclusivity &#8220;for the same drug for the same disease or condition&#8221; as meaning the same &#8220;use or indication&#8221; was inappropriately narrow. This decision had the potential to significantly broaden the scope of orphan drug exclusivity for drugs that receive marketing approval for orphan indications that are narrower than their orphan-designated conditions in the United States. On January 24, 2023, the FDA issued a statement to address the uncertainty created by the circuit court&#8217;s decision in <i style="font-style:italic;">Catalyst</i>. This notification announced that, at this time, in matters beyond the scope of that court order (i.e., ordering the FDA to set aside its approval of the specific drug at issue), the FDA intends to continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We cannot guarantee which rules and interpretations will be governing going forward in different situations, that the FDA will maintain this current position, or that other judicial actions will not impact the FDA&#8217;s application of the Orphan Drug Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Patent term restoration and extension</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA less any time the applicant did not act with due diligence during the period, plus the time between the submission date of an NDA and the ultimate approval date less any time the applicant did not act with due diligence during the period. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">extended, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulations outside the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will be subject to similar foreign laws and regulations concerning the development of our product candidates outside of the United States in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Coverage and reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for the procedures utilizing our product candidates, performed by health care providers, once approved, will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and establish reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party payors to reimburse all or part of the costs associated with the procedures which utilize our products. Treating physicians are unlikely to use and order our products unless coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products. Therefore, coverage and adequate reimbursement for procedures which utilize new products is critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government authorities and other third-party payors are developing increasingly sophisticated methods of cost containment, such as including price controls, restrictions on coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government and other third-party payors are increasingly challenging the prices charged for health care products and procedures, examining the cost effectiveness of procedures, and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among third-party payors in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement of newly approved products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can differ significantly from payor to payor and health care provider to health care provider. As a result, the coverage determination process is often a time-consuming and costly process that requires the provision of scientific and clinical support for the use of new products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA. Moreover, eligibility for coverage and reimbursement does not imply that a product, or the procedures which utilize such product, will be paid for in all cases or at a rate which the health care providers who purchase those products will find cost effective. Additionally, we expect pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes.&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize, or the procedures which utilize such product, and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare law and regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, our activities are potentially subject to regulation by various federal, state, and local authorities in addition to the FDA, including but not limited to, CMS, other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General, or OIG, and the Health Resources and Service Administration), the U.S. Department of Justice, and individual U.S. Attorney offices, and state and local governments. For example, sales, marketing, and scientific/educational grant programs are subject to the federal Anti-Kickback Statute and the federal False Claims Act, may have to comply with the privacy and security provisions of HIPAA (defined below), and may be subject to similar state laws, each as amended, as applicable. Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to these broadly applicable healthcare laws and regulations that may constrain our business and/or financial arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The applicable federal and state healthcare laws and regulations, include, without limitation, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Federal Anti-Kickback Statute</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;An intent-based federal criminal statute that prohibits, among other things, any person from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made, in whole or in part, by a federal health care program, such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The PPACA (as defined below), among other things, amended the intent requirement of the federal Anti-Kickback Statute, to clarify that a person or entity need not have actual knowledge of this statute or specific intent to violate it. The Anti-Kickback Statute applies to arrangements between pharmaceutical manufacturers on the one hand and individuals, such as prescribers, patients, purchasers, and formulary managers on the other hand, including, for example, consulting/speaking arrangements, discount and rebate offers, grants, charitable contributions, and patient support offerings, among others. A conviction for violation of the Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion may also be imposed if the government determines that an entity has committed acts that are prohibited by the Anti-Kickback Statute. Although there are a number of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute that protect certain common industry practices from prosecution, the exceptions and safe harbors are narrowly drawn, and arrangements may be subject to scrutiny or penalty if they do not fully satisfy all elements of an available exception or safe harbor. The Anti-Kickback Statute safe harbors have been the subject of recent regulatory reforms. As a general matter, however, any changes to the safe harbors may impact our future contractual and other arrangements with pharmacy benefit managers, group purchasing organizations, third-party payors, wholesalers and distributors, healthcare providers and prescribers, and other entities, as well as our future pricing strategies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Federal Civil False Claims Act</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Imposes civil penalties, including through civil whistleblower or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment to a federal health care program or knowingly making using or causing to be made or used a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $11,803 to $23,607 per false claim or statement for penalties assessed after December 13, 2021, with respect to violations occurring after November 2, 2015. Pharmaceutical companies have been investigated and/or subject to government enforcement actions asserting liability under the federal civil False Claims Act in </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes (e.g., under the Medicaid Drug Rebate Program), and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. There is also the federal criminal False Claims Act, which is similar to the federal civil False Claims Act and imposes criminal liability on those that make or present a false, fictitious, or fraudulent claim to the federal government.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Federal Criminal Statute on False Statements Relating to Health Care Matters</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">HIPAA Criminal Federal Health Care Fraud Statute</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Enacted as part of the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), makes it a crime to knowingly and willfully execute, or attempt to execute, a scheme or artifice to defraud any health care benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of any health care benefit program in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government sponsored programs, or integrity oversight and reporting obligations to resolve allegations of non-compliance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Federal Civil Monetary Penalties Law</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">HIPAA Health Information Privacy and Security</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Numerous federal and state laws, rules and regulations govern the collection, dissemination, use, privacy, security and confidentiality of personal information. HIPAA, as amended by the federal Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), in addition to the criminal powers described above, HIPAA requires covered entities, including health plans and most health care providers, to implement administrative, physical, and technical safeguards to protect the privacy and security of covered information (known as &#8220;protected health information&#8221;) and sets limits and conditions on the uses and disclosures that may be made of such information without the authorization of the relevant individual. HIPAA&#8217;s Security Rule and certain provisions of the HIPAA Privacy Rule and Breach Notification Rule apply to business associates of covered entities (i.e., entities that provide services to covered entities that may require access and use of handle protected health information on behalf of covered entities), and business associates are subject to direct liability for violation of these Rules. In addition, a covered entity may be subject to criminal and civil penalties as a result of a business associate violating HIPAA, if the business associate is found to be an agent of the covered entity. Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay and notification must also be made to the U.S. Department of Health &amp; Human Services, Office for Civil Rights (OCR) and, in certain situations involving large breaches, to the media. HITECH also created tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. OCR enforces the HIPAA Rules and performs compliance audits and investigations. In addition to enforcement by OCR, HIPAA authorizes state attorneys general to bring civil actions seeking either injunction or damages in response to HIPAA violations that impact state residents. On December 1, 2022, OCR issued a bulletin on the requirements under HIPAA for online tracking technologies (e.g., cookies, pixels) to protect the privacy and security of health information. This bulletin outlined OCR&#8217;s position on the use of online tracking technology vendors, when certain information received by such vendors constitutes protected health information under HIPAA, and accordingly, when business associate agreements must be executed between covered entities and such vendors. The HIPAA Rules impose and will continue to impose significant costs on us in order to comply with these standards.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Privacy Laws</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;HIPAA establishes a federal &#8220;floor&#8221; with respect to privacy, security, and breach notification requirements and does not supersede any state laws insofar as they are broader or more stringent than HIPAA. There are numerous other laws, regulations and legislative and regulatory initiatives at the federal and state levels addressing privacy and security of personal data. Depending on the data we receive, we may be subject to federal and state privacy-related laws that may be more restrictive or contain different requirements than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties and requirements related to such data. For example, the Federal Trade Commission (FTC) uses its consumer protection authority to initiate enforcement actions against companies relating to their use and disclosure of personally identifiable information. Specifically, FTC has asserted authority and issued enforcement actions in response to actual or perceived unfair or deceptive practices by a company in the handling of consumer information. The FTC has also pursued enforcement actions against companies for violations of its Health Breach Notification Rule and the Children&#8217;s Online Privacy Protection Act. Further, certain states have proposed or enacted legislation that will create new data privacy and security obligations for certain entities. These new laws include the California Consumer Privacy Act, or CCPA, which came into effect January 1, 2020 and was amended and expanded by the California Privacy Rights Act, or CPRA, passed on November 3, 2020, and effective as of January 1, 2023; the Virginia Consumer Data Protection Act, effective as of January 1, 2023; the Colorado Privacy Act and the Connecticut Data Privacy Act, both effective as of July 1, 2023; the Utah Consumer Privacy Act, effective as of December 31, 2023, and the Washington My Health My Data Act (&#8220;MHMDA&#8221;), with certain provisions effective as of July 1, 2023 and other provisions effective March 31, 2024. Among other things, these state-specific laws create new data privacy obligations for covered companies and provide new privacy rights to state residents, including the right to opt out of certain disclosures of their information. The CCPA also created a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. The MHMDA also contains a private right of actions. Draft regulations implementing the state statutes have been published, but many questions remain as to how all of the new statutes will be interpreted. The effects of state data protection laws are significant and have required us to modify our data processing practices and may cause us to incur substantial costs and expenses to ensure ongoing compliance, particularly given our base of operations in California. Various U.S. state laws and regulations may also require us to notify affected individuals and state agencies in the event of a data breach involving individually identifiable information. In addition to the laws discussed above, we may see more stringent state and federal privacy legislation passed in 2024 and beyond, as the increased cyber-attacks during the ongoing COVID-19 pandemic have once again put a spotlight on data privacy and security in the U.S. and other jurisdictions. We cannot predict where new legislation might arise, the scope of such legislation, or the potential impact to our business and operations. We expect to incur additional costs to ensure that our data privacy and security policies, procedures, and activities comply with applicable and evolving legal requirements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Federal Physician Payments Sunshine Act</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Requires &#8220;applicable manufacturers&#8221; of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, among others, to track and report annually to the federal government (for disclosure to the public) certain payments and other transfers of value they make to &#8220;covered recipients.&#8221; The term covered recipients includes U.S.-licensed physicians, teaching hospitals, physician </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, and certified nurse midwives. If we become an applicable manufacturer, reimbursable by federal healthcare programs, then we will be subject to this law, which would require us to track and annually report certain direct or indirect payments and other transfers of value to such covered recipients. We are also required to report certain ownership or investment interests held by physicians and their immediate family members. CMS has the potential to impose penalties of up to $1.36 million per year for violations of the Physician Payment Sunshine Act, depending on the circumstances, and reported payments also have the potential to draw scrutiny to our relationships with health care practitioners and academic medical institutions, which may have implications under the Anti-Kickback Statute and other healthcare laws.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Federal Food, Drug and Cosmetic Act</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;A set of laws, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Analogous State and Foreign Laws</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;There are state and foreign law equivalents of the above federal laws, such as the Anti-Kickback Statute and the False Claims Act, which may apply to items or services reimbursed by any third-party payor, including commercial insurers (i.e., so-called &#8220;all-payor anti-kickback laws&#8221;), as well as state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and, with respect to state laws, are often not pre-empted by HIPAA, thus requiring additional compliance efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">State and Foreign Laws Regulating Pharmaceutical Manufacturer Compliance Programs, Drug Price Transparency, and Other Practices</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;Some state and foreign laws require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation, or other remuneration to physicians and other healthcare providers. Several U.S. states and localities have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports, and/or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including the provision of gifts, meals or other items to certain healthcare providers, and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. In addition, several recently passed state laws require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes. Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">FCPA and Other Anti-Bribery and Anti-Corruption Laws</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA would include interactions with certain healthcare professionals in many countries, either directly or through our contracted distributors. Our present and future business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect that one or more of our products, if approved, may be eligible for coverage under Medicare, the federal health care program that provides health care benefits to the aged and disabled, including coverage for outpatient services and supplies, such as certain drug products, that are medically necessary to treat a beneficiary&#8217;s health condition. In addition, one or more of our products, if approved, may be covered and reimbursed under other federal health care programs, such as Medicaid and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national drug rebate agreement with the Secretary of the Department of Health and Human Services in exchange for state Medicaid coverage of most of the manufacturer&#8217;s drugs and pay </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">quarterly rebates based on utilization of a manufacturer&#8217;s covered outpatient drugs under the program as a condition for states to receive federal matching funds for a manufacturer&#8217;s covered outpatient drugs furnished to Medicaid patients and in order for payment to be available for a manufacturer&#8217;s drugs under Medicare Part B. When a manufacturer markets a new covered outpatient drug (COD), it must also submit product and pricing data concerning the drug to CMS via the Medicaid Drug Programs (MDP) system. Pharmaceutical manufacturers are also required to participate in the 340B Drug Pricing Program, administered by the Health Resources and Services Administration (HRSA) in order for payment to be available for a manufacturer&#8217;s drugs under Medicaid and Medicare Part B. Under the 340B Drug Pricing Program, a manufacturer must charge no more than the 340B &#8220;ceiling price&#8221; for its covered outpatient drugs purchased by statutorily defined covered entities that participate in the program. </p><a id="_cp_text_1_171"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, federal law requires that, in order for payment to be available for a manufacturer&#8217;s drugs under Medicaid and Medicare Part B, as well as to be purchased by certain federal agencies and grantees, it must also participate in the Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. To participate, manufacturers are required to enter into an FSS contract and other agreements with the VA for their covered drugs. Under these agreements, manufacturers must make their covered drugs available to the &#8220;Big Four&#8221; federal agencies&#8212; the VA, the Department of Defense (&#8220;DoD&#8221;), the Public Health Service (including the Indian Health Service), and the Coast Guard&#8212;at pricing that is capped pursuant to a statutory federal ceiling price, or FCP, formula. The FCP is based on a weighted average non-federal average manufacturer price, which manufacturers are required to report on a quarterly and annual basis to the VA. Further, pursuant to regulations issued by the DoD to implement Section 703 of the National Defense Authorization Act for Fiscal Year 2008, manufacturers may enter into an agreement with the Defense Health Agency (DHA) under which they agree to honor &#8220;Big Four&#8221; pricing for their covered drugs when they are dispensed to TRICARE beneficiaries by TRICARE retail network pharmacies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the requirements to participate in these government programs, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average manufacturer price, best price, average sales price, and non-federal average manufacturer price. The calculations can be complex and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Governmental agencies may also make changes in program interpretations, requirements, or conditions of participation, some of which may have implications for amounts previously estimated or paid. Any failure to comply with these price reporting and rebate payment obligations, when applicable, could negatively impact our financial results. Civil monetary penalties can be applied if a manufacturer is found to have knowingly submitted any false price information to the government, if a manufacturer is found to have made a misrepresentation in the reporting of its average sales price, or if a manufacturer fails to submit the required price data on a timely basis. Such conduct also could be grounds for CMS to terminate a manufacturer&#8217;s Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for a manufacturer&#8217;s covered outpatient drugs and may provide a basis for other potential liability under other federal laws such as the False Claims Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, guidance, case law or other applicable law. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, exclusion from participation in federal health care programs, such as Medicare and Medicaid, disgorgement, reputational harm, additional oversight and reporting obligations pursuant to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with applicable laws and regulations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to market our products, if approved, and adversely impact our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws and regulations, these risks cannot be eliminated entirely. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be costly to us in terms of money, time and resources, and they may be subject to criminal, civil or administrative sanctions, including exclusion from government-funded healthcare programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. healthcare reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of our future collaborators, to effectively sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or our future collaborators, may receive for any approved drugs. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, &#8220;PPACA&#8221;) has substantially changed and continues to impact healthcare financing and delivery by both government payors and private insurers. Among the PPACA provisions of importance to the pharmaceutical industry, in addition to those otherwise described above, are the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain federal programs identified in the PPACA;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price&#8221; for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a separate methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the types of entities eligible for the 340B drug discount program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of the Medicare Part D coverage gap discount program that, as a condition for the manufacturers outpatient drugs to be covered under Medicare Part D, requires manufacturers to provide a now 70% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">creation of the Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting of certain financial arrangements between manufacturers of drugs, biologics, devices, and medical supplies and physicians and teaching hospitals under the Physician Payments Sunshine Act; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The framework of the PPACA continues to evolve as a result of executive, legislative, regulatory, and administrative developments that have challenged the law and contribute to legal uncertainty that could affect the profitability of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">products. While Congress has not enacted legislation to comprehensively repeal the PPACA, legislation affecting the PPACA has been signed into law, including the elimination, effective January 1, 2019, of the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate.&#8221; In December 2018, a federal district court in Texas ruled that the PPACA&#8217;s individual mandate, without the penalty that was eliminated effective January 1, 2019, was unconstitutional and could not be severed from the PPACA. As a result, the court ruled the remaining provisions of the PPACA were also invalid. The Fifth Circuit Court of Appeals affirmed the district court&#8217;s ruling that the individual mandate was unconstitutional, but it remanded the case back to the district court for further analysis of whether the mandate could be severed from the PPACA (i.e., whether the entire PPACA was therefore also unconstitutional). On June 17, 2021, the U.S. Supreme Court dismissed this challenge without specifically ruling on the constitutionality of the PPACA.</p><a id="_cp_text_1_198"></a><a id="_cp_text_4_199"></a><a id="_cp_text_1_200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2019, the Bipartisan Budget Act of 2018, among other things, further amended portions of the Social Security Act implemented as part of the PPACA to increase from 50% to 70% the point-of-sale discount that pharmaceutical manufacturers participating in the Coverage Gap Discount Program must provide to eligible Medicare Part D beneficiaries during the coverage gap phase of the Part D benefit, commonly referred to as the &#8220;donut hole,&#8221; and to reduce standard beneficiary cost sharing in the coverage gap from 30% to 25% in most Medicare Part D plans. In addition, the Further Consolidated Appropriations Act of 2020, signed into law December&#160;20, 2019, fully repealed the PPACA&#8217;s &#8220;Cadillac Tax&#8221; on certain high-cost employer-sponsored insurance plans (for tax years beginning after December 31, 2019), the annual fee imposed on certain health insurance providers based on market share (for calendar year 2021), and the medical device excise tax on non-exempt medical devices (for sales after December 31, 2019). In the future, there may be additional challenges and/or amendments to the PPACA. It remains to be seen precisely what any new legislation will provide, when or if it will be enacted, and what impact it will have on the availability and cost of healthcare items and services, including drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Most recently, on August 16, 2022 the Inflation Reduction Act of 2022, or IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, and the impact of the IRA on the pharmaceutical industry cannot yet be fully determined. On December 14, 2023, President Biden announced that, through the IRA, dozens of pharmaceutical companies are required to pay rebates to Medicare for price hikes on prescription drugs.</p><a id="_cp_text_1_201"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. For example, the Budget Control Act of 2011, among other things, resulted in reductions in payments to Medicare providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislation, will remain in effect through 2031, with the exception of a temporary suspension of the payment reduction from May 1, 2020 through March 31, 2022 due to the coronavirus pandemic. Sequestration will start again on April 1, 2022. From April 1, 2022 to June 30, 2022, payment for Medicare fee-for-service claims will be adjusted downwards by 1%; beginning on July 1, 2022, the payment will be adjusted downwards by 2%. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These legislative changes may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recently, the cost of prescription pharmaceuticals has been the subject of considerable discussion in the United States. Congress considered and passed legislation, and the former Trump administration pursued several regulatory reforms to further increase transparency around prices and price increases, lower out-of-pocket costs for consumers, and decrease spending on prescription drugs by government programs. Congress also continued to conduct inquiries into the prescription drug industry&#8217;s pricing practices. While several proposed reform measures will require Congress to pass </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">legislation to become effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to address prescription drug costs. The Biden administration has taken several recent executive actions that signal changes in policy from the prior administration. For example, on July 9, 2021, President Biden signed an executive order to promote competition in the US economy that included several initiatives addressing prescription drugs. Among other provisions, the executive order directed the Secretary of HHS to issue a report to the White House within 45 days that includes a plan to, among other things, reduce prices for prescription drugs, including prices paid by the federal government for such drugs. In response to the Executive Order, on September 9, 2021, HHS issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. Additionally, on February 2, 2022, the Biden Administration signaled its continued commitment to the Cancer Moonshot initiative, which was initially launched in 2016. In its recent announcement, the administration noted that its new goals under the initiative include addressing inequities in order to ensure broader access to cutting-edge cancer therapeutics and investing in a robust pipeline for new treatments. At the state level, legislatures are increasingly passing legislation and states are implementing regulations designed to control spending on and patient out-of-pocket costs for drug products. Implementation of cost containment measures or other healthcare reforms that affect the pricing and/or availability of drug products may impact our ability to generate revenue, attain or maintain profitability, or commercialize products for which we may receive regulatory approval in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and/or new payment methodologies, and place additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians and other healthcare providers receive for administering any approved product we might bring to market. Reductions in reimbursement levels and imposition of more rigorous coverage criteria or new payment methodologies may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any coverage or reimbursement policies instituted by Medicare or other federal health care programs may result in similar policies from private payors. The implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our drug candidates. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources and Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, we had 8 full-time employees, of which 5 employees are directly engaged in research and development with the rest providing administrative, business and operations support. We also utilize outside consultants and independent contractors to supplement our full-time workforce. None of our employees are represented by a labor union or covered by collective bargaining agreements. We consider the relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our human capital resource objectives include, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees. The principal purpose of our equity incentive plan is to attract, retain and motivate employees and directors through the granting of stock-based compensation awards. Our future performance depends significantly upon the continued service of our key scientific, technical and senior management personnel and our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives. In addition to salaries, these programs include potential annual discretionary bonuses, stock awards, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and flexible work schedules, among other benefits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information about Our Executive Officers </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth certain information about our executive officers as of December&#160;31,&#160;2025.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:30.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:52.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:30.64%;background:#2f5496;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#ffffff;font-style:italic;font-weight:bold;">Name</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;background:#2f5496;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.6%;background:#2f5496;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#ffffff;font-style:italic;font-weight:bold;">Age</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;background:#2f5496;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#ffffff;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:52.08%;background:#2f5496;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#ffffff;font-style:italic;font-weight:bold;">Position</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:30.64%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Oren Gilad, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive officer</p></td></tr><tr style=""><td style="vertical-align:bottom;width:30.64%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">John P. Hamill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Chief Financial Officer and Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Oren Gilad, Ph.D.</span>&#160;has served as Chief Executive Officer of Aprea Therapeutics since July 2022 and as President and a member of its Board of Directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics. Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities. Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR pathway in cancer development and treatment. Dr. Gilad earned his doctorate from the University of California at Davis and his B.S. from the Hebrew University, Jerusalem, Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">John P. Hamill</span>&#160;joined Aprea in January 2023 from Windtree Therapeutics where he served as Senior Vice President and Chief Financial Officer since 2020. He brings more than 30 years of financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. He has broad-based experience in financial, administrative, information technology, and facility functions, in addition to having successfully completed IPO and follow-on offerings for several pharmaceutical companies. John has also recently provided consulting services to various life science companies, headed up finance at Trevena, Inc., where he was instrumental in successfully raising equity; NephroGenex, Inc., where he actively led the IPO and subsequent financial restructuring and sale of the company; Savient Pharmaceuticals, where he led a sale process resulting in $120 million in proceeds; and PharmaNet where he successfully completed its sale for approximately $250 million, which then became known as PharmaNet Development Group, where he directed financial and administrative operations for the company. John received a B.S. in Accounting and Business and Computer Science from DeSales University and is a certified public accountant.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Environmental Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We believe we are compliant in all material respects with applicable environmental laws. Presently, we do not anticipate such compliance will have a material effect on capital expenditures, earnings, or our competitive position with respect to any of our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in May 2019. Our corporate headquarters are located at 3805 Old Easton Road, Doylestown, Pennsylvania 18902, and our telephone number is (215) 948-4119.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our corporate website address is www.aprea.com. Information contained on or accessible through our website are not part of this Annual Report on Form 10-K, and inclusion of our website address in this annual report is an inactive textual reference only. We make our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the Securities and Exchange Commission, or SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company,&#8221; as such term is defined in Rule 12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our common stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0186f384_8dc7_4f21_a3dd_2731d40e19cf"></a><a id="Item1ARiskFactors_779731"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item 1A. Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our business is subject to substantial risks and uncertainties. Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors below together with the information contained elsewhere in this Annual Report on Form 10-K, including Part II, Item 8 &#8220;Financial Statements and Supplementary Data&#8221; and Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our other public filings in evaluating our business. Any of the risks and uncertainties described below and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward looking statements contained in this Form 10-K (please read the Cautionary Note Regarding Forward-Looking Statements in this Form 10-K).</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An investment in our securities is subject to various risks, these risks include, among others, the brief bulleted list of our principal risk factors set forth below that make an investment in our company speculative or risky.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks related to our financial position and the need for additional capital</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses in each year since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to maintain compliance with the minimum listing requirements, our common stock will be subject to delisting and our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is delisted.</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. We have never generated commercial revenues and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding, which may not be available to us on acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks related to the discovery, development and commercialization of our product candidates</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on the success of APR-1051 and ATRN-119. Our clinical trials of APR-1051 and ATRN-119 may not be successful. If we are unable to obtain approval for and commercialize APR-1051 or ATRN-119 or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are in the early stages of testing APR-1051 and ATRN-119. The results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience as a company conducting clinical trials and may be unable to complete clinical trials for any product candidates we may develop.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If serious adverse or unacceptable side effects are identified during the development of our product candidates or we observe limited efficacy of our product candidates, we may need to abandon or limit the development of one or more of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks related to our dependence on third parties</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to conduct their operations in compliance with regulatory requirements or to meet deadlines for the completion of such trials, research and studies.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks related to our intellectual property</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain intellectual property protection for our product candidates or for our technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issued patents covering our product candidates and other technologies could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to other claims challenging the inventorship of our patents and other intellectual property.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks related to regulatory and marketing approval and other legal compliance matters</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us, or any future collaborators, from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The FDA&#8217;s and other comparable regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate commercial revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recently enacted and future legislation, and any change in existing government regulations and policies, may increase the difficulty and cost for us and our future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks related to our common stock</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our executive officers, directors and principal stockholders may have substantial influence over matters submitted to stockholders for approval.</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are required to meet the Nasdaq Stock Market, or Nasdaq, continued listing requirements and other Nasdaq rules, and if we fail to meet such rules and requirements, we may be subject to delisting. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The summary risk factors described above should be read together with the text of the full risk factors below in this section entitled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; and the other information set forth in this Annual Report on Form 10-K. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to our financial position and need for additional capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses in each year since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Since our inception, we have incurred significant losses on an aggregate basis. Our net loss was $12.6 million and $13.0 million for the years ended December&#160;31,&#160;2025 and 2024, respectively. Our accumulated deficit was $333.6 million as of December&#160;31,&#160;2025. We have not generated any commercial revenue to date from sales of any drugs and have financed our operations principally through private placements and the net proceeds received from the initial public offering (IPO) of our common stock. We have devoted substantially all of our efforts to research and development. We expect that it will be several years, if ever, before we have any product candidates ready for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To become and remain profitable, we must develop, obtain approval for and eventually commercialize a drug or drugs with significant market potential, either on our own or with a collaborator. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those drugs for which we may obtain marketing approval and establishing and managing any collaborations for the development, marketing and/or commercialization of our product candidates. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if at all. If we are unable to obtain product approvals or generate significant commercial revenues, our business will be materially harmed.<span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have incurred net losses and utilized cash in operations since inception. In addition, as of December&#160;31,&#160;2025, we had approximately $14.6 million in cash and cash equivalents and expect to continue to incur significant cash outflows and incur future additional losses to execute our operating plan. While we intend to finance our cash needs principally through collaborations, strategic alliances, or license agreements with third parties and/or debt or equity financings, there is no assurance that new financing will be available to us on commercially acceptable terms or in the amounts required, if at all.&#160; Due to the uncertainty in securing additional funding, and the insufficient amount of cash and cash equivalents as of December&#160;31,&#160;2025, we have concluded that substantial doubt exists about our ability to continue as a going concern within one year after the date of the filing of this Annual Report. If we are unsuccessful in securing sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely affect our business prospects, or cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our consolidated financial statements included in this Annual Report have been prepared on a going concern basis under which an entity is able to realize its assets and satisfy its liabilities in the ordinary course of business. The consolidated financial statements do not give effect to any adjustments relating to the carrying values and classification of assets and liabilities that would be necessary should we be unable to continue as a going concern within one year after the date that the financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our future operations are dependent upon the successful entry into collaborations, strategic alliances, or license agreements with third parties and/or on the identification and successful completion of equity or debt financing and the achievement of profitable operations at an indeterminate time in the future. There can be no assurances that we will be successful in completing these collaborations or alliances, equity or debt financing or in achieving profitability. As such, there can be no assurance that we will be able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock, and it may be more difficult for us to obtain financing. If potential collaborators decline to do business with us or potential investors decline to participate in any future financings due to such concerns, our ability to increase our cash position may be limited. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations. If we are unable to continue as a going concern, you could lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. We have never generated commercial revenues and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are an early-stage company. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our product candidates, identifying potential product candidates, conducting preclinical studies of our product candidates and conducting clinical trials of our product candidates. APR-1051 and ATRN-119, are in clinical development and our other product candidates are in preclinical development. We have currently paused further patient enrollment in both the once daily and twice daily monotherapy dosing arms of ABOYA-119 and started the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale drug products, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful drug commercialization. Typically, it takes about six to ten years to develop a new drug from the time it is in Phase&#160;1 clinical trials to when it is approved for treating patients, but in many cases it may take longer. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We may need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual periods as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We will need substantial additional funding, which may not be available to us on acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Developing drug products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any such product candidate. Furthermore, since the completion of our IPO, we have incurred and expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. The recent uncertainty and volatility in financial markets which in turn may make raising additional funds even more difficult or impossible for us. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash and cash equivalents as of December&#160;31,&#160;2025 and the proceeds from our January 2026 private placement will be sufficient to meet our currently projected operating expenses and capital expenditure requirements into the first quarter of 2027. Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of our current and future clinical trials of APR-1051 and ATRN-119 and our other product candidates for our current targeted indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for APR-1051, ATRN-119 and our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, and results of exploring ATTN-119 in potential combination approaches</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or collaboration arrangements for product candidates on favorable terms, although we currently have no commitments or agreements to complete any such transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Raising additional capital may cause dilution to our stockholders and restrict our operations or require us to relinquish rights to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect our expenses to increase in connection with our planned operations. Until such time, if ever, as we can generate substantial revenues from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests in our securities may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. In addition, debt financing, if available, would result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce and/or eliminate our product candidate development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are currently operating in a period of global economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical conflicts, natural and man-made disasters, global health emergencies and uncertainties in regulatory developments and legislative actions, which could adversely affect our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our results of operations could be adversely affected by general conditions in the global economy, uncertainty from political conditions and changing regulations, and disruption of global financial markets that may result in a recession or market correction. The financial markets and the global economy may be adversely affected by the current or anticipated impact of war, terrorism and geopolitical conflicts, including in Russia and Ukraine, the Middle East and other areas. Sanctions and enhanced export controls imposed by the United States and other countries in response to such conflicts may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in regulations and policies by the U.S. administration and the resulting political and economic uncertainty in the United States may also impact us, the financial markets and the global economy. For example, in April 2025, increased tariffs were imposed on all countries and individualized &#8220;reciprocal&#8221; higher tariffs on certain countries with which the United States has the largest trade deficits, with the highest tariffs imposed on imports from China. China and other countries responded by announcing retaliatory tariffs on U.S. imports. A few days later, the tariffs imposed on most </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">countries were reduced to 10 percent, with the exception of China, for a period of 90 days to allow trade negotiations with those countries. It is unclear whether the tariff increases with China will continue to escalate. The tariff increases have significantly disrupted the global markets and may significantly escalate tensions between the U.S. and other countries, especially China. We procure APIs and other raw materials from a supplier in China . The extent of the impact that such tariffs, trade policies, or new legislation or regulations will have on our business specifically, or on the U.S. market and global economy generally, are uncertain and in the long term, unpredictable, and could adversely affect our business, financial condition, and results of operations. The continued impact of these tariffs may impair our plans for further drug development in the U.S. market as well as our ability to generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The current U.S. administration has recently issued regulations to restrict direct and indirect investment by U.S. persons into companies with specified connections to China that use specific technologies of concern. Such changes in the regulations and policies by the current U.S. administration and the resulting political and economic uncertainty materially impact our operations and those of our third-party service providers and reduce our ability to access capital, which could negatively affect our liquidity and adversely affect our business and the value of our common stock. The current U.S. administration may also enact other new regulations or policies that affect trade with China or otherwise impact the pharmaceutical industry by enacting laws to restrict U.S. pharmaceutical companies from contracting with Chinese companies on the development, research or manufacturing of pharmaceutical products. In April 2025, the U.S. Department of Commerce initiated national security investigations into the importation of pharmaceuticals and pharmaceutical ingredients pursuant to Section 232 of the Trade Expansion Act of 1962, which could result in the imposition of new tariffs on imports within the pharmaceutical industry. Further, in April 2025, an executive order to lower prescription drug prices was signed. The details of such proposed regulations and policies are unclear, and the final terms and impact remain uncertain and may pose long-term risks to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, natural and man-made disasters and global health emergencies, including pandemics and epidemics, may adversely affect the financial markets and global economy, increase inflation and result in significant business disruptions. We and our third-party services providers could be subject to the impact of natural or man-made disasters and other business disruptions, which include, but are not limited to, hurricanes, flooding, typhoons, tornados, wildfires and fires, drought, extreme heat, earthquakes, water shortages, blizzards and other extreme weather conditions, resulting in significant damage to our facilities, inventory or equipment, which could disrupt, delay or curtail our operations. Such business disruptions may also heighten the risk of power outages, telecommunications, transportation or other infrastructure failure, cybersecurity incidents or physical security breaches. The cost of insurance has increased significantly, including as a result of the impact of climate change and inflation, and we may not be able to obtain sufficient coverage at a reasonable cost to protect us against losses from such disasters and unforeseen events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The volatile business environment or continued unpredictable and unstable market conditions may result in further deterioration of the equity and credit markets, significant volatility in commodity prices, as well as supply chain interruptions and result in an economic downturn, which would make any equity or debt financing more difficult, costly and dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, limit, reduce, or terminate our product development or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although our business has not been materially impacted by the tariffs adopted to date or adverse effects of geopolitical events, natural or man-made disasters or other business disruptions to date, such matters may affect our business in the future and it is impossible to predict the extent to which our operations, or those of our suppliers and manufacturers, will be impacted in the short and long term, or the ways in which such matters may impact our business. The extent and duration of such adverse geopolitical events, natural or man-made disasters or other business disruptions and actual or perceived political or economic instability and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages, government shutdowns or global health emergencies, their inability to hire, retain or deploy key leadership and other personnel, a high turnover of key leadership positions, or significant changes in policies and processes based on political considerations could prevent products from being developed, approved or commercialized in a timely manner or at all or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The ability of the FDA and other government agencies to review and approve products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, a government agency&#8217;s ability to hire and retain key personnel and accept the payment of user fees, high turnover in key leadership positions, and other events that may otherwise affect the government agency&#8217;s ability to perform routine functions. Average review times at the FDA and other government agencies have fluctuated in recent years as a result. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and SEC, have had to furlough critical employees and stop critical activities. In addition, government funding of agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Such disruptions at the FDA and other agencies may also increase the time necessary for new therapies or modifications to approved therapies to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The political and economic environment in the United States could materially impact our business operations and financial performance, and uncertainty surrounding the potential legal, regulatory and policy changes by the U.S. administration may directly affect us and the global economy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The political and economic environment in the United States and elsewhere has resulted in and will continue to result in some uncertainty. Changing regulatory policies because of the changing political environment could impact our regulatory and compliance costs and future revenues, all of which could materially and adversely affect our business, financial condition and operating results. For example, significant layoffs or turnover at FDA could affect the FDA&#8217;s ability to respond to regulatory filings. High turnover of key FDA leadership positions could result in regulatory inconsistency and unpredictability that may undermine product development and approval. Failure to adapt to or comply with evolving regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation, ability to do business with certain partners, access to capital and our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, the current U.S. administration and congressional seat turnover may result in increased regulatory and economic uncertainty. Changes in federal policy by the executive branch and regulatory agencies may occur over time through the new presidential administration&#8217;s and/or Congress&#8217;s policy and personnel changes, which could lead to changes involving the level of oversight and focus on the pharmaceutical industry; however, the nature, timing and economic and political effects of such potential changes remain highly uncertain. Any future changes in federal and state laws and regulations, as well as the interpretation and implementation of such laws and regulations, could affect us in substantial and unpredictable ways. At this time, it is unclear what laws, regulations and policies may change and whether future changes or uncertainty surrounding future changes will adversely affect our operating environment and therefore our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. If any of our counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, if any parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected. In this regard, counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of SVB and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by parties with whom we conduct business, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a party with whom we conduct business may fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy. Any bankruptcy or insolvency, or the failure to make payments when due, of any counterparty of ours, or the loss of any significant relationships, could result in material losses to us and may material adverse impacts on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks related to the discovery, development and commercialization of our product candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are substantially dependent on the success of APR-1051 and ATRN-119</span> <span style="font-style:italic;font-weight:bold;">which are in clinical development. Our clinical trials of APR-1051 and ATRN-119 may not be successful. If we are unable to obtain approval for and commercialize APR-1051 and ATRN-119 or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have no products approved for sale. Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, ATRN-119 and APR-1051. We are investing a majority of our efforts and financial resources in the research and development of ATRN-119 and APR-1051. Our business depends entirely on the successful development and commercialization of our product candidates. We currently have no drugs approved for sale and generate no revenues from sales of any products, and we may never be able to develop a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product candidates will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market commercially or promote any of our product candidates in the U.S. before we receive marketing approval from the FDA, and in other jurisdictions subject to marketing authorization from comparable foreign regulatory authorities, and we may never receive such marketing approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The success of APR-1051 and ATRN-119 will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful patient enrollment and timely completion of clinical trials of APR-1051 and ATRN-119;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful initiation and successful patient enrollment and completion of additional clinical trials, for APR-1051 or ATRN-119 or our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">While we are currently considering further ATRN-119 development in combination approaches that could expand its therapeutic potential, we may be unable to advance development of ATRN-119 in combinations in a timely manner, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to demonstrate APR-1051&#8217;s and ATRN-119&#8217;s safety and efficacy to the FDA or any comparable foreign regulatory authority for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely receipt of marketing approvals for APR-1051 and ATRN-119;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully defending and enforcing our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avoiding and successfully defending against any claims that we have infringed, misappropriated or otherwise violated any intellectual property of any third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of our future collaborators, if any;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent of, and our ability to timely complete, any post-marketing approval commitments or requirements imposed by FDA or other applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully developing a companion diagnostic test on a timely and cost effective basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of supply arrangements with third-party raw materials and drug product suppliers and manufacturers who are able to manufacture clinical trial and commercial quantities of APR-1051 and ATRN-119 drug substance and drug product and to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP, at a scale sufficient to meet anticipated demand and over time enable us to reduce our cost of manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of scaled production arrangements with third-party manufacturers to obtain finished products that are compliant with cGMP and appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety and efficacy profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with other therapies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not have control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of our product candidates. If we are not successful in commercializing APR-1051 or ATRN-119, or are significantly delayed in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are in the early stages of testing APR-1051 and ATRN-119 in Phase 1 clinical trials and we have not tested APR-1051 or ATRN-119 in later phase clinical trials. The results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are in the early stages of testing APR-1051 and ATRN-119 in clinical trials and we have not tested APR-1051 or ATRN-119 in later phase clinical trials. The results of preclinical studies, whether or not conducted by us, may not be predictive of the results of clinical trials, and the results of the early-stage clinical trials that we are conducting today and that we may commence in the future may not be predictive of the results of the later-phase clinical trials. For example, even if successful, the results of our Phase 1 clinical trials of our product candidates APR-1051 and ATRN-119 and other product candidates may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed on in later stage clinical trials. In particular, the small number of patients in our current and planned early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain marketing licensure of their product candidates. Our current and future clinical trials for APR-1051 and ATRN-119 may not ultimately be successful or support further clinical development. There is a high failure rate for product candidates proceeding through clinical trials. In addition, with the current pause on further patient </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have filed and obtained issuance of INDs for APR-1051 and ATRN-119, but we may not be able to file and obtain issuance of INDs that may be required for our other product candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that lead FDA, IRBs, or other authorities to suspend, terminate, or require changes to our clinical trials. Additionally, even if such regulatory and other authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials and changes to existing clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file and obtain issuance of INDs on the timelines we expect or to obtain regulatory clearance or approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We&#160;have&#160;limited&#160;experience&#160;as&#160;a&#160;company&#160;conducting&#160;clinical&#160;trials&#160;and may be unable to complete pivotal clinical trials for any product candidates we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our success is dependent upon our ability to initiate and successfully complete clinical trials and obtain regulatory approval for and commercialization of our product candidates. We have not demonstrated an ability to perform the functions necessary for the approval or successful commercialization of any product candidate. The successful commercialization of any product candidate may require us to perform a variety of functions, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing to undertake preclinical development;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designing and obtaining approval to commence clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully planning and enrolling subjects in clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully completing clinical trials to obtain data that support regulatory approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participating in regulatory approval processes;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing products; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting sales and marketing activities</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">While we have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics, we have limited experience designing, conducting and enrolling subjects in clinical trials. While certain members of our management and staff have significant experience in conducting clinical trials, to date, we have not completed any clinical trials as a company. Our operations to date provide a limited basis to assess our ability to develop and commercialize our product candidates. In addition, with the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Because of this lack of experience, any future clinical trials we may conduct may not be completed on time, if at all. Large-scale trials require significant financial and management resources, monitoring and oversight, and may require reliance on third-party clinical investigators, consultants or contract research organizations, or CROs. Relying on third-party clinical investigators, CROs and manufacturers, which are all also subject to governmental oversight and regulations, may also cause us to encounter delays that are outside of our control. Failure to commence or complete, or delays in, clinical trials, could prevent us from or delay us in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials and our ability to enroll eligible patients and maintain their enrollment may be limited or may result in slower enrollment than we anticipate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment may be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment may also be affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved drugs for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient eligibility criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; and clinicians&#8217; perceived risks and benefits of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials or compassionate use programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians&#8217; attitudes and practices with respect to clinical trial enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued enrollment of prospective patients by clinical trial sites; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our inability to enroll a sufficient number of patients for our clinical trials and maintain their enrollment would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leveraging synthetic lethality in therapeutic targeting of DDR represents an emerging strategy to treat a broad spectrum of cancers, and negative perceptions of the efficacy, safety, or tolerability of this class of targets, including any that we develop, could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">Aside from PARP inhibitors, such as Lynparza, Rubraca, Zejula and Talzenna, no synthetic lethality small molecule inhibitor therapeutics have been approved to date by the FDA. Pamiparib, a PARP inhibitor developed by Beigene, was approved in 2021 in China. Adverse events in future clinical trials of our product candidates or in clinical trials of other similar products and the resulting publicity, as well as any other adverse events in the field of synthetic lethality and DDR, or any adverse events involving other products that are perceived to be similar to DDR, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by healthcare professionals, patients and CROs in our product candidates, difficulties and delays in regulatory clearance or approval for, enrollment of patients in, and conduct of, our clinical trials, and less demand for any product that we may develop. Our pipeline of product candidates could experience a greater quantity of reportable adverse events or other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delays or holds by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our product development programs, as well as our business as a whole. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">In addition, responses by U.S. federal or foreign governments to adverse events or negative public perception may result in new legislation or regulations that could limit our ability to develop any product candidates or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects, and may delay or impair the development of our product candidates and commercialization of any approved products or demand for any products we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">If serious adverse or unacceptable side effects are identified during the development of our product candidates or we observe limited efficacy of our product candidates, we may need to abandon or limit the development of one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adverse events or unacceptable side effects caused by, or other unexpected properties of, our product candidates could cause us, any future collaborators, an institutional review board, or IRB, ethics committee, or EC, or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in the (i)&#160;delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities, (ii)&#160;approval with significant restrictions on distribution or use or (iii)&#160;required labeling information regarding safety concerns, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In general, our clinical trials of APR-1051 and ATRN-119 will or currently include cancer patients who are very sick and whose health is deteriorating. We expect that patients may experience adverse events, serious adverse events or may die during their participation in our current or future clinical trials for APR-1051 and ATRN-119 or other product candidates. We cannot predict with certainty what adverse events may occur in our clinical trials. Any adverse events, serious adverse events, or deaths occurring in our clinical trials, whether related to our product candidates or not, could affect perceptions relating to our product candidates. In addition, our previous clinical trials of eprenetapopt included cancer patients who were very sick and whose health was deteriorating, and we expect that additional clinical trials of eprenetapopt and our other product candidates would include similar patients with deteriorating health. Multiple patients in these trials have experienced adverse events. The most commonly reported adverse events include nausea, vomiting, constipation, dizziness, fatigue, and neutropenia. Some patients in these trials have experienced serious adverse events. The most common serious adverse events include febrile neutropenia, pneumonia, sepsis, and pyrexia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, if any of our product candidates are associated with adverse events or undesirable side effects or have properties that are unexpected, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. We, or any future collaborators, may abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Drug-related side effects could affect patient </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, results of operations, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We currently have no drugs approved for sale and we cannot guarantee that we will ever have marketable drugs. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any future collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. Additionally, with the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all. We will be required to demonstrate with substantial evidence through adequate and well-controlled clinical trials that our product candidates are safe and effective for use in treating specific conditions in order to obtain marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Product candidates that have shown promising results in preclinical studies and early-stage clinical trials may still suffer significant setbacks in subsequent later-stage clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials. Further, in our oncology clinical trials to date, we have used achievement of stable disease as evidence for disease control (stable disease, partial response or complete response) by our product candidates; however, the FDA does not view stable disease as an objective response for the purposes of FDA approval. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish or report interim or preliminary data from our clinical trials. Interim or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the design of a clinical trial can determine whether its results will support approval of a drug and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and conduct a clinical trial to support marketing approval. Further, if our product candidates are found to be unsafe or lack efficacy, we will not be able to obtain marketing approval for them and our business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in preclinical studies and earlier clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, in the event that a safety issue, clinical hold, or other adverse finding occurs in one of our clinical trials, that event could adversely affect any other clinical trials for the same product candidate. Moreover, there is a relatively limited safety data set for product candidates with the same mechanism of action as APR-1051, ATRN-119 or our other product candidates. An adverse safety issue or other adverse finding in a clinical trial conducted by a third party with a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">similar mechanism of action could adversely affect clinical trials involving APR-1051, ATRN-119 or our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, our product candidates may not be approved even if they achieve their primary endpoints in clinical trials, including registration trials. The FDA or comparable foreign regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in approval by the FDA or comparable foreign regulatory authorities. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. In addition, the FDA or other comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Before obtaining marketing approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA and elsewhere to the satisfaction of other comparable foreign regulatory authorities, that the product candidate is safe and effective for use for that target indication. There is no assurance that the FDA or other comparable foreign regulatory authorities will consider our future clinical trials to be sufficient to serve as the basis for approval of one of our product candidates for any indication. The FDA and other comparable foreign regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that a product candidate is safe and effective. If we are required to conduct additional clinical trials of a product candidate than we expect prior to its approval, we will need substantial additional funds and there is no assurance that the results of any such additional clinical trials will be sufficient for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical drug development is a lengthy and expensive process, with an uncertain outcome. If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs, experience delays in completing, or ultimately be unable to complete, the development of our product candidates or be unable to obtain marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Additionally, with the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not know whether ongoing clinical trials will be completed on schedule or at all, or whether future clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory authorization to commence a trial;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board, or IRB, or ethics committee, or EC, approval at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any outbreak or pandemic on patient screening, patient enrollment, and follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to comply with the clinical trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites failing to comply with the clinical trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deviations from approved clinical trial protocols that may occur; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any conflicts with new or existing laws or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need to add new clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of product candidate for use in clinical trials and ensuring clinical trial material is provided to clinical sites in a timely manner; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining advice from regulatory authorities regarding the statistical analysis plan to be used to evaluate the clinical trial data or other trial design issues.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors, including our CROs, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, our investigators, or any of the overseeing IRBs or ethics committees might decide to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any future collaborators that conduct clinical trials may face any of the above issues and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are insufficiently positive to support marketing approval, or if there are safety concerns, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval in some countries and not in others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for indications or patient populations that are narrower or more limited in scope than intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval subject to significant use or distribution restrictions or with labeling that includes significant safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the drug removed from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Furthermore, we rely on third-party CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring drugs to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate<span style="font-style:italic;font-weight:bold;">.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are required to in the future and if we are unable to successfully develop companion diagnostic tests for our product candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may be required by the FDA to develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for certain indications. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA approval for companion diagnostic tests on our own, we will require additional personnel. We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that require such tests. If these parties are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. Any failure to successfully develop this companion diagnostic may cause or contribute to delayed enrollment of this trial, and may prevent us from initiating or completing further clinical trials to support marketing approval for our product candidates. As a result, our business, results of operations and financial condition could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We may not be successful in our efforts to identify or discover additional potential product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research methodology used may not be successful in identifying potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be safe or effective in treating their targeted diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less safe or effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any future collaborators, to market the drug could be compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Clinical trials of our product candidates must be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing approval and we, or others, discover that the drug is less safe or effective than previously believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the drug or seize the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drug may become less competitive in the marketplace; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well-established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from sales of drugs and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential advantages of the product compared to alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the product is designated under physician and other provider treatment guidelines as a first-, second- or third-line therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product&#8217;s convenience and ease of administration for patients and healthcare practitioners compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try, and of physicians to prescribe, the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings, including distribution or use restrictions and safety information contained in the product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of sales, marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for the product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage by, and the amount of reimbursement from, government payors, managed care plans and other third-party payors.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries generally, and the cancer drug sector specifically, are highly competitive and characterized by rapidly advancing technologies, evolving understanding of disease etiology and a strong emphasis on proprietary new drugs. We face competition with respect to APR-1051, ATRN-119 and our other product candidates, and will face competition with respect to any product candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies. There are a number of major pharmaceutical, specialty pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drugs for the treatment of cancer. Potential competitors also include academic institutions and governmental agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are a large number of companies developing or marketing treatments for cancer, including the indications for which we may develop product candidates. Many of the companies that we compete or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other comparable foreign regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently-approved drug therapies are branded and subject to patent protection and may be established as the standard of care for treatment of indications for which we may choose to seek regulatory approvals. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors, and, even if our product candidates were to be approved, there can be no assurance that our product candidates would displace existing treatments. In addition to currently marketed therapies, there are also a number of drugs in late-stage clinical development to treat cancer, including the indications for which we are developing product candidates. These clinical-stage product candidates may provide efficacy, safety, tolerability, convenience and other benefits that are not provided by currently-marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are developing APR-1051, which is an orally bioavailable small molecule inhibitor of WEE1, a key regulator of multiple phases of the cell cycle. We are aware of other product candidates that are in preclinical and clinical development for the treatment of various cancers through similar mechanisms of action, including product candidates developed by Zentalis Pharmaceuticals, Debiopharm, IMPACT Therapeutics, Schrodinger and Acrivon Therapeutics, among others. If APR-1051 were to be approved, it will compete with currently marketed drugs or drugs that may be approved for marketing by the FDA or comparable foreign regulatory authorities in the future and such competition will not be limited to drugs with similar mechanisms of action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are also developing ATRN-119 which is an orally bioavailable small molecule product candidate that targets Ataxia ATR protein within the DNA damage response pathway. We are aware of other product candidates that are in clinical development for the treatment of various cancers through similar mechanisms of action, including product candidates in clinical development being tested by Artios Pharma Ltd., AstraZeneca Plc, Bayer AG, IMPACT Therapeutics, Inc., and Xeno Therapeutics (formerly Repare Therapeutics, Inc.), among others. If ATRN-119 were to be approved, it will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">compete with currently marketed drugs or drugs that may be approved for marketing by the FDA or comparable foreign regulatory authorities in the future and such competition will not be limited to drugs with similar mechanisms of action. With the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Our business and operations would suffer in the event of IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in our or our third-party vendors&#8217; information security program or defenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Our business relies upon information technology systems operated by us and by our third party service providers. These systems may fail or experience operational disruption, experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have developed, and continue to mature our policies and procedures to ensure the security and integrity of our information technology systems and confidential and proprietary information. If we do not continue to mature our cybersecurity defensive technological safeguards, policies and procedures or those safeguards, policies and procedures are insufficient to ensure the protection of our information technology systems and confidential and proprietary information, we may be vulnerable to security breaches or disruptions and system breakdowns or other damage or interruptions, and face legal and reputational risk. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors and other contractors and consultants who have access to or store our confidential information.  While we endeavor to select providers with reasonable and industry standard information security programs, we are reliant on these third-party vendors&#8217; commitments regarding their information technology systems and cybersecurity programs. If our third-party vendors fail to protect their information technology systems and our confidential and proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information and we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed. While we have not, to our knowledge, experienced any material IT system failures or cybersecurity attacks to date, we frequently must defend against and respond to cybersecurity incidents and attacks and cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, compromises of personal information or confidential commercial information, other operationally significant breaches in our systems or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary information. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or vulnerabilities to our or our third-party vendors&#8217; information security programs or defenses could result in legal liability, reputational damage, business interruption, and our competitive position could be harmed and the further development and commercialization of our products or any future products could be delayed or disrupted. Moreover, containing and remediating any IT system failure, cybersecurity attack or vulnerability may require significant investment of resources. Furthermore, significant security breaches or disruptions of our internal information technology systems or those of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of pharmaceutical drugs. We are not currently a party to a strategic collaboration that provides us with access to a collaborator&#8217;s resources </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in selling or marketing drugs. To achieve commercial success for any approved drug for which sales and marketing is not the responsibility of any strategic collaborator that we may have in the future, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a sales and marketing infrastructure to market or co-promote some of our product candidates if and when they are approved, or enter into collaborations with respect to the sale and marketing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any commercial launch of a product candidate. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or restrictions on the ability of sales personnel to appropriately market the product to physicians or other healthcare professionals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we enter into arrangements with third parties to perform sales and marketing services, our revenues from the sale of drugs or the profitability of these revenues to us are likely to be lower than if we were to market and sell any drugs that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. Third parties may also fail to devote the necessary resources and attention to sell and market our product candidates effectively and we may not have sufficient control or oversight over third parties to ensure they sell and market our product candidates in compliance with all applicable law. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data or market exclusivity before approving generic versions of our product candidates, the sales of our product candidates could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Once an NDA is approved, the drug covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials demonstrating safety and efficacy. Rather, the applicant generally must show that its drug is pharmaceutically equivalent to the reference listed drug, in that it has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug, and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic drugs may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">drugs are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent regulatory exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of data exclusivity for a new drug containing a new chemical entity, or NCE. During the data exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2)&#160;NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year marketing exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent for other conditions of use. Five-year data exclusivity and three-year marketing exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch these generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for our drug competition that our product candidates may face from generic versions of our product candidates could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our product candidates, if and when approved, are not afforded the appropriate periods of non-patent exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval of any product candidate, the approved product may be subject to post-approval studies and will remain subject to ongoing regulatory requirements. If we fail to comply, or if concerns are identified in subsequent studies, our approval could be withdrawn, and our product sales could be suspended.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we are successful at obtaining regulatory approval for APR-1051, ATRN-119, or any of our other product candidates, regulatory agencies in the United States and other countries where a product will be sold may require extensive additional clinical trials or post-approval clinical trials that are expensive and time-consuming to conduct. With the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all. These trials may reveal side effects or other harmful effects in patients that use our products after they are on the market, which may result in the limitation or withdrawal of our drugs from the market. Alternatively, we may not be able to conduct such additional trials, which might force us to abandon our efforts to develop or commercialize certain product candidates. Even if post-approval studies are not requested or required, after our products are approved and on the market, there might be safety issues that emerge over time that require a change in product labeling, additional post-market studies or clinical trials, imposition of distribution and use restrictions under a Risk Evaluation and Mitigation Strategy, or REMS, or withdrawal of the product from the market, which would cause our revenue to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, any products that we may successfully develop will be subject to ongoing regulatory requirements after they are approved. These requirements will govern the manufacturing, packaging, marketing, distribution, and use of our products. If we fail to comply with such regulatory requirements, approval for our products may be withdrawn, and product sales may be suspended. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations, third-party coverage and reimbursement policies or healthcare reform initiatives, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern marketing approval, pricing, coverage and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our ability to commercialize any products successfully also will depend in part on the extent to which reimbursement and coverage for these products and related treatments will be available from government authorities, private health insurers and other organizations, and if reimbursement and coverage is available, the level of reimbursement and coverage. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for medical products. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if coverage and reimbursement are available, we cannot be sure as to the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, may be incorporated into existing payments for other items or services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new products that we develop and for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any drugs that we may develop. Our insurance policies may be inadequate and may potentially expose us to unrecoverable risk.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ourselves against claims that our product candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or drugs that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any drugs that we may develop.</span></td></tr></table><div style="margin-top:12pt;"><a id="_cp_text_1_244"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently hold clinical trial liability insurance coverage for up to $5.0&#160;million, but that coverage may not be adequate to cover any and all liabilities that we may incur. We would need to increase our insurance coverage when we begin the commercialization of our product candidates, if ever. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues from the sales of our products, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In some countries, particularly member states of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our future collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reactivation of p53 is a novel and unproven therapeutic approach and our development of eprenetapopt may never lead to a marketable product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that mutant p53 still has the potential to be an attractive target for novel cancer therapy due to the high incidence of p53 mutations across a range of cancer types and the universally inferior prognosis for cancer patients with mutated p53. However, to our knowledge, no one has advanced a product candidate with this mechanism of action into the market. The scientific evidence to support the feasibility of developing these product candidates is both preliminary and limited. For instance, even though eprenetapopt has shown promising results in preclinical studies and early-stage clinical trials, we may not succeed in demonstrating safety and efficacy of eprenetapopt in larger-scale clinical trials. In December 2020, we announced that our pivotal Phase 3 trial failed to meet its predefined primary endpoint of complete remission (CR) rate. On August 4, 2021, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the clinical trials of eprenetapopt in combination with azacitidine in our myeloid malignancy programs. On August 11, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021, the FDA placed a clinical hold on our clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. In the first quarter of 2022, FDA notified us that it would continue the partial clinical hold on three ongoing clinical studies in our myeloid program. However, we received clearance from FDA to proceed under our existing IND with a new trial in R/R MDS and AML.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Given these results, FDA feedback and the costs of continuing the p53 reactivator development programs, we have shifted our primary focus of our activities to the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality. Advancing eprenetapopt as a novel product to reactivate p53 creates significant challenges for us, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining marketing approval, as obtaining regulatory approval of a p53 reactivator from the FDA or comparable foreign regulatory authorities has never been done before;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthening and extending the duration of the IP protection of the p53 reactivator; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing the sale and marketing capabilities to gain market acceptance, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">Risks related to our dependence on third parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to conduct their operations in compliance with regulatory requirements or to meet deadlines for the completion of such trials, research and studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and expect to continue to rely upon third parties to conduct additional clinical trials. We currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our drug development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan, study protocols for the trial, statistical analysis plan and other study-specific documents (for example, monitoring and blinding plans). Moreover, the FDA requires us to comply with standards, commonly referred to as GCP,&#160;International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines, and regulations regarding the informed consent process, safety reporting requirements, data collection guidelines, and other regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA, also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP and other applicable regulations. In addition, our clinical trials must be conducted with product produced under current Good Manufacturing Practices, or cGMP, regulations. Our failure to comply with these regulations may require us to conduct new clinical trials, which would delay the marketing approval process. We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of such third parties could delay clinical development or marketing approval of our product candidates or commercialization of our product candidates, producing additional losses and depriving us of potential revenue from sales of drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Although we currently plan to retain all commercial rights to our product candidates, we may enter into strategic collaborations for the development, marketing and commercialization of our product candidates. If those collaborations are not successful, the development, marketing and/or commercialization of our product candidates that are the subject of such collaborations would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we further develop our product candidates, we may build a commercial infrastructure with the capability to directly market it to a variety of markets and geographies. Although we currently plan to retain all commercial rights to our product candidates, we may enter into strategic collaborations for the development, marketing and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development, marketing and/or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Collaborations involving our product candidates would pose the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development, marketing and/or commercialization of our product candidates or may elect not to continue or renew development, marketing or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our product candidates or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and distribution of such drug or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly obtain, maintain, defend and enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may learn about our discoveries, data, proprietary information, trade secrets, or compounds and use this knowledge to compete with us in the future; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are currently dependent on a single third party manufacturer for the manufacture of the active pharmaceutical ingredient for our product candidates. This reliance on a single third party increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not have any manufacturing facilities or personnel, and we currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently contract with third parties for the manufacture of our product candidates for certain preclinical trials and clinical trial materials, including raw materials and consumables necessary for their manufacture, consistent with applicable cGMP requirements. We intend to continue to contract for these materials in the future, including commercial manufacture if our product candidates receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The API and drug product for our product candidates is currently manufactured by a single contract manufacturer. Although we may do so in the future, we do not currently have arrangements in place for redundant supply of the API and drug product for our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to rely on third-party manufacturers or third-party collaborators for the manufacture of our product candidates for commercial supply of any of our product candidates for which we or any of our future collaborators obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of the third party to manufacture our product candidate according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach by the third-party contractors of our agreements with them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of third-party contractors to comply with applicable regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of the third party to manufacture our product candidates according to our specifications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible mislabeling of clinical supplies, potentially resulting in issues including the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or the EMA pursuant to inspections that will be conducted after we submit our NDA to the FDA or our MAA to the EMA. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory bodies, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have complete control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, the EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not currently have arrangements in place for redundant supply of the API of our product candidates. If our current contract manufacturer cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to our intellectual property </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain intellectual property protection for our product candidates or for our technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our product candidates as well as other technologies that are important to our business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The chemical structure of eprenetapopt is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of eprenetapopt and will not in the future own or license any composition of matter patents claiming the chemical structure of eprenetapopt as described in the public domain. Our patent portfolio for eprenetapopt currently consists of method-of-use and formulation patent claims, and dosing, manufacturing processes, crystalline solid form, and combination therapy patent application claims. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. Any failure to obtain or maintain patent protection with respect to eprenetapopt and our other product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects. If it is later determined that our activities or product candidates infringe, misappropriate or otherwise violate the intellectual property of third parties we may be liable for damages, enhanced damages or subjected to an injunction, any of which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our patent portfolio for our portfolio of DDR inhibitors, including our WEE1 and ATR programs, currently includes compositions of matter, pharmaceutical compositions, and methods of use patent claims. Our existing patents and any future patents we may obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. Any failure to obtain or maintain patent protection with respect to our portfolio of DDR inhibitors could have a material adverse effect on our business, financial condition, results of operations and growth prospects. If it is later determined that our activities or product candidates infringe, misappropriate or otherwise violate the intellectual property of third parties we may be liable for damages, enhanced damages or subjected to an injunction, any of which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. During the course of business, we have decided not to pursue certain products or processes and have not pursued certain corresponding intellectual property. However, we may decide to pursue such products or processes again in the future. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which many legal principles remain unresolved. In recent years patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art, including our own previously filed patent applications and scientific publications, allow our inventions to be patentable over the prior art. We are aware of certain scientific publications by our inventors and other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">third parties that disclose subject matter relating to certain of our patents, that may be used by third parties to challenge the validity and enforceability of our patents and patent applications. If such third parties are successful, we could lose valuable patent rights. In the United States, an inventor&#8217;s own publication cannot be used as prior art to the inventor&#8217;s patent application on the same subject matter when published less than one year before the effective filing date of the patent application. Such a publication may be considered prior art in certain jurisdictions that do not provide such a grace period. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the U.S. Patent and Trademark Office, or USPTO, might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, certain of these parties have and others may in the future breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the patent claims of our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, some of our owned patents and patent applications may in the future be co-owned with third parties. If we do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our co-owned patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, which may be extended due to epidemic or pandemic disease outbreaks, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions based on patent exclusivity. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our proprietary position for eprenetapopt depends upon patents that consist of formulation patent claims, which may not prevent a competitor or other third party from using the same product candidate for another use or in another formulation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Composition-of-matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to be the favored form of intellectual property protection for drug products because such patents may provide protection without regard to any particular method of use or manufacture or formulation of the API used. The chemical structure of eprenetapopt is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of eprenetapopt and will not in the future own or license any composition of matter patents claiming the chemical structure of eprenetapopt as described in the public domain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method-of-use patent claims protect the use of a product for the specified method and dosing or formulation patent claims cover dosing regimens or formulations of the API. These types of patent claims do not prevent a competitor or other third party from marketing an identical API for an indication that is outside the scope of the method claims or from developing a different dosing regimen or formulation that is outside the scope of the dosing or formulation claims. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, there are numerous publications and other prior art that may be relevant to our patents and may be used to challenge the validity of such patents in litigation or other intellectual property-related proceedings. If such challenges are successful, our patents may be narrowed or found to be invalid and we may lose valuable intellectual property rights. Any of the foregoing could have a material adverse effect on our business, financial conditions and results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issued patents covering our product candidates and other technologies could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we seek to enforce a patent covering our product candidates or other technologies against a third party, that third party could assert that such patent is invalid or unenforceable. In patent litigation in the United States, challenges to validity or enforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of novelty, obviousness, inadequate written description, indefiniteness, or lack of enablement. Grounds for an unenforceability assertion could be an allegation that relevant information was withheld from or a misleading statement was made to the USPTO during prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include preissuance submission of prior art to the USPTO and re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (<i style="font-style:italic;">e.g.</i>, opposition proceedings). Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, an inventor&#8217;s own publication may not be effective prior art to the inventor&#8217;s patent application on the same subject matter when published less than one year before the effective filing date of the patent application. Such a publication might be considered prior art in certain jurisdictions that do not provide such a grace period. For those non-US jurisdictions, reliance on non-patent exclusivity may provide sufficient competitive protection to exclude others from commercializing generic versions of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">We may be subject to other claims challenging the inventorship of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may also be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension or data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and growth prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, rights that may be necessary to our product candidates or other technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The growth of our business may depend in part on our future ability to acquire or in-license any relevant third-party proprietary rights that we may identify as necessary or important to our business operations. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. These pharmaceutical compounds may be covered by intellectual property rights held by others. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license such third-party intellectual property rights. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe, misappropriate or otherwise violate intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license to such intellectual property rights, any such license may be non-exclusive, which may allow our competitors access to the same technologies licensed to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, we sometimes collaborate with academic institutions and clinical research organizations to accelerate our research or development under written agreements with these institutions and organizations. In certain cases, these institutions and organizations may own or jointly own with us inventions that are created under such collaborations and provide us with an option to negotiate a license to any of the institution&#8217;s rights in such inventions. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution or organization may offer the intellectual property rights to others, potentially blocking our ability to pursue our program and allowing third parties to compete with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. If we are unable to successfully obtain rights to third-party intellectual property that may be necessary, we may have to abandon development of such program and our business, results of operations, financial condition and prospects could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent regardless of whether another inventor had made the invention earlier. In March&#160;2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files&#160;a patent application in the USPTO after March&#160;2013, but before us, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patents or patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes</i> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, all of which could have a material adverse effect on our business and financial condition. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents, or we may be required to defend against claims of infringement. In addition, our patents also may become involved in inventorship, priority, validity or unenforceability disputes. To counter or defend against such claims can be expensive and time consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. For example, in an infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the third party on the ground that such third party&#8217;s activities do not infringe our owned patents, including finding that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;&#160;271(e)(1). Even if resolved in our favor, these lawsuits are expensive and would consume time and other resources, including distracting our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may not be able to detect infringement against our patents which may be more difficult for formulation patents. Even if we detect infringement by a third party of our patents, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce our patents against such third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If another party questions the patentability of any of our claims in our U.S. patents, the third party can request that the USPTO review the patent claims such as in an <i style="font-style:italic;">inter partes</i> review, <i style="font-style:italic;">ex parte</i> re-exam or post-grant review proceedings. These proceedings are expensive and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in the European Patent Office, or EPO, or similar proceedings in other foreign patent offices, where either our foreign patents are challenged. The costs of these opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are sued for infringing, misappropriating or otherwise violating patents or other intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot guarantee that our product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our product candidates infringe the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If a third party claims that we infringe its intellectual property rights, we may face a number of issues even if we believe such claims are without merit, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate, may divert our management&#8217;s attention from our core business and may impact our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates or from using our proprietary technologies, unless the third party licenses its patent rights to us, which it is not required to do;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates or such license is only available on a non-exclusive basis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an <i style="font-style:italic;">ex-parte</i> re-exam, <i style="font-style:italic;">inter partes</i> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights with patents throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive, and the laws of some foreign countries may not protect our rights to the same extent as the laws of the United States. Competitors may use our technology in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings to enforce our intellectual property rights or proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business and could put our patents at risk of being invalidated or interpreted narrowly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and growth prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends upon compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent prosecution process and following the issuance of a patent. In some cases, an inadvertent failure to comply with such requirements can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance could result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case if our patent were in force, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although no claims against us are currently pending, we may be subject to claims that these employees, consultants or advisors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their current or former employers. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our platform technology and discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with parties who have access them, such as our employees, consultants, and outside scientific advisors, contractors and collaborators, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, our competitors or other third parties may independently develop equivalent knowledge, methods and know-how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts inside and outside the United States sometimes are less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. If any of our trade secrets were determined to be lawfully obtained or independently developed by a competitor or other third party, we may not be able to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position, business, results of operations and prospects would be materially and adversely harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Intellectual property rights do not necessarily address all potential threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make or use compounds that are similar to the pharmaceutical compounds used in our product candidates but that are not covered by the claims of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the APIs in our current product candidates will eventually become commercially available in generic drug products, and no patent protection may be available with regard to formulation or method of use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future licensors or collaborators, might not have been the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by our issued patents or pending patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our current or future pending or licensed patent applications will not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that public disclosures or publications, including disclosures or publications made by us, could be used in an attempt to invalidate our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that others may circumvent our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of our issued patents or patent applications, if and when issued, may not cover our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventors of our patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have engaged in scientific collaborations in the past and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to pursue patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently obtain a patent covering such intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If trademarks, brand names and trade names are not adequately protected or available, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may rely on trademarks, service marks, tradenames and brand names. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, any registered or unregistered trademarks or trade names that we currently have or may in the future acquire may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to regulatory and marketing approval and other legal compliance matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, extraneous factors, including an epidemic or pandemic disease outbreak, or other public health situations, could impact the timeline for FDA and comparable foreign regulatory authorities to review an application for one of our product candidates. It is possible that the FDA and comparable foreign regulatory authorities may refuse to accept for filing and substantive review any new drug applications, or NDAs, marketing authorization applications, or MAA, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA, or comparable foreign regulatory authorities do not accept or approve our NDAs or MAAs for our product candidates, it may require that we conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other regulatory authority-required studies, approval of any NDA, MAA or other application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA or comparable foreign regulatory authorities to approve our NDAs or our MAAs. The current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, may further extend the time required to obtain approval by the FDA and comparable foreign regulatory authorities for ATRN-119.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us, or any future collaborators, from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drugs are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, whose laws and regulations may differ from country to country. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other countries until we or they receive approval of an NDA from the FDA or marketing approval from comparable foreign regulatory authorities. Our product candidates are in early stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is a lengthy, expensive and uncertain process. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other comparable foreign regulatory authorities have substantial discretion and may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive marketing approval, or marketing approval for our product candidates could be limited or delayed, for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission and applications or to obtain marketing approval in the United States or elsewhere;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve any companion diagnostics that may be required in connection with approval of our therapeutic product candidates</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or the applicable foreign regulatory agency may fail to approve the formulation, labeling and/or the specifications for our product candidate</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted drug application; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the current voluntary pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to collaborate successfully with third parties as needed for the potential development of ATRN-119 in combinations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain marketing approval to market APR-1051 or ATRN-119, which would significantly harm our business, results of operations and prospects. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other studies and testing. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any collaborators we may have in the future, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any collaborators we may have to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell our product candidates in the EU and many other jurisdictions, we, and any collaborators we may have in the future, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. We, and any collaborators we may have in the future, may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The U.K. having left the EU, the TCA and the Northern Ireland Protocol is likely to continue to affect European and worldwide economic conditions and could contribute to greater instability in the global financial markets. These effects </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">could have an adverse effect on our business, investments, and future operations in Europe. There is a risk that trade between U.K. and EU businesses will be materially adversely affected, particularly in relation to highly regulated products such as pharmaceuticals and products of animal-origin, due to the additional regulatory burdens being imposed on exporters/importers which may affect the availability of these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consequences for the economies of the U.K. and the EU member states as a result of the U.K.&#8217;s withdrawal from the EU are still largely unknown and unpredictable. Given the lack of comparable precedent, it is unclear what the broader macro-economic and financial implications the U.K. having left the EU will have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We, or any future collaborators, may not be able to obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the European Commission from approving competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, the company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be &#8220;clinically superior&#8221; to the original orphan drug in that it is more effective, safer or otherwise makes a &#8220;major contribution to patient care&#8221; or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The European Commission can grant orphan drug product designation to products for which the sponsor can establish that it is intended for the diagnosis, prevention, or treatment of (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in 10,000 people in the European Union, or (2)&#160;a life threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that sales of the drug in the European Union would generate a sufficient return to justify the necessary investment. In addition, it must be established that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation is not a marketing authorization. It is a designation that provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized EU marketing authorization, as well as 10&#160;years of market exclusivity following a marketing authorization. During this market exclusivity period, neither the EMA nor the European Commission nor the EU member states can accept an application or grant a marketing authorization for a &#8216;similar medicinal product.&#8217; A &#8216;similar medicinal product&#8217; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, a competing similar medicinal product may in limited circumstances be authorized prior to the expiration of the market exclusivity period, including if it is shown to be safer, more effective or otherwise clinically superior to our product. Our product can lose orphan designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the orphan designation criteria are no longer met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">designated indication due to the uncertainties associated with developing drug products. If this happens, marketing approval for our product candidate may be delayed due to the first-approved product&#8217;s orphan drug exclusivity, unless we demonstrate clinical superiority. We may not be able to demonstrate that our product is clinically superior to a first-approved product with orphan drug exclusivity, i.e.,&#160;that it provides greater safety or efficacy or a major contribution to patient care. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, Congress is also considering updates to the orphan drug provisions of the FDCA in response to a recent 11th Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and could materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Even if we, or any collaborators we may have in the future, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our product candidates could require substantial expenditure of resources and may limit how we, or they, manufacture and market our product candidates, which could materially impair our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once marketing approval has been granted, an approved drug and its manufacturer and marketer are subject to ongoing review and extensive regulation. These requirements include submissions of safety and other post-marketing information and reports, user fee requirements, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We, and any collaborators we may have in the future, must also comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug&#8217;s approved labeling. Thus, we, and any collaborators we may have in the future, may not be able to promote any drugs we develop for indications or uses for which they are not approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA or comparable foreign regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a drug. For example, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a REMS or comparable foreign equivalents, like the EU Risk Management Plan, or RMP, which could include requirements for a restricted distribution system. Manufacturers of approved drugs and those manufacturers&#8217; facilities are also required to comply with extensive FDA or comparable foreign regulatory authorities requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA or comparable foreign regulatory authorities to monitor and ensure compliance with cGMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, assuming we, or our future collaborators, receive marketing approval for one or more of our product candidates, we, and our future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we, and our future collaborators, are not able to comply with post-approval regulatory requirements, regulatory agencies or enforcement authorities may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by us or our collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on our operations, including closing our or our collaborators&#8217; manufacturing facilities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a recall.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The regulatory requirements and policies may change, and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or any future collaboration partner are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, may face government enforcement action and our business will suffer. Moreover, our or our future collaborators&#8217; ability to market any future drugs could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">The FDA&#8217;s and other comparable regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory licensure of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing licensure that we may have obtained and we may not achieve or sustain profitability. If these actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Any of our product candidates for which we, or our future collaborators, obtain marketing approval in the future will be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our product candidates following approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of our product candidates for which we, or our future collaborators, obtain marketing approval in the future, will be subject to continual review by the FDA or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For example, in the United States, the FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we, or our future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation involving patients taking our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such drugs, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on drug distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the drugs from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to relationships with any potential collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on coverage by third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable press coverage and damage to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug seizure; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Recently enacted and future legislation, and any change in existing government regulations and policies, may increase the difficulty and cost for us and our future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of our future collaborators, to effectively sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or our future collaborators, may receive for any approved drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Congress and recent presidential administrations have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products, if approved, and to do so effectively. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, the pharmaceutical industry has been a particular focus of efforts to reform the healthcare system and has been significantly affected by major legislative initiatives, including the PPACA, which contains provisions that may potentially affect the profitability of our products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs, and expansion of the entities eligible for discounts under the 340B pricing program. The framework of the PPACA continues to evolve as a result of executive, legislative, regulatory and administrative developments that have challenged the law and contribute to legal uncertainty that could affect the profitability of our products. See Part I, Item 1, &#8220;Government Regulation &#8211; U.S. Healthcare Reform&#8221; for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and/or new payment methodologies, and place additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels and imposition of more rigorous coverage criteria or new payment methodologies may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any coverage or reimbursement policies instituted by Medicare or other federal health care programs may result in similar policies from private payors. The implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our product candidates. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In countries outside of the United States, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to that of other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for drug products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the United States </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent drug labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Regulatory proposals have been made to allow the importation of prescription drugs into the United States that are approved for marketing in Canada, and potentially other countries. If such proposal are implemented, and if any of our product candidates or other similar or equivalent drug products are approved in another ex-US jurisdiction, these regulatory proposals may impact the competition our product may face, if approved. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek a breakthrough therapy designation for APR-1051 or ATRN-119, or one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may seek a breakthrough therapy designation for APR-1051, ATRN-119 or one or more of our other product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA, and parts of the NDA may be submitted and reviewed on a rolling basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. For example, in June 2022, FDA published a draft guidance document outlining considerations for the Agency in rescinding Breakthrough Therapy designation for products that no longer meet the requirements for that designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">A fast track designation by the FDA for APR-1051, ATRN-119, or any of our other product candidates may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If a drug is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a drug sponsor may apply for FDA fast track designation. We may not experience a faster development or regulatory review or approval process for any product candidates, if any, for which we obtain fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from the 60-day filing date, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we do not currently have any products on the market, we are subject to a variety of regulatory requirements, including healthcare statutory and regulatory requirements and enforcement by the U.S. federal and state governments and the foreign governments of the countries in which we conduct our business. Even though we are not in a position to make patient referrals and do not bill Medicare, Medicaid, or other government or commercial third-party payors, our relationships with healthcare providers, physicians and third-party payors will subject us to healthcare statutory and regulatory requirements and enforcement by the U.S. federal government and the states and foreign governments in which we conduct our business. Our future arrangements with healthcare providers, physicians and third-party payors and patients may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. See Part I, Item 1, &#8220;Government Regulation &#8211; Healthcare Law and Regulation&#8221; for more detail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, guidance, case law or other applicable law. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, disgorgement, reputational harm, additional oversight and reporting obligations pursuant to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with applicable laws and regulations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to market our products, if approved, and adversely impact our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws and regulations, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be costly to us in terms of money, time and resources, and they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are exposed to the risk of our employees and consultants committing fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, incentive programs and other business arrangements. Employee </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we expand our operations outside of the United States, we must comply with numerous laws and regulations in each jurisdiction in which we plan to operate, such as the applicable anti-bribery, anti-corruption, anti-money laundering regulations. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The Securities and Exchange Commission, or SEC, is involved with enforcement of the books and records provisions of the FCPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also subject to other laws and regulations governing our international operations, including applicable import and export control regulations, economic sanctions on countries and persons administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury), anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as the trade control laws. We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable legal requirements, including trade control laws. If we are not in compliance with applicable trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, results of operations, financial condition and prospects. Likewise, any investigation of any potential violations of these trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and product candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store sensitive data, including personally identifiable information, intellectual property and proprietary business information owned or controlled by ourselves and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data centers and cloud-based data centers. We utilize external security and infrastructure vendors to manage our information technology systems and data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information, and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access or disruptions to our IT systems, inappropriate use or disclosure of protected information, inappropriate modification, and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, including the development of policies and procedures to protect our information technology systems and confidential and proprietary information, there is no guarantee we can protect our data from data security incidents, and our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee or vendor error, malfeasance or other malicious or inadvertent disruptions from internal or external threats. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as HIPAA, HITECH, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and notice may need to be made to the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">media or other data protection regulators. Such incidents, and the publicity they may generate, could harm our reputation and our ability to compete. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, process claims and appeals, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly and include civil monetary penalties of up to (as recently adjusted for inflation) $55,910 per violation, not to exceed approximately $1.68&#160;million per calendar year for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment. However, a single breach incident can result in multiple violations, which can lead to significant financial penalties. In addition, numerous breach incidents could lead to possible penalties in excess of $1.68&#160;million. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. Moreover, privacy and cybersecurity laws and regulations are evolving, and may continue to add additional compliance costs and legal risks. For example, the California legislature passed the CCPA, which came into effect January 1, 2020. The CCPA requires companies doing business in California to disclose information regarding the collection, use and sharing of a consumer&#8217;s personal data, and comply with certain qualified privacy rights requests, including rights to request deletion of or to stop the sale of their personal information. While the CCPA includes certain exemptions for data protected by HIPAA or in certain research contexts, the law covers a wide range of data we may process in other contexts. The CCPA also permits the imposition of civil penalties and expands existing state security laws by providing a private right of action for consumers in certain circumstances where consumer data is subject to a breach. Interpretations of the CCPA may continue to evolve with regulatory guidance and enforcement actions from the California Attorney General. The CPRA, which expands the CCPA, passed in November 2020. The CPRA will, among other things, impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It has also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. That rulemaking process is ongoing. Following the CPRA, Virginia, Colorado, Utah and Connecticut have enacted similar, but not completely consistent, comprehensive privacy legislation that will also go into effect in January and July 2023, respectively. Many other states are considering similar legislation in addition to the consideration of comprehensive privacy legislation at the federal level. If passed, such laws will require additional resources to ensure compliance, and may have potentially conflicting requirements that would make compliance challenging. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We have policies and procedures in place, and have conducted an independent third-party audit, to support our compliance with all applicable data protection laws and regulations, and are continually improving our data protection program to address compliance risks and evolving requirements. Nevertheless, our efforts to comply with data protection laws and evaluate as well as oversee our third party vendors&#8217; compliance with data protection laws and our contractual requirements may be insufficient to mitigate all data protection risks or compliance obligations, which could result in regulatory scrutiny, legal liability, reputational risk or operational disruption. Failure by us or by our third-party vendors to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we or our third-party vendors have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we or our third-party vendor, as applicable, are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area (&#8220;EEA&#8221;)/UK may subject us to the EU General Data Protection Regulation&#160;2016/679 (the &#8220;EU GDPR&#8221;) as implemented by countries within the EEA. In addition, where we conduct programs and collaborations in the UK we may be subject to the UK Data Protection Act 2018 and the UK General Data Protection Regulation, (together the &#8220;UK GDPR&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to the EU GDPR, which applies extra-territorially and implements stringent operational requirements on controllers (e.g.,&#160;sponsors) and processors (e.g.,&#160;CROs, laboratories) of personal data. For controllers this includes, for example, high standards for obtaining valid consent from individuals to process their personal data (where consent is the legal ground relied upon), the requirements to provide detailed disclosures to individuals, short timelines for personal data breach notifications to data protection authorities and data subjects, limitations on retention of personal data, additional considerations where processing health data and other &#8220;special categories of personal data&#8221; and specific obligations where third-party processors are engaged. The EU GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have &#8220;adequate&#8221; data privacy laws by the European Commission or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the EU-US Privacy Shield. However, in July 2020 the Court of Justice of the European Union (&#8220;CJEU&#8221;) declared the Privacy Shield to be invalid for purposes of international transfers. The CJEU also imposed further restrictions on use of standard contractual clauses (SCCs) (i.e., an EU-style data transfer agreement) including, a requirement for companies to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. Moreover, new versions of the SCCs (new EU SCCs) have recently been published requiring additional compliance and implementation efforts. In turn, the findings of the CJEU will have significant implications for cross-border data flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, the EU GDPR provides that EU Member States may establish their own laws and regulations further restricting the processing of genetic data, biometric data, health data and other personal data, which could limit our ability to use and share such personal data or could cause our costs to increase. The EU GDPR imposes onerous accountability obligations requiring controllers and processors to maintain a record of their data processing activities and policies and procedures to demonstrate compliance with the EU GDPR. The EU GDPR also grants certain privacy rights to individuals (e.g.,&#160;the right to access or erase their personal data). While we have established some data protection policies and have a maturing compliance program, additional resources will be needed to fully comply with the EU GDPR, including for evolving regulatory guidance. If our or our vendors&#8217; or service providers&#8217; privacy or data security measures fail to comply with the EU GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to stop or change the way we use personal data and/or fines of up to 20&#160;million Euros of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims for financial or non-financial loss by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Relatedly, following the UK&#8217;s withdrawal from the EU (i.e., Brexit), the EU GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR site alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into UK law. The requirements of the UK GDPR are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines for non-compliance of up to &#163;17.5 million or 4% of annual worldwide turnover. As a result, we are potentially exposed to two parallel data protection regimes, each of which authorizes fines and the potential for divergent enforcement actions. It should also be noted that reliance on the new EU SCCs for transfers from the UK requires additional documentation in the form of a UK Addendum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to employee matters and managing growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, and to attract, retain and motivate qualified personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on Oren Gilad, Ph.D., our President and Chief Executive Officer and John P. Hamill, our Senior Vice President and Chief Financial Officer, as well as the other principal members of the scientific team. Our agreements with Dr. Gilad and Mr.&#160;Hamill do not prevent them from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. However, the loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We expect to expand our development and regulatory capabilities and potentially our sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We will need to expand our organization, and may experience difficulties in managing this growth, which could disrupt operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. We expect to hire additional employees for our managerial, clinical, scientific and engineering, operational, manufacturing, sales and marketing teams. We may have operational difficulties in connection with identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to managing these </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our product candidates. If we are unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than us. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can select and develop our product candidates and our business will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:3pt;padding-top:3pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:3pt;text-align:justify;background:#ffffff;margin:0pt;">We are exposed to the risk that our employees and contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies, manufacturing standards, federal and state healthcare fraud and abuse and health regulatory laws and other similar foreign fraudulent misconduct laws, or laws that require the true, complete and accurate reporting of financial information or data. Misconduct by these parties may also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to tax matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We have significant deferred tax assets, which may become devalued if we do not generate sufficient future taxable income, applicable corporate tax rates are reduced or if we experience an ownership change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our total net deferred tax assets as of December&#160;31,&#160;2025 were $56.3 million. Of that amount, $29.5 million relates to gross deferred tax assets in Aprea AB. Our anticipated activities are also expected to result in future significant net operating losses in the United States and Sweden resulting in additional deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate jurisdiction and/or entity. The company has provided a valuation allowance of $56.3 million on our net deferred tax assets as of December&#160;31,&#160;2025, because, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Sweden or the United States. Accordingly, in the event of a reduction of any such corporate income tax rates, the carrying value of certain of our deferred tax assets would decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Moreover, our ability to use our net operating losses and other deferred tax assets to offset future taxable income in Sweden and the United States may be significantly limited if we experience an ownership change. For Swedish income tax purposes, an ownership change will generally occur when one, or several shareholders together, acquire shares </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">representing more than 50&#160;percent of the voting power over a five&#160;year period (under special provisions in Chapter 40 of the Swedish Income Tax Act; 1999:1229). Such an ownership change results in the forfeiture of tax losses carried forward exceeding 200&#160;percent of the cost of the change of control. In this calculation, capital contributions to the company prior to the ownership change and in the preceding two&#160;years should reduce the cost of the change of control. Due to potential ownership changes under the Swedish Income Tax Act, we may be limited in our ability to realize a tax benefit on our deferred tax assets, whether or not we attain profitability in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For U.S. federal income tax purposes, an ownership change will generally occur when the percentage of our stock (by value) owned by one or more &#8220;5&#160;percent shareholders&#8221; (as defined in the U.S. Internal Revenue Code of 1986, as amended) has increased by more than 50% over the lowest percentage owned by such shareholders at any time during the prior three years (calculated on a rolling basis). We anticipate that we will incur losses in the United States in the foreseeable future related to our research and development activities. Due to potential ownership changes under Section&#160;382 of the Code, we may be limited in our ability to realize a tax benefit from the use of our deferred tax assets, whether or not we attain profitability in future years. We believe the Merger likely resulted in an ownership change under Section 382 of the Code, and, accordingly, our net operating losses and other deferred tax assets are subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, our ability to utilize any future net operating losses may be limited by Pub.&#160;L.&#160;115-97, commonly known as the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;). Under the TCJA, as amended by the CARES Act, the amount of our net operating losses incurred in taxable years beginning after December 31, 2020 that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself, while allowing unused net operating losses to be carried forward indefinitely. Under the CARES Act, net operating losses arising in taxable years beginning before January 1, 2021 are not subject to the 80% limitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For these reasons, a material devaluation in our deferred tax assets due to insufficient taxable income, lower corporate income tax rates or ownership change would have an adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We may have taxable income as a result of the purging election made following the Holdco Reorganization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While not entirely clear, we intend to treat Aprea AB as having been a passive foreign investment company, or PFIC, for U.S. federal income tax purposes prior to the Holdco Reorganization and treat the Company as having succeeded to the tax basis and holding periods of those shareholders in Aprea AB that exchanged their shares for our common stock. Based on such treatment, and absent a purging election as described below, the stock of Aprea AB held by the Company would have retained its status as stock of a PFIC with respect to all periods prior to the Holdco Reorganization (the &#8220;PFIC Taint&#8221;) and therefore, absent a prior election by those shareholders to treat Aprea AB as a qualified electing fund, the Company, would have been subject to certain adverse U.S. federal income tax consequences with respect to distributions received on such stock and gain recognized on the disposition of such stock. In order to purge the PFIC Taint on the stock of Aprea AB, and avoid such adverse tax consequences, following the Holdco Reorganization we made a purging election in the form of a deemed dividend election under which, for U.S. federal income tax purposes, Aprea AB will be deemed to have made a distribution to the Company of all of its current and accumulated earnings and profits as determined for U.S. federal income tax purposes. Because Aprea AB did not have any accumulated or current year earnings and profits as of December 31, 2019, we do not expect the purging election to result in any incremental U.S. federal income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We may be subject to current taxation on some of the income of our foreign subsidiaries even absent any cash distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because we hold directly or indirectly all of the shares of our foreign subsidiaries, including Aprea AB, such subsidiaries are treated as controlled foreign corporations (&#8220;CFC&#8221;) for U.S. federal income tax purposes. For U.S. federal income tax purposes, the Company will therefore need to include in its taxable income each year Aprea AB&#8217;s &#8220;subpart&#160;F income,&#8221; and &#8220;global intangible low-taxed income&#8221;, if any, even if no distributions are made.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Our foreign subsidiaries may directly become subject to U.S. federal income tax and be subject to a branch profits tax in the United States, which could reduce our after-tax returns and the value of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently intend to conduct substantially all of our businesses and operations in a manner such that our foreign subsidiaries will not be treated as engaged in a trade or business in the United States and will not be subject to additional U.S. income tax or branch profits tax. However, it is not entirely clear when a foreign subsidiary is treated as being engaged in a trade or business in the United States for U.S. federal income tax purposes and travel restrictions may further limit our ability to reduce the risk of our foreign subsidiaries being treated as engaged in a U.S. trade or business. Accordingly, we cannot assure you that the Internal Revenue Service (&#8220;IRS&#8221;) will not contend, perhaps successfully, that our foreign subsidiaries were engaged in a trade or business in the United States or are subject to more U.S. income tax than they currently incur. A foreign corporation deemed to be so engaged would be subject to U.S. federal income tax, as well as branch profits tax, on its income that is treated as effectively connected with the conduct of that trade or business unless the corporation is entitled to relief under an applicable tax treaty, which is determined on an annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">The ongoing effects of the 2017 Tax Cuts and Jobs Act and GILTI could make our results difficult to predict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our effective tax rate may fluctuate in the future as a result of the TCJA, which included significant enacted changes in U.S. income tax law many aspects of which are not entirely clear and with respect to which some guidance has not yet been finalized. The enacted tax legislation included, among other new provisions, a reduction in the corporate tax rate, new limitations on the deductibility of net interest, the base erosion and anti-abuse minimum tax and new rules&#160;related to the global intangible low-taxed income of our foreign subsidiaries (&#8220;GILTI&#8221;). GILTI may require us to include in taxable income certain income of our foreign subsidiaries that are CFCs, though we may be eligible to claim foreign tax credits with respect to some of the taxes paid by such subsidiaries. While the U.S. tax authorities issued proposed and final regulations for GILTI, there are still certain aspects of the TCJA that remain unclear. We will continue to review the impact of GILTI and the other changes resulting from the TCJA as further guidance is issued. Any further guidance may result in changes to the interpretations and assumptions we made and actions we may take, which as a result may impact the amounts recorded with respect to international provisions of the TCJA, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Changes in U.S. federal income tax law and other jurisdictions could materially adversely affect an investment in our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It is possible that tax laws in the United States and other jurisdictions will be changed. It remains difficult to predict whether or when there will be any tax law changes or further guidance by the authorities in the U.S. or elsewhere in the world that will have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to our common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our executive officers, directors and principal stockholders may have substantial influence over matters submitted to stockholders for approval. This may prevent new investors from influencing significant corporate decisions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, our executive officers and directors and our stockholders which own more than 5% of our outstanding common stock beneficially owned shares representing approximately 13.8% of our common stock. As a result, if these stockholders were to choose to act together, they may have substantial influence over matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company, or other significant corporate decisions, on terms that other stockholders may desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which common </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stockholders might otherwise receive a premium for our shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors such that not all members of the board are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which stockholders can remove directors from the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">If securities analysts do not or do not continue to publish research or reports about our business or if they publish negative evaluations of our business, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock is and will rely in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts who currently cover our business downgrade their evaluations of our business, or in the event we obtain additional coverage and one or more of the new analysts issues an adverse evaluation of our business, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">The price of our common stock has been and may continue to be volatile and fluctuate substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell our common stock at or above the price they paid for it. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and results of clinical trials of APR-1051 or ATRN-119 and any of our other product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the current voluntary pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of existing or new competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment or termination of collaborations for our product candidates or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure or discontinuation of any of our development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of product candidates of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results or development timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, our insiders or other stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of January 1, 2025, we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Act of 2012, of the JOBS Act. However, we remain a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our common stock held by non-affiliates is less than $250 million or (ii)&#160;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">We continue to incur increased costs as a result of operating as a public company as we become subject to additional laws, regulations and listing exchange standards, and our management will continue to be required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we no longer are a &#8220;smaller reporting company,&#8221; we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules&#160;subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;404 Sarbanes-Oxley Act of 2002, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accounting principles and related pronouncements, implementation guidelines and interpretations we apply to a wide range of matters that are relevant to our business, including, but not limited to, revenue recognition, leases and stock-based compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in accounting pronouncements or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported or expected financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Because we do not anticipate paying any cash dividends on our common stock for the foreseeable future, capital appreciation, if any, of our common stock may be investors&#8217; sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be investors&#8217; sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2pt 0pt 0pt 0pt;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf under Delaware law, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, any action asserting a claim against us governed by the internal affairs doctrine, or any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section&#160;115 of the Delaware General Corporation Law. These exclusive-forum provisions do not apply to claims under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act. This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the exclusive-forum provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are required to meet the Nasdaq Stock Market, or Nasdaq, continued listing requirements and other Nasdaq rules, and if we fail to meet such rules and requirements,&#160;we may be subject to delisting. Delisting could negatively affect the price of our common stock, which could make it more difficult for us to sell securities in a future financing or for you to sell our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are required to meet the continued listing requirements of Nasdaq and other Nasdaq rules, including those regarding director independence and independent committee requirements, minimum stockholders&#8217; equity, minimum share price and certain other corporate governance requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The continued listing standards of Nasdaq applicable to the Nasdaq Capital Market require, among other things, that the minimum price of a listed company&#8217;s stock be at or above $1.00. If the minimum bid price is below $1.00 for a period of more than 30 consecutive trading days, the listed company will fail to be in compliance with Nasdaq&#8217;s listing rules and, if the listed company does not regain compliance within a 180-day grace period, it may be subject to delisting. In order to regain compliance, the bid price of the listed company&#8217;s common stock must close at a price of at least $1.00 per share for a minimum of 10 consecutive trading days within a 180-day grace period. On January 23, 2026, we received a deficiency letter from Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we would be afforded 180 calendar days to regain compliance with the bid price requirement. There can be no assurance that we will regain compliance with the minimum bid price requirement or, if we do so, that we will maintain compliance with the minimum bid price requirement or any other Nasdaq listing standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If we fail to regain compliance with the minimum bid price requirement or other Nasdaq listing standards, our common stock will be subject to delisting. Delisting from Nasdaq could adversely affect our ability to raise additional financing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">through the public or private sale of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities. Delisting could also cause us to pursue eligibility for trading of securities on other markets or exchanges, including the OTC BB or QB markets, or on the OTC &#8220;pink sheets.&#8221; In such case, our stockholders&#8217; ability to trade, or obtain quotations of the market value of our common stock would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of our securities. There can be no assurance that our securities, if delisted from the Nasdaq Capital Market in the future, would be listed on a national securities exchange, a national quotation service, the OTC markets or the pink sheets. Delisting from Nasdaq would also result in negative publicity, make it more difficult for us to raise additional capital, cause us to lose eligibility to register the sale or resale of our shares on Form S-3 and the automatic exemption from registration under state securities laws for exchange-listed securities, adversely affect the market liquidity of our securities, decrease securities analysts&#8217; coverage of us or diminish investor, supplier and employee confidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_df7ea843_4f68_459e_87ed_0ad432c4161a"></a><a id="Item1BUnresolvedStaffComments_845403"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:10pt;">Not applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_39930405_36fa_4542_82a1_16024e5571e8"></a><a id="Item1CCybersecurity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Item 1C. Cybersecurity</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_unU2dLPsR0y7qoTx9g8Kxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We are a clinical-stage biopharmaceutical company and we are solely focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response pathways. Therefore, we do not consider that we face significant cybersecurity risk and have not adopted a formal cybersecurity risk management program or process for assessing cybersecurity risk currently. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_4iXDy739FESH0o5W7r86Ew" escape="true">We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized access to or occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. To this end, <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_6HPX-q5LRkiPT1QF_Ojlsw">we utilize an outsourced information technology consultant</ix:nonNumeric>, who we believe has sufficient experience and expertise with regard to cybersecurity matters, to implement systems and procedures designed to reduce, respond to and monitor for cybersecurity threats and vulnerabilities. Our <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_N-lteahHREa-lflYIW8R_g">outsourced information technology consultant <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_Wlsk0DN9R068yCnsgYqt4w">conducts</ix:nonNumeric> proactive patching and monitoring</ix:nonNumeric> of all of our existing systems and has implemented systems and procedures to mitigate cybersecurity risks that we believe are appropriate for a company of our size, stage of growth and financial condition. In addition, we carry insurance with coverage for cyber events that we believe is suitable for a company of our size, stage of growth and financial condition.</ix:nonNumeric> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of the date of this Annual Report on Form 10-K, <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_5a0PP8WLPk-DEJ4MiBSOxA">we are not aware of any cybersecurity threats, </ix:nonNumeric><span style="white-space:pre-wrap;">including as a result of any previous cybersecurity incidents, that have materially affected us, including our business strategy, results of operations or financial condition. However, as discussed under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition.  For additional information concerning risks related to cybersecurity, </span><i style="font-style:italic;">see</i> Item 1.A.&#160;<i style="font-style:italic;">Risk Factors: &#8220;Our business and operations would suffer in the event of IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in our or our third-party vendors&#8217; information security program or defenses.</i>&#8221;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;"><i style="font-size:10pt;font-style:italic;">Governance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Group_E__SEL-s2UOeDD7mC5ghAQ" continuedAt="Group_E__SEL-s2UOeDD7mC5ghAQ_2" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_MFgVXvEEfUyeucIxpkczww">Management</ix:nonNumeric> is responsible for the day-to-day management of the risks we face, <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Group_uEt2JygDxk2NtN8jsEzbSQ" continuedAt="Group_uEt2JygDxk2NtN8jsEzbSQ_2" escape="true">while our <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_nhDR7EY7kUaavTPctkV5qw"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_uBJKJE_4-ku_fM9LwXgFXQ" escape="true">Board of Directors</ix:nonNumeric> as a whole has responsibility </ix:nonNumeric>for the oversight of risk management, including as to material risks from cybersecurity threats.</ix:nonNumeric></ix:nonNumeric><span style="white-space:pre-wrap;">  </span><ix:continuation id="Group_uEt2JygDxk2NtN8jsEzbSQ_2"><ix:continuation id="Group_E__SEL-s2UOeDD7mC5ghAQ_2"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Group_EuZPP_x9aU6MY04_T8Dbcg" continuedAt="Group_EuZPP_x9aU6MY04_T8Dbcg_2" escape="true">In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed.</ix:nonNumeric> </ix:continuation> <ix:continuation id="Group_EuZPP_x9aU6MY04_T8Dbcg_2">The Board of Directors has delegated to the <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_TxG8ZdmZ4UWBXct20B8Xbw" escape="true">Audit Committee</ix:nonNumeric> of the Board of Directors the responsibility for the oversight of information technology (including cybersecurity) risks.</ix:continuation></ix:continuation><span style="white-space:pre-wrap;">  </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_TkEVlNlGY0OaC3zEDZrMZw" continuedAt="Tb_TkEVlNlGY0OaC3zEDZrMZw_cont1" escape="true">In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, integrity, and availability of the information that we collect </ix:nonNumeric></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:continuation id="Tb_TkEVlNlGY0OaC3zEDZrMZw_cont1">and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur</ix:continuation>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_463d0912_e8dd_4524_90d0_71bd612b8739"></a><a id="Item2Properties"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2. Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">We have a facility in Doylestown, Pennsylvania which consists of office and laboratory space of approximately 1,550 square feet under an operating lease agreement that expires in October 2026.  We believe that our current facilities are suitable and adequate to meet our current needs.  We believe that suitable additional or substitute space will be available as needed to accommodate any potential expansion of our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_3ce43a8f_12e6_4ea1_ae31_014cd17c3be3"></a><a id="PARTIIOTHERINFORMATION_384131"></a><a id="PARTIIOTHERINFORMATION_907842"></a><a id="Item1LegalProceedings_809320"></a><a id="Item3LegalProceedings_459401"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There are no matters which constitute material pending legal proceedings to which we are a party other than those incorporated into this item by reference to Note 9 of the section of this Annual Report on Form 10-K in Item 8, entitled &#8220;Financial Statements and Supplementary Data.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_28249583_a652_48a3_946b_c192429ebce3"></a><a id="Item4MineSafetyDisclosures_869418"></a><a id="Item4MineSafetyDisclosures_10830"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c681fe15_dde5_4558_a24a_1c559c576ff9"></a><a id="PARTII_76010"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PART II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5. M</b><b style="font-weight:bold;">arket for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Market Information and Holders of Record</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our common stock is listed on the Nasdaq Capital Market under the symbol "APRE".</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of March 16, 2026, we had approximately 132 holders of record of our common stock. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include shareholders whose shares may be held in trust by other entities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid a cash dividend on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any future determinations to pay cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on a number of factors, including our financial condition, results of operations, capital requirements, contractual restrictions, general business conditions, and any other factors that our board may deem relevant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Securities Authorized for Issuance under Equity Compensation Plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Information regarding the Securities Authorized for Issuance under our Equity Compensation Plans will be included in an amendment to this Annual Report in Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Rule 14A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Performance Graph </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As a smaller reporting company, we are not required to provide the information requested by this item pursuant to Item 201 of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unregistered sales of equity securities </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2025, we issued 20,000, 5,000 and 2,500 shares of our common stock, par value $0.001 per share, respectively, to three consultants in consideration for bona fide services rendered to us (collectively, the &#8220;Consultant Issuances&#8221;). The Consultant Issuances were made pursuant to actions approved by our Board of Directors on October 11, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The foregoing shares were issued in private transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance upon Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder, as transactions not involving a public offering. Each consultant represented, among other things, that they were acquiring the securities for investment and not with a view to distribution, and either was an &#8220;accredited investor&#8221; within the meaning of Rule 501(a) of Regulation D or, to the extent applicable, possessed such knowledge and experience in financial and business matters that they were capable of evaluating the merits and risks of the investment. The issuances did not involve any general solicitation or general advertising. The securities issued have not been registered under the Securities Act and were issued as &#8220;restricted securities&#8221; as defined in Rule 144 under the Securities Act, and appropriate restrictive legends were affixed to the certificates or book entry statements evidencing such securities. No underwriting discounts or commissions were paid, and no underwriters were involved in the transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no other unregistered sales of equity securities during the period covered by this report that were not previously disclosed in a Current Report on Form 8 K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Repurchases of equity securities by the issuer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no share repurchases during the year ended December&#160;31,&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3b6f1159_cc0c_4cdd_a52e_7297ea273731"></a><a id="Item6SelectedFinancialData_571863"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 6. </b><b style="font-weight:bold;">[Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d2b557a3_56ce_4fb8_8553_1a5d1b2043c6"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;">The following discussion and analysis of financial condition and results of operations is provided to enhance the understanding of, and should be read in conjunction with Part I, Item I, &#8220;Business&#8221; and Item 8, &#8216;Financial Statements and Supplementary Data.&#8221;  For information on risks and uncertainties related to our business that may make past performance not indicative of future results or cause actual results to differ materially from any forward-looking statements, see &#8220;Special Note Regarding Forward-Looking Statements,&#8221; and Part I, Item 1A, &#8216;Risk Factors.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Our approach is built upon a platform of integrated discovery technologies to enrich our pipeline with novel targets in synthetic lethality and cancer treatment. Together with our expertise in small molecule drug discovery, we are applying the capabilities of our discovery platform to the development of new precision oncology therapies and the identification of patient populations most likely to benefit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that synthetic lethality has the potential to impact patients&#8217; lives and treatment strategies for a wide range of cancer types. We aspire to become a leader in this emerging field and are establishing a pipeline of clinical and preclinical programs that we believe may have broad application to cancer treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Our lead WEE1 inhibitor product candidate is APR-1051. In March 2024, our IND for APR-1051 (IND 169359) went into effect and in the second quarter of 2024 we enrolled the first patient into ACESOT-1051, our Phase 1 dose escalation study. Preliminary results provide early clinical proof-of-concept of APR-1051. A potential dose-response trend was observed, with increasing single-agent activity across the 70 mg, 100 mg, 150 mg and 220 mg cohorts. On January 29, 2026, we announced the first unconfirmed partial response (uPR) observed in a patient enrolled in the ongoing Phase 1 ACESOT-1051 dose-escalation study: a patient with PPP2R1A-mutated uterine serous carcinoma, a form of endometrial cancer, treated at the 150 mg dose level of APR-1051. At the protocol-defined 8-week first imaging assessment, the patient achieved a 50% reduction in target lesion size per RECIST v1.1 criteria, along with a marked reduction in cancer antigen 125 (CA-125) levels, from 732 to 70 U/mL. CA-125 is a well-recognized tumor marker in endometrial cancer. On February 18, 2026, we announced the second uPR observed in a patient with PPP2R1A-mutated endometrial cancer, treated at the 220 mg dose level: at the first imaging assessment the patient achieved a 50% reduction in target lesion size, along with a marked decline in CA-125 from 362 at baseline to 47 U/mL, further supporting the anti-tumor activity of APR-1051. In addition, preliminary results from the ACESOT-1051 study indicate that APR-1051 has been safe and well-tolerated to date, supporting our development strategy to differentiate WEE1 inhibition through a potentially improved therapeutic index. We anticipate open-label safety/efficacy data to be available in the second quarter of 2026 and expect to complete dose-escalation in the third quarter of 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our second clinical-stage synthetic lethality product candidate is ATRN-119, an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR. The ATR kinase is a master regulator of the DNA damage response, with key roles in cell cycle control and DNA repair following replication stress. On October 15, 2025, we determined the recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 in the monotherapy arm of the ongoing ABOYA-119 Phase 1/2a dose-escalation study, in patients with advanced solid tumors. Building on the completion of dose escalation and supported by new preclinical data suggesting potential synergistic anti-tumor effects, we are considering further ATRN-119 development in combination approaches that could expand its therapeutic potential. We believe ATRN-119's mechanism of action, favorable safety profile, and pharmacologic characteristics make it an ideal candidate for combination with other anti-cancer therapies, including radiation therapy, antibody-drug conjugates and immune checkpoint inhibitors. As part of this strategic focus, we voluntarily paused further enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and we started an orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently in discussions with leading academic centers to explore combining ATRN-119 with radiation in patients with HPV+ head and neck cancer. Additional investigator-led studies evaluating ATRN-119 in combination </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with an I/O agent and antibody-drug conjugates, are also being explored, based on preclinical evidence that ATR inhibition can enhance anti-tumor immune responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we also have an early-stage program, APR-1602, a macrocyclic DYRK1A/B inhibitor, that will be ready to enter IND-enabling studies in the fourth quarter of 2026. We do not currently have any ongoing preclinical studies or clinical trials involving our reactivators of mutant p53 and our primary focus is on the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have assembled a team with extensive experience in the discovery, development and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Corporate Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aprea Therapeutics AB, or Aprea AB, was originally incorporated in 2002 and commenced principal operations in 2006. We incorporated Aprea Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) in May&#160;2019. In September&#160;2019 we completed a corporate reorganization and, as a result, all of the issued and outstanding stock of Aprea AB was exchanged for common stock, preferred stock or options, as applicable, of the Company. As a result of such transactions, Aprea AB became a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have devoted substantially all of our resources to developing our product candidates, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the net proceeds received from the initial public offering of our common stock and sales of common stock through public and private offerings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant losses on an aggregate basis. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $12.6 million and $13.0 million for the years ended December&#160;31,&#160;2025 and 2024, respectively. As of December&#160;31,&#160;2025, we had an accumulated deficit of $333.6 million. These losses have resulted primarily from costs incurred in connection with research and development activities, patent investment, and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our expenses will increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and conduct clinical trials and additional preclinical research for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify and develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the manufacture of larger quantities of our product candidates for clinical development and potential commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand, protect and enforce our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other drugs and technologies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend against any claims of infringement, misappropriation or other violation of third-party intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire and retain additional clinical, quality control and scientific personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">build out new facilities or expand existing facilities to support our ongoing development activity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to operate as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties and grants from government and other (non-government) organizations. We may be unable to raise additional funds or enter into other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. In addition, our ability to engage in certain types of capital raising transactions may be limited by the Listing Rules of the Nasdaq Stock Market and/or General Instruction I.B.6 of Form S-3 if the market value of our common stock held by non-affiliates is ever below $75 million at a time we seek to utilize our effective registration statement on Form S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, we had cash and cash equivalents of $14.6 million. We believe that our existing cash and cash equivalents as of December&#160;31,&#160;2025 and the gross proceeds of approximately $5.6 million received from our private placement of our common stock and warrants in January 2026, before deducting placement agent fees and offering costs of approximately $0.4 million, will be sufficient to meet our currently projected operating expenses and capital expenditure requirements into the first quarter of 2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221; We have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these audited consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;margin:0pt;"><b style="font-weight:bold;">Components of our results of operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;margin:0pt;"><span style="font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for any of our product candidates are successful and result in marketing approval or collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements that we may enter into with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Associated expenses are recognized when incurred as research and development expense. We concluded that payments received under these grants represent conditional, nonreciprocal contributions, as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i><i style="font-style:italic;">Not</i><i style="font-style:italic;">-</i>for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Operating expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our expenses since inception have consisted solely of research and development costs and general and administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Research and development expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct research, preclinical activities and clinical trials on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture our product candidates for use in our preclinical and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to compliance with regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We typically use our employee and infrastructure resources across our development programs. We track outsourced development costs and payments made to our research partners by product candidate or development program, but we do not allocate personnel costs or other internal costs to specific development programs or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we progress clinical trials for APR-1051. With the current pause on further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches, we may be unable to advance development of ATRN-119 for monotherapy in a timely manner, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We cannot determine with certainty the duration and costs of planned clinical trials of our product candidates or if, when, or to what extent we will generate revenue from the commercialization and sale of any our product candidates for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any of our product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, expense and results of any future clinical trials of our product candidates and other research and development activities that we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties in clinical trial design and patient enrollment rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation and regulatory guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and receipt of, and any limitations imposed by regulatory bodies on, any marketing approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration, or FDA, or another regulatory authority in a foreign jurisdiction were to require us to conduct clinical trials beyond the scope we currently anticipate, or additional clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">General and administrative expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase in the future as we increase our headcount to support personnel in research and development and to support our operations generally, and as we increase our activities related to the potential commercialization of our product candidates. We also expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements; director and officer insurance costs; and investor and public relations costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other income and expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Interest income and expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income consists of income earned on our cash and cash equivalents. Interest income is decreasing as (i) our cash balance decreases as we continue to fund operations and (ii) a change in interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Foreign currency gain and loss</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our consolidated financial statements are presented in U.S. dollars, which is our reporting currency. The financial position and results of operations of our subsidiary Aprea AB is measured using the foreign subsidiary&#8217;s local currency as the functional currency. Aprea AB cash accounts holding U.S. dollars are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the consolidated statement of operations and comprehensive loss. Expenses of such subsidiaries have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the consolidated balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stockholders&#8217; equity and as other comprehensive loss on the consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have not recorded any U.S. federal, state or foreign income tax expense or benefits for the net losses we have incurred in any year, due to our uncertainty of realizing a benefit from those items. We have provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical accounting policies and use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our financial statements, we are required to accrue for research and development expenses at each balance sheet. This process involves reviewing open contract and purchase orders, communicating with our personnel and service providers to identify services that have been performed on our behalf and the level of service performed and the associated costs incurred for the services when we have not yet been invoiced. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We accrue research and development expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of accrued research and development expenses include fees paid to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigative sites or other service providers in connection with clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with preclinical and clinical development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors related to product manufacturing and development and distribution of preclinical and clinical supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We base our expenses related to preclinical studies and clinical trials on the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts are fee for service or depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. If the actual timing of the performance of services or the level of effort varies from the amount accrued, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our accrued research and development expenses </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior accruals of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Smaller reporting company status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our common stock held by non-affiliates is less than $250 million or (ii)&#160;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Comparison of the years ended December&#160;31,&#160;2025 and 2024 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 285,759</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,502,581</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,216,822)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,043,035</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,363,537</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,320,502)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,476,560</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,458,699</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,861</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,519,595</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,822,236</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,302,641)</span></p></td></tr><tr style=""><td style="vertical-align:top;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,233,836)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14,319,655)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,085,819</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 652,086</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,289,144</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (637,058)</span></p></td></tr><tr style=""><td style="vertical-align:top;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 77,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 77,500</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency (loss) gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (95,319)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 71,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (167,119)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 634,267</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,360,944</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (726,677)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,599,569)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,958,711)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 359,142</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Grant revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Grant revenue from the National Cancer Institute of the National Institutes of Health (&#8220;NIH&#8221;) for the years ended December&#160;31,&#160;2025 and 2024 was approximately $0.3 million and $1.5 million, respectively. The decrease in grant revenue of $1.2 million is due to recognizing less grant revenue from the NIH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style=""><td style="vertical-align:top;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">APR-1051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,582,989</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,348,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (765,061)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ATRN-119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,170,099</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,649,965</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (479,866)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">APR&#8209;246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,279</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,325</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,046)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other early&#8209;stage development programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 126,945</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 270,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (143,335)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unallocated research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,149,723</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,079,917</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (930,194)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,043,035</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,363,537</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,320,502)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the year ended December&#160;31,&#160;2025 were $7.0 million, compared to $9.4&#160;million for the year ended December&#160;31,&#160;2024. The overall decrease of $2.3&#160;million was primarily due to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.8 million related to ACESOT-1051, our Phase 1 dose-escalation study for APR-1051, our small molecule WEE1 inhibitor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.5 million related to the ABOYA-119 clinical trial to evaluate ATRN-119, our clinical-stage oral small molecule inhibitor of ATR. The ABOYA-119 clinical trial was voluntarily paused in October 2025 and we started an orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.9 million in non-program consulting expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the year ended December&#160;31,&#160;2025 were $6.5&#160;million, compared to $6.5&#160;million for the year ended December&#160;31,&#160;2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Other income and expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Foreign currency loss was $95,319 for the year ended December&#160;31,&#160;2025 compared to a foreign currency gain of $71,800 for the year ended December&#160;31,&#160;2024. The change in the foreign currency of $167,119 was primarily due to a weakening of the U.S. dollar against the Swedish Krona during the year ended December&#160;31,&#160;2025 as compared to the year ended December&#160;31,&#160;2024. Other income was $77,500 for the year ended December&#160;31,&#160;2025 and was related to the monetization of a portion of the Company&#8217;s state net operating loss carryforwards. Interest income for the years ended December&#160;31,&#160;2025 and 2024 primarily consisted of interest earned on our cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and capital resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant losses on an aggregate basis. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Since 2019, our primary source of funds has been from the public and private sales of our common stock. As of December&#160;31,&#160;2025, we had cash and cash equivalents of $14.6 million. We believe that our existing cash and cash equivalents as of December&#160;31,&#160;2025, together with the capital raised in our January 2026 private placement financing, will be sufficient to meet our currently projected operating expenses and capital expenditure requirements into the first quarter of 2027. We have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these audited consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On January 26, 2024, we filed a shelf registration statement, or the 2024 Shelf Registration Statement, with the SEC for issuance of up to $150 million, including a prospectus for the sale of $1.0 million under the ATM Agreement, as discussed below, which was declared effective on February 2, 2024.  We subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to $2.0 million of shares of our common stock pursuant to the ATM Agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On January 26, 2024, we entered into an At the Market Offering Agreement, or the ATM Agreement, with H.C. Wainright &amp; Co., LLC, or HCW.  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, we may, from time to time, in our sole discretion, issue and sell through HCW, acting as sales agent and/or principal, up to $2.0 million of shares of our common stock.  We have not made any sales under the ATM Agreement to date.  In March 2024, we terminated the ATM agreement with HCW.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 11, 2024, we entered into a securities purchase agreement with certain purchasers, or the Purchasers, pursuant to which we agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from us (i) 1,687,712 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">shares of our common stock at a purchase price of $7.29 per share, (ii) pre-funded common stock purchase warrants to purchase an aggregate of up to 507,076 shares of our common stock at an exercise price of $0.001 per share, (iii) tranche A common stock purchase warrants to purchase up to 1,097,394 shares of our common stock at an exercise price of $7.29 per share, or the Tranche A Warrants, and (iv) tranche B common stock purchase warrants to purchase up to 1,097,394 shares of our common stock at an exercise price of $9.1125 per share, or the Tranche B Warrants. The Tranche A Warrants will be exercisable until the earlier of (i) the three-year anniversary of issuance and (ii) 30 days after we announce the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of our common stock equals or exceeds $14.58 for 30 consecutive trading days. The Tranche B Warrants will be exercisable until the earlier of (i) the five-year anniversary of issuance and (ii) 30 days after we announce the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of our common stock equals or exceeds $18.225 for 30 consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than 4.99% (or, at the election of the holder, greater than 9.99%) of our outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate gross proceeds from the issuance of common stock and warrants totaled approximately $16.0 million, before deducting placement agent fees and offering costs of approximately $1.3 million, and the gross proceeds from potential future warrant cash exercises is expected to be approximately $18.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On November 8, 2024, we entered into an At the Market Offering Agreement, or the 2024 ATM Agreement, with H.C. Wainright &amp; Co., LLC, or HCW.  Pursuant to the 2024 ATM Agreement and the prospectus supplement filed in connection therewith, we may, from time to time, in our sole discretion, issue and sell through HCW, acting as sales agent and/or principal, up to $3.0 million of shares of our common stock.  During the year ended year ended December&#160;31,&#160;2025, we issued and sold 1,337,948 shares of common stock under the Sales Agreement resulting in net proceeds of approximately $1.9 million. During the year ended December&#160;31,&#160;2024, we issued and sold 41,152 shares of common stock under the Sales Agreement resulting in net proceeds of approximately $0.1 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On December 8, 2025, we entered into a securities purchase agreement with certain purchasers (the &#8220;December Purchasers&#8221;) pursuant to which we agreed to issue and sell to the December Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the December Purchasers agreed to purchase from us (i) 26,459 shares of our common stock at a purchase price of $1.165 per share (the &#8220;December 2025 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $1.164 to purchase an aggregate of up to 2,596,564 shares of our common stock at an exercise price of $0.001 per share (the &#8220;December 2025 Pre-Funded Shares&#8221;), (iii) common stock purchase warrants to purchase up to 2,880,533 shares of our common stock at an exercise price of $1.04 per share, including this issuance of a warrant to purchase up to 257,510 shares of our common stock to the placement agent (the &#8220;December 2025 Warrants&#8221;). The December 2025 Warrants will be exercisable until the five-year anniversary of issuance. To the extent that the exercise of a December 2025 Warrant would result in the holder beneficially owning greater than 4.99% (or, at the election of the holder, greater than 9.99%) of our outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $3.1 million, before deducting placement agent fees and offering costs of approximately $0.4 million. In December 2025, we registered on Form S-3 the resale of the December 2025 Shares, the December 2025 Pre-Funded Shares and the shares underlying the December 2025 Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 28, 2026, we entered into a securities purchase agreement with certain purchasers (the &#8220;Purchasers&#8221;) pursuant to which we agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from us (i)&#160;1,877,677&#160;shares of our common stock at a purchase price of $0.8891&#160;per share (the &#8220;January 2026 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $0.8890&#160;to purchase an aggregate of up to&#160;4,411,180&#160;shares of our common stock at an exercise price of $0.001&#160;per share (the &#8220;January 2026 Pre-Funded Shares&#8221;), (iii) common stock purchase warrants to purchase up to&#160;6,288,857&#160;shares of our common stock at an exercise price of $0.765&#160;per share (the &#8220;January 2026 Warrants&#8221;). The January 2026 Warrants will be exercisable until the&#160;two-year anniversary of issuance. To the extent that the exercise of a January 2026 Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of our outstanding common </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $5.6&#160;million, before deducting placement agent fees and offering costs of approximately $0.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the future, we may periodically offer securities in amounts, prices and terms to be announced when and if the securities are offered. If any of the securities covered by the 2024 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of such offering at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes our sources and uses of cash for each of the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,894,439)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,556,718)</span></p></td></tr><tr style=""><td style="vertical-align:top;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,478)</span></p></td></tr><tr style=""><td style="vertical-align:top;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,640,238</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,821,895</span></p></td></tr><tr style=""><td style="vertical-align:top;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,254,201)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,249,699</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Operating activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities was $12.9 million for the year ended December&#160;31,&#160;2025 compared to $13.6 million for the year ended December&#160;31,&#160;2024. The decrease in net cash used in operating activities of $0.7 million was primarily attributable to a change in operating assets and liabilities of $0.1 million, partially offset by a decrease in our net loss of $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Investing activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">No cash was used in or provided by investing activities for the year ended December&#160;31,&#160;2025.&#160;</span>Cash used in investing activities for the year ended December&#160;31,&#160;2024 of $15,478 was for the purchase of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Financing activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $4.6 million for the year ended December&#160;31,&#160;2025. Cash provided by financing activities was attributable to the net proceeds of $2.7 million, after deducting underwriting discounts and offering expenses of approximately $0.3 million, received from the sale of 26,459 shares of common stock, 2,596,564 pre-funded common stock purchase warrants, 2,623,023 common stock purchase warrants and 257,510 placement agent common stock purchase warrants in December 2025 and net proceeds of $1.9 million from the sale of 1,337,948 shares of common stock pursuant to at-the-market stock sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $14.8 million for the year ended December&#160;31,&#160;2024. Cash provided by financing activities was attributable to the net proceeds of $14.7 million, after deducting underwriting discounts and offering expenses of approximately $1.3 million, received from the sale of 1,687,712 shares of common stock, 507,076 pre-funded common stock purchase warrants, 1,097,394 tranche A common stock purchase warrants and 1,097,394 tranche B common stock purchase warrants in March 2024 and net proceeds of $0.1 million from the sale of 41,152 shares of common stock pursuant to at-the-market stock sales.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase in connection with our ongoing and planned development activities. In addition, we have incurred and continue to incur additional costs associated with operating as a public company. We expect that our expenses will increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and conduct clinical trials and additional preclinical research for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify and develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand, protect and enforce our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other drugs and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend against any claims of infringement, misappropriation or other violation of third-party intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire and retain additional clinical, quality control and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">build out new facilities or expand existing facilities to support our ongoing development activity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to operate as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, we had cash and cash equivalents of $14.6 million. We believe that our existing cash and cash equivalents as of the year ended December&#160;31,&#160;2025 and the gross proceeds of approximately $5.6 million received from our private placement of our common stock and warrants in January 2026, before deducting placement agent fees and offering costs of approximately $0.4 million, will be sufficient to meet our currently projected operating expenses and capital expenditure requirements into the first quarter of 2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these audited consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with the development of our product candidates and programs and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of our planned clinical trials, drug discovery and preclinical research for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or collaboration arrangements for product candidates on favorable terms, and although we may explore such opportunities from time to time during the normal course of business, we currently have no commitments or agreements to complete any such transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining, protecting and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties and grants from government and other (non-government) organizations. We may be unable to raise additional funds or enter into other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. In addition, our ability to engage in certain types of capital raising transactions may be limited by the Listing Rules of the Nasdaq Stock Market and/or General Instruction I.B.6 of Form S-3 if the market value of our common stock held by non-affiliates is ever below $75 million at a time we seek to utilize our effective registration statement on Form S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Developing drug products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any products for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests in our securities may be diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Additional debt or preferred equity financing, if available, may involve agreements that include </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">restrictive covenants that may limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute existing ownership interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual obligations and commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which is currently set to expire on October 31, 2026. Rent expense under this lease is $115,000 annually and the company has applied the short-term exception to this lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice of 30 days and, as a result, are not included in the table of contractual obligations above. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-balance sheet arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information about recent accounting pronouncements, the timing of adoption, and our assessment, if any, of their potential impact on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_798f7517_5c1a_4939_96e8_051f360d56b1"></a><a id="Item3Quantitativeandqualitativedisclosur"></a><a id="Item7aQuantitativeandqualitativedisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7A. Quantitative and qualitative disclosures about market risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Interest Rate Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risk related changes in interest rates. As of December&#160;31,&#160;2025, our cash equivalents consisted of bank deposits and money market accounts. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, historical fluctuations in interest income have not been significant for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Foreign Currency Exchange Rate Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We face market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency foreign subsidiary&#8217;s revenues, expenses, assets and liabilities. The financial position and results of operations of our subsidiary Aprea AB is measured using the foreign subsidiary&#8217;s local currency as the functional currency. Aprea AB cash accounts holding U.S. dollars are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the consolidated statement of operations and comprehensive loss.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our investments in foreign subsidiaries with a functional currency other than the U.S. dollar are generally considered long-term. In addition, we do not believe that we currently have any significant direct foreign exchange risk. Accordingly, we have not used any derivative financial instruments to hedge exposure to such risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inflation</i> <i style="font-style:italic;">Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflation generally affects us by increasing our cost of labor and pricing of contracts. We do not believe that inflation has had a material effect on our business, financial condition, or results of operations during the year ended December&#160;31,&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2f907791_29ed_4fe8_a585_7096c21412e9"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8. Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Index to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:AuditorFirmId" id="Narr_qxFEa0uezkWQ2yU4OoY9vg">274</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">F-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><a href="#ConsolidatedBalanceSheets_63894"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of </span><span style="font-style:normal;font-weight:normal;">December 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">F-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the years ended </span><span style="font-style:normal;font-weight:normal;">December 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">F-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><a href="#ConsolidatedStatementsofConvertiblePrefe"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity for the years ended </span><span style="font-style:normal;font-weight:normal;">December 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">F-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><a href="#ConsolidatedStatementsofCashFlows_358511"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended </span><span style="font-style:normal;font-weight:normal;">December 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">F-7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><a href="#Natureofbusinessandbasisofpresentation_2"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;">F-8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_314b072e_f1c7_418e_a665_c5cfc54c44c1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Board of Directors and Stockholders of Aprea Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk193187947"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">We have audited the accompanying consolidated balance sheets of Aprea Therapeutics, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December&#160;31,&#160;2025 and 2024, and the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). &#160;In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </p><a id="_Hlk193184609"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. &#160;As discussed in Note 1 to the financial statements, the Company continues to generate losses, has an accumulated deficit and its cash balance will not be sufficient to meet its projected operating expenses and capital expenditures for at least the next twelve months, which raises substantial doubt about its ability to continue as a going concern. &#160;Management&#8217;s plans in regard to these matters are also described in Note 1. &#160;The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management. &#160;Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. &#160;We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. &#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. &#160;The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. &#160;As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. &#160;Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. &#160;Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. &#160;Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. &#160;We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matter</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Accruals for Clinical Trial Expenses&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;">As described in Note 2 to the consolidated financial statements, at each balance sheet date, the Company records its accrued clinical trial expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants in connection with performing research and development activities, and in making that accrual, may depend on factors such as successful enrollment of certain numbers of patients, site initiation, and the completion of contract milestones. The Company accounts for research and development expenses based on services that have been performed on the Company&#8217;s behalf and the level of service performed and the associated cost incurred for the service when an invoice has not been received. The Company&#8217;s accrual for clinical trial expenses of $0.9 million is included in accrued expenses on the December 31, 2025 consolidated balance sheet. The amounts accrued for clinical trial expenses represent the unpaid clinical trial expenses based on the information available to the Company at that time.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;">We identified the completeness of the accrual for clinical trial expenses as a critical audit matter due to the materiality of the contract values between the Company and certain clinical research organizations and the need to determine progress or state of completion of trials or services completed. This in turn led to significant audit effort in performing our procedures and evaluating audit evidence relating to accruals made by management.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. We obtained an understanding and evaluated the design of controls over the Company&#8217;s accrual process, including the process of accruing the expenses incurred to date based on the status of the clinical trials. Our procedures also included, among others, reading agreements and contract amendments entered into with vendors in connection with conducting clinical trials, evaluating the methods used in developing the accrual for clinical trial expenses and calculating the amounts that were unpaid at the balance sheet date. We confirmed selected amounts accrued directly with the third parties involved in performing the research and development services on behalf of the Company. We made direct inquiries of financial and clinical trial client personnel regarding status, change orders and progress towards completion of clinical trials and descriptions of future commitments.&#160; We also examined invoices issued by and payments made to service providers after the consolidated balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:AuditorName" id="Narr_sLGkZC8dpkOE47FrxQFNpw">EisnerAmper LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 2.15pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#8217;s auditor since 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EISNERAMPER LLP </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="dei:AuditorLocation" id="Narr_bro0QsOvZkO7D7qfz53VKw">Philadelphia, Pennsylvania</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 16, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item1FinancialStatements_974418"></a><a id="PartIFinancialInformation_655269"></a><a id="_d0fd4925_7735_4e44_80f2_72166c8f08bf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><a id="ConsolidatedBalanceSheets_63894"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ca1467be_1284_4528_8de3_99d1c6e1fa34"></a><a id="Tc_LcB4TZKeC02x_EmxksNa3w_1_2"></a><a id="Tc_YccEi1LgJEqoRZ26KAA6Rg_1_5"></a><a id="Tc_g5Olgcexv0m6TzLKaXzm7g_2_2"></a><a id="Tc_OVV1T2ZOhE-XTQ-3qe_J3w_2_5"></a><a id="Tc_OMTg9OiVvk-DDj0UGpvugg_3_0"></a><a id="Tc_XGLxRT7PmkGPFqUAoibi7w_4_0"></a><a id="Tc_DFJfSTdy5Uyma_8IoVtCNg_5_0"></a><a id="Tc_LLcrwy4-f067kLruXsMjoQ_5_2"></a><a id="Tc_JwEE8jqjIkeYrbZIHUYUaw_5_5"></a><a id="Tc_2fzRC6nfME-C1q3434mJSQ_6_0"></a><a id="Tc_NCA-XcjoiE25bxadEk8hZg_7_0"></a><a id="Tc_OAZ6ufJsSkmvrnJQGXVdBA_8_0"></a><a id="Tc_U3S9JnbSK0WDyxZRM7g32w_9_0"></a><a id="Tc_I5iyj0PjqE606Rl-qi6oyw_10_0"></a><a id="Tc_9RokxGb6Y0WMLKymnX6-vg_11_0"></a><a id="Tc_v4l46pYhzkuIj8YA6nlxKw_11_2"></a><a id="Tc_vyiHHt_xmkuIuVXOmJV5WQ_11_5"></a><a id="Tc_lTVMi3HjlU-JOqYHH6ZjzA_12_0"></a><a id="Tc_iMdcQjV7YU-7TyyV8fIaig_13_0"></a><a id="Tc_c_im3rv180ON-hGlJW8KUg_14_0"></a><a id="Tc_EhFkDryoHEGfs8axTzK0Eg_14_2"></a><a id="Tc_dKOgHS17lkeTdEzPefO5Ew_14_5"></a><a id="Tc_imGkExolhEqTK8w7JgeQZQ_15_0"></a><a id="Tc_Z0_t3EZhOUmqnroBaUpKfA_16_0"></a><a id="Tc_QSj-cihAiki8spUXz3dtZQ_17_0"></a><a id="Tc_2wfYDiuEQ0WyGXxyvJMCxQ_18_0"></a><a id="Tc_wzVfqD4WtUq3cgn4bDStDQ_19_0"></a><a id="Tc_j3FHNdE-nE-H5_5yetvDXA_20_0"></a><a id="Tc_bLhHDYPIU0GwGaM5GKMUqQ_21_0"></a><a id="Tc_3VZvd_SbE0ClWe842ICbHA_22_0"></a><a id="Tc_o0u07dTnQE-xu0kfFgPRQQ_23_0"></a><a id="Tc_CEWCBw-KbE2ibzy3OwGrmQ_24_0"></a><a id="Tc_3uNELaMunEiwm-IU2FoS7A_25_0"></a><a id="Tc_SU-VmJX2YkS_D61mtXTHyg_25_2"></a><a id="Tc_RMcUizm21UOwA9l-0mKR5A_25_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_WH4kw_yB1Uu_iqJSFRP72w_5_3">14,599,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Vw3Kt42_b0y-g-UnrJu-8w_5_6">22,849,885</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_Xkk7m7WwMU-3rReRONsb1Q_6_3">961,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_0nMVAQCD90mEBFjVTNMJ_w_6_6">726,254</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_zysOtpyKu0qH6NDGzrRMrA_7_3">15,561,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_muDAIicf00WyfuwHABa9fw_7_6">23,576,139</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_xGIB1O5YE0qyneRaYYzrkA_8_3">59,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_Ae1u05TZiUygyI1A1S578Q_8_6">81,522</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_1nz5a065KkmYZRGaZyzzuQ_9_3">41,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_PDWwMooQtU6LVopTKpYu2w_9_6">40,170</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other noncurrent assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_ND4tW0z2oU-v0FOZCyV5QA_10_3">271,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_zOWDU1p2qkyu1scWNlrIEw_10_6">281,662</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_2iftL89HlEesf7vasEEwvQ_11_3">15,933,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_FxnvGAQPbk-QN1D_FoiOZQ_11_6">23,979,493</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_RMBaN6_y8kW63ToJ_80jAw_14_3">713,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_rFinBbH_oUCvEqYDPmyQag_14_6">1,352,240</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_yFRS6KIUgES5dbBjPKdO4A_15_3">2,050,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_ga-y0TED1kqC1ju0eYS1Tg_15_6">2,008,735</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_1sFdAX2leEKa38oiMd4nZg_16_3">2,764,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_4PLtS-kw802ttYZkWCTbIw_16_6">3,360,975</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note&#160;9)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Series A convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_IqJ6BLiOP0GbkNjfTG1rXw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_dwII8s4ICUaxs9kyMHMjwQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_AlFrP1vyfEuDAb7xbKAo1g"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_ikiJ5NJMHEOGwLHrsZFnow">40,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_bLLfu64C_UqFMMrFSm-XWA">31,194</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_jPoDLkuP9E6HZC_LJ65ORg">56,227</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_f-pPCqIy8E-ac35O2X99gw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_Wt4Cqy-K_0eS7ycaDAWEUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2025 and December&#160;31,&#160;2024, respectively</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_PX5_uJFl7E62IMVcvzPZSA_18_3">727,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_AsXw5-PGHkmviFfMGuW-Pg_18_6">1,311,063</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_NpeZImQCWku5w7MGerAulw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7D-W8TrOPEyOwldZFCLjsw">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_GrRbU7DE6EiyC8act_e-Og"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_bCKlwD_c3kiiO3-z1HHtTg">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_iaH-4tdqJE2z9N-qQAaY9A">8,192,538</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_lAvkuqlHpEeXndczZt2VZQ">5,481,055</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_T-uNdx4YOk20X25X5TdsLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_VO-coJ2sxUK7ihYecHFhqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2025 and December&#160;31,&#160;2024, respectively</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_mHzdgiq4X0afInPFmmQEDA_20_3">8,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_oQGUjjZMd0SmozgHjGqAUQ_20_6">5,481</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_80vrbRSz3UW80RTZd5xwUw_21_3">356,709,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_QQjX-cmme0yg0IsQRJ4PdQ_21_6">350,971,225</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_rfjQ7aO-W0q85IuSPAaUsw_22_3">10,634,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_5elbOoIc80S6RxijAvbHTQ_22_6">10,627,379</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_2ZZP2fLs6k2kz-UL3PmSMQ_23_3">333,641,441</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_SrNzXnsVbkWMev3VjDFK5A_23_6">321,041,872</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_8zSLGN8S6UyWJ9N7Ny9Xvg_24_3">12,441,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_FY42SZuqsk-LIieNK0576g_24_6">19,307,455</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders' equity </p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_C-az3pPIxEmC0g9FuydMaw_25_3">15,933,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_yVb0bf550EiLG_xW5uCrPw_25_6">23,979,493</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9402fb6e_b41a_4793_be82_22a0a0f1deb8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><a id="ConsolidatedStatementsofOperationsandCom"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</b></p><a id="_32c216e9_7942_477c_8dae_f11303642b8d"></a><a id="Tc_oJF6vfpdXUO1Wmlx0MgUrA_1_2"></a><a id="Tc_gG8jRjn0Lkm1LN-oBKfZZw_2_2"></a><a id="Tc_ldtiuq-GKkCiCb-dsbCqIg_2_5"></a><a id="Tc_9dd-eXK3m0enQmbDIwUQsg_3_0"></a><a id="Tc_lhQx-PennU-4W7plJCdjZg_3_2"></a><a id="Tc_SDRCvHT_ckyezjVm__BsAQ_3_5"></a><a id="Tc_c4qkg0uza06fRep_mL6ypQ_4_0"></a><a id="Tc_Yz0MRihWTUKZN44aCj1GIw_5_0"></a><a id="Tc_19Ymj7OZtEWllH_S3a6MnA_6_0"></a><a id="Tc_MlUras_XaUONGPvbQhf7HA_7_0"></a><a id="Tc_F6v50hUS7UuVU0wAiJ5caA_8_0"></a><a id="Tc_0OIB2CvSZkWTlAK2mykV4A_9_0"></a><a id="Tc_ZAm5C4KY-UiBJMZnrRe6XQ_10_0"></a><a id="Tc_TaezFVNjHk2s8oLMt4xVhw_11_0"></a><a id="Tc_U5-wbjLNJ0mpnF1DEXxCvQ_11_6"></a><a id="Tc_hUV509UGP0W_xcafsKnjPg_12_0"></a><a id="Tc_k3CtHtdOTkOAygAirlD7YQ_13_0"></a><a id="Tc_Q7wtFsPEUEGwFNanOAPv7A_14_0"></a><a id="Tc_j880GSKTTUqMQah8_fMSTQ_14_2"></a><a id="Tc_DJOEShg7vUO6ZcMv6Nr-tg_14_5"></a><a id="Tc_0nHUCW1F0Uack3NBzwcpRg_15_0"></a><a id="Tc_WBl0xyimtEaR_wV39t5vjg_16_0"></a><a id="Tc_qL0WGAcPk0KmmEsrSdpUzw_17_0"></a><a id="Tc_k0CWjdz2F02Vh9Oz45X5dw_17_2"></a><a id="Tc_SCGG2n3dVUingVtLAYYFZA_18_0"></a><a id="Tc_2EcPacxG4kWfuc9n-ByLqQ_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_XQVUQPgy5UmEFfZl6_W4Sg_3_3">285,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_S4be3dchUEOFgCEfAu0E5w_3_6">1,502,581</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_0h42JqRxxEaGRMuX90gkRQ_5_3">7,043,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_zYa1hx9QU0GLuhAkS6jn2w_5_6">9,363,537</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_f4UMm83Bz0CIeloWHypZqA_6_3">6,476,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_bjY2Tm59xUyFQ3QmhK57Eg_6_6">6,458,699</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_QUzfox4yM0-kgWy4-Duyng_7_3">13,519,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_zBGHx3RkWEifwRNayvVYrA_7_6">15,822,236</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_67jdReUGgk-XIfps8O8-fA_8_3">13,233,836</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_IWwpZrIaEUC0GSTTAh6YPQ_8_6">14,319,655</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_x_yx5gYG4UCCb_Bqhqp8aA_10_3">652,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_Sw_3m9kvb0KdOF5xGhIYeA_10_6">1,289,144</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_gUjG6t6s1ES8T9XOEQauoA_11_3">77,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency (loss) gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_XAx3tbcHh0y0Pu0e5T1AJQ_12_3">95,319</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_i5Orm--gkE-lptrIS2knaQ_12_6">71,800</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_LLJFjp2dN0-1MvLzc2AT1Q_13_3">634,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_v_5SiMkBDkayga76EqiUew_13_6">1,360,944</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_CL4lvuO1xUaI_ZFbOyx16w_14_3">12,599,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_I8VLKocUmk-j-syDbZZDlw_14_6">12,958,711</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_tl41kbCtOk-WRyWBvGJ68g_16_3">7,335</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_D965BVoa1E2fKMm01ofYMg_16_6">16,106</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_J0lcz_nBSkiJFI2eDn_lkw_17_3">12,606,904</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_choOLT4pd06BQPY2EDnDbg_17_6">12,974,817</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_UtaHMkDmT0ap2lFEPXUUqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_uBrdFnNaP02BXg-hZCjE8A_18_3">1.93</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rVAU4-Gn2EmhmVcPiU32CQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NJkTqWRXCkKNopYEZ0Zu2A_18_6">2.35</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:70.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_hnEjoz-6S0GJodnX01PpbQ_19_3">6,538,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_uo63NEJL9Em8OFAxWTV5QQ_19_6">5,509,921</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:3.45%;padding-right:3.45%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6680a84e_6be0_4a30_b25f_b09885a2af2e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><a id="ConsolidatedStatementsofConvertiblePrefe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0d4d26a2_c1a8_4700_a85b_fbeebf4ec7f8"></a><a id="Tc_jvIV3-IgykKOqE1mcxqFEw_1_12"></a><a id="Tc_6oE-wwLDTE6sgluhmb62Wg_1_15"></a><a id="Tc_dFByizYk5Ey_ooVS1qgZeQ_2_2"></a><a id="Tc_3s86BTdRdkOjsLg7KonB0w_2_7"></a><a id="Tc_3Nq4J75rVkuJ_SWTm0NfPA_2_12"></a><a id="Tc_otnF432W7UeALOK9aQH3JA_2_15"></a><a id="Tc_QaBczCUkrUCNC7ebMm4h4A_2_18"></a><a id="Tc_W9lI3oV-oEatDUcGqOReCw_2_21"></a><a id="Tc_vXsvOT4rd0uc1VwHkyO4xw_3_2"></a><a id="Tc_yZCdDrrKK0idOMmBcJtd_Q_3_4"></a><a id="Tc_fMWmiCqK4k-6MHq-JpGIkw_3_7"></a><a id="Tc_EAiyxL7N6UqniXFLulgAJw_3_9"></a><a id="Tc_lhVhubJHAkCoNHIcGFB0yw_3_12"></a><a id="Tc_3jKcaTw7V0qqnj4JLr6xpQ_3_15"></a><a id="Tc_MKPmfY9zkkeLm3BkumrHDw_3_18"></a><a id="Tc_KAt3dcIjIEGOmnwXZCceOw_3_22"></a><a id="Tc_8jxfx_4swk2QhwniIrsKoQ_4_0"></a><a id="Tc_oZYLhEzoh0iuuPQx2DgUGQ_4_4"></a><a id="Tc_znxrMYXSi0q9bwTYYohGMw_4_9"></a><a id="Tc_y935lB7FYkK_qYl1qppD9Q_4_12"></a><a id="Tc_DgUWYe4xHkqVAIwBdqTMGA_4_15"></a><a id="Tc_EMXYwX72QUeLxjJEMIZ8jQ_4_18"></a><a id="Tc_ONhawUAp9EGbkkSanZL08A_4_21"></a><a id="Tc_esDjHH7T00mFNtmKimhiEw_5_0"></a><a id="Tc_bIkwrvlrHEyWKJhZ-u7T7g_5_16"></a><a id="Tc_B-KhSv2eaU6fnKnDH8NYNw_5_19"></a><a id="Tc_mdWP3T-6Dk2cbJ0mZwggBg_5_22"></a><a id="Tc_Cpk3sblRk0WNbNs9FmsuFQ_6_0"></a><a id="Tc_rB6HS4S_4UOcz3Juj6gK6A_6_2"></a><a id="Tc_aYF8Izve1E65k9em0uYWpQ_6_5"></a><a id="Tc_p3btbH9dQ0urGUw6cutAGg_6_16"></a><a id="Tc_MEPqSSNec0CxS2pmdMjeQg_6_19"></a><a id="Tc_qqyom_BduUybVKYEz-Cv8w_7_0"></a><a id="Tc_H2SSMOZES0esLEDXWvKONw_7_2"></a><a id="Tc_ItcMuuHLfku_Evg-K9Oc2Q_7_5"></a><a id="Tc_fPh2jJvjOkyoIQ6JlUr9Jw_7_16"></a><a id="Tc_sMWAZ9tw70aW1zb8U-csAA_7_19"></a><a id="Tc_s-kJaUHjw0qHL7dbllL2lQ_8_0"></a><a id="Tc_DxEhrnhHEku8DtEh8ND-HA_8_2"></a><a id="Tc_ChIsUW9qvkywD9CqHVmiDg_8_5"></a><a id="Tc_4tPNktwcC0u_qhOH0EX4Kg_8_16"></a><a id="Tc_zez3VUHWRUCMYVa5CFqnqQ_8_19"></a><a id="Tc_z7N2I9FpiU23a2RYDUIdTw_9_0"></a><a id="Tc_CYhFaoN830qsdwW3aw8dhw_9_2"></a><a id="Tc_XQLa-LTZPkyChXvkUtcAYA_9_5"></a><a id="Tc_XTz49sydDUSwy42H3tUz4g_9_7"></a><a id="Tc_-M6RBHLg3UewoYLQXtOpbw_9_10"></a><a id="Tc_8N54JxCqrk2FmAOgN2qGDQ_9_16"></a><a id="Tc_YTIHrSppmUOeXXGJlWOSbw_9_19"></a><a id="Tc_jt5cQK7iH0m7tUn6VuLmTw_10_0"></a><a id="Tc_WLYPM2DQBEemLAF9ui3hMg_10_2"></a><a id="Tc_yoL5R89CrkO5RM4BfrNsMg_10_5"></a><a id="Tc_wLP-OqCRUEyNxl7Envq3AQ_10_7"></a><a id="Tc_E69j67Y0PkajOHfHQKqgdw_10_10"></a><a id="Tc_5XXELeLxpESSCXcht78qBw_10_13"></a><a id="Tc_36FX58WGq0W--4RUpIrtQw_10_19"></a><a id="Tc_dUIzFjVrfEa7rkyxKXyHvw_11_0"></a><a id="Tc_BspQ50M2BUuMWq8AN3utTg_11_2"></a><a id="Tc_gahiHAghJECKGekzJKmXJA_11_5"></a><a id="Tc_PTxG7nYzr0605HCMALRjRw_11_7"></a><a id="Tc_7wjE2iffV0Cf0EaYGGrW-w_11_10"></a><a id="Tc_yniiO6xCok6zs0dBmhNvgA_11_13"></a><a id="Tc_T9jJ5lr8tkCZfnWAhuTyCw_11_16"></a><a id="Tc_P23zg4RkfUmRu2Gqcy9MEQ_12_0"></a><a id="Tc_dUbFhEbNmk-8p2GYNaaJGg_12_4"></a><a id="Tc_z2SHmckvG0qF-8Z8QayyNg_12_9"></a><a id="Tc_TCdTD07N3EWXiJz3gLF-RQ_12_12"></a><a id="Tc_kR52mjDDn0SZ5FXYr9xDAA_12_15"></a><a id="Tc_pZueJ3g_uEKILyNoPlIWtg_12_18"></a><a id="Tc_a7hrW2SzH0eGWPQu9Vkq_A_12_21"></a><a id="Tc_16aTFF_I-UCVbMIO1HjlOw_13_0"></a><a id="Tc_VwdluYP2mEybQVM75jn7Lw_13_16"></a><a id="Tc_-gJ00goitEWsyGpqUiQxww_13_19"></a><a id="Tc_JnOnBnPVu02wQpSW7f3bFw_14_0"></a><a id="Tc_wbxrfY4pwUCm6d7skDYjzA_14_16"></a><a id="Tc_P3g261TMoUi3kKPjYrYlBA_14_19"></a><a id="Tc_RJoS5ovE3USIdHic70RELA_14_22"></a><a id="Tc_8OQ1D0CpdkClwdDdSDslrA_15_0"></a><a id="Tc_VN2j2qd_CUO35_IUxkWZ0w_15_2"></a><a id="Tc_rtnW_51B10SDDj5qtjBGug_15_5"></a><a id="Tc_2l5KCmksJ0uFkaCKOi7ZYg_15_16"></a><a id="Tc_2Th8l8hlkkudUG6vSF-1HQ_15_19"></a><a id="Tc_1UUhHKts3EaO2GDOxvSTKg_16_0"></a><a id="Tc_HkR4k6HX_ECAUQc_m9Hf9A_16_2"></a><a id="Tc_wSPO6s0UAkuicPAcI8KYMQ_16_5"></a><a id="Tc_RhmXXZgPkEy2Y3avO7Hkrw_16_16"></a><a id="Tc_4DfdWooeAkGawddcBBB6nA_16_19"></a><a id="Tc_WoJ-F0EFHUC33fQk7OT6_A_17_0"></a><a id="Tc_LzvsU8cfsEOGSLcaq6jn9w_17_2"></a><a id="Tc_DFEZNNSRVkmWd5Cc5VIc9w_17_5"></a><a id="Tc_miKKEDDFY0uRVYh7ntMEXA_17_16"></a><a id="Tc_f9cCCUZub0m4tO_CvR97fg_17_19"></a><a id="Tc_TLHk6KY20EuBn2WfX47NRg_18_0"></a><a id="Tc_KKiF7fJimku8UXJGDBg-FQ_18_2"></a><a id="Tc_PyzIWtKnC0GjNeE_qFH4yw_18_5"></a><a id="Tc_V8iXRI0_yEeNC5G5UJjHxQ_18_16"></a><a id="Tc_UCMxvdzjSkGCwmObNC7Ojw_18_19"></a><a id="Tc_dZq0MLdd_Uqedb8de-grhQ_19_0"></a><a id="Tc_rUCgauYFi0y1LyFQpFigoQ_19_2"></a><a id="Tc_K95moWKrKkOyNeJV0dcyXQ_19_5"></a><a id="Tc_xSwhK4O4JEG22sy1dD1P7Q_19_7"></a><a id="Tc_xxY3RIYG90Ckeg6GGSslhg_19_10"></a><a id="Tc_8_Bxxc-Kkke70g3u436G2Q_19_16"></a><a id="Tc_PEZrO9D_kkKkXCqe8e9wZg_19_19"></a><a id="Tc_snJXgwkzQ0KDTMEJXh6Hvw_20_0"></a><a id="Tc_hQ3ITnPNEEmHaUAhdl_Ufg_20_2"></a><a id="Tc_J2OcyfpY7kmb4XeY5_Oc_w_20_5"></a><a id="Tc_tXfrwyz1EE281jl0WpREUw_20_7"></a><a id="Tc_QLts-YvidUqtD1jpMLEcfQ_20_10"></a><a id="Tc_K8SjRwNKP0iS4lbn-ZFXTg_20_13"></a><a id="Tc_95sXoPaIIU2fsrodPCdarA_20_19"></a><a id="Tc_WWoh0wJ_9U-LGdbz54vzzg_21_0"></a><a id="Tc_C6IZRxmFAEaFMb3xa117QQ_21_2"></a><a id="Tc_Ba84ZQVwZkWS5G6KI273QQ_21_5"></a><a id="Tc_Lbul1I66ukelO6aoCFb-6g_21_7"></a><a id="Tc_GbPIEOG5qUu1GCH01oDRXw_21_10"></a><a id="Tc_FvGvU-uwfUGHyJYNoZ_keg_21_13"></a><a id="Tc_Fehlnoj73EedbJMCEDCvlQ_21_16"></a><a id="Tc_AV1uXhx13kS1fGh2icy-tQ_22_0"></a><a id="Tc_WyAk9rihsEqVnTnbnpVQlA_22_4"></a><a id="Tc_h3YxUnnlI0Gd2Kn1Ep-DzA_22_9"></a><a id="Tc_HrJ5NQQts0-9xLyN1APQ3Q_22_12"></a><a id="Tc_yNA5Qlaj-E2l9aNPHdq_vQ_22_15"></a><a id="Tc_PgPdrQohw0OxOr_W0FUDAw_22_18"></a><a id="Tc_68itWo2IDk-IdT_0ndrf9A_22_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.07%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;A Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total stockholders&#8217;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_8Ws7dVYx6Uqf69viL-JZRw_4_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_nN0JDZuCJ0uN6Xm8hK7mTw_4_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8TENrsfRpEip6COKOMdc6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_c-qD3vGhZEOw6KojnMPmPQ_4_7">3,736,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8TENrsfRpEip6COKOMdc6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ckkPIu-pHEmTx8GqgsVUEA_4_10">3,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uxcYngPZ4Ueh1LhH_AOjNw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_dvMYorMrAEmBFAu1k_H3gQ_4_13">335,644,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HdVMa0DdwEmc14llqTxLvA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Sarlsf6vnUOrXNJPZiH_rA_4_16">10,611,273</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W8VMjZfm3kqAuG4zdxRBGg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_rJjQ7igR1U2jE8mP8VdzTA_4_19">308,083,161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_u-klsmDGyUiLo2nwvg6xwA_4_22">16,953,506</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_hsDIZixODk-nEmWp-57o9w_5_7">10,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Tc_kt06ERe6cUinrCnhTeoIFg_5_10">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" sign="-" scale="0" id="Tc_82VZs14Nk0ONh4SdrA0Nlg_5_13">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and pre-funded warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_osfMVAXMfkGIj-zduuAjSA_6_7">1,687,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_F3kuEBpfVkOaXyj1p-Oamw_6_10">1,688</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_31qY-_bfpU2Ki-IGygsvpA_6_13">14,685,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_zgmcxKSiXESqquhtjPlE-w_6_22">14,687,490</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock pursuant to at-the-market stock sales, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_3j5lWFF8JEWOa1ah--AL8A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_HkQpgUUpqE2nttuKyrcnFA_7_7">41,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_3j5lWFF8JEWOa1ah--AL8A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_eykU_eobrEikptvqQDB7gA_7_10">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember__-_le6ti2UOYE_b8iPNg5g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_2xzJmlI3oEKKX_9puFDuLQ_7_13">134,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_0OTUY_lcakyo9dePfZ4fUw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_BCZlPjFsuU6EVBmjslgG9g_7_22">134,405</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock to consultant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_TT13S4P6J0ukgjkzaQR_NQ_8_7">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_PPYCSbQAmUOnSu9srVdSRg_8_10">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_7etNWwg5UUKCIwC5F2q-GQ_8_13">17,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_WZujxwp5QE-CCqDk4JY_dA_8_22">17,435</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_J44a7fOKWECwbntivlVquQ_9_13">489,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_sWDEFjVCckKm0vsK7aI9pw_9_22">489,436</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rfpje9runUCtL_Q69zMdAA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_p_TLWjjQDkuXRew_gBjMzQ_10_16">16,106</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_8iFkoDViskunRHc_ug-9Qg_10_22">16,106</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7BZm_z9xCkSv0FQpO74xqQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_RiIbtuHZLEaP8muV1zc4fA_11_19">12,958,711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_W6F9j7tp5ECrA6VdIKHsFg_11_22">12,958,711</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IJ8zJ18I4EClq_KQWPYSqw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Y7iSv2ZZUUSO9Vz2C7nuAA_12_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IJ8zJ18I4EClq_KQWPYSqw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_CQmv_61wvEKs94TBuFgJ6A_12_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K43Lpib1Z0SaiG-7BlUL6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WrearMmAwkSiDIj85b06Ig_12_7">5,481,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K43Lpib1Z0SaiG-7BlUL6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rs3m6SwqD0C60VIUz-Lf7Q_12_10">5,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T49vl6RPsU-nKirVaTJE3A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-P0SSQyaNUOVq496epfjcA_12_13">350,971,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7S-nLeE1P0KWLPTOkK9J0Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_2MonwH2kWUy3U0f0YT4Uhg_12_16">10,627,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F_cddC-SRkOjmWWwt-fqVg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_X2FU_AZw1UGamaZvExtHWg_12_19">321,041,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_mALnVDEh6UaxUj_ccVn_uA_12_22">19,307,455</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BAoeaXQje0CtAvGY50doJg" decimals="INF" format="ixt:num-dot-decimal" name="apre:TemporaryEquityConversionOfStockSharesConverted" scale="0" id="Tc_38-3p78ik06RiPCGQAsRYQ_13_2">25,033</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BAoeaXQje0CtAvGY50doJg" decimals="0" format="ixt:num-dot-decimal" name="apre:TemporaryEquityConversionOfStockAmountConverted" scale="0" id="Tc__IfxYTwQK0irS2hA4XQkFw_13_5">583,702</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_5zZFaPgozE6pQ25HhLSHJA_13_7">12,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_BpPRnZpz4EK1uFQd9f2SVA_13_10">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_jrZKjI57r0KNSErXAaDbow_13_13">583,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_6clkwkQC70O9xU_bLN_DXQ_13_22">583,702</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_7pSGlW5j9UWzOci5vYwY0w_14_7">17,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Tc_Wr7zKGkDkUK1NcZYUtoA0g_14_10">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" sign="-" scale="0" id="Tc_un9amfXwzkS7hf1aCYfFlQ_14_13">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and pre-funded warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_tRVpbnz5_06cGJ1BHnzhNA_15_7">26,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_L1GDsPY59UKVRpnISr525A_15_10">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_9cZremIV6UySkPyksP2oDg_15_13">2,724,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_rIm9aVZ4N0-NWL-e3wk2OQ_15_22">2,724,922</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock pursuant to at-the-market stock sales, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_ukSBibSsYkOC0ffd9tzE2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_PNCtVVOCJUe4g2EbWlVX2w_16_7">1,337,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_ukSBibSsYkOC0ffd9tzE2w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_wpkU-wMLBE-dF36-DCcImQ_16_10">1,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_X9yxNCi1eUiwkdxf-fOimw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_EOQ9oBSuvkaAaAvnzfcmcQ_16_13">1,913,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_tzboIpMCLE6jmiSEJoPsxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_vq5PQTtMM0yzBTTbOpsG6Q_16_22">1,915,225</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock to consultants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_65GHa0Yxzk6jvNBJG7rWmg_17_7">27,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_OcJCDvc270aQfa91Xcgdew_17_10">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_sW7z2gZ0NkmW7t43GQPquw_17_13">39,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_No2vYpCcf0SNmB9aN0CXTA_17_22">39,050</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="INF" format="ixt:num-dot-decimal" name="apre:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_qpvQHiWHt0WVRQI5ccUhkQ_18_7">1,289,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw" decimals="0" format="ixt:num-dot-decimal" name="apre:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_UScn8lC5xUSbiSf107VzBA_18_10">1,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw" decimals="0" format="ixt:num-dot-decimal" name="apre:StockIssuedDuringPeriodValueWarrantsExercised" sign="-" scale="0" id="Tc_fevU9B_sCk2ylqQkwup2hg_18_13">1,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="apre:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_nsHI97AmIUi_OkOgQ5JaZA_18_22">91</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_PlEG9mSHQUagFpeJNPD3Rw_19_13">478,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_Y5yrOIX0NEeISbS9KqkEKw_19_22">478,141</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rw7WXSTzPUS_r8Ou3XFKVg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_7b9DdsYGCkqEvDDeA2ED1Q_20_16">7,335</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_sA94sZAHq0KGcFqEskj8_g_20_22">7,335</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mRdeq00MTEmoRCUVaSWaIg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_yYlF5fh-b02fR0W_63FP9A_21_19">12,599,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_uhu1DNPfqU6CRr_6k3xTDQ_21_22">12,599,569</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UTwtKV-qkEOxVLKfaZVgbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_V0mY4N0UJ0ymrpjG0mwdZg_22_2">31,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UTwtKV-qkEOxVLKfaZVgbg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_uurZgqVhb0uRXkhW-_HrUw_22_5">727,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtIejotXFUSQPrZvskRYfw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_LqKy6gJL8EKCoLKLDKkuGQ_22_7">8,192,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtIejotXFUSQPrZvskRYfw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_H0JFcdIpG02pzScTUh2epw_22_10">8,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J9HtUxOqeEaXcgWIs4717Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_EXH_CttqT0eLZDQJ-aIvWQ_22_13">356,709,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PilxZKpEyEi9WNFYDfCOhA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_chn_GeV77UCW40cBkTd-8w_22_16">10,634,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAL2DshPD0OdJw_EpkpGGg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_oZY7DrtaR0Sq3zLoAJ3x0w_22_19">333,641,441</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_py0XfPoJ5UaMpADTNjiatA_22_22">12,441,682</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:4pt 0pt 0pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:93.09%;border:0;margin:30pt 3.45% 30pt 3.45%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8012c5bc_6b1d_4583_b918_ab454830e3c4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><a id="ConsolidatedStatementsofCashFlows_358511"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4c190804_d140_4231_a9d8_23a563a01004"></a><a id="Tc_IusP7QY15kS8Em6Ek0BGBQ_1_2"></a><a id="Tc_kmXQ0aMom0aMVzCgqAyg5g_2_2"></a><a id="Tc_c4Y8yBsaEUae5GVwzWEhdw_2_5"></a><a id="Tc_GzQY4sN9d06nfQhCsaMJSg_3_0"></a><a id="Tc_4nIj3Yw3KkS9irJIM45x3g_4_0"></a><a id="Tc_zsnxAhGUik63eysLBPzLfg_4_2"></a><a id="Tc_Z7TnvoG3-Eu6-2__2lWguw_4_5"></a><a id="Tc_5jrAlC_eJ0q42PcIY6w4Wg_5_0"></a><a id="Tc_1H7GCdYig0qit-Q9IXtT5w_6_0"></a><a id="Tc_LC4bEWlviEGYugq2LVA_fg_7_0"></a><a id="Tc_wLVTamvEwEWPfuIkqgmuqw_8_0"></a><a id="Tc_3FzLG2rWFEax7Oy18jJ36Q_9_0"></a><a id="Tc_ziQpqaXA4ESJ2-yYdY2A6A_10_0"></a><a id="Tc__E5G1mI_xEaHlMRZkfMN1g_11_0"></a><a id="Tc_1Hyxkj-cf0O6K6qNUexOCQ_12_0"></a><a id="Tc_9sni6WWmD0CecneheZJUug_13_0"></a><a id="Tc_fF7qf-tStE2aTu1fT3_yEw_14_0"></a><a id="Tc_9TDd4BJ3s0GNnEPwr9GcRQ_14_3"></a><a id="Tc_xXomfvZMfUanxs5CD9ZlmA_15_0"></a><a id="Tc_ovnXfTYCW0OXZC0B-IvF2A_16_0"></a><a id="Tc_5zasE1qApkqvIX01Hhi8BA_17_0"></a><a id="Tc_U33QPwfEc0q_XnwUffvC3A_17_3"></a><a id="Tc_cX0mC5y8dEG0-k3vB1oVzQ_18_0"></a><a id="Tc_XBsceQms5ke1VXlaaUk_3w_18_3"></a><a id="Tc_ApbgmApcwESi981sJZPe5g_19_0"></a><a id="Tc_jh4dmyHRFE6t4mZ_jp7dcw_20_0"></a><a id="Tc_qAlzAGdRd06M_Rlz8g1hBA_20_6"></a><a id="Tc_E3cPUt9LGkS6Kccl5N4z9g_21_0"></a><a id="Tc_-tSnc_RtH0OWOUug1eJFuQ_22_0"></a><a id="Tc__UvxnnZ6IkCE5_Zcy7OM1w_23_0"></a><a id="Tc_tpo_lBTWrkGqk_MK3oXVBw_24_0"></a><a id="Tc_OG278bPW2ky--OBvXA8cXA_25_0"></a><a id="Tc_TebwSFryfkCCqUJQERX4CA_26_0"></a><a id="Tc_ChF3iq2WeUibz0ubbY8TLw_27_0"></a><a id="Tc_3fmfpJHor0-Gts63m8g42g_27_2"></a><a id="Tc_0wxEBK0it0-4XkGODsJauw_27_5"></a><a id="Tc_24L_GpjMxkqkXDLuRbe_fQ_29_0"></a><a id="Tc_7a3By_kHIk-H9MorH16drw_30_0"></a><a id="Tc_Sq49UWvzp06HkOIPmG4pZw_30_2"></a><a id="Tc_CszC-71-q0ePiAy7f-ErvQ_30_5"></a><a id="Tc_7YLS1B4z60SHaxJoI27BuQ_31_0"></a><a id="Tc_yY569KFMB0i-cQzVGjN62w_32_0"></a><a id="Tc_EOiXP8Ve8EqRU8U5S7vJZw_32_2"></a><a id="Tc_PpiZYAn9sEu_wgA08ouYcw_32_5"></a><a id="Tc_p9x1re28K06R59m6WvSa5g_34_0"></a><a id="Tc_5xg04rns20Gxf3uVZxIbiQ_35_0"></a><a id="Tc_q9S27yW_p0Gy0b9PpsVu1w_35_2"></a><a id="Tc_8JPhJPRyeESUUHNFA19trw_35_5"></a><a id="Tc_8cmfQYK0fE2uzHLj2GqkWg_35_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.041217804%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_phKZIxvKZki5dNYyz4xJRQ_4_3">12,599,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_4OdbiXkUhEG4J4HgWE4neQ_4_6">12,958,711</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_LIo4yw6-hEGgT8wPeAfbUA_6_3">21,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_IbdhY3DK_EmvhJQFREneeQ_6_6">22,318</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="0" id="Tc_mPjhEP-x2EqIcqKxzDIwgg_7_3">478,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="0" id="Tc_PozDa3PoC0S_5KagLKWUZw_7_6">489,436</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Issuance of common stock to consultants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="apre:NoncashConsultingFees" scale="0" id="Tc_aSN8N4qZqEqxPpVn3dgUjg_8_3">39,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="apre:NoncashConsultingFees" scale="0" id="Tc_Mah4rp5wMUqUIbGbn8-SyQ_8_6">17,435</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Foreign currency loss (gain)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_Zj4s0rHaTkC_r5udofMA1g_9_3">95,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_lXXAbTHP9EOUuKhJdRJhGA_9_6">71,800</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other current and noncurrent assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_DH-QQrRH2UueEPTR-kYJXw_11_3">217,906</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc__lYowyhgkE2NLd4geCjzjg_11_6">96,674</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_vwNM9qE_j0SATsOOpGDcLQ_12_3">646,701</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_YMEpaFMBKkaUbDvfVpp6bA_12_6">314,207</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_2gWDaCTsTkWJLONyiyZ8KQ_13_3">64,488</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_khAthY-cT0qoM_ue9G4TNA_13_6">115,541</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Deferred grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="0" id="Tc_2bmEiSkLgk6mqsW7W9YRPA_14_6">528,974</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_xX2rV8apgkW8Lm1xiscqjQ_15_3">12,894,439</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_JUYAJPBz5UacpuvjD9oUbA_15_6">13,556,718</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_kLSWQ1CCn0SOdvnFD5j1mg_17_6">15,478</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_4DUHAwMfykChKvhmt6OkBg_18_6">15,478</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_yeCY05szxEubHSeQqn4srg_20_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_sIRy3tqS-EizkNA8XXY6SQ_21_3">5,047,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_HfiOlvCT_EmhVVPKIFSu3w_21_6">16,140,356</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_iT-AX_1osUusr4ZEuT4XTA_22_3">407,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_N-27zl60OEienk4XxMhBjQ_22_6">1,318,461</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_Z3X-Q7NfeEmgKdYtXUO4lQ_23_3">4,640,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_mJQsioGwJUydFmCjRNRCIQ_23_6">14,821,895</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_wr9JjcU3eEu9CJAHQKUj1A_24_3">8,254,201</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_2lZ6adbUBEip6lzHaWB_Nw_24_6">1,249,699</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_YAsiRHFKDEiKmQOFRnSOvQ_25_3">4,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_y2oAI1NbM0-BGCc2qKBH_w_25_6">7,181</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash&#8212;beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_x2AgZaPJk06N71wtBS0OYQ_26_3">22,890,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_hydXrsU8mU2Y1LMrlvqyAg_26_6">21,647,537</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash&#8212;end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_onwvAvS6sUeek-DBNS_1og_27_3">14,640,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_n7wZxwJZK0ytffzSH-pNsg_27_6">22,890,055</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reconciliation of cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_TI2ZfbaSBE-AyCFrlGkdgg_30_3">14,599,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_a-D3ZmTQqEiJFymzBBvpYA_30_6">22,849,885</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" id="Tc_rJZArZ_8VEuvJd08z9e8og_31_3">41,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" id="Tc_Rr8_l_wREEqGAuDogI8dPA_31_6">40,170</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_o475PSFCbkGu_Rn2yBzffA_32_3">14,640,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_nD6vMBMEaUaPBl1uKBJU7A_32_6">22,890,055</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-cash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series A convertible preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="Tc_OBSc3gUdfU-ASI1Nt3agNg_35_3">583,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Natureofbusinessandbasisofpresentation_2"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_4FMynduzZkSeC97h5YUEkQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business and basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nature of business</b>&#8212; Aprea Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-<span style="white-space:pre-wrap;">stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania.  The Company&#8217;s two clinical programs are a next-generation oral inhibitor of the WEE1 kinase, APR-1051, and our novel oral macrocyclic ATR inhibitor, ATRN-119. We have voluntarily paused further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and started the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation and management plans</b>&#8212;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S.&#160;GAAP&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management and technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company believes that the December&#160;31,&#160;2025 cash balance of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr__5YX357FnEOOPlZfKlLlTg">14.6</ix:nonFraction> million and the gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_28_2026_To_1_28_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_dtwms4JdkkCkrALAA9rEeA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_fmkrvxQ46kqbsWnJBuc_pw">5.6</ix:nonFraction> million received from our private placement of our common stock and warrants in January 2026, before deducting placement agent fees and offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_28_2026_To_1_28_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_dtwms4JdkkCkrALAA9rEeA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_z_YMm5QrG0WzGkSbeQwOXQ">0.4</ix:nonFraction> million, will not be sufficient to meet our currently projected operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these consolidated financial statements. Therefore, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these audited consolidated financial statements. The Company is in the process of seeking additional equity financing. In the event that additional funds are not available, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_nsX7oikbxE2dXRdF0vsNgA" continuedAt="Tb_nsX7oikbxE2dXRdF0vsNgA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of significant accounting policies</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_OA-vMj0f_0KE_5qEVM2m0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principles of consolidation</b>&#8212;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:UseOfEstimates" id="Tb_cuvV8Qc2kEGQuHVZmRBTSg" continuedAt="Tb_cuvV8Qc2kEGQuHVZmRBTSg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>&#8212;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions include, but not limited to, stock-based compensation and accounting for research and development costs.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_WN7pbE6Sj0CM5WiKBcPTew_1_0"></a><a id="Tc_oDKG-GrXBEitVjc9-EDmgQ_1_2"></a><a id="Tc_pqXL6zv6vEmVIH0i8ETB4A_2_0"></a><a id="Tc_hgzpZ4irT0C8dyyt_zRPVQ_3_0"></a><ix:continuation id="Tb_nsX7oikbxE2dXRdF0vsNgA_cont1" continuedAt="Tb_nsX7oikbxE2dXRdF0vsNgA_cont2"><ix:continuation id="Tb_cuvV8Qc2kEGQuHVZmRBTSg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_sW_KehfiB0ictIiA01X6SQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign currency and currency translation</b>&#8212;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#8217; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_OaEjHakQ8EiuHozl-uVpQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk</b>&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_4sWRw4_qIk2gOWtSqz0Exw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents&#8212; </b>The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted cash&#8212; </b>The Company has restricted cash of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Narr_K6FWRfHjSkeUVGyR7i7Sog">41,186</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Narr_hxI0lPkOrUCFNIPhQsrGgw">40,170</ix:nonFraction> as of December&#160;31,&#160;2025 and 2024, respectively, that is securing the Company&#8217;s credit card program.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_wIebo9UGFEidykq3h9E4Mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Property and equipment</b>&#8212;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="apre:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_u0jC7xfaq0i7-lRT2AvsPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_CGXEBDoB80uMJgtwrAZVgw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_3CtQVUR160SZlRwSjhJQ-w_2_2">3 years</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment and office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_OfficeFurnitureAndLaboratoryEquipmentMember_N7HQnrCgnk6dOXicETh-5w" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_l8_2qYJ_Z0aaHSzGIeNMLw_3_2">7 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_TjO__aRXhkOIFaXo3HS1eQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of long-lived assets</b>&#8212;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_bC-TSWnxu0mbQkWtyzJw0A" continuedAt="Tb_bC-TSWnxu0mbQkWtyzJw0A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b>&#8212;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nsX7oikbxE2dXRdF0vsNgA_cont2" continuedAt="Tb_nsX7oikbxE2dXRdF0vsNgA_cont3"><ix:continuation id="Tb_bC-TSWnxu0mbQkWtyzJw0A_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="apre:TemporaryEquityPolicyTextBlock" id="Tb_r-7LgWd9E06EWy20TrsZZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Series A Convertible Preferred Stock</b>&#8212;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#8217; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_wudcW2zq306UVJVc581EPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounting for leases</b>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_MmhwbVqo5UunafekePRqMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b>&#8212; The Company&#8217;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expense. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i><i style="font-style:italic;">Not</i><i style="font-style:italic;">-</i>for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_XKCswMNODECG_VsovjCXRg" continuedAt="Tb_XKCswMNODECG_VsovjCXRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development costs</b>&#8212;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.<span style="background:#ffffff;"> Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nsX7oikbxE2dXRdF0vsNgA_cont3" continuedAt="Tb_nsX7oikbxE2dXRdF0vsNgA_cont4"><ix:continuation id="Tb_XKCswMNODECG_VsovjCXRg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_HlXg3-M4FUqlW6PiGDgPjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b>&#8212;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC&#160;718.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company also awards restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_4n46abSfXUK8D6gH-C_XDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes</b>&#8212;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes (&#8220;ASC 740-10&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_ulxJHbNHc0-FZ605HYIy2Q" continuedAt="Tb_ulxJHbNHc0-FZ605HYIy2Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b>&#8212;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Included within weighted average common shares outstanding for the year ended December&#160;31,&#160;2025 are&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6EMQYsKTe06p12xtaqpj7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_xiQSwU_2lkePwv9d3n1ngg">1,813,734</ix:nonFraction>&#160;common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0760ad81_dfa7_4af3_8f58_d48f07a674da"></a><a id="Tc_8smeRWhZDUK4erlnHUPgVg_1_2"></a><a id="Tc_qy6WbjQzJk-JacW-ixnaKg_2_2"></a><a id="Tc_emVXcfrIT06Gf-6UCPbJTQ_2_4"></a><a id="Tc_hSTt441CPkGmRq5aYZS1fA_3_0"></a><a id="Tc_In7B1CJeVEu__cXen9LAMQ_4_0"></a><a id="Tc_BEfHGyyngkiEE6sGugyfAw_5_0"></a><a id="Tc_Um24KfKBgUWLvjGmK7tSgg_6_0"></a><a id="Tc_dcrLOySQq0i-SnuC9Cdtlw_7_0"></a><ix:continuation id="Tb_nsX7oikbxE2dXRdF0vsNgA_cont4" continuedAt="Tb_nsX7oikbxE2dXRdF0vsNgA_cont5"><ix:continuation id="Tb_ulxJHbNHc0-FZ605HYIy2Q_cont1"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_S1lG8LydLkKPYINNj8Bbyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oq3hsrqBykm0qXaMoCxjKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_L_2rGOqpxUKJ_eX9iybtmg_3_2">15,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_yFpzhwTg9Ea949XNcHNkug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_EMhwiOlti0CWDVDIAM82BA_3_4">28,112</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_REODE2xYG0ygbK6Gt1iCwQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_IkZoIIfR1EeVx8DOfKVzMQ_4_2">811,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_05GUoR4aq0ubc6DwiLlP2g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_eNciHTGj2E-S9kXngZIVsA_4_4">715,620</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_CJR1S7G5HUqhj3cWK_5B4Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8Pt6BaAXe0eol09nXzZ6tg_5_2">5,075,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7byEi2lE20ibECXouEsanw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gHE4GgX7T0OP-ebmsKFxEg_5_4">2,194,788</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Pk_DcJsgPU6S0cEiZFfnSw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_jzfsKVZXjEOS04Cwdr8YMg_6_2">31,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_hqbRhvOLLEi90FCZNRS2RA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_P3YABIdQBECRK8OCoqgTjg_6_4">29,712</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_X0FYkAEykkCkRLp9cqubLA_7_2">5,933,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_L6IAwy73bEKTz0d3bX7dHw_7_4">2,968,232</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_DTNZGLX3qEe9hJVOBB1UNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Segment Information</b>&#8212;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment at the consolidated level considering the nature of the Company&#8217;s product candidates and services, class of customers and the regulatory environment in which the Company operates. Accordingly, the Company&#8217;s CODM manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s long-term strategic goals. In making these decisions, the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, and allocating resources. The CODM performs this assessment based on the Company&#8217;s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual net loss versus the budget and then decides how to allocate resources to invest in the Company&#8217;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets. Other segment items included in consolidated net loss are interest income and foreign currency gain (loss), which are reflected in the consolidated statements of operations and comprehensive loss. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_gJmNm3cVbUOL8slkDuEBhA" continuedAt="Tb_gJmNm3cVbUOL8slkDuEBhA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recently issued accounting pronouncements</b>&#8212;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses,&#8221; which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In January 2025, the FASB issued ASU 2025-10, &#8220;Government Grants (Topic 832),&#8221; which establishes a new Topic 832, <i style="font-style:italic;">Government Grants</i>, and provides comprehensive recognition, measurement, and disclosure guidance for government assistance arrangements. The ASU requires entities to recognize government grants when the grant agreement is legally enforceable and all eligibility requirements have been met, and to present grant income separately from revenue. The guidance also introduces expanded qualitative and quantitative disclosures related to the nature, terms, and financial statement effects of government grants. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2025, the FASB issued ASU 2025-11, &#8220;Interim Reporting (Topic 270): Narrow-Scope Improvements,&#8221; which amends Topic 270 to enhance interim reporting requirements. The amendments require additional disaggregation of certain expense categories, expanded interim disclosures for significant events or transactions, and alignment of certain interim disclosure requirements with annual reporting requirements. ASU 2025-11 is effective for interim periods beginning after December 15, 2027, and for fiscal years beginning after the same date. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recently adopted accounting pronouncements</b>&#8212;In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#8221;, which requires disaggregated information about a reporting </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nsX7oikbxE2dXRdF0vsNgA_cont5"><ix:continuation id="Tb_gJmNm3cVbUOL8slkDuEBhA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted this standard prospectively on January 1, 2025, which expanded the Company&#8217;s disclosures beginning with its annual consolidated financial statements for the year ended December 31, 2025, but did not have an impact on the consolidated financial results.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_kmdPCRjsqUmFfQt9iqgw4A_1_2"></a><a id="Tc_GzxYlPHwGEyFDq6CEcTnUw_2_2"></a><a id="Tc_dnCeg38N9EaXOAR3KUIitw_2_5"></a><a id="Tc_3ufclrJuH0iNOY9wv9DQJw_3_0"></a><a id="Tc_wkZWFJMgskekHQYq-j0ryQ_3_2"></a><a id="Tc_39t5FB0Awky9FUa01y1Tlw_3_5"></a><a id="Tc_BzT94cjZ60G4y_J4kUtEBg_4_0"></a><a id="Tc_nw_v3Ku-L0Wdbgx4GzFSWA_5_0"></a><a id="Tc_M9nfL4F6qk6qDfVQbu4d3Q_6_0"></a><a id="Tc_su0rVt2MMEOkq4nY6WKrFQ_7_0"></a><a id="Tc_aDufish6mkCNFK_FHOEOHw_7_2"></a><a id="Tc_hz4OoaByjE-0JuG-U9qXZQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_hqcCK8OM6k2GLQxcmWZ54Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Property and equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_UNS6ampgqUWTwjtB1jtlJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_sUM0Rd5XwUaQcZ4Pzaib0Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Q-4ha_y54US2uCaT-Y8jmA_3_3">148,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_uJ12jSW3IE2IlsnxHNVHYg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_GlaDAcZPOUybyrMDqD5kZg_3_6">148,704</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ZLW0Hz7D7kWIA9AazR-fdg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_N3MV9w5Wm0SfvMlS6o1eNw_4_3">5,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajl5U0Fik0WBAVlJp8BOHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_xV3SGfFBW0aUZ_Z7zpiVvA_4_6">5,258</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, at cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_IWY62v9fwEeI9r9wrx8WNw_5_3">153,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_I00OHUnhx0ufZgxtkKooDQ_5_6">153,962</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_KfAfDDX7iE6IlQ9omkAxwQ_6_3">94,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_0vSlbg-oqUWxStLUplaOjw_6_6">72,440</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment&#8212;net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_cpq7S-t_mkCcJfR13NBAqA_7_3">59,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_NPbyuH1URUSwmy5I94QcoA_7_6">81,522</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the years ended December&#160;31,&#160;2025 and 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_LcaaX25gKE2PtxE6XcgyUA">21,715</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_oHSVaDDuXUWmqt5XjAPixQ">22,318</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="apre:LeaseDisclosureTextBlock" id="Tb_JtqBdbDzMkSRPpB2Y_ntAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is party to <ix:nonFraction unitRef="Unit_Standard_lease_QaFYmEckJU-MqyGJp97u6A" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt-sec:numwordsen" name="apre:LesseeOperatingLeaseNumberOfOperatingLeases" scale="0" id="Narr_inHzoxNpjEW6hT3mYYdktg">one</ix:nonFraction><span style="white-space:pre-wrap;"> operating lease for office and laboratory space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less.  Rent expense for years ended December&#160;31,&#160;2025 and 2024 was </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_OyQ7wp2wFUSYaMzly9YdTg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_c3GbCkY_2kGJy2Fxy0fMCw">93,366</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_kq5Z_aQ4GkOW-yWNsb-P5Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_gzQfsyTWtEG-P6ulw088yg">91,179</ix:nonFraction>, respectively, which is included in operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was amended in October 2025 and is currently set to expire on October 31, 2026. Rent expense under this lease is $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="apre:LesseeOperatingLeaseAnnualBaseRent" scale="0" id="Narr_fOxsWzU71kmjb9y0QkJCOQ">115,000</ix:nonFraction> annually and the Company has applied the short-term exception to this lease. The Company has no lease obligations beyond October 2026.</p></ix:nonNumeric><a id="Tc_eXgOmd5q8E6fmskDvDq6ew_1_2"></a><a id="Tc_5ykr37dBBkWBserJN0EdCg_1_5"></a><a id="Tc_8B01fyyJKU-PzooL2dnG5g_2_2"></a><a id="Tc_MHkpNM4EjkudMSNKpnNA-g_2_5"></a><a id="Tc_5nIH3CeotU6DyqKK1qJCxA_3_0"></a><a id="Tc_jymiW-Fzf0uyG6hUoI8lpw_3_2"></a><a id="Tc_faFV_KABR0G7ZjPH55JW-w_3_5"></a><a id="Tc_X5xHPiJDsUS1ZXdPw767YQ_4_0"></a><a id="Tc_H0JVwyI-eEqFF0COeJjIsg_5_0"></a><a id="Tc_KT2jQRcf-0ye34V2iefApg_6_0"></a><a id="Tc_pEl1fW2bMEu3l6hyTrw4dA_7_0"></a><a id="Tc_92JWJ4BfvE6nprSvHXPOlQ_7_2"></a><a id="Tc_m56lPQRHuEe02sTZRGtEsw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_lByz84FpaECIUz1rGIyS9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Accrued expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_ynxeQrGBJEqsQCAxKo_DPQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional&#160;fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_m1Dd-XHGqkmmq3JLY2QvCA_3_3">248,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_xFefa-lat0m7gre3dkx-UA_3_6">143,765</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation, severance&#160;and&#160;benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_1kOY8AG2AUCiBPO94BI0rA_4_3">770,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_B-Zf4oiWwU2O9AJ8X8ktlA_4_6">465,015</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research&#160;and&#160;development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="0" id="Tc_paHCRBAFXEamJ4aEzVrUFg_5_3">870,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="0" id="Tc_ou2hqranEkeCTRxJ6_pcgw_5_6">1,243,975</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_ho-nQ5iHIU6M2O-m-tdJjw_6_3">161,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_b56lyBseEkW4XTwWxyLKxA_6_6">155,980</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total&#160;accrued&#160;expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_dkPU7pdZLUKmGQRKA1jahQ_7_3">2,050,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_ldhoQWm50EOPzESPFxuSjg_7_6">2,008,735</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_D8VrmnZ5WUetJOrWBHEynw_1_2"></a><a id="Tc_RzpaAOQQdkaaxxeO1mfC3w_2_2"></a><a id="Tc_JAdVhA9on0q9mb0irtwHhQ_2_5"></a><a id="Tc_gCdLMg8UT0qToanEpSvKdg_3_0"></a><a id="Tc_8zHwGaUpWE62k7qctd2bkg_3_2"></a><a id="Tc_dCI-cwX4eEmPQGpQgCH1Cg_3_5"></a><a id="Tc_pGRXCBvGoEq47gTGPbMasw_4_0"></a><a id="Tc_TrKB8zUClEWuddqb0b2COg_5_0"></a><a id="Tc_vjku3BCbvUGSY3mRtvQN2A_5_2"></a><a id="Tc_BMYl9mzy_USFIqkikCuM2A_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_5HOxAcLi2U2yIzNg4GaEtA" continuedAt="Tb_5HOxAcLi2U2yIzNg4GaEtA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Income taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of net loss are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_fs316a8JSUqtdLE_HzM09Q" continuedAt="Tb_fs316a8JSUqtdLE_HzM09Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_x2waWdI6y06iIcRFhALG5Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_7ch0_pMKX0C-4lFjkC7RmQ_3_3">256,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_iTqHbEL2pkeKPob89U4UMA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_QqafQSYGsECwgV2U7BZWDg_3_6">218,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_mZZT_4w8FUqzJrb9O-iaKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_MNxXDlDabkenYTn7VSffeg_4_3">12,343,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_gXVMK2ewSUubD_HBDBGCyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_159z8I5adky0DYpJ7jiL9w_4_6">12,740,450</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_EBqGlsaNjUqe5G1X1xEBKQ_5_3">12,599,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_H8CnzAgMtUOfplwMSkTeNg_5_6">12,958,711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_dlA4i3gSqUmOslkqVU2IMw_1_1"></a><a id="Tc_2cr4Ki9U4kqaTNRcWi1GEA_2_1"></a><a id="Tc_2uSEfBx__ESUwYsbVhBuOQ_2_4"></a><a id="Tc_gx--WJpZWES2MWy_DV1fRA_3_0"></a><a id="Tc_u19eBR7A9ECSFNYReabvsg_3_1"></a><a id="Tc_7s8pVnIYhEizL749i3mYqg_3_5"></a><a id="Tc_ts95PM_qJE6PSP4hfiqK9A_4_0"></a><a id="Tc_AC4VtdwwBkiAQyj11GLNVA_5_0"></a><a id="Tc_XRPfDHyUmkWkn0EfzrRwgA_5_5"></a><a id="Tc_-jW4KJJKD0OvX7pp0YYpTw_6_0"></a><a id="Tc_vylUxUOzKUGQIAcIHUBIdQ_7_0"></a><a id="Tc_6DH6NBXhSUeQC6WVYFKpVg_7_5"></a><a id="Tc_FcdQnonVuUGKnvKw2LDUtg_8_0"></a><a id="Tc_ehNLX90SLkacJJ0CrxsT7A_8_5"></a><a id="Tc_mnE22sMLXUODq6BWF1T5Dw_9_0"></a><a id="Tc_gWdj4LHsuU29T_mzAGCB5g_9_5"></a><a id="Tc_2VEZlBJgQEmAZ2Uz4QowaA_10_0"></a><a id="Tc_XIurbCKkCEaLHvcB2Y_mgQ_11_0"></a><a id="Tc_NDCROO_sqUK2on0ZAMBBgQ_11_5"></a><a id="Tc_AzLWehF1g0Co-ZNr8j2CcQ_12_1"></a><a id="Tc_VEdl4FODAUuPC6EmdgE1wA_12_5"></a><a id="Tc_HKcD5q_KSkOnRcCQsyFc_A_1_2"></a><a id="Tc_kF37Igz-zU6AzxyR3VzDNQ_2_2"></a><a id="Tc_1Vxji_OlhUuG_yLmm7ZlXw_3_0"></a><a id="Tc_2TJB-WXsFUuVI4R9xpvSfw_3_3"></a><a id="Tc_qOvlSzIgL02SutJN8dHgOw_4_0"></a><a id="Tc_GGp0DBeQB0mQkxzHUS39Aw_4_3"></a><a id="Tc_fhcBsAYQtkCrc_bcv3o7oQ_5_0"></a><a id="Tc_OuR0L4Upi0qo3Q318JCznA_5_2"></a><a id="Tc_J9gLWOEmaUSofWRhgqfWpA_5_3"></a><a id="Tc_LGMmmNPaaEytr57P1jnsiA_6_0"></a><a id="Tc_IhAZgElmhkO2_B_-HHtF4w_6_3"></a><a id="Tc_ato1KSQIMkCCZWskEb3efA_7_0"></a><a id="Tc_df1-JtRslkOmhf1-iCWIdQ_7_3"></a><a id="Tc_5CyZ21xjlEm0FIBiTizJDg_8_0"></a><a id="Tc_xvOQq1lCekWeKp4wp0Z2VA_8_3"></a><a id="Tc_GjnAOEFTQ0mvsKOJ0Ivk1A_1_2"></a><a id="Tc_7y67Eve0BUy2eYbwhp65Lg_2_2"></a><a id="Tc_DDvbtqEbJkO5c9QPalpUXw_2_5"></a><a id="Tc_t5kZutAtUkeSF1_Ea-5f_Q_3_0"></a><a id="Tc_Cy0FmVW4eki-lXEBBZ-7yA_4_0"></a><a id="Tc_itAW8BV8OUO76XowfXv_Mg_4_2"></a><a id="Tc_nCgbxomp2E21GQrUSGIElA_4_5"></a><a id="Tc_-PVDQKkToUKKlQExrS57lQ_5_0"></a><a id="Tc_nmaI9L2EKEaQawCNPtiC2w_6_0"></a><a id="Tc_ngJJEHF-n0aiJ2TCSsg0Hg_7_0"></a><a id="Tc_i_jJkS6MME-W8yrg8I9cpQ_8_0"></a><a id="Tc_FIhUzLs7WkG8JrIY1w1qFg_9_0"></a><a id="Tc_cwSGBxacvku8alTc1jj9tg_9_6"></a><a id="Tc_0wzH6xnvuESJa7RBN_rjIg_10_0"></a><a id="Tc_aA9Do1ElgEeB5xfYMu0e7g_11_0"></a><a id="Tc_HcAv4w20s0uuS0KM8lUmgg_12_0"></a><a id="Tc_ZWCmJn1670OsmVqJI4lK-g_13_0"></a><a id="Tc_fkfbh8Y--EmlNq0PbnQhPA_13_2"></a><a id="Tc_-3sqZmcKXUmbtkEqYhAX_A_13_3"></a><a id="Tc_h7XNh_ipX0Cv_jBWBdZbAw_13_5"></a><a id="Tc_d2s-ERECdEKq31cOuxvuTg_13_6"></a><ix:continuation id="Tb_5HOxAcLi2U2yIzNg4GaEtA_cont1" continuedAt="Tb_5HOxAcLi2U2yIzNg4GaEtA_cont2"><ix:continuation id="Tb_fs316a8JSUqtdLE_HzM09Q_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effective tax rate varies from the federal statutory tax rate as a result of the following differences:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Group_Tb3OY83dh0GT2MZSQ1uujA" continuedAt="Group_Tb3OY83dh0GT2MZSQ1uujA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at U.S. statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_D_AZWUBKM0Od5B51H0GytA_3_2">2,646,101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_i_VXJvI2JEqAWIXBFH7lQw_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax effects </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="Tc_S4dRfsWTs0adMLI9QTUkTg_5_2">1,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GAiVwh82eUmdKx4UoyCRCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" id="Tc_C1geEHpPIkCyj6RAlcmqEQ_7_2">42,220</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_HrhczReTbk-gLlvH2HFa7Q_7_4">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_AzeK96mY5Em10wWbhKO-0w_8_2">2,592,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_2m2ui5cjPUmBoAdtHTPMTg_8_4">20.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nontaxable and nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_FRc_wc4IPkGb392BEn92mg_9_2">20,946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_XaDlyEFMQUafJ_u3XkC3Sw_9_4">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in unrecognized tax benefits </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="0" id="Tc_5dLVuKMC0EuarmSvi-TFvA_11_2">73,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesOther" sign="-" scale="-2" id="Tc_6VRHKWzRpkqqay6Q4eahWA_11_4">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eE2fcbd4R0eebi4itMmEZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Effective tax rate</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_3152p6KFFUCBvYHawMKlLQ_12_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_M7VCAWDZdEm62KWsUvwUEA_12_4">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As the Company did not recognize any state tax expense for the year ended December 31, 2025 there are no states making up greater than 50% of the tax effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate is as follows:</p><ix:continuation id="Group_Tb3OY83dh0GT2MZSQ1uujA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_yYaKlAg5DUS1yGNYqEjEWA_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="Tc_8eFi7I2QM0m2UTNRLOLpzA_4_2">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 162(m) limitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_isoW3wvcv0ue8yP_11fgng_6_2">19.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_502ClfJV-UGozJUHfPmC_g_7_2">1.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_2L9hDC3srUW_LDrSLlssTw_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred taxes as of December&#160;31,&#160;2025 and 2024 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_dCrULkWFJkKJHiFwtGu6Mg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_4xIRbYOo-kCNBdSGp2Ze-w_4_3">48,568,167</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_ZbCXES4ctEmVYlNHSVptqQ_4_6">41,058,034</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_nTXYIkMnJEeRMME23V-KLw_5_3">4,130,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_m43CozsFCUq8TzCWzUhNQw_5_6">4,051,018</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="apre:DeferredTaxAssetsAmortization" scale="0" id="Tc_4ri0Lr0Nsk-d_0NwwNqJvA_6_3">21,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="apre:DeferredTaxAssetsAmortization" scale="0" id="Tc_vzSuXRoE7EaZyyjuLCFTEg_6_6">39,412</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_fXI7e8hM2UePEjE1sDn-Hw_7_3">3,386,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_4s2UO_ZK3UqjsDDcYzP3zQ_7_6">4,850,529</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" id="Tc_qfN34OUtJkmzctymGZRkaw_8_3">878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" id="Tc_lUkuyPBA0kCSdO04zqsHEA_8_6">981</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="apre:DeferredTaxAssetResearchAndDevelopmentCredits" scale="0" id="Tc_p_o8OoEUl0O2RygMU3chqw_9_3">42,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="Tc_64N_qP2zZ0CWfePBdNj3eQ_10_3">199,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="Tc_sIGlktZ1E0eMlnR4hSRjLg_10_6">165,558</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_wPLvxw36w06ImTSArXftSQ_11_3">56,349,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_9-pyxXIgiEykRW3N2w5imA_11_6">50,165,532</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_LM_cUmmDZE-EFH8sOns0Ng_12_3">56,349,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_e4CmsBAnIU2klsAShxw7yg_12_6">50,165,532</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_qAYIyUobPUCbcZZXwvT9kQ"><ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_eAcHp2RtcUee0EON7zQXDg">no</ix:nonFraction></ix:nonFraction> income tax expense due to operating losses incurred for the years ended December&#160;31,&#160;2025 and 2024. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December&#160;31,&#160;2025, the Company has $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_-mt0Lba2K0O1my_pp5wpyg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_B5EYuFa4TEuG8gVOg_fMtg">143.3</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_ZoIolndLmUyXsd1mQPpAUQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_lGpTadA0jkiIea2Ru41lAA">85.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_sq6NeJo7pkSi5n0W2_R52w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_mYTEApUTkUu0PI2gq5xoOQ">91.8</ix:nonFraction> million of foreign, federal and state net operating loss carryforwards, respectively, that expire at various dates through 2037. Certain of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5HOxAcLi2U2yIzNg4GaEtA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section 382 or similar provisions, which impose limitations on their utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company amended its Federal income tax return for year ended December 31, 2023, to claim Research and Development credits of $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ" decimals="0" format="ixt:num-dot-decimal" name="apre:DeferredTaxAssetResearchAndDevelopmentCredits" scale="0" id="Narr_K-9FDj8Ft0S8wJ-8bQR3ig">42,220</ix:nonFraction> and reducing NOL carryforward. Certain of these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section 382 or similar provisions, which impose limitations on their utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The valuation allowance increased in 2025 and 2024 by $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_5Q9Z9MP8DkGbYKX6yB_Dow">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_hMtUET0ADkSXlDqPkB-Rww">0.7</ix:nonFraction> million, respectively, due to an increase in the deferred tax assets by the same amounts, primarily due to the increase in net operating loss generation. Realization of the future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company&#8217;s formation due to the complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future. For Swedish income tax purposes, the Company&#8217;s net operating losses may be subject to limitations in accordance with the country&#8217;s group contribution restriction laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2022 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2019 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company&#8217;s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company&#8217;s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company&#8217;s effective income tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025 and 2024, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="Narr_TwR0hlaDvUSSZesa2Xkj9A"><ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="Narr_cn02YIgTkk-UFg3sfRhUOw">0.1</ix:nonFraction></ix:nonFraction> million of liabilities, respectively, related to uncertain tax positions. As the Company&#8217;s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has not made payments or received refunds for income taxes for the years ended December&#160;31,&#160;2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; (OBBBA) was enacted into law. The legislation made several changes to the U.S. tax code, including the return of 100% bonus depreciation, the ability to immediately deduct domestic research and development costs, a more favorable rule for deducting interest expenses, and updates to international tax rules around global intangible low-taxed income and foreign-derived intangible income. The Company has evaluated the impact of the new tax provision and determined it to have an immaterial impact on the consolidated financial results. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="apre:CommonStockTextBlock" id="Tb_jpKoo_mt_0upKYTLhxaI7w" continuedAt="Tb_jpKoo_mt_0upKYTLhxaI7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Stockholders&#8217; equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of all classes of capital stock that the Company is authorized to issue is <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="apre:StockSharesAuthorized" scale="0" id="Narr_4TYbdS6R4UitZ0U4ea8JaA"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="apre:StockSharesAuthorized" scale="0" id="Narr_7rQMRLmEGk-sA69T_0_JLw">440,000,000</ix:nonFraction></ix:nonFraction> shares, consisting of <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_LQJQODyO6E24dRMOu_Etww">400,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7K6WoDXDH0el8BoX5s7Yhg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_veNjMYaaiEC6KzmLqJbLkA">0.001</ix:nonFraction></ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_CYOhz1KtJUepG4vgLt39CQ"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_DQY0mHjVSUm6LhDm1EcJwQ">40,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_eLa8s0KM7EO-_i4WnX8qPg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_t1RvY7k8x0K1oOLY11FevA">0.001</ix:nonFraction></ix:nonFraction> per share.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_jpKoo_mt_0upKYTLhxaI7w_cont1" continuedAt="Tb_jpKoo_mt_0upKYTLhxaI7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Series A Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December&#160;31,&#160;2025, a total of <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_l2H1ORwuzUeRmNZ3Wdbo9A">31,194</ix:nonFraction> shares of Series A Preferred Stock remained outstanding, which are convertible into <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow" decimals="INF" format="ixt:num-dot-decimal" name="apre:TemporaryEquityRemainingSharesToBeConverted" scale="0" id="Narr_R9kdy8OvQEyn4N8dafTKJg">15,596</ix:nonFraction> shares of common stock. In April 2025, a total of <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_0jPUe0y1K0OJ53mzIl5oew" decimals="INF" format="ixt:num-dot-decimal" name="apre:TemporaryEquityConversionOfStockSharesConverted" scale="0" id="Narr_4IAF-ETGl0Knz4eFSLN4cw">25,033</ix:nonFraction> shares of Series A Preferred stock were converted into <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-QRsPFW0-E--PaKIJUY7Ag" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_kVT-Yb0ncEq6IvDFPFHO5A">12,516</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_xL2dOMznHEmc_uWBXbUEqA" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="INF" format="ixt-sec:numwordsen" name="apre:CommonStockNumberOfVotingRightsPerShare" scale="0" id="Narr_B-Ub5dcHLECwYnJV2CJU2Q">one</ix:nonFraction> vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Shelf Registration Statement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 26, 2024, the Company filed a shelf registration statement (the &#8220;2024 Shelf Registration Statement&#8221;) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ" decimals="-5" format="ixt:num-dot-decimal" name="apre:UniversalShelfRegistrationMaximumAmountToBeIssued" scale="6" id="Narr_VfCM9ge48EisMx-_1BYy2Q">150.0</ix:nonFraction> million, including a prospectus for the sale of $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ" decimals="-5" format="ixt:num-dot-decimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssued" scale="6" id="Narr_1swmd1PV60-R1yy6KXK-Ig">1.0</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of common stock under the ATM Agreement, as discussed below, which was declared effective on February 2, 2024.  The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ" decimals="-5" format="ixt:num-dot-decimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" scale="6" id="Narr_Hanb7k3cGEaQVQEkJsgLbw">2.0</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of common stock pursuant to the ATM Agreement.  On January 26, 2024, the Company entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainright &amp; Co., LLC (&#8220;HCW&#8221;).  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_e9RDxBm4kkmD7GckPR-Osw" decimals="-5" format="ixt:num-dot-decimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssued" scale="6" id="Narr_fBwzTTBiI0yJXcddeLTTmw">2.0</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of common stock.  The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On November 8, 2024, the Company filed a prospectus supplement to the 2024 Shelf Registration Statement with the SEC for the sale of up to $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_11_8_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_1IwBxFQ5D06BZajC8QiMmQ" decimals="-5" format="ixt:num-dot-decimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" scale="6" id="Narr_YC3zFmdHbUOUlxN5JTKxVA">3.0</ix:nonFraction><span style="white-space:pre-wrap;"> million pursuant to the 2024 ATM Agreement, as discussed below. On November 8, 2024, the Company entered into an At the Market Offering Agreement (the &#8220;2024 ATM Agreement&#8221;) with HCW.  Pursuant to the 2024 ATM Agreement and the prospectus supplement filed in connection therewith, the Company may, from time to time, in its sole discretion, issue and sell through HCW, acting as sales agent and/or principal, up to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_11_8_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_wfZiBhJ28kKlJpaYLmFFOw" decimals="-5" format="ixt:num-dot-decimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssued" scale="6" id="Narr_5KEpeTuqu0i0ESc8CvwNGw">3.0</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of common stock.  During the year ended December&#160;31,&#160;2024, the Company issued and sold </span><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SoCfpnLnY0mMCdXRyNqU9Q">41,152</ix:nonFraction> shares of common stock under the 2024 ATM Agreement resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_zTrsMMEn-UOwdGQZ1udYOg">0.1</ix:nonFraction> million after deducting approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_6GY15NcDJU6s6cmx6BPohw">6,000</ix:nonFraction> in issuance costs. During the year ended December&#160;31,&#160;2025, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VaaXhK0mzkCWmTEn4YhyBA">1,337,948</ix:nonFraction> shares of common stock under the 2024 ATM Agreement resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_wfYFM2-__UOpnXNN9QAhLA">1.9</ix:nonFraction> million after deducting approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_HkJRDxuE3U6vztP8AVKh_g">76,000</ix:nonFraction> in issuance costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">March 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;March Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the March Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the March Purchasers agreed to purchase from the Company (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_4M3WWqsLMUuCAFh35_4-rA">1,687,712</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_SUay5q6g3UuXMsBzy7wIMA">7.29</ix:nonFraction>&#160;per share (the &#8220;March 2024 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JlhBUytMKkeo3cvNZE4vVg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_qObnA8VIF0CgnQO0s65xCg">7.289</ix:nonFraction>&#160;to purchase an aggregate of up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JlhBUytMKkeo3cvNZE4vVg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_sPXOoO-kMkOUsYSJ_DkFGw">507,076</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0ilofRNh_USHz8XrPNgeuQ">0.001</ix:nonFraction>&#160;per share (the &#8220;March 2024 Pre-Funded Shares&#8221;), (iii) tranche A common stock purchase warrants to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_JCtfMhV7qEK9Dz5QrKqeEQ">1,097,394</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lr4BUAGLJ0ex_JUNgG5sPQ">7.29</ix:nonFraction>&#160;per share (the &#8220;Tranche A Warrants&#8221;), and (iv) tranche B common stock purchase warrants to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_lKdx8wZkg0CpjaoZE4OJHA">1,097,394</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_BoXqU_p1VEGjo7sPu7LmJw">9.1125</ix:nonFraction> per share (the &#8220;Tranche B Warrants&#8221;). The Tranche A Warrants will be exercisable until the earlier of (i) the&#160;<ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q" format="ixt-sec:durwordsen" name="apre:StockIssuanceAnniversaryPeriod" id="Narr_5x8tUjdlmUigB9nb7Qx9Ug">three-year</ix:nonNumeric> anniversary of issuance and (ii)&#160;<ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q" format="ixt-sec:durwordsen" name="apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" id="Narr_5hPaiM0AM0Oenm9uRFkDuA">30 days</ix:nonNumeric>&#160;after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ" decimals="2" format="ixt:num-dot-decimal" name="apre:SharesIssuedVolumeWeightedAveragePricePerShare" scale="0" id="Narr_7RPEJYmsz0OEmi1gemkYMw">14.58</ix:nonFraction>&#160;for&#160;<ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q" format="ixt-sec:durday" name="apre:NumberOfConsecutiveTradingDays" id="Narr_dOz9KXotu0uUtMzR0jQ1mw">30</ix:nonNumeric>&#160;consecutive trading days. The Tranche B Warrants will be </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_03bce262_9d4e_47ee_aacf_616a5f311810"></a><a id="_03bce262_9d4e_47ee_aacf_616a5f311810_2"></a><a id="_03bce262_9d4e_47ee_aacf_616a5f311810_3"></a><a id="Tc_4v6wUOP1fkOObdUHkXqV_g_1_4"></a><a id="Tc_u1HY3wlmtEikp3AgBaSoTA_2_2"></a><a id="Tc_96vttODTgkSDBY6SeZoixA_2_4"></a><a id="Tc_XJw0WzoLeUylLeN3L9DkcA_2_7"></a><a id="Tc_55YKivy3qkWivwqyyt0IQA_3_0"></a><a id="Tc_WuzrtIiXF06eZaMs5hvo7Q_3_2"></a><a id="Tc_2qLJoaXZkUy2AqXUrRFHow_3_4"></a><a id="Tc_fdOeQbqBD06vk57AbP9ojQ_3_7"></a><a id="Tc_jwZkTQ6O90WO0DSDe3mErQ_4_0"></a><a id="Tc_Z4Yz04rVFU-QUiqPunKhtg_4_4"></a><a id="Tc_9nbkQajDMEObHFjqSMljyQ_4_7"></a><a id="Tc_6iGNUyg_6kOagwIHchpT_g_5_0"></a><a id="Tc_KVjA-tgUUUawvkrtvgPR7Q_5_4"></a><a id="Tc_MZtkGEweTkm92iFRLNLYlQ_5_7"></a><a id="Tc_WvumrRZ0sEW0rYTfPTlv7A_6_0"></a><a id="Tc_zw0P66LmREGzSnEKTzyglA_6_4"></a><a id="Tc_n_nKeNz2VEeIyo4DllfKFg_6_7"></a><a id="Tc_ao-4TCmN_Emb-dRRVtEt3w_7_0"></a><a id="Tc_nIMCJRQiyk-6-v-o97oL_g_7_4"></a><a id="Tc_Id1KvYVhVUKDrxKKfUI1tQ_7_7"></a><a id="Tc_qXbAIO1ikUalkIuKl5YOTw_8_0"></a><a id="Tc_gt5tuXeLi0WyrTg782Tc2Q_8_4"></a><a id="Tc_vN0QUqroaUOG6kI_AT_bEQ_8_7"></a><a id="Tc_-D3_0YEoiUOo0meMxYgHzg_9_0"></a><ix:continuation id="Tb_jpKoo_mt_0upKYTLhxaI7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">exercisable until the earlier of (i) the <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ" format="ixt-sec:durwordsen" name="apre:StockIssuanceAnniversaryPeriod" id="Narr_GPu8On5mzEqeHV4RbqI74A">five-year</ix:nonNumeric>&#160;anniversary of issuance and (ii)&#160;<ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ" format="ixt-sec:durwordsen" name="apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" id="Narr_5mNx8YKIo0i2CfK_9wu-MQ">30 days</ix:nonNumeric>&#160;after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ" decimals="3" format="ixt:num-dot-decimal" name="apre:SharesIssuedVolumeWeightedAveragePricePerShare" scale="0" id="Narr_1RqbMcUfuUuYPLVxUaaB0A">18.225</ix:nonFraction>&#160;for&#160;<ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ" format="ixt-sec:durday" name="apre:NumberOfConsecutiveTradingDays" id="Narr_RKeDPpLNYEKopVNQ-82Vpg">30</ix:nonNumeric>&#160;consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ" decimals="4" format="ixt:num-dot-decimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_4LzVi2SgW0uFWZty0nu_AQ">4.99</ix:nonFraction>% (or, at the election of the holder, greater than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zk8TLXVZiU-91j2mSRo40Q" decimals="4" format="ixt:num-dot-decimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_UvZUAA2U5kmARNMq5NnVYg">9.99</ix:nonFraction>%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_bkViGh8Wkkymwkx1fVEUfA">16.0</ix:nonFraction>&#160;million, before deducting placement agent fees and offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_u8kaEAhI4E-D7EtBM6toIQ">1.3</ix:nonFraction> million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg" decimals="-5" format="ixt:num-dot-decimal" name="apre:ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" scale="6" id="Narr_uX02co_MYUy_-RzVUGCWfA">18.0</ix:nonFraction> million, before deducting placement agent fees. In April 2024, the Company registered on Form S-3 the resale of the March 2024 Shares, the March 2024 Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">December 2025 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On December 8, 2025, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zwo4giaoEkSNWwEoe9XUCg">26,459</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MGDWpqe1Kkq0c-y3kaCxwg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Ms8YyZ5VG0O4WBHpw5wrIA">1.165</ix:nonFraction>&#160;per share (the &#8220;December 2025 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_8h4a3ebVSkCHonNIO6L0-g">1.164</ix:nonFraction>&#160;to purchase an aggregate of up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_xtmeugomiEq_n3aTXb7hvg">2,596,564</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_21MipUxIlkWseqhVGxI2IA">0.001</ix:nonFraction>&#160;per share (the &#8220;December 2025 Pre-Funded Shares&#8221;), (iii) common stock purchase warrants to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JysbG2LVi0WviMI_bz_gpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_HfCN6JHUmUuu0zJmE43gsw">2,880,533</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JysbG2LVi0WviMI_bz_gpw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_DSU71B4WVkaY05TJQvrVcw">1.04</ix:nonFraction>&#160;per share, including this issuance of a warrant to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_PlacementAgentMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_nCqKvJ6VqEOdmrCe-eB1xw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_CMAxsO4DAEOwiRiHn_cVMw">257,510</ix:nonFraction> shares of the Company&#8217;s common stock to the placement agent (the &#8220;December 2025 Warrants&#8221;). The December 2025 Warrants will be exercisable until the&#160;<ix:nonNumeric contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A" format="ixt-sec:durwordsen" name="apre:StockIssuanceAnniversaryPeriod" id="Narr_3xODfYiJ2kyMjWcGbo6OXw">five-year</ix:nonNumeric> anniversary of issuance. To the extent that the exercise of a December 2025 Warrant would result in the holder beneficially owning greater than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MGDWpqe1Kkq0c-y3kaCxwg" decimals="4" format="ixt:num-dot-decimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_mHiTl6tG2EWmFsUCDvbhrA">4.99</ix:nonFraction>% (or, at the election of the holder, greater than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Vm4iVeX890G-C4Gmcq830Q" decimals="4" format="ixt:num-dot-decimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_sLzyngdyW0CsnSlwI37sLA">9.99</ix:nonFraction>%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_ol8hzVEyK0eNK32nBkUVMw">3.1</ix:nonFraction>&#160;million, before deducting placement agent fees and offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_H9lFmKYNJEe94IUxylo35g">0.4</ix:nonFraction> million. In December 2025, the Company registered on Form S-3 the resale of the December 2025 Shares, the December 2025 Pre-Funded Shares and the shares underlying the December 2025 Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company evaluated the terms of the warrants issued in the March 2024 and December 2025 Private Placements and determined that they should be classified as equity instruments within additional paid-in capital. As of December&#160;31,&#160;2025 and 2024,&#160;none&#160;of the Tranche A Warrants or Tranche B Warrants have been exercised. During 2025, <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_jtkh2IFT8EeIdDld8qFq5w" decimals="INF" format="ixt:num-dot-decimal" name="apre:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_CCT03FBjtk2cm3yHUuplbw">91,206</ix:nonFraction> warrants to purchase March 2024 Pre-Funded Shares were exercised for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_jtkh2IFT8EeIdDld8qFq5w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_XzldKfUnpUWVhqA07vcHgg">91</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_lILoXMI7xUCZVU-gQHudoA" decimals="INF" format="ixt:num-dot-decimal" name="apre:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_JpJvIAS0NEytjUSv35EBhg">1,198,700</ix:nonFraction> warrants to purchase December 2025 Pre-Funded Shares were exercised for <ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_lILoXMI7xUCZVU-gQHudoA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_ouahwI6DsEymQ526U1o63g">no</ix:nonFraction> proceeds. <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_R5lNv0SMpkG5QNmfjLhHmw" decimals="INF" format="ixt-sec:numwordsen" name="apre:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_OFUkBKuaakC-yv4_b0MoGw">No</ix:nonFraction> warrants to purchase March 2024 Pre-Funded Shares were exercised during 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A summary of warrants outstanding as of December&#160;31,&#160;2025 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_ZALsErMLbEi0BAK48kT9EA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 Tranche A Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsMember_HnwiahFpV0Kqxh7uoQXQfw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_cj-YYpBIakC77lAHymG-8Q_4_2">1,097,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsMember_HnwiahFpV0Kqxh7uoQXQfw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_mFQeldk4SUGSSgbqC3w53g_4_5">7.2900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/11/2027</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 Tranche B Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheBWarrantsMember_fQ1ml1hVHU6nU0Lh1uc_aA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_TNQYQ9PdMUa95Wj-lxPAWg_5_2">1,097,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheBWarrantsMember_fQ1ml1hVHU6nU0Lh1uc_aA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_x8i_T0ZuN0WQqsObc85VaA_5_5">9.1125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/11/2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024PreFundedWarrantsMember_a-axkHFuHU6wmJ8RwuZaXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_B0H9KY0ZZUu9f5YW_ANPNA_6_2">415,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024PreFundedWarrantsMember_a-axkHFuHU6wmJ8RwuZaXA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_XItOxzg7EkmhRUFGeVy0bA_6_5">0.0010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2025 pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025PreFundedWarrantsMember_-GQYBDW1ekGtGJann-TV6A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_l8_HYDetsUewSAIoyS7sqw_7_2">1,397,864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025PreFundedWarrantsMember_-GQYBDW1ekGtGJann-TV6A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_J1aDzvWG8EGfsaezMiq4RQ_7_5">0.0010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2025 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_IWhpmSyLkkquMghWrBhMLg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_AZHSFHSGa0GXlPi7jAH9dw_8_2">2,880,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_IWhpmSyLkkquMghWrBhMLg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Xx4RfrDX2EeNidqFZRxnTA_8_5">1.0400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/10/2030</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_NtrgUORAgEmeTDRhyvBEpg_9_2">6,889,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IvkGBbuJ4EmUH8Dvcg0HOQ_1_2"></a><a id="Tc_gwFEUUcDfEqQRIuSU-5ThQ_2_2"></a><a id="Tc_iApGfN-H_Ui9KQKmZ0wFVA_2_4"></a><a id="Tc_5TiG3S_YzE-2AuHzaUP9Bw_3_0"></a><a id="Tc_MIdYX83kLEi-nDJq5aBgfg_3_2"></a><a id="Tc_Spr88lvyZ0GWCI2_9xMdcw_3_4"></a><a id="Tc_tJMSkkNIPUSmu2QPs49O7Q_4_0"></a><a id="Tc_Y3yQ4A9_NUeXnaHBtr9weQ_4_2"></a><a id="Tc_DtsjyNzhskimVB-bLZ9AjA_4_4"></a><a id="Tc_FDz-QR_yH0CGb5Ok0Jd3wg_5_0"></a><a id="Tc_xZqdZKOuc0iwcUPFEQaznQ_6_0"></a><a id="Tc_x2A8TqXldkC910Fu2zaiyA_6_2"></a><a id="Tc_rPjBEUja2kGTmcuUMJ87Vw_6_4"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_xIvXIL6vTkuHzGjyQe74yg" continuedAt="Tb_xIvXIL6vTkuHzGjyQe74yg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company&#8217;s Board of Directors approved the 2019 Equity Incentive Plan (the &#8220;2019 Plan) and each outstanding option to purchase Aprea AB ordinary shares pursuant to a previous plan was cancelled and the Company issued to each holder of such Aprea AB option, a substitute option to purchase, on the same terms and conditions as were applicable to such Aprea AB option, shares of the Company&#8217;s common stock pursuant to the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors has the discretion to provide for accelerated vesting under the 2019 Plan. At December&#160;31,&#160;2025, there were <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_jPMoEwg9gUiVCVvIlI1JQw">180,880</ix:nonFraction> shares available for future grant under the 2019 Plan. Effective January 1, 2026, the number of shares available for future grant under the 2019 Plan was increased by <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="INF" format="ixt:num-dot-decimal" name="apre:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="Narr_q7Mb8ySOmEC8u5UcygsBnw">327,701</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_WE2Yaoqsn0O-fiiukhXDhA">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_vmewpsxCXUeBYlvoZMAuNA">0.5</ix:nonFraction> million during the years ended December&#160;31,&#160;2025 and 2024, respectively. As of December&#160;31,&#160;2025, there was $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_P7V8qUEam0qTi62gWaCZAw">0.5</ix:nonFraction> million of unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the 2019 Plan, which is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_dhDmZ6lYikyy0nCnG_ehpg">2.1</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option award is estimated on the date of grant using Black-Scholes, with the assumptions noted in the table below. Expected volatility for the Company&#8217;s common stock was determined based on an average of the historical volatility of a peer group of similar public companies. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employee. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the implied yield on a U.S. Treasury security in effect at the time of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in Black-Scholes are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_GO_3XJpAW06_IGmivtId2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_lG2LXxfIBU-RkesygO0z-Q">83.0</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_iDfDpbedJEK3qfU1roFS2Q">83.6</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_qPJJRpu0_kmi4KOL-IEI9g">83.8</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_3DyDFeHhWkSjss7rKi8FjA">92.3</ix:nonFraction>%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_QAQJpHR5n0Kje7cKnrSQaQ">3.99</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_2ybM4SMIAkmWxpr7QWwGGw">4.38</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_-d22Yp9T_k6gLcxPXi9ddw">4.18</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_aglhZ6Xrv0uX48PhEc3_SQ">4.64</ix:nonFraction>%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_qPkrs1Znnka5Km6rXeMcfQ_5_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_xpklrCwCfUCb0IyJPLdy3Q_5_4">0</ix:nonFraction>%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_svVivUO6SEy1bko-xpnpmw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_JUStlXN5GEeDZBg07mFP4g">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_vo0Rp1fMEEe6cXCjrjqRkQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_7nVCxegYSEOM2ia4M_QDfw">10.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_uALQGM6dfkS0eVFcd0iIJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Ilv3emo7c0SwFvok26CKuA">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_RiL5VScdAUCDUTJd-n0MRQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_8ehnQWLarU-iXsD70rnmcQ">10.0</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_LR7ybMTzgEaMhnriEVHpVg_1_5"></a><a id="Tc_it4g-n_Bq0SH24SYhcgIlw_1_8"></a><a id="Tc_MbRwVpBmZUaA783HEEb1Jg_2_5"></a><a id="Tc_DuS-_vOEkkOcUiMGeyujqg_2_8"></a><a id="Tc_vD5Qu06Ngk6PUOW-w123wg_3_5"></a><a id="Tc_okvhAnn0jkK-ocBywMskvQ_3_8"></a><a id="Tc_LQQZ-WIYtUSAfY1cRnHCCQ_3_10"></a><a id="Tc_AHmxvajyA0OAZC0PeN6Cjw_4_2"></a><a id="Tc_OJXhM_T17Uabb8OglegY2w_4_5"></a><a id="Tc_HxyargrwJ0-S6u0mrUs2yg_4_8"></a><a id="Tc_zcB6Ex9G0km4LnsbU6isbQ_4_10"></a><a id="Tc_A59GMV0u00ito9iaGfoNRg_5_2"></a><a id="Tc_Zh4B_9kbHUyHe7V30YrsmQ_5_5"></a><a id="Tc_RFWOoKG5p0yk9Tq9myNDKA_5_8"></a><a id="Tc_ndxYU1GXZUKxGoonrd6Vng_5_10"></a><a id="Tc_a7dY0YWid0yYIXjhqn8Uag_6_0"></a><a id="Tc_LHEZzNcSJEmw74g-1gwBMA_6_5"></a><a id="Tc_VHQbFTxhJECfMncRuwLx3A_7_0"></a><a id="Tc_IQMe9h-rIESXoUBdgCImgw_8_0"></a><a id="Tc_S5QCbIJmIk2OHsUUWx4U6g_9_0"></a><a id="Tc__iCZHaQplEihrDKmoQnPIQ_9_5"></a><a id="Tc_UFth5ZQSe0GphFL1Ez8-Jw_10_0"></a><a id="Tc_J9a8Zn6LYUWkI58x9JdKFQ_11_0"></a><a id="Tc_9XaQnAyHWEyby1qqgzoItA_12_0"></a><a id="Tc_MYmBjhIhTU28cN_GK4mA5A_12_5"></a><a id="Tc_3tbt7C2l8EuvChtrQgaf-w_12_10"></a><a id="Tc_3PBdKXKKokaXsQ5LEs0A0w_12_11"></a><a id="Tc__ZUduwDP802FthXnj3E4dg_13_0"></a><a id="Tc_p8d3-RYiok-Vltb_Mhd_jw_13_5"></a><a id="Tc_hGVfN4IvYkeTN_MJePWr0w_13_10"></a><a id="Tc_m0l5lUbJpE2KOGzsfXpulQ_13_11"></a><a id="Tc_vwmIfbwPRE24p5zSxJ-efA_14_0"></a><a id="Tc_vsKTq1L67E-QSdF8ijxpsQ_14_5"></a><a id="Tc_QLHHSzEq4EG2w_6Fpx_i0A_14_10"></a><a id="Tc_aLNUwpP6AUKR-NlEA8IVng_14_11"></a><ix:continuation id="Tb_xIvXIL6vTkuHzGjyQe74yg_cont1" continuedAt="Tb_xIvXIL6vTkuHzGjyQe74yg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of option activity under the Plan during the years ended December&#160;31,&#160;2025 and 2024 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_jrR20ui8J06atBk9L5dznA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term&#160;(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_VhYbqu6uqEa_Z5RqOOudRA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_W7txncZ2uU-OsWpqqObCdQ_6_3">596,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_VhYbqu6uqEa_Z5RqOOudRA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_VBxCTTvypUm1gjQjYHDUvg_6_6">72.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_EQUr4jqfV0eUSMk3W0IsWQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_iplY3rNWi0qQVlTBXqAR-w_6_8"> 6.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_5FXM6rY-YUqQlPbUeoOHVQ_7_3">147,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_giivbmDiP0eEF6OnbECYHQ_7_6">5.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_A6VCfIgca0a7H0FRiJuBVQ_8_3">28,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_OIS3mywfJUGVWzP5FyYkaA_8_6">5.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_u0-Ar2Tqm0KjjxiVQ0T_mg_9_3">715,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_I5IBwco6E06rN3mKcDF23g_9_6">61.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_9Caj6B-zfEagQDSmVAOrzg_9_8"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_eGQGspjSL0-MK6F8DwGqGg_10_3">116,040</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_8hzORMPVl0OshOO0AZuLRQ_10_6">2.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_P69_8qc_Mka1fpJIjal9aA_11_3">20,539</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_QS6Q-WL0_Um_ExSMSFDHRA_11_6">7.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_mLohVKtxYk6iTA_VWgei2A_12_3">811,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_5R1KTg0Ql0OkiOJeLlLqzg_12_6">54.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_XtkVaIrILEuTQ7vIWvRUgg_12_8"> 5.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_adXO11SU9UGngK5T4dEp2A_13_3">624,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_GhxjTFxkpESEnnyxnUreow_13_6">69.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_fPWtC6qYfEenT6erKr1G_Q_13_8"> 4.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_RNdE1s_LyESHLxT_gGQ4EQ_14_3">811,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9FE-Wm1iMUGKBmoJtZjGcA_14_6">54.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_P7CeC6XgKkaNC9eHS97s5Q_14_8"> 5.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted during the years ended December&#160;31,&#160;2025 and 2024, was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_0k0aCHFJM02yL7-iWC_i4w">1.57</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_0Y3qb4QAYUql7SYkrtAv8A">4.53</ix:nonFraction>, per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock</i> <i style="font-style:italic;">Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2025, the Company granted the following RSU&#8217;s:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_76awlW8Ih02pce5XsSRECw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_H2D9KB5X0EKqXZF8NlgJHg">10,090</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to executive officers of the Company which vest ratably on the </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_ppTWFla4xU-u0Ra-s34Jfw" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_pRl61QhGSkKeyDSESJz3nw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></ix:nonNumeric><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">st</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_ObCThvYr3EuNhTdvZHWN5Q" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_NbdAuIBDc0uaW_XI5ct56A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></ix:nonNumeric><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">nd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_51RPXCrdCEOuPhYMJBeuWw" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Aams-Ds29EWsx0Up1BCe4w"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></ix:nonNumeric><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">rd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversaries of the grant date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_S_ge6OQffkO1GwngF7q5dg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_Zxip6_-rB0-SUnaRF2qmYQ">8,360</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to non-employee directors of the Company which vest on the </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_K66RcqO0CUSYIecB3rtHQg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_lxBrN0nRlEOLJk-x8OVjiA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary of the grant date.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2024, the Company granted the following RSU&#8217;s:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_KhoEA3ZPM0CBUJFvhI2tBA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr__Rbzi04H5kG1s8EfPJ4UvA">16,820</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to executive officers of the Company which vest ratably on the </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LU7BJLvVE0iqW66H9_OrGg" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ENvui_DvhUCYI1bwIz0Fyw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></ix:nonNumeric><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">st</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_XAXHtIodGE2ofHLJnzdW0g" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_23S2sDipC0SBm0m6AQcMtA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></ix:nonNumeric><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">nd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_kvlb4D8nYUSyelfb-KCo2w" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_c6NykJbsQ0mTsCO27qAnnQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></ix:nonNumeric><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">rd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversaries of the grant date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_c5rmFiY3ek-6CbIN1sUk5g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_T6Bil0R_FEupy5HmQy6gTQ">6,270</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to non-employee directors of the Company which vest on the </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LrUkAv7nCEugy4KCFPIs0A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ASOvmybBfkuMVWZIAJQu3g"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary of the grant date. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, there was $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_d3Eisifw3Ey5Cxr1wbNYew">0.1</ix:nonFraction> million of unrecognized compensation cost related to RSUs granted under the 2019 Plan, which is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_eX8OXRH7HEuVp86phR151Q">1.8</ix:nonNumeric> years.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_T4BYc19ydEylJYUz_hznVg_1_4"></a><a id="Tc_n84Phz1OhEO7jKFfT5APfA_2_4"></a><a id="Tc_e0hTqWh2lU6KoBGwFZ2qkw_3_4"></a><a id="Tc_5dG33bvYZUq58jZvAb357g_4_2"></a><a id="Tc_HXtUnb9oPUiko-zPEg4sxQ_4_4"></a><a id="Tc_9Y49BbIx8EC9n7z_HtgaBQ_5_0"></a><a id="Tc_zigjthZyUkm4M4k5gIAJrA_5_4"></a><a id="Tc_H64jtyEX80CpiG-mxOvO8g_6_0"></a><a id="Tc_zJMFETPz5EGVneu0ybt3kQ_7_0"></a><a id="Tc_1lLXeywUuEivr0CdleC9Jw_8_0"></a><a id="Tc_9cIhp7IhHUqYNbyv-s22ew_9_0"></a><a id="Tc_jl_4i1FfqEqIo7GO1Jvt6Q_9_4"></a><a id="Tc_OsdiupcAAkyAOE6xO7mKtw_10_0"></a><a id="Tc_E7j62b_5yEu4jodnDKs54A_11_0"></a><a id="Tc_bRemLrcmf0-NPASVv6VgKA_12_0"></a><a id="Tc_pHb9cJgkW0Od8wAJU9oX6w_12_2"></a><a id="Tc_fKdj7gIjXkiIKSjwUBhfUQ_12_5"></a><a id="Tc_jXWyRVJ0CkGj3wg4bBqgaw_13_0"></a><a id="Tc_IAdRHtdHu0aeL6ZZOaxcvw_13_4"></a><ix:continuation id="Tb_xIvXIL6vTkuHzGjyQe74yg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table shows restricted stock unit activity during the year ended December&#160;31,&#160;2025:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_A0aTbvLOr0CIJVzTKoYZog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vI7qdqQk_0OgoyeWE7tHaQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_bHcZcMuWpUuWhZlw9Bgocg_5_2">23,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vI7qdqQk_0OgoyeWE7tHaQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_7vyr5tpgd0es4-nwfYw_bQ_5_5">10.00</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_MQ4ilclP0UCB1w_tcFSH4g_6_2">23,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_26PQOB66z0-Hu2Z5GnxB1Q_6_5">5.56</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_0qcSlGpUnUOCVlBJpV_uZQ_7_2">10,518</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_ESuCe1tZsk-iTgoNSjumCg_7_5">9.42</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_4vd7cWqRkU25MqihdmEB9Q_8_2">6,730</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_CEy_YdsCUUOQ8vmrpoxejg_8_5">5.25</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_evHTOe8x2keNSJoG80M35Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_-y6g8vomak2Xrbim6e7B5w_9_2">29,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_evHTOe8x2keNSJoG80M35Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_UHnz98wobEepLM6PjxRwCw_9_5">7.83</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_a4DlDWpsdkuA2C34UtdXDg_10_2">18,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_QpgxvakRSEqDfMB9-LshFA_10_5">2.02</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_3nk069he-0W59USWLh6n6g_11_2">17,154</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_MBBYWE_A_02GBUf3WXiFIQ_11_5">7.94</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_joQ6-cKN3keWCq_ienLkMQ_13_2">31,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_Fsj8PyYxkkOncgKYOjX8Yg_13_5">4.31</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_05G77KkcSUi6u7OEBtSaLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">9. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time to time, the Company may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the years ended December&#160;31,&#160;<span style="white-space:pre-wrap;">2025 and 2024, and, to its knowledge, no material legal proceedings are currently pending or threatened. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.  As of December&#160;31,&#160;2025, the Company has </span><ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualProvision" scale="0" id="Narr_3tzaCfBd60yP9qViCpJW0Q">no</ix:nonFraction>t recorded a provision for any contingent losses.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_uvBmRoLDE0WpF6SqWhPwig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">10. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 28, 2026, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;January Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the January Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the January Purchasers agreed to purchase from the Company (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YxQxhu00KECPiD_8anDHtw">1,877,677</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_X3e_9uk1uEKJQCgyQcQNiA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_gdxjZMnGRE2zKgKL6SqAeQ">0.8891</ix:nonFraction>&#160;per share (the &#8220;January 2026 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_sVJjCN2Uv0qull_ZDw0TnQ">0.8890</ix:nonFraction>&#160;to purchase an aggregate of up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_aRQKTzTG-UyxCw4SI5GqTw">4,411,180</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Tzst32cPJ0eCLDfZeYNBgw">0.001</ix:nonFraction>&#160;per share (the &#8220;January 2026 Pre-Funded Shares&#8221;), (iii) common stock purchase warrants to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_12HariDjbkGdtP5EmFWGYA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_BYJpI3rZL0qh5GLVkmtEQw">6,288,857</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_12HariDjbkGdtP5EmFWGYA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_benDwa52WEiBemXelpzjjA">0.765</ix:nonFraction>&#160;per share (the &#8220;January 2026 Warrants&#8221;). The January 2026 Warrants will be exercisable until the&#160;<ix:nonNumeric contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lqTYSTP7MUWrNQSGACl75w" format="ixt-sec:durwordsen" name="apre:StockIssuanceAnniversaryPeriod" id="Narr_30RlMolsBEK7ap3jyoYUeg">two-year</ix:nonNumeric> anniversary of issuance. To the extent that the exercise of a January 2026 Warrant would result in the holder beneficially owning greater than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_X3e_9uk1uEKJQCgyQcQNiA" decimals="4" format="ixt:num-dot-decimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_pFN_Qql5G0aZ7kMBUMRXHw">4.99</ix:nonFraction>% (or, at the election of the holder, greater than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw" contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_dYgdlu90I0-v-bYG_Tb6iQ" decimals="4" format="ixt:num-dot-decimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_tWMLp1aG3UGnZLkrjdiA9g">9.99</ix:nonFraction>%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_og8pm1DYH0OWAVHjOmFBlA">5.6</ix:nonFraction>&#160;million, before deducting placement agent fees and offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww" contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_BrneuhuJFUuiWCMmBRr80A">0.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c1729278_f1f9_445a_987c_9372dbdb68af"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9ac15c8a_417f_4e11_93e2_1697d57b9f57"></a><a id="Item4ControlsandProcedures_266"></a><a id="Item9AControlsandProcedures_745095"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31,&#160;2025. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31,&#160;2025, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Controls Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control system was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes, in accordance with generally accepted accounting principles in the United States. Due to inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of the internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate. Our management, under the supervision and with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report on Form 10-K based on the framework in Internal Control---Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on such evaluation, our management concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">This Annual Report on Form 10-K does not include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our auditors will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 until we are no longer a smaller reporting company with annual revenues of less than $100 million and a public float of less than $700 million.<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Changes in Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1b3e0bb_d541_45c6_808c_ec39e4952416"></a><a id="Item5OtherInformation_682434"></a><a id="Item9BOtherInformation_252198"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three (3) months ended December&#160;31,&#160;2025, no director or officer adopted or terminated any contract, instruction or written plan for the purchase or sale of company securities intended to satisfy the affirmative defense conditions of Rule <span style="-sec-ix-hidden:Hidden_qn32aboQakGIBXr3nC5CDw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>b<span style="-sec-ix-hidden:Hidden_cLaLWqpS3UqfFJPfyGBgqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>-1(c) of the Exchange Act and/or any non-Rule <span style="-sec-ix-hidden:Hidden_qPJf3vDE6U6wN26nyYncQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>b<span style="-sec-ix-hidden:Hidden_otCW9f-QjESf3tKfAs3j6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>-1 trading arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_33bb4dcc_84d7_463b_9f8c_fc50a3c04203"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item</b> <b style="font-weight:bold;">9C. Disclosure</b> <b style="font-weight:bold;">Regarding Foreign Jurisdictions that Prevent Inspection</b><b style="font-weight:bold;">s</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_82600551_13c9_4019_8f39_f062fa9a2e07"></a><a id="PARTIII_316696"></a><a id="PARTIII_178079"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PART III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_8oe8PRUQLEO1i-oIZC4UqQ"><b style="font-weight:bold;">Item 10</b></ix:nonNumeric><b style="font-weight:bold;">. Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in an amendment to this Annual Report on Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Rule 14A.</p><a id="_174d5cb3_3c17_4596_98d3_ce5bbe5eb0b1"></a><a id="Item11ExecutiveCompensation_47666"></a><a id="Item11ExecutiveCompensation_421004"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 11. Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in an amendment to this Annual Report on Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Rule 14A.</p><a id="_90934e7e_a590_4b9c_97ba_55b74ee7ec93"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in an amendment to this Annual Report on Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Rule 14A.</p><a id="_c3a0d574_e7bf_42a6_a935_2d2eadb939e6"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 13. Certain Relationships and Related Transactions and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item will be included in an amendment to this Annual Report on Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Rule 14A.</p><a id="_a75ea126_2981_4c93_bf87_5fd772235f43"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 14. Principal Accounting Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by this item will be included in an amendment to this Annual Report on Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Rule 14A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cb886658_8563_4e66_89d7_1150bb065fb6"></a><a id="PARTIV_228969"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART IV</b></p><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 15. Exhibits, Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following documents are filed as part of this Annual Report on Form 10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information concerning our consolidated financial statements, and Report of Independent Registered Public Accounting Firm required by this Item is incorporated by reference herein to the section of this Annual Report on Form 10-K in Item 8, entitled &#8220;Financial Statements and Supplementary Data.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-weight:bold;">Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All schedules have been omitted because the required information is not present or not present in amounts sufficient to require submission of the schedules, or because the information required is included in the Financial Statements or notes thereto.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;"> Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">List of Exhibits required by Item 601 of Regulation S-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000110465919053259/a19-12476_12ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of Aprea Therapeutics, Inc. (incorporated by reference to Exhibit&#160;3.1 to the Current Report on Form&#160;8-K filed on October&#160;7, 2019)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/tm236225d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aprea Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 13, 2023)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 17, 2022)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837020013179/apre-20200930ex31ca25522.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Aprea Therapeutics, Inc. (incorporated by reference to Exhibit&#160;3.1 to the Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2020, filed on November&#160;6, 2020)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837021003083/apre-20201231ex412221ad7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Aprea Therapeutics, Inc. Common Stock, $0.001 par value (incorporated by reference to Exhibit 4.1 to the Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 16, 2021)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001781983/000110465924033494/tm248508d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (March 2024 Offering) (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-k filed on March 12, 2024).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001781983/000110465924033494/tm248508d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche A Warrant (March 2024 Offering) (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-k filed on March 12, 2024).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001781983/000110465924033494/tm248508d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche B Warrant (March 2024 Offering) (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-k filed on March 12, 2024).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/tm2533057d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (December 2025 Offering) (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-k filed on December 9, 2025).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/tm2533057d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Warrant (December 2025 Offering) (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-k filed on December 9, 2025).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/tm2533057d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant (December 2025 Offering) (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-k filed on December 9, 2025).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (January 2026 Offering) (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-k filed on January 29, 2026).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Warrant (January 2026 Offering) (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-k filed on January 29, 2026).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of 2019 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.1 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662)).</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.2 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662))</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3*+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of 2019 Equity Incentive Plan Stock Option Agreement</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4*+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of 2019 Equity Incentive Plan Stock Option Award Notice</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5*+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex10d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6*+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of 2019 Equity Incentive Plan Restricted Stock Unit Award Notice</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7&#8224;</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Service Agreement, between Aprea&#160;AB and Syngene International Private Limited (incorporated by reference to Exhibit&#160;10.3 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Registration Rights Agreement by and among Aprea Therapeutics, Inc. and the shareholders party thereto (incorporated by reference to Exhibit&#160;10.4 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement, by and among Aprea Therapeutics, Inc. and certain securityholders (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May 17, 2022)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005375/a2239728zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between Aprea Therapeutics, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit&#160;10.5 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000104746919005499/a2239779zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Executive Employment Agreement (incorporated by reference to Exhibit&#160;10.7 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837023005126/apre-20221231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Aprea Therapeutics, Inc. and Oren Gilad (incorporated by reference to Exhibit 10.20 to the Annual Report on Form 10-K filed on March 30, 2023)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837023005126/apre-20221231xex10d21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Aprea Therapeutics, Inc. and John P. Hamill (incorporated by reference to Exhibit 10.21 to the Annual Report on Form 10-K filed on March 30, 2023)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837025003588/apre-20241231xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement between Aprea Therapeutics, Inc. and John P. Hamill (incorporated by reference to Exhibit 10.18 to the Annual Report on Form 10-K filed on March 25, 2025)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15&#8224;</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Master Manufacturing and Supply Agreement, between Aprea Therapeutics AB and Siegfried Hameln GmbH (incorporated by reference to Exhibit&#160;10.11 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-233662))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465922068116/tm2217601d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Atrin Pharmaceuticals LLC 2016 Amended and Restated Equity Compensation Plan (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 (File No. 333-265411))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17+</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465922068116/tm2217601d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No.&#160;1 to the 2016 Amended and Restated Equity Compensation Plan (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-8 (File No. 333-265411))</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001781983/000110465924033494/tm248508d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement dated as of March 11, 2024 by and between Aprea Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on March 12, 2024)</span></a> </p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/tm2533057d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement dated as of December 8, 2025, by and between Aprea Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on December 9, 2025)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement dated as of January 29, 2026, by and between Aprea Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 29, 2026)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837024003886/apre-20231231xex19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aprea Therapeutics, Inc. Insider Trading Policy (incorporated by reference to Exhibit 19 to the Annual Report on Form 10-K filed on March 26, 2024)</span></a> </p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837024003886/apre-20231231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Aprea Therapeutics, Inc. (incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K filed on March 26, 2024)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1*</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1**</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2**</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20251231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1781983/000155837024003886/apre-20231231xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Aprea Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Incentive Compensation (incorporated by reference to Exhibit 97 to the Annual Report on Form 10-K filed on March 26, 2024)</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates a management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Portions of this exhibit have been omitted pursuant to Item&#160;601(b)(2)&#160;of&#160;Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Registrant may request confidential treatment pursuant to Rule&#160;24b-2&#160;of the&#160;Exchange Act&#160;for any schedule so furnished.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The certifications furnished in Exhibit&#160;32.1 and Exhibit&#160;32.2 hereto are deemed to accompany this Annual Report and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.</p></td></tr></table><a id="_8fbd671f_ec54_44dc_96d9_021ec12bec01"></a><a id="Item16Form10KSummary_288121"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 16. Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b2f7b82e_922b_473b_b876_b67be833cdf3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 16, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="text-transform:uppercase;">Aprea Therapeutics,&#160;Inc.</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">By</p></td><td style="vertical-align:top;width:47.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">/s/ OREN GILAD</p></td></tr><tr style=""><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Oren Gilad, Ph.D.</p></td></tr><tr style=""><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer </i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;background:#ffffff;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-top:6pt;text-align:justify;text-indent:27.75pt;background:#ffffff;margin:0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Oren Gilad<span style="font-size:10pt;"> </span>and John Hamill, as his or her attorney-in-fact, with the power of substitution, for each of them in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-facts, or their substitutes, may do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ OREN GILAD</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Executive Officer and President (Principal Executive Officer)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Oren Gilad, Ph.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ JOHN P. HAMILL</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">John P. Hamill</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ JEAN-PIERRE BIZZARI</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Jean-Pierre Bizzari, M.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ MARC DUEY</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Marc Duey</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ MICHAEL GRISSINGER</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Michael Grissinger</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ GABRIELA GRUIA</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Gabriela Gruia, M.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ JOHN B. HENNEMAN, III</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">John B. Henneman, III.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ RIFAT PAMUKCU.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Rifat Pamukcu, M.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ RICHARD PETERS</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Richard Peters, M.D., Ph.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:37.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/ BERND R. SEIZINGER</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:39.87%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:middle;width:17.47%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Bernd R. Seizinger, M.D., Ph.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.35pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:39.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>apre-20251231xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:22 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">APREA&#160;THERAPEUTICS,&#160;INC.</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">2019 STOCK&#160;INCENTIVE&#160;PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Stock Option Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;background:#ffffff;margin:0pt;">Aprea Therapeutics,&#160;Inc., a Delaware corporation (the&#160;&#8221;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;),&#160;hereby grants to the individual&#160;(&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder</u>&#8221;)&#160;named in the award notice attached hereto (the&#160;&#8221;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award Notice</u>&#8221;)&#160; as of the date set forth in the Award Notice, pursuant to the provisions of the Aprea Therapeutics,&#160;Inc. 2019 Stock Incentive Plan (the &#8220;Plan&#8221;), an option to purchase from the Company the number of shares of the Company&#8217;s Common Stock, par value $0.001 per share&#160;(&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</u>&#8221;)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u>&#160;set forth in the Award Notice at the price per share set forth in the Award Notice (the&#160;&#8221;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u>&#8221;)&#160;(the&#160;&#8221;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u>&#8221;)<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u>&#160;upon and subject to the terms and conditions set forth below, in the Award Notice and in the Plan. Capitalized terms not defined herein shall have the meanings specified in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Subject to Acceptance of Agreement.</u><font style="font-size:10pt;">&#160;The Option shall be null and void unless Holder shall accept this Agreement by executing the Award Notice in the space provided therefor and returning an original execution copy of the Award Notice to the Company (or electronically accepting this Agreement within the Holder&#8217;s stock plan account with the Company&#8217;s stock plan administrator according to the procedures then in effect).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time and Manner of Exercise of Option.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">2.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Term of Option.</u><font style="font-size:10pt;">&#160;In no event may the Option be exercised, in whole or in part, after the expiration date set forth in the Award Notice (the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expiration Date</u><font style="font-size:10pt;">&#8221;)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">2.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting and Exercise of Option.</u><font style="font-size:10pt;">&#160;The Option shall become vested and exercisable in accordance with the vesting schedule set forth in the Award Notice (the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</u><font style="font-size:10pt;">&#8221;)&#160;if, and only if, Holder is, and has been, continuously (except for any absence for vacation, leave,&#160;etc. in accordance with the Company&#8217;s or its Subsidiaries&#8217; policies): (i)&#160;employed by the Company or any of its Subsidiaries; (ii)&#160;serving as a Non-Employee Director or (iii)&#160;providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the Original Option Date through and including the applicable vesting date. The Option shall also be subject to the following terms and conditions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voluntary Resignation by Holder, Termination by Company Other Than&#160; for Cause or Termination Due to Retirement, Death or Disability.</u><font style="font-size:10pt;">&#160;If Holder&#8217;s employment with the Company terminates due to (i)&#160;Holder&#8217;s voluntary resignation, (ii)&#160;termination by the Company other than for Cause, (iii)&#160;Holder&#8217;s retirement pursuant to the terms of Holder&#8217;s employment agreement with the Company or applicable regulatory requirements, (iv)&#160;death or (v)&#160;termination by the Company due to physical disability, the Option, to the extent vested on the effective date of such termination of employment, may thereafter be exercised by Holder (or, in the event of Holder&#8217;s death, Holder&#8217;s estate) until and including the earlier to occur of (i)&#160;the date which is six (6)&#160;months after the date of such termination of employment and (ii)&#160;the Expiration Date. Except to the extent the Option is vested and exercisable as of Holder&#8217;s termination of employment under this&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</u><font style="font-size:10pt;">(</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">a</u><font style="font-size:10pt;">)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u><font style="font-size:10pt;">&#160;the unvested portion of the Option shall terminate immediately upon such termination of employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by Company for Cause.</u><font style="font-size:10pt;">&#160;If Holder&#8217;s employment with the Company is terminated by the Company for Cause, then the Option, whether or not vested, shall terminate immediately upon such termination of employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control.</u><font style="font-size:10pt;">&#160;In the event Holder&#8217;s employment is terminated by the Company without Cause or by Holder due to Good Reason, in each case, within one-year following a Change in Control, the Option, to the extent it is then outstanding, shall become fully vested and may thereafter be exercised by Holder until and including the earlier to occur of (i)&#160;the date which is one-year after the date of such termination of employment and (ii)&#160;the Expiration Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause.</u><font style="font-size:10pt;">&#160;For purposes of this Agreement,&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="font-size:10pt;">&#8221;&#160;shall mean, in the sole discretion of the Board: (1)&#160;conduct by Holder in connection with Holder&#8217;s service to the Company or any affiliate that is fraudulent, unlawful or grossly negligent; (2)&#160;Holder&#8217;s material breach of Holder&#8217;s material responsibilities to the Company or any affiliate or Holder&#8217;s willful failure to comply with reasonable and lawful directives of the Board; (3)&#160;Holder&#8217;s material breach of Holder&#8217;s material representations, warranties, covenants and/or obligations under Holder&#8217;s employment agreement; (4)&#160;material misconduct by Holder that seriously discredits or damages the Company or any affiliate; or (5)&#160;nonperformance or unsatisfactory performance of Holder&#8217;s material duties or responsibilities to the Company or any affiliate. In the case of each of (2), (3), (4)&#160;and (5)&#160;as determined in good faith by the Board after written notice to Holder providing reasonable details of the alleged breach and not less than a 30 day period to cure the alleged breach.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason.</u><font style="font-size:10pt;">&#160;For purposes of this Agreement,&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u><font style="font-size:10pt;">&#8221;&#160;shall mean that Holder has complied with the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u><font style="font-size:10pt;">&#8221;&#160;(hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without Holder&#8217;s express prior written consent: (1)&#160;&#160;&#160;a material diminution in Holder&#8217;s position, responsibilities, authority or function; (2)&#160;a material reduction in Holder&#8217;s base salary and/or annual target bonus opportunity;&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u><font style="font-size:10pt;">&#160;that Good Reason shall not be deemed to have occurred in the event of a reduction in Holder&#8217;s base salary and/or annual target bonus opportunity that is pursuant to a reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect Holder to a greater extent than other similarly situated senior level employees; or (3)&#160;a change of more than 50 miles in the geographic location at which Holder must regularly report to work and perform services, except for required travel on business of the Company;&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u><font style="font-size:10pt;">&#160;that&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u><font style="font-size:10pt;">&#8221;&#160;shall not include, following a Change of Control, a reduction in title, position, responsibilities or duties solely by virtue of the Company being acquired and made part of, or operating as a subsidiary or division of a larger company or organization, as long as Holder&#8217;s new duties and responsibilities are reasonably commensurate with Holder&#8217;s experience. For purposes of the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u><font style="font-size:10pt;">&#8221;&#160;definition,&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u><font style="font-size:10pt;">&#8221;&#160;shall mean that: (v)&#160;Holder has reasonably determined in good faith that a&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u><font style="font-size:10pt;">&#8221;&#160;has occurred; (w)&#160;Holder has notified the Board in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (x)&#160;Holder has cooperated in good faith with the efforts of the Company, for a period not less than 30 days following such notice (the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u><font style="font-size:10pt;">&#8221;)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u><font style="font-size:10pt;">&#160;to remedy the condition; (y)&#160;notwithstanding such efforts, the Good Reason condition continues to exist; and (z)&#160;Holder terminates employment within 60 days after the end of the Cure Period. If the Good Reason condition is cured by the Company during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">2.3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method of Exercise.</u><font style="font-size:10pt;">&#160;Subject to the limitations set forth in this Agreement, the Option, to the extent vested, may be exercised by Holder (a)&#160;by delivering to the Company an exercise notice in the form prescribed by the Company specifying the number of whole shares of Common Stock to be purchased and by accompanying such notice with payment therefor in full (or by arranging for such payment to the Company&#8217;s satisfaction) either (i)&#160;in cash, (ii)&#160;by delivery to the Company (either actual delivery or by attestation procedures established by the Company) of shares of Common Stock having an aggregate Fair Market Value, determined as of the date of exercise, equal to the aggregate purchase price payable pursuant to the Option by reason of such exercise, (iii)&#160;by authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered having an aggregate Fair Market Value, determined as of the date of exercise, equal to the amount necessary to satisfy such obligation, (iv)&#160;except as may be prohibited by applicable law, in cash by a broker-dealer acceptable to the Company to whom Holder has submitted an irrevocable notice of exercise or (v)&#160;by a combination of (i), (ii)&#160;and (iii), and (b)&#160;by executing such documents as the Company may reasonably request. Any fraction of a share of Common Stock which would be required to pay such purchase price shall be disregarded and the remaining amount due shall be paid in cash by Holder. No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the full purchase price therefor and any withholding taxes thereon, as described in&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1,</u><font style="font-size:10pt;">&#160;have been paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">2.4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Option.</u><font style="font-size:10pt;">&#160;In no event may the Option be exercised after it terminates as set forth in this&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4.</u><font style="font-size:10pt;">&#160;The Option shall terminate, to the extent not earlier terminated pursuant to&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</u><font style="font-size:10pt;">&#160;or exercised pursuant to&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.3,</u><font style="font-size:10pt;">&#160;on the Expiration Date. Upon the termination of the Option, the Option and all rights hereunder shall immediately become null and void.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restrictions and Investment Representations.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">3.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nontransferability of Option.</u><font style="font-size:10pt;">&#160;The Option may not be transferred by Holder other than by will or the laws of descent and distribution or pursuant to the designation of one or more beneficiaries on the form prescribed by the Company. Except to the extent permitted by the foregoing sentence, (i)&#160;during Holder&#8217;s lifetime the Option is exercisable only by Holder or Holder&#8217;s legal representative, guardian or similar person and (ii)&#160;the Option may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of the Option, the Option and all rights hereunder shall immediately become null and void.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">3.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representation.</u><font style="font-size:10pt;">&#160;Holder hereby represents and covenants that (a)&#160;any shares of Common Stock purchased upon exercise of the Option will be purchased for investment and not with a view to the distribution thereof within the meaning of the Securities Act of 1933, as amended (the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities&#160;</u><font style="font-size:10pt;">Act&#8221;), unless such purchase has been registered under the Securities Act and any applicable state securities laws; (b)&#160;any subsequent sale of any such shares shall be made either pursuant to an effective registration statement under the Securities Act and any applicable state securities laws, or pursuant to an exemption from registration under the Securities Act and such state securities laws; and (c)&#160;if requested by the Company, Holder shall submit a written statement, in a form satisfactory to the Company, to the effect that such representation (x)&#160;is true and correct as of the date of any purchase of any shares hereunder or (y)&#160;is true and correct as of the date of any sale of any such shares, as applicable. As a further condition precedent to any exercise of the Option, Holder shall comply with all regulations and requirements of any regulatory authority having control of or supervision over the issuance or delivery of the shares and, in connection therewith, shall execute any documents which the Board or the Committee shall in its sole discretion deem necessary or advisable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Terms and Conditions.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Taxes.</u><font style="font-size:10pt;">&#160;(a)&#160;As a condition precedent to the issuance of Common Stock following the exercise of the Option, Holder shall, upon request by the Company, pay to the Company in addition to the purchase price of the shares, such amount as the Company may be required, under all applicable federal, state, local or other laws or regulations, to withhold and pay over as income or other withholding taxes (the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Tax&#160; Payments</u><font style="font-size:10pt;">&#8221;)&#160;with respect to such exercise of the Option. If Holder shall fail to advance the Required Tax Payments after request by the Company, the Company may, in its discretion, deduct any Required Tax Payments from any amount then or thereafter payable by the Company to Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Holder may elect to satisfy his or her obligation to advance the Required Tax Payments by any of the following means: (i)&#160;a cash payment to the Company; (ii)&#160;delivery to the Company (either actual delivery or by attestation procedures established by the Company) of previously owned whole shares of Common Stock having an aggregate Fair Market Value, determined as of the date on which such withholding obligation arises (the&#160;&#8221;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Date</u><font style="font-size:10pt;">&#8221;)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u><font style="font-size:10pt;">&#160;equal to the Required Tax Payments; (iii)&#160;authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered to Holder upon exercise of the Option having an aggregate Fair Market Value, determined as of the Tax Date, equal to the Required Tax Payments; (iv)&#160;except as may be prohibited by applicable law, a cash payment by a broker-dealer acceptable to the Company to whom Holder has submitted an irrevocable notice of exercise or (v)&#160;any combination of (i), (ii)&#160;and (iii). Shares of Common Stock to be delivered or withheld may not have a Fair Market Value in excess of the minimum amount of the Required Tax Payments (or such higher withholding rate as permitted by the Committee and which does not result in adverse accounting consequences for the Company). Any fraction of a share of Common Stock which would be required to satisfy any such obligation shall be disregarded and the remaining amount due shall be paid in cash by Holder. No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the Required Tax Payments have been satisfied in full.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment.</u><font style="font-size:10pt;">&#160;In the event of any equity restructuring (within the meaning of Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#8212;Stock Compensation) that causes the per share value of shares of Common Stock to change, such as a stock dividend, stock split, spinoff, rights offering or recapitalization through an extraordinary dividend, the number and class of securities subject to the </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">Option and the Exercise Price shall be equitably adjusted by the Committee, such adjustment to be made in accordance with Section&#160;409A of the Code. In the event of any other change in corporate capitalization, including a merger, consolidation, reorganization, or partial or complete liquidation of the Company, such equitable adjustments described in the foregoing sentence may be made as determined to be appropriate and equitable by the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation) to prevent dilution or enlargement of rights of participants. The decision of the Committee regarding any such adjustment shall be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Applicable Law.</u><font style="font-size:10pt;">&#160;The Option is subject to the condition that if the listing, registration or qualification of the shares subject to the Option upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other action is necessary or desirable as a condition of, or in connection with, the purchase or issuance of shares hereunder, the Option may not be exercised, in whole or in part, and such shares may not be issued, unless such listing, registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company. The Company agrees to use reasonable efforts to effect or obtain any such listing, registration, qualification, consent, approval or other action.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance or Delivery of Shares.</u><font style="font-size:10pt;">&#160;Upon the exercise of the Option, in whole or in part, the Company shall issue or deliver, subject to the conditions of this Agreement, the number of shares of Common Stock purchased against full payment therefor. Such issuance shall be evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company. The Company shall pay all original issue or transfer taxes and all fees and expenses incident to such issuance, except as otherwise provided in&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Confers No Rights as Stockholder.</u><font style="font-size:10pt;">&#160;Holder shall not be entitled to any privileges of ownership with respect to shares of Common Stock subject to the Option unless and until such shares are purchased and issued upon the exercise of the Option, in whole or in part, and Holder becomes a stockholder of record with respect to such issued shares. Holder shall not be considered a stockholder of the Company with respect to any such shares not so purchased and issued.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Confers No Rights to Continued Employment.</u><font style="font-size:10pt;">&#160;In no event shall the granting of the Option or its acceptance by Holder, or any provision of this Agreement or the Plan, give or be deemed to give Holder any right to continued employment by the Company, any Subsidiary or any affiliate of the Company or affect in any manner the right of the Company, any Subsidiary or any affiliate of the Company to terminate the employment of any person at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Decisions of Board or Committee.</u><font style="font-size:10pt;">&#160;The Board or the Committee shall have the right to resolve all questions which may arise in connection with the Option or its exercise. Any interpretation, determination or other action made or taken by the Board or the Committee regarding the Plan or this Agreement shall be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors.</u><font style="font-size:10pt;">&#160;This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon the death of Holder, acquire any rights hereunder in accordance with this Agreement or the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices.</u><font style="font-size:10pt;">&#160;All notices, requests or other communications provided for in this Agreement shall be made, if to the Company, to Aprea Therapeutics,&#160;Inc., Attn: Treasury Department, 535 Boylston Street, Boston MA 02116, and if to Holder, to the last known mailing address of Holder contained in the records of the Company. All notices, requests or other communications provided for in this Agreement shall be made in writing either (a)&#160;by personal delivery, (b)&#160;by facsimile or electronic mail with confirmation of receipt, (c)&#160;by mailing in the United States mails or (d)&#160;by express courier service. The notice, request or other communication shall be deemed to be received upon personal delivery, upon confirmation of receipt of facsimile or electronic mail transmission or upon receipt by the party entitled thereto if by United States mail or express courier service;&#160;</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u><font style="font-size:10pt;">&#160;that if a notice, request or other communication sent to the Company is not received during regular business hours, it shall be deemed to be received on the next succeeding business day of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law.</u><font style="font-size:10pt;">&#160;This Agreement, the Option and all determinations made and actions taken pursuant hereto and thereto, to the extent not governed by the Code or the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement Subject to the Plan.</u><font style="font-size:10pt;">&#160;This Agreement is subject to the provisions of the Plan and shall be interpreted in accordance therewith. In the event that the provisions of this Agreement and the Plan conflict, the Plan shall control. The Holder hereby acknowledges receipt of a copy of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement.</u><font style="font-size:10pt;">&#160;This Agreement and the Plan constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Holder with respect to the subject matter hereof and may not be modified adversely to the Holder&#8217;s interest except by means of a writing signed by the Company and the Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partial Invalidity.</u><font style="font-size:10pt;">&#160;The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Waiver.</u><font style="font-size:10pt;">&#160;The provisions of this Agreement may be amended or waived only by the written agreement of the Company and the Holder, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;background:#ffffff;margin:0pt;"><font style="font-size:10pt;">4.15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts.</u><font style="font-size:10pt;">&#160;The Award Notice may be executed in two counterparts, each of which shall be deemed an original and both of which together shall constitute one and the same instrument</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>apre-20251231xex10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:22 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APREA THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019 STOCK INCENTIVE PLAN</b><br><br><b style="font-weight:bold;">STOCK OPTION AWARD NOTICE</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&lt;Awardee Name&gt;<br><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">You have been awarded an option to purchase shares of Common Stock of Aprea Therapeutics, Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), pursuant to the terms and conditions of the Aprea Therapeutics, Inc. 2019 Stock Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;) and the Stock Option Agreement (together with this Award Notice, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;). Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:122.4pt;text-indent:-122.4pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:50.4pt;"></font>You have been awarded an Option to purchase from the Company shares of its Common Stock, par value $0.001 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</u>&#8221;), subject to adjustment as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u> of the Agreement as follows:<font style="display:inline-block;width:4.49pt;"></font><font style="display:inline-block;width:36pt;"></font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.6891022%;padding-left:0pt;padding-right:0pt;width:101.37%;" align="center"><tr style=""><td style="vertical-align:bottom;width:100%;background:#ffffff;margin:0pt;padding:0pt;"><div style="clear:left;float:left;width:27.58%;margin:-7pt 1.9% 1em 60.649994pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Options Granted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">xxxx</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Grant Price</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$xxx</p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 162pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:122.4pt;text-indent:-122.4pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:</font></font><font style="display:inline-block;width:50.4pt;"></font>&lt;Date of Award&gt;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:122.4pt;text-indent:-122.4pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u>:<font style="display:inline-block;width:11.75pt;"></font><font style="display:inline-block;width:50.4pt;"></font>See above, subject to adjustment as provided in<b style="font-weight:bold;"> </b><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u> of the Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:122.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</u><font style="font-size:10pt;">:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10pt;white-space:pre-wrap;">Except as otherwise provided in the Plan, the Agreement or any other agreement between the Company or any of its Subsidiaries and Optionee, the Option shall vest and become exercisable as follows:  (i) one quarter of the shares subject to the Option on the Option Date shall vest on the one-year anniversary of the Option Date and (ii) 1/36th of the shares subject to the Option on the Option Date shall vest thereafter on a monthly basis on each monthly anniversary of the Option Date, </font><font style="font-size:10pt;background:#ffffff;">if</font><font style="font-size:10pt;">, and only if, you are, and have been, continuously (except for any absence for vacation, leave, etc. in accordance with the Company&#39;s or its Subsidiaries&#39; policies): (i) employed by the Company or any of its Subsidiaries, (ii) serving as a Non-Employee Director or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the date of this Agreement through and including the applicable vesting date. </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:122.4pt;text-indent:-122.4pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:122.4pt;text-indent:-122.4pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expiration Date</u>:<font style="display:inline-block;width:5.63pt;"></font><font style="display:inline-block;width:50.4pt;"></font>Except to the extent earlier terminated pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u> of the Agreement or earlier exercised pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</u> of the Agreement, the Option shall terminate at 5:00 p.m., U.S. Eastern time, on the ten-year anniversary of the Option Date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 216pt;"><font style="text-transform:uppercase;">APREA THERAPEUTICS, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:10pt;">By:</font><font style="display:inline-block;width:21.55pt;"></font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> _______________________</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="white-space:pre-wrap;">Name:    Oren Gilad</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 216pt;"><font style="white-space:pre-wrap;">Title:      President and CEO</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment, Acceptance and Agreement</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By signing below and returning this Award Notice to Aprea Therapeutics, Inc. at the address stated herein, I hereby acknowledge receipt of the Agreement and the Plan, accept the Option granted to me and agree to be bound by the terms and conditions of this Award Notice, the Agreement and the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:252pt;text-indent:-252pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">___________________________</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:252pt;text-indent:-252pt;margin:0pt;">Optionee</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>apre-20251231xex10d5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:22 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.2pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Aprea Therapeutics</b><b style="font-variant:small-caps;font-weight:bold;">, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.2pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">2019 Equity Incentive Plan</b><font style="font-variant:small-caps;">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.2pt;text-align:center;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><b style="font-weight:bold;">RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:13.2pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;">Aprea Therapeutics, Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), hereby grants to the individual (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder</u>&#8221;) named in the award notice attached hereto (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award Notice</u>&#8221;) as of the date set forth in the Award Notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant Date</u>&#8221;), pursuant to the provisions of the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;), a restricted stock unit award (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award</u>&#8221;) with respect to the number of shares of the Company&#8217;s Common Stock, par value $0.001 per share (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</u>&#8221;), set forth in the Award Notice, upon and subject to the restrictions, terms and conditions set forth in the Plan and this agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;). Capitalized terms not defined herein shall have the meanings specified in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Subject to Acceptance of Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Award shall be null and void </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unless</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the Holder accepts this Agreement by executing the Award Notice in the space provided therefor and returning an original execution copy of the Award Notice to the Company (or electronically accepting this Agreement within the Holder&#8217;s stock plan account with the Company&#8217;s stock plan administrator according to the procedures then in effect).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights as a Stockholder</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Holder shall not be entitled to any privileges of ownership with respect to the shares of Common Stock subject to the Award unless and until, and only to the extent, such shares become vested pursuant to&#160;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;hereof and the Holder becomes a stockholder of record with respect to such shares. </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Award includes a right to Dividend Equivalents equal to the value of any dividends paid on the Common Stock for which the dividend record date occurs between the Grant Date and the date the Award is settled or forfeited. Subject to vesting, each Dividend Equivalent entitles Holder to receive the equivalent cash value of any such dividends paid on the number of shares of Common Stock underlying the Award that are outstanding during such period. Dividend Equivalents will be accrued (without interest) and will be subject to the same conditions as the shares of Common Stock to which they are attributable, including, without limitation, the vesting conditions, the provisions governing the time and form of settlement of the Award.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restriction Period and Vesting</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">3.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service-</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Based</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Vesting Conditions</u><font style="white-space:pre-wrap;">.  Except as otherwise provided for in this Agreement, the Award shall vest in accordance with the vesting schedule set forth in the Award Notice if, and only if, the Holder is, and has been, </font><font style="white-space:pre-wrap;">continuously  (except for any absence for vacation, leave, etc. in accordance with the Company&#8217;s or its Subsidiaries&#8217; policies): (i) employed by the Company or any of its Subsidiaries; (ii) serving as a Non-Employee Director; or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the date of this Agreement through and including the applicable Vesting Date specified in the Award Notice.  </font>The period of time prior to the vesting shall be referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restriction Period</u><font style="white-space:pre-wrap;">.&#8221;   </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="white-space:pre-wrap;">3.2  </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Employment</u><font style="white-space:pre-wrap;">.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:23.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Employment due to Death or Disability</u><font style="white-space:pre-wrap;">.  If Holder&#8217;s employment with the Company terminates prior to the expiration of the Restriction Period by reason of Holder&#8217;s death or termination by the Company due to Disability, then the Award</font><font style="font-family:'inherit';"> </font>shall be 100% vested as of the date of such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:23.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by Company without Cause</u>. If Holder&#8217;s employment with the Company is terminated by the Company without Cause prior to the end of the Restriction Period, t<font style="background:#ffffff;">hen a pro-rated portion of the Award shall become vested upon such termination of employment. Such pro-rated portion shall be equal to the number of shares of Common Stock scheduled to vest on the next scheduled Vesting Date multiplied by a fraction, the numerator of which shall equal the number of days that elapsed during the period beginning </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="background:#ffffff;">on the most recent Vesting Date (or the Vesting Commencement Date, if no Vesting Date has occurred prior to such termination) and ending on the termination date and the denominator of which shall equal the number of days during the period beginning on the most recent Vesting Date (or the Vesting Commencement Date, if no Vesting Date has occurred prior to such termination) and ending on the next scheduled Vesting Date. T</font>he portion of the Award that was not vested prior to such termination or does not vest in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2(b)</u> shall be forfeited in its entirety. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:23.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> (c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>. In the event of a Change in Control prior to the expiration of the Restriction Period, the <font style="background:#ffffff;">Award shall be 100% vested immediately prior to such Change in Control and shall be settled as set forth in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Section 4</u><font style="background:#ffffff;">.</font><font style="font-size:12pt;"><a name="_Ref8909032"></a></font> </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:23.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d) </font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Other than without Cause, Death, Disability or by Holder</u><font style="white-space:pre-wrap;">.   If Holder&#8217;s employment with the Company terminates for any reason other than as set forth in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 3.2(a)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.2(b)</u> hereof, then the portion of the Award that was not vested prior to such termination shall be forfeited in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="white-space:pre-wrap;">3.3  </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="white-space:pre-wrap;">.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:23.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a) </font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="white-space:pre-wrap;">&#8221; shall mean, in the sole discretion of the Board:  (1) conduct by Holder in connection with Holder&#8217;s service to the Company or any affiliate that is fraudulent, unlawful or grossly negligent; (2) Holder&#8217;s material breach of Holder&#8217;s material responsibilities to the Company or any affiliate or Holder&#8217;s willful failure to comply with reasonable and lawful directives of the Board; (3)</font><font style="display:inline-block;width:4.65pt;"></font><font style="white-space:pre-wrap;">Holder&#8217;s material breach of Holder&#8217;s material representations, warranties, covenants and/or obligations under Holder&#8217;s employment agreement; (4) material misconduct by Holder that seriously discredits or damages the Company or any affiliate; or (5) nonperformance or unsatisfactory performance of Holder&#8217;s material duties or responsibilities to the Company or any affiliate.  In the case of each of (2), (3), (4) and (5) as determined in good faith by the Board after written notice to Holder providing reasonable details of the alleged breach and not less than a 30-day period to cure the alleged breach.</font><font style="white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:23.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font> &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; means Holder has become incapacitated for a period of at least 180 days by accident, sickness or other circumstance that renders Holder mentally or physically incapable of performing Holder&#8217;s material duties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance or Delivery of Shares</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#160; Except as otherwise provided for herein, within 60 days after the vesting of any portion of the Award, the Company shall issue or deliver, subject to the conditions of this Agreement, the vested shares of Common Stock to the Holder. Such issuance or delivery of shares shall be evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company. The Company shall pay all original issue or transfer taxes and all fees and expenses incident to such issuance or delivery, except as otherwise provided in&#160;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#160; Prior to the issuance to the Holder of the shares of Common Stock subject to the Award, the Holder shall have no direct or secured claim in any specific assets of the Company or in such shares of Common Stock, and will have the status of a general unsecured creditor of the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restrictions and Investment Representation</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">5.1.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nontransferability of Award</u>. The Award may not be transferred by the Holder other than by will or the laws of descent and distribution.&#160; Except to the extent permitted by the foregoing sentence, the Award may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process.&#160; Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of the Award, the Award and all rights hereunder shall immediately become null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">5.2.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representation</u>. The Holder hereby covenants that (a)&#160;any sale of any share of Common Stock acquired upon the vesting of the Award shall be made either pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Act</u>&#8221;), and any applicable state securities laws, or pursuant to an exemption from registration under the Securities Act and such state securities laws and (b) the Holder shall comply with all regulations and requirements of any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">regulatory authority having control of or supervision over the issuance of the shares and, in connection therewith, shall execute any documents which the Committee shall in its sole discretion deem necessary or advisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:78.75pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Terms and Conditions of Award</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:48.95pt;margin:0pt;">6.1.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Taxes</u>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>As a condition precedent to the delivery to the Holder of any of the shares of Common Stock subject to the Award, the Holder shall, upon request by the Company, pay to the Company (or shall cause a broker-dealer on behalf of the Holder to pay to the Company) such amount of cash as the Company may be required, under all applicable federal, state, local or other laws or regulations, to withhold and pay over as income or other withholding taxes (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Tax Payments</u><font style="white-space:pre-wrap;">&#8221;) with respect to the Award.  If the Holder shall fail to advance the Required Tax Payments after request by the Company, the Company may, in its discretion, deduct any Required Tax Payments from any amount then or thereafter payable by the Company to the Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Holder shall satisfy his or her obligation to advance the Required Tax Payments by the Company withholding whole shares of Common Stock which would otherwise be delivered to Holder upon vesting of the Award having an aggregate Fair Market Value, determined as of the date on which such withholding obligation arises (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Date</u><font style="white-space:pre-wrap;">&#8221;), equal to the Required Tax Payments.  Notwithstanding the foregoing, the Holder may elect to satisfy his or her obligation to advance the Required Tax Payments by any of the following means: (i) a check or cash payment to the Company, (ii)&#160;</font><font style="white-space:pre-wrap;">delivery to the Company (either actual delivery or by attestation procedures established by the Company) of previously owned whole shares having an aggregate Fair Market Value, determined as of the Tax Date, equal to the Required Tax Payments, (iii) if approved by the Company (or, if the Holder is subject to Section 16 of the Exchange Act, by the Committee), authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered to Holder upon the vesting of the Award having an aggregate Fair Market Value, determined as of the Tax Date, equal to the Required Tax Payments, (iv) except as may be prohibited by applicable law, a cash payment by a broker whom the Company has selected for this purpose and to whom the Holder has authorized to sell any shares acquired upon the vesting of the Award to meet the Required Tax Payments, or (v) any combination of (i), (ii) and (iii). Shares to be delivered to the Company or withheld may not have a Fair Market Value in excess of the minimum amount of the Required Tax Payments (or such greater withholding amount to the extent permitted by applicable withholding rules and accounting rules without resulting in variable accounting treatment).  Any fraction of a share which would be required to satisfy any such obligation shall be disregarded and the remaining amount due shall be paid in cash by the Holder.  No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the Required Tax Payments have been satisfied in full.</font><sup style="font-size:7.5pt;vertical-align:top;"> </sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.2.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Applicable Law</u>. The Award is subject to the condition that if the listing, registration or qualification of the shares of Common Stock subject to the Award upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other action is necessary or desirable as a condition of, or in connection with, the delivery of shares hereunder, the shares of Common Stock subject to the Award shall not be delivered, in whole or in part, unless such listing, registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company. The Company agrees to use reasonable efforts to effect or obtain any such listing, registration, qualification, consent, approval or other action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.3.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award Confers No Rights to Continued Employment</u>. In no event shall the granting of the Award or its acceptance by the Holder, or any provision of the Agreement or the Plan, give or be deemed to give the Holder any right to continued employment by the Company, any Subsidiary or any affiliate of the Company or affect in any manner the right of the Company, any Subsidiary or any affiliate of the Company to terminate the employment of any person at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.4.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Decisions of Board or Committee</u>. The Board or the Committee shall have the right to resolve all questions which may arise in connection with the Award. Any interpretation, determination or other action </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">made or taken by the Board or the Committee regarding the Plan or this Agreement shall be final, binding and conclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.5.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</u>. This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon the death of the Holder, acquire any rights hereunder in accordance with this Agreement or the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.6.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All notices, requests or other communications provided for in this Agreement shall be made, if to the Company, to Aprea Therapeutics, Inc., Attention: Scott Coiante, 535 Boylston Street, Boston, MA 02116, and if to the Holder, to the last known mailing address of the Holder contained in the records of the Company. All notices, requests or other communications provided for in this Agreement shall be made in writing either (a) by personal delivery, (b) by facsimile or electronic mail with confirmation of receipt, (c) by<b style="font-weight:bold;">&#160;</b>mailing in the United&#160;States mails or (d)&#160;by express courier service. The notice, request or other communication shall be deemed to be received upon personal delivery, upon confirmation of receipt of facsimile or electronic mail transmission or upon receipt by the party entitled thereto if by United States mail or express courier service;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>,&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that if a notice, request or other communication sent to the Company is not received during regular business hours, it shall be deemed to be received on the next succeeding business day of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.7.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement, the Award and all determinations made and actions taken pursuant hereto and thereto, to the extent not governed by the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.8.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement Subject to the Plan</u>. This Agreement is subject to the provisions of the Plan, including Section 5.8 with respect to a Change in Control, and shall be interpreted in accordance therewith. In the event that the provisions of this Agreement and the Plan conflict, the Plan shall control. The Holder hereby acknowledges receipt of a copy of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.9.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement and the Plan constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Holder with respect to the subject matter hereof, and may not be modified adversely to the Holder&#8217;s interest except by means of a writing signed by the Company and the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.10.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partial Invalidity</u>. The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof and this Agreement shall be construed in all respects as if such invalid or unenforceable provision was omitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.11.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Waiver</u>. The Company may amend the provisions of this Agreement at any time;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>&#160;that an amendment that would materially impair the Holder&#8217;s rights under this Agreement shall be subject to the written consent of the Holder. No course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:48.95pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt 0pt 0pt 36pt;">6.12.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance With Section 409A of the Code</u>. <font style="white-space:pre-wrap;">This Award is intended to be exempt from or comply with Section 409A of the Code, and shall be interpreted and construed accordingly, and each payment hereunder shall be considered a separate payment.  To the extent this Agreement provides for the Award to become vested and be settled upon the Holder&#8217;s termination of employment, the applicable shares of Common Stock shall be transferred to the Holder or his or her beneficiary upon the Holder&#8217;s &#8220;separation from service,&#8221; within the meaning of Section 409A of the Code; provided that if the Holder is a &#8220;specified employee,&#8221; within the meaning of Section 409A of the Code, then to the extent the Award constitutes nonqualified deferred compensation, within the meaning of Section 409A of the Code, such shares of Common Stock shall be transferred to the Holder or his or her beneficiary upon the earlier to occur of (i) the six-month anniversary of such separation from service and (ii) the date of the Holder&#8217;s death.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>5
<FILENAME>apre-20251231xex10d6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:22 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:706.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 72pt 0pt 72pt;"><font style="font-family:'Times New Roman Bold';font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="height:22.5pt;left:0%;position:absolute;top:684pt;width:468pt;z-index:251658240;"><div style="height:21.6pt;left:0pt;padding-bottom:0.9pt;position:relative;top:0pt;width:468pt;"><div style="height:21.6pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:468pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 72pt 0pt 72pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">2019 Equity Incentive Plan</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Unit Award Notice</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:14.4pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;margin:0pt;">&lt;Awardee Name&gt;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:14.4pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;text-indent:72pt;margin:0pt;">You have been awarded a restricted stock unit award with respect to shares of common stock of Aprea Therapeutics, Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), pursuant to the terms and conditions of the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;) and the Restricted Stock Unit Award Agreement (together with this Award Notice, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;). Copies of the Plan and the Restricted Stock Unit Award Agreement are attached hereto. Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:14.4pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.6891022%;padding-left:0pt;padding-right:0pt;width:101.37%;" align="center"><tr style=""><td style="vertical-align:middle;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:82.84%;background:#ffffff;margin:0pt;padding:0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Units</u>:</p></td><td style="vertical-align:bottom;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:82.84%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">You have been awarded a restricted stock unit award with respect to shares of Common Stock, par value $0.001 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</u>&#8221;) as follows, subject to adjustment as provided in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">RSUs Awarded</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">xxxx</p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:84.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant Date</u>:</p></td><td style="vertical-align:bottom;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:82.84%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&lt;Date of Award&gt;</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:84.82%;background:#ffffff;margin:0pt;padding:0pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Commencement Date</u>:</p></td><td style="vertical-align:middle;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:82.84%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&lt;Vesting Commencement Date&gt;</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:84.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:15.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</u>:</p></td><td style="vertical-align:bottom;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:82.84%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Except as otherwise provided in the Plan, the Agreement or any other agreement between the Company or any of its Subsidiaries and you, the Award shall vest in three (3) equal installments on each of the first, second and <font style="white-space:pre-wrap;">third anniversaries of the Vesting Commencement Date (each such date, a &#8220;Vesting Date&#8221;) if, and only if, you are, and have been, continuously  (except for any absence for vacation, leave, etc. in accordance with the Company&#8217;s or its Subsidiaries&#8217; policies): (i) employed by the Company or any of its Subsidiaries; (ii) serving as a Non-Employee Director; or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the date of this Agreement through and including the applicable Vesting Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;margin:0pt;">APREA THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:14.4pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:14.4pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:64.69%;"><tr style=""><td style="vertical-align:middle;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:95.22%;margin:0pt;padding:0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:4.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:95.22%;margin:0pt;padding:0pt 0pt 0pt 288pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:14.4pt;text-indent:-288pt;margin:0pt;"><font style="font-size:10pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;margin:0pt;"><font style="white-space:pre-wrap;">Name:  Oren Gilad. Ph.D.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.4pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:   President and Chief Executive Officer </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment, Acceptance and Agreement</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By signing below and returning this Award Notice to Aprea Therapeutics, Inc., I hereby acknowledge receipt of the Agreement and the Plan, accept the Award granted to me and agree to be bound by the terms and conditions of this Award Notice, the Agreement and the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">____________________________________</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:252pt;text-indent:-252pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Holder</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>apre-20251231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:31 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the Registration Statements of Aprea Therapeutics, Inc. on Form S-3 (No. 333-276702, 333-278485, 333-292286 and 333-293609) and Form S-8 (Nos. 333-234765, 333-250043, 333-260884, 333-265411, 333-268816, 333-275440, 333-281683 and 333-291998) of our report dated March 16, 2026, on our audits of the financial statements as of December 31, 2025 and 2024 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 16, 2026. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&#39;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;">/s/ EisnerAmper LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;">EISNERAMPER LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;">March 16, 2026</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>apre-20251231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:31 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Oren Gilad, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Aprea Therapeutics, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: &#160;March 16, 2026</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Oren Gilad</p></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Oren Gilad, Ph.D.</p></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Chief Executive Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>apre-20251231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:31 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, John P. Hamill, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Aprea Therapeutics, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 16, 2026</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ John P. Hamill</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">John P. Hamill</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>apre-20251231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:32 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Aprea Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I,&#160;Oren Gilad, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1)&#160;&#160;&#160;The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 16, 2026</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Oren Gilad</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oren Gilad, Ph.D.</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>apre-20251231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/14/2026 01:08:40 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&#160;1350, </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Aprea Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, John P. Hamill, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">1)&#160;&#160;&#160;The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">2)&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: March 16, 2026</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ John P. Hamill</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">John P. Hamill</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>apre-20251231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &; YX# 2(  A$! Q$!_\0
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M:/S%7S(SN&)%RIP<$X-;=%D%V:/]L1_\\I?R'^-']L1_\\I?R'^-<'K7Q/\
M#V@^*V\,W%U+)KZZ//KHT^VMY)I6LXI$C=U50=QWR*H4?,3T!Q6WH&M0>(]#
MT_5;:*Y@M[V!+B.*]MWMYD5U# /$X#(V#RK $'@BBR"[.A_MB/\ YY2_D/\
M&C^V(_\ GE+^0_QK.HHL@NS1_MB/_GE+^0_QH_MB/_GE+^0_QK.HHL@NS1_M
MB/\ YY2_D/\ &C^V(_\ GE+^0_QK.HHL@NS1_MB/_GE+^0_QH_MB/_GE+^0_
MQK.HHL@NS0_MJ+=M\J7.,]!_C2_VQ'_SRE_(?XUE?\MS_N_UJ2BR"[-'^V(_
M^>4OY#_&C^V(_P#GE+^0_P :SJ\V^*G[0'A+X.ZUH.CZ]_:]QJNN1SRV%EHV
MD7.HS2K#L\T[($<@+YB=1W]J+(+L]:_MB/\ YY2_D/\ &C^V(_\ GE+^0_QK
MSKX4_&#PM\:?#]SJ_A6^ENK>TNY+&[@NK:2VN+6X3&Z*6*15=&&0<$=Z[2BR
M"[-'^V(_^>4OY#_&C^V(_P#GE+^0_P :P]7U2VT/2;W4KQS':6<#W$SA2Q5$
M4LQP.3P#Q7'^ OC1X;^)BZ++X?\ [2N[/6-)76;._?3)X[5[=G* &9D"+)E2
M?+)WXP<8.:+(+L],_MB/_GE+^0_QH_MB/_GE+^0_QKF_$WB"W\*:!?ZQ=PW=
MQ;641FDBL+62ZG8#LD48+N?9035ZUN%N[:&=%=4E0.%D0HP!&>5/(/L:+(+L
MUO[8C_YY2_D/\:/[8C_YY2_D/\:SJY?X<?$G0/BOX97Q!X:NGO-+:XFMA+)"
MT1\R*0QN-K 'AE(SWHL@NSN?[8C_ .>4OY#_ !H_MB/_ )Y2_D/\:SJ*+(+L
MT!K41) BER.#P/\ &E_MB/\ YY2_D/\ &LF+_63?[P_D*EHL@NS1_MB/_GE+
M^0_QH_MB/_GE+^0_QK.HHL@NS1_MB/\ YY2_D/\ &C^V(_\ GE+^0_QK.KG/
MB)X_T7X6>"M6\5^([E[/1-*A\^ZGCB:5D3(&0J@D\D=!19!=G:?VQ'_SRE_(
M?XT?VQ'_ ,\I?R'^->2Z1^T1X"UOQSKG@^UUK/B+1]*BUJZL9(71OLDD:R+(
MF1A\*Z9"Y(W#-<:/VW/A?<-H2:?/X@UJ;6M)77+.#1_#M]>R-9F:2$2LL43%
M!YD,@PP'0>HHT'=GT9_;$?\ SRE_(?XT?VQ'_P \I?R'^-<-\-OB;X;^+OA.
MV\2>%-335-)G9HQ(JLCQR*</&Z, R.IX*L 174460KLT?[8C_P">4OY#_&C^
MV(_^>4OY#_&LZBBR"[-'^V(_^>4OY#_&D;6HD&3%*!]!_C6?45S_ *H_4?S%
M%D%V:W]L1_\ /*7\A_C1_;$?_/*7\A_C6=119!=FC_;$?_/*7\A_C1_;$?\
MSRE_(?XUP7Q0^)^@?!WP9=^*?$UQ/;:/:R112/;6TEQ(6DD6- L: LQ+,HX'
M>O-U_;1^%\5OK[W][K.ASZ)91:C=V6M:%>6-S]FDF$*RI%+$K.OF$*2H.*-
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M?C'2?B#X5TSQ'H5S]MT?4H1<6MQL*>9&>C8(!&?>BR"[.K_MB/\ YY2_D/\
M&C^V(_\ GE+^0_QKE_%WBK3O WA76/$>L3-;Z3I-I+?7<RH7*0QH7<A0"3@
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M6Y^QV$+37$^Q2WEQQJ"7=L8"CDDBC^W8O^?6_P#_  #E_P#B:/[=B_Y];_\
M\ Y?_B:+"/SI\,_!GX[?#_2_ ?Q>N-%TRZO[;Q/)XCU30M+TZ\?Q \>I.L-U
M#,I8JXCB*#:L8*B,,?NDU3\8? *YU#P['XB\3?"O7_$]MI_QEUB_N],MM(FF
MO;C1;AI27CA^5I(G=8#D<' .< U^D7]NQ?\ /K?_ /@'+_\ $T?V[%_SZW__
M (!R_P#Q-%BKGYM?#+X%?%2+]J6_UO5(O%MIK::IJ=SJ6IGP_&NGWFG.K>3$
M=1,X-P'1HD6%48QL%^7$9*N@_9\O_!?[&'@F&'X5ZK=^)/$&J%/%CC2+J^U&
MU@CDO/L\AL%EB,P0NA6-SY8)5G5L"OTC_MV+_GUO_P#P#E_^)H_MV+_GUO\
M_P  Y?\ XFBPKGYH^#/@1KVC^'OV>;[QE\-/$NO#PIXJUBPU.U32'DN+>U=Y
M'LW\I6($"R,CAD8HNT@,< &YX1^$?BK2/A!\&QX]^&_BOQ5\.]+NM<_M_P &
MV%C*UY]IEN6-G<26>4>5 -Q!Z+G/>OTB_MV+_GUO_P#P#E_^)H_MV+_GUO\
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M]5'^W8O^?6__ / .7_XFF1:[%E_]%OC\W:SD_P#B:=@-6BLW^W8O^?6__P#
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MZ.T2A9T>X61!9,)<.S/@$ Y.,FON[^W8O^?6_P#_  #E_P#B:/[=B_Y];_\
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MM(HR09&"X5HE8D[2O)X/Z)?V[%_SZW__ (!R_P#Q-']NQ?\ /K?_ /@'+_\
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M>4]9)$&QG_X$5)_&NV'_ "$'_P"N0_F:B4>63B^A$XN$G%]"Q1114DA1110
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MEZS7/ &HZG\<?"/C**:V72](T74]-GA=F$S27,MF\90;=I4"W?)+ \K@')P
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M?AIH&L>%?A_X?TCQ!J[Z]K=E91PWFI.2QGE"_,Q8\MZ;CR<9/)-=-0 4444
M0#_C];_KF/YFIZ@'_'ZW_7,?S-3T"04444#"BBB@ HHHH **** "BBB@ HHH
MH K6W^ON_P#KH/\ T%:LU6MO]?=_]=!_Z"M6:!(****!A1110 4444 %%%%
M!1110 55U'_CT/\ O)_Z$*M55U'_ (]#_O)_Z$*:W M4444@"BBB@ HHHH *
M*** "JFK_P#()O?^N#_^@FK=5-7_ .03>_\ 7!__ $$TUN-;GFW[+7_)O_@O
M_KS;_P!&/7I@_P"0@_\ UR'\S7F?[+7_ ";_ ."_^O-O_1CUZ8/^0@__ %R'
M\S6M;^)+U?YFE?\ BR]66****Q,@HHHH **** "BBB@ HHHH **** "BBB@
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M!6!!\OG.37LGA#X767@;QEXHUK2+VYM['Q#*EY=:-\IMDO0-LES'QE&D4('
M.TE-V,DD\UX4_9RT7PQ;> K-]1N]4TWP=!>1VEC>)&T4\UP1^_D&WET4R*N,
M "5NIQ@ U_@%X_F^)'PMTG4[Z\MK_6+=I=.U*>U*^6]W;R-#*X"\ ,R;P!QA
MQCC%>AUQG@?X7:=\/_$WB_5-)GEAM?$EW%J$^EA5%O!<K"D+R1@#(,BQ1[AT
MRN>YKLZ "BBB@ HHHH *KVO6?_KH?Y"K%5[7K/\ ]=#_ "% %BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@" ?\?K?]<Q_,U/4 _X
M_6_ZYC^9J>@2"BBB@84444 %%%% !1110 4444 %%%% %:V_U]W_ -=!_P"@
MK5FJUM_K[O\ ZZ#_ -!6K- D%%%% PHHHH **** "BBB@ HHHH *JZC_ ,>A
M_P!Y/_0A5JJNH_\ 'H?]Y/\ T(4UN!:HHHI %%%% !1110 4444 %5-7_P"0
M3>_]<'_]!-6ZJ:O_ ,@F]_ZX/_Z"::W&MSS;]EK_ )-_\%_]>;?^C'KTP?\
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M^8JQ3$5_L:_\])?^_AH^QK_STE_[^&K%%(97^QK_ ,])?^_AH^QK_P ])?\
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M?#>R^)_A7XCRV=WK^KZUJ-VGAB2(37_B*RN&(M8[6V/S7>8ML&U P#(0<8-
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M5-7_ .03>_\ 7!__ $$U;JIJ_P#R";W_ *X/_P"@FFMQK<\V_9:_Y-_\%_\
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MPB0@Y(7<1G&1^=<]_P -+?"?_HHWAG_P9Q?_ !5?+_\ P5(_Y G@+_KXNO\
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M62YD+RW;,Z$^:9&CX3:$)P?JNBBL:M1U6FT8U:KJM-H****Q,0HHHH ****
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M B4NLN\;, 950ISM<D\8K%\+:KXDU;Q;\-(M)U>+0+&?QQKL<EK%!)+%(\3
M[Y TOS$H64#HI)(]*F5"I*[E+^MR98>I.[E/^MS[QHKY.\,_M&^-[S_A#O$E
MY=Z/<Z)XPO+ZR@\/V]J5NM,\H2;',N\^:5\L>8"BXR:]7_9G\3^+_'OPST_Q
M7XMU6QO)=7C$MO9V-EY"VJJSIR^\^86VJQX7:20,]:Y*F'E3CS2?]:_Y')4P
M\J47*37]7_R/6J***YCE"BBB@"&\_P"/2;_</\JE7[H^E17G_'I-_N'^52K]
MT?2@!:\H^+FOZC=_$#X>> [.]N](LO$<M[=:AJ%E(8IC!:1(_P!FCD',;2M*
MF64A@D<FT@G</5ZYWQKX&T[QU964-\]Q;7-A=+?6-_92^5<6DZAE$D;8(Y5W
M4@@JRNP(()% 'AOC3XI>(/@#XC\1Z'9RR^,+ IH=SI5OK-VQFLFO]2-A)$]P
M0SR1@XE0ON?/F+N*A=NEXN_:9O\ P3X[L/#M_IFGW,C:KINCW*6$TUQ*'NFM
MT:;,<;)!&CW* "X:-GVDJ.5SVTOP"\*:AI^HV]\]]JE_J.H6.IW^JW5UNN[F
M6SG2:V5F  6-&08C157E^,LQ,/B']G[PSXHUZ[U";4-6MTNM6M->FTZSO!';
M/?VQB\J<J%SD>1'E<[&*Y*D\T 7/@'KFH>(O 5Q=ZG=RWMRNMZM )9FW,(X]
M0GCC7/HJ*JCV KT:L3PAX0T_P1I#Z;IBR+:O=7%X1*^X^9/,\TG/IOD; ["M
MN@"O?_\ 'JWU7^8JQ5>__P"/5OJO\Q5BGT ****0!1110 4444 %%%% !111
M0 4444 %5[7K/_UT/\A5BJ]KUG_ZZ'^0H \O\/\ QOOO%$O]H:5X4EU/PL-9
M?1)+ZQO5GO;>1)#$TTMHJ_)$' )^<NJ,'* 9 ZA?C#X'?7WT-?%FD'5UEDA-
MD+M/-WQJ6D4#/)0*2P'W<<XKQ;5O@=?^(?&NGZ_!X"L_!?Q!MM82>X\;^&]0
M6UM;RT%RCR^=$CB6Y:6",1F.>-@&8C?M&X\W+X \2^$=3^$/@75=(MA967B/
M68HO$Z3HS7:W%I?R0L(A\X8HY,V[ \R-=I<-N4 ^G1\0?#)M8+D:]I_V>?3V
MU:*7[0NU[,;<S@Y_U8WK\W3YA68/C/X%.DR:G_PEFDBPCN%M&G:Z4 3,NY8^
M?XF'('4]J^?+?X._$J[\,Z58?\([8:?<:)X&7PXC7ES;72W=TMQ;.YC1@Z!&
MC@;8T@R'/S(H R_PI\ O&*?$G4==NM,O8M.N?$FB:NC:[K2W]XR6T5TL[.0S
M+&0\B%8XSL"E=H&"J@'T%H/QC\#>*-1@L-)\6:1J-[.DDD4%O=HS.$^_@9ZJ
M.2.H')J*'XP?#_4M/O\ 4D\5:)<6>D(+FYN?M492V0DH)2V>%)RN[H>1FO"]
M?_9M\5Z[X=\+Z5$+?39(/%?B;4KV[CF&Z*VO[;4X8)!CEC_I4&5'(&?2J7Q#
M^ 7CSXL^$FLY-$TWPK>Z1X&N?#5O"+Q)$U&[EDM7^5D'R6R_8QL+@-F<Y1=I
MW 'TGKOQ)\*^&);V+5O$&GZ?+9F 7$<]PJO&9BPA!7.<OM;:.^T^AJ8>._#[
M^"Y_%L>KVL_AN"TDOGU.&0/"((U+.^X=E"MGZ&OGSQ#\*_%WC3QSXG\5ZQX'
MGAAN;G1I]*BT[Q%';:K8O;17227$;J#$9 ;@KY;2!&BD;+;LQUZ-HGPU\0>-
M/@#X@\%>/KUC?:]:ZC823Q^49X;6X,B0^88E6-IEB==Q0;2P.,CD@$5AXBA\
M8^)?".K^(_A:D4.I9;1];GBBO+K3SL,L8N5\O-J6"G!5W ?"L5)&;_C3]HOP
M?X:\ >,?$VE:I9>)W\,:?-J%UI^G7:&1TC+ X/(QN4KNY&16.MI\4_$VA:+X
M6ETVS\)P0VLEMKFN?:4N5N5$#QH+)%.\;I"CEI0A15( 8G(\0U7]F3XB:]\)
MYO#$UELU#1_ ][X8LVN]2MVM[B>588U%FL4:%+<BV5S]HPPS& O#-0!]0^ ?
MBG9>.;7Q;<FV;38/#NKW&E7$D\@(?R8XY&EXZ+B3H?0UA^'/BW?>+8_#6MCP
M3>+X2UR=!INJ-('NHUD1C#<S6VS,,3CHV\LHD3>J9;;6^%OPJO\ 2-!^)VDZ
M_&L-MXF\07]W"8)0S&UG@BC#9'W6^5^#TXJEX(L?B?X?\,>#?!7]D6-F-$:V
MLM1\3/<1RVUY8VZ;=T$ /F+-,%12K@+'O<AWVKN .[A^+?@NXO=0M(_%&EO<
M:?%-/=1BZ7,4<1Q*YYZ(>&/;O56Z^-_@"RTVWU&?QAH\5C<*[PW#W:A'1,;W
M!SR@R,MTY'-?,.I_LY_$?6=2T*2;2IA-8:%KNDW4DFK01Z?YEU:ND!L[.+;'
M%$7^\S()<NH;<JY'KEG\/_%?P_\ &EIXDTWP[;^*8[CP98^''TU;R*W:SN+9
MY7'S/\OD2>>0Q7<RF)2$?/ !WLOQM\':9+?)JWB?0K P7DMI&JZBLC.8TB=P
M5P"KJ)D)0;L!E.>>+^I?%WP3H\>ER7OBO2+:/5(%NK)Y+Q L\+$!95.>4)91
MNZ<]:\7^''P,\5:'\<I?%>K:=8P:<^MZWJ($%RLHC2ZL].BBVY4'[UM.O0'
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MZQ?D:/\ 2?6+\C4]% $'^D^L7Y&C_2?6+\C4]% $'^D^L7Y&C_2?6+\C4]%
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MAJO[-FAZCK6I74&K:IIVFZAK=AXCET>W:/[*NH6LR2^<@9"R>:8T$@!P<;@
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MM>I44>VJ?S/[P]M5_F?WGEO_  RY\)/^B=^'_P#P"6C_ (9<^$G_ $3OP_\
M^ 2UZE11[:I_,_O#VU7^9_>>6_\ #+GPD_Z)WX?_ / ):/\ AESX2?\ 1._#
M_P#X!+7J5%'MJG\S^\/;5?YG]YY;_P ,N?"3_HG?A_\ \ EH_P"&7/A)_P!$
M[\/_ /@$M>I44>VJ?S/[P]M5_F?WGEO_  RY\)/^B=^'_P#P"6H+[]E_X2QV
MQ9?A[H"G<HR+)?[PKUFJNH_\>A_WD_\ 0A0JU3^9_>'MJO\ ,_O/-_\ AESX
M2?\ 1._#_P#X!+1_PRY\)/\ HG?A_P#\ EKU*BCVU3^9_>'MJO\ ,_O/+?\
MAESX2?\ 1._#_P#X!+1_PRY\)/\ HG?A_P#\ EKU*BCVU3^9_>'MJO\ ,_O/
M+?\ AESX2?\ 1._#_P#X!+1_PRY\)/\ HG?A_P#\ EKU*BCVU3^9_>'MJO\
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M=Z9XKO)+Z\5I0KP3,B*&@95!C*&)&5N2K#.:]$HH \QU?X'&_FL[RP\=>*M
MUI+"/3;_ %?39+/[1JL,>=GV@2VSQ[P6<B2)(W&]L,!@#M/!G@W1_A]X6TWP
M[H-F+'2-/B$-O!O:0@9))9V)9V8DLS,2S$DDDDFMJB@ HHHH **** "BBB@
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M'_WT*FQ1B@-2'[=;_P#/:/\ [Z%'VZW_ .>T?_?0J;%&* U(?MUO_P ]H_\
MOH4?;K?_ )[1_P#?0J;%&* U(?MUO_SVC_[Z%06UY #-F9!F0G[WTJ[BH+4<
MS_\ 70_R%,!?MUO_ ,]H_P#OH4?;K?\ Y[1_]]"IL48I!J0_;K?_ )[1_P#?
M0H^W6_\ SVC_ .^A4V*,4!J0_;K?_GM'_P!]"C[=;_\ /:/_ +Z%38HQ0&I#
M]NM_^>T?_?0H^W6__/:/_OH5-BC% :D/VZW_ .>T?_?0H^W6_P#SVC_[Z%38
MHQ0&I#]NM_\ GM'_ -]"C[=;_P#/:/\ [Z%38HQ0&I#]NM_^>T?_ 'T*/MUO
M_P ]H_\ OH5-BC% :D/VZW_Y[1_]]"C[=;_\]H_^^A4V*,4!J0_;K?\ Y[1_
M]]"C[=;_ //:/_OH5-BC% :D/VZW_P">T?\ WT*/MUO_ ,]H_P#OH5-BC% :
ME:*:.:\8HX<",9VG/<U:J ?\?K?]<Q_,U/0""BBB@84444 %%%% !1110 44
M44 %%%% %:V_U]W_ -=!_P"@K5FJUM_K[O\ ZZ#_ -!6K- D%%%% PHHHH *
M*** "BBB@ HHHH *JZC_ ,>A_P!Y/_0A5JJNH_\ 'H?]Y/\ T(4UN!:HHHI
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M7I@_Y"#_ /7(?S-:UOXDO5_F:5_XLO5EBBBBL3(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"MJ7_(/N?\ KFW\JL#H*KZE_P @^Y_ZYM_*K Z"
M@74AE_X^H/\ @7\JGJ"7_CZ@_P"!?RJ>@84444 %%%% !1110 4444 %%%%
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M0N(QZG\?O" \6R:3'J/PQ/Q'T2..="=*OX;36-/F< >9;R336ZJC(&5F2=9
M=F%89*^Q44 ?(NH?!KXF>'['P5JMO<>*]4;3K/5=-.FZ1>Z1<:I:6]S<"6VC
MEFU19(95CAC2"1D<OG;@RJ":ATG]E3Q=%X"^('A5C;Q7.I> ]"\/V&H7EX)X
M99[=KUKBV=T17\G$L,9?REW(V0AP5'V!10!\N>,OA_XW^(JZ[XK@\!W'ABY@
M&@I;>&;F]LC>:@=/U!;N5E>&9H%!1C%%OD4DH=PC4@U5U/X>>,]3N=:\53>"
M?%6E:S<>*'U73/\ A&]9TH:K8POI]O =Z7,C6<JL8W22-G;:0"F_AJ^K:* /
M([GX<^)_%W[.6G^%M:ET^T\7C3[1IFMT$5HMW \<JJ1&"%0O& VP$ $[1C%8
MGB[5OBU\4?!OB+2=/^']KX-\S0;N!X_%EU:7HOKV2%EBB@6VFE3R%;)=YPI8
M,H$7+;?=Z* /BZS^!OCW6[C7[FY\+^($BU"R\/6X_P"$IUBPN+J5[/61<SYB
MMI3;01K"Q\N.$*I$9^4.V#[-9Z%XD\,?$;Q5:'P*WB;3/$FLV^K0:_\ :[2.
MUL$2"*/;,LC^?YL;0%D\N)U)D3+I\Q7VNB@#Y$TOX ^-+;X;^(["30(QK%S\
M-K+P_;*;FW):^CFO':'=OP /-B.XG;D]>#CI-8^%GC&YUK5?#<7AYWM=4\9V
M/BM?&(NK?R;6"&6WE:%D,@G\\"W:)=L;1[7&7'*CZ7HH ^:?AW\#M<T37OA'
M=:AX>MXHM G\33Z@YD@?R'O)RT#<,2Q=&/*YQDAL5X7<?LV_%P_!,>#9_"^I
MRWMQX"LM&ABTC5=-M;5;R%+D/%J,Y<7,H0NGE)$SP,7Q(%&YA^A5% %'0XYH
M=$T^.XC:*X6WC62-R"RL%&02"02#Z$CWJ]110! /^/UO^N8_F:GJ ?\ 'ZW_
M %S'\S4] D%%%% PHHHH **** "BBB@ HHHH **** *UM_K[O_KH/_05JS5:
MV_U]W_UT'_H*U9H$@HHHH&%%%% !1110 4444 %%%% !574?^/0_[R?^A"K5
M5=1_X]#_ +R?^A"FMP+5%%%( HHHH **** "BBB@ JIJ_P#R";W_ *X/_P"@
MFK=<5\7/B)I/PW\%7^H:E.!/+&UO96:?--=W#C;'%&@Y9F8@<=.2< 544Y-)
M%PBY221@?LM?\F_^"_\ KS;_ -&/7I@_Y"#_ /7(?S-<A\$?"5WX%^$?A/0K
M\!;^TT^);E1T65AN=1[!F(_"NO'_ "$'_P"N0_F:NJTZDFN['6:=237=EBBB
MBLC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"MJ7_(/N?^N;?R
MJP.@JOJ7_(/N?^N;?RJP.@H%U(9?^/J#_@7\JGK-U>"[N# EE=+9S9)\QXO,
M&,=,9%4?[*\0_P#0?@_\%X_^+IV"YT%%<_\ V5XA_P"@_!_X+Q_\71_97B'_
M *#\'_@O'_Q=%O,5_(Z"BN?_ +*\0_\ 0?@_\%X_^+H_LKQ#_P!!^#_P7C_X
MNBWF%_(Z"BN?_LKQ#_T'X/\ P7C_ .+H_LKQ#_T'X/\ P7C_ .+HMYA?R.@H
MKG_[*\0_]!^#_P %X_\ BZ/[*\0_]!^#_P %X_\ BZ+>87\CH**Y_P#LKQ#_
M -!^#_P7C_XNC^RO$/\ T'X/_!>/_BZ+>87\C:O/^/2;_</\JE7[H^E<W=:7
MKXMI2VO0,-IR/L &?_'ZE72O$&T?\3^#_P %X_\ BZ=O,+^1T%%<_P#V5XA_
MZ#\'_@O'_P 71_97B'_H/P?^"\?_ !=*WF%_(Z"BN?\ [*\0_P#0?@_\%X_^
M+H_LKQ#_ -!^#_P7C_XNBWF%_(Z"BN?_ +*\0_\ 0?@_\%X_^+H_LKQ#_P!!
M^#_P7C_XNBWF%_(V+_\ X]6^J_S%6*YF\TO7Q;L6UV!AD<?8 .X_VZF_LKQ#
M_P!!^#_P7C_XNG;S"_D=!17/_P!E>(?^@_!_X+Q_\71_97B'_H/P?^"\?_%T
MK>87\CH**Y_^RO$/_0?@_P#!>/\ XNC^RO$/_0?@_P#!>/\ XNBWF%_(Z"BN
M?_LKQ#_T'X/_  7C_P"+H_LKQ#_T'X/_  7C_P"+HMYA?R.@HKG_ .RO$/\
MT'X/_!>/_BZ/[*\0_P#0?@_\%X_^+HMYA?R.@HKG_P"RO$/_ $'X/_!>/_BZ
M/[*\0_\ 0?@_\%X_^+HMYA?R.@HKG_[*\0_]!^#_ ,%X_P#BZ/[*\0_]!^#_
M ,%X_P#BZ+>87\CH*KVO6?\ ZZ'^0K'_ +*\0_\ 0?@_\%X_^+J&VTO7R9L:
M[ /WAS_H .3Q_MT[>87\CIJ*Y_\ LKQ#_P!!^#_P7C_XNC^RO$/_ $'X/_!>
M/_BZ5O,+^1T%%<__ &5XA_Z#\'_@O'_Q=']E>(?^@_!_X+Q_\71;S"_D=!17
M/_V5XA_Z#\'_ (+Q_P#%T?V5XA_Z#\'_ (+Q_P#%T6\POY'045S_ /97B'_H
M/P?^"\?_ !=']E>(?^@_!_X+Q_\ %T6\POY'045S_P#97B'_ *#\'_@O'_Q=
M']E>(?\ H/P?^"\?_%T6\POY'045S_\ 97B'_H/P?^"\?_%T?V5XA_Z#\'_@
MO'_Q=%O,+^1T%%<__97B'_H/P?\ @O'_ ,71_97B'_H/P?\ @O'_ ,71;S"_
MD=!17/\ ]E>(?^@_!_X+Q_\ %T?V5XA_Z#\'_@O'_P 71;S"_D=!17/_ -E>
M(?\ H/P?^"\?_%T?V5XA_P"@_!_X+Q_\71;S"_D=!17/_P!E>(?^@_!_X+Q_
M\71_97B'_H/P?^"\?_%T6\POY&R/^/UO^N8_F:GKFAI>O_:R/[=@W;!S]@'3
M)_VZE_LKQ#_T'X/_  7C_P"+IV\P3\CH**Y_^RO$/_0?@_\ !>/_ (NC^RO$
M/_0?@_\ !>/_ (NE;S"_D=!17/\ ]E>(?^@_!_X+Q_\ %T?V5XA_Z#\'_@O'
M_P 71;S"_D=!17/_ -E>(?\ H/P?^"\?_%T?V5XA_P"@_!_X+Q_\71;S"_D=
M!17/_P!E>(?^@_!_X+Q_\71_97B'_H/P?^"\?_%T6\POY'045S_]E>(?^@_!
M_P""\?\ Q=']E>(?^@_!_P""\?\ Q=%O,+^1T%%<_P#V5XA_Z#\'_@O'_P 7
M1_97B'_H/P?^"\?_ !=%O,+^1KVW^ON_^N@_]!6K-<S;Z7KYFN<:[ "'&3]@
M'/RC_;J;^RO$/_0?@_\ !>/_ (NG;S!/R.@HKG_[*\0_]!^#_P %X_\ BZ/[
M*\0_]!^#_P %X_\ BZ5O,+^1T%%<_P#V5XA_Z#\'_@O'_P 71_97B'_H/P?^
M"\?_ !=%O,+^1T%%<_\ V5XA_P"@_!_X+Q_\71_97B'_ *#\'_@O'_Q=%O,+
M^1T%%<__ &5XA_Z#\'_@O'_Q=']E>(?^@_!_X+Q_\71;S"_D=!17/_V5XA_Z
M#\'_ (+Q_P#%T?V5XA_Z#\'_ (+Q_P#%T6\POY'055U'_CT/^\G_ *$*R?[*
M\0_]!^#_ ,%X_P#BZ@OM+U];8EM=@8;EX%@!_$/]NFEYA?R.GHKG_P"RO$/_
M $'X/_!>/_BZ/[*\0_\ 0?@_\%X_^+I6\POY'045S_\ 97B'_H/P?^"\?_%T
M?V5XA_Z#\'_@O'_Q=%O,+^1T%%<__97B'_H/P?\ @O'_ ,71_97B'_H/P?\
M@O'_ ,71;S"_D=!17/\ ]E>(?^@_!_X+Q_\ %T?V5XA_Z#\'_@O'_P 71;S"
M_D;5W:I>VDUO(9%CF1HV,4C1N 1@[74AE/H001U!KS_P5\!?"O@O55U@K?\
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M% !1110 55U'_CT/^\G_ *$*M55U'_CT/^\G_H0IK<"U1112 **** "BBB@
MHHHH *\D^)/[+_@7X@VTEQ;Z6GA7Q/'NDLO$OA\?8KZTF[.'CQO&>J/E3W'>
MO6Z*VI5JE&7-3DTQ-)[GD?[+_P 3-7^)GPTG/B,1GQ1X>U:]\-ZO+",)/=6D
MIB:51VW@*Q'8L0.*]4'_ "$'_P"N0_F:^?\ ]C+_ )!WQE_[*CXC_P#2@5]
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M$T22>[CU77+BUL;S5[RXTG1FAB@L8+R>WDE96F?&PP$$!V=_O*F-RIT/B/\
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M,Z_#_0?"N@+,GB"_\4RZF]YI5H8;"P@N0\>H+@DK%$;66954DEI&4@9/'?\
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MKZNUU>'5KVYB@6.&VA+! 9?E)DG>W0CKM9\>H4:>*A75*ZNVW?1V[OJUMM^
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M#Q'!;Z+_ ,(/X?\ $=OX:NM-FBE_M*Y>26&%[F.X\P1H%>YCQ"8F+A&_>*6
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MZMK=CI\L=FFH:7;7*+;ZD;552%IB8S(#M1%;RGC#A%#!@,5I:9\&- TF_P!
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M&*.68S2!(3\J_O#O!QNW<EB"17T#151J58N\:DO_  )_YA]<G_+'_P  A_\
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M /AT!\#/^?\ \7_^#.'_ .,4?\.@/@9_S_\ B_\ \&</_P 8K[@HH_MS,_\
MG_+[P]E#L?#_ /PZ ^!G_/\ ^+__  9P_P#QBC_AT!\#/^?_ ,7_ /@SA_\
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MH;<]0#$BX!(& 2#WM%%$ZDZCO.3?J"26P4445F,**** "BBB@"MJ7_(/N?\
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ML2PRWGPZ\8^)A$\>G>+/&VM^(--:1=IDM)[D^5)CT8+N![@@]#7OH_Y"#_\
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MNW8YQC.*Z.::.VADEE=8HHU+.[G"J!R23V%*[[ARKL8G_"#:+_SZ/_X$2?\
MQ5'_  @VB_\ /H__ ($2?_%5<T;Q)I/B*/S-*U2SU./RXYM]G.LH\N1=T;94
MGAEY!Z$<BF+XKT5]+O\ 4EU>Q;3M/DFBO+L7*&*V>)BLJR/G"E"I# XVD'.*
M+ON'*NQ6_P"$&T7_ )]'_P# B3_XJC_A!M%_Y]'_ / B3_XJLWPW\8_ 7C'5
MO[+T'QKX>UO4MS)]CT_5()YMRKO8;$8G(7YB,=.:["B[[ARKL8/_  @VB_\
M/H__ ($2?_%4?\(-HO\ SZ/_ .!$G_Q5;U%%WW#E78P?^$&T7_GT?_P(D_\
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MZA0!7O\ _CU;ZK_,5F^*_&&E^"=-%_J\EQ#:;MIDM[2:XVX!8EA$C%1@'YB
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M[-F,$'.-N.<XQ7.Z<GP^AMKVXMK#1[)+0+;W(>Q6!XA*-JJRLH8!]VT<8;)
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M'.>6WWPO\1W7P(\3>"(/!UT_Q2>'5U/BDPQI'=--/)(SK>LX?_28F"  Y4L
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M'W/_ %S;^56!T% NIGZO_:*F!].BMYI%)W"XD*#!'; -4/M/B?\ Y\=,_P#
MA_\ XFN@HIW"QS_VGQ/_ ,^.F?\ @0__ ,31]I\3_P#/CIG_ ($/_P#$UT%%
M%Q6\SG_M/B?_ )\=,_\  A__ (FC[3XG_P"?'3/_  (?_P")KH**+A;S.?\
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M +3XG_Y\=,_\"'_^)H^T^)_^?'3/_ A__B:Z"BBX6\SG_M/B?_GQTS_P(?\
M^)H^T^)_^?'3/_ A_P#XFN@HHN%O,Y_[3XG_ .?'3/\ P(?_ .)H^T^)_P#G
MQTS_ ,"'_P#B:Z"BBX6\SG_M/B?_ )\=,_\  A__ (FHXI/$T9?%EIIW-N_X
M^'_^)KI**+A;S.?^T^)_^?'3/_ A_P#XFC[3XG_Y\=,_\"'_ /B:Z"BBX6\S
MG_M/B?\ Y\=,_P# A_\ XFC[3XG_ .?'3/\ P(?_ .)KH**+A;S.?^T^)_\
MGQTS_P "'_\ B:/M/B?_ )\=,_\  A__ (FN@HHN%O,Y_P"T^)_^?'3/_ A_
M_B:/M/B?_GQTS_P(?_XFN@HHN%O,Y_[3XG_Y\=,_\"'_ /B:/M/B?_GQTS_P
M(?\ ^)KH**+A;S.?^T^)_P#GQTS_ ,"'_P#B:/M/B?\ Y\=,_P# A_\ XFN@
MHHN%O,Y_[3XG_P"?'3/_  (?_P")H^T^)_\ GQTS_P "'_\ B:Z"BBX6\SG_
M +3XG_Y\=,_\"'_^)H^T^)_^?'3/_ A__B:Z"BBX6\SG_M/B?_GQTS_P(?\
M^)H^T^)_^?'3/_ A_P#XFN@HHN%O,Y_[3XG_ .?'3/\ P(?_ .)H^T^)_P#G
MQTS_ ,"'_P#B:Z"BBX6\SG/-\3^<9/L6FY*[<?:']?\ =I_VGQ/_ ,^.F?\
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M .?'3/\ P(?_ .)KH**+A;S.?^T^)_\ GQTS_P "'_\ B:/M/B?_ )\=,_\
M A__ (FN@HHN%O,Y_P"T^)_^?'3/_ A__B:C$GB83F7[%IN2H7'VA_4_[/O7
M2447"WF<_P#:?$__ #XZ9_X$/_\ $T?:?$__ #XZ9_X$/_\ $UT%%%PMYG/_
M &GQ/_SXZ9_X$/\ _$T?:?$__/CIG_@0_P#\370447"WF<_]I\3_ //CIG_@
M0_\ \31]I\3_ //CIG_@0_\ \370447"WF<_]I\3_P#/CIG_ ($/_P#$T?:?
M$_\ SXZ9_P"!#_\ Q-=!11<+>9S_ -I\3_\ /CIG_@0__P 31]I\3_\ /CIG
M_@0__P 370447"WF<_\ :?$__/CIG_@0_P#\31]I\3_\^.F?^!#_ /Q-=!11
M<+>9S_VGQ/\ \^.F?^!#_P#Q-'VGQ/\ \^.F?^!#_P#Q-=!11<+>9S_VGQ/_
M ,^.F?\ @0__ ,31]I\3_P#/CIG_ ($/_P#$UT%%%PMYG/\ VGQ/_P ^.F?^
M!#__ !-'VGQ/_P ^.F?^!#__ !-=!11<+>9S=P_B:X@DC-EIH#J5R+A__B:Z
+,=!GK2T47&E8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>apre-20251231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &\ Y4# 2(  A$! Q$!_\0
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M?PJ\4Z=^VAXG\;7&DM'X7O-*6W@U#S8R'DPHV[0VX=#U%<M\+/@'XRL==_:
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MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_%&V:^@PV.P^+5Z,T_S^[<[Z=:G5^!W+E%%%=QN%%%% !1110 4444 %%%%
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MS5^Q9-4=3 4F^UON=CZ_!RYJ$6%%%%>R=@4444 %%%% !1110 4444 %%%%
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MZYKTNOV')J;IX"DGVO\ >[GU^#CRT(IA1117M'8%%%% !1110 4444 %%%%
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MM(;"UBM[>-8H8E"(BC  %35^QX#!QP-"-&/S\V?7T**H4U!!1117H'0%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!B^+_"]MXNT.?3[CY=PS')C
ME&[&OEC7=$N_#NJ3Z?>QF.>)L'T8=B/8U]@UQ_Q$^'MMXWL,C$.H1#]S/C_Q
MT^U?,9UE7UZ'M:7QK\5V_P CS,9A?;KFC\2_$^7Z*OZWH=[X>U"2ROX&@G0]
M".&'J#W%4*_+I1E"3C)6:/F&G%V84445 @HHHH **** "BBM#0M!OO$FH1V=
MA T\S'G'11ZD]A5PA*<E&*NV4DY.R%\/Z#=^)=5@T^S0O-*>O91W8^PKZG\*
M>&K;PGHEOIUJ/EC&7<]78]6-97P^^']KX(T_ Q-?R@>=/C]![5UM?J62Y5]1
MA[2K\;_!=O\ ,^GP>%]A'FE\3_ ****^F/2"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPCXU?#U["Y?7K"
M+=:R'_244?ZMO[WT->[U'<6\=W!)#,@DBD4JR,,@@]J\W'X&GCZ+I3WZ/LSF
MKT(UX<K/C.BO1_B7\*9_#4LNH:;&T^F$Y95&6A^OM[UYQ7Y#BL+5P=1TJRL_
MS]#Y*K2E1ERS04445R&04444 %%%% !1110 5[+\$_A\QD3Q!J$6 /\ CUC<
M?^/_ .%9?PQ^$DVMRQ:GJ\;0Z>I#1P,,--]?05[Y%$D,:QQJ$11A548 %?=9
M'E$G)8O$*R6R_7_(]S X1W56HO0?1117Z">^%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74M,MM7LI;2\A6
M>WE&UD8<&OGOXA?"6]\+227E@KWFEYSD#+Q#W'I[U]'4C*&4@@$'J#7DYAEM
M',(6J:26SZ_\,<F(PT,0K2W[GQA17M7Q$\)^#Y?$UEI45V-+U[4,F.&%=R$]
MBRC[N:X77_A3XBT%F)LFNX1_RUMOFX^G6OS?&9+C,&[RAS1[H^<JX2K2;TNO
M(X^BG30R6[E)4:-AU#C!%,S7A['$+129I\<;S,%C1I&/0*,FEN VBNLT'X7>
M(M?93'8O;0G_ ):W'R#\CS7K/A'X(:7HK)<:FW]I72\A&&(U/T[_ (U[>$R?
M%XMKECRQ[O0[:6$JUME9>9YIX ^%5_XOECN;E7L]+!R96&&D'HH_K7T1H^C6
MF@Z?%964*P01C 4=_<^IJXB+&@1%"JHP% P *=7Z1EV64<OC[FLGN_ZV1]'A
M\-##K3?N%%%%>P=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8GBCPAIGB^Q-MJ$ <C[DJ\.A]0:\*\7?!O6/#SO+9K_ &E9CD-&
M/G4>Z_X5[[XD\1V'A31[C4]2G6WM85R6/4^P'<FO*OA]_P ))\3_ !@OC&_G
MGTGP];;DT[3T8J9E/5G]0?U[=*\K&Y-A\PBYU%RM=5OZ>9P8C#TJS2:][R/&
M9(WB<HZE''56&"*;7UIK?@G1/$2G[=IT,KG_ ):!=K#\1S7#ZG^S[H]P2UE>
MW5F>RL1(H_/G]:^'K\-8JF_W34E]S_R_$\FIEU6/P.YX'17L$W[.MT#^ZUN)
MA_MP$?U-$/[.MT3^]UN)1_L0$_UKSO[#S"]O9?BO\SG^I8C^7\CQ^G11O-($
MC1I'/15&2:][TS]G[1K8JU[>W5X1U52(U/Y<_K737&G>%?AGHTVI2VT%A:P@
M;YRFYO0<]:]+#\-8NJU[5J*^]_A_F=$,NJ/6;21X]X0^#&K^(&2:^!TVS/),
M@_>,/8?XU[KX8\):;X2L1;:? (Q_'(W+N?4FK^FZE:ZO8PWEG,D]M,H9)$.0
M15JOM,#E6'R_6"O+N]_^ >S0PM.AK'5]PHHHKV#L"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=01Z_P Z[J?))<LM/,4^9>\ON/6J*XCX8?$ZT^(6F,&3['K%M\EW9/PR,.I
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M*=.=62A35V^Q48N;M%79WU%? 7Q'_P""D>JW4DMOX*T"&SAY"WNIGS'/N$'
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MVQ.(EB:KJ2/[9R3**&28&&#H+;=]WU;_ *VT"BBBN8]T**** "BBB@ HHHH
M**** />OV/\ ]HV\^ /Q'@:XF=O#&INL.I6V?E S@2@?WE_E7['6%];ZG907
M=K*L]M.BR1RH<AE(R"*_GWK]3_\ @G!\;G\??#*Z\(:E<&75O#A58BYRTEJW
MW#_P$@K^5?49-BVI?5Y/3H?@_B3P_&5)9Q0C[RLI^:V3^6WW=C[!HHIDTR6\
M3RRN(XT4LSL<!0.237UI_.Y\W_MM?'QOA/X"&BZ3<>7XBUM6BC9#\T$/1Y/8
M\X%?F S%V+,2S$Y)/4FO2OVC/BI+\8/BWKFN^8S6"RFVL4/\,"$A?SY/XUYI
M7Z]E.!6"PRBU[SU?^7R/L,)05"DEU>X4445[1VA1110 4444 %%%% !1110
M5^D?[!_[03_$+PK+X,UNX\S7]%C!MY9#\US;=!]63H?8BOS<KL_@Y\0[KX6?
M$G0_$EJY06LX$R@\/$W#J?P_E7DYI@HX[#2A]I:KU_X)R8J@J]-QZ]#]H**J
M:1J<&M:5::A:N)+>ZB6:-AT*L,C^=%?CS36C/C=C#^)?CW3_ (8^!=9\3ZHX
M6TTZW:8@G&]@/E4>Y.!7X>_$SX@:K\4O'6L^*-9F:>_U&=I6R<A%Z*B^@5<
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M<Z'JEIJ-G(T-W:RK-%(IP593D']*_<_X*_$"'XI?"KPSXHA(/]HV222 ?PR
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M.<A@>#U->5'*:D4KR6G+IT=FW9_?H^^YR+"25KO:WX,^E/VA[7Q7=Z7\&O\
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M\QDULY2_-GYXT445^PGT85K^$O"6K^.O$%KHFA63ZAJMT2(;:,@,^ 2>I Z
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M2Y@PY"R-[[1D_6NM^)W@+PK<_"GQ5=QZ3HEMKGAO5;2%&T6RFB6V)D4-&99
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M[(/U/M7Z'5^;\1XQ5:RP\'I'?U?^1\UF5;GFJ:Z?F%%%%?'GCA1110 4444
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MCUG5XPEE#(OS6]MUW>Q<\_0"O#_V./V4[GXF:O;>+O$UJT/A2T</!#*N#?2
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MK7?^N0_F*] KS_X\_P#)*M=_ZY#^8K6E_$CZF=3X&;?PU_Y)_P"'?^O"'_T
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MUJ9JTG<J.L4%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !575?^07>?]<7_ /035JJNJ_\ (+O/^N+_ /H)IK<#RS]F#_DF
MC?\ 7]-_2O7:\C_9@&/AHW_7]-_2O7*VK_Q)>IE2^!!1116!J%%%% !1110
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M>(/$\^CW6GVGV9'ANX[6./$CR,2['NV5P*]>^%/@M_C!^U,\OC?5M1U6?0O
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M4_ F#X7^*M1UJ+59+YKS2-/THQ/&%"BUCV!\^K=<4 >JT444 %%%% !1110
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M_&&B_$7PZV@>([6[G\2/=V^A:!I-M!I5S;K<(RW<UQMWS2.J[CR#GM7=>-=
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>apre-20251231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #2 KD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=_9R^+7A[Q%<?L;_  \LGOCXK\'Z[JL'B"SGL)H1ITS)<;(I'=0I=AN(52Q
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M:ZWB?7+:UCBO=9:TCM#>S ?/+Y,?RQ[CD[1P.F3UK;H **** "BBB@ HHHH
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MXY_:(\(:WJGB*[GGUO6;NT\0:!JOQ$TMK1+8O(ABMM =DN;:2$HC!@69A&2
M5D((!^E/QH^#&B?'3PI9^']>NK^TL[74[354?3I$20RV\@D1271QM)'(QG'0
MBNTL-5LM56=K*\@O%@F>WE-O*KB.5#AXVP>&4\$'D=Z_.']F/X@?\)_K/@SQ
M1XG_ &E_$ME\2_%VJ:GI6L_#)96O((,M-&D,%G&-VGM&L:2BY<;1M/9FSZ;_
M ,$KO#^F>'_A7XQ@@\::GK^L)K]U;W^AW^K)=+I?EW-PL<BP@9A:<;G=C_K"
MF1TH ^VZ*_.'X3_$X>(/BT/&/BG]I'7?#OQ ?XCW7A^7X7DM?6#V22O!'9)I
M<6'A9D5?]-(*(P)<-(2QYS0?CP-7_:M^&VO^ _BYXPUG2?$_B^YTK4O#/B7Q
M9#.4B!E1]NC0P!+:WR%\J5Y=Y_YY@_,0#]0:*_+'0O$'Q&TO3M ^*C?%WQO=
MSQ_&QO"O_"-W&JL^E/I;W;(\+Q-DNW4!F8A%(554J&'7Z'\3_P"V_C;XL\4>
M,/VD->\!>,-#^)<OA[3?AW&6N["\TU)5B@@.E1XDF,ZN1]J7A20WWE! !]_>
M/O"<WCGPEJ&A0>(-5\,&]C\I]2T7R!=1H>&"&>*5!N&1G9D9RI4X(A^&7PXT
M/X1> -"\&^&K9K30]&M5M;:-VW.5')9F[LQ)8GN6-?F!X9^/WQEUW]K:XO8O
M$=S%>1>/WT27P_J/Q$TNSTTZ<MP+8VL>@SLDS3;,;9E8EWY"LQS7TY^R%H/B
M#QU\=?C;XSUSXB^,M0M/#?CW6-"TSPO+K$C:1'#A""T#9SM#@(H(5-N0,G@
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MXLZ;^RC\;?*\;ZI'9Z==Z#-HVK+\2+#Q1K&GR3WJ1SQR7MBZNL;A,JCHHP)
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M!J3Q7_;7CK4E>RT;5C,(Q<1Y79;P+N8[0#M!R2^U10!^BM%? G_!/'XF3_\
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MRDKPW0D5OQS.T!>8>7QRO<?EWZ<5,)@6P.HZ^U%P<6CFF^%7@EO'2^-6\'Z
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MJQ$H0DW&W-&4K6\T]/>=^BMI;<]8N-5A33IM1,4T[6L4LQAB!RQ5<,%Z9/!
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MB@ HHHH **** "BHWGCB(#R*A/.&8"G@@C(.10 M%%% !1110 4444 %%%%
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MF*EA:G.MNI^1?@_Q."$!?(K[0_9(^*]Q'K4?A"ZD,UC>*\EF6.3#(JEV7Z$
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MZM,T=E)OD:-#@S;%+>6#VSCKZ9QSBOO.PL+;2K*"SLX([:U@01Q0Q*%5% P
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M1J/^'H_[,7_13?\ R@:I_P#(U?55% 'RK_P]'_9B_P"BF_\ E U3_P"1J/\
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MXSMW8XW8SCC-=%7D0RA6?//TMV/T3$>(E1.#PU!6M[W-?XNMK/;UU/"?V6/
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MA*S\/_">_N[A_!>IW$_AZP\1Q7]]9-/JJSLSW=_-&LI>1PTH$K;7<[#*J[R
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M3&[86 ;;G&0#VJ[10 4444 %%%% !1110 4444 %%%% !1110 4A&<>U+10
MF.<TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>apre-20251231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $K N4# 2(  A$! Q$!_\0
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MB;PMJ>A:AX4UW08H+J>VU22%@]O-GRY%>-V7G&"I.0:Y3Q7\</$VG_M*^%?
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MB,Y],T?X&P:!J7Q>U&_OI=7LO'3B:6PMK?9)"BVQA:-6+'>S#D'"X./K5O\
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M (3N?2YES8E_L7V-E;!_>#S-^W_9QGO6AX[_ &:9/&GB[QGK8\0K9CQ%X/\
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M!^SOJVLZOXAU_P 7^+H]>\2:AX=F\-6ES:Z8+.WM+>0-O<Q"1B\C,0Q.X#C
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M,O@;J7P_^#VM?#RY\4'6=-EBNK32[J:T*2V5M*K!8G^<^9LW<'Y>...*N_\
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MK;4I;>4NDXDV,K02R+_RR;()!Z4G2DDW^J$Z4DF^WFCO:***R,@KRKX8@_\
M"X?C%D'!U33L9'_4,MZ]5I,5<9<J:[_YIEQERIKO_FG^@8HQ2T5! F*,4M%
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MKC[Y_P"%5^#!XM'BH>$="'B<,7&M?V9!]MW;=I/G;-^=O&<].*D;X:>$6&N
M^%M%(UT@ZL#IT/\ Q,".AN/E_>]3]_- 'Q-K'_!03XB:=??$/R?"OAR?3M#6
M_@T^X>Z52\]G=P6SR21BZ,K12M*Q&(D\O?%\TH.ZNE\0?M2?&WP[\4+KP;)9
M_#^ZEM_$^E^$&NA!?1!KN_TPWB3A?-;]W$004^](. T?WJ^L!\*_!8FU"8>$
M="$NH0Q6UY(-,@W7,46T11R'9\ZIL3:K9"[1C&!6A/X+\/W.HO?S:%ILM\]U
M%?-<O9QF5KB-/+CF+%<^8J?*K9R%X! H ^&_ _[9?CKQ?):ZSI5AI4>M^(/^
M$4TL6>H7=S)IEO/>7&J032Q1A\IS:JW&6885B2 1)K__  4$\9:%:^'8?[-\
M*W6L6NHS6/B2TB6Y4.B:RVFK-;,\BB)6\LN 3,^6 *!5+U]JV7PV\):;Y/V3
MPOHUKY+PR1^3I\*;&B9VB887@HTDA4C[I=B,;CF"\^%'@G49(I+KP?H-S)$9
MFC:;2X'*&5]\I!*<;W^9L?>/)R: /AGP[^U1\0/ <NMZSXFU2S\8W6D1^-9U
ML+&ZFMUC^Q:G;01I<Q;F4(GF%E;;N2$'[Q)8]_8?M9_%#6O&5KX"TG_A7^J^
M(SJ]QI\GB2S^U2Z+.BZ5_:"F)5E+^8F#&Z;V^\ARN<#ZPM/AUX5L-5O=3M?#
M.CVVI7IE-U>16$*33F0 2%W"Y;<%7=DG.T9SBDT3X<>$_#=M86VD^&-&TNWT
M]Y9+.*RT^&%+9I 5D:,*H"%P2&*XR#SF@##^ /Q+G^,?P5\%>-KJTBL+K7=*
MM[Z:VA8M'%(Z LJD\X!SC/.*[^J>DZ18Z!IMMIVF65OIVGVR"*"UM(EBBB0=
M%5% "@>@%7* "BBB@ HHHH **** "BBB@#Y#_:@\>?%N'XWCPI\,[WQ,UTGA
M)=3L[#0;32I;8WS7<L:/?O>X=;<[%5O).[ ) K17]H'6+7X2_']]0\6Z=!XU
M\-76MQZ3 LEN);86]@DL>R(C,BJ_F,"ZL2!SD5]0?V18_P!J'4_L5O\ VB81
M;&[\I?.,08L$WXSMW$G;G&3FN9N_@WX!O]?N=<N?!'ARXUJY#K/J,ND6[7,H
M=2CAI"FYMRDJ<GD$@\4 ?-/PQ^./Q0\>^%/BA?W5]#X6\<Z1HUK<:7X4UN")
M[>VLGMA*NJ.\0W7$DI$OR*RQQM&(R,AF/H?B/XH^)+3]E7X>>+[?53%K^K#P
MM]KOO*B)E^UW5FEQ\I78-ZRR#@#&[C&!7MY\)Z(UX+LZ/8&Z%F=/$YM8]XM2
M<F#=C/EYYV?=]JDE\.:3/I%OI4FF6<FF6XB$-DUNAAB\HJ8MJ8VC854K@?*5
M&,8% 'RI\*OCI?ZCJ]CXL\5_&73K,W,^MC4/AO)86Q:SBLS/\D10"X26)(0\
MC2LZON.%7*U[IX7^/OA7Q7KVCZ-:RW<6HZK:BYMXYK<A>5D=$9U)4.T<4DBK
MGE4)]JWM2^%WA74KC7+P:%I]IJVM6CV5]JMK:11WDT3+M*M,%W-QC 8D<#BN
M2\%?LT^#_ GBFS\0Z>+^34[=I9W>>X!2>YD$H:X=%55W[)Y4&T*H5\;> 0 ?
M/WC_ .-'C+0/B3\3=0LOBAY$WAKQ;I.D:5X F@L&BU."XBL?,C ,8NB[-<RE
M65\ J." 16-X@_X*&^+M6U?6M-\+> ["PBL]?@TN/5]?O)H[5(AJ264OVAO)
M"Q,S."I5G55W%OF4*WV6WPQ\'OXM'BIO"FB-XG!R-:.FP_;<[=N?.V[_ +O'
M7IQ4=U\*?!5[/K,]QX0T&>;6@HU2272X&:^"D%?/)3,N" 1NS@B@#Y3_ .'B
M.H7#?$I[;X=2-:^&(KEK.>:]DCCGD@O8[1XYW, 6,NSED*&3A2&VDXI;W]NS
MQWX?OM=@UCX::#Y>C7.H0W4UAXHDD 6QNK2&Z95>U4DG[;%L'&XAMVT 9^KF
M^&'@YK[5;T^%-#-YJRJFH7!TV'S+P*05$S;<R $ C=G&!Z58N/A_X8NC<&;P
MYI,QN3*TQDL8F\TRLC2ELKSO:.,MGJ44G.!0!\_>-_VC_%GA+XO>)_"F@:);
M^)KU]9ATVRM=5U5;*VM5&AMJ$CAH[=GP?+8$-O)+9!4<#.\-?MOW'C3Q]X%\
M/:+H.B7 \5Z3'.L9UMS=Z=?2:8U^D-Q%Y&WRR@"[XW<_,#M'W:^FY/"6AS:F
MVHR:/I[Z@TGFM=M:QF4OY1AW%\9SY9*9SG:2O3BJ-G\-O"6GZG;:C:^%]&MM
M0M8HX8+N'3X4EBCC4K&BN%RJJK,% . "0.M 'QYX#_;;\7W/AO1]:UNRT.[U
M?6]&T0V]I#K"6^C6US>WM]");B8P-)!A;<!U+288*BKN)+='!^W?KFH06-_9
M> ;";2;>TLKG6;AM>P8A-K$VEL;3$)6Y3S(A(CDQAD)Z' /TU'\*O!<.F7NF
MIX1T%-/OHS%=6BZ9 (KA"[2%9$V88;W9L$'YF)ZDU=/@3PTUNL!\/Z485MX;
M01FRBVB&)]\4>-N-B/\ ,J]%/( - &X#FEHHH **** "BBB@ HHHH Y_XA:I
M<Z'X"\2:C9RB"[M--N;B&4@'8Z1,RM@Y'! /-?$O@+XR_&G2O WA[Q9XDUS7
M[3PIJLWA97U3QC;:1;N\]U?1+=BV^RC:+1[>3AY@L@)&,'-?>MS;17EO+!/$
MD\$JE)(I%#*ZD8((/!!':LG5_!'AW7_#B^']3T'3-1T%42,:7=V<<MJ%3&Q?
M*92N%P,#'&!B@#Y,_:7_ &G?&/@_XCRVG@*_75/"LGA$:CJ&KZ:EO>QZ%$-1
M$-SJ83.;AXHB=L(;;D%F&%(/667Q(\0O^U'X8\*Z)\3[;Q1HC:='=:AHYALP
MD=@;)C%<R3J \MY/<!9$6'$8A5R4 VL??M ^&GA'PK;?9]%\+:+I$'D/;>58
M:=# OE.VYX\(H&UFY*]">3573OA#X%TC7+/6;'P9X>LM8LHQ%;:A;Z5;QW$"
M!/+"I($#* GRX!'R\=* /G#Q-\;O%KZ_JWA^;QK'X/TN[^)5UX;/BB2WMBVE
M6<>E174<$9E4Q"264E%>4/C>1@G;CT/X?_M >'O#WA?3;#7?B';?$*Z6VU&]
MD\3Z=9QPPR6EK,Z-)*(VV%EV["8AAF4D*!7K^H^"/#NL:9J>G7^@Z9>Z?J<O
MGWUI<6<<D5W)A1OE0J0[81>6!/RCT%<3XW_9O\$^/GTR+4K!H=*T^U-I%I-C
MLM[78 X3Y54%=GF.0$91R,AL"@#A?C_\9;B[^$?A;6O"/BFZ\&Q:MXMT_0KW
M57MX$N+&-[HP72,ERCQHZE6!W*0"/2O(=:_;9\0?!?3=2T=_^+PS1>)KG2M*
M\1*4MTO+>&QM[J1)&M(71YT:=HLHBH=N6V[37UGI/P<\*6/@9?"=_I5OXCT<
MSR7<\>NPQWGVF>21I7ED#KM+%W8Y"@#/ %7;GX6>#+SPQ:^&[CPCH4_AZT<2
M6^DR:9 UI"P)(9(BFQ2"3R!W- 'R9XK_ &\O%G@F\\7SWW@[39[5-3T?3]$T
M[[7.EY#]LT[[:6O42*1@ H*YC4_/\HR 7.CI_P"W)XV\36LU]H_PSTVUM5U3
M1=#6WUO7Y+:Z%[J,<+(KHMLX6-/-.7R2P"D+R<?4VK_#/PAX@&H?VGX5T34?
M[0BB@O/M>G0R_:8XCF))-RG>J'E0V0.V*G@\!^&K6,1P^'M*B0307 5+&)1Y
MD*A87P%^]&%4*>JA0!C% 'R[X;_;#\0_$+P@M[<>'5\(7)OO"DT']GZM'=M+
M:ZGJ)M75R]OM7YH)?E )*.N&1ONW/"/[;NI:IHNL:EXA\,Z'X9LE\.RZ_I=Y
M<:[))!*J:@UCLN2ML6AW2;"NQ9.&P<'BOI:#P'X:M8EBA\/:5%$H@ 1+&)0!
M Y>#@+_RS=F9?[I)(P33'^'GA:2RDLV\-:0UI):O8O ;"(HUN[[WA*[<%"Q+
M%>A/)&: /BS7_P!N7QWK>ARW=MH^A^'+!?#FNW5Q):ZP);O[;I]]':L;222!
MHW7YU8!XR=K.QQL ;L_%G[>MUX9U3Q@B>$-/O++2HM<6QBCUP&_:;2\"4WEL
M(O\ 1HI2?W;[G/*;E&\5]+R?"CP5-;6UO)X0T%X+;S1!$VEP%8O- 67:-F%W
MA5#8Z@#.<59G^'GA6ZU#5K^;PUH\U]JT(MM0N9+")I+R(=(YF*YD48'RL2*
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M\ >:Z,I#/A0-Q&>!SQ7&^-?V</"/CS78M4U%+N*2WMTBM(;21(8[62,8BFC
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M\5_M[7?AN_\ &&SP?IU[9Z9%K?V"&+70;\RZ9(L<OVVW$7^BQREOW;[G_AW
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MNHI %=)HU=6 .0"".<'GZTVVT>QLY8Y8+.W@DC@6V1XXE4K$#D1@@<*.R]*
M,?P7X[L/'$>H_8[>_LY].N!:W-MJ5F]M+&YC20?*XY!213D<<^H-=)7 ?#T
M>._B7@8_XFUK_P"FVTKOZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6 !['I6OK/Q/\+>'M/%YJ&M6T$.Y4*Y+2 GH#& 6'J<C@=:Z18(TD>1459'
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MF;_389<^8JK\ODB+!X[[OPK94::E%2J*S7F['4J-/FBI5%9K?5V/I6BO-_\
MA%?'7A[P=]@TOQ/9WES8V'D6OG:1F25TCVIN8W&,D@9)XR:\N_9A\6_M >*M
M)UJ7XAZ/9:=+;7$0M8]5LC927 *9D53$2 H(7YRAY8XSC A4;Q<E):$*C>+F
MI+3[SZ9HKYD7XA_&ZQ_:?FTW4?"]U+\,TASNTJR2XCW&V4@K<N(V;$A.1@'.
M5&<<^X)\5/"8@>2ZUVSTMHRHDAU6064T9/0-'-M9<\XR.<'TI3HRA;K=7TU%
M.C*%NMU?34ZNBH;2[@O[6&ZMIH[BVF02131.&1U(R&4C@@@Y!%35@8!1110
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MK=\:?$_3_!&OZ!I-W:W<\VL3>5$]O&&6/YE7+<Y/+#@ G )[52^'H \>?$O
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MEBO+=X)5'R#YHW 93QT(Z8/>M;Q1\5;'POXUTGPP^G:A>W^HQ^9&;6-64#+
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M.F&'<I\DFD_/0^O**\P\<>*O%W@/PO?:WJ%_X6BM[5,XN!/"KL3@+N:3 )/
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MPC*'M+ZK3Y'LU%5]/NUO[*"X4;1(@;:>JGN/P/%6*P,PHHHH **** "BBB@
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M[C$5Q'/ KK,@SA7!!W 9/!SU-<C\6K>*U\(Z/##&D,4?B#0T2.-0JJHU.U
M Z "@#O!T%+2#H*6@ HHHH **** /)[[5]7B^-TFE:7H]Q#!)8K/+?M-(+9V
MPWS/&/E/($>1\P(SR 17I>FZFM^CJR&"YB(6:!CDH>W/<'L>_P!<@(-&MEU9
MM2 E^UM&(B?/?9M]-F=OXXKE?B=X0\0>)X-.?PUKBZ#>V\X::?:=TD7=<CJ
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M,3M4#JS**Y'2OBAK]OXYMM#\1:7:Z;$--1Y'L]]VUS>K )KB.#RR6"HI  =
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M_K&1S5H$$9'-<KX_\!6_C70]1M8Y3I]_=6QMOMD8Y*YR%<?Q+GMVR<5+\.=
MM_"OA*RT>W:Y860:-Q=L&D#9+'IQCG(QQ@BE96N.[O9G35R_B_X7^$?']Q9W
M'B3PUI6NSV886TNH6B3-#D@G86&5R54\>@]*ZBBDFXNZ9:DXNZ9Y%\4/B#;_
M +-7@^X\2Z@UWJWA*"2.%K-65[JV>214C$3.0&CR0-KG*]0Q^[7;?#3Q_8?%
M+P'H?BS2XIX-/U>U2[ABN=OF*K= VTD9X[$UMZMH]AKMDUGJ5E;ZA:,0S074
M*RH2#D$JP(X/-<M?:5_PK[9?Z#88T@NBWVDV<:JD:$@-<1(, %!\S(H^=0<
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MJI8L0#0!RGP,U:RUVQ\6ZAIMW!?V-QXDOGAN;:021R#*#*L.#R"/PKK/'7Q
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M8^$?AG6+![3[%)80FWM[6/\ LV=[4P1PN[Q",QD;,&6097&0Q!XJ23&G^/\
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M444 %%%% !7'?$KXE6OPVTVUN9K"ZU*6X>0);VA0-LBA>>5\N0/ECC<XSDG
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M^(.MV.K,&\^"&PTS8OSL%Q_H[?PA3U/6@#U>BN"_X5YXE_Z*9K__ ( :9_\
M(M8WBSP/X\LM&,NA_$'6[W4/M%NOE2V&F;?*,R"9O^/=>5B,C#GJ!UZ$ ]6H
MK@O^%>>)?^BF:_\ ^ &F?_(M'_"O/$O_ $4S7_\ P TS_P"1: .]HKRA/ _C
MT^,);9OB#K8T 6*2)=?8-,WFY\Q@R?\ 'OT"!3]WOU[5M?\ "O/$O_13-?\
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M&XSP.374JL:D^:OKZ;^1UJK&I/FQ&OIOY'T(#FEK@O\ A7GB4?\ -2]?_P#
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M5Y4X*D#UZN2N_%MW;?%/2_#*PQ-8W>C7>HO,0QD$D4]M&JCG&TB=R>,Y ]Z
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M=Q<NA6/:PPPB@N",Y^8Q\8S0!Z+X*LM1TWPAHMIJWD_VI!9PQW7V>1WC\T(
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MA/E"UD:]\8(/"?AC0-1U#3+R]NM1L6OY8-.1/W$,<*RW$I\QU^5 WW02QR
M35+1_P!HCPSJ>I7<%Q#?:58QJDEMJ=XB>1>JUTUHOEA'9\F92 &53@@]#0!Z
MC7FWCSP'J7CGQ!HB:A::?-I%CJT5XEQ%)(ES%%''YFT\@$O,D2D#@Q[@0<FE
M\7_%VT3P3XJU'PM=6][JFBL(&2[MY?*64R>6&*G89$R' 9&VDHP#9!QGZI^T
M%9:-;S3R>'=:N[59KJ&&[MTMPET+3S?M<B*TVY5C\F3A\,W&T-F@#U<<56U/
M[6=-NO[/\G[=Y3>1]IW>5YF/EW;>=N<9QS7F-[^T3I%KKEUIB:'K$[K-]DLY
MD6 1W]QNME$4>Z4%<F\A^:0*OWN?EI5^+NJ6&D_$+4-4TY+8: D,MK9-'MG3
MS+9'$4Q61U9A(V-R'&TC XR0"+X5>"O%OAWQ_P"*-2UYH[B'4&>5[H3!ED+2
M;H4A PVR.,LA\X;@0HC.TMGUROG9_P!H;Q/:SWFESV6D/K47BR/3(Q&DHC;2
MA<K!+<;2^?,#AT'.W<R<'FO9_ /B:;Q9X9BOKJ!+>\2>XM+B.(DH)8)WA<KG
MG:6C)&>Q% !XYL=;U/0Y[31)HK:6XCEBEF,ACF16C8!H7VLJR!BI!=64=2#T
MK%^"OAG4/"'@2VTN_LH]/\F67R( R-*(2WR&8H2AD/)8H<'COFN\HH *\J^*
MOA3X@>*+_1SHFI:;::78:W8WKVPDN(9;F".:%G$CJP!  E.S&'^0'H0?5:*
M$I:** "BBB@ HHHH **** "BBB@ HHHH *YGQ7\-O#GC:_L;[6=+CN[VQ1X[
M>XWO')&CE6=0R,#M)C0D'C*CTKIJY/XB^,+[P7I5O>6.G0:I)+,(%M9+EHI9
M9&X1(@$;>Q.>#C !.>*:5W9";25V8?BCX$>&=:TO5+?3;*VT*[U&YBNKB[M[
M.*4NT<IE *R @ N6;Y-I#,6!!))RXOV<-#T[PUIVCZ3J5]I:6.FP:7#<1K$[
M^4GG!B0R$$LEQ,O3"[LJ 15VX^-)T[Q!<Z)?:2+?4(KFSMDQ<%HY3+Y8E"MM
M',?F XQ\PYXKHF^)NC3:S;Z=IWGZV[X\V?2D%S%; N4!E93Q\P/0'&"3@<U7
M+(GGB^I3UGX2:3K_ (HDU._9KNRFTJ+2IM,F16B813&:*4-C>KHS'!##L>H!
MJ1?@OX&2<RCPOIF\V+:<?W P8&0QLI'0DHS(6/S%21G!Q4GAOQY<:G'KIU/2
MTTY],43;(KM9O,C*%@<X4 X7KDKGHQP<'AGXF67C#2=5O=*L;F>2P3=]F\R%
MGF8J655V2, 3C')'6ERL?,B75?A5X1UNY^T7OA^QGG-T+QI&B^9Y!'''EB/O
M I#$I4Y4B-,@X%9^F_":TL_!^G:-/J-S>75CJCZS%J31QI*MRUR\[,%50@!,
MKIC'W6(Z\T67Q'OIO!&KZW-H1%UI\S0_9K:X,T<I4J"RR!,E5+$,0IQL;&<5
M+IWQ2M+GP5%K\UG.VZ[%@;:R'G,TQF\I=FX*64L002 <'D"CE8N>)8M?A/X4
MTI(FTO0M/TRZ@B@CMKFWM4WP>0DB6Y7(Y\M9I0H/ #L.]:_A'PO9^"_#>GZ)
M8;S:V40B5Y3EY#U9W/=F8EB>Y8UP&H?'ZQM+V)8],F-I-ILMXDDSB.03H[H+
M=DP<$M&PR">?6N]\&>(6\6>%M-U=[86CW<(E: /OV'N-V!GIUQ0XM:L%.,G9
M&U1114EA1110 4444 %%%% !1110 4444 %%%% !7.^)?A_H'B[4-/O]5TY+
MJ]T_<+:XWNCQABK, 589!*(2#D?**VK^:6WL;B6!(Y)TC9D2:3RT+ <!FP=H
M]3@X]*\NM?C?=0V>E7^J:"EKIFH7TELEW;7;2KY*+EKD9C4F//?CY06Z8S2B
MWL2Y*.Y?\:_ 7PUXJTK5K:TM8-&NM4N$N+J[M[6.5I6!8D$2 @9,CM\NT[F)
MYRV;%_\ !'0;WP_9:0EQJ-G;VEI:V,4EK<^7((88I(@F=N/FCFD5N.0V1@@$
M3Z?\7=)F\-6>HW3(FH70S%I%K,LUS+F4Q)L7@D,1UX'OQFI9/B%=_P!M:) N
MARPZ=J++$\]Y,(9X)"'.UH2.VS&2PW;AMW#FCE8N>(FL?"71O$&NW]YJ2?;=
M/O+"ULGTV5%\M&MY)7BE1QAU<><XX;&,>^;>F_"CP?H]S=3V7AS3[62Y>!Y/
M*A !,+K)&0.BX=%?C&6 )R>:CE^)^EP^-AX8,,YOS((_,$D&S)3?T\S?T_V?
MTYK)N?BS<P>+=4T%- FFN8(Y3:1K*5DN715;HRA51@QPP9ONG('%'*PYXB^*
M_@1X5\1Z9=P6MA!HUY/;&S%_9P(9(XF8EPH8%=Q#R+N() =L$5T6I^ ]*U?Q
M-!K=U")[B.%(3%(H:-S')YD+D$<-&S2;2/\ GHV<\8I:3XZO-1\$W&N?V*TE
MS"\J+:VMPKI-L8KO25@H,9QG=CIT!XS)<?$*WL/".A:W<6-U,VK+;B*TLE$L
MGF2Q[PHR5SW&>*.5CYD06?PD\,Z5=:$^EZ9!I-MHYC:WM+*)8XCY<+PP@@#I
M&DLFT# &[V%=G7D>I?M!V=K<7 @TMYK9M+CO[.2278T\KG @*[3M/7G)^Z:]
M+\.:M_;WA_3-3,7D&\MH[CR@V[9O4-C.!G&>N*'%K5B4XR=D:-%%%26%%%%
M!1110 4444 %%%% !1110 445QWC_P 9:GX4FTN+3=*MM6FOYA;Q6[WC0RO(
M?[JB-@5"Y9F) 4"FE=V0FTE=E.'X%>!(=/%B/#5FUD)EG6WDWO&C $852Q"J
M0S J,*0<$$53C^!FCGQ_K_BJ>YFDN]5LI['RXXHH?)CF$8EPZ*&9CY*89N1S
MDGC$=M\:X'\1RZ+<:>+6ZCU4V!9Y_D>$*Q:=3MY"LNTKVR#GFMU?B?I5[J9L
M]*BN=:01AVOM/19;1"59E5I0<#.WK]T9&2,U7+)$J<7U,FX^".E'POXGT6VU
M'4H(];C$0FDE68V<:LSI'"K+M"*\DC ,&^^03@ #1N?@WX.OUU0WF@65Q-JC
M))>RF,JTLBMNWC!&PEB6)3&223DFG:1\0Y)/#>LZGJ^FKI\VE2E)[:"Z27(V
MJP(9M@_CQS@'!()!!+](^(D7B?PO?:MHUBUQ+;R>2EM<7,*!W^7JZ.Z@?,/?
MC@'C*Y6/F1+<_"OPC=6DMK)X=T[R)$=#&L 4 .L2MC&-O$$/(P1Y:8Q@5G0?
M!W183KUN"RZ3JFDP:*NFQQHD=M!'YQ^0@;BS-.[%F)Y ]\U8OBEJ4MOH,R^'
M<QW\PMY\7@W1R&9HBD:[<R$!6D8$)M4<X.0-#4?B,UCXXBT,:=YEIYT-K->F
M;#)-+&\D8$>WYEQ'R<C!(X/-/E8N>):F^%WAF_99]2T:RU2_,<J2WMU;H993
M+%'#,Q('61(HU;& 0H':M3PGX9MO"&A6^EVLDLR1M)(\TQ!>621VDD=L #+.
M['@8YXKGM8^+6G:5JNHZ;]AOGN+3S(_/:(+;O,EN9_+WY)!*#TK(\&_&Q?%V
MOZ%I::5]G>^LY)[EOM&[[+*I;]UC;\QPN<\<$<<T<DK7L'/&]KGJ%%%%06%%
M%% !1110 4444 %%%% !1110 5!>V<&HV<]K<Q)/;3QM%+$XRKJPP01Z$$BI
MZX[Q[XRU3PK<Z5!INE6VK3:A,+>*![QH96?/)51&P*JN69B0 !32N[(3:2NR
M"+X)^"(M&MM)/AZUETZVN!<PV\Q>18WVA>-S$A2H"E?ND<$&LC0O@'HFC>(_
M$VLM<SSW6N;5D\N..#RT6=IPH\M1D[W.2>HZY)8EUE\:[>?Q$^C7%@+2Z359
M+!FDGPAA17)N%)49 :,J1QC(.:W8_B=I=_J4EII4-SK*)%O-_8JLEHK%"ZHT
MP.!D#[WW1D9(S5.$ET)4XOJ9=[\%=,G\-^)])@U/4H?[<Q^_DE69K15D:1(X
M59=H17=R%8'[Y!)& +E[\$_!.J3W=Q?>&]/N[F\E$]Q+)%S))\VXXS@;MS[@
M,!MS;@<FI-+^(CGPQJ^JZQIPL)M+F,4]M!=)+D84@AGV#^/'S8!P2"003&OQ
M2M;_ ,#:GXCTVPN+O[(QB2TW(SRR?*  8FDZEQZGVI<K#G1I:E\-/"VK)=+=
MZ%93_:?-,I:+EC)Y>]LCD$F"$Y&"#&I&,"L;2_@UHNF:7XJTL,[:7KR) ;-$
M1$M84@6%4CP,G&"VYB3N/6JUE\5;^\.@LFAQRQ7\PMYVBNV#12>:R%$1XU=F
M0*7D#!-H[FMS5/&=[IWC33M&&CF2SNV""\\\!\[&9F6/!RB;5#,2,&10 <T<
MK#G3%A^%WAE9HKJ;1K&ZU)$*M?26Z>;(3.MRS$@#[TZ+*0.-PS6IX3\-6WA#
M0;;2[626:.(N[33$%Y9'=I)';&!EG9F...>*YS6?BWIVE:EJ>GBQOGN+/SD$
MS1A;>29+?S_+#Y)!*?[-97@WXU+XO\0:)I<>E>0][9/<7+_:-WV:52W[K&WY
MCA<YXX(XYI\DK7L+GC>UST^BBBH- HHHH **** "BBB@ HHHH **** "BBB@
M HHHH Q/%WC70O 6E)J7B'5+;2+!YX[9;BZ?:IED8*BY]23BN&^(GC'X:7'C
M;2?#WB3Q#'8^)+=T-I;QWLUM(C3_ ")\T9 !?&T9/J!UJK\>/@IJOQKN=&L5
M\01Z%H5E%=23!+1+F6:>6/R4^20% JQR3'=]X,RD8QFL7PQ^S=-?>(_[9\<Z
MD^L3#3M(MVM;"_NH;6YN+/>3+/"&5)@7,;J'#8(;\>N$:2CS2EKY'5&G0<+S
MEKV_(U?"GB#X2>.=?;0M(UJVUC6;>[%_Y3W<SS&:VQ&7#.<L5P P!/O6]XBN
MOAVWBV>/4]2L;;6M&L/[3NH$O3"8;5'#"2=%8*4#\C>.O(KSGP)^S!K'A'6]
M+OY/%%S+_HVIV]R%NYG.GR7$[2)<:>L@9(9"K!) 5VGJ.<[M;QO^S=/XFO-7
M^SZNBIJ'A.70I;Z[B#W=Q=&:.1;B<HJJ_$0#< ]@ *MQI<]E-V&Z6'YK*6AL
M>&OB#\)O"FFZ;?:3K=BEKXEF:WLW666;SS&^PQ*""45&DQLPH4OT&:[;3=<\
M+^*F\0Z-I>H6=S)8-]CU.*PF"M;NR9V,R8VMM)Z'(]J\%U']ESQ;J]YI.K3:
MSHUKKTFJ76I7M[:->1MIS37,,I-EM<!SMA"'S5YW$],J?7O"7PL7PWXL\?7J
M?9+?2O$3VQ@M;.((80EOY<A8;=N68ENASGFIJ1I)7C*[_P"#_D$Z=",?<?\
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MR/,_LJOW7W_\ _5NDK\G?^'@?QJ_Z#>E_P#@HB_QH_X>!_&G_H-Z5_X*(O\
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M_P#X O[*KOJOO_X!^K?2OG']HC]MKPC\$9)=(T]5\4^*D(#Z?:S!8K;U\Z4
M[3_L@$^N*^*/&7[7_P >]9\,WMKJ=_<Z3ILSFTGO+71C9LK@D-%YVWY&R""
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M&]+_ /!1%_C7/_95?NOZ^1S_ -DU^Z^__@'ZQ8I:_)S_ (>!_&G_ *#>E?\
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M)\0]"\):5YOVW4=,L+N3^T2(Q;RRVHGF#D#Y5C^?J"0%[FG3Y.:_,]/^'O\
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M2] RB*%#(T1DA7)8[OG.%P!7)KX%O9- 37H;FUNM"1XH[R_MF9_L#.0-LT>
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MEBOX$_1_D8XK^!/T?Y'ZT4445\&? A1110 C?=/TK\6?VEO^3A_B5_V'[O\
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M\JRA@000"*PZT335T:IIJZ/K'_@FC_R<!JG_ &+US_Z/MZ_3^OS _P"":/\
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MD).0" \K[5 7+X"C'/ZX[1[_ )FC:/?\S4_6Z=^;D?\ X$R?[2A>_LOQ_P"
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MI_C_ , ]-YNWHZ?X_P# /QC/CGQLLEPT7@ZU@6]N?M>HQ1^')#'J,FQES,K
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M9K^70IVN+A+:-XH!(W0[4<KP!D!<Y(S7[&[1[_F:-H]_S-']IQ:M[)??_P
M/[4BU;V2^_\ X!^-5M\3/B3:Q11)HMP8%5(I(6T:?;-&MBECY;X )4PQIG!!
MW#<"#BF'XC_$99=*:#0YK6/3+B2>WA@T68)B2V2VDB?()=&B3:VXEB68EB3D
M?LQM'O\ F:-H]_S-']IQ_P"?2^__ ( ?VG'_ )]+[_\ @'XS0?$+X@6<NE&U
M\.-;0Z7J%MJ5I!'HD^Q)8(WCCW$Y9P1(Y;>S,Q/+< 4B>/\ QZM\U^WA@3:G
M-:_8;S4)-#G,][;^5Y7E2MQP4V@E C'8A+97-?LUM'O^9HVCW_,T?VG'_GTO
MO_X ?VI'_GTOO_X!^'/B2S\3^*-5>_N_#U]#(8TB2*UTJ:..-$4*J@;23@#J
MQ+$Y)))S69_PB6O?] +5O_!?-_\ $5^[.T>_YFC:/?\ ,UHLW:T5/\?^ :+.
M&M%3_'_@'YH?\$WM"U/3?CWJ<MYIE]9Q'P_<*)+FUDB4GS[?C+*!G@\5^F-(
M%QZ_G2UY.)K_ %FI[2UCR,5B/K-3VEK!1117(<A!?#-G/CD^6W\C7X5CPEKV
M/^0%JW_@OF_^(K]VZ;M'O^9KT<)C'A.;W;W/2P>,>$YK1O>Q^$K>$==92#H6
MK8(Q_P @^;_XBN]O?'/CG5]2O[S5?"B:P+N_35/LM_H4[P0W*QK'YD:C&-R(
M@9265MJY4X%?L[M'O^9HVCW_ #-=SS7FWI_C_P  [WFW-O3_ !_X!^,0^('Q
M&26>\BT>X@UN=OWVN0Z'(E](OGBXV%PFTCS ISLW855W;1MK(\1:IXQ\17.F
MR'P[<Z9'ITLL]K;:;H\T4,4LDOFR2;2&RS/@\D@!54   5^VFT>_YFC:/?\
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M (1+7O\ H!:M_P""^;_XBOW9VCW_ #-&T>_YFK6;-*RI_C_P#19NTK*G^/\
MP#X=_P""8&DWVEZ5\1!>V-U9%[JQ*"ZMWBW8CESC<!G\*^Y*0#'_ .NEKQ\1
M6]O5=2UKGBXBM]8JNI:UPHHHKG.<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_"/PCK_A>_\ #\N@V-MIMY#Y$B65O' RC8R J57Y2%=P".0&..IKL** , ^
M/#)TH:8?#VE'3MBQ_9#8Q>3M5RZKLVXP'9F QP23U-3:AX-T'5@HO=$TZ\"S
M-< 3VD<F)6&&<94_,1P3U(K9HH Q7\%>'Y)Q.VAZ:TP$RB0V<9;$V?.&=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>apre-20251231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Q YH# 2(  A$! Q$!_\0
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M% !1110 5QGB?XJZ;X3U9]/N='\37DJ*K&72_#M[>0G(S@211,I/J,\5V=%
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MO;:R52Q\F(9=V(X4>F>O:EY#\S(_X7SHO_0N^-__  C]3_\ C%'_  OG1?\
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MF/\ PTEX2_Z!'C[_ ,-UX@_^0:/^&DO"7_0(\??^&Z\0?_(->GQ3Q3@F*1)
M.I1@<5)0!\T?&?7/A;\==(TVSU_3/BA8W.EW0O=/U31?!'B.SO;.7!4M%,EC
ME<J2#[&MKX8_$?X;_"3P?:>&_#^B_$9;"W9Y#)=^ ?$4\\TCL6>221K'+.Q)
M))ZDU[[10M$TNH/6U^AY9_PTEX2_Z!'C[_PW7B#_ .0:/^&DO"7_ $"/'W_A
MNO$'_P @UV.M?$7PMX;OFLM6\1Z5IMXH#&WN[R.)P#T.UB#5_0?$VD>*;1[K
M1M3M-5MD?RVFLYUE0-@':2I(S@CCWH6NP;'G_P#PTEX2_P"@1X^_\-UX@_\
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M4QSZY)]1T3X)?#GQ'I%GJFF1ZE>:?>1+-!<1Z_J&V1",AAF?H:N_\,\>!O\
MGRU7_P '^H?_ !^G9KW?*UOP^_1:[Z!S<SYO._SW_7T/(M*_9.\>6\/B'Q'<
M?$Y;;XE:B^GI#JND:>;2P6"RW^3#+;*_[Q6\UMXW 'C &*PM=_8'FU;P-I,4
MGB#1=6\:6VJ:AJMS?:_H27NFR27I!G6.T9L1J" 4P>"">237H'Q*TOX$?!V?
M38?&NNR>')=2$ALTO?$6HJ9]FW?M F.<;ES]13OA[HOP-^*]S=V_A'6+C79K
M1!).EKK^I9C4G )S,.]%^>_]?UMK^(OAM?\ KHOP=D>G?!KX;0?![X6>%_!5
MM>3:A!H=C'9K=3_>DVCDX[#.<#H!@=J[.O-O^&>/ W_/EJO_ (/]0_\ C]'_
M  SQX&_Y\M5_\'^H?_'Z<I.<G*6[)C%12BMD>DT5YM_PSQX&_P"?+5?_  ?Z
MA_\ 'Z[3PSX8T_PAI$6F:7'-'9QLS*L]S+<-DG)^>1F8\GN:DHU:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^0M5_X*"?V1XUUCPY=_
M#+5M,FL+N6U2YUG4;?3X;D(Q421M,5!5@,CGH:^H_!?B%_%GA/2=9DM5L7OK
M=)S;I<)<"/<,X$B$J_U4D&A>]'G6P/27*]S:HHHH *_/K]OV7X:K\9=*&J>)
M_$]CX_318WM])L1;G3);?S9=CS?:)(D!W[P2) V ..E?H+7@'[84CZ1X%T[4
MK4G3Y9-2M[6]U:R\/IJU]!:DG=Y4;1N,Y[E2 ":SDM8OS_/3]?N-(NRDO+_@
M_I]YRG_!/NXO[GX?:^^HP^$(9S>I@>$]0:Z^79Q]HS+*J2>R,17U57A7[*,V
MFS>'=;.F>)=<\2QBY3=-KGAZ+2'C.W[JI'!"''N0<>M>ZUT5'=_)?D<]-67S
M?YA11169H?G%^W)_PA%S\>;J.'P)JK>/(["W9O%=S=RPZ9L(/EKL2WN?-9><
MKY0^M?1_["4=U%\'+I+[6])UZZ74I-]QH^@OI,2'RX_D*-'&9&'_ #TV#.0.
MU;'[6=MXANO#OA8:-:^,-0TX:PIU:R\$2B&^FM_*DQ^]W*54/L)P><8K?_9P
MMDM?!=ZJ:3XUT@&^8^3X[NVN+QOD3YD9G<B/L!GJ&XIT?=A./];I_KT"KK*+
M_K9K]#U>BBBD!7U"]CTVPN;N;=Y-O&TK[1D[5&3@=^E?.7@[]OWX;?$!B/#F
MF>+M9PVQOL>@S/M.<<@=*^B]5^T_V7=_8DCEO/)?R4E^XSX.T'VSBOS?U3]G
M/XN^/O$-EJWQ-^'\3WT4PF%KX1U_2M#MP<]W6)[AQ]9>:4=9V>Q37N76Y^DM
MM.+JVBF"N@D0.%D7:PR,X([&I:J:1";?2;*(QF(I"BF-I/,*X4<%OXOKWJW5
M/1NQG&[2;"O%?C-^USX"^!/C#3/#'B4ZL^L:C!]HMHM/T][@.N[;U'&<]J]J
MKY3_ &OO!?Q>\<^(].T_PCX;T75/!7V,F^O)5L!J"3;ONQO>!T1=O?RR?<5#
M;35C1)-.Y[M\+_BQIWQ7L+J\TW2=<TN&W8)_Q.M.>T,F1G*!OO#W%=M7S=^Q
M3\([CX1>%M=L+GP[J>@R7%RDK'4O$D&KF<[<%E$")'".VU5 KZ1K622>AG%M
M[A1114%!1110 4444 %%%% !1110 4444 %%%(WW3SCCK2>B 6BOR?U74]0T
MCQAJ2^#_ (@:W\;[22^E5K3^V=1T%K0[SN070N&A(7[O^K'2OT_^'9=O 7AT
MRV\EI(=/@+02WGVQXSY8RIG_ .6I'3?_ !=>]5%<T.?T_K_AM E[LW#U_K_A
MSH:^(/VP?A!J#?$)/$>K_%J_M]'UZ1+/2_!<?A6YUE1)'%F0I'#=Q[@0"S%D
MP*^WZ\Q^-WPKTSXGVVC/>>-M=\#76ASOJ$&H^'KVWMIU&PHVYIHI!LVL<X ]
MSCBLY+5/^O,N+W7?^E^)A_LCZ2FB?"5;.-E:..^EV[?"S>'@!A?^75G<_P#
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M(L;MW.<_='3OW];3=VC&*M<\N_:5D\40_"/59?!WBW2O!.NQM&\6KZS(([9
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M TZRB0RGJ,,6(ZYXS7Z.ULTN5-=3.[YFF%%%%04%%%% !1110 4444 %%%%
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M.H!KY_\  /[3WQ*\4_%>V\#V'PUT35K2RE6'6-:T+6FNK32@.J22F)4,N/\
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M%6JVF[R;L905HI7N?'WC[X<?"W1_C1X]\1?$CQ=X>O[MWMM8LM-OKO-W;Q+
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M>;Y9./X\9]Z]GK21FNI@>.?'/A[X=>'9]:\4:I;Z/HT;)%+=W9Q$I<A5#''
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M_P"!6@?_ "TIQ?+'E]/P_P ^O<)>]+F]?Q_K3L>T45XO_P -$ZW_ -$4\?\
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M#E0V.0#W&:EKQ?\ X:)UO_HBGC__ ,"M _\ EI1_PT3K?_1%/'__ (%:!_\
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M87_@&ZO)KSQQXB\6"X0(L6MRQ.L)!SE=B+R?>N4_X:)UO_HBGC__ ,"M _\
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M'? PJQ!P:D2\4C- &A15);Y2V,59,F$SB@"2G#I587&3TIYE/84 3T?LT_\
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MQYJ>X^*(91Y43L?84 >MI(">M/# &N/\):]+J\&]XV3/]ZNC+/GI0!>WBE#
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MPB9@"V1TKZ=JI12_K^OZW%%W"BBBH*"BBB@#P;XO2&/]I#X;$#)_X1/Q(/\
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M1_W!^5-;3T*D;!^58G_"5^*/^B4^,?\ OK3?_DRD/BOQ1_T2GQC_ -]:;_\
M)E %#7OASI>MR[[FSBE;U= :SF^$VBF$Q_8(-N.GEBMT^*/%!_YI3XQ_[ZTW
M_P"3*3_A)O%'_1*?&/YZ;_\ )E '#S? #PU-.)&TFV+9SGRE_P *[C2O!-CI
MUC';1P(L2# 4*,"D_P"$E\49_P"24^,?^^M-_P#DRGCQ3XH'_-*?&/\ WUIO
M_P F4 6T\*V:#B%1]!4D7A:T20.(ER/:J(\4^*/^B4^,?STW_P"3*4>*_% _
MYI3XQ_/3?_DR@#I5LD"!<<"E6S0=JYO_ (2WQ1_T2KQC^>F__)E'_"6^)_\
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MKP*S_8<>*)HY=4N9 >YKZIE_:2^#K]?BOX'/_<QV?_QRJY_:+^#G_15O _\
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M  TW\'3_ ,U8\#_^%'9__'* /173(/%9\^G)*WS*#]:XG_AIKX._]%8\#_\
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M)/QM^+8&?M_@K_P1W?\ \FT >B_\*7\:?]%.E_\ !%;?XT?\*7\:?]%.E_\
M!%;?XUYPOQQ^++''V_P7G_L!W?\ \FU*/C5\6B/^0AX*SZ?V'=__ ";0!Z%_
MPI?QI_T4Z7_P16W^-'_"E_&G_13I?_!%;?XUYR/CC\6"^W^T?!0;T.AW?_R;
M5A?C)\6V&?[1\%?^"*[_ /DZ@#OO^%+^,_\ HITO_@BMO\:/^%+^,_\ HITO
M_@BMO\:X(_&+XMC_ )B/@K_P17?_ ,G4?\+C^+?_ $$?!?\ X(KO_P"3J .]
M_P"%+^,_^BG2_P#@BMO\:/\ A2_C/_HITO\ X(K;_&N#_P"%P_%O_H(^"_\
MP17?_P G4G_"XOBW_P!!'P7_ ."*[_\ DZ@#O?\ A2_C/_HITO\ X(K;_&C_
M (4OXT_Z*=+_ ."*V_QK@_\ A</Q;_Z"/@K_ ,$5W_\ )U)_PN+XMXS_ &CX
M*_\ !%=__)U '>_\*7\:?]%.E_\ !%;?XT?\*7\:?]%.E_\ !%;?XUP/_"Y?
MBW_T$?!?_@BN_P#Y.IP^,7Q:(S_:/@O_ ,$-W_\ )U '>?\ "E_&G_13I?\
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M_HITO_@BMO\ &N*'Q6^+K?\ ,3\%?^"&[_\ DZG_ /"T_BY_T%/!7_@AN_\
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M:@^U.'BA<\^%?'7_ (0^L_\ R+4T?BY%/_(J^.0/^Q'UG_Y$H UK>P6)0NW
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M8(2,>%_'7_A#ZS_\B4 6=)T>.QC"HF*75]'2_B*N,CTJNGC*-1SX7\=$^O\
MP@^L_P#R)0_C)&_YE?QS_P"$/K/_ ,B4 4=/\(P6QX3%:C:%$RE=E5_^$P3/
M_(K^.?P\#ZS_ /(E3)XTB48/A?QS_P"$/K/_ ,B4 5!X.B^T!_+!KI+?3A!;
M[/:L?_A-HO\ H5_'7_A#ZS_\B5)_PG46/^18\=?^$-K/_P B4 5+SP\MS>AV
M&0#TK2318PHPE4SXRASG_A&/'.?^Q&UG_P"1*>/&T('_ "+'CG_PAM:_^1*
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M=6\4RC_RCZE7SOK_ ,,M9N=:DFAGD6-CD &OHW]J'[3;+\-M2BTO5M4MM/\
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M-_SZ>-O_  @->_\ D*C_ (:E\#?\^GC;_P (#7O_ )"JWNHS0!4_X:E\#?\
M/IXV_P#" U[_ .0J/^&I? W_ #Z>-O\ P@->_P#D*K1<"D#T 5O^&I? W_/I
MXV_\(#7O_D*C_AJ;P+_SZ^-O_" U[_Y"JR6!HS0!6_X:E\#?\^GC;_P@->_^
M0J/^&I? W_/IXV_\(#7O_D*K0-*30!4_X:E\"_\ /KXV_P#" U[_ .0J/^&I
M? O_ #Z>-O\ P@->_P#D*K.:* *W_#4O@7_GT\;?^$!KW_R%1_PU+X&_Y]/&
MW_A :]_\A59IP/% %3_AJ7P+_P ^GC;_ ,(#7O\ Y"I/^&IO O\ SZ^-?_"
MU[_Y"JTQIE $'_#4W@7_ )]?&O\ X0&O?_(5'_#4W@7_ )]?&O\ X0&O?_(5
M3DT@S0!#_P -3>!?^?7QK_X0&O?_ "%1_P -3>!?^?7QK_X0&O?_ "%4]!-
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MW$MJ%SE@P%4/B1KD^A3Q7*HQA;AL'I0![+_PTY\'S_S53P9_X/[7_P".4O\
MPTU\(/\ HJ?@S_P?6O\ \<KQ/PQ\0(KUXD)XR.IKU&TU1)(%9"#D=,T ;?\
MPTU\(/\ HJ7@S_P?6O\ \<H_X::^$'_14O!G_@^M?_CE9RW;,FXJ!4;WL@&0
M%_.@#5_X::^$'_14O!O_ (/K7_XY1_PTU\(/^BI>#/\ P?6O_P <JA#=;E^8
M@'ZT><[$X*X% %__ (::^$'_ $5+P9_X/K7_ ..4?\--?"#_ **EX,_\'UK_
M /'*S'E;=]\4Z*?!^:0&@#1_X::^$'_14O!G_@^M?_CE'_#37P@_Z*EX,_\
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M3L__  (3_&C_ (2'2O\ H)V?_@0G^->&_P#"F/A]_P!"+X:_\%%O_P#$4?\
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M'_"FOA[_ -"+X9_\%%O_ /$4 >Y_\)#I7_03L_\ P(3_ !H_X2'2O^@G9_\
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M+E/VB_%I'_0IZ'_Z6:O7):M\6+;2-<>QNAY>.C$5U^NKN_:,\6C_ *E/0O\
MTLU>LOQ'\--+\1W2S75NK2#^+'- %>V^)>F2Q@^>M64^(NF-_P O"BEM?AGI
M%M&J+:Q\>JT]OASI+?\ +JGY4 .'Q TL_P#+TGYUHZ3XFM-5;;;S+(?8U@7'
MPITF?/[@+GTXK7\.>";/P\#]G3!/>@"IXN\8#PU+"TRGR7."V.E/L_&^GW4*
MNMRF"/6K7BWPM#XCTZ2VE4$$<'N*\[T_X)_9V8/>2E,\ ,>* /0QXNL2<"YC
M_.GCQ39_\_"?G7"S_!J%E^2ZF4^H8UC7/P6U#?\ NM5G"^FXT >Q6&K07O\
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M!*UW%:KEW"D#IG'(J74?V>O".J)LGT6V=3ZQBNI\$?"W1/ U@]KI%A%9PO\
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MF0X5&C89_,5UL'[,O@NWC$::%:!0, >6/\*U_#/P#\+>'=52^L])@@N$Z.B
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M8G@O5?#^KZCIFIIJ$6FQ^9.+?YR!C- 'TB^HQ+GYA^=1/K$*#EU_.OS?U_\
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M[I4-JEE]GNT$JR1*H4*X(PV0.<CFM**)((DBB18XT4*J(,!0.@ ["G!\CO\
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MFZ* /F9/VA?A2W7XE^#Q_P!Q^U_^.4C?M ?"G=G_ (67X._\']I_\<KZ:HH
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MG_"SO!Y/OK]I_P#'*^HJ* /DH?&WX8!R3\3_  >03_T'K7_XY3_^%W?"X_\
M-3O!_P#X/[7_ ..5]944 ?+%G\=?A7 #GXF^#\^^OVO_ ,<J";XW_"R68M_P
MLWPA@_\ 4?M?_CE?5U% 'RB?C;\*L$?\+,\'C_N/VO\ \<IMM\;?A5%.'_X6
M;X0^G]OVO_QROK"B@#Y>N_CQ\*IU _X6;X/_  U^U_\ CE0)\<OA4H_Y*;X/
M_P#!_:__ !ROJBB@#Y9_X7K\*L_\E-\'_P#@^M/_ (Y5S_AH#X5>3M_X69X.
M_P#!_:?_ !ROIJB@#Y@7X]_"E?\ FI?@[_P?6O\ \<IDWQY^%$@P?B5X./\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*%2E&,YK1FK1117.<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444UF"]: '45'YZ>HH\]/44 245'YZ>HH\]/44 245'YZ>HH\]/44
M245'YZ>HH\]/44 245'YZ>HH\]/44 245'YZ>HH\]/44 245'YZ>HH\]/44
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MJ;Q#:6-_<:O;ZT='N-"2R;S8<1;_ #&;=D<X7;M[CGM5.M32NV'MZ>GO;_\
M#GENFZC<Z1J%O?64[VUW;R++%-&<,C Y!!KZ$A_;[^+D,*1_VCIK[5"[GL5)
M/N3GK7&_#7]G^_\ '^I:=IUR=7T2[NM1GTYYI])#VL<D<)D*"3S58R\8,>P8
M!SN/2L2+X+^)++Q-;Z5K.AZ[9"Y69H&M--\^681@Y*HSH"!CGYN!V/2L:GU>
MK*T[-HRG]7JNT[-KO_7D>H?\-_\ Q=_Y_P#2_P#P 7_&C_AO_P"+O_/_ *7_
M . "_P"-<!XU_9W\6>$;SPU9PV%UJUWK>E1ZFL-M;-NAW;B8SUR5 !8\ 9]L
MGG[?X/>-[K5I],A\*ZK)?P0"ZDMUMF++">DA_P!GWZ5FJ.$>T5_PQFJ.$DE)
M1C8]?_X;_P#B[_S_ .E_^ "_XT?\-_\ Q=_Y_P#2_P#P 7_&O)/ WPHU?QIX
MRNM D:/16T^&6ZU.ZO@0EC!$,RR.!SQTP.22!6Q=?"_PSJ_AS4]2\(^-3J]U
MILL:3Z=J^G#3I98W;:)(,32B0!B,@[6 YQ0Z.%3MR+[N^PG1PB=G!?=^IZ'_
M ,-__%W_ )_]+_\  !?\:/\ AO\ ^+O_ #_Z7_X +_C7*>*/@3H/A'5K_P .
MZEXX-AXJM+/[28K[2_)TV5P@<PQW1F+%L' )B"D\ ]*GM_V8=1OI/!<EOK$0
MT[7-$77=0U&Y@\J#28-[*V]MYWXV\?=))QCO6?)@[)\JL_+R;_),GDP=K\J^
M[_@>9TG_  W_ /%W_G_TO_P 7_&C_AO_ .+O_/\ Z7_X +_C7@/B*TTVPUR]
MMM'U"75=,BD*07L]M]G:91_%Y>]]H/8;B<8SCH/3M0_9JU_3_AWX-\127"_V
MEXJU%;"RT<QX=0^/*=WW<;LC V],'/-:.AA4DW!:[:=RYT,)3LI12OY=E?\
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M3F4>57?]?J'L<)?EY5?T_KN=]_PW_P#%W_G_ -+_ / !?\:/^&__ (N_\_\
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MR3F0 !2>>E9^C?L\S^)_BI_PBFC>(].O=*66W6377_=)$LQ"HK1$[O-R=OE
MD[N,@9(Y92P]>SDD]+[='9_JM#FJ2PU2\JB3MW7]?<=E_P -_P#Q=_Y_]+_\
M %_QH_X;_P#B[_S_ .E_^ "_XUY[H/PHT&?5O$5KK_C2+1DTO41IEO#;V7VJ
M]O9#(4WI!YB808RS;CC. ":Z9_V7Y=$U#7SXCUZ2RT?3-4CTB.]TK36OI+F9
MT$F1%YB;41"K.2V1D  FLG3PB^RON]/\T92IX.#<905_3\M-?D;G_#?_ ,7?
M^?\ TO\ \ %_QH_X;_\ B[_S_P"E_P#@ O\ C7%?#K]GF_\ B5\8;KP1I>LV
M<]E:2L)]>MU,ENL0Z2 9&2<@!<@YX[5QNB^"6U;XA#PPG]H7;?:Y;4'2K(7-
MS)L+<I"9$#$[<XWC SSQ5*CA&[**VOMT+]CA+R7*O=WT[_\ #'L__#?_ ,7?
M^?\ TO\ \ %_QH_X;_\ B[_S_P"E_P#@ O\ C7D5K\'/&]_I::G:>%=6N--D
MB>>.Y2U8J\:YW.,=0,'.,XQ6QXJ^ /BGPW%X06*RN-4O/$EE]L@M;6W8LG)^
M3W(4!B<#&:?L<(G;E7]7_P F#HX1/EY8_ATW/1?^&_\ XN_\_P#I?_@ O^-'
M_#?_ ,7?^?\ TO\ \ %_QKQZ#X1>-;K7GT6'POJDNJI;&\:T6V8R" $ R8_N
MY(&>G-=OXB_9FUWPQ\/_  UK%U%JLWB'7YI8K;0[;3 XB$;A?WLOFAE9AE@H
MC88')%*5'"1M>*U_K]!.C@XM)Q6O_#G5?\-__%W_ )_]+_\  !?\:/\ AO\
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M_E!7=@81GB(QDKK7\COP,(U,1&,E=:_DSQL_\% /BZ?^7_2__ !?\:/^&_\
MXN_\_P#I?_@ O^-?.%%?6_5,/_(ON/KOJF'_ )%]Q]'_ /#?_P 7?^?_ $O_
M , %_P :/^&__B[_ ,_^E_\ @ O^-?.%%'U3#_R+[@^J8?\ D7W'T?\ \-__
M !=_Y_\ 2_\ P 7_ !H_X;_^+O\ S_Z7_P" "_XU\X44?5,/_(ON#ZIA_P"1
M?<?1_P#PW_\ %W_G_P!+_P# !?\ &C_AO_XN_P#/_I?_ ( +_C7SA11]4P_\
MB^X/JF'_ )%]Q]'_ /#?_P 7?^?_ $O_ , %_P :/^&__B[_ ,_^E_\ @ O^
M-?.%%'U3#_R+[@^J8?\ D7W'T?\ \-__ !=_Y_\ 2_\ P 7_ !H_X;_^+O\
MS_Z7_P" "_XU\X44?5,/_(ON#ZIA_P"1?<?1_P#PW_\ %W_G_P!+_P# !?\
M&C_AO_XN_P#/_I?_ ( +_C7SA11]4P_\B^X/JF'_ )%]QV_Q8^,WBGXTZW!J
MGBB^6ZFMXO)ABA3RXHUZG:HX!/<]^*XBBBNB,8P7+%61TQC&"Y8JR"BBBJ*+
MFCZO>>']5M-2T^X>TOK659H9XSAD<'((-?02?M^_%U$5?[0TQL#&38+D_K7S
MC16-2C3JZSBF8U*-.KK.*9]'_P##?_Q=_P"?_2__   7_&C_ (;_ /B[_P _
M^E_^ "_XU\X45G]4P_\ (ON,OJF'_D7W'T?_ ,-__%W_ )_]+_\  !?\:/\
MAO\ ^+O_ #_Z7_X +_C7SA11]4P_\B^X/JF'_D7W'T?_ ,-__%W_ )_]+_\
M !?\:/\ AO\ ^+O_ #_Z7_X +_C7SA11]4P_\B^X/JF'_D7W'T?_ ,-__%W_
M )_]+_\  !?\:/\ AO\ ^+O_ #_Z7_X +_C7SA11]4P_\B^X/JF'_D7W'T?_
M ,-__%W_ )_]+_\  !?\:/\ AO\ ^+O_ #_Z7_X +_C7SA11]4P_\B^X/JF'
M_D7W'T?_ ,-__%W_ )_]+_\  !?\:/\ AO\ ^+O_ #_Z7_X +_C7SA11]4P_
M\B^X/JF'_D7W'T?_ ,-__%W_ )_]+_\  !?\:]5_9@_;'^(_Q-^./AKPQKMW
M82Z3?FX$ZPV:HYV6TLBX;/'S(M?#=>Y?L1?\G0>"?]Z\_P#2.>N?$86A&C-J
M"O9_D<^(PM"-&;4%=)]/(_7N,[D!I]10?ZL5+7QA\4%%%% "'H:^-?\ @I;_
M ,D:T7_L8(/_ $GN:^RCT-?&O_!2W_DC6B_]C!!_Z3W-=N"_WB'J=N"_WB'J
M?#/P UNP\-_&CP=JFJ74=CI]KJ44L]S,<)&@/))]*]'\$:AHWPH\8>+_ !IJ
M/B#2-2\VWO+?3],TZ[6YENFG)4%@O"*%8DECZ<5\\T5]E.GSO?=6^1]G.BJC
M=WH[7^5_\SZYUWXC>&O^%@>./'J>+K*YT37/#@L;+1U<FY29H$B6)X<?*(W4
MMGIC&,FH=9^(GAG4$E\2>.+[PYK.OVMUIMQ;WWA>[F5]56.2,R)=6K?+Q&I&
MXJF", &ODU%WNJ^IQP,UU5Y\,/$?]L7=AINB:OJWV>3RS)!IDZG=M#$%"FY3
M@]".G/0USK#P@X^]M:WHGW_/N<SPM-:2E^FEDOT/?/C1\1M%O-"^)LNFZMX6
MN+;Q3=P2VR60O;F^NE$HD#2"6Y*6S(!@D1G/*@ '(XS1O&NAP_ CP1H5SK36
ML]OXN>\OH+60B>*V,87S,?B<5X=+!)!,\,D;1RHQ1HV!#*P.""/6M74/!GB#
M2)[.&^T+4K*:]Q]ECN+.2-I^GW 0-W4=,]:J&'A3BHWZI_=;_(U="/*HN75O
M\+?D?9TGQ-\(V^F>.TF\0^%H4U#6=,NK#[%<2375W##<JSS7$CEB7V\XX/WN
M.E<QX2^+_ANS\<_%:\N]076+?4/%>FWNGVD9,KWD27,A9HEP=VU2IX[8KY:F
M\#^([;5UTJ;P_JD6J,AE%D]E()RG7<$*[L<'G%6U\"^,=&N9;A?#VN65Q8*M
MS)+]AFC:W7JLC';\HX."<=*RCAJ<5\7]+E_^17XG/]4I\LH\V]OT/KCPEJ%C
M\.-#\;^*-:\06WB#1&\;6%VT$#M*Z*)'8NZD K( 1E#\PV=.E>;?&'QQI:^"
M_&MC9ZIX4NDU[6EO(8](^V7=S<J&9A.[S7++;G#8*A"3DC@#-<1\5?#?Q+/A
MOP_J.O:MK/BC1=1TR'6EG+3SV]J)2P"R,PVJ_P O//<5Q+?#K7;DV0TS2=3U
M8W-M%<8MM.G^7>"0!\OS#@X89!P<$XJ*>'C\4I;.WW6_^1_K0JE2A?VKEOKY
M>7YGL_A#Q)HOB#P5\*88?%=CX9G\*:I)/J<-Y,86*F42":, ?O"5!3 YSCM5
M/]HGXE>&_'W@31CH=S$)#XCU>]:Q VR10RM%Y;,O;=M)KQ6S\&Z_J.KSZ5::
M'J5SJD&?-L8;21YX\==R ;A^(KHM&^"WBK6?"GB+Q NEW<-GH4T,%W');2>:
M&=B#A=N?D RV>@(]:W=*FI*;EUO][_SL:1I4Z4U-RU7Z\W_R3.Z\0_%R+0_A
M'\++#17T:_U33HKXW:7FG07<MJYG#1X,B-LR.>.N*NVWBX_$WX!^(K#5O$VG
M+XMOO%2:E(NJ7:6[21"V5-P+8& 1@ >E>13?#[79=4U*STW2-3U4:>V)WM]/
MFS&/5U*[D_X$!5;3/ WB36K7[3I_A_5+^V^?]];64DB?+C=RJD<9&?3-4Z5-
MIZZWO?\ [>YON&J-.-G%ZI_Y_P"9]"_#+XWGX ?!R;3;"^T;5=9_X24275BD
MBW GLFMT#A'' #<J6'((KQ[XT:'X2TSQ8+[P1JL=_P"&]4C%Y;VK-^_T_=RU
MO*/5#P#W&/K7$VFF7E_Y_P!FM)[C[.AEF\J,MY:#JS8' 'J:LP>&M5G>!5TR
M](GA-S&5MG.^%<[I%P.5&#EAQP:J-&,:GM+ZO?ST_P"!=?,N%*-*3DGO>_GK
M?\+_ -:'U-\=_BOX;UOP-XCM-&\16]Q<W6KZ/*L=O*<R116A60^X5\ ^^*N?
M'SXP>&M<\*0V^B^);:YG?Q?97\J6TIRT*685I#Z@.,9]17BVG_LT>*M2ETEX
MX98-/U+65T:*\N[.>$([;0))%9 47+ <\DUP?C#P+K?@;49;76-,O+)1+)%#
M/<6SQ1W&QL%HRP&X=#QZBN:G1H\RY9:IW^[E_P D<E+#T7R1C*_*G^-U^C/M
MB'XS^!V\2)(GBW3K9&\<7]^+CS#A('L#&DW3[I<XSZUQ?PL\?^&?AQIVD:'K
M?C#3=6O)-8U+5/M=O.98+2%[5HE4R$?>D?YMH]>>:^4M&\(Z[XC@GGTG1=1U
M2&W_ -=)96DDRQ\9^8J"!^-4+2PN=0O([2UMI;F[D;8D$*%Y';T"CDGVH^I0
MLX<VZ2?R6A2P=.S7-^7][_Y)GUK=>/?"NJ^'(+6W\5:;97FJ> +30(IWE*M:
MW<+EI(Y>,HKCY=W0Y]*2U^)_AGP]\'+[PD_B6SO->M/!MS8F[MY2R22RW&];
M:-_X]J$CCCTXKYG3P'K%O?WMEJ>G:AI-W;6CWA@N;";S"BC.2NW*J?[Q^4=S
M5;4_ _B/1;!KW4/#^J6%DKA&N;FRDCC#'H"S*!GVJI8>G.Z<M]?OO_F_ZWI8
M:G[JYMFG]UOT2.X^ _CG2O#FK>*-*\073V6F>*-%N-'EU'89#:R/AHY6 Y*A
ME 8#L?:NN\/1>$O"/@/Q18^+-6\):K)+9&TT631;..YOH[@NI%P9%16 "[OO
ML#DCBO'H? /B26RAOFT'4X].E =;Y[*00;"0-^_;C;DCG/>M;Q3\(O$7A[QM
MK7AFTL;G7[S26 N)-*MI)E (!W$!<@<]36TX0E+XK77Y?EN:RIPE)M2M=I_-
M67^29[OH?Q!72?M>F^+O'>@?$#X>KI\J0K>1HVHG*$1+&C RQ.&QQN*C'4UJ
MS_M"^&4\(?#?P%J-Q:WW@F_\-K8:\+=0;FQG,C>6Q?KF/Y6V]/F;UKY!6"5Y
MQ"L;F8ML$84[BV<8QZY[5V^J?!OQ'H?@.'Q-J5E<:>)M4&E1Z==6TD5R[F(2
M!PK*,J<X&.XK&>&I.SF^OI?==.NN_H9/#4U)7=GTZ:]UYZ&M!/\ #WX<^*?L
M]_HM[XZETV]WK?6.OQ0:=?Q!]R?NOLCN 5P&'F=<_2O:[S]H[P=J'AKPOXBD
MM]2CUNU\:IJ\VGW.JQ73P0KY>XA5MHP8]BE$0;=I Y/2OES4/!GB#2=1MK"^
MT+4[.^NL>1:W%G)'++Z;%(RWX477@SQ!8ZQ!I-SH6I6^JSX\JQELY%GDSTVH
M1N/X"M72A/E<G=KS[6OY=-32IAZ55WD^_7HTU^I[Q\4O'FG3>!OB%;W_ (HM
M?%=YK^NPWNA"WG,K6<2NS-(P/^JRA$>WKGMQFN:\8ZWX<\6?#SX-:'<^($L_
ML:7L6J3Q1&XDL1),A#-'E<\9.,]J\?U;1[_0;Z2RU.QN=.O(\;[>[A:*1<],
MJP!%7(_!NORZ2FJIH>I/ICL$2]6TD,+,3@ /C:3GC&:4*$()6?5/_P EY?R_
M$I48QL^;77\3ZH^&'Q:T3X3Z+IVG^*/%=CXEEL];4Z)<:>WGG3[4Q-'+*V/N
MA@4^0DG(-85E\7]$^'/AJU;Q/-;_ !*\01Z_/J=A]CU,$V<9BVK)YK1R*"7P
MPC*D< D"O%_BI\(]3^$EQI5IK$A^WWMLMTT'V:6,1*RJP&]U"N?FP=N<$$&N
M%J(X>G4O-.]]_EV[;:VW,886E-<Z=T]?S_#4]U^/7C_PKXT^&7PWCT@Z@^KV
MT=\]VE]JB7<UN9+IG(F*P1[G<G<&&W .,'K47[$__)SW@G_?NO\ TDFKP^O<
M/V)_^3GO!/\ OW7_ *23556FJ>'J*/:3^^[-:L%3PTXKM+\;L_7NW_U8^E2U
M%;_ZL?2I:^'/@Q#T-?$/_!3;_DG_ (5_["I_]$O7V\>AKXA_X*;?\D_\*_\
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MIU) 6-HSY9 3:#Y?R9Z5U.;]I%+KT_7^O0Z5.3JVZ6^[;_@_TC@KGP3XBL]
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M8G_Y.>\$_P"_=?\ I)-7A]>X_L2*7_:@\$ ?W[O_ -(YZY\3_ GZ/\CFQ/\
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M_P#XFNJHHYGW#FEW.5_X5MX;_P"@#IO_ ("1_P#Q-'_"MO#?_0!TW_P$C_\
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M]Q ,#%+114DA6;J^@6&N1K'?V5O>QH=RK<1+( ?4 @UI44;!L<J?AMX;)_Y
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M6WAO_H Z;_X"1_\ Q-'_  K;PW_T =-_\!(__B:ZJBCF?<.:7<Y7_A6WAO\
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M>&_^@#IO_@)'_P#$UU5%',^X<TNYRO\ PK;PW_T =-_\!(__ (FC_A6WAO\
MZ .F_P#@)'_\37544<S[AS2[G*_\*V\-_P#0!TW_ ,!(_P#XFC_A6WAO_H Z
M;_X"1_\ Q-=511S/N'-+N<K_ ,*V\-_] '3?_ 2/_P")H_X5MX;_ .@#IO\
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M - '3?\ P$C_ /B:/^%;>&_^@#IO_@)'_P#$UU5%',^X<TNYRO\ PK;PW_T
M=-_\!(__ (FC_A6WAO\ Z .F_P#@)'_\37544<S[AS2[G*_\*V\-_P#0!TW_
M ,!(_P#XFKFF^"M$TFY2XM-(L;:X3.V6*V1'7(P<$#/0D5O44<S[AS/N(!@4
MM%%22%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>apre-20251231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (/ O\# 2(  A$! Q$!_\0
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M/WGOM%>!?\-L_#GTU?\ \ Q_\71_PVS\.?35_P#P#'_Q='L:G\H?VYEO_/\
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M_*']N9;_ ,_X_>>^T5X%_P -L_#GTU?_ , Q_P#%T?\ #;/PY]-7_P# ,?\
MQ='L:G\H?VYEO_/^/WGOM%>!?\-L_#GTU?\ \ Q_\71_PVS\.?35_P#P#'_Q
M='L:G\H?VYEO_/\ C]Y[[17@7_#;/PY]-7_\ Q_\71_PVS\.?35__ ,?_%T>
MQJ?RA_;F6_\ /^/WGOM%>!?\-L_#GTU?_P  Q_\ %T?\-L_#GTU?_P  Q_\
M%T>QJ?RA_;F6_P#/^/WGOM%>!?\ #;/PY]-7_P# ,?\ Q='_  VS\.?35_\
MP#'_ ,71[&I_*']N9;_S_C]Y[[17@7_#;/PY]-7_ / ,?_%T?\-L_#GTU?\
M\ Q_\71[&I_*']N9;_S_ (_>>^T5X%_PVS\.?35__ ,?_%T?\-L_#GTU?_P#
M'_Q='L:G\H?VYEO_ #_C]Y[[17@7_#;/PY]-7_\  ,?_ !='_#;/PY]-7_\
M ,?_ !='L:G\H?VYEO\ S_C]Y[[17@7_  VS\.?35_\ P#'_ ,71_P -L_#G
MTU?_ , Q_P#%T>QJ?RA_;F6_\_X_>>^T5X%_PVS\.?35_P#P#'_Q='_#;/PY
M]-7_ / ,?_%T>QJ?RA_;F6_\_P"/WGOM%>!?\-L_#GTU?_P#'_Q='_#;/PY]
M-7_\ Q_\71[&I_*']N9;_P _X_>>^T5X%_PVS\.?35__  #'_P 71_PVS\.?
M35__  #'_P 71[&I_*']N9;_ ,_X_>>^T5X%_P -L_#GTU?_ , Q_P#%T?\
M#;/PY]-7_P# ,?\ Q='L:G\H?VYEO_/^/WGOM%>!?\-L_#GTU?\ \ Q_\71_
MPVS\.?35_P#P#'_Q='L:G\H?VYEO_/\ C]Y[[17@7_#;/PY]-7_\ Q_\71_P
MVS\.?35__ ,?_%T>QJ?RA_;F6_\ /^/WGOM%>!?\-L_#GTU?_P  Q_\ %T?\
M-L_#GTU?_P  Q_\ %T>QJ?RA_;F6_P#/^/WGOM%>!?\ #;/PY]-7_P# ,?\
MQ='_  VS\.?35_\ P#'_ ,71[&I_*']N9;_S_C]Y[[17@7_#;/PY]-7_ / ,
M?_%T?\-L_#GTU?\ \ Q_\71[&I_*']N9;_S_ (_>>^T5X%_PVS\.?35__ ,?
M_%T?\-L_#GTU?_P#'_Q='L:G\H?VYEO_ #_C]Y[[17@7_#;/PY]-7_\  ,?_
M !='_#;/PY]-7_\  ,?_ !='L:G\H?VYEO\ S_C]Y[[17@7_  VS\.?35_\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+&C2NJ(-S,<
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M=0I X./6OF,C!Q6D*BFW%=/U/-QF7U<%&$ZC34KV:=UINOD%%%%:GF!1110
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MJW-T[06,URBS2C9#RJ$Y(X/0=C7SE15RH)J2ONHK_P !..EGE2E[.T%[G/\
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M,.?#W_G\U[_P*B_^-4?6Z8?ZH9GVC]__  #X-HK[R_X8<^'O_/YKW_@5%_\
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MX>_\_FO?^!47_P :H^MTP_U0S/M'[_\ @'P;17WE_P ,.?#W_G\U[_P*B_\
MC5'_  PY\/?^?S7O_ J+_P"-4?6Z8?ZH9GVC]_\ P#X-HK[R_P"&'/A[_P _
MFO?^!47_ ,:H_P"&'/A[_P _FO?^!47_ ,:H^MTP_P!4,S[1^_\ X!\&T5]Y
M?\,.?#W_ )_->_\  J+_ .-4?\,.?#W_ )_->_\  J+_ .-4?6Z8?ZH9GVC]
M_P#P#X-HK[R_X8<^'O\ S^:]_P"!47_QJC_AASX>_P#/YKW_ (%1?_&J/K=,
M/]4,S[1^_P#X!\&T5]Y?\,.?#W_G\U[_ ,"HO_C5'_##GP]_Y_->_P# J+_X
MU1];IA_JAF?:/W_\ ^#:*^\O^&'/A[_S^:]_X%1?_&J/^&'/A[_S^:]_X%1?
M_&J/K=,/]4,S[1^__@'P]H'B/5/"VHI?:1?3Z?=ITE@?:?H?7\:ZG7OCGX]\
M3:>]CJ7BB^N;5QAH]RH"/<J :^N/^&'/A[_S^:]_X%1?_&J/^&'/A[_S^:]_
MX%1?_&JEXBC+XE?Y'33X9SJC%PIS23Z*31\&AB&R#SUS72>)_B/XE\9Z;86&
MM:Q<:C9V(Q;12XQ'QMXP.>!CFOL[_AASX>_\_FO?^!47_P :H_X8<^'O_/YK
MW_@5%_\ &J;Q-)[F4>%<V@G&+23W][?U/AK1]:O_  _?QWNFWDUC=Q_=F@<J
MPKJ_$'QN\=^*=-;3]4\37MU9L,-$6501[[0":^NO^&'/A[_S^:]_X%1?_&J/
M^&'/A[_S^:]_X%1?_&J3Q-&6ZO\ (TI\,YS1BXTY))[I2:N?&.A_$CQ+X:T*
M]T;2]6FLM,O,BXMX@N),C!R<9Z>]9>@>(-1\+:O;:II-W)8ZA;-NBGCQN0XQ
MW]B:^XO^&'/A[_S^:]_X%1?_ !JC_AASX>_\_FO?^!47_P :I_6J5[]27PMF
M[44Y*T=O>V].Q\A0?&GQM;:]>ZU%X@N8]4O8UAN+D*FZ5%& #\N.*YW1?$VJ
M>'=;BUC3;R2TU*)S(ERF-P8]3R,5]O\ _##GP]_Y_->_\"HO_C5'_##GP]_Y
M_->_\"HO_C5)8FC'9?@5/AG.JEG.:=G?63W[^OF?$/B3Q/JGB_5I=3UB[:^O
MY0 \[J 6QZX H\-^*-6\(:I'J.C7\VG7L?"S0-@X]#V(]C7V]_PPY\/?^?S7
MO_ J+_XU1_PPY\/?^?S7O_ J+_XU36)I)66Q#X5S>4_:MKFWOS:W]3XX\7_%
M7Q;X]MXX-?UVZU*",Y6.4@*#ZX  -<I7WE_PPY\/?^?S7O\ P*B_^-4?\,.?
M#W_G\U[_ ,"HO_C5"Q-&.BT^05>%LWKRYZLE)]W*_P"9\&T5]Y?\,.?#W_G\
MU[_P*B_^-4?\,.?#W_G\U[_P*B_^-4_K=,R_U0S/M'[_ /@'P;17WE_PPY\/
M?^?S7O\ P*B_^-4?\,.?#W_G\U[_ ,"HO_C5'UNF'^J&9]H_?_P#X-HK[R_X
M8<^'O_/YKW_@5%_\:H_X8<^'O_/YKW_@5%_\:H^MTP_U0S/M'[_^ ?!M%?>7
M_##GP]_Y_->_\"HO_C5'_##GP]_Y_->_\"HO_C5'UNF'^J&9]H_?_P  ^#:*
M^\O^&'/A[_S^:]_X%1?_ !JC_AASX>_\_FO?^!47_P :H^MTP_U0S/M'[_\
M@'P;17WE_P ,.?#W_G\U[_P*B_\ C5'_  PY\/?^?S7O_ J+_P"-4?6Z8?ZH
M9GVC]_\ P#X-HK[R_P"&'/A[_P _FO?^!47_ ,:H_P"&'/A[_P _FO?^!47_
M ,:H^MTP_P!4,S[1^_\ X!\&T5]Y?\,.?#W_ )_->_\  J+_ .-4?\,.?#W_
M )_->_\  J+_ .-4?6Z8?ZH9GVC]_P#P#X-HK[R_X8<^'O\ S^:]_P"!47_Q
MJC_AASX>_P#/YKW_ (%1?_&J/K=,/]4,S[1^_P#X!\&T5]Y?\,.?#W_G\U[_
M ,"HO_C5'_##GP]_Y_->_P# J+_XU1];IA_JAF?:/W_\ ^#:*^\O^&'/A[_S
M^:]_X%1?_&J/^&'/A[_S^:]_X%1?_&J/K=,/]4,S[1^__@'P;17WE_PPY\/?
M^?S7O_ J+_XU1_PPY\/?^?S7O_ J+_XU1];IA_JAF?:/W_\  /@VBOO+_AAS
MX>_\_FO?^!47_P :H_X8<^'O_/YKW_@5%_\ &J/K=,/]4,S[1^__ (!\&T5]
MY?\ ##GP]_Y_->_\"HO_ (U1_P ,.?#W_G\U[_P*B_\ C5'UNF'^J&9]H_?_
M , ^#:*^\O\ AASX>_\ /YKW_@5%_P#&J/\ AASX>_\ /YKW_@5%_P#&J/K=
M,/\ 5#,^T?O_ . ?!M%?>7_##GP]_P"?S7O_  *B_P#C5'_##GP]_P"?S7O_
M  *B_P#C5'UNF'^J&9]H_?\ \ ^#:*^\O^&'/A[_ ,_FO?\ @5%_\:H_X8<^
M'O\ S^:]_P"!47_QJCZW3#_5#,^T?O\ ^ ?!M%?>7_##GP]_Y_->_P# J+_X
MU1_PPY\/?^?S7O\ P*B_^-4?6Z8?ZH9GVC]__ /@VBOO+_AASX>_\_FO?^!4
M7_QJC_AASX>_\_FO?^!47_QJCZW3#_5#,^T?O_X!\&U]X?L,_P#)'M0_[#,W
M_HF&G?\ ##GP]_Y_->_\"HO_ (U7I'P=^'.E_"W1=6T+1Y+F6R346E#7;AWR
MT,6>0 .WI6%>O"I#EB?29!P_C<MQJKU[<MFM'<[ZBBBO-/TP**** "LK7?O:
M9_U^)_)JU:RM=^]IG_7XG\FIH3V-6BBBD,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "LK1?^/S6?^OS_P!HQ5JUE:+_ ,?FL_\ 7Y_[
M1BIH74U:***0PHHHH *RM=^]IG_7XG\FK5K*UW[VF?\ 7XG\FIH3V-6BBBD,
M**** "BBB@#,U_Q+I?A6R2\U>^AT^V>:.W62=MH:21PB*/4EF 'UK'\6?%3P
MGX%O;:TU[7+73;FX&Z..4DDC.,G .T9[G KS/]K?P7INN^#]!UB:R>YU73-?
MTK[+(LDG[H-?P!SL!VGC/)!Q7F7[0=Q?Q?$?QO:R>((/!]IJ7AZ"TMQ>67VG
M^V7PQ,<+9&Q@6V<;CDYQ2O[M_-K[HI_K_P !E\NMO)?B[?U^A]+>(_BUX/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!P'Q7^)VH?#.#2KBV\)WOB.WOKR"P
M\RSN[>'RIYYDAA4B5U)W/(.1P,'.*ZSPWJ-_JVBVUWJ>DRZ'?2;O,L)IHYGB
MPQ R\9*G( /![^M<+\?_ /D5O#?_ &-WA_\ ].EM7IM !1110 4444 %%%%
M!65HO_'YK/\ U^?^T8JU:RM%_P"/S6?^OS_VC%30NIJT444AA1110 5E:[][
M3/\ K\3^35JUE:[][3/^OQ/Y-30GL:M%%%(84444 %%-21),[&5L=<'-.H *
M*\3_ &HM7\8^'_#6@W_AS6[?2--76]-@U!5A<W4Z27D*;(Y X"*0Q#94Y'&1
MDURW[3?QQ.B0W7AO0_%%GX>U'3A:W>HW,EY'#/M>5-L,0)!)9268CHN/4T+5
M)^=ON2=_Q+46W;RO^-OS/I6BOF77-=U3XA>)/'=Q;^*]2TZQ\+:3;W.F#2-0
M>&*:5XC(99-AQ*,C&&ROM7'Z3X[\5?$SX?\ CGQU=>)=4T/4_#.E6TVGV=C>
M/!;>;]F$SR31+\LH=L##@C .!0_=3<M+:OT?];"C%R:4>NB]=/\ /<^A_P!H
MO_DWSXG?]BOJG_I)+7<Z5_R"[/\ ZXI_Z"*\Q^,&JRZ[^RIXVU*>+R9[SP7?
M7$D?]QGL78C\":].TK_D%V?_ %Q3_P!!%5*+C)Q?0SC)3BI+J6J***DH****
M "BBB@ HHHH \G\1_LK_  O\6:[?:SJOAC[5J5]*T]Q-]ONDWN3DG:LH _ "
MNV\!_#[0/AGH(T7PW8?V;IHE:80>=)+\[8R=SLQ[#O7145;G*2LWH2HQ3ND%
M>9^*/V?/"GB[XP^'OB3?I<G7]$@:"&-'46\OWMC2*5)9DWOM((QN/6O3**A:
M-26Z*W371GE?B?\ 9YTCQ!K6M7UGKVN^'8->(.M6&DS1+!J6%V_/YD3NA*C!
M,3(2.IK=\&?"'0O =YKDVD&XACU:*""2W9U,<*11E%$?RYZ'G<3S7;T4+1<J
MVV^7;_+L#U=V>+6/[)?@FWM([.[DU+5+%=)O=&>VNYDVR074XFD)*(I#!AA2
M",#U/-1W'[*>@ZO87\&O^)?$GB6:;2)-#M+O4IX/,TZT?&Y(?+A52QVKF217
M<[1EC7MM%.[_ *^?^;^]]QWUO_73_)?<CR35_P!G#2+R[O)]+\1:_P"&?[2M
MH[358])FA"ZE&B!%\SS(G*-M&"T1C8CO7I/ASP]8>$]"L='TN 6NGV42PP1
MD[5'3D\GZUI4479-EH%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F
M7Q__ .16\-_]C=X?_P#3I;5Z;7S3^T;^T-X*T^YM?"T]_<+K&D>(]'O;N(6K
ME5B@O(+B0AL8)$:DX'7I7M/PS^*7A[XN:#/K'AJYENK&&Y:T=Y86B(D558C#
M 'HZ\UHZ<TN9K0E3BW9/4ZVBBBLR@HHHH **** "LK1?^/S6?^OS_P!HQ5JU
ME:+_ ,?FL_\ 7Y_[1BIH74U:***0PHHHH *RM=^]IG_7XG\FK5K*UW[VF?\
M7XG\FIH3V-6BBBD,*\D_::\):AXK^'<+:7/HEM?Z9J$&H1S>(IC%9+L)SYA"
MMD8/0C\>*];KPO\ :_MS=?#K1XHM*CUR];7+06NF76!:W4F6PDY/ CQGG!Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(KAOVB_^3?/B=_V*^J?^DDM=SI7_ ""[/_KBG_H(I;ZL$K*R+5%%% !1110
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MHM4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ3GW(KT[2O\ D%V?_7%/_017#?M%_P#)OGQ._P"Q7U3_ -)):[G2O^079_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS_KPT;_T&ZKTFY\W[/+Y!03[3Y9D!*[L<9QSC->5^ O!/Q T?XF:WXDU^_\
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M<,?S!KT_2O\ D%V?_7%/_017#?M%_P#)OGQ._P"Q7U3_ -)):[G2O^079_\
M7%/_ $$4Y2YI.3ZF<(J$5%="U1114E!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !165XA\5Z/X2L'O=9U.UTRU09,MU*J+^IKRBZ_:/D\43O9_#GPIJ?C
M*<';]N*&VL4/^U,X_D.:N,)2V1+DEN>UD@#)X%<+XW^-W@WP 3'JFL1->'[M
ME:_OIV^B+DUQ*_"SXC_$/Y_&_C/^Q-/?.='\,CRSCL&G;G/TX-=WX*^#'@[X
M?_O-'T2W2[)W->SCSKAV[DNV3D^V*OEA'=W]";R>RL<)_P +(^)GQ&&WP?X4
M7PYIS\+JWB$[6Q_>6(<D5X5^T=^RYXN;2=>^(&L^,;?6SI6E27=PDT+)(1$K
M.8XP!@+Z9]3FON:O,OVG/^3=?B7_ -B]??\ HAZJ-9P=X*PG24]):G)?LM_L
M[:M\!6\3'4]5L]3_ +5%L(_LBN-GE>;G.X#KY@_(U[U1164YNI+FEN7&*@N5
M!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %96B_\?FL_P#7Y_[1BK5K*T7_ (_-9_Z_/_:,5-"ZFK1112&%%%%
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M%<1R7=NJM-"K9:,-G:2.V<''TH%=(M4444#"BBB@ HHILDB1*6=@BCJ6.!0
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M['2LRPDOAJ)^AZS17D[?'2]DXMO /B*=NX,2KC\S44OQL\2M@6GPM\07+?Q
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M%>EG]GVW7F'Q;XDAD'1Q?,2/SJ91@G92-Z&)QE2E&<Z%FUJN;_@'K%%>3?\
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M%S_X%R?XT#]G/P-GYM.GD7NKW4A!^O->FT4<\NX_J&$_Y]1^Y'FW_#.OP_\
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M"?\ X)X/_B:/^&8_A%_T3+PG_P"">#_XF@#TVBO,O^&8_A%_T3+PG_X)X/\
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M9C^$7_1,O"?_ ()X/_B: /3:*\R_X9C^$7_1,O"?_@G@_P#B:/\ AF/X1?\
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M $3+PG_X)X/_ (F@#TVBO,O^&8_A%_T3+PG_ .">#_XFC_AF/X1?]$R\)_\
M@G@_^)H ]-HKS+_AF/X1?]$R\)_^">#_ .)H_P"&8_A%_P!$R\)_^">#_P")
MH ]-HKS+_AF/X1?]$R\)_P#@G@_^)H_X9C^$7_1,O"?_ ()X/_B: /3:*\R_
MX9C^$7_1,O"?_@G@_P#B:/\ AF/X1?\ 1,O"?_@G@_\ B: /3:*\R_X9C^$7
M_1,O"?\ X)X/_B:/^&8_A%_T3+PG_P"">#_XF@#TVBO,O^&8_A%_T3+PG_X)
MX/\ XFC_ (9C^$7_ $3+PG_X)X/_ (F@#TVBO,O^&8_A%_T3+PG_ .">#_XF
MC_AF/X1?]$R\)_\ @G@_^)H ]-HKS+_AF/X1?]$R\)_^">#_ .)H_P"&8_A%
M_P!$R\)_^">#_P")H ]-HKS+_AF/X1?]$R\)_P#@G@_^)H_X9C^$7_1,O"?_
M ()X/_B: /3:*\R_X9C^$7_1,O"?_@G@_P#B:/\ AF/X1?\ 1,O"?_@G@_\
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M0 5E:[][3/\ K\3^35JUE:[][3/^OQ/Y-30GL:M%%%(84444 %%%% !1110
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M WF>8D;NA_>01G<K%21D<-7UK3<>7[VON?\ E8E.]O-)_I^:84445!04444
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M4?V%_P!1&_\ ^_W_ -:M2BB["R,O^PO^HC?_ /?[_P"M1_87_41O_P#O]_\
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M_L+_ *B-_P#]_O\ ZU']A?\ 41O_ /O]_P#6K4HHNPLC+_L+_J(W_P#W^_\
MK4?V%_U$;_\ [_?_ %JU**+L+(R_["_ZB-__ -_O_K4?V%_U$;__ +_?_6K4
MHHNPLC+_ +"_ZB-__P!_O_K4?V%_U$;_ /[_ '_UJU**+L+(R_["_P"HC?\
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M /?[_P"M1_87_41O_P#O]_\ 6K4HHNPLC+_L+_J(W_\ W^_^M1_87_41O_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW(5DE9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>apre-20251231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $B 9T# 2(  A$! Q$!_\0
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M6?#MG)>7NF6%ZDDJ*JEL'&<9QC/.,TFTDY=!I-NQZ)17QE\._P!NSXD_$?\
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M5=_: _:1UOX>^"_A[JO@+PS!XVO_ !G>QVUA9RW0MPR/"9E.[!'04 9>F?\
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M-UW1CI\]_>7;7&H>&KGR]K/#)(Q(C?)R .#7V%>WEOIUL\]S<1V\*8#22L%
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MV'7R]^WU\9=?^$_P_P#"=AX9DO+;5_%GB*UT-;G3T5KB.-\LXBW<>8P7:I/
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M=1RC I:04M>BCF"BBBF 4444 (:\2_9._P"1.\8?]CGKG_I8]>VFO$OV3O\
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M-)G@8)4E>2*^CJ*=WM_78-W?^OZU/G?1/V9]9TK6]1UO^VK!=0N]9T_5Q#%
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MC[0?#EG'/K6K6.EK@9$]PJX..1UKSGQ)^V-\+M #"/7_ .U9!QY>F0M.V?\
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M;3]:UG2_CGXE\-F.PTOQ+XTN;_P]<7UNPADC"1H\P3@[6*MCUQF@#L_B8?\
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M&E.'/)1NE?N?2;SLA7Y<YIDMZD&3(RH@ZLQP!7REXD^$O[1>NHTL7CG3K9I
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MLK/HVI-IV\T>>>'O^";>@VJ@:AXENI1GGR(52O0[+]AOP1:6T<5SJNN7JH"
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MG7; V<S>#+*)R&,MI)=&3@YQ\Q(Q6[\+/V>OCM\%H9(?#6K^$YHI<Y34(I&
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MOB-IZRP^-O%'Q$U73=;NA,Q>]MWNKE&CD!."JK&F!VQ0!^F5%(.E+0 4444
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M?FK#W:2\_P +/\F<MX\_8D\,^//'J^*9_$.MV,]Q;V%OJMI:3!8=6%HP:,W
M_B)P :^BU0+G'>O!]=_:WT/PWK^E:-J.DW4.I3V5C?7MLC>8]HEU)Y<0 4'S
M"#RV.@YJM9?MB:&;DR:GHE[IFDF3684OVD5PSZ:3YWRCD J,J?PH::O\_P -
MP6NWE^.Q]!T5X7>_M4Z;H]E.FI:%=VFLO!I]S8Z;YJL;J.]E\JW._HI+\$'I
M5/3OVKX]3\5Z?X9B\)WBZU=Z_?>'S$]R@2.6U@6:1RW]TJV!]*?*V[?UTO\
M==7$VDKO^M+_ (K8^@**^7/'O[84@\.?$.T\.:-)'KVC^'[K6=.NI)5>">.*
M4PL^0,95N<<YKL?V=OBKXF\:Z]XF\-^(-.$?_"/6FFG^T'G5Y+B2XMA,VX*
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M +./@?10YAL)I9GOK74&GGG+R&2V8M -W]U"3@>]>GT47=[]?\M@Z6/-K?\
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M5SQG^R!IGBCQRVI6WB"]TKPYJ T_^V?#\**8M0-EC[-ECRH 4 XZ@"O&]?\
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>apre-20251231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %B 88# 2(  A$! Q$!_\0
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M_9W\2ZI=?"KXZR7VJW<US9:UJ*0O/<LSP*$.T*2<J!VQ7E?PQ^.WQG2+X3>
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M,7.0CEN_R]C7T?1)KD@ET3_%MK\&B$GSR;\OP23_ !04445F6%%%% !1110
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M%3U+_OW1_P ,]>.?^BIZE_W[KV?_ (33P]_T'=,_\#(_\:/^$T\/?]!W3/\
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MC"*VC'T_%ZG&Q_!GP%$X=/!FA*X.0PTZ+.?^^:Z^*)((TCC18XT 5448  Z
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M<&U<6DDRYS$LV-I<8/%>O:Y:2W^BZA;0.8YIK>2-&'9BI /YFOS$^$-A\3_
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MTUAZ&M6>B7K_ %^I]=E5/#99A*G$69PYJ-)J,(=:U9_!37EUF^D5J=Q^R3\
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M_AN[T/N*BOSTTWXP?$VVO='^+DWCJ]N-$U/Q>GA]_!K1)]CCMFG6+<IQG?\
M,3FOJCXF_M*6?PQUV/2Y_!GBS6W>%9?M.CZ;Y\//;=N'-7ROD4W_ %HG^30F
MTIN';_-K\TS@/BM_R?'\(?\ L$:E_.&OJ*OAFW^,]M\7OVW/AA+;^'-?\/\
MV32=0!77++[.9,F'[O)STK[FJ!A1110 4444 ?%W[2&AVMOX_P#B:DFBN][K
M?AF&.PFAL&D,[K*ID4.JG#8]2,U5^*7P_F\+^(?AI?\ G'POX'BT3RKF6UT"
M/48X;TH,-- 5/)&1NVD@FOMNBB/NQ45T_P#MO_DOO0Y/FDY/K_E%?^V_B?%@
M$'P\\"^&8S#>>*/#VHZS//)KGB'1&$6G*<$&.TB!^5CG;E<#T%<)HWAZ6?X>
M?%!KO2+B]TV'Q7:ZA;J^CF%/L^Q-TD4(7A>#]T9]17Z'45I&?*V_3\'%_P#M
MOD1**G'E>VOX\W_R1\$:G\/=/\2?"_XW:G!X<>XGN_$$$FGR_8764Q?N\&(%
M0P&"?NXKHO''@'7K'QYXDT[P1ITVDM>^ 1\UI 422X$L'4XP9-N_KSR:^B]#
M^..EZ[\;==^&L5G<)JFDV,=_+<MCRV1V( '?/!KTJHOKIM:W_DO+_P $K?7S
MO_Y,I?I8^%_ 7A&UU1[2YLO%.MW^K:;HUU%=:9:^%H]/B1C RF.YE55,ASTQ
MNR<5I>&/A\OASP%^S_<Z=X?>RU)M35-1FBM"LQC;.X3'&=I]&XK[6HK3G\NJ
M?W-O\;D<ON\ODU]ZM^!X/^R;;6&BZ%XKT5-/_LW5K77+F2YA-H824=LQG=M
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M']14?_#,_P */^B>^'O_   3_"H<:S^VON_X)T*M@([4)/UG_E%'YDP_M/\
M[7/B8%G\;^&+%2V"87L4"_\ CPKSCXY6_P"T%\2O!UU%XM^*MAK>E?+YFD1Z
MO L4A!)#%%;!ZU^OO_#,_P */^B>^'O_   3_"C_ (9G^%'_ $3WP]_X )_A
M4NC5O?VK^Y?Y'0L?@E9?4XV_Q3O_ .E6O\OD?STVWP1\0)<#>VDRA<94ZC&
M?UK]$_@'^SSI%C\/=*>^^,GA[P9-/$&FTRQO8P\9/4,P;DU^@?\ PS/\*/\
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M*))+%[ZW5)L=FP<XKZ M]3_9ZM7#Q7_@A&'0BX@_QKIO^&9_A1_T3WP]_P"
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MRB_^*KH?"_COPYXV29_#^NZ?K2PD"0V-RDNP^^TG%<A_PS/\*/\ HGOA[_P
M3_"NH\'?#?PM\/8[B/PUH&GZ&EP0TJV,"Q!R.A..M '24444 %%%% !1110
M4444 %%%(QP": ,6^\)Z#J'B?3]=NM/M9M<L(I(;6\=098D?&\*>P.U?RK;K
M\T_'JWFH3>/_ (NR>)-8M/&_AWQ='I>G6L6H2) MMY@7RO(SA@P.>F:_2+2[
MB2\TRTGE79)+"CLOH2 33BN:FI^GXI27X/[Q2]VHX>OX-I_BBU1112&%%%%
M!1110 4444 %%%,E#-$X1MCD$*V,X/K0!G^(O#^E>+-)N=(UBS@U&PN5VRVM
MPH97'N*MVL5O90Q6EN(XHXE")$F!M4#  %?&_AJP\3>$OVZ[FUUGQ9?^)9)O
M"TUXL<W[N"$[CM1(UX  P,]37CVF&^LH=$^,L7B36)O'E]XV?2;BS;4)&MS:
M_:#'Y/V?.  H!Z9YJZ<?:.'G^'O<B_'?R[BF^13M]G\?=YW^&WZ'Z8T4R%B\
M,;'J5!/Y4^H!:A1110,**** "BBB@ HHHH :\B1#+NJ#U8XK)T7PSHOA=]0G
MTRQMM/;4;AKJZDA4+YTK=78]R:^:OVT?!&D^(KC2[WQ=XJU.'P]' \5EX5T.
MXD@O-1O6(V%61AG'OP,\UY#JO@?Q1K9^#7PC^)'B351IMW875[?2VVH/#-(Z
M >5$\RD%BH/KSBE&\HWZWM^;^^RO;S6NI32B_*U_R_5V];]C]"@01D'(/<4M
M?.O[#'B'5-9^$%[8ZEJ%QJT>C:Q>:99WUU(9))K>*5DC)<_>^4#FOHJKDDGI
MMH_O5S--ZI[IM?<[!1114E!1110 4444 %%%% !TK'N?#.B:GK]GKDUC;7&K
MV*/%;WA4&2%6^\%/;.*Q?C#<6-K\-/$#ZEXDF\(V/V8K-K5N,R6BD@%EX//.
M.G>O@NV9OV:]9\?6GA7Q-J]S::IX1?4=(:?4I-0%[(=N^\8MS"^&)"CBIO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>apre-20251231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %& Y4# 2(  A$! Q$!_\0
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M_P#$4?V=B?Y?Q7^8?V;BOY?Q7^9^B%%?G?\ \/1M>_Z$/3__  8/_P#$4?\
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M]FXK^7\5_F?HA17YW_\ #T;7O^A#T_\ \&#_ /Q%'_#T;7O^A#T__P &#_\
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MFKKY'Z(45^=__#T;7O\ H0]/_P#!@_\ \11_P]&U[_H0]/\ _!@__P 16_\
M9V)_E_%?YF_]FXK^7\5_F?HA17YW_P##T;7O^A#T_P#\&#__ !%'_#T;7O\
MH0]/_P#!@_\ \11_9V)_E_%?YA_9N*_E_%?YGZ(45^=__#T;7O\ H0]/_P#!
M@_\ \11_P]&U[_H0]/\ _!@__P 11_9V)_E_%?YA_9N*_E_%?YGZ(45^=_\
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M_P#!@_\ \11_9V)_E_%?YA_9N*_E_%?YGZ(45^=__#T;7O\ H0]/_P#!@_\
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M9N*_E_%?YGZ(45^=_P#P]&U[_H0]/_\ !@__ ,11_P /1M>_Z$/3_P#P8/\
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M_H0]/_\ !@__ ,11_9V)_E_%?YA_9N*_E_%?YGZ(45^=_P#P]&U[_H0]/_\
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M@@X]ZE5(--IHGVD+7YE8Y.BNJ\6_"KQEX"MHKCQ)X6U?0K>5MJ2ZA9R0JQ]
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MNJX7_@IU_P EM\.?]B]%_P"E-Q7@Q_Y&4O3]$?/P_P"1G+T_1'Q_1117O'T
M45J^&/">M>--573- TJ\UG464NMK8PM+(5'4[5!.!6=<6\MI<2P3QM#-$Q1X
MW&&5@<$$=B#2NKV%=-V(Z*T]%\,:OXCCOGTO3;K4$L83<W36T3.(8@<%WQT7
MD<FLRG=7L%TPHHHH&%%%% !1110 45<L=%U#4IK6*TLKBYDNI!# L498ROG&
MU?4^PK1U/P%XDT;3;O4+_0M0L[&TN_L%Q<SV[+'%<8SY3,1@/CG:>:3DENR>
M97M<PJ**NZ-H>H>(M02QTNRGU"\=698+:,NY"@LQP.P )/TIMV5V-NVK*5%:
MOAGPGK7C354TS0-*O-9U%U+K:V,+2R%1U.U03@4:1X4UGQ!KRZ)IFE7=_K#.
MT8L+>%GF++G<NP#.1@Y^E*ZO83E%7N]C*HKTC_AFOXKC_FG/B;_P5S?_ !-9
M^A_ OXB>)K$WFD^"->U*T$CPF>UT^61-ZDJRY Z@@@BH]K3_ )E]Y'M:=K\R
M^\X>BMGQ3X+U_P #WZV/B'1K[1+QEW""_MVA<CU 8"L:K34E=,T33U045H7G
MAW5-.TVQU"ZT^YM[&_W&UN)8BL<^TX;8QX;!XXKN%_9M^*SJ&7X=>)BI&01I
M<W/_ ([2<XQU;(=2$=VCS>BN_LOV?OB9J1N!:^ O$5P;>4P3"+396\N0 $HV
M%X(R./>J&L_!SQUX=U'3=/U3PAK6GWVI.8K*WN;&1)+EQC*H",L>1T]:E5(-
MV4D"J0>BDCCZ*[CQ!\#?B'X4TN74M9\$Z[I>GQ$"2ZN["2.-,D 98C R2!6)
MI7@;7M:\50>&[;39O[;F?8MI,!$P.W<2Q; 4!0222  ,TU.,M4Q\\+<U]#"H
MKH/&'@36? MQ:1:O!"@NXO/MYK6ZBN89DR1E9(F93R".#VKGZI24E=,I--70
M5]B?\$R/^2N^(_\ L$'_ -&K7QW7V)_P3(_Y*[XC_P"P0?\ T:M<6._W:9PX
M_P#W:9^EE%%%?$'PP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7YY_\%2?^1G\ ?\ 7G=_^AQU^AE?GG_P5)_Y&?P!_P!>
M=W_Z''7IY=_O,?G^1ZF6_P"\Q^?Y'PW1117V1]H%%%% !1110!]7_LM:3XF^
M'OPNUOXB^'/#>J>(-:O-1@TRRBTRRDN9%@1A)<,0BG (PN3ZFM75OAX? /[>
MGA:6*VEM=/UZ^AUJUBFC,;1B8,7C*GD%9 XQVXKQCQ9^T-JT_A'P=X:\'W6J
M^$M+T*P\F86=\\37ERQW23,8]O4] <XS72Z/^U,C1_#&\\0Z7>:UXA\&7TLC
M:I)=YDO+9B2(V+ G<"1\Q)X%>:Z=7VKJVWNO.UK+\4G\V>+*C6:G*VLU*Z^7
MNW]%I\SV#3/#FJ^!OC;<^*M=^//A2+P_9:C-=7&DP>)GNKEHMQ)@^S$ %B/E
MV\XIOP_B?XB?LY?$^?PUXETSP'%>^,Q<6^H:KJ)TZ".,JA"&0#(+#HO>OC;Q
M?KB^)O%6KZND1@2^NY;E8F.2@9BV">_6NXTCXP6VF?L]Z[\.&TV5[K4M8BU-
M;\2@(BHJC85QDD[>N:R>%G[*/\WNKII:2;];6_JYO4PTN923N[KHME?I\SWS
M6=#USX??LL^/4USQ?IWQ1@UB[M+2VET35#J5OIDH?=YLDK8*$\  #KCUKY]\
M;_L_>/\ X4Z%9>(_$N@0V6E331I%*;ZVN [,"RJ4CD9L$ ]15KX<?%W3?"7P
MH\?^"]3TNZO8_$J0&&XMIU3[/)$V]2P(.X;@N0,<9KRRNJE3J0G/7=K6VZLO
M/1[FM"G4@FI;7?3?16:UT^X^G/'_ (KN/%W[&7AZZN+.PL3#XDE@2+3K98(P
MJQ#'RKU//4\U9^,_CC7?A+H'P4T?PIJ5UIEA#X?M=7864A1;JYE.YV?'WN>,
M'/6O(;OXK6]S\!['X?C3Y%N;;5Y-3-]Y@V,K(%V;<9SQUS7:^%OV@O"-QX3\
M*:=X\\%3^)M2\*@QZ7>6]]Y"M$&W)',NT[E4XZ8X%9^R<)<W+=*=[=URV_,Y
M_8RC%>Y=+GTTZO1_=I\SVOX@^(/ GPQ^,?Q9_MO7M0\-3^(M)T^2)-$MF>[\
MR1$DG$;#"(Q*@_.R_?[UXI\:?!L$'@GPO\1?#?B_5O&GA"ZO'LA;>)R7N+.Z
M5=S1R)N*D,H_A]!R<BJEA^T1I/B3Q#XPN_B)X0M_$]EXCG2X)MV6"[LB@VHL
M,Q4E5"A5QT.T5C?%KXS:9XO\(Z%X,\)^'SX9\(:1-)=I;33^?<7%PXP9)'P,
MG' P.]8TJ-2GR*SNK=K6MJN^FWXE4J-2$TM?[STL_=MIUW2_$]#^-?B>X\7?
MLD?"V_N;6RLW_M>_B$.GVZP1 +P,*O&<#KWKRW6?'EOJ_P "=&\.7&J3W>KV
M6LS7"VLWF-Y5N845=K$;0,@_*#^%-\2?%>WUWX'^$O ::?)%<:)?W5X]Z9 4
ME$IX4+C(Q]:\XKKIT;<Z:LN:Z.BC1Y81YE9Q<FOFY?HPHHHKL.P**** "O1_
MV;?^3@?AS_V'[+_T<M><5Z/^S;_R<#\.?^P_9?\ HY:RJ_PY>C,JO\.7HS]+
M?V[O^34_''_;C_Z76]?D77ZZ?MW?\FI^./\ MQ_]+K>OR+KRLI_@/U_1'DY1
M_ ?K^B"BBBO:/;"NC^''@ZZ^(/CO0O#MFA>?4;N.  =@6Y/X#-<Y7HGP0^*5
MM\(/$NH>(&TU]0U0:?-;::ZR!5MIY!M$IX.< MC&.M3)N,6XJ[,:W/[-^SWZ
M?UY'UM\:/#&N_$OX4_$7P[<>%=8T>P\#S0:AX;NK[3I8(KBVBC\J9$9E 8E0
MSX&<Y'I7BO[._ACX:_$6&/3]:\ Z@XTRW:ZUSQ1)X@:VL[6%<DR%/+(!QP$!
MRQ_$CC_A7^TQXL\$>.+75M=UG6/%&C,DL-[I-YJ,DD=Q%(A5AAR5!&00<=J[
M2W^/OPH/PTA\%S^ M?@TO[2UW=#3]82$W<F[*&4^62P48P.@Q7E*C5HQ<$KW
MMJGUV;W79/S9YOLJM./L8IVOHT]EUZK6_?37RL;WPN_9Z\)?%:_\8^+?#7AG
M5M?\)6%XMEI6@)JD-G/<';DRR3S,-B\9QR>>E=8?V.O# ^)'@ :AHFH>'M*U
MZ2XM[[P]<:K%=RV[QQEU9+B%CN4_GQT%>(>&_C7X,T6V\1>%KGPA?:A\.=4F
MCNH=-EU "]M)T7 =)@N,G)_AZ5K>&OVE/#'@GXE>$M7\/>!TTOPYX>CE5;59
M4:]NG=2"\L^W+'G@8P*)0Q%_<;M;3_P'KKO?R^9-2&*?-RM];?=IUW[Z?,V8
M?A7\+O'W@;XAQ>$-+UJRUWPC&)H]3OKP.E^/,V$&$#$>3T&3QU-2ZI\-O@_\
M,/%&A?#WQ5IFN:UXHO(+<ZCK5E>B&*QFG4,B)#@^8%#*221U[UYI\/?C7;^"
M=&^)%D^F37#^*[4V\,B2A?LQ,F_)X^;TXQ7</^TMX)\27NB^)O%OP^FU?QUI
M5O'"M_;W_E6MTT0 B>:+:22,#H1TJN2M%V=W'2^NNW^?3]#6I"LI22NXZVUU
MVC9OR^+_ ".H\&_LN^'-)G\=VE_I=U\1?$6A:N+&'P[INK1V$_V4H&%T=W+9
MSMVJ#R#[UE> OV:-%^)'Q>U^QL=!\3:3HFAZ<M_=>']6\NUOWF8X6W221@NQ
MCDB1L<#W%<GHG[0OA[7H]<7XB>#SKES?ZJ=7@U31YULKZWE/6,3;23'Z#M6O
M?_M>#4/'<]U/X<^U>#;K1!X?N=%NKHR33VH)8,TQ&3("20WO2Y<4O6WRORKS
M[^7SL1*.*]ZU_P"FMM>U[?#]^IU_Q8_96TO1? MMXGC\)ZAX$GMM5M;.YTJ\
MUNWU);J"614\Q)(F)5@6'! ZUW_P]\*_"_X4_MD:9X.\/>'=4?5;;S2NI7&I
M$QPLUN6VB/:=PVY&2>K>U?,GBOXM^"TTK2M(\$^"/["L+?4(]0N[O4)UNKZ<
MH01&LNT;$]AU[UMS?M-V_P#PU(GQ9AT.46@EW-ICS@N5,/ED;\8SSGI2]E7E
M%QDW9J?Y)*^KZWZF<Z%>I3E&5W[KMKUOIU?3N_4[[P+X<\.ZHEMXKT2TU'28
ME^(5E:P:?-J+S1(A8;BPX5F+ D-C(!Q6SXT\'_"/XH_M$>,/ W]GZW!XNU"_
MNRGB)KL"!;S+-Y0@Q]P'Y=Q.3CI7E.G_ +1'ASP]8MINB^&K^WTU?%-MXAAC
MN+Q9'5(P-T1;:,DMD@]LUOZI^U1X*'C/6_'FC?#V>P\>7IF$%Z^H;K:$OD"4
MQ!?]9M/)S@GG%9NE6O=)[-+77X86Z]T[ERIUN>4HIW>VO]YM7UUT?F>!^'?"
M[:MX[T_P^Y^:?4$LW(..L@4_UKTW]H76]6L?C_JVD^&Y[W3SI!CT+3X=/D:-
MUBC 4(NP@_,V3CN37DNC:_<:1XELM:5BUU;W276<\E@P:OIS5?B7X5^&?Q[G
M^)]_X?G\3Z7XGT\:CI$MM.L9MKA\+,V64C?&X=<=1D'TKT*CE&<&U?27S>EO
MPO\ B==9RC4;C&^FB^:O^GW,J>,OB)K?[/'@*X\)#Q'?ZM\1->MU_MBXGO9)
MTTBW89%M&"Q'FM_$W;I].^O-0TCQG\+/A?\ "KQ \-I!XA\/>=I&IR\"SU)9
M9!%N/]V3[A^HKP_6_'_P1UJ:]O)? OBV;4KDO(US/XA1R9#D[F_=<\UR'Q)^
M*<7CC0/ EA:V4MA-X:TW["TS2@^:WF,X=< ;>OZ5R^P=1)2BTV[MZ=I6MKT=
MK?\ #F"P[DXM*S5W?3?2ST>W2W;0]>\1_"[Q/JGP#\ ^"+;3&;Q./$VI6OV&
M65(?WB(I8;G95 PI().#VZUA>$/V6[_PKKNLW7Q6L9]'T31-,.JW%M87<$TM
MTN\(L:O&[*N6(')S63\:/VD6^,GPU\)Z#>:2;;6M*D:6]U(2 K>N45-Y7&0Q
M"C)SS7*?!GXK1?#'5-4CU+2EUWP[K%H;+4M-:3RS+&3D%6[," 0:TC#$<DMD
M]?GYIWT\KIEQA75%+;5W2WUDV[.]MMM/F=N/&OPO\,W'A[QOX"T>YT[Q/I=^
M?,\+:U++>Q3Q[?EG6954<'^$D'ZUZO\ ##Q!-XX^''Q*U&/X@-XX\6:SHDDM
MSX.O4F@2R^;<[(T@*RE .!'@<\GI7EMG^TAX<^']_P"'C\.O \>BVNGWC7=U
M/J<RW5Y>!AM,1F"@JF#T%2O^T%X$\)P:_?\ @'P'=Z'XFUFWDMGOK[4OM$5J
MDF?,\E HQG)')-8U:4YP:47KM=I_)WZ/?1W]-$9RI3DU:+O=:MIZ*5[/KITM
M\[EG2M&T_P 9_L[^#/%&L:A+H[^&/$W]A7.JPAC(EC(HE4C:"Q,;$@8!.&-<
M3\;?$FDZA:Z5I/AO5]%N_#EC+,]M::8E[YP9]NZ:X>Y@CW.X4?=)QCMWV/&^
ML+X'_9O\*^!2^-6US4&\3:A%WAB*>7;JWNRY?'T]:\0KJIPYIRD]E)V^Y7_&
MYTX>G>U3S=O2[L_N>GD%%%%=IVA1110!]]?\$K_]5\3?KIG_ +=5PO\ P4Z_
MY+;X<_[%Z+_TIN*[K_@E?_JOB;]=,_\ ;JN%_P""G7_);?#G_8O1?^E-Q7@Q
M_P"1E+T_1'S\/^1G+T_1'Q_1117O'T!]4?LMZ-XF\"?#+Q)\1_#/AW4M?U^:
M[@TO3HM-LY+EU0.LD[$(I(!50N?]JK_Q4_9WB\5?M816LB7&B^'O$UM_PDDP
MEA,4UO$4WW$95N0X8-D$<;O:O)/$O[0>JGP3X0\,>$+G5/"EAHMJRW+6=\T3
M7EP[9>5C'MX[ '.!74>'_P!KC4=*T;P3)?6,VL^)?#=S<*VIWUP9/MEE-]^"
M0MEB>>#GL*\N=.NZCK0WU2]+67XI/YL\=TL1%RJ16LK^OE]R5O5GI'PDU+X8
M:EX;^+0\#:'K&@WMMX=N(F&H7@N4NH=Z_O.@\ML@?+R.>M9'PP^!?@3Q+IWA
M+3E\">-O%3ZS;HU]XNM(KBUL=/F?.44/$%D5.,MNP>Q-<S8_M%?#OPGI'B^S
M\)_#R\TJ7Q)I\MK/<7&I"9HF8@@(-HQ&.>.O3FMM_P!LW29H] U&7PQJS:YI
M5M;VPM4UJ2/22(NC_9E !;ZD\XK)TZUVXIZVW>NE_/:[[_AH9RIUUS>S3U;M
MKY12OKZ]7YIG)^*O@7HMG\,_&SZ3YMSXK\%^(UL;^3S"1<64I9(I!'T4AP 2
M/0UU</[.W@FQUV^_M=K^+2/!GAN'5/$WV:7,UU=R\I!'DX3J%/N/?-<IX>_:
M4TCP[\<O%7C"/PU/=>&O$<,D=]H=Q<AF9F*ONW[<<2*".. 2*QO!'[1EQH/Q
M \8ZQKFEKK^B>+HY;?5]+DD*&2)F)7:_9EZ UHHXEQWUM?YV2M^;[7:['1*.
M(=][+SU:;3?S2NEZHZ2_^&OPX^)GPXE\8>#[:_\ !4.E:M:V&K6^J7GVN-8)
MG"B='V@Y7.2,=,UU?QD^!/@OP/X=U@67P_\ %GV*WMR^G>,].U"/4K2[8 $/
M+&GRPQMZDY'I7GNO?'[P]HWABT\-_#[P@=$T?^TH=4OEUBX%\][)$<I&^5"F
M/U7'-=)-^U!X,T.S\37?A#P+>Z#KOB"SEM;B,ZENTV(RKM=H[8* #UQGI2E&
MOO%.UW97UV6[OWOWTW1*CB%.+UMZ]+]=>WK\F>F^&/V+=.TK1?#MKJW@35_%
M5UJ5K#<W^N6?B&TLHK!I #LC@=PTNP'DG&>V:XG0OV>O W@L_&9O&45]KD'@
MJYMA:&PN?)>>.0,P4D9 )&P$\XYQ7+Q_M$>"?$L.A:IXY\ 2^(_%^C6D5I%?
M1WWE6UVL0Q&;B+:=Q'?!&:YC1_CS%:>"?B=HUSHT:W/C*:&5&L0D%O9[&8[1
M&!]W#  #'2APQ+Y]7_4EMK_+?HOF13IXEQM-N_NW^_6VKTMZ>A]!RS>"?$O[
M./P=L+7PYJ.G6VH>)9;>S*:JQDM9/-_>R;@H+;AG XVYZ\4_6]-\%^#O@/\
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M9C\Q4C//-8GBGXK_  5\9^(+_6]8\#>+KW4[Z4S3SR>(4)9C_P!LN !@ =@
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M:Z1;^*]7M)=6O'NKZXBO9(U13\TLI 8#@ _I7I%C\?='UG]I30=3UO6KC3_
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MI^./^W'_ -+K>OR+KRLI_@/U_1'DY1_ ?K^B"BBBO:/;"BBB@ HHHH ****
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M[%?\_9?^!/\ S-K_ (3;7O\ H+W?_?TT?\)MKW_07N_^_IK%HHY5V#Z]BO\
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MAV@_] 73_P#P&3_"M&P_X\;?_KFO\JGKYZ[/Z4YGW,?_ (0[0?\ H"Z?_P"
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M&WFOH6MI6UMW=O3I^-_E8YXWT]%?UUO^%@HHHK,T"OSV_:9_Y+AXH_ZZ0_\
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M^M)6_'E^>NQ53X5R[Z_G#].:WX:G7_L^>/M3\3/XX\.:U<O?ZCX3UV73!>R
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MI+]A;_DI.K_]@X_^AK7/B/X4CZ+AW_D:T/7]&?<U%%%>$?T&%%%% !5;4?\
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M_17L'_#*'Q%_Z!=O_P"!24?\,H?$7_H%V_\ X%)1[:G_ #(/[&S'_H'E_P"
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MJ*]>_P"&4/B+_P! NW_\"DI4_92^(JNI.EP8!S_Q])1[:G_,AK)LQ_Y\2_\
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M%B4D@ +DD]JY*W^,'@>[\0?V'#XLT>76-VW[$MXADSZ8SUYJ]W8R\SL****
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M444#"BBB@ HHHH *DM?^/B+_ 'A4=26O_'Q%_O"@#4O_ /CTD_#^8K'K8O\
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M/WGB+3+;6YL>7I\MTBS-GIA2<\T;V\P>E[]#I:*** -#2>DOX?UJ/5/]>O\
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MX\8QVEK-9V<-W;1Q+%'*FQRVW[[E.-QQU/'-+HT_ZTM;_@^?JG5]OZ[:_P#
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MO+.QVQ)^+E:Y'2?V;_#/P]U?QWXD\):9::/K6NVBQVITK3K:%]/9(2@^SG:
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M0_\ ?9_PH L4AZ&H-UU_<A_[[/\ A2%KK!^2'_OL_P"% #K#_CQM_P#KFO\
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M (4;KK^Y#_WV?\* +%%5]UU_<A_[[/\ A1NNO[D/_?9_PH L57OO]0/]]/\
MT(4;KK^Y#_WV?\*@O&N?(&4BQO3HY_O#VI 7Z*K[KK^Y#_WV?\*-UU_<A_[[
M/^%,"Q15?==?W(?^^S_A1NNO[D/_ 'V?\* +%%5]UU_<A_[[/^%&ZZ_N0_\
M?9_PH L457W77]R'_OL_X4;KK^Y#_P!]G_"@"Q15?==?W(?^^S_A1NNO[D/_
M 'V?\* "]_U2_P#72/\ ]#%6*H7;7/E+E(L>8G1S_>'M4^ZZ_N0_]]G_  I
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MF!\JD@$@8!Q6K5SES/YM_>V_U%U^[\$D%%%%9C"BBB@ HHHH **** "BBB@
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M_P!0/]]/_0A5BJ]]_J!_OI_Z$* +%%%% !1110 5X1\'_P#DY'XU_P"_IO\
MZ(->[U3MM'L+*^NKVWLK:"\N]OVBXBB59)MHPN]@,M@<#/2A:._E;\A/56+E
M%%% PHHHH KWO^J7_KI'_P"ABK%5[W_5+_UTC_\ 0Q5B@ HHHH **** /!OV
M8/\ D:OCE_V/=S_Z2VU>\U3L-'L-*DNY+*QMK-[N8W%RUO"J&:4@ NY ^9L
M#)YX%7*=_=BNRBON27Z ]92?=M_>VPHHHI %.M/^0G:_\#_E3:=:?\A.U_X'
M_*DQK<WJ***DT"BBB@ JMJ/_ "#[K_KDW\C5FJNJ('TVZ!R!Y3="0>GM0!CQ
M_P"K7Z"G54CL(BB_--T'_+=_\:=]@B_O3_\ ?]_\:LR+-%5OL$7]Z?\ [_O_
M (T?8(O[T_\ W_?_ !H LT56^P1?WI_^_P"_^-'V"+^]/_W_ '_QH LT56^P
M1?WI_P#O^_\ C1]@B_O3_P#?]_\ &@"S15;[!%_>G_[_ +_XT?8(O[T__?\
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M_P!<LO\ Y)_='_Y(_0NBOST_X:6^)?\ T-,__@/#_P#$4?\ #2WQ+_Z&F?\
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MT56^P1?WI_\ O^_^-'V"+^]/_P!_W_QH LT56^P1?WI_^_[_ .-'V"+^]/\
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MW$8.<(5[)R\UIWOVL8%%>]^*?A!\/+;P#H^N:9JNOZ3>:S=)#8P^(6MU!C+
M/,PC!P@&3G<.E3:I\"_ NH^%O$UUX6\1:M>WN@1+))?7447]GWA[B%EYZY')
M/X]:GVT5?R_X'^9T?V+BF^5.+=KKWEJFFU;Y)OTMW1\_45]'P_LV^$K34](\
M'ZEK^JIX[U/3_MT9@AC-A&2"1&V?G)^4C(],\=*^>=3T^72=1NK*<8FMY6B<
M>X.#5QJ1D^5?UT.3%9?B,'!3JK1Z;IV=D[/L[-%:BBBM#S0HHHH **** "NV
M^"'_ "6+P5_V&+7_ -&K7$UVWP0_Y+%X*_[#%K_Z-6IG\+.S!?[S2_Q+\T?I
MU?\ _'I)^'\Q6/6Q?_\ 'I)^'\Q6/7SR/Z6EN%%%>%?M6_&K6_A5X/CC\)1P
MS>(YI(I9'F4,EI:><B22L"""?F"J#U)]J.J7<25SW6BLV^U*:Q\.3Z@EN]Y<
M0VK3K!']Z5@F[:/<GBOG/PU\;?$4UG\.?$8\41:]<^+=1BLKSP?%;6X^PHX;
MS&B* 3!H=N7\QG& W"\8I*\N7T7WZ+^NG4G[/-Z_@KO^ON/IZBOFR]^-%WXS
MU[Q#_9GQ+TGP5+I^I3:5H^DW:6[IJ,T.T.UR9%:0(7)4"(H0.<DD8ZSQ#KGC
M35O$.IP77B ?#W0M(T^WE;58+6&6*_NW1FD5);E"K0I@#Y55SSR*F_N\W]=_
MZZE6U<>O_!L>ST5P7P*\=:G\2?A5H'B+6+-+*_O8F+K&I5)0KLJRH"3A7 #@
M9/#=3UKO:J2<6TR4[A7Y[?M,_P#)</%'_72'_P!$1U^A-?GM^TS_ ,EP\4?]
M=(?_ $1'77A/XC]/\CX3C+_D7P_QK_TF1YA117??!SX;67Q*\3PV6H>(=-T.
MU6:)72\FV3W.XD;(%QAFXQR1C<.O2O6\S\@HTIUZBI4]V<#17J?BWPIX&\%?
M%[Q!HFN_VXGA^S)2W_LDQ/<;_E(W&7 VXW>_2MOXC?##X?\ A[X767B;2;SQ
M';:AJ4@%A8:T;<-+&#\TA6,'"^AS6/MH\L9=';\3TWE=92JQYHWIWOKVW_R7
M=GB-%>H?"KX8:+XD\,^(?%7BF^OK+P]HX1&33$1KB:1NBKO^7\Z[E?V8M'NO
M&VD):ZY>/X2U/23K$$K1*;QHPH8Q!?NE\,.<=^E.56,':7]:7_+4*&4XK$TX
MU*23YME=7LWRWMVYM+GSM17OFL_L]^'[]_!%WX>UC4K+3?$=XUF8->A1+F$J
M3E\+@$':<?4<TSXB_ KPMH_@;7]=\/:CK<4^A7RV5S#KD$:+<L2!F$J!QSGG
M)]AUJ?;P6_\ 6J7ZHU>2XQ*4K*R5]UJK<VGR5SP:G1?ZU/J*;3HO]:GU%;GA
M+<_4^P_X\;?_ *YK_*IZ@L/^/&W_ .N:_P JGKYP_J **\O^(.J>*=0\<6VA
M:;JL_@WPY#IS7][XE2TBDS+Y@2.W1YT:('&YFR"<8QC.:\\\-?'+Q5XQ\,^#
M-+CN(=/U;Q#X@U#1X_$,=NC)-:VOFG[7#&V4W2+&, [ER2<$<4XIRV_K6WY_
MY[ ]-_ZTO^7^6Y])T5Y5\*_']_=_$/QO\/=9U)M:U/PPEE<IJ<D,<4ES;W,;
M,OF+&%0.K1N"55005X'-2_%VWU#PUHVM^+I_B3KGAC1-.M6N);2RL]/EC0*O
M\)FMG<ECVW'D\4I/E5WMN-1;?+U/4**^>?!.M?%O5O#/@+2-3N[ZVU+Q!'=:
MAJGB%]-@:32[< &"WPL8A$[;UY="/E?Y3QBC8?&;QT-6\7>!]-C;Q3KNCZW8
M:7%XA2P#+#;W"AI)[F.+";HE#9P%4DKD#FK<6I<O7_@I?F_Z1-U;FZ?U^A]*
M45XIX6\<>(/"_P >$^&VKZ[+XNM[O16U>+4;BV@AN;5ED"&.3R51"C9ROR Y
M!Y->UU-M$^_^;7YH.K7;_*_Y,T-)Z2_A_6H]4_UZ_P"[_4U)I/27\/ZU'JG^
MO7_=_J:74M[%.BBFNQ5&8*7(&0JXR?;F@D=17AWPF^,7BSQU\<?'/AK7?#=Q
MX4TW1["TFL]/O9K::X?S&?,KO!)(HSMX7><8KV76-7L] TF\U+4)UMK*TB:>
M:9^B(HR3^0HVBI/8+-R<>I<HKY<\&?M)^+KCPU\:O$&OZ=!:?\([J%O'HNEL
MN#!;S6T4D/GD $L?-5W!/RDE0>*[=?&GB'X;>/? 6D^(?$C^)K7QI)/;!9;.
M"#[%<)#YR^48E4F(@,N'WMDJ=W7-)-V\[?BKI>H/17]?PW?H>V45\_\ C[XX
M^(+;]HOX=^#O#\<(\+7.HW%AKE^ZAFEN19RSQV\61QL"!G88Y9%_O"OH"E;W
M5+N#T=OZ_K0*KWW^H'^^G_H0JQ5>^_U _P!]/_0A0!8HHHH **X_XN_$&+X6
M_#C7?%$J))_9]N7CCD;:K2$A4!/8;B*X/X7^*M;UOQ?9I!\2]$\9V[6[MK6C
M[8(YM/D*@QFU\E,L@;*L)68XP0V1@B7,V@>B39[917G_ ,5=8\4PWGAG1/#(
MDL!J]Y)'J.OBU$ZZ7:QPO(9,,"@=F"(OF KEB2#C!YCX7_$K7KS4O'VCR/<>
M/H?#;Q"RU.R6UBGU!GCW-!D-'!YBG SE%Y&<4+6_D#TL>ST5X)\&/C9XN\9^
M&?BGJ^O>&[BUU/P[JMS;67AR QW%PJQP*Z0[H25D=B?X2>6P"<53M/'OCCPC
MXC^'4.M>(XO$&K^*)4BU7PQ':0PC2]T/F,\.T"8+&<*?-9\Y[4TFVEWM_P"3
M*Z_KIU!Z)^5__)=_ZZ]#Z'HHHI <+\=/^2/^+O\ L'2_RK\X:_1[XZ?\D?\
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M.1/LDY^SXBDROR.=K?*<'@\5]7T41?+MY?@I+_VX'K_7=I_H?+OC7P5K6M_
MO7=4CT+4G\0^)?%%OJ\]C]DD-S'"MU&D0:/&Y=EO%'D$<<YQ7<'P_JG_  UA
M?ZQ_9MW_ &2W@5+-;_R&\@S_ &UV\H/C;OVD';G..:]JHI;6MTO^,>3\$#U3
M\[?A)2_-'R+\%O WB/2O&'P3GO= U2SAT^T\2+>23V<B+;&66,Q"0D?(7 .W
M.,XXS7UU115.5TE_6[?ZAU;"H_B5_P DZ\5?]@JZ_P#1+5)4?Q*_Y)UXJ_[!
M5U_Z):I7Q(RK?P9^C_(_*NBBBOHC^9 HHHH **** "BBB@ KWSXB>.-)M-(^
M"UW:7]KJ$NC6N^[M[:=9'A(>,[7 .5/!X/I7@=%)J[B^SO\ @U^IV8?%2P\*
MD(KXTEZ6DI?H?9^J?$;0M/U/QMXNN_'NG:UX?UG2C;V/AR.X,ER)6'"M#_!C
MD9_VCG&*^?;GX3Z7I$O@*ZN/$]E=Z=XAEC^U.I6-+)=ZB0.^XC*@G).,8KS*
MK^IZ]?ZQ#:0WERTT-I'Y4$> JQKZ   ?CU-84Z7LFG%]ON5_U9Z^+S:./B_;
MT]5=K5_%)IM[[65DNAZU\;_&&@^+/C7;6\UTLW@S3#!8QOI\@=!;@#<T97(/
M4]/2O2EU3PW\// ?C#3)/'FD>)?!]U:LFA:)!<B:ZB=B6!90,H0Q)Y_3I7R9
M12=!>S5._P#P?/U\_,5/.IPKU,1[-.4GIOHK-<NF\;6T>FB/MCPQ\4/#-M;>
M'?%5]XC\+Z@=/TSRII[K*:TK@?ZE8@>1GC=CU(R#FOCCQ'JO]N:_J.H[=@NK
MAYMOIN8G^M9U%7&DH3<_ZWN88[-JN.I0HRBDHZ^KLE?7R7]:!1116QX@4444
M %%%% !7;?!#_DL7@K_L,6O_ *-6N)KMO@A_R6+P5_V&+7_T:M3/X6=F"_WF
ME_B7YH_3J_\ ^/23\/YBL>MB_P#^/23\/YBL>OGD?TM+<*^4_P!HGX1?$B;P
MM\1=3TK4=)U]M<N+7R;)-%N9KZ*VCEC\N!&2?!"G<Y(3G+$^WU911;6_]?UH
M).QY5K_BC6DTVT\ R1W*>,]8T"ZFMM:L;-H=-BF10H3<\C,CY92%^;@$Y%>(
M^&/A_'<^$O .@:#X&U3PU\3=%U"SN-6UJYT::W2-5<&[=M0*"*Z$B[AMCD<G
M>,@8./K=])M)-5CU)H%:^CA,"3$DE4)!( Z#) R?85<JD[2YNMT_N;:^6NO<
MG[/+_6J2?Y:=CY2TKP@_PR\,?%3P-=>#M6U;4O%>I7]YIMQI^E2W-KJ"3KE!
M+<HIC@*$X/GLG3*YKI;.[O?!OAVS\"_$[P?=>+M$MM,M(M.U#3=!N=86ZG6+
M9*LPC23RG#?==PBX.=W6OHBBI^SR^27R2LOG_5BF[N_J_F]7^1Y5^S'X/\0>
M!O@_I>E^)%EM[X37$T5E-*)7LK=Y6:&W+ D$HA4<$@=,\5ZK1152?,[DI6"O
MSV_:9_Y+AXH_ZZ0_^B(Z_0FOSV_:9_Y+AXH_ZZ0_^B(ZZ\)_$?I_D?"<9?\
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MQ%6E%P]FMK;O^5Q][7WM'I?9A3HO]:GU%-IT7^M3ZBNL^26Y^I]A_P >-O\
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M^0>4\BXP<XYKZAHI1=G'^ZH_^2JWX]1O527?F_\ )O\ +I^H4444 <+\=/\
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M<;AF9C$P  '4D]JZC8O]T?E1L7^Z/RH3L[D3ASP<.ZL?E)_P@WB3_H7]5_\
M *3_ .)H_P"$&\2?]"_JO_@%)_\ $U^K>Q?[H_*C8O\ ='Y5Z'UQ_P I^<_Z
MD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q
M?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)
M_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)
M/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?Z
MD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q
M?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)
M_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)
M/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?Z
MD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q
M?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)
M_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)
M/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?Z
MD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)H_X0;Q)_P!"_JO_ (!2?_$U^K>Q
M?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\ "#>)/^A?U7_P"D_^)KL?@WX1
MUVP^+/@^YNM%U"VMHM5MGDFFM9%1%$BDDDC  ]37Z5;%_NC\J-B_W1^5)XMM
M6L;4>#*-&I&HJST:>RZ&??:G9M:N!=P$\<"1?7ZUE?;[;_GXB_[[%=+L7^Z/
MRHV+_='Y5P7/T1JYS7V^V_Y^(O\ OL4?;[;_ )^(O^^Q72[%_NC\J-B_W1^5
M%Q<IS7V^V_Y^(O\ OL4?;[;_ )^(O^^Q72[%_NC\J-B_W1^5%PY3FOM]M_S\
M1?\ ?8H^WVW_ #\1?]]BNEV+_='Y4;%_NC\J+ARG-?;[;_GXB_[[%'V^V_Y^
M(O\ OL5TNQ?[H_*C8O\ ='Y47#E.:^WVW_/Q%_WV*^$/VB?"VLZK\9?$EU9:
M1?WEK))$4GM[9W1L0H#A@,'D&OT4V+_='Y4BQ(@PJ*HR3@#')Y-;4JKI2YDC
MQ,WRJ&;4%0G/EL[_ (-?J?E+_P (-XD_Z%_5?_ *3_XFC_A!O$G_ $+^J_\
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M0;Q)_P!"_JO_ (!2?_$U^K>Q?[H_*C8O]T?E1]<?\H?ZD4?^?[^Y?YGY2?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWDL.A8@\>O6_P+UVQ^!_CSP1I=W;:%-JE[>R:3]@<I%;6\DFZ.,87]V",J0
M0-QQFBWN<U]==/G^NX65[>:7X?IL>L_\(UX8GN+Z\_LK29)]0B,5W/\ 9XBU
MS'CE9&QEUQV.16/K?A[X?>'/#U_>ZAH>A0:5IL!OK@+I\3B*.%2V_8J$G:H.
M, GTKYMF_8^\0W/@ZVTO3[:RT&9;V2_D#:F9AY?E!&L?W4,2B&XQB3:HP!G!
M;FK)_9^\3^*H_&,-IX7TCPW-<W6I"+5FF=+B9);,P):X\H?N-[!MP)7Y!A<T
MFMTGT_R_5O[O-74&G**ELW9_UZ+TU\F?3SZ)X6U[0+339=,TJ\T98DE@L)[:
M-H43&4(B884 =.!BC4/"OA35W5K[2-'O7E1(E-Q;12%T0Y11D'(4\@=C7SWK
M7[-WB;4AJ]O'I^BQW]S'<NOB<7+?;)TDM6B2R=?+R(E)'.XC"YVYS6;X[_9A
M\6WDGA:#P_I/AR*UT/2M.@M9FE\J6VGAEWW(0F)B/,_OKM)R=V[/%63E:^[7
MXWN_E;Y_=>4WR7>]G^EOOO?RM]WT'I6F^ ?%]C8ZA::7HE];VS2V=I+)8Q@Q
M%)"KQQAE!4!E/ X.,UK?\(IX9FN[*;^Q])>ZT_<+63[+$7ML\MY9QE/?&*^:
M=/\ V8M>TTW<*>$O"TD$[30V;"<1_P!ENUW--]OA40_ZYDEC0@;6'D+\^#@.
MUKX*:_X \%Q+I%LL_CO4/%UW<V][8VTLJRV]T9(W-S*J8C"P2%LN0NZ-0"21
ME=+K?]6[?K=_\.->?]:7_P"!_P "Q] ZAJW@SX=ZUIRM;6FF:KXHO?LD!L-/
M9Y;V?:SDN8D)P%5B7?"J!R16I<>'_#-Y:-#/INDSVN)(3')!$R8D.9%P1CYB
M,D=\<UYC\1?@ OB6'X<VVFQ6"GPLMU&E]=1AIH-]C+#')&<$[A*T;GD?=SU
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M"U)E[L=-[?\ #?>_\SV7PK'X(US4=1O/#]GI%Q>V#G2[JZM+5 \94#,)<+R
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MS!5:PU^RU&.5XWDB6.X>V/VJ"2W+.AP=HD52PST9<JPY!(KY='['4BII\O\
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M_$KQU\*? W@6XTBWL-<\27^LVUAJ,!B*)<Q^1-+.L(W?(Q\HA22>3S7!:/\
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MH/"7P<\)^!O$-UK>C:?<0:A<1M#NGU"YN(H(V8,Z012R,D"LRJ6$2J&*J3G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU6Q'B63P/IMS9O!8;9O]=F[N&*F79N(V83S,Y'1/%&F6VMVNHV/PWT^V\0>
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M04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .<\:?#SP[\0[6WM_$.EQ:E%;N7B
MWLR,A(P<,I! (X(S@]ZOZ/X9TKP\7.FV$-EOCCB(A7:-B+M10.P X %%%"TV
M#<U**** "BBB@ HHHH *IV.D6>F37<MK;I#)=R^?.R]9'P%W'\ !^%%% %RB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>apre-20251231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $. [L# 2(  A$! Q$!_\0
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M-&\7:YI]EXHNK>SM+Z>"")4CPB+(RJHRO8 "L?\ X:7^)O\ T-UY_P!^XO\
MXFN3^(G_ "4#Q-_V%+K_ -&M7/5[\:<.5>ZC^=L3F>.C7FE7G:[^U+OZGIO_
M  TO\3?^ANO/^_<7_P 31_PTO\3?^ANO/^_<7_Q->9457LJ?\J^XYO[4Q_\
MT$3_ / I?YGIO_#2_P 3?^ANO/\ OW%_\31_PTO\3?\ H;KS_OW%_P#$UYE1
M1[*G_*ON#^U,?_T$3_\  I?YGIO_  TO\3?^ANO/^_<7_P 31_PTO\3?^ANO
M/^_<7_Q->944>RI_RK[@_M3'_P#01/\ \"E_F>F_\-+_ !-_Z&Z\_P"_<7_Q
M-'_#2_Q-_P"ANO/^_<7_ ,37F5%'LJ?\J^X/[4Q__01/_P "E_F>F_\ #2_Q
M-_Z&Z\_[]Q?_ !-'_#2_Q-_Z&Z\_[]Q?_$UYE11[*G_*ON#^U,?_ -!$_P#P
M*7^9Z;_PTO\ $W_H;KS_ +]Q?_$T?\-+_$W_ *&Z\_[]Q?\ Q->944>RI_RK
M[@_M3'_]!$__  *7^9Z;_P -+_$W_H;KS_OW%_\ $T?\-+_$W_H;KS_OW%_\
M37F5%'LJ?\J^X/[4Q_\ T$3_ / I?YGIO_#2_P 3?^ANO/\ OW%_\31_PTO\
M3?\ H;KS_OW%_P#$UYE11[*G_*ON#^U,?_T$3_\  I?YGIO_  TO\3?^ANO/
M^_<7_P 31_PTO\3?^ANO/^_<7_Q->944>RI_RK[@_M3'_P#01/\ \"E_F>F_
M\-+_ !-_Z&Z\_P"_<7_Q-'_#2_Q-_P"ANO/^_<7_ ,37F5%'LJ?\J^X/[4Q_
M_01/_P "E_F>F_\ #2_Q-_Z&Z\_[]Q?_ !-'_#2_Q-_Z&Z\_[]Q?_$UYE11[
M*G_*ON#^U,?_ -!$_P#P*7^9Z;_PTO\ $W_H;KS_ +]Q?_$T?\-+_$W_ *&Z
M\_[]Q?\ Q->944>RI_RK[@_M3'_]!$__  *7^9Z;_P -+_$W_H;KS_OW%_\
M$T?\-+_$W_H;KS_OW%_\37F5%'LJ?\J^X/[4Q_\ T$3_ / I?YGIO_#2_P 3
M?^ANO/\ OW%_\31_PTO\3?\ H;KS_OW%_P#$UYE11[*G_*ON#^U,?_T$3_\
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M_P!#Y>_^ \'_ ,;KQ6BCZM1_D7W(/JU#^1?<CVK_ (;/^-/_ $/E[_X#P?\
MQNC_ (;/^-/_ $/E[_X#P?\ QNO%:*/JU'^1?<@^K4/Y%]R/:O\ AL_XT_\
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MW(^B]"_:W^+M]X5\37L_C6[DNK&.W:WD,$&8R\P5L?)W!(YKGO\ AL_XT_\
M0^7O_@/!_P#&ZX+PO_R(OC3_ *XVG_I0M<E41P]&\O<6_9=D9QP]&\O<6_9=
MD>U?\-G_ !I_Z'R]_P# >#_XW1_PV?\ &G_H?+W_ ,!X/_C=>*T5?U:C_(ON
M1I]6H?R+[D>U?\-G_&G_ *'R]_\  >#_ .-T?\-G_&G_ *'R]_\  >#_ .-U
MXK11]6H_R+[D'U:A_(ON1[5_PV?\:?\ H?+W_P !X/\ XW1_PV?\:?\ H?+W
M_P !X/\ XW7BM%'U:C_(ON0?5J'\B^Y'M7_#9_QI_P"A\O?_  '@_P#C='_#
M9_QI_P"A\O?_  '@_P#C=>*T4?5J/\B^Y!]6H?R+[D>U?\-G_&G_ *'R]_\
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MJ&>QU2TDMIU!Z$HX# 'Z5*P&62ERJC3OVY8_Y!S3WNSW;_AXC^T3_P!%-O\
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M@>'_ (#'_(7/+N?1O_#Q']HG_HIM_P#^ 5I_\:H_X>(_M$_]%-O_ /P"M/\
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MLPX741:W=LY.#@D,,CZ5Z%XS^!D/A;Q_8/</9VD&J:[]GT[090Y,EMYH7>S
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MX0TO1/#\PN;DW>BWSW,=ZD:;MA<D@$;<<?WCZ5P?Q<\-^';WP%HGC#P]HZZ
MES>3V,]E%(SH2A^5@6).2.M;B?M$Z#X5U'P?8^%-(U >&-$EN)9H]3D0W-QY
MX*N!M.T8#-CWQZ5R'Q5^)7A_Q!X=TGPWX3T_4++0[*>6[9M39#-)+(>?N9
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M:ZNDT2(81%$$W*26!W':<<8]ZZJ:J>S:LU[RZ].97_"YV+VRHQLM;OS[_P#
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MK_E+YWO8U]=_9Y\%V_PD^)NOW6HZ9I.NZ9XB>RMXXQ.T-J$/RVR Y),G9CG
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M2&.Y+[C\K*ZX#+@\^E2> /@IIGBC]IGP'X0\?_LZZ5\-K"]MKNX-E#J,TXU
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M_A@@_P#0W#_P#_\ LJ/K-+N'^JV;?\^O_)H_YGR+17UU_P ,$'_H;A_X!_\
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M?6:7</\ 5;-O^?7_ )-'_,^1:*^NO^&"#_T-P_\  /\ ^RH_X8(/_0W#_P
M_P#[*CZS2[A_JMFW_/K_ ,FC_F?(M=!X;_Y GBO_ +!L?_I9;5]-?\,$'_H;
MA_X!_P#V56K3]B4Z3;WUI_PE/F?VG"+3=]DQY>)$FW?>Y_U./QJ7B:3ZF]'A
MC-82;E2Z/[4>J:[GQW17UU_PP0?^AN'_ (!__94?\,$'_H;A_P" ?_V55]9I
M=S#_ %6S;_GU_P"31_S/D6BOKK_A@@_]#</_  #_ /LJ/^&"#_T-P_\  /\
M^RH^LTNX?ZK9M_SZ_P#)H_YGR+17UU_PP0?^AN'_ (!__94?\,$'_H;A_P"
M?_V5'UFEW#_5;-O^?7_DT?\ ,^1:*^NO^&"#_P!#</\ P#_^RH_X8(/_ $-P
M_P# /_[*CZS2[A_JMFW_ #Z_\FC_ )GR+17UU_PP0?\ H;A_X!__ &5'_#!!
M_P"AN'_@'_\ 94?6:7</]5LV_P"?7_DT?\SY%HKZZ_X8(/\ T-P_\ __ +*C
M_A@@_P#0W#_P#_\ LJ/K-+N'^JV;?\^O_)H_YGR+17UU_P ,$'_H;A_X!_\
MV5'_  P0?^AN'_@'_P#94?6:7</]5LV_Y]?^31_S/E#2?^0I9_\ 79/_ $(5
MXS\0?^1]\2?]A.Y_]&M7Z,P?L(FRGCN/^$M#>4PDV_8^N#G'WJXW5_\ @F@G
MB35KW5_^$Z:#[?.]UY7]GYV;V+8SOYQG%=.'QE"$FY2_!GZQP+@ZV2_6/KRY
M>?EML]KWVOW/SYHK[Z_X=;1_]#^W_@M_^V4?\.MH_P#H?V_\%O\ ]LKN_M'#
M?S?@S]7_ +2PO\WX/_(^!:*^^O\ AUM'_P!#^W_@M_\ ME'_  ZVC_Z']O\
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M\.MH_P#H?V_\%O\ ]LH_M'#?S?@P_M+"_P WX/\ R/@6BOOK_AUM'_T/[?\
M@M_^V4?\.MH_^A_;_P %O_VRC^T<-_-^##^TL+_-^#_R/@6BOOK_ (=;1_\
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M_@G'_P =H_UHRG_G[_Y++_(/85.Q^6U%?J3_ ,.5+7_HJ<W_ ()Q_P#':/\
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M:'_T8M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G=?\ '_9?5_\
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M1110 4444 4[K_C_ ++ZO_Z#5RJ=U_Q_V7U?_P!!JY0 4444 %%%% !1110
M4444 %%%% !1110 53NO^0A9?5__ $&KE4[K_D(67U?_ -!H N4444 %%%%
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M3\)R^'O#NGWVG6FG:K+IZ23O TEQ<.L3+Y^)%V>7('0;/N_,:;/XC\0_$GX
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M4?#Z1:5JL6I0:QIVF-;ZPZ1N'%L\H;:8V^ZW'(^M>]5"^!7W_P" M?ST_P"
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M]7-?]I+5O%>C_ 9O%5O+)H&N^'KJRUN^M=)OGDCD@@G1[J#S-L9DC:'S =R
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M3UL8P35.SWLOS5]?2YZ%1116!H4M%_Y ]A_UPC_]!%7:I:+_ ,@>P_ZX1_\
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M<?ZB3_=/\JCT[_D'VW_7)?Y"I+C_ %$G^Z?Y5'IW_(/MO^N2_P A0!8HHHH
MX'XD?$&\\-^(?"7AS1X[>;6M?O2B_:59DAMHQOFD(4@D@8 YZL/3%>1?L\_M
M.>)?B#\3/B=X>\9V6DZ;INB75T^@W5@DD;7-I;7,MO/YN]V!=&6(DKM&)!Q7
M8_%*%]#^/GPN\23@?V8XO-'>5ND4TR!H^>VXH17ANK_LW?$:708+K1K!=.UV
M3QKKD5T9)XR6T/49SYDH(?&0%BD"_>^7IGBJ@KV\U)>CNDOT;\FQRM;YK[K2
M;^^W+ZV/0_@G^UA=>*=+\?:QXZAL-'TS2M:CL=&CTZ&5[BZAE0- "NYC)*^0
M0$ SD<5ZI;_'[P;+X<U36)KZXL%TR=+:\L;VTDAO89GQY<9MV ?<^1M&.<\5
M\Z>+/V9O%LVN>(-1TK3+N"RTSQ;9:QIUKI^H1VUQ>VD5D8'$$F["2+N^7?M!
M(QD YJW+\ O%>I3:KXRLM U>'4XM7TN_M]-\2ZRMSJ6H16C.665ED>&,_.=@
M#'_:8=!2Y96ULO=_*-WZZN_FB7=7^?WW>GIL=6O[6T=]XM^(EJUU%X=T+PVF
MB+'<:IH=T]U'->3F-XYH/,1N?D52-NW?N.X#%>IW/Q_\'6WBR3P^+F]GN8KM
M;":[M[":2T@N6 (A>=5**_(X)[U\W?$;X6_$KXI:K\6-73P!<Z(FN/X7&F6M
MU>6AN)TM+X2W#2;)6561<G&XY  !)XKU;X5Z/XV^#VL^*/#R>#+GQ!9ZQXDN
M-6M]=COK>&UCMYV5F$NYO-#IR JQL" /F%**3LG_ %\/W;O[O4<M$VO+\G]^
MJ7WC=*_:2DOOB;X2T:'4]+U'PYJ(\1?VAJ)T^:S>W;3Y8T"*'E8?+N<,YR'V
M@J%'%=SX=_:(\%>)K]+2VO+RW>>WDN[.2]L98([^&,9=[=W4"4 <_+FOF>P_
M9C\>ZO>Z?9W>E-I=O(?&T<UXUQ$P@%_<H]HQ"N20Z@G@$C^+!KO9/A_XZ\?-
M\-M.O_"$OAF+P/:7'VF\GNK=X[Z8V;6R1VPC=FV,6W$R!", 8[UFW:G=;V_^
M2_*RTW=RK+GMTN_PM;[]==D>F^!?VGO 7Q&NO#T&C7U\$\16YN-(N[S3IX+>
M] 7<5CD=0K.!U7.1@UN_"GQ_=^,HO$&G:O';P:_H&I2:=?1VH(C; #Q2*"20
M'C9&P2<9->'^!O@QXQTCX??LP:==Z(T-[X/$/]N1>?$?L>+-HVR0V'^<@?)N
MKT+X#VKZI\1/B[XKB7&F:KKD=K:-C'FBUMT@D<>H+JX!_P!FNB48J<XQ=TK_
M (.-G\TW^9DFW"+?6WWOFNOPN>U4445@64]5_P"/5?\ KM#_ .C%JY5/5?\
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M$GBO1OBO\-/'WQJBUS5U\&W/AN73O!-]X>LM-O+JV:?4;NY>%F*F.1D6%!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIZ<K;_K^NY[QXJ\1ZQ:>!IM7\-:&VO:O)#&]IIKS+#O9RH!=F( 50VYN^%.
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M%% %2STFST^YN[BVMHH9[MQ)/(BX:5@, L>_ Q5NBB@ HHHH **** "BBB@
MHHHH IZK_P >J_\ 7:'_ -&+5RJ>J_\ 'JO_ %VA_P#1BU<H **** "BBB@
MHHHH **** "BBB@ HHHH **** *=U_Q_V7U?_P!!JY5.Z_X_[+ZO_P"@U<H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>apre-20251231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '% YH# 2(  A$! Q$!_\0
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MHT_3;_1-?UF=_!S6,>HW$L6I7"JHDO&$8B0,7<#+$ = "1[!X8^-OQ.^-;?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,W1_#FFZ!+J,FG6<=H^HW37MVT?_+:9E52Y]R%4?A7->*?@EX%\;>(#
MK>N^&+#4]3:%;>6>="?/C4DJDJ@[9%!)P'! R:[>B@#F/"GPR\+^![D7&A:+
M;Z;.-/MM*$D.<_9("Y@AY)^5#+)C_>-7/!W@K0_A_H46C>'=.BTK2HG9X[2
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MA79?#J3P';^!=(M_",MPMW)I44.V*28,&$C$'+,"!R2> !T%>G44 <]!\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5F^(_$>F^$=$O-8UB\CL=.M(S)-/)G"@=@!RQ)X"@$DD
M  D@5I5S'B[P@_BG6/#$[S(+'2;\W\UNX)\YUC<18]U=@_/=10!@6OCKQKX@
MB%WH_@4VNGOS"^OWWV.XD7LQ@".T?^Z^&'=14_\ ;OQ)_P"A2T/_ ,'3_P#Q
MBN_HH X#^W?B3_T*6A_^#I__ (Q1_;OQ)_Z%+0__  =/_P#&*[^B@#@/[=^)
M/_0I:'_X.G_^,4?V[\2?^A2T/_P=/_\ &*[^B@#@/[=^)/\ T*6A_P#@Z?\
M^,4?V[\2?^A2T/\ \'3_ /QBN_HH X#^W?B3_P!"EH?_ (.G_P#C%']N_$G_
M *%+0_\ P=/_ /&*[^B@#@/[=^)/_0I:'_X.G_\ C%']N_$G_H4M#_\ !T__
M ,8KOZ* . _MWXD_]"EH?_@Z?_XQ1_;OQ)_Z%+0__!T__P 8KOZ* . _MWXD
M_P#0I:'_ .#I_P#XQ1_;OQ)_Z%+0_P#P=/\ _&*[^B@#@/[=^)/_ $*6A_\
M@Z?_ .,4?V[\2?\ H4M#_P#!T_\ \8KOZ* . _MWXD_]"EH?_@Z?_P",4?V[
M\2?^A2T/_P '3_\ QBN_HH X#^W?B3_T*6A_^#I__C%']N_$G_H4M#_\'3__
M !BN_HH X#^W?B3_ -"EH?\ X.G_ /C%']N_$G_H4M#_ /!T_P#\8KOZ* .
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MBC^W?B3_ -"EH?\ X.G_ /C%=_10!P']N_$G_H4M#_\ !T__ ,8H_MWXD_\
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M $*6A_\ @Z?_ .,5W]% ' ?V[\2?^A2T/_P=/_\ &*/[=^)/_0I:'_X.G_\
MC%=_10!P']N_$G_H4M#_ /!T_P#\8H_MWXD_]"EH?_@Z?_XQ7?T4 <!_;OQ)
M_P"A2T/_ ,'3_P#QBC^W?B3_ -"EH?\ X.G_ /C%=_10!P']N_$G_H4M#_\
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M?^A2T/\ \'3_ /QBN_HH X#^W?B3_P!"EH?_ (.G_P#C%']N_$G_ *%+0_\
MP=/_ /&*[^B@#@/[=^)/_0I:'_X.G_\ C%']N_$G_H4M#_\ !T__ ,8KOZ*
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MTP_\]4_[Z% $M%1?:8?^>J?]]"C[3#_SU3_OH4 2T5%]IA_YZI_WT*/M,/\
MSU3_ +Z% $M%1?:8?^>J?]]"C[3#_P ]4_[Z% $M%1?:8?\ GJG_ 'T*/M,/
M_/5/^^A0!+147VF'_GJG_?0H^TP_\]4_[Z% $M%1BXB8X$B$^S"I* "BBB@
MHHKY._;5^-&M>%;_ $OP=H5[-ICW5H+^]N;=MDC1L[(D88<@$QN3CK@#IFNW
M!82>-KQH4]V<.-Q<,%1=:>MOQ/K&BOR-;7]5=BS:I?,Q.23<N2?UI/[=U/\
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MPDEB0Y5) 2K@9[;E.*\/,\HJ9:HSE+FB]/F>UEN;PS&4H*/+):]]#JZ***\
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M#TYJ'A\=S-J3LW?67G+333;E+6(P7*DXJZ5OA\HZZZ[\QY'1117U!\R%%%%
M!7Z4?LJ_\D \(?\ 7&;_ -'R5^:]?I1^RK_R0#PA_P!<9O\ T?)7QO%'^ZP_
MQ?HSZSAK_>Y_X7^:/6****_-#])"BBB@ HHHH **** "BBB@ HHHH *^0_\
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M_P D'\0_]C-/_P"DEI7YEU^FG_!,;_D@_B'_ +&:?_TDM*Y<S_W=^J.3-/\
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MG.>L4V>HU\G?\%+-)NM2_9_TV>VA:6.Q\06]S<,HSY<9@N(]Q]MTB#\:]?\
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M2%I<A-9N-9N+K3FNF@0/&L:1!KF..1F 7GY, ;!N<EB/HK_AGW]DK_HIK?\
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M6JW0D6$P&=0_F,I94VYSN*@D#J0":KG8N1&/X.\*2^&;OQ!-+.DXU+4'O$"
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MD=0 /;%9IU;:Q_K[R[4[Z,BLOAGX[O[-[F*WG\M6E0K)>HCEH\[P$+AB1@\
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M<[VD#211, "NXH2PPH^]GI7 QR&*177!92"-RAA^(/!_&OK/_A@2?_H=X_\
MP5G_ ./4?\,"3_\ 0[Q_^"L__'J2KT5L_P #2ID&>5K>T@Y6[RB^W][R7W+L
M>/S_ +47Q-N0!+XD60 8&_3K4X'_ 'ZJGX=_:-^(GA31+32-*\1M::=:)Y<,
M(L[=MB^F6C)/XFO;/^&!)_\ H=X__!6?_CU'_# D_P#T.\?_ (*S_P#'JCVN
M'VT^XZO[*XDYN:\[]_:+_P"2/EWQ'XEU3Q=J\^J:S?3:CJ$YS)/.V6/H!Z =
M@.!697UK_P ,"3_]#O'_ ."L_P#QZG1_L"2AU\SQLA3/(73"#C_O[6GUBDMF
M<$N&LXG)RE2NWUYH_P"9H_L#(PT?QD^#M-Q; 'L2%DS_ #%?5U<7\*/A5I'P
MB\,+H^E;Y2[F6XNI?OS.>,G'3 P *[2O)K34YN2/V+)\)4P. I8>K\45K\VW
M^H4445B>R9^M?\>T?_75:YKQ9=V-AX6UFYU2::WTR&RFDNIK:5XI8X@A+LCQ
MD.K!02&4A@>00:Z76O\ CVC_ .NJUF321PPO)*RI$BEG9SA0!U))[52V,WN>
M)_ _Q]J'BKQ%=P+XJTS4=!6#=::?>:O:7VM<'!:46O[N-!V^>4D%<["""WX@
M^$[:V_:7^&/B-KN_N;RX6_M$MYKIFMK:-;;)$47W59S@LV"QVJ,X4 >R:1J%
MAK.FVFI:;-#=65W$LT%Q#@K)&PRK ]P00:=<Z38WM[:7EQ96\]W9EC;7$L2M
M) 6&&*,1E<C@XZBF(^5_AHLG_"4_#?6&-J=+U'Q'K@LK6$;=0@E?[2SFYDZ2
MK^[8% J%&,>6?;D]C\;?B!XQ\%^/_P#A&M'U%Q+XWM;6P\.NT".-.O5N-EY*
M./F"VTGG@,&Y@;L<5['8> /"^E>)KSQ'9>&](L_$-XNVYU:WL8DNYQQP\H7>
MPX'4]A575? 4&N>.]&\27UW).-&CE^P6)C01PS2*4>;=C<6*$KC. ">.:0'B
MV@_$;Q.R>%_$;^(Y[Z[U?QC+X>N/#!BA\F&!998F"A4$JR1QQ"=F9B#\W 4C
M%C]H#Q]XY\+>+[KPWX6U%XM0\2Z9 ^AEX8W6TGMY9)+YAE>=UL%P&R P&.N*
M]:TK1? L_P 1M<U+3])T3_A.;6*%-3U&&RC%^L<B?NEDF"[R"D8P"3P@]!71
MW>B:=?W]K>W-A:W%[:JZV]S+"K20AQAPC$94,.#CJ.M 'QGXA^*GBSXI^%O$
M6H_VS<6OA;Q+H7B";3+*WAB4I!:6MO%G<4+?/.MT3D_=< 8P#5B.?7O [_%;
MQ-I'B?4+>ZT'2_#<X@:.!X[TBU0LL^8\D,N5^39C)(YQ7U,=&\%Z;J6D^'QI
M6CV]W]BN%L+!;.-=MKE!.L:A<*AWH&48!R,@U8L?AMX1TS2;G2[/PMHMIIEU
M%'!/90:="D,T<8Q&CH%PRJ. ", =*!G#?'#QAJ^F7?A+1M GU)=5UF2Y=+/2
MQ;1RW"Q0ER&N+EMD"*2K,0DCD [4ZUX=X ^+/BSXM_#?5[?Q!XN_L.33?#VJ
MW#7NG>0Z7[0WUU:^8\CQ .BI#'DHL>3+G"Y 'U1X\\*^$_%.BQ0>+] TSQ!I
MD,\;QVVIZ<E[&DI/EHRHRM@_/C<!P">0,U6O?@_X#U&SMK2[\$^'+JTMKB2[
M@@FTF!TBGD.9)54IA78\EAR>YH$?-GA'XJ>)?#.E>"?A[;:E,VI^*;#0+C0;
ME84)L[(6RMJ'&W#!$M92"<D-<(,]*Y_6/VA/B!IU[X7U&RUFZET7Q1I^NRP7
M.H_8XVE,%E<7,,UM9Q"1HHT,,:;IIBS;F#1@\C[,@\)Z):W>FW4.C:?#<Z;;
MFTL9H[5%>UA( ,43 91"%4;5P/E'I6#'\%?A[#>75W'X#\,I=74[W-Q.NCVX
M>:5U=7D=MF69EED!8\D2./XCD&>$Z[\2_&/@C[/8/XIO-2?5] TC4'O[RW@_
MT"2XOXK>XEC"HH"!)2P#[@"HR<9K8\?^+?$WA3XD>&/ NE^)/$'B2+4EO;RX
MDTYM+74HWBC@\NU#SF*( B1YCD&0A1@;0Q'O4_A'0KK?YVBZ=-OL_P"SF\RT
MC;=:]?(.1S'_ +'W?:L;_A3G@'_A%O\ A&?^$'\-_P#"-^=]I_L?^R+?['YO
M_/3R=FS=_M8S0(^6M2^)?B?XI?!KXB#7_%+:!_8WA.>>,69M'34U9[J+SY6'
MF(<K#&I$3[5=VPQRM>Y>,;OQ1:_"'P*/"=RL5_*]A'/;1W<%M=W=OY!,D5J\
MZF/SN P5L JCC*]1WFO_  N\&>*H]-CUOPCH6L1Z;&T-BE_IL,XM4("E8@ZG
M8"%4$+@8 ]*O:]X,\/\ BK0/["UK0M-UC1,(/[-O[..>VPA!3]VX*_*0,<<8
M&* /G;PE\4]3^(?B"[T,>-]8\*V.B:%<W<MWJ-K9I?3745U-!/Y^ \3);^4F
M[RN&\P$L,BO.O"?QI\7BSF\:168@\0:U-HMS>Z9'#Q<.="N)_) 8%E#21IC'
MS#IFOKZ_^%/@G5-&TK2+WP?H%WI6DL'T^QGTR!X+-AP##&5VQD?[(%:<GA+0
MY=1.H/HVGO?F=+DW36L9E\U$*))NQG<J,RANH#$#@T#/FSP!?W&K_M _"35;
MKQC)XJGU;P+J&I,DB0JL!EDLB6C$:@B-B"JAMQ'E'YB<U]8Z-_Q_7?\ USB_
MF]<EH?PS\'^&=7FU;1_"FB:3JDSRR2WUCIT,,[M*5,K,ZJ&)<HA8D_-M7.<"
MNMT;_C^N_P#KG%_-Z.@+<V****DT"O@;]N[_ )+?IW_8NVO_ *4W=??-?%/[
M>?@?4%\5:+XPCA>72VT]--GE496!TED=-WH&\X@'U7Z5])P_.,,?'F=KIH^;
MX@A*6!;BMFF?*M%(#D9'(I:_63\N"NM^&'Q'O?A=XDDU:SM;>^\VUELYK>YW
M!7C<8(RI#*<@'(/:N2HJ*E.-6+A-73+ISE2DIP=FCU[Q%^T?J?B#P_>:.-#T
MVQL[C2DTA5MS)^ZA23>NW+'D=.:?<_M):CJ:36NJ>']+U329M.M;"33KCS/+
M8V[EHY<JP8-D\C.".,5X]17&L!ADK*'Y^7^2.MX[$MW<_P O/_-GH/BKXRZA
MXK^)FF^,Y=.L[6[L3;^7:0;A"1#C:.3G!QZU)X>^->I>'?$GC#68;"TEF\3)
M,EQ&Y;;%YDGF'9@]CQS7G5%:?5*'*H<NEK?):F?UJMS<_-K>_P ]CI/B-XXN
MOB1XRU#Q%>6\-K<WGE[X8,[%V1K&,9)/1 ?QK>U7XVZYJWPDT[P!*D0TZSF#
M_:@6,TJ!F98F).-JE@0.VU?2O/:*MX>DXPBXZ0M;RMHB%B*JE.2EK*]_.^YK
M7/BS5KSPU9^'YKQGT>SG>X@M=B@)(PPS9QDY]S63116\8J/PJQBY.6[N%%%%
M,05^E'[*O_) /"'_ %QF_P#1\E?FU;6\U[=0VMM%)<7,S!(H(E+/(QZ!0.2:
M_4+X&>$;SP+\)/#&AZBOEW]K: SQY!V.[%V7(]"V/PKXKBB<?J].%];W_!GU
M_#49/$SG;11M^*_R/S/^,5[M^+7C49Z:U>#_ ,CO7JDO[)FL0^$O#^M-K&'U
M":Q6Y@:Q=4MH[IE5724MB5EWKN48QD\^OEGQA\ >,[OXM>-)[;PEKMQ;2ZU>
M/%-%ILS(ZF=R&4A<$$=Q6K)XO^+<]EH<4O@":2[T>2V>WU-O"Q-Z1 08D:;R
M]Q4;5&,C@8KY!S=ERL^<A@Z2JU7B*3E=NUK]ST.Z_97A/B3P_IFG>-H-1AU#
M5[K1+JY73G0VEQ#"9<;2_P X(!R<C'&-W;.TC]GC2=>CL6L?B'9O_;=Q/:>'
MO,TZ9?[1EA7]YOY/DH'(4,=V<YQT!YJP^)'QKT[4;>]A\(:H)X-9GUU-V@SD
M?:98C$YQM^[M)P/6J?@GQM\9_ /AY-&TSPCJCV\$DDUE+=^'7FFL)'4J[V[M
M'F-B">G]3F.:=OB.GZM@>;^ [?\ ;W]W^]_B^=NFAWE_\%]$L/"<=S*ES%J8
M\.6NH2 S;D6Y?45MGX'\.TGC/7G-:2_LK6&H:O<VQ\9Q:5/-K-WI%A9MISR^
M=)"F_P"]YGR@C/7ICOFO*Y?%7QCGTI-/D\):S)"NG1:7N?19R[0QW(N5RVWE
MO,&2>XK4/Q,^-K:O9:D?"&J?:;35+C6(C_8,V/M$R;')&WE<'@=J.:?212H8
M)M<]!M:=&NNNS70WM*_9TBNO#JW%]XQMK'7WT2YU]=%6R>1C;1;P#YNX+EBA
M&.WO7AOV_P!S7U#IOQBU:S^"SZ)+\-O&DWC/^Q[S2%N3H@-OMG8_,)ROFJJA
MBPC"X) !/\0^7_\ A7'CK_H3/$/_ (*I_P#XBKA4>O,SBQV7TDJ?U:+VUW\M
M[]=]K>@GV_W-?4?['7[/[>.=2C\9>(+5O["LY,V<$@P+J4?Q>Z*?S/T->4?
M#]F?Q5\4O'=O9ZUH^I:#H-MB:]NKVU> L@/W$W@99NG'3K7Z@Z+HUEX=TFTT
MS3K=+6QM(EAAAC& B@8 K*O7LN6)[&0Y#[6HL3B8^['9/J_\D?F9_P %+0%_
M:!TP 8 \.VV /^N]Q7R?7VG_ ,%-/ NK1?$;0O%RVLDFC3Z8FGM<*I*QRI+(
M^UCVR)!C/7!KXLKZ/!-/#PMV/Z-P+3PT+=@KM_A%?>*8/$TMIX,@']OW]N]M
M%>HN)K)#@R2QRY'DG:"#)P0K,,C)KB*Z+P;\0-<\ R:B^B7,%O\ VC;&SNUG
MLX;E9H"P8QLLJ,-I*J2,<[1GH*ZYIN+2_$ZYIN+2_$^@[KQQKGB/XE3V7@;7
M$LK&RM=//BCQQ GV8W#VZ!)YWF')C=R<*<F5E7ALUH6/BVS?7_!TW@FT_LKP
MWXN\8WZWVF11[([NW#PHD,J#@ILD=A']U?,X' ->"6WQJ\56>GWNGPR:1'IU
MY)'+<6(T"P^SR.@(1C%Y&S<,GG&>:ATOXR>+M#BNHM.U.*PBN)C<>5;6-O&D
M$I0H9(%$>(&*D@M%M)KC^KR\OZ770XGAY=+?TNNAT'@+P;X;U/7_ (E/J-O-
MJ6F^'=)NM0LHH+CRO-=+N")-S '*E96SCVKUO2?V=/!/C?QC=^%]-@OM&F_L
MC2M:2_EO/.\M;EH!+#M*@$ 3?*W7(YSGCYCT?Q+J>@1:I%8736Z:I:-8W@"@
M^= 71RAR#CYHT.1@\=:Z32_C!XEL];^WW6I7-PLMK;6%RD+K!)+:P,ACC615
MRA7RDPZ_,"H.36E2G4;;C+^M/^":5*=5MN,OZT_X)TOC#PQX0OO@R_B[0=&O
MM%OH_$S:08;F[,ZF#R&E7.5'S_=![<< 9KR.O5OBM\>[KXD>&+;P_%8O8Z:F
MI2ZM,;AX'EEN7!4L3#!"O0L22I9BQ+,>,>4UK24E'W_\S6BI*/O_ )W"FR?<
M;Z&G5TGPZ^'^K?%'QCIGAO1;9[F]OIECRBY$:D_,['LJC))/I6K:BKLV;45=
M['[)?%7X4Z?\3='\J7;;:I"#]FO-O*G^ZWJI]*^+_$OAK4/"6L7&F:I;FWNX
M3@J>C#LP/<'UK]"JX?XJ?"K3OB;H_E3;;;4H0?LUX%R4/]UO53Z5\3A\0Z3Y
M9;'Y;6H\^L=SXFT2P35=9L+*2401W-Q'"TIZ(&8 M^&<UZUJGA?P]>ZGXOT"
M#PVVF-H=E-<PZD)I&D=HAD>8&.W#]L =17->'?@AXBU[Q;J'AYC;Z=J%C%YS
MFZ9@C+N !4JIR#GK7JVK?!KXIZ[HHTF_\7V%S8 *#$TDGS!>FYA%EN@ZD]*]
M"K4CS+WK')3A*S]TY+Q=\+?"IN+][&[N]'.GM8?;1-&#;)%/L4NC$EB1N+'.
M.^*8GP/TF^\16Z6E[J(T+[%-=O>2M;'SMAP!%(LA09R,[]N._7CM-1^$7Q6U
M6TM[6Y\8Z>\%O(DT2J[IM=""ARL0/! (^E/N?A-\6+O5[34Y?&6GF]M49(7#
M.H56^\-HBVG/'4'H/05@JME;G7]?(U=.[^ \YO\ X7>&- CU^\U'6;RZTVQ>
MV%NVFF&5W\X-\KG)4%2IS@]!D=0*LQ? RT?6[*R?4YHH]1OBMC(RK^\M%M_/
M:3M\V"%'09!KJ=5^ 'Q%UQ;];_Q-IET+^2.6YWO)\[("$_Y9<8!. ,"E_P"%
M!?$?SM'E'BC3EETA/+L76213 OH,1\CMSGCBJ]JK?Q/Z_P"')]G_ '#E-0^#
M_AW3;R^O)-;NKC0[2Q6ZD2S\F>[1VD$>P[&*=2#G/0^V:Y/XP:!IWAKQQ<6&
ME0F"R6WMW1&)SEHE8DY).223BO:?^%2_%C^VSJW_  F5A]O,/D>9O?&S.<;?
M*V]>>E87B#]FOQUXIU234=5U[2;R]D"J\S-("0H '2,#H!3A62E>4_Z^X4J;
M:M&)\_45[A_PR5XI_P"@KH__ '\E_P#C='_#)7BG_H*Z/_W\E_\ C=='UBE_
M,8^QJ=CZCTG_ )!5E_UQ3_T$5;J"R@-K9P0L06CC5"1T.!BIZ^>9[*"BN7\3
M_$[PMX,U:#3-:UF"POYK:2]2"0,6\B/ >4X!PBD@%C@991U(SSTW[1WPWMC"
ML_BJUMY93*!#-'*DB^7Y7F%D*AD"^?$26  #@].:0STFO)?'/B/Q3I/QZ^'N
MDVFL00^'M9MM2$FG_8P6:6&!75Y)"V2 S#"KLZ').1B]K'[1G@70_&X\+W.J
M_P"F):WEW<W*K_H]HML8!(LCDC+YN$ 5 W((.TX!JZY\:OA'<W.GW.KZUHTU
MVL,OV=KRW+301NYMY<ADW1!G0Q,#MR<*>H! *^N^)/%FD?M$_#_0IM9MI/#V
MKZ+JLT^GV]EY>ZXM_LF)"[,S8S.^%&,#KN/->O5Y-9_%WX8O<)>VXM3'X>LX
MXK>^M]/\QK**=YHVA1$4RP &P8.&1%_=J.=N GBK]J;X<>%?"NH:\VN?VG;6
MFF/JRPZ?"SO<Q"#[0%B+!49S$0P4L" <G R: /6JKMI]JS%FMH22<DF,<UP=
ME\?_  /<I9FXUF+3FO;EK:VCNR \C QJ6(4GRUW31+F3;AG4$ D"M?PG\6/"
M/CG6+W2M"URWU'4+,.TT$88$!)#$Y!( 8*X*DKG!X- %+XB_!+P9\61I,/BW
M1+?6].TVY^V1:;<KFUEF PK2Q]) N3A6RO.2#QCQ3_@H;:0:?^S,UM:PQVUM
M%J=HD<,*!$11N   X 'H*^I:^:_^"@VD7NK_ +.-^ME:RW36]_;7$JQ(6*1J
M6W,0.PR*Z\)I7AZHZ\)IB(>J/RCHHHK[H^]"O:O@_P#LK>)OBGIR:O/-%H.@
MS6EW<V]Y.8WEN/(4D[(#(KLA;Y?, *@UXK7T/\.OVL;3P=X:T&SU/P6-9UG0
MM,O='L-3BU0VRK:W&20\7E.&=23\V1D<8SS7/7=51_=+4YJ[JJ/[I:G 7W[.
MWC[3O!L7B:;0\:=)#'<F)+B)KJ.&1BJ2O &\Q48CABH'(YJ;5OV</'>C^)-)
MT";3[.76=3D:*&RMM2MII8V5=["55<F+:H))?& #GI76:K^U)%?>&M0%OX1B
ML_&&J:/#H.HZZNH.T4MK'A1LM]H\N0HJ*6WGH2 ">.F;]MR6VU;P5J-GX4EF
MO?#LDN;[5]5%Y=S0R0-"\*SF%61?F+9;S#N"DYQ@X<^)_E77\M.O?^D8\^*_
ME77\M.O?^D>&>,/A;XA\!^);'1-;MX+2XODCDMKA+F.6VFC<X61)D+(RYR"0
M3C!]*ZWXP_ S3_AIX<T[6M'\96GBZSFOY]+N7MK5H%ANH55G$9+$3)\^/,7B
MHOC=\=9?C;XRTO5M2LKU=.L(UA6SN;Y)IF3=N<>:L* 9[?(<>]2?'#XQ^'?B
MI::)#HO@ZX\)II40MK>V75OM-K% !RL<(AC"LSY=GR2Q)SVQJG6;AS*W?:W^
M?W&B=9N',K=]K?Y_<>34445U'6%?KI^Q!8VTO[+?@=GMXG8QW669 2?]+FK\
MBP"Q  R3P *_8;]C/1[[0?V9_!%EJ-K+97:P3R-#,I5PKW$KH2#TRK*?QKQ,
MV_@Q]?T9X>;_ ,&*\_T9[#_9UI_SZP_]^Q4\<:Q($10BCHJC %.HKY4^3"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#/UK_CVC_ZZK7)>.],.M>"=?L
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MG_T3OPG_ ."2V_\ B*/^%#?#/_HG?A/_ ,$EM_\ $5W5%'UBM_._O8?5</\
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MXB^.?AGPK\1;+P?JDDUG>748=;N9-EN&8@*N\^OJ.!T)KT.N!^,/P?TCXO\
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MW$;1C=Z8KI+KX^ZY=7=E<FP*26EQ)<Q^4L" NT93<<+R7#'=G.SJ/,Z#M9_
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M4K=;B!R,'!'0CL0<@CU!KBKXNOAGS3IK7J<5?%XC#-2J4UKU/QE_X4%\3_\
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MT;X8WEY<Z7=7UP]U&L;B[=&  .>-J+7>T45C*3F[R>II&*BK(****DH****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UK_CVC_ZZK69+*D$3
MR2.L<: LSN<!0.I)["M/6O\ CVC_ .NJUSWB/18_$GA[5-(FD:**_M9;5Y$^
M\JNA4D>XS5+8S>YP^A?&5]>CT34H/"VJCPQK4T<-CK V-O$G^JE>$'S$C?C#
M$<!@3@=(Y/C69+>?5K'PMJVJ>%H+MK.35[0)(S%9/+>2.W!\R1 _&5&3@D C
MKC>";_X@>'/!_A'P=;^$C!J&EK::;?:W>RQ/I[6L(5))HE242L[HORJ57#-\
MW YI>&4\??#3P#)X*T'PDVI:Q933P:7K=[/#_9;1.[/'-.!*LWRA\,BKDE>&
M .X &OX<_:7\,^)9_B3:0074.I>!O/DN[*8*KW<$:L?/@.<.A:-TSV9<'&1E
M?#/QWO/'&K:M9>'/!M[J*Z9'9/<32WL$ S<VD5TB@,V3A)5!/J#7E?C3X$>-
M+GX=^,]4T*QB3QW'K&LS6-N\B(FJ:?=C;) 6W$)Y@PR;C\KHN>,T[X?_  KO
MO#'BKQ1<^)_AWKFLK>V^C+:7.F7D 0>1I=M!,I'VJ,Y66-QTYQD'% 'M'B#X
MWZ)X9\>^#_!5[#<-XF\1L0+.W7S5LE\J60/,X^50QA=5YRQ!P"%)'7^)_%NA
M^"=*;4_$6M:?H.FJRHUYJ=U';0AB< %W(&2>@S7#^./#6I^(M;^%-]I^ESPV
MNDZP;N\BGD026D)L;B,;OG.XAG1?E+=?3FCXGZ#JP\?>!_%5EH\WB*RT4WB7
M&GVKQ"=&FB")-&)6525PRGY@<2'&>001U5U\2O"-C<Z1;W/BK1+>?5_+_LV*
M7485:]WG:GD@MF3<2 -N<DX%5/$_Q!;2/$5OX>TK1[G7]<EMC>O;02)$D$&[
M:'>1R ,MP!R3@^AKRGX)_"CQ%X3^(-AK&K:6MG:'3-4V1K)&PL3<ZFUS';#!
M/2-AG;\H((!X%=OXBTW6/"OQ:/B^PT.\\1Z?J.D1:5<V^GR0K-;/%++*D@65
MT5E;S64X;((7@@G !-'\:8;NVTRVM/#NK2^)KZ:Y@&@RQK#+";=@L\DDC'8(
M@63$@)#[TVYSQSGC']J/1_ATND+XJ\/ZQHD]YK@T.X62-7CM283,+CS%)62'
M8,ED)VX;<!M-1QVOQ 'BS1_B%JOAF.XEB2^TP^'=+GC%W;6,TL#02.\DGE23
M PLSJK*H$@"[BF7R_&'A;QI\6O'7@:]USPE!9>$M/U^Y9K&XEC>Z6R?2[N!Y
M;G;(R'?+*JJD>XA2"QY.T&=CX]^/5AX(U:^TQ-(N]5O+?^RQ&+>2-4F:^N&@
MB 9C@89<DGL>,ULW7CWQ!INDW5W>^!M2$ZO%#:VEE<17,EQ)(X3DH<1HN=S.
MY"A023Q7S/JOP"^(6GR^)])OM+G\6Z%97N@0Z/=07,27-[IMM?O.T;[I$Q)#
M%)Y>XE=XC5AR37M%QJ6L>#?".M3> _A?KL>O2>6D$&I75LT;L6VF0YNVR$!+
M%<J6P #SD '?>!?'J^,I=:LY].GT?5]&NA:7UC/(DAC9HUD1@Z$A@R.I_'!'
M%<GX"^-NI>/_  =I_BRT\%WEMX=O;9KM+J:_@WK$ QR8P<Y^7I6C\$/#3>&_
M#=XMWI^LPZU>71N]4U'7/(^T:A<LH#2XAD=50 !%3("JJJ.F3Q/P'^"NH^"?
M@5HEAJAUFW\2PZ/-;S:7-J\LMLDK*XVB(2&+^(8QP#S0(W_#'Q_EU[3_  1J
M-UX1O],TSQG"CZ/<O=0R^9)):M=11R*K$H6C1^3D K@D9%-L?VDM(U>WTFST
M[1]0N_%U[=W-G-X74H+RQ>WS]H:;G:L:G8 ^<-YL>W.X5Y9\.OA3J^@>&_A!
M]E\ :YHGBCPG;6K:K?37T#13+'9&*Y@B47+AC*Y &551UR,8K>\&?#3Q[X2^
M)\/Q8GT^*YU;Q<XLO$WAJ!HB=.L\C[&\4I(#R0 $2\D2>8Q4?(E SL8_VG?#
MLUE\+;B/3[^0>/H%N;=%"[K"(B(,UQSP%DGBB.,_,_UJ[XC^.C:)8^+]3@\.
M3WFB>%YIH;_46O884!BB21RH8Y;&_;CKN4BO+K'X ^)_LWQ6C:S%N]JLMOX)
M)F3:(VNGU %<'* SM%'\V.(!VP:ZBV^&OB35OA;X/TK4=*>"\UGQ,NN^)[0S
M1M]F1YY;MXF(;#A7$,1"EL@=Q0![/X0URZ\2^%]+U6\TBZT&ZO;=)WTR^V^?
M;%AG9)M) 8=QG@\5T&C?\?UW_P!<XOYO5>K&C?\ ']=_]<XOYO1T!;FQ1114
MF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115?43="PN38K$U
MZ(V\D3DB,OCY=V.<9QG% F[*Y8HKP#X0?'K5?^$MNO GQ&B33O%"3-]FN0H2
M*Y!)(0=LX^Z>X]^K/C=\>;T:M_P@/P_1M2\6W;>1+<0<K:9ZX/3<!U)X7ZUM
M[&7-RGB?VSA/JWUF[WMR_:YOY;=_ZV.E^(7[1.F>#_&FE^%=*T^?Q+K=S.B7
M-K8G+0(?T+]]O''4BO#O^"GS$_"GPCU7.M<C_MA)7N?P,^ UE\+;%]1U!QJG
MBN\^>[U"0EBA/5$SVZY/4_E7AG_!4#_DE?A'_L-'_P!$25VX7D6)@HGK9%];
MG757%Z.3TBOLJVS?5]_P/SAM?^/F'_?'\Z_0C4/&OBCQ/^U]J7P[U2XDU7X<
M3Z4!J&DW:![6&#^SED,G(^4B7:=V>">U?GFK%6!!P0<@UZ)KG[1'Q+\2Z%<:
M+J?C;6+S2KB/R9K5[D[)$_NG'4=L=Z^FKT75:M;9KTO;5>EC]"Q%%U6K6V:]
M+VU7I8^D(OV:/AQ/<6/@:'1M7FUC4?"TGB*'QPMXWD1N-S)'Y&-C1C:%)SNY
MQG)#"OJ_[-?P^\2> =,M?"^F7]CXDMGTA-5O+ZYFAN[87,D4<CS6DZ(-G[PL
MK19' Y Z_,<7QA\;P^#&\(Q^*=43PVR&,Z8MPWE%"<E<?W3Z=*]&UW1OC9J.
MA^!_!FL:OJ;:=XA@^TZ9I%W>%1'#"20\H/W%4*7YZ*N>,5SNE5BU>I^/W_AT
MV1S.E5@U>IU[OY_ATV1UW[4/P>^&?@GP?/=>#(;RVU;2=:.CW>TWL\,V$)8R
MRRPI&DP*@[$8C#9&1T]-\._"CPW\3O ?PDG\5EI=&T'P3?:E)9K+)%]H99P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME?S,JNT '=N('(K.\,?M IK/P+U?XC:EH<VB&QFOX!I-Q,&F,D%S);QQL5&
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M-&LD;K(C#(93D'\: 'T4TRHKJA=0[9*J3R<=<4CRHC(K.JLYPH)P6.,X'Y4
M/HICRI%MWNJ;CM7<<9/H/>GT %%%,:5%D6,NHD8$JI/)QUP* 'T444 %%%%
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M&X*H*#A5X->":K<Z+!^W7X9ETVWLM-MHM:T[[4MI=12VZSCR_-8.B(@.>6
M ;=CC%:0JTZETJ:T5_Z_S-(5:=2Z5-:*_P#7EYGFNL?M"?&30-6O--O_ (@>
M)(+VSF:">+^TW;8ZDAAD,0<$'D'%4_\ AIOXL_\ 11?$G_@QD_QK[7\(CP7_
M ,(9?7-M8:1JUL^J:T_BAKV^L($4^9+L^T&6)YMNS:4,)7HN[()KR_7_ !/X
M&D^!L/Q"MH=/CUG7+"'P=<6 B1C;A+AO.N=O!#M;8 8\\H?6IC6IR=O9+>W0
MF-:G)V]DM[=#PSPO\=?C7XS\1:=H6C>//$EYJNH3K;6UO_:K)YDC'"KN9@HR
M>Y(%7M#^+7QX\2>-XO"&F^-?$ESXBEN6M$LAJQ7,JYW+O+A!C:><XXZU]A^)
M9O"6G>+O"!AT[2[?3%\3:4?#FH)?V&/*!4N8$@B$OE[,A_M#G#;2">*^6?@9
MJUOIG[7&H7JSZ4EZ+O4ETXZO*T=K)<.)$1&8<?,&8#)P20,Y(HA4A4C*2II6
M5]@A4A4C*2II65]C.^(WQ$_:!^$^H6MCXH\:Z]I]U<QF6)(M>2YRH."289'
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M]<>:G.17M]9>A^&M/\.-J#6,4B2:A=->7,DT\DSR2E57.YV8@!550H^50H
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M#4O#-SXCM6AU18O*\ORBL,TDVV->)E)DW8&&XX&>N3X"Z/;:E--%J>JS:/\
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MXR7]I[Q+\4?A=XDNM"TJ'0#!X,N=9N+U[F5+BWF62[MRL*[000]L65FP0."
M:]>UO]GC1=3\:W'B^QUO7/#_ (DGGEE;4-,F@W".6"&&6$++$Z[&%M"V<;U9
M<JRY(JEX7_9:\'^$/#FMZ'87.KG3]6TB71)%GNED>*VDFN)B$<IDL&NI,,Y8
MX"YR020-#C?#_P"U,UW\-K#Q';II_P#95U?6N@6%]JUVT+RW1CW33W (S%&
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M*=B0>B=_5OI7U'%"EO$D42+'&@"JB# 4#H *<JA%"J J@8 '04M9SFYOR.W
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M% 79+_:-[_STA_[]'_XJC^T;W_GI#_WZ/_Q5144!=DO]HWO_ #TA_P"_1_\
MBJ/[1O?^>D/_ 'Z/_P 545% 79+_ &C>_P#/2'_OT?\ XJC^T;W_ )Z0_P#?
MH_\ Q5144!=DO]HWO_/2'_OT?_BJ/[1O?^>D/_?H_P#Q5144!=DO]HWO_/2'
M_OT?_BJ/[1O?^>D/_?H__%5%10%V2_VC>_\ /2'_ +]'_P"*H_M&]_YZ0_\
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MB!_H[[HL<!,<5)8?L[^ =,U+2[RVT>XC&FM!);V1U2[:Q\R! D,SVIE\F25
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MQ>4":=8P"[*O4A01DT :=%8%CX^\.:HNO-::W8W(T&1H=4,4ZM]B=4WLLO\
M=(7GGM6=X8^+W@OQI>V]IHGB73]2N;B(S01PRY,J8!W)G[PP0>,\&@#L**JZ
MGJ=IHNFW>H7]Q':6-I"\]Q<3-M2*-5+,S'L  23[5RWA_P",G@CQ5J%K8Z3X
MFT^^N[M2]O#'+S,H7<2F?O?+SQVYH [.BN)T7XV>!/$=]:6>F^*M-O+B[?RK
M=8YAB9^?E0]&/!X![5-:?%_P5?2ZC'!XHTR5].@ENKK;<+B**+_6N3T*KW(Z
M=Z .PHKE/"_Q6\(>-+Y;+1/$-CJ5V\7GI##)\SQ\990?O#D<CUKJZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6P_Y"47^X_\
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MGCCX5>#M7O+Z"]UB]T.PO;XPE01+-;H[$JOW<DL0, >E=>^GVLK*SVT+LI+
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MX48PG*:W9U0HQA.4UNS[9_X)=?\ (^>./^P;!_Z--?HO7YT?\$NO^1\\<?\
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M\1?%S2_#.O0>!3IWA76X[V<:H^K1N\$<<NRV8P[ S>>H+C:<*,9)S7CWQ_\
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MSUG^T;K&B7FO:CXKCMH_#UKXPN--M+K2KWS,646GRW1:5&MQD;8@V%;)9_O
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M110 4444 %6-&_X_KO\ ZYQ?S>J]6-&_X_KO_KG'_-Z70:W-BBBBI- HHHH
M**** "BBB@ HHK$\:>+;/P+X7U#7=069[2RC\QUMXR[MS@  >Y'/0=Z:5W9$
M3G&G%SF[):LVZ*YKX??$+1?B9X<@UG1+GS[=_E>-N)(7[HX[$?\ ZJXSXZ?'
MBP^%.G"QLT_M/Q3> +9Z?'R03P'?'('H.I./J*4).7*EJ<E7&X>CA_K4IKDM
M>_?T[W/0+WQ?HNG>(++0[K4K>#5KU6>WM'<!Y .N!_G.#7AG[9NMW=GX=\/Z
M7%*R6E[/+).@/W_+";0?49?/U ]*L?!/X$:A-K1\?_$1VU+Q7<OYT%M,=PM
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M;WJ7$ES+*%5%4+\B)R0$ [ L ?55Y^U[\&=/BT62Y^(VA0QZSO\ [/9[C N
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M*\T@1C=NW D?PD=3D0L'EZNI1=U>^[U5_P#)D+!9<KJ<6FKWW>JOI^#/4_\
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M7@\3Z=XSL+/QO!+'+'?2:&\M@?\ 0HK6=&M?M0<J_E"1<3 HP4%G (8 V?\
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MK??;5U?6)M5 \@1>2)%C7R^"0<>7U&.O08KKJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@^-GQHU?X0:YH-P^@_
M;O"DY*7U^C'?&YX55'08Z\_>Z#'6N]C^('A^7P>/%(U2W&A&'S_M;. H7T^O
M;'7/%:>N:'8>)=)N=,U.UCO+&Y0QRPRKD,#_ )ZU\N?\,>:N?%[:-_;\R_#G
MS?MOV<2G>6SCR]O3./XO3WKHBJ<U[VC7XGSF+J9CA*SE0C[6$]EMR/\ ^1[]
M41:EJOB?]KOQ.^G:29M"^'5C(%GN6!W7)!S^+'LO1>IS7TWX.\%Z1X"T*#2-
M$LTL[.$=%^\Y[LQ[D^M6_#WA[3O"NCVVEZ5:QV=C;($CBC& !ZGU/O6C4SJ<
MWNQT1U8'+_J[=>O+GK2WE^D>R7X]3\ZOBI_R4[Q?_P!A>[_]'/4'@_Q]K'@8
MWW]E20*M[&(KB.XMTF210<X*N"*G^*G_ "4[Q?\ ]A>[_P#1SURU?J%*$9T(
MQDKJR/W2E"-2A&,U=61V4_Q=\4S:UI^IKJ"VT]@C16\5M D4*(WWE\M0%PV>
M>.:N6OQ<\9:AKMK):W2R3F(V45A!:1_9W1SDIY(78<G!Z=:X&M#0+&^U/6[&
MTTPL-0FF6. H^PAR>.>WUIRH44K\JT78)8>BHWY%HNQZ;-XS^)NG:_'O:&YG
MU)EM(K5([:XM=\)&$5%W1HZ'''!7.3BN1N-<\4^#O&,/B*YN,ZS-NN([TO'<
M)+G*%@RED;H1P>,8[5Z/8:3<^"[_ $SPR;*\CMV-X)=4O+9X(;J^DMI(XTB9
MP/E'0'/S9)Z8QY_XVLY]%\*>%]*U")K?5(5N)I+>48DAC=QL5@>5/RL<'LV>
M]<-%PE)148V?9;K7\-%IYG!0E3E)148VEIHMUK^&BT\R&U^+'B:S\.G1(KY!
M9^2]LK&!#,D3'+1K(1N"GT!Q5&7X@Z_+HVBZ7_:#QV>CRM-9)& IB<G.[(Y)
M!SC/3)]:]>\=:FFFK\16M;73XFTJ]TY;#;9Q?N1(LGF8^7G..<YKHKCPS';_
M !2TZU\/:1:W&C?VI=#55%M'(D9.TA7)!V+M(*#C)+8S67UFE%<SII;O_P E
M3[;V=C/ZS2BN9TDKW?\ Y*GVWM*WK<\=N/CMXRN=0L[QM1A26UE:=!':Q(K2
M,I4NRA<,V"1DY/-8'@OQWJ_P_P!2FO\ 19HH+J6(P,\L"2_(2"0 P.,X%<]1
M7JJA247%15GY'K+#T5%P4%9^1K>)/$MWXJODN[R.TBE6,1@6=K';I@$G[J #
M//6NL_9^_P"2R^%O^OA__13UY[7H7[/W_)9?"W_7P_\ Z*>LL3%1PU116G*_
MR,<5%1PM2,59<K_(^_****_*S\G"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\:UG]L3X.:!JMUIM[XYLTN[61HI5B@GE57!P1N2,J<'T)KV6O
MP.4EE!)R2,DFO5P.$ABN;G;5K'JX#"0Q7-SMJUMC]@/^&V_@E_T/=O\ ^ 5U
M_P#&JDMOVT_@K=7$<*>/+-7D8*#+:W$:@GU9HP /<D"OQ\HKU?[)H_S/\/\
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M44 %%%% !1110 4444 %%%?-&O?$OQE\!OBI=3>,KB76O!&N3[H+N*/BS(X
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M>AA+#2A4UK;-.VO^?]>AZ'\']&T_Q!\.;73]595T^?Q3;+,&. P\F0[<]LD
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MYQ_OU3Y?D@HHHKQSQ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^?$^W(38IPP\L<-@?-U&*]*_X8MU?_H9[+_P%?\ ^*H_X8MU?_H9[+_P%?\
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M&\8VP\8/!&3D-M7L-0_;$\+Z+KNKV]_';KIFEW-]974UIJ,<]Y%-:)(TY:T
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>apre-20251231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '0 VL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&1U.0P/0BI*2:>J ****8!1110 4444 %%%% !1110 4444 %%%% !1110!
MDK->S1D_(J(P^I+9_D*GJK%_R$[C_KE'_-ZM4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 56OYGM[5G0@,"HY'J0*LU3U;_CQ?ZK_ .A"@"W2
MT@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K13.][<1DC8
M@0CCUSG^56:IP?\ (2N_]V/^1H N4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!7OIF@@#(<'>@Y]"P!_0U8JIJG_'J/^ND?_H:U;H ****
M "BBB@ I&8(I+$!0,DGI2UQGQITG4M>^#_CG3=&5WU>\T*^M[-8OO&9[=U0#
MW+$ ?6@"_P"#_B+X6\?0WLGAO7M/UJ*S<1W!L9UD$9(R,X[$9(/0X.":U-"U
M_3?$^D6VJ:1?VVIZ;<KN@N[24212KDC*L.",@]*^;? &F>'?C-XX6.RM3?\
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M** "BBB@ HHHH **** "BBB@"K%_R$[C_KE'_-ZM55B_Y"=Q_P!<H_YO5J@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>K?\>+_5?_0A5RJ>
MK?\ 'B_U7_T(4 6Q2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9^;^\^&_M%_\^8?^ GW#_P )/^Q/_P!"Y?\ _?C5/_BZ/^$G_8G_ .A<O_\
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M]7;O]!P.PKJ:**JK5J5YNI5DW)[MFM##TL+2C1H148QV25D@HHHK(Z HHHH
M**** "BBB@ HHHH **** *L7_(3N/^N4?\WJU56+_D)W'_7*/^;U:H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJW_'B_U7_P!"%7*IZM_Q
MXO\ 5?\ T(4 6Q2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *IP?\A*[_ -V/^1JY5.#_ )"5W_NQ_P C0!<HHHH **** "BBB@ HHHH
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M^G]B>)-8>64W0:XU()K,J*MS,5WE<X8JA7=@*?ERI /N*.-8D5$4(BC 51@
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M_LW!_P#/M'QY>_\ !,_X9VUI+*NN^*2RC(S=6_\ \8J?_AV3\,O^@]XJ_P#
MJW_^,5]8:M_R#;C_ ':MBCVD^X?V;@_^?:/D?_AV?\-O-\W_ (2/Q;YO_/3[
M;!N_/R,TP_\ !,CX9-G.O>*B3U)NK?G_ ,@5]>44>TGW#^S<'_S[1PWQ,^$>
MD?$SX?>*/"DTL^C1^(K7[+>:EI82*[( "AMY4Y8* ,L#QQ756NB6=I<QW8MX
MY+]+=;4WKHIG:,'(4OC)&><=,G-7Z*S/3"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"K%_R$[C_KE'_-ZM55B_Y"=Q_URC_F]6J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *IZM_QXO]5_\ 0A5RJ>K?\>+_ %7_ -"%
M %L4M(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J<'_(2N
M_P#=C_D:N53@_P"0E=_[L?\ (T 7**** "BBB@ HHHH **** "BBB@ HHHH
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M?@-KY\4?!3P+JK:C=:Q)=:):22:A?1"*>Y?RE#2.H) 9F!)P2,G@GK7YK_\
M!6E0W[0GA/(!_P"*6'4?]/D];T(\]11O8:P]/%OV-573_P"'/3/^&1OV?/\
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M'F?48_S'[]?\-$_"O_HI/A+_ ,'=M_\ %T?\-$_"O_HI/A+_ ,'=M_\ %U^
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MO#_W[7_"CV57_GY^"#V=3_GY^"/T&_X=M?#7_HO-K_WYM/\ X_1_P[:^&O\
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M=3_GY^"/T#F_X)N_#:.)F'QXM6(&<>3:<_\ DQ3_ /AVU\-?^B\VO_?FT_\
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M?#7_ *+S:_\ ?FT_^/T?\.VOAK_T7FU_[\VG_P ?K\^?LL'_ #[P_P#?M?\
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M_"9_#[PYKQO+/4&U'3X+IKK3D=+>5G0$M&LGSJI).%;YAT/(KQ?XBZC=Z?\
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M2]_\"'_QH_X2/5O^@I>_^!#_ .-']GR_F#^SI?S'T;17SE_PD>K?]!2]_P#
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M/&Y#B,'4E&:LDW9V=G\SZ1HKYR_X2/5O^@I>_P#@0_\ C1_PD>K?]!2]_P#
MA_\ &OH_[/E_,>?_ &=+^8^C:*^<O^$CU;_H*7O_ ($/_C1_PD>K?]!2]_\
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MQ_R- %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FJ?\
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MP*/^%G^(?^?J'_OP*]R^([+\3W;XCLOQ,[_A"M>_Z!-U_P!\4?\ "%:]_P!
MFZ_[XK1_X6?XA_Y^H?\ OP*/^%G^(?\ GZA_[\"B^([+\0OB.R_$SO\ A"M>
M_P"@3=?]\4?\(5KW_0)NO^^*T?\ A9_B'_GZA_[\"C_A9_B'_GZA_P"_ HOB
M.R_$+XCLOQ,[_A"M>_Z!-U_WQ1_PA6O?] FZ_P"^*T?^%G^(?^?J'_OP*/\
MA9_B'_GZA_[\"B^([+\0OB.R_$SO^$*U[_H$W7_?%'_"%:]_T";K_OBM'_A9
M_B'_ )^H?^_ H_X6?XA_Y^H?^_ HOB.R_$+XCLOQ,[_A"M>_Z!-U_P!\4?\
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M;@4^]\M='H7Q6T'7?AA_PGHEEL] 2SFOIWN8RKP)#N\T.HSRAC<'&?N\9XH
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MJG!_R$KO_=C_ )&@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_DR/5=C?W3^5&QO[I_*O*O\ AY'J'_0@67_@S;_XS1_P\CU#_H0++_P9M_\
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M1O\ XU1_9&,_D_%?YA_8^-_D_%?YGW?44=S%+-+$CAI(L!U'5<C(_2OA8?\
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M\&C?_&J/^'E&J?\ 0AVG_@T;_P"-4?V1C/Y/Q7^8?V/C?Y/Q7^9]WT5\(?\
M#RC5/^A#M/\ P:-_\:H_X>4:I_T(=I_X-&_^-4?V1C/Y/Q7^8?V/C?Y/Q7^9
M]WT5\(?\/*-4_P"A#M/_  :-_P#&J/\ AY1JG_0AVG_@T;_XU1_9&,_D_%?Y
MA_8^-_D_%?YGW?17PA_P\HU3_H0[3_P:-_\ &J/^'E&J?]"':?\ @T;_ .-4
M?V1C/Y/Q7^8?V/C?Y/Q7^9]RQ?\ (3N/^N4?\WJU7P8O_!2'4UN))?\ A!+3
M+JJX_M1NQ/\ TR]ZD_X>4:I_T(=I_P"#1O\ XU1_9&,_D_%?YA_8^-_D_%?Y
MGW?17PA_P\HU3_H0[3_P:-_\:H_X>4:I_P!"':?^#1O_ (U1_9&,_D_%?YA_
M8^-_D_%?YGW?17PA_P /*-4_Z$.T_P#!HW_QJC_AY1JG_0AVG_@T;_XU1_9&
M,_D_%?YA_8^-_D_%?YGW?17PA_P\HU3_ *$.T_\ !HW_ ,:H_P"'E&J?]"':
M?^#1O_C5']D8S^3\5_F']CXW^3\5_F?=-W=PV,!FGD6*($*68X&20!^I%35\
M00_M>:Y\9=+N=+?PNF@6T;13F\2[:7<RN"J@&->X!SGM2:U_P4,UWP_J-Q97
M/@&WW0R&/S#J+J'P?O#]UWZU\UAJ[Q6;5\IA;GI1C)ZK[5[]>BY?O.Z?#V-A
MAH5^763:M=:)6M]^OW'W!17PA_P\HU3_ *$.T_\ !HW_ ,:H_P"'E&J?]"':
M?^#1O_C5?2_V1C/Y/Q7^9P_V/C?Y/Q7^9]WT5\(?\/*-4_Z$.T_\&C?_ !JC
M_AY1JG_0AVG_ (-&_P#C5']D8S^3\5_F']CXW^3\5_F?=]%?"'_#RC5/^A#M
M/_!HW_QJC_AY1JG_ $(=I_X-&_\ C5']D8S^3\5_F']CXW^3\5_F?=]%?"'_
M  \HU3_H0[3_ ,&C?_&J/^'E&J?]"':?^#1O_C5']D8S^3\5_F']CXW^3\5_
MF?=]4]6_X\7^J_\ H0KX<_X>4:I_T(=I_P"#1O\ XU45S_P4AU.YA,9\"6@!
M(.?[48]"#_SR]J/[(QG\GXK_ ##^Q\;_ "?BO\S[S%+7PA_P\HU3_H0[3_P:
M-_\ &J/^'E&J?]"':?\ @T;_ .-4?V1C/Y/Q7^8?V/C?Y/Q7^9]WT5\(?\/*
M-4_Z$.T_\&C?_&J/^'E&J?\ 0AVG_@T;_P"-4?V1C/Y/Q7^8?V/C?Y/Q7^9]
MWT5\(?\ #RC5/^A#M/\ P:-_\:H'_!2?5">/ =K_ .#1O_C5']D8S^3\5_F'
M]CXW^3\5_F?=%S>P69B\Z58_-D$2;C]YCT _(U/7Q/:?M6Z_\6;>TN'\.)X?
MCTN]CNHB+II/M#J"0.47 &??K5&^_P""B^N:;<20W'P^@BD1BI#ZDXZ'WAKY
MG 8AX_,L5EM*SG0Y;ZK7F5]-=;;.VW4[JW#V-I4*=;E^*]]5I9Z?>?<U%?"'
M_#RC5/\ H0[3_P &C?\ QJC_ (>4:I_T(=I_X-&_^-5]-_9&,_D_%?YG#_8^
M-_D_%?YGW?17PA_P\HU3_H0[3_P:-_\ &J/^'E&J?]"':?\ @T;_ .-4?V1C
M/Y/Q7^8?V/C?Y/Q7^9]WT5\(?\/*-4_Z$.T_\&C?_&J/^'E&J?\ 0AVG_@T;
M_P"-4?V1C/Y/Q7^8?V/C?Y/Q7^9]WT5\(?\ #RC5/^A#M/\ P:-_\:H_X>4:
MI_T(=I_X-&_^-4?V1C/Y/Q7^8?V/C?Y/Q7^9]WT5\(?\/*-4_P"A#M/_  :-
M_P#&J/\ AY1JG_0AVG_@T;_XU1_9&,_D_%?YA_8^-_D_%?YGW?5.#_D)7?\
MNQ_R-?#G_#RC5/\ H0[3_P &C?\ QJHD_P""D.II<2R_\():9<*,?VHW;/\
MTR]Z/[(QG\GXK_,/['QO\GXK_,^]**^$/^'E&J?]"':?^#1O_C5'_#RC5/\
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MSK]I/^$*\/\ _0#TW_P#C_\ B:/^$*\/_P#0#TW_ , X_P#XFC^WH_\ /O\
M'_@!_K!'_GW^/_ /Q;R/[R_G1D?WE_.OVD_X0KP__P! /3?_  #C_P#B:/\
MA"O#_P#T ]-_\ X__B:/[>C_ ,^_Q_X ?ZP1_P"??X_\ _%O(_O+^=&1_>7\
MZ_:3_A"O#_\ T ]-_P# ./\ ^)H_X0KP_P#] /3?_ ./_P")H_MZ/_/O\?\
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M9:\SWN]DTGIJSVZG&4Y8:$5%\UW?;;2W3K=_<?C#=W1O+AYF$,;-_#$H11]
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MOV6.>0@E&-/1>?\ P#P?]8(O_EW^/_ /Q;R/[R_G1D?WE_.OVD_X0KP__P!
M/3?_  #C_P#B:/\ A"O#_P#T ]-_\ X__B:K^WH_\^_Q_P" +_6"/_/O\?\
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M /0#TW_P#C_^)H_X0KP__P! /3?_  #C_P#B:/[>C_S[_'_@!_K!'_GW^/\
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M3O\ \\P><8XWK?6_#D/A_P =WFI7MQX3L/%NMZM)H7BM-,$RI:F*U2=(V92
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M\8KZH_X71^QG_P!"[?\ _@)?_P#Q5'_"Z/V,_P#H7;__ ,!+_P#^*H_M2/\
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MAC2<H"ZJ<$J&QD X''M5>WT#3;07HAT^UA%\S/=".!5\]FSN+X'S$Y.2<]:
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M\5?'FU^%.K:U?2R_#R\U>[\3ZE+!&IU6TDD T=20NT;HIF<A<']P.>M>2?\
M!0'XD:OJ%Q\<_">M^/I?"FG:7H6E_P#".^%_L\)3Q$)QNN)"74NY20;1Y9&S
MR\GC.?NCX8_!30/A5J?BC5-,FU'4-7\27@N]1U'5KQKF>3:"(H@QZ1Q@L%7L
M":ZW4_#>DZU,LNH:99WLJH8U>YMTD(0]5!8'@^E 'P/JOQ_\<Z?\0[WR/',M
MCXKTSQII_A_2?A<+.)DU32'$*M<DE?-)9)99/.5@B^4 17+V/[5GQ.\.^,?B
M3'!XND\:ZJ-)\0W>E:7IT$%Q;6C6SGR#- %2YM'C4$;)0XE[,*_2-M!TU]4A
MU)K"U.H0Q^5'=&%?-1.?E#XR!R> <<FBVT#3;/4;C4(-/M8;ZY&V:YC@599!
MQPS 9;H.I[4 ?*'[ ?Q0\>?$'_A,8/%?BK3O%^FVD=C-:W=KJ$5[+!-(CF6)
MY88(HR#M5@F"R'(8G(KZP3_C^O?]Q/Y-2Z5HUAH=L;?3K*WL("Q<Q6T2QJ6/
M4X4 9]Z6#_D)7?\ NQ_R- 'YF)=:#9?M#_&AM:O/@E:1?\)Q*[CXD6X;4S%Y
M%ODP$C'E\-C_ &]^:[V;XL_$S3_&\_B>+X@7\^BP?&Z+P3%X<^RVYM3IDSHK
M N$WE@'^4[N,<YK[DOO /AK4[N2ZN_#^EW5S(VYYIK&)W8^I8KDU=/A[2RNT
MZ=:%?M N\>0F/.'23I]__:Z^] 'YZ>#_ (J_$H? _P"'?BSQ)\6-5TS1_&OB
M>[TS6?$4]K:B/P_:6]Q>+%Y;>7M5IFBC0R2[@HX '6N*\3>.M>^(\#WVNZ@?
M$=O8^"_B/I>E>(Y8%B.LZ?#;Q+!=E5 7YLNN5 #;,CK7Z@GP]I;:2VEG3K0Z
M:V=UF8$\DY;<<IC;][GIUYIK>'-*>*&-M-LVCA@:UC0VZ82)AAHP,<*0 "HX
M- 'YB_\ "VOBCH/@CQ7?>&_B#?Z)I_@3P_\ #\:;HJ65O-:R&_MK2.?S=R;R
MF&9MH8<GJ!6Q\3OCY\8/ >N:Q\/X/',LFG:;XSN-/D\8ZU<VFFR"$:9#<1V\
MEPT#0Q[I'D()CRVS8"":_2 ^%M',4T9TJR,<RQ+(OV9,.(\>6",<A<#;GI@8
MQ1>>%]'U"*ZBNM+LKB.ZD$LZ2VR.)7 P&8$?,0 .3S0!^=%[\7_C1XN\.Z]J
M,GQ*N-#N=!^$@\6E="M(7AO[U)[H12YFBW*LD<49< #D_+@#GTC]C_5+K5_V
ML?BMJ^L^++IM6U[P_P"']6BT.5HECN8YK"*1Y$7;OV0._EK@X D^;+'-?:DN
MA:;.TS26%K(TT'V64M"I+Q<_NVXY7D_*>.>E$&@Z;;7L=Y%86L5W'"+=)T@4
M.L0Z(& R%]NE 'Y[2_&GQ[K?[0WC#P/>_$*ZO[376U_3++3M#2WD.G1Q6LK0
MF2!T2>VD0QJ!*WFQR;FQM!!KQ"']HOQ5\-?V;_A]HW@CXDW\>IZ;X..LM;E[
M*.$3^>4:TWNC/,\2QG_1T0, S,\G0#]>(]!TV+5I-42PM4U*5/+>\6%1,R\<
M%\;B.!QGL*IKX)\/(B*NAZ:%02!0+.+"B08D ^7C<#@^HZYH _-R3XBZU\*/
MBK\6?$$?Q"O+2[NO&WA6ZU.SG-OY:Z5<QVCSSD;"RPQK+Y ;. I&26YK4\?_
M +47C+Q"?'-YX8^)UM8^'(?'\EE8WOVFWM%FT]-.63R;:[EB:%<R%F7S<>9C
M"L.37Z*3^$]%N7F:72+&5IH5MY"]K&2\0QA#D<J,#@\<#TIK^#]"DLIK-M&T
M]K29E>2 VD91RH 4E=N"0  ,],4 </\ LQ^/;KXG? 3P1XGOKB[N[O4-.226
MYOK1;6:9@2ID:)695W;=WRD@YR.#7J%1P01VL$<,,:Q0QJ$2-  JJ!@  = /
M2I* "BBB@ HHHH J:I_QZC_KI'_Z&M6ZJ:I_QZC_ *Z1_P#H:U;H **** "B
MBB@ KR7]JN>6W^ _B5XY'A@)M$O)(V*E;-KN%;HDCD#R3+D^F:]:J*ZMX;JV
MEAN8XYK>1"DD<JAD92,$$'@@CL: /ERVT3P7+\2?'GA](=#CTA=2L#H&F7HQ
MI)UC^SI&F3R4_=L1%Y3E,8W?.!NYJGX;\?:AIW[(^L:%H=GK=UK5GH.M6UGK
M-M;226;RV[74:R0W"@J$)CS$"<A3&.O-?1H\$^#1X7.CC0-#'ATR>8=/%E#]
MDW[L[O+V[,[N<XZUO6-C:6-E;VUG;PV]I#&L<,,*!8T0# 55'  '0"@#XI\6
MV.@Z9\0/#^E>%XK*/X<WD7A0Z]!:8^QR%[NX\DR@?*3)B /N^^NW=D8K$^,F
MIZFOP9^+WA30M/U9/ ?]I:].=0T6V>6"*WAM8F^Q(4&(HWNS.7/"JD<BC&1C
M[7L?!WA*ST._TZST/1H-'NF+7EI#9Q+;S,<9,B!=K'@9R.U6H]%T"S\/)I,=
MAIT.AO$;=;%8(UMC&V<H(\;=IR>,8.30!#X!O_[4\$:#=^1/;>;8PMY5U$8I
M%^0<,AY4^U?F3_P55_Y.$\,?]BLG_I9/7ZI11)#&L<:*D: *JJ,  = !7PA^
MV?H'P9US]H6U_P"%N>)-6\/B+PM:_P!F_P!EQLWFYO+OS=V(GZ8BQT^\>O;K
MPLN6M%V_JQUX67+6B[?U8_-&BOLC_A /V,?^BD>+?_ =_P#Y%H_X0#]C'_HI
M'BW_ ,!W_P#D6OH/K"_E?W'T/MU_*_N9\;T5]D?\(!^QC_T4CQ;_ . [_P#R
M+1_P@'[&/_12/%O_ (#O_P#(M'UA?RO[@]NOY7]S/C>BOLC_ (0#]C'_ **1
MXM_\!W_^1:/^$ _8Q_Z*1XM_\!W_ /D6CZPOY7]P>W7\K^YGQO17V1_P@'[&
M/_12/%O_ (#O_P#(M'_" ?L8_P#12/%O_@.__P BT?6%_*_N#VZ_E?W,^-Z*
M^R/^$ _8Q_Z*1XM_\!W_ /D6C_A /V,?^BD>+?\ P'?_ .1:/K"_E?W![=?R
MO[F?&]%?9'_" ?L8_P#12/%O_@.__P BT?\ " ?L8_\ 12/%O_@._P#\BT?6
M%_*_N#VZ_E?W,^-Z*^R/^$ _8Q_Z*1XM_P# =_\ Y%H_X0#]C'_HI'BW_P !
MW_\ D6CZPOY7]P>W7\K^YGQO17V1_P (!^QC_P!%(\6_^ [_ /R+1_P@'[&/
M_12/%O\ X#O_ /(M'UA?RO[@]NOY7]S/C>BOLC_A /V,?^BD>+?_  '?_P"1
M:/\ A /V,?\ HI'BW_P'?_Y%H^L+^5_<'MU_*_N9\:N-T;C.W*D9]..M?<%C
M'IFI_$;1==\6V.H>&+'3=9TRRTO3;[64O-+U!?[/=8FMT($0\MTMV#KN3]Z-
MQ!S6/+\/_P!C8Q-Y'Q%\6O+CY5^SOR?_  %J<_#[]C:4"-OB1XP<1C 0P2$*
M/0#[+Q6-2HI]&ODS*I44_LO[F>*?'I+Z;P_X&O-7_M6PU>2&^BET?7IQ<WUO
M&MQE96F*J[)(S2;5<?*4?;\I%?HW^P<LS_L5: MM?II5P4U01W\B!UMF^UW&
M)"I(!"GYL$\XKY;T3X4?L@>*_$&G:39?$;Q==:GJ-U%9VZ21OF261PB*6:VX
MRS 9)P*_0CX6?!7P]\*/A9;_  _T\3ZEX?B2XC9-399'E29W>17PH!!\QAC'
M2N'%U8NDH6:=[ZJW<X,94BZ2A9IWOJK=SYL7QY=2^(?"OBS5-=\,^+?$GA73
M[W3K7Q58O+%I]TMT566=U5&"B 6\9EVL0!+P1G ^F_@O<ZC>_#;1[C5?%NG^
M.+Z99)'US2H5BMKC,C$"-59AM487.>=O/-92_!O3X/&?@K4M#OH]'\-^%]-O
M]*'AFRMT%I.MP(0-P!PNSRNF#G<<]\]GX1\&Z'X"T*#1?#NDVFB:3 SO%96,
M0BB0NY=MJC@99B?QKR#QS9HHHH **** "BBB@ HHHH **** "BBB@ HHHH J
MQ?\ (3N/^N4?\WJU56+_ )"=Q_URC_F]6J "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *IZM_QXO\ 5?\ T(5<JGJW_'B_U7_T(4 6Q2T@I: (
M9;VW@?;+/%&V,X=P#7&^//C!H'P]NX+2_%_>7<MK+?M!IEC+=O%:QE1).XC4
M[4!91D]2>,U\>_MI_LN_$[XM_&2XUWPGHOV_2FTFWMEE^WQ0_O%\W<-K.#_$
MO.*]P^*FI^*])\&^$?A]8:/K-I'J6D);ZYXDTS39KXZ= D21R11")6S<R$L$
M)^5 &<DX56MQ22:9PT:]2I5G3E3:4=GW_ [V^_:*\%6-_#"+ZXNK-TLWEU2U
MM)9;*V%WM^S>;.JE$\S>A&3T=2< BM+PS\:?"_BSQ0VA6-Q<?:G:Y6UFGM9(
MX+TVT@CN/(D8!9?+<@-M)_*O'?%TA\0ZYX=^'$7A3Q)HOPLT6WTVXEE@T.ZF
M;5#'L>WL@0A\J*/RXC,SX8X\L#[Y$/PB\%^)+?5_A+H%]H6HV<G@'^U?[4U.
M\@*6]P7CD@A\F3I+YHD\WY<[0N&P<"H.X^G'OK:*3RWN(DD_NLX!]>E(;^V6
M-)#<1"-SA6+C#?0]Z^3/B#\$[_Q'\1?&&L2^%KB]ENOB!X>G@O#$Q8Z:EO:I
M=%&SD0\2K(!@,-P;(KB?$'A-?!FI^.(/%WA6[O\ PC';^)4T'2+:VWBQ:2X2
M2.XBC'^I1D)"3@!8]K#<F[D ^\%974,I#*1D$'@BEK@/V?H)K;X$?#F&X1XY
MX_#>FI(DN=P86L0(.>^:[^@"":_MK=]DMQ%&_7:[@&N<\?\ Q/\ #7PPM-.N
M/$FJ0Z<-2OH-.LXVR9+BXED6-$11RQW,,X' R3@"OA/]MO\ 9+^*_P 7_P!H
MJ+Q1X1T+[?H2Z?80&?\ M&&'YXY)"XVLX/ 8=N:^N?VEO!4WB[P+9'3]&75=
M9M=;TF2%XX!)/#"NI6TDY5L95=D99L'HO/2M9P48IIWO^!K."C&+3O?\#IM1
M^+>DV'CMO"45EJVH:I$D#W#V.G2S06PF+"/S)57:O",3D\#!/!%0^"_C9X7\
M>ZX=+TJXN&E>*6XM)I[62*&^BCD$<DEO(P"RJK%02I/WE/0@UY!\6/ US??$
M'Q!-X:\->)M+\>ZG?:8]AXGM[B9]-:%!&LLDFU_)C"1),C1R+N?(*@EE-+\&
MO".OG6OA-I=WX?U+1E^'V@WNF:E<WL!C@GF=88(E@?I,&6%I"RY !7)!.*R,
MCZ4>_MHW*/<1*XSE2X!'K2-?VR(CM<1*C_=8N,-]/6ODOQ%\$;W6_'>K:M=>
M$YKR6Y^*EE=&ZDA+%])&GPI(<_\ /N7#*Z_=8Y# UYSXO\*'P=H/Q'M?%_A:
M^O\ 18M$\1P^&[&" O\ V6&U&[D21%S^X5XFA,<W"JL14,/ND _0$,& (((/
M(([TM<Q\+X9;?X:^%(IU9)TTFT617&&#"! 0<]\UT] !5*(XU"\/HJ?R:KM4
M8_\ C_O?]Q/Y-0!Y)\.?VI/"_C%H[34V_L#4V.W9<M^Z<_[,G3\\5[-%*D\:
MR1NKHPR&4Y!%?FMX4\":[XYU'[)HFFS7TA;YF1?D3GJS'@#ZU]F? GX1^(_A
MQ: ZQXDEN8F7 TF,[X(C_O-SD>BX%??<09-E^ 3G0K<LOY'K]W5?/[S\AX/X
MFS?-FJ6+P[E#_GXO=7S3T?\ V[]QW'C_ .)7A_X8Z6NI>([[^S[$[R9S$[H@
M5=S,Q4': .23Q4G@CXA:'\1-+;4="NS=V8<)YIB>,,2H88W 9!!!R.*R?CQ;
M37GP/^(<%O')-<2^'=12..)2SNQMI   .22>@KQ+Q3H/B?5/$/A9=)35&O=-
M^&-Y>Z9;+/-';?VPAMA;&10P5G!+@*^1@MD'M\"?KQ]2AU()R,#K[50N_$.F
MV.IZ?IUQ>P17VH>9]EMW<!YO+7<^T=]H()],U\*Z-K?BG3_#%^]O-J5WI4EC
MIEOK<<%UJ 6&X:]C$LUS/*GF1-L\T31P+G80<I@&N?T[3=:FU#^T+V74]1&C
MZAXFL]$U"**]B11-HMK+;B /(S^6\_G["S-N(..,  'Z,^8O]X=<?C1O7=MW
M#/I7PEKO@O6],\*>);RTN?%GVW3OAQHNMV9&H7CL=8+S^;-MW?--B.,,GW<=
M4YIT5YX[E\7Z\;JXO+;Q<M_KC:A!;RW\DO\ 9_DW/V=?+*BWCAV?9&CE0EMP
M09+,XH ^W=8U[3O#]E]LU&\AL[;S8X/-F<*OF2.J1KSW9V50.Y(%7F=5&20!
MZFO@;QAX'NX_"OANTU"+7;W2YO#/A'7M5:^N[N7%Y%J]N+F9CNRLGD/,7"XX
M4-@%01]"_'F:W3QEX%_X2.;4(/AV;>_^WR64\\4?VS;#]D$SPD.%V?:-O(!8
M+G)VT >Z;U#!<C)[53UC6[#P_I5[J>HW<-E864+W%Q<3.%2*-069F)Z  $YK
MY!FGU :YJ"6USXJD\8_VWHP\'1W3W:B31L6GF-(C85AM%[Y[2C?QR0=M<-XH
M\&Z_>_!"S!A\0ZCJ/B/0/&4&J17=S=2^=Y1FDLE:,L0I4QHL> "1Q\P)R ?>
MUCK5IJ,]W%!)N:V9%D)4@?,BN,$C!^5ATJ]N'K[U\::+H]WXP^,FDZ5'<:])
MX$FUY1%%#>7<=N]H/#,#(N_<#Y?GY/49D!SSG/%_\)IXJT#X2^,K;5+GQ,FJ
MZG\/C8:&,7,D\MW;WVJ1$H0,^<L)M&9^&*[6).,T ??V]=V,C/7%"L'^Z0>W
M%?$5O/XZN/BE?17FI7^F>(&\17JR&Q%[<W*Z/Y<@BVP;?L_E>3Y3+(,MYH Y
M8E:])_9%U&ZAO]>T<^=K%I;V-E*WB.*YO6M[N<F961X;K+0W 54>148K\ZYP
M1R ?2U%%% %35/\ CU'_ %TC_P#0UJW535/^/4?]=(__ $-:MT %%%% !111
M0 5Y1^U-?W.G? OQ'+;W$EHKM:07,\,A1H[62[ACN&W#E<0M)DCH,G(KU>J^
MH6%KJEC<6=[;Q7=G/&T4T$Z!XY$(PRLIX((X(- 'S'9^%O"DWQ"\>>$8UTS^
MP[2_L+G0_#U[=F'3)M2;3Y'FA**"&4((YC&%(#'?MSS57P_\3[S1OV3-9TK3
M&UFZ\5:9H6LV]OJ4=I/+;">U:YCW1W0#)L#1'RRS[BH3/)KWL?"OP,/"?]A#
MPWI/]@>?]J^R?9D\KSL_ZS_?[;LYQQG%=+I>BZ?H^CP:7I]E;V>F01"&*T@B
M5(DCQC:% P!CM0!\9^+;'2_#_C[0/"_AHI'\/M7B\+MKD,$Y,$ADN[E4:0YZ
MS^7"CD_ZP ;LYYZ"U\):%XKT3QWX?@GTFYNM*UO6(/"FEZU?O%80P&*U^T2H
MB9)\B:655('[LL5!3.1]%Z=\+_!.F^']2TBS\-Z1!H]\VZ\M([5!%*1C!88Y
MVX&/[N!C&*CU+X4^!=3\.:=H][X9T>?1K)BUI:26J&*(MG<5&/XLG/\ >R<Y
MH @^!6OKXI^#'@;55EO+@7>BVDAFU''VB4^2H+R$$@LQ&202#G(-?G)_P55_
MY.$\,?\ 8K)_Z63U^J-O;Q6D$<,$:0PQJ$2.-0JJH&  !T ':OBG]K#X-?#G
MXM_M!K_PG_CI?!?V#PO9_8MUQ!%]IWWE[YG^LZ[=B=/[W/:NK"S4*T9/^M#J
MPLU"M&3_ *T/RYS1FOO7_AC/]G/_ *+I'_X,;*C_ (8S_9S_ .BZ1_\ @QLJ
M]_ZU3[/[F?0?6J?G]S/@K-&:^]?^&,_V<_\ HND?_@QLJ/\ AC/]G/\ Z+I'
M_P"#&RH^M4^S^YA]:I^?W,^"LT9K[U_X8S_9S_Z+I'_X,;*C_AC/]G/_ *+I
M'_X,;*CZU3[/[F'UJGY_<SX*S1FOO7_AC/\ 9S_Z+I'_ .#&RH_X8S_9S_Z+
MI'_X,;*CZU3[/[F'UJGY_<SX*S1FOO7_ (8S_9S_ .BZ1_\ @QLJ/^&,_P!G
M/_HND?\ X,;*CZU3[/[F'UJGY_<SX*S1FOO7_AC/]G/_ *+I'_X,;*C_ (8S
M_9S_ .BZ1_\ @QLJ/K5/L_N8?6J?G]S/@K-&:^]?^&,_V<_^BZ1_^#&RH_X8
MS_9S_P"BZ1_^#&RH^M4^S^YA]:I^?W,^"LT9K[U_X8S_ &<_^BZ1_P#@QLJ/
M^&,_V<_^BZ1_^#&RH^M4_/[F'UJGY_<SX*S1FOT0\)?\$_/@GX]U"6P\.?%J
MZUR]BB,\EOI]S:3.L8(4L0H) RP&?<5UG_#J/P-_T.'B'_OB#_XFI>-HK1_D
M0\;16C?X'PM^S[JTV@ZYXIU"VTC4M9N8O#=['''I$Z174!D,:&="P)^12V2B
MLP#9Q@$U[9H^BW&@:EK6C68\8ZC+XDU[0X[W7+&]B6_TKS+4O]FNN"Q>,S'=
MPB-Y0!92,5[VG_!+GP7I6Z]M/'/B6"X@SMFMS"CH<8.&4 @X)'![U=@_X)=^
M%;66XD@\?^+()+G(G>*6-&FSG.\@9;.3G.>IKFGB:,FW?\&<\\51DV[_ ('Y
M_P#PKLETW]H[P?9I>+J"6_B^SA6\3[LX6_1?,'LV-WXU^QOQKUSQ/X7L]#U?
MP_K_ (<T>TM;W=J5MXC9HH[V KCRHI0?W<F>02".F>*^?O!W_!,?P9X-\7:%
MK]OXKUV:?2;^WOXHI$AV.T4BR*IPN<$J!Q7U5XI^'7AKQOJ&AWNOZ+::M<Z)
M=?;M.>[3>+:?;M\Q0>-P!X)!P<$<BN'&5H5G%P>QPXRM"LXN#V/F7X8>(M6L
M=4FT3P;K&@>'&\1>)7\4ZE)KMV;F9HKEPTME;Q*?]>H0*P) 3<O7=7UX*\B\
M._L\Z7/9:Q;^.?LGC3S?%ESXHTM[JVV-IK/(KQ(ASG*%?O C.<$8KUWI7GGG
M"T444 %%%% !1110 4444 %%%% !1110 4444 58O^0G<?\ 7*/^;U:JK%_R
M$[C_ *Y1_P WJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M/5O^/%_JO_H0JY5/5O\ CQ?ZK_Z$* +8I:04M !2$ ]1FN3\3?$:R\,:DUG/
M;7$KB,2;H]N,'/J?:N)_:1^)OBSX>_#:VUWPEIMI/ONK47EY?R?+:6\D\2$K
M&.9)&\S:HX /)/ !TE3E%*36C-)4Y12DUHSV+:/048&:^>?B=\8?%.C>(?B#
MJ.CW5I!HOP^73S=Z=-;[WU(SJLT_[S(\O;"Z!, _/G/'%)\,/C'XH\0:[\/]
M6U&ZM+KP_P#$$ZB;.PCM_+DTU85>:W^?)\S=#&P?(&'(QQ69F?0^*P?$G@'P
MSXQN+2?7O#^F:S-:$_9Y+^SCF:+)!.TL#@$JN1WP/2O,O%G[3EKX8\7ZMHB>
M$]:U*/3-9LM GOK8PB,W=W%');J@:0,P)F16;&%SDX'-5_\ AJBTGMKR*Q\)
M:SJ&MZ7'J$^KZ3 \'FV,5G*(I6+&0+(68_(J$E@#@<&@#W, *  , =A2UA^!
M_%=MX[\%Z!XELXI8+36-/M]1ABG $B)-$LBJV"1D!@#@]:W* $H.*\&^,'[7
MWASX-^/5\*ZGHVJWMXT$$_G6@B\O$K, /F<'(VG/%:G[2.N^*?"V@6E]X6\1
MC3M7O[B'1]*TQ[%)TN[^=RL99BP*HHR[XZ)&QZUM.C4IQC*:LI;&TZ-2G&,Y
MJREMYGLN!G/>C KYM\2_%KQEX=NO%FK#5+.XTCP)J&E:-?V?V+:^JR31VS7,
MP;=^ZP+M2BC<,QD$D-QZ#\5/CK#\,]<@TA/#NI:]>/H][KC_ &%H42*UM6C6
M8LTCKS^]7 '7FL3$]1Q6!XA^'WACQ;?6=[K?A[2]7O+/_CWN+ZSCF>'D-\K,
M"1R ?J*\HT_]JRUU7Q!I'AZU\(:R_B+7+&WU;2-.=[=&N[&5)7^T%C)MB"B%
M@RR%6!9!C+"O2/A/\1[3XM> M.\4V5A>:9;WCSQ_9+]56>)HIGA=7 ) .Z-N
M] '7T444 %4X!G4;L?[,?\C5RJ*2"*^O7(+!40X49)X;H*-@(]-TG2_"FE>1
M8VMOIMA"N=D*!%4#N?\ $UH@Y&1TKQ_XK_$V.30;[1K>QOH)[@>4T\\)C4+D
M;L9Y.1Q^-;G@#XHQZ[I]E:RZ??\ VI(E229("\;$#!.X=,^]>(LZPU7&/#N=
MW:]]=7=W7Y'#3K482]C"R26EMO0]$-&*\>_:0^(>H> ;+P0MGK]IX8MM9\0I
MIM[JEY"LBP0FUN)<@,R@$O$@R3W-<?X:_:(U+P]!XD_M!AXWT:VU&*UTKQ#8
MI%:6]RIM//N/,E=Q"HB(*[]V&+*HRP->V=Q]([1@]?SHVCW_ #KYA\5_MFKJ
M'PVUG6O _A>^U6^M_"%QXG$US)#';VJH]Q"!(3("Y66VDR$SN !4G(KHU_:3
M&C?VVNH:1J$VHV4UG#/:,UM#;VADT]+MV:Y,GEA K'YG(RQVKNH ][Q1M&<U
MXA\%?C]_PN?QW</I?R>%YO#%CJMM#+&!/'</>WUO.K,&((!M0!CC@D$@BF0_
MM3V-W9V\UOX9U(R:CJMYI.E0SW%M$;U[1YDNI<M(!'&A@8;I"NXL@7)84 >Y
M;0:" 1S7AVA?M7:+XKU_2-)T31-0U"YN[:*YN4,L$3VJM<R6S@(\@,IBDAD#
M^4&  !YW#,=O^UIH=OIYUC6M!U?0?#,DNIV]OK%TL3Q3RV/G&90J.SC*VTS(
M2 &V$#G H ]UVC.:,5X=J?[4,6@O;6.K>"]<T_7KV;3DLM)=K=I9TO96AA<,
M)"B[9$VNI8%,@D8(-0R_M8:>M_I^DQ^&-3DU^::_@GTM[BVB>)[214E1'>4)
M*Y#AU6-F)7F@#W<*!_\ KH*@^OYUXY=?M+Z(OC"71(K*X^Q+JZ>'3K#/%Y*:
MBX4+$8M_FE0[I&7"[=YQG@XT_@_XG\<7'A?6]1^(]A;Z1-:SO) D,6S-J%\Q
M7;YVYVG!7JI4@YQD@'J&!G/]:  O_P"NODP?'CQ%K.O^!EUCQII?@'2?$WAR
M[\3127%K&Y"M<VZVMON=P"P@FRQ'5LXP!6?I?[0GB+5/$.CZ=XE\>Z5X%TQM
M#O+]-5NK%(QJ2Q:E+;PW"B5QL62!$EV\_>R#C% 'V)17S[\//C)XHGM/AIJ'
MB(VTNE^*+V^T(7$=NT)GE0SR65ZBDDK'<06[';V+H02#7T%0!4U3_CU'_72/
M_P!#6K=5-4_X]1_UTC_]#6K= !1110 4444 %>5_M/:M>Z+\$?$$]C=2V$DD
MEI:RW4#['A@FNX8IW5OX2(G<[NW7M7JE4M9T>Q\0Z5=Z9J=I#?:?=Q-#<6UP
M@>.5&&&5@>""* /FZR\*://XX\>^"(KIYM#TV\L;S1_#\^K206UQ>26,K2VS
M2?,YC 5)R@)PQW8(XJEHOQFF\/\ [+6KZ;;ZE?7?CO2]"UB**9X9) MS:&YC
M.V;!5U1H2%8ME@BD\G%>X?\ "D/ _P#PC0T/_A'[8Z>+O[>"7D\X7&-OG>=N
M\S?M&W=NSM^7[O%=-HWA;2/#_A^WT/3M.MK/1X(?L\=C%&!$(SG*[>A!R<YZ
MY.<YH ^0O%L">$?'N@^"M"O[S_A"M>C\-OK!^WRR9,MW<HS&0L64W BB1\$;
M@/<YNZD?#EIH'BO3=4;5?$LFF>)-2T'P=X8M=0E!NY)(+>;:NU@Q\EVF42,V
MV&,/G&W(^C-/^"?@?2_#NI:';>'+*/3-0:-KF'#-O,>/*PQ)9?+P"@4C81\N
M*HWO[/?P^OH])5_#L,;:7%-#9RP3S121+,X>;YT<,2[ ,Q))8\DF@#H_AMI.
MKZ!\/?#.F:_J U77+/3;:WO[X'(N)UC59),]\L"<]\U^9O\ P564']H3POD
M_P#%+)U'_3Y/7ZEZ5IEOHNFVMA:(R6UM&L42L[.0H& "S$D_4DFOAC]M']GR
MV^.O[0=M]H\;:/X._LOPO:A?[6/_ !\>9>7F=G(^[Y8S_O"NO"R4*T92V_X!
MUX22A6C*7]:'YG[%_N+_ -\BC8O]Q?\ OD5]C?\ #OK3?^BV>#_S_P#LZ/\
MAWUIO_1;/!_Y_P#V=?0_6:7?\&?0_6:7?\&?'.Q?[B_]\BC8O]Q?^^17V-_P
M[ZTW_HMG@_\ /_[.C_AWUIO_ $6SP?\ G_\ 9T?6:7?\&'UFEW_!GQSL7^XO
M_?(HV+_<7_OD5]C?\.^M-_Z+9X/_ #_^SH_X=]:;_P!%L\'_ )__ &='UFEW
M_!A]9I=_P9\<[%_N+_WR*-B_W%_[Y%?8W_#OK3?^BV>#_P __LZ/^'?6F_\
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M$'E&L_L_6&LZYK.I/JMS&^I>)],\3.BQJ0DEE'"BQ#_9;R 2>HW'%>8_$3X
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MVH?S(^B]M1_F7WH\(_X3[Q1_T,VM_P#@TN/_ (NC_A/O%'_0S:W_ .#2X_\
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M<#&3GN_ /PA3P!XLU+5=-US54T:^M(HD\,7$_G65C*I&7@+99 0,;,[1SC'
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M.]NY1<W=IK,L=MI5BD.XW<A8G> VXLN4 5>I)JE_PPK\</\ H0[K_P "8/\
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M:;>PM!<VMP@>.6-AAE8'J"*FTW3;71]/MK"QMXK2RMHUAAMX4"I&BC"JH'
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MQU_T*VB?]_Y?\*/^'F_CK_H5M$_[_P O^%?(?]DWW_/C<_\ ?EO\*/[)OO\
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M4?\ -ZM54B8?VE<<_P#+*/\ F]6=Z^HH =13=Z^HHWKZB@!U%-WKZBC>OJ*
M'44W>OJ*-Z^HH =13=Z^HHWKZB@!U%-WKZBC>OJ* '44W>OJ*-Z^HH =13=Z
M^HHWKZB@!U%-WKZBC>OJ* '53U;_ (\7^J_^A"K6]?454U5@;)\'/*_^A"@"
MX*6FAU]11O7U% #J*;O7U%&]?44 .HIN]?44;U]10 ZBF[U]11O7U% #J*;O
M7U%&]?44 .HIN]?44;U]10 ZBF[U]11O7U% #J*;O7U%&]?44 .HIN]?44;U
M]10 ZJ<'_(2N_P#=C_D:M;U]152!A_:-WS_#'_6@#Y4^-P*_%;7RRD!OLY!P
M>1Y"5T'[-*D^/=28*=HTS!..,^<E?2IV$\X- *+TP/I0!YC\=O#NJZE'X)US
M2=/DU:3PSXBAU>XLH"/.E@\B>"3RP?O,HGW;>IVD#G KQSQ5\,/$/Q,^(4?B
MR;PM<QZ-?^*O#K-I^I1JLHM+&.[\V>6,GA/,N% 4\G;G&#7UD64]2* 5'3%
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M- 'P7HOP0^(^E^%+FT30;N[U_3=!U*SU O;1VT.J2S%009TDWW9D(:5<E<'
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M9?\ 0T^*?_!I_P#85Z?10!YA_P *(LO^AI\4_P#@T_\ L*/^%$67_0T^*?\
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M_P#H:O%?_@V/_P 31_PHBS_Z&KQ7_P"#8_\ Q->G44 >8_\ "B+/_H:O%?\
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M_P#!L?\ XFI)/VA_ ]O\.[3QI<:G+:Z+>7)L[47%K*D]Q.&9?+2$KO9B5;
MZ GI72_#_P"(N@?%#PZFM^'+]-0L3(\#D J\4J'#QNIP58'JI (H Y;_ (41
M9_\ 0U>*_P#P;'_XFC_A1%G_ -#5XK_\&Q_^)KTZB@#S'_A1%G_T-7BO_P &
MQ_\ B:/^%$6?_0U>*_\ P;'_ .)KTZB@#S'_ (419_\ 0U>*_P#P;'_XFC_A
M1%G_ -#5XK_\&Q_^)KTZB@#S'_A1%G_T-7BO_P &Q_\ B:/^%$6?_0U>*_\
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M-XOM_"^EP^)92SOJ:6RB8LPPSY[,0,%AR>YH [ 4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5#=SK:VLTS':L:,Y.,XP,]*FHH ^%?"-YJOP2^
M'OP>D\$?%.3Q_I_B#6XM(;2'MHHX[F&ZDF>6>)5'F1R1,6=BQ(X;(%5]!O\
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MGPS\$1>*/^$Q\)/XFLY[[4!:?9V262)HI<J0 K1%202<G !H ^NJ*\@_9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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<:U@>60274GF2LTDC2.6; R2SL: -VBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>apre-20251231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '& S0# 2(  A$! Q$!_\0
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M\/\ X,>(;?1/%>K2V&HSVJWD<:6TD@,3.Z Y4$=8VX]JXW_AO;X,?]#)/_X
M3?\ Q-?)W_!3?_DO.A?]BW!_Z575>/?#K]F7QC\4OAEKWCG0OL$FDZ-)/%<0
M33LMP[10I*P10I!^5UQR,G-?0TL#AY48U:DFKGT5' 8>5&-6I)JY^B7_  WM
M\&/^ADG_ / ";_XFC_AO;X,?]#)/_P" $W_Q-?G9X7_9G\8^+/@]JOQ+M/L$
M/AO3A,T@N)F6>18L;RB["",DCJ.0?2O**Z(Y;AIMJ,GIY_\  .B.68:;:C)N
MWG_P#]:O^&]O@Q_T,D__ ( 3?_$T?\-[?!C_ *&2?_P F_\ B:_++P+X-O\
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MASC+X..A]N.M:2RS#P7-*32_KR+EE>&@N:4FE_7D?I/_ ,-[?!C_ *&2?_P
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M<,KWD]-_ZL9O+,,KWD]-_P"K'ZA?\-[?!C_H9)__   F_P#B:/\ AO;X,?\
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M95#N_P"OD']DT.[_ *^1^M7_  WM\&/^ADG_ / ";_XFC_AO;X,?]#)/_P"
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M\&/^ADG_ / ";_XFOR5HJO[*H=W_ %\BO[)H=W_7R/UJ_P"&]O@Q_P!#)/\
M^ $W_P 31_PWM\&/^ADG_P# ";_XFOS.\%?!W7O'O@KQ9XHTV2S73?#,"SWR
MSRLLA4YQL 4@G@]2*X:I668=MI-Z?UV)65X=MI2>G]=C]:O^&]O@Q_T,D_\
MX 3?_$T?\-[?!C_H9)__   F_P#B:_*;PWX=U#Q=X@T[1-*MVN]2U"X2VMX5
MX+NY  SV&3U/ KU:T_9+\=:I:^.YM..FZF?!LK0ZC%:3N[R,J;V$(V#?@ \<
M'(P,U,LNPL/BDU\U_D1++<+#XI-?-?Y'Z!_\-[?!C_H9)_\ P F_^)H_X;V^
M#'_0R3_^ $W_ ,37YE77PDURS^$MG\1)'M/[ NM2;2XT$A\\3!68Y7;C;A3S
MG\*XH D@ 9)JEEF'ELW_ %\BUE>'EM)_U\C]:O\ AO;X,?\ 0R3_ /@!-_\
M$T?\-[?!C_H9)_\ P F_^)KX'O\ ]C;XA:=H5S>2_P!C-JMM8?VG-X<BU)'U
M2.VQDN8![=@<]NO%5_"G[(OC[QCX/LM?L!I"G4+66\L-*N-02.^O(8_O/%$>
MHZ=2.H]16/U+!VOS_BO\C'ZC@K7Y_P 5_D?H!_PWM\&/^ADG_P# ";_XFC_A
MO;X,?]#)/_X 3?\ Q-?F#J_PRUG1OA_I'C*402Z-J-W-8@PN6DMIXCS',N/D
M8CY@,G(.:Y.MUE>'ELW_ %\C997AY;-_U\C]:O\ AO;X,?\ 0R3_ /@!-_\
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M7Q@\>Z%)>R:;XW\1Z?)?3FYNGM=6N(C<2D &20JXW,0!\QR>*OZG-2YDU?\
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M-<;;?\?,7^^/YUV7QM_Y*[XP_P"PG/\ ^AFLW\:]'^AF_C7H_P!#B:***T-
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M;_Z)'I'_ '[3_P")KG:*ZOJM/S^]_P"9U_5*?G][_P SHO[+^#?_ $2/2/\
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M#_KYGM\G[2_PVAU@Z7)XE5+Q=0;2G#65P(X[I6"F-Y/+V)R< L0#S@G!JO\
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M_P#.LJ/_ %B_45J^+O\ D:-4_P"OA_YUF_C7H_T,G\:]'^AD4445H:A1110
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M3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\
M/&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_
M\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H
M_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%
M+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O
M^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M
M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!
M"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6
M:'\Z^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z
M^\/K5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K
M5#^=?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=
M?><+17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+
M17=?\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?
M\*7\3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\
M3?\ /&V_\"%H_P"%+^)O^>-M_P"!"T?6:'\Z^\/K5#^=?><+17=?\*7\3?\
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M.&.=W0D=3]5?V.__ #VB_P#'O\*/['?_ )[1?^/?X4M!ZGPIXB\(ZM\%M/\
MB#I0ETK5M;\7>&)+#^S;G[4"6^U:@T(M2("MRSB]*M"I#*RJ2<.#79#]GCQT
MF@:UH=JND?V?K?B+0O$4MU<7DB3VPM$T]9H!&L; M_H1*ONP=V"!UKZY_L=_
M^>T7_CW^%']CO_SVB_\ 'O\ "@-3YF^%_P"SMJW@W6?!L6H06MU9^%[BXGAU
M.77]2N&F+1RQHT5DT@@@<K,V\_.N-P51N!7Z)K0_L=_^>T7_ (]_A1_8[_\
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M*Z$?!;Q+KWQ&L/&^MW6EV>I)K%E=2Z=8S23PQVMM:7D**LK1H7D:2]=R2B@
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MUM_SU/\ WR:^4=#_ &A?%TW@;Q[J^JV=A9WL6@S>*?#40A8![ M,(1,"WSN
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M6)?#H&JVQCG$I>TNEG!MV<*H/#C()Q@[:^FO[('_ #W_ /'/_KT?V0/^>_\
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MY;:JKDDD$^[_ -D#_GO_ ..?_7H_L@?\]_\ QS_Z]%T&IEQQI$@1%5%'15&
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MMYNY4 *OB0(SIDQJ^#6[8?M(Z3+/K]K=^']=@N/#MM:2:M(MO"\<,]S!%+!
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MZ2?D*+A8RJ*U?[*@_P">DGY"C^RH/^>DGY"BX6,JBM7^RH/^>DGY"C^RH/\
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M\])/R%']E0?\])/R%%Q6,JBM7^RH/^>DGY"C^RH/^>DGY"BX6,JBM7^RH/\
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M2QMM*M-+L*!=H;:,   $=U\.]4NM<^'_ (8U*^E\^]O-+M;B>7:%WR/$K,V
M !DDG &*Z&L[PYH</AGP]I>CVSR26^GVL5I&\I!=EC0*"V !G YP*T:8!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%  .M/F_UK_6F#K3YO]:_UI ,HHHI@
M%%%% !1110 4444 %>-_M/\ C#QKX'\'Z/J?A*ZTZPM1K.GV^IW5RIDN/)FO
M;>'RX8RI3+"5]SL?E"_*I+93V2N7^)'P_L/B;X7.A:E/<6UJ;RTO?,M2H??;
MW$<Z#Y@1@M$H/'0G&#S0!C?&_P <7W@GPC9)I+"/6]=U:RT'3YF4%8);F98S
M,000?+0R28(.2@'>O._'7Q?\20_'[X;^&- O5'A7^VI-'UVZ:)':^N3IUS<"
M%6VX7R_*1G*8.YPO&U@?2OC/X$N?'O@V.'365-<TJ_M=:TMG(53=6TJRHC$]
M%D"M&Q[+(37/:_\ LN?#7Q5XR\.^,9_!>BZ9XATS5&UJ:XM-+M5EO;AXI%(N
M9/++28>7S,YSYB(V>*0%WXXCQ5I^@7>M:!KNK6<5A83M'I6@:7#=W=Y=D#R<
MM*& C&""H5<[LEU YR_A[\2=8U#QAX3M]2U*SU?2_&'A=-8LY+#:T5O=P"$7
M2QN "T,@N8F3=E@4?G! 7J?$?PUU#7I;6Y@\<^(M'OHK::TDGL9(0D\<C;LM
M"T;1"1< +(JAP!C)R:Q?!?PF/AKQ]I<T%LEEX5\)Z NA>'[<R^;*YE9&N9G/
M4?+!;HN>21*3P10!ZI1113 **** "BBB@ HHHH *?#_K4^M,I\/^M3ZT ,HH
MHH **** "BBB@#ROX@:MKNL_$W3/".D:_=>&X?[$NM7ENK*"&22619(XHT/F
MHZ[ 79B  3@<COE-\8-6O?V:?#GC&$16WB'7;33K>-]F8XKNZDBA\S;W57DW
M 'L *[3QS\,H_&.K66JVVN:EX=U6VMIK+[9IOE%I+>7:7C82HXZHK!@ 01P>
M36?XV^%45U\'H?"'AR..V?2(;1M(CF;""6T>.2!7;!X+1*"V,\DT@/.M:\?^
M*=*F\1Z_'XBNWL/#?B?3O#_]DR6]OY5W"[6L<TLC>6'\UC<LP*LJC:ORXS7I
M/PL\97NLZWXY\-:K.;O4O#.KBU^TLBJ9K>:".Y@8A0!D++L.!_RSSWJG=?!6
MQUW7'U>YU#5+&SO[ZUUF^\.[H&MI+R$(49VV%^#''E5?:3&#SSG3^&/@RZ\/
M7OB_7-4B2+6/$FKM?3(K!_*ACBCM[>/<.N(H58_[3M0!W5%%%, HHHH *DM_
M]>GUJ.I+?_7I]:!FO1114%&/K%]';7*JZ,Q* Y!QW-4?[6A_YY2?]]#_  I?
M$O\ Q_1_]<Q_,UDUHEH9MZFK_:T/_/*3_OH?X4?VM#_SRD_[Z'^%95%%@N:O
M]K0_\\I/^^A_A1_:T/\ SRD_[Z'^%958'Q!\4_\ "#^!/$/B'RA/_96GSWOE
M'H_EQEL?CBBP7.T_M:'_ )Y2?]]#_"C^UH?^>4G_ 'T/\*\2M(/&'A*PM?&.
ML>.VU71UMI+[7-+O+"W2VMH/*:0FR:*-95*,% $SR[ESDAL&N?U[]J1_!^AQ
M:CK_ (+O[%]0TK^V=(M(;N.66\@$T$3Q.>%BG47,+;,LI#$"3Y31H%SZ-_M:
M'_GE)_WT/\*/[6A_YY2?]]#_  KY\U;]I)_#U]=:-J^@6NE>(;?4K;3W2[U=
M4T]!/ 989&NO+^7=M:,*8\[\#H0:Q/%WQX\2Z7K&L27&G#2M!M?"4&M$6-[!
M->)/)=-$=K&*2)A\N <D8YZD!30-3Z>_M:'_ )Y2?]]#_"C^UH?^>4G_ 'T/
M\*^??#_[2<NIR+>WOA&[L/#3^(KOPQ'JBW2S2/=0S2Q*_D*N?*=XB@8$L'8#
M9M^>O/\ Q]^V3>)X3URWT+2K2P\2R:#+K.F[]02Y:VC66&-ENHU0B&X5;B-A
M'F1<A@6^7#&@:GV%_:T/_/*3_OH?X4?VM#_SRD_[Z'^%>":;\;-0D\1:GX=M
MM(FU3Q.VN3:?'8W%]'':VZPV%K<3,LRPAO*4W"J-R.Y=^H7 2E-^TU+<P7$N
ME>$)[W[!HD^M:BMQ?) ;<07,]M/ ORMOD$EO(!T5L<LO&30-3Z(_M:'_ )Y2
M?]]#_"C^UH?^>4G_ 'T/\*PM.OXM4T^UO8,F&YB6:/<,':P!&?P-6*+!<U?[
M6A_YY2?]]#_"C^UH?^>4G_?0_P *RJ*+!<U?[6A_YY2?]]#_  H_M:'_ )Y2
M?]]#_"LJBBP7-7^UH?\ GE)_WT/\*/[6A_YY2?\ ?0_PK*HHL%S5_M:'_GE)
M_P!]#_"C^UH?^>4G_?0_PK*HHL%S5_M:'_GE)_WT/\*/[6A_YY2?]]#_  K*
MHHL%S5_M:'_GE)_WT/\ "C^UH?\ GE)_WT/\*RJ*+!<U?[6A_P">4G_?0_PH
M_M:'_GE)_P!]#_"LJBBP7-7^UH?^>4G_ 'T/\*/[6A_YY2?]]#_"LJBBP7-7
M^UH?^>4G_?0_PH_M:'_GE)_WT/\ "LJBBP7-7^UH?^>4G_?0_P */[6A_P">
M4G_?0_PK*HHL%S5_M:'_ )Y2?]]#_"C^UH?^>4G_ 'T/\*RJ*+!<U?[6A_YY
M2?\ ?0_PH_M:'_GE)_WT/\*RJ*+!<U?[6A_YY2?]]#_"C^UH?^>4G_?0_P *
MRJ*+!<U?[6A_YY2?]]#_  H_M:'_ )Y2?]]#_"LJBBP7-7^UH?\ GE)_WT/\
M*/[6A_YY2?\ ?0_PK*HHL%S5_M:'_GE)_P!]#_"C^UH?^>4G_?0_PK*HHL%S
M5_M:'_GE)_WT/\*/[6A_YY2?]]#_  K*HHL%S5_M:'_GE)_WT/\ "C^UH?\
MGE)_WT/\*RJ*+!<U?[6A_P">4G_?0_PH_M:'_GE)_P!]#_"LJBBP7-7^UH?^
M>4G_ 'T/\*/[6A_YY2?]]#_"LJBBP7-7^UH?^>4G_?0_PH_M:'_GE)_WT/\
M"LJBBP7-7^UH?^>4G_?0_P */[6A_P">4G_?0_PK*HHL%S5&K0Y'[I_^^A_A
M4ESJ<23R*8W)#$9##_"L<=14U]_Q^3?[QHL%R]_:T/\ SRD_[Z'^%']K0_\
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M[(((*CMD5S+_ ++.DKX?;1[?6KNWM)M'?1[C;!'F16NFN@Z\ )B21P% P%(
MZ5]#?V=;?W'_ .^__K4?V=;?W'_[[_\ K47"Q\M_#K]G'5[K1=6T[QIJUW'H
MK^*]8UJUT. Q8Q-=3M;R><F6 VRB4)D$.1GIMJ>[_9 L]5T_3K/4?%E[<1:=
MX>G\-VJ0V-O"J02>0?-8*OS2[K>,D]#C&!7T[_9UM_<?_OO_ .M1_9UM_<?_
M +[_ /K4: >'P_ 8V6LS^(+/Q)<VWB:759=4_M#[+&R9EL[>UEB,1X*,+:-^
MN0PZXX)I?[.^D:38:I;1:G>-_:6A3Z+<2.%+,9KB>XEGZ??:2YD..@XKW#^S
MK;^X_P#WW_\ 6H_LZV_N/_WW_P#6HN!S6AZ6FAZ+I^FQNTD=G;QVZNW5@BA0
M3^57:V/[.MO[C_\ ??\ ]:C^SK;^X_\ WW_]:BX6,>BMC^SK;^X__??_ -:C
M^SK;^X__ 'W_ /6HN%C'HK8_LZV_N/\ ]]__ %J/[.MO[C_]]_\ UJ+A8QZ*
MV/[.MO[C_P#??_UJ/[.MO[C_ /??_P!:BX6,>BMC^SK;^X__ 'W_ /6H_LZV
M_N/_ -]__6HN%C'HK8_LZV_N/_WW_P#6H_LZV_N/_P!]_P#UJ+A8QZ*V/[.M
MO[C_ /??_P!:C^SK;^X__??_ -:BX6,>BMC^SK;^X_\ WW_]:C^SK;^X_P#W
MW_\ 6HN%C'HK8_LZV_N/_P!]_P#UJ/[.MO[C_P#??_UJ+A8QZ*V/[.MO[C_]
M]_\ UJ/[.MO[C_\ ??\ ]:BX6,>BMC^SK;^X_P#WW_\ 6H_LZV_N/_WW_P#6
MHN%C'HK8_LZV_N/_ -]__6H_LZV_N/\ ]]__ %J+A8QZ*V/[.MO[C_\ ??\
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M_P!]_P#UJ/[.MO[C_P#??_UJ+A8QZ*V/[.MO[C_]]_\ UJ/[.MO[C_\ ??\
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M_N/_ -]__6H_LZV_N/\ ]]__ %J+A8QZ*V/[.MO[C_\ ??\ ]:C^SK;^X_\
MWW_]:BX6,>BMC^SK;^X__??_ -:C^SK;^X__ 'W_ /6HN%C'HK8_LZV_N/\
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M.(J2:-#9OI4<[ *TEH\<D*NV.-QB4%L=R:]>_LZV_N/_ -]__6H_LZV_N/\
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M((]C0!X7XM\47?P)L/AYXL?Q%JVHZ+JL_P!CUNPU6[:Z#QFPN+D30ESE)$>
M<#AE9@1D*1Q7CG]L67Q!\/M0@T272;?7KS2HM7T]_#FOQ:E);JMY:H]O=;4
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M/F]01Z71113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=118+FC_ &Q_TP7_ +Z-']L?],%_[Z-9U%%@N:/]L?\ 3!?^^C1_;'_3!?\
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M^*;_ ,/>$])L-+G>SO\ Q%K=AH*7D;%7M4N)@LLJD<[UB$FT]FVGM7BOCO\
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M_?3?XT7"QAT5N?9+;_GV3_OIO\:/LEM_S[)_WTW^-%PL8=%;GV2V_P"?9/\
MOIO\:/LEM_S[)_WTW^-%PL8=%;GV2V_Y]D_[Z;_&C[);?\^R?]]-_C1<+&'1
M6Y]DMO\ GV3_ +Z;_&C[);?\^R?]]-_C1<+&'16Y]DMO^?9/^^F_QH^R6W_/
MLG_?3?XT7"QAT5N?9+;_ )]D_P"^F_QH^R6W_/LG_?3?XT7"QAT5N?9+;_GV
M3_OIO\:/LEM_S[)_WTW^-%PL8=%;GV2V_P"?9/\ OIO\:/LEM_S[)_WTW^-%
MPL8=%;GV2V_Y]D_[Z;_&C[);?\^R?]]-_C1<+&'16Y]DMO\ GV3_ +Z;_&C[
M);?\^R?]]-_C1<+&'16Y]DMO^?9/^^F_QH^R6W_/LG_?3?XT7"QAT5N?9+;_
M )]D_P"^F_QH^R6W_/LG_?3?XT7"QB#J*FOO^/R;_>-:HM+;/_'NO_?3?XT^
M>UMVF<FW4DGD[F_QHN%C HK<^R6W_/LG_?3?XT?9+;_GV3_OIO\ &BX6,.BM
MS[);?\^R?]]-_C1]DMO^?9/^^F_QHN%C#HK<^R6W_/LG_?3?XT?9+;_GV3_O
MIO\ &BX6,.BMS[);?\^R?]]-_C1]DMO^?9/^^F_QHN%C#K$\8^#=+\>:)_9.
MLPM<6/VBWNMB2,A\R&9)HSD'/#QJ<=\8KM_LEM_S[)_WTW^-'V2V_P"?9/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^Y'_ -\G_&J-<M\5-?OO"OPS\5ZSIBA]1T_2KJZME*[@9$B9EX[\@46 [?\
MM>7^Y'_WR?\ &C^UY?[D?_?)_P :^;]7TO2?A]IG@WQ!'%XHDG>>Q>Z\56=]
M%/'<-<2QQM'<QRW 9TE:0?<C8)D%<;<5RUG^U!X_UG7-.BT#P_IWB.TUZ#4T
MTA8K*>Q@DNH(C+ L=Y<2K]JC95PTJ01Q9<;93M.5H,^N?[7E_N1_]\G_ !H_
MM>7^Y'_WR?\ &OD4?&7Q1X^O/!ME:^(;+3M9@\5646I:=<^&[[2KN&":SED6
M.XLYY]X!9'VR*[QOMX.48'I_"7Q?^(/BZ/PM;1S^&K*_\37.HFWD?3+B2*QM
M[.5XVWK]I!GDDPA !B"9;[^!DT ^D_[7E_N1_P#?)_QH_M>7^Y'_ -\G_&OD
M(?M;^)=5GU'3K#2XH=6T*.]34!:>&M4UJ&^N+>]GM0D36@/V:-_LKL))2V-X
M&UMK$]9#^T)X@@\7V;Z[IW_"+>&K^.UFT^#4M!O&>]2:V\W8+])#!#<+(&3R
M)HU8X&"=W!H&I](_VO+_ '(_^^3_ (T?VO+_ '(_^^3_ (U\E^*?VEO'7A7X
M5:1XTEM?#ET/$NAS:MI5BEO.AL76-)4CG?SCYZE'PS*L6U@."#PSXO\ CKX@
M6?C3P=X/NM0T8:X?$6D7]KJ6G6MQ!:F"=;V-H9X3,S2;7@+<2*'!480KD@:G
MUO\ VO+_ '(_^^3_ (T?VO+_ '(_^^3_ (U\K3_M&>,W:7P_;1:5<>+++5-4
ML9_[.T.\O_M2VKQ+&Z6RSHMLC"XCW2W%RJ*5(&[=E<2T_:J\>>,/@CK?Q%\/
M:?X>TV/0]$LK^YTW4[>>=KF>:$2R!)%FC$:(&7&5<L=PRN,T:!J?8G]KR_W(
M_P#OD_XT?VO+_<C_ .^3_C7S''^TSK4WC>2&'2[BXT-?$9T!K6'POJ;&-!)Y
M)NFU(+]E"K)EF3'" _/N!%</XG_:/\5>*O"GBO3YK=8]+U'PCJNHV&K6>E76
MF^7+#'$<0R3R^9<IMG7$ZPQ(2IV%N=IH&I]J?VO+_<C_ .^3_C1_:\O]R/\
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M_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\
MOD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP
M7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C
M_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\
MOD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP
M7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C
M_P"^3_C5&BBP7+W]KR_W(_\ OD_XT?VO+_<C_P"^3_C5&BBP7+W]KR_W(_\
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M#4OVEOAKIUGXJ@TS0-%\1S:)+I7VQ8WO9O[/N3))*A.XHDBQ1)N&"Y<C.5-
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M:+A8P:*WO)A_YX1_]\T>3#_SPC_[YHN%C!HK>\F'_GA'_P!\T>3#_P \(_\
MOFBX6,&L?Q7X1TGQOH_]EZW:?;;#SX+GRO,>/]Y#*LL390@\.BG&<'&#D9%=
MMY,/_/"/_OFCR8?^>$?_ 'S1<+'G'Q+\"P_$3PE/I+S?9;I)H+VQN\9-M=P2
MK-!+@$9"R(N1D9&1T-7=6\'Z9XDOO#VH:O:K=:CH=R;ZRE21T6&X:%X6< ,
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M_P"^:/)A_P">$?\ WS1<+&#16]Y,/_/"/_OFCR8?^>$?_?-%PL8-%;WDP_\
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M'_WS1Y,/_/"/_OFBX6,&BM[R8?\ GA'_ -\T>3#_ ,\(_P#OFBX6,&K.F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 #K3YO]:_UI@ZT^;_6O]:0#****8!1110
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MG61_[.ATC3;&*$10Z=:(2[H@!.6=R"QX&V.)0!M)8$=?1113 **** "BBB@
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M"Y<_M:Z_YZ+_ -^U_P */[6NO^>B_P#?M?\ "J=%%@N7/[6NO^>B_P#?M?\
M"C^UKK_GHO\ W[7_  JG118+ES^UKK_GHO\ W[7_  H_M:Z_YZ+_ -^U_P *
MIT46"Y<_M:Z_YZ+_ -^U_P */[6NO^>B_P#?M?\ "J=%%@N7/[6NO^>B_P#?
MM?\ "C^UKK_GHO\ W[7_  JG118+ES^UKK_GHO\ W[7_  H_M:Z_YZ+_ -^U
M_P *IT46"Y<_M:Z_YZ+_ -^U_P */[6NO^>B_P#?M?\ "J=%%@N7/[6NO^>B
M_P#?M?\ "C^UKK_GHO\ W[7_  JG118+ES^UKK_GHO\ W[7_  H_M:Z_YZ+_
M -^U_P *IT46"Y<&K761^\7_ +]K_A4MWJ=S'<RJKJ &('R+_A6>.HJ:^_X_
M)O\ >-(+DO\ :UU_ST7_ +]K_A1_:UU_ST7_ +]K_A5.BG8+ES^UKK_GHO\
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MSQC_ .^11S!RG$T5VWV6#_GC'_WR*/LL'_/&/_OD4<P<IQ-%=M]E@_YXQ_\
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MFBNV^RP?\\8_^^11]E@_YXQ_]\BCF#E.)J>Q_P"/N+_>KK_LL'_/&/\ [Y%
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M:_K6F^*O#3^'?B9I2>#[V_U>&VA@LKPW46HS1E+B-K>;RD:1<( VZ-2-CCH
MQ /'_BG^USXK\ ^$+^YL#HNMZG82ZK(EY;V2BRU&WLX[=]Z%[U"F6N#&1&9W
M)0D)@'&'%\=/%GA'5?&>LRB'Q9JFFS^()+&V)E5[2%9[ 1QE3<",QA9M_P P
M7"KPR@L3]*1_%GX8W-M?HFL:1)#H_E"6(19\L3R/#'Y:[?G$DB.@* ABI S6
M3X'^/G@+Q1HMEJ=S/IVC3ZK>WME!#(0S3)#>R60D9M@VK(T2@;\#+!<DB@#Q
MJ#]J3XEW]EJP2S\.V,NDZ+K6M-//%%=?;$LFLMB;+2_F2%C]K=&_?2']V&P-
MVT=;:_%KQ5X5^%G[0'BV74+75=1\.W5Y?Z397<3^7:QK813Q1./,R4^;^$IG
MYB,9X]$^*WC_ /X5+'I,D7A;3;K0KB:.RFFEOX[64M-*JB"U@$;&XE(W2&,F
M,%4)#,<@=1XE\;>$/"$M];:WJ.GZ:XTR?5[J.X &;* HDTSC'*)YD8)/]X4
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M$^9A$*R?=Y;GCF?@5^T1XA^)FK^$VU"P=M.\2Z9)J*K'X;U&P33B%1TC^U7
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M7:P&1P"IP?4<5!J7A71=9MKBWU#1["^@N&5YHKFV219&484L&!!( XSTHHH
M6[\+Z-J&GSV%UI-C<V-PXDFM9K9'BD88PS*1@GY5Y/H/2HI?!V@3W-O<2:'I
MLEQ;1)#!*UI&7BC1@Z(IQE55@& ' (!'-%% #(_ _AR*QOK)/#^EI9WS^9=V
MZV48CN&SG=(NW#'/<YI\W@W0+AM/,NAZ;*=.18K,O:1G[,@QA8\CY -JX"XZ
M#THHH EU/POHVM7<-UJ&D6-_<PJ4CFN;9)'12<D*S D#(!P/2HIO!N@7$T$T
MNAZ;)+ I2*1[2,M&I;>0IQP-WS<=^>M%% $R^&](58E&EV06)0L8%NF$ <.
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>apre-20251231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $Q [@# 2(  A$! Q$!_\0
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M%% #719%*L RD8((R"*2*)((UCC18XU&%51@ >@%/HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_QW>16/AJZD
ME@N9\X5#::<U^\;$X5_)4$L%//3M7S5%\/?%.F>'[6/5]"EU59=+U.QMO[/L
M&3-S-.'CF>$9\@NN[). O^SG%?6M)B@#)\(V-YI?A31K/4)/-O[>RAAN)"V[
M=(L:ACGOD@\UA:?XUO+OXKZMX8>&$6-IIL-XDH!\PN[E2#SC''I7:5Y7HO\
MR<=XC_[ -K_Z-- 'JE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCN<'4($_ZZ-L_GBC^TL#>WMX_P#@2_S#ZO6_D?W,V**H1:]ID_\ JM1M)/\
M<G4_UJW'/',,HZN/]D@UUTZ]*K_#FGZ-,RE"4?B5B2BDS44-W#<O,D4BR-"V
MR0*<E6P#@_@16KE%-)O<FS>I-129HS5"%HI,T9H 6BFM(BC)8 >YJ-KR!3\T
MT8^KBH<XQW92BWLB:BJK:I9IG==P#'7,B_XU&VNZ:GWM0M5^LZC^M8O$T([S
M2^:*5.;VBR]16?\ \)#I6<?VG9Y_Z[I_C36\2:4@R=1M<>TJFLGC\(MZL?\
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M;:JLD+-+(L\41C23S2?O.#@ ;6S0(^KI=<TZ""SFDU"UCAO&1+:1IE"SLWW
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MPWV@3(B-N8Y)$?8 '(Z 'T''()8U< @, 0&!!_$'I7ENB_\ )QWB/_L VO\
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M.(7.+5H&D,/E#J"!][KWK6K+<_\ %20_]>K_ /H:UJ4 %%%% !1110 4444
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MF0.U0_$WQ-XXT7QWX0GMI)K#P/,\<5]=V$5O<2-.YPBS1R+O2+L7B)89Y&*
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M7%W<R!(XD'5F8\ 5X^FF:M^TBZ7&KV]UH/PN#!H-(F5H;SQ .TETO#16IZK
M<-(.9,*=A /@G6_CC\;KS]K*XO\ 0M7\<ZY\.?\ A*2;9=&LYKBTN=-%R,K"
M53:\948&#@]CS7Z@^!OB)X=^(^E-J'A[58=2AC<Q3HN4FMY!UCFB8!XG'=7
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MJ4\6\3[CJ<W)I:][>7D84O@K29O$%SK;Q3G4;BU^Q22?;)@AASG:(]^Q>>X
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M.<U['10!5TK3+?1=,M-/M$\NUM84@B3.=J*H51^0%>:Z+_R<=XC_ .P#:_\
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M,=WX.\)6'@;PY9:)IBR"SM5;:97W.[,Q=W8]V9F9C[DUM44 >667_)S&J?\
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M-->J5Y7HO_)QWB/_ + -K_Z-- 'JE%%% !1110 4444 %%%% !1110 4444
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ME:%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I<2:8I2Q5+1 +93R1&,?*/84 ;.G3"XT^VE42!7C5@)OOX('WO?UKS31?\
MDX[Q'_V ;7_T::]4KRO1?^3CO$?_ & ;7_T:: /5**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'7IM8LK*W-S&-.GT*1+"2+S1]EFAO"VPMY7#(HW$L=P4KR"/=:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>OVL[:SNI?!:ZA9Z7=V@N;
MHL-9TZ^U*V#>2,?Z-:\LW7#L0%YP#NX]%^ T5K!\*=#CLH;"WM5$HCBTNPGL
M;91YS_<@G_>1C/9N<Y/0BL3XLV&I?$!X['PWI]UJ4^D7;1WFWQ'>:#&C-$K
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M%5$& H'  '84 >7V7_)S&J?]BM;_ /I7)7J=>667_)S&J?\ 8K6__I7)7J=
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M'5RNR6&TN$F@*)+MQYB(V!U)4\Y%8?C&6+PO\6O$MI8:O-I>C:3J&BK<Z_\
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M>'I;6>];28-&\I[:,NJ6X-P9"6)^<GY1G8>E 'JM%%% !1110 4444 %%%%
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MI8+"MSZ*3BE^#?YG;A,F56O&EB*T()]Y)??=JWS1]%7/B/3K%Q ;@33C@00
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MID6H1WU[?:E/Y%I8:7:M=7,Q RQ$:\[5')/0"@#L*\KT7_DX[Q'_ -@&U_\
M1IKU&*3S8D?:R[@#M88(]B*\NT7_ )..\1_]@&U_]&F@#U2BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFM;^'^D>(=0-Y>I,\Y
M *S,H '3 '2NEKD/%?Q7\+^"==TO1]8U..UOM0;;$AY"^C.?X03P">]<N(RV
MAFL/J]>BJBWLU?;K;R*6+>"_>JIR=+WMN=9#&(8DC!)"@ %CDUD7?A.QO?%%
MGK\CW?V^T@>WB5;J00A'(+9B!V$G:OS$9X'-;*L& (((/((KC/&/Q'&@>)=*
M\,Z9ILFM>(]2ADNH[19EACB@C*AY99"#M7+  !6).<# )'2DHJR)O?4R[+X
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ME%J%K+;3AC%(-K!'9"1]5((J>BD45-+TJVT:RCM+172!/NJ\C/C\6)-6Z**
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MDC/;.*S]9\(Z?KB6,-RC"RM+A;H6<>%AED4[E+@#D!L-CH2!G- &T#D4M%%
M@HHHH **** "BBB@ KSGXQ?#E/B986^DW'A_2]1@.635+N;9<:=*""LD($9.
MX=<JZGBO1J* (;.!K6TAA>5YVC14,K_><@8R?<]:\QT7_DX[Q'_V ;7_ -&F
MO5*\KT7_ )..\1_]@&U_]&F@#U2BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KP;XL_LL6/Q(\;VNO0:B^GI.X_M.(Y<RJ!P8\_=8
M]/3O7O-%=>&Q5;!S]I1E9[''BL'0QL/9UXW5[E/2-*M]#TNTT^T5DMK6)8HU
M9BQ"@8&2>37'>,OAI<ZQXVT?QAH6JQZ/XAT^VEL6:ZM3<V]S;2,K&-T#HP(9
M0596!&3G(-=[17*VV[LZTE%61XWX\^ %YX^U&^N[SQ*J'6-&.A:M#]@#1R6_
MF,X, WYB<;W&6+CD'&5KG9?V7M8-V\L?BVP2(WFK72H='<D"]B\O;G[1U3KN
MQ\WH*^AJ*0SY:\"_L]ZS?ZUXA\/^(9I8/#EI=Z;(EVE@(&U(VUC' 'A?SG,2
M[D)(*EN!@X:NL\'_ +,MWX4L-)B'B#2I+O2]2MKR"]M?#Z6LMQ##%+$L=RRR
MYE;;,WSC: >B<FO>,8I: /G6/]DN>?PR^CWGBX$2:==6#36FG>7@R7OVN*15
M:5A\C\,IR' Q\O-=%IGP OK/XDZ=XUFU^SDU)=1DU#4(HM-9([@FRCM$6+]\
M3'A(PQ)WEB3T  'M%% 'E'Q$^!:_%&Z\3?V_J,<]GJ&F'3-/MX5N(/L:MDNT
MGESJ)MSE6P57&Q1[U-X:^%OB;3?&GA3Q#K'BFQUB?1M"FT6Y*:6\#WID>%VG
MSY[!#F!/EP1\S\],>HT4 >&>&OV==4\)>(6\3:9XBTZU\3RZK?7=S=QZ.1%>
MV=U.T[VDZ>=N8I(P,<NX%=N,$,P/??![X?W/PP\!VGAVZU*'5I+>XN9A<P6I
MMU(FGDFV["[XVF0C.><#I7:T4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !28YSS^=+10 F.*6BB@#RRR_Y.8U3_L5K?_TKDKU.O+++_DYC5/\ L5K?
M_P!*Y*]3H H:]=M8:+?7*2QP/# \@EE&54A2<D>E?G[\+?B)\2]+UU?$NH?$
M+3=*TWQ/;RWLMWK4B&$[,E#&CE=IV#(Q@!>M?H'KFG'5]'O;)76)KB%X@[+N
M"EE(R1WZ]*^;?A)^RIXV\)>-M(U/QM\0-&\;Z'IB,;?23X7BMC'+L*1R))YC
M;2N>PKQL?',I5J'U&48PN^>^]NEE9IN^NNFA]!EV/P^$P^(I5J,9N:23<;M6
MOL[IQWW6NB.<TGQ;\2/',S?V'JFO^-(6)V7>FVQTG3A[F[D9 X_ZY+)70G]G
MSXG7UA/JE_XAT.;5E<26VB-]HFMNO22ZE+.2!W2-1D>E?4(4#H*6NBM@8XJG
M*EBIRG&2LTY-)I_W8\L?G:YYM+%NA65>E3@FO[D7^+3?XW/ ?AE\ ]8:\OM6
M\<2QV.HS+'%%#X:U:ZC38N[/F-\A).1]W'O7H4?P,\"K())_#T&I2 YWZI))
M>MGZS,U=Y15X3!8?!4(8:A&T(JR6]E\SJKYOC:]253VCC?I%M+[DSS/QS^S?
M\._B#IMM9:GX9M((K=_,B;3E^R.I[C='C(/H:[KPYX<T[PEH5EH^DVJ66FV<
M8B@@3.$4?7^=:5%=:A%.Z6IRU<=BJ]*-"K5E*$7=)MM)OJD%%%%6<(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Y7HO_ "<=XC_[ -K_ .C37JE>5Z+_ ,G'>(_^P#:_
M^C30!ZI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI_PTU\*O^A]T+_P+%'_#37PJ_P"A]T+_ ,"Q7I?EI_='Y4>6A_A'Y4 >:?\
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M]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\
MB: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA
M+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__
M ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?
M]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_
M /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_
M $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_
M ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?
M]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\
MB: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA
M+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__
M ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?
M]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_
M /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_
M $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_
M ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?
M]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\
MB: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA
M+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__
M ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?
M]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_
M /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_
M $.WAS_P;6__ ,71_P +C\!?]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_
M ,31_P *V\)?]"QHW_@NA_\ B: *?_"X_ 7_ $.WAS_P;6__ ,71_P +C\!?
M]#MX<_\ !M;_ /Q=7/\ A6WA+_H6-&_\%T/_ ,31_P *V\)?]"QHW_@NA_\
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M\!7=PW[3>KDF:>WDU"_A >0QZC;LL$9_TE.CV+ 9@88VL5ZYX^G*3 SGO2T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO5_A7X:NO!WPV\,:%?2"6\T[3;>UF<'(+I&%.#Z9% CJJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $'2
MEHHH *3UHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-+110 4
K444 (>E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>apre-20251231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Y Z<# 2(  A$! Q$!_\0
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M6NS/W0HK\+Z*]C_5?_I]_P"2_P#VQX'^NO\ U#_^3?\ VI^Z%%?A?11_JO\
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MU7_Z??\ DO\ ]L3_ *Z_]0__ )-_]J?NA17X7T $D #)-'^J_P#T^_\ )?\
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M&VM9KVXC@MXGGGD.U(XE+,Q] !R:2X937,J^G^'_ .V*?&<HRY7AM?\ %_\
M:G[F45^)G_""Z_\ \(>?%7]ES_\ "/"X^R'4,#R_-_N=<YK"H7#*E>U>]O[O
M_P!L$N,I0MS8:U]?B_\ M3]T**_"^BJ_U7_Z??\ DO\ ]L3_ *Z_]0__ )-_
M]J?NA17X7T4?ZK_]/O\ R7_[8/\ 77_J'_\ )O\ [4_="BOPOHH_U7_Z??\
MDO\ ]L'^NO\ U#_^3?\ VI^Z%%?A?11_JO\ ]/O_ "7_ .V#_77_ *A__)O_
M +4_="BOPOHH_P!5_P#I]_Y+_P#;!_KK_P!0_P#Y-_\ :G[H45^%]%'^J_\
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M -J?NA17X7T4?ZK_ /3[_P E_P#M@_UU_P"H?_R;_P"U/W0HK\+Z*/\ 5?\
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M6D0G9M)D[#M[\?.VN_M ^*-<\)S^'!'INEZ5)J2:JL6EV8MO)G4 +Y>TX0#
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M(_NQ?]^?_K4?VEI']V+_ +\__6KEZ*+ =1_:6D?W8O\ OS_]:C^TM(_NQ?\
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ME/7/VM4T")Y)_#,4P_X3J#P4@M=:AG.93&!</Y8;RR-_,+8;CJ,BO5?^%O\
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M_?G_ .M1_:6D?W8O^_/_ -:N7HHL!U']I:1_=B_[\_\ UJ/[2TC^[%_WY_\
MK5R]%%@.H_M+2/[L7_?G_P"M1_:6D?W8O^_/_P!:N7HHL!U']I:1_=B_[\__
M %J/[2TC^[%_WY_^M7+T46 ZC^TM(_NQ?]^?_K4?VEI']V+_ +\__6KEZ*+
M=1_:6D?W8O\ OS_]:C^TM(_NQ?\ ?G_ZU<O118#J/[2TC^[%_P!^?_K4?VEI
M']V+_OS_ /6KEZ*+ =1_:6D?W8O^_/\ ]:C^TM(_NQ?]^?\ ZU<O118#J/[2
MTC^[%_WY_P#K4?VEI']V+_OS_P#6KEZ*+ =1_:6D?W8O^_/_ -:C^TM(_NQ?
M]^?_ *U<O118#J/[2TC^[%_WY_\ K4?VEI']V+_OS_\ 6KEZ*+ =1_:6D?W8
MO^_/_P!:C^TM(_NQ?]^?_K5R]%%@.H_M+2/[L7_?G_ZU']I:1_=B_P"_/_UJ
MY>BBP'4?VEI']V+_ +\__6H_M+2/[L7_ 'Y_^M7+T46 [>PGMIX2UJ%$8;!V
MKMY_SBBJ'A?_ )!\G_74_P A14/<T6QHWW_'E<?]<V_E7#5WD\?G021YQO4K
MGTR*P/\ A%'_ .?A?^^?_KTTQ-7,*BMW_A%'_P"?A?\ OG_Z]'_"*/\ \_"_
M]\__ %ZJZ)LS"HK=_P"$4?\ Y^%_[Y_^O1_PBC_\_"_]\_\ UZ+H+,PJ*W?^
M$4?_ )^%_P"^?_KT?\(H_P#S\+_WS_\ 7HN@LS"HK=_X11_^?A?^^?\ Z]'_
M  BC_P#/PO\ WS_]>BZ"S,*H[A#);RJHRS*0!^%=#_PBC_\ /PO_ 'S_ /7H
M_P"$4?\ Y^%_[Y_^O1=!9GPYIO[-GC2Y_8$B^'UQIO\ 9WQ#TQ'U#3;874+-
M'>Q7+3PA90YC!;@ EL#=R1@UYU\/_P!BGXAZ1\3_ (;ZQJEC NC:LT.N>/8?
MM$+!=5MKF>YAR Y,@9IU7Y0P 0Y."*_2C_A%'_Y^%_[Y_P#KT?\ "*/_ ,_"
M_P#?/_UZ6@[,^ !^S?\ $K2=.U?Q#9>'H;W6]'^*MUXQT[0I]0@C&KV,D21#
M;)N*1O@LR^85P5Y R,V?BU\$_BU\9OAQINMW7@^U\&^(])\7-KMOX;\+ZU%9
M:A/;-&T;%KY/W0NLMN$F<%0<D$X'WM_PBC_\_"_]\_\ UZ/^$4?_ )^%_P"^
M?_KT[H5F?#GPV_9$\7:C\']4TZ]\8>,_A7XAUGQ&==N9[/Q*=0U-D6%H5CN+
MJ/8KEP5=MI891.<CCG?%'P'^,'P^M_BUX4\->%XOB5IGCO3;94\4:EK,-O<0
M3Q6@MW%RLIWRNY0."O&7Y8<X_07_ (11_P#GX7_OG_Z]'_"*/_S\+_WS_P#7
MI:#LS\QOB#^RW\:?$OA70_#5SX9N]?T=/A]I6D6MC%XJ2PL=)U.WM@LIN84<
M?:G#KA"-R<C)QT[>[_9T^)%]<ZI<?\(PT7VGX,0>%$1K^U)_M13#NM^)<<;&
M^?[G'WJ_0+_A%'_Y^%_[Y_\ KT?\(H__ #\+_P!\_P#UZ- U/S)^._PZUSP^
M_P #O!NE7=KI_B[QEX4LO 'B;2EG62>*WC2WDDD^0D?((YDW@XPQP2#7VI\6
M_A4?'7P'\2?#W2)TTTW^BR:5:2OG9%^[V)G'.W@ X[9KT4_!CPZWBX>*SH^D
MGQ.(/LPUHV,?VP1?\\_.QOV^V<5N_P#"*/\ \_"_]\__ %Z+H5F?G_I'PF^,
M?Q#^)?P;F\4?#JU\%Z)X2TG4]&OM2MM9M;IB9=-EMTF2-&W",NRX498$Y( &
M:C\,_L]?%G7-%^%'PNU_PEI6@>&?AYK4.J2>,[;4XIAJB6[LT:P6Z_O4>3<-
MYD"C@GT!_03_ (11_P#GX7_OG_Z]'_"*/_S\+_WS_P#7HT'9GY_^!/@/\6?
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MA^ %Q\#+[3-7GT]/#MUXJEN!_9,=LB;6G5@-N?+4$8<Y;@ DA:_1[_A&+O\
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MU+]H'5="^&FL^#+;Q#:Z%<:?I6M0)8R:JMM*[3PMM8HKNJ[2I;H5SUK],/\
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M97\%_')=,_X370K?5Y=-=GL[B*\N+2>$L"& E@9'VD'E<X/!QD"C0>I\[?\
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MO_"*/_S\+_WS_P#7H_X11_\ GX7_ +Y_^O1=!9F%16[_ ,(H_P#S\+_WS_\
M7H_X11_^?A?^^?\ Z]%T%F85%;O_  BC_P#/PO\ WS_]>C_A%'_Y^%_[Y_\
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MH_X11_\ GX7_ +Y_^O1=!9F%16[_ ,(H_P#S\+_WS_\ 7H_X11_^?A?^^?\
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M8^9ONOE2-Q+M=AR2P#BOF+X->)-0\,?%3P_<:;,MM<37\-LTIB1V5'E4-M+
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X+_X*:_\
M(7\ _P#7"\_]"BKXEAFDMY4EB=HI48,CH<,I'((/8U]S?\%,M(NY/^$'U-87
M:RB%S \H4[5=C&5!/;(4_E7PO7ZQDC3R^G\_S9^%<2)K-:K]/_24;UOK$WB.
MX6V\0>(=02R4%P\F^ZPW;"%Q[\YKTK5?A+>6TPM9O&EU<V^EZ3#K,D:V\CR6
M8D=%BC$>\XD(=6P#P"._ \W^'HT<^._#Q\03K;Z$NH0-?R.C.! ) 9/E4$GY
M01@#O79?\)U/XD\8^-]33QK/X6GU>9I8I0DJPW,?FY6-VB!=,+M*_*1\N#BN
MZLIJ5J>B2[>?H^E_P/.P[IN%ZNK;MO9Z*^NJZVM\^HS3O"%SK+2>([_QG<Z=
MI=O?Q:3:ZU?QR^:UPRERNT,6C1%)9F)X## ).*YG5O!WBI?'FI:$]G?ZKXEL
MIY(YH[59+F8M&>6& 6(&,Y],5ZYXV^('A/XFZ'-X:F\0QZ0MMJ]K?MK-U:2L
ME\/LD=M<2!40MO+1B0!P-P8Y(-85G\5]*OOC3X[\6-<2Z7::K8:I'9,RL9-\
ML#I"#M!PQ.WGH">M84ZM:SDX]-K>ENFM];_H=-6CA[QBIZ-K6_K=VN[6TMWO
MNSBKSPI\0](L-3ENM'\3V5E_K+]YK6XCCY ^:4D <@CEO450U#P?XOTWPXEW
M?:)K=KH *S)/<6DR6H+X"N&(V_-N&#WR/6O6_#?Q4T"SOO!_VJ^-W;:?X-O-
M+GM)(Y2AN7,Y6 @+SNW1C(R.1SQQU7Q/VR>"/C?K)U.X\O6]7TV:/2KVTGMI
M[5O-9Q'(LJ*-ZJ2NU"WRIG(&*GZS4A-1E"UVNC_F2_X/X%K!T:E.4X5&[)Z7
M7\KE^>GX^1XWIOAV]O\ P?I_B;6?$VI6<!N9[2P2."6Z=1&D9D8$.!&OSJO7
MG!["J6@?#Z*YT*VU^^\266B6I6>8"1LW)\MT1?*CR#(S,YP!T",21BNI^$GB
MZT\/)X:N[WQ[/IVGZ9J$D]YX>EAG9)(CM)\L(&20R %2'VXP.HJ>WO/ /BKQ
ME9#6-7AT[PQHFE(UO9E9PM[<L?->W#I$S(@DD=2Y7.U!CJ"-'4J1E)6=EV73
M71:;[=^^QE&E1G&,KJ[TLY==-7KMOV?3<XGQIH>K?#77HT@UN6X35+&'48;^
MUDDB-S!,N]2X.&!ZY!SR.]<:22<GDUUOQ2\1W?BOQA<:E=ZGI^IM(B+%_9<<
MD=M;Q*-L<$:R(C!44  8Z=R<FN2KNH\W(G/>VIY>(Y?:25/X;Z?UJ?:?_!,S
M_D:/'7_7G:_^AR5]^U\'_P#!,[1[M+_QOJC0LMD\5O;K*0=K.&=B ?8$?G7W
MA7Y?GK3Q\[>7Y(_:N&4UE=._G_Z4PJAH8O%TBT&H<WNP>;G'WOPX_*K]4-"M
M[JTTBTAO9/-ND0"1]V[)^M>"?4=2_1112&8?C7PE9^.O"^H:%?M*EK>1&-GA
M?:Z^A!]C7@$*_%#7 ?A-<^9:BUQ]L\5KG][IYX3;_P!-&PR]?X3[FOINBM85
M'%6L>7B\!'%34^9Q>SM]J/9_Y[K6VYB^#_!^E^!/#UIHNCVPMK&V7"K_ !,>
M[,>Y/<UY?=WWC3QUXL\:7&B^-AX5M/"MY'96NF?9+:2UO'$$<TCWSRQO*$(D
M"J('B*@%B7R OM5<+XG^"7@_QAK%YJ6IZ?<//?1QQ7T5OJ%S;V]\D>=BW$,<
MBQS@ D?O%;CCIQ6;=]6>C"$:<5""LELCQ2__ &Q;3X<W^OZ?XDDBU2]AU76)
MX%FN[:Q$>G6DD2>7$7V^?,3* D0RSX;)&!GI_&W[7^@>"O$]UI4EC#J$26EU
M<Q-9ZI!)<L8;)KS$ML"7@5T1@IDVDD?=QS7;ZG^SUX#U2Y:Y?2+BVNFGN9WN
M+'4KJUD?[04,\;/%(I,3F.,F(G9E!\O%5M<_9I^'?B/4;V]U#1)YY;N6:>1!
MJ=TL0DFMFMIF6-90B%XG96V@9^4GE00BSDM4_:WTGP]XCL-%UC3+?3KZ6*RF
MGM9-6A^TJEW(4A\F'AIR  SA.%!X+8-,\"_'G6OB3\:?"5O864NF^!M7T#6;
M^U:9XG;4#;WEI#%.0%WQ?*\A"[L%9%)Y&%]*U#X-^%=1UNTU:2SNH;VWBMX<
MVNHW,$<Z0$M"LT:2!9@A)QY@;J:K^%O@7X+\%^+$\1Z/I<UIJD<-U;PYO[AX
M+>.XE2:=(H&D,<:M)&K811SG&,G(!WU%%% !1110 4444 %%%% !1110 444
M4 %%%% 'XV?'[_DNGQ#_ .QAU#_TH>N4MO$VL6=D+.#5KZ"T *BWCN76, Y)
M&T''.3^==S^TMHMYH7Q\\>PWD#P/-K-U=1[U(W1RRM(C#U!5AS7FE?MF'Y9T
M(/?1?D?SCB^:&)JK9\S_ #-SPC;Z]K6J0Z%H5Q<K<:BXB^SQ3F))..2_(&T#
M))/  )/%=UXD^&M[X.\1^(O"&O>-K:RTW0H()Y%29Y$N&E6.14MX-P\PYER2
M.  6) KRFO9/B!K7AGQU\6M=URS\6+HYCM;&32[Z6TE:&6>*WA1U?"ETP4;!
MV,"1Z'-9UN=5%;X;/I?6ZMWZ-]/,UH>SE2=_BNEJ[*S4K]NJ77LM"#6?A)JE
MK<7UMXF\6?9],TZZM;*UN)5EN%D>XA$L>U,Y0",J6[KG&#3].^#/B#3=0TVQ
MU#Q(N@:Q/J%UI.B0;Y&$TT9VOM=3^Z1Y&$8;NS'( R:ZKQGX_P#!WC_3_P"R
M#X@AT^YM;^QOKG6+FVG\O4YEMQ%=3*B(S*244JI50>2<$U9U7XL^$O''BGPK
MK]UJ_P#8T?A?7KS4?LD]M(\U[ ]R+J,1[%*ARP,9#E0,@YQFO.57$\JNGYZ>
M6EM.KW_0]9T,'SMJ2Z6][?WM;Z]%MWWU/#=+T+Q7KNK:E%IECJ^IZD@=+T64
M4L\NTG:PDV9.">#G@U:N_"OCCPYHUPMSH_B#2])>7RIA+:SPP-(3MVMD!2V1
MC!YXQ6[X:\<V5MX>^*0FNFL;W7[2-+2%0Q,A-['(Z9 P!L#9S@$#'?%>M^$_
MC)X>B^*NI7YGGUN"XLO#]K8V45O-))<302VADBC3;G<I20@' 8CC.>>NK6K0
M;M3NE_\ :_YO[F<5##X>HES5;-^:T^+IOT7WKY_/GB7P=XJT"*.\\0:'K&G1
M.5B2XU.TEB#$ [5#.!GA3@>BGTK*U#6+_5S&;Z^N;TQ#:GVB9I-@]!DG%>Z_
M%6P&D_ R6)M<.K_:O&MS<HK03PF/]P0X*S(K;N5+8! + 9)S7S_71AZGMH<S
M6S:_JYQXNC]7GR1>Z3WO^05^N7[(_P#R;AX%_P"O(_\ HUZ_(T#)K]?_ -E_
M2+O0?@!X(LKV%[>Y2P#-%(I5EW,S#(/3AA7S?$S7U:"_O?HS[#@U/ZW4?]W]
M4>HT445^<GZX9^B"]6SD%_S/]IN"N2/]5YS^5T_Z9[/?UYS6A6?HEO=6ME(E
MY)YLIN;AU;=NQ&TSM&/P0J,=L8K0IL2V"BBBD,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /+_B[^TCX%^"=S;6GB3491?W">8EE9PF679G&XC@ ?4\UYO\ \/"?
MA/\ WM;_ /  ?_%U\>_MPW,L_P"TYXO21RRPK9QQ@_PK]DA; _%B?QKPFOT+
M!Y!A:N'A4J-WDD]^^O8_*,PXHQM#%U*-)148MK57V=NY^KVI_M<^&M%TI]4U
M#PIXXL-,C57>]N?#TL<*JQ 4EVP "64 YYR/6N9_X>$_"?\ O:W_ .  _P#B
MZ^9-2@U)_P!L2*2S$BV<<%A)J;\B(6(L(#<^8>FPQ[@<]R!UQ4[> ?#,WB6P
M\.P>'+67PA<^#I=<;75C*W!F$+2B=93S@2A(?*SCYL$$UR1RO!12<T]4I:/I
MV]>W<[Y9UF,G)4W%6DXZK=I[Z=._;N[GT%X@_;F^"?BO3)=.UFQU+4["3&^W
MNM,61#CH<%JX,_&[]E$G_D0U_P#!*O\ \77GWA_X;^%_B'XNLH?[.L]+\/VV
MJPV]UIMUISZ?J-K*8)G2S9@3YP=X@A)_>$GY=N:\P^*^C::? NB:W'80VFIR
MZC=6;366GM86\\*!6 \ICDO&[.A<* 1M!)93790P&$4E2@YQOYVWOY>1YV)S
M3'.#K58TY6O:\;[6OU\_SV>A],ZC\6OV7=(N!;WWPXFLIRB2"*XT$1ML90R-
M@L#@J00>X(-5O^%V_LH_]"&O_@E7_P"+KA_%_A[14M;OQ#+%97FL!M"T\Q7U
M@U\L4)TR%U'E*.#*V5W<'Y"%(.:9+\.O!,:ZMXAAT:"&Q\ WFH1:KI5V%+W:
M,F^Q63#?\]2T6>2=G-3&A0Y4W*I_X%ULOU:2]326)Q7,U&%+3^XMKO7Y)-OR
M1WT/QG_95N9HXHOA^999&"(B:(I9B>   _)J[_PLO]F;^W/[%_X5?=_VSYWV
M?^SO^$>_TCS<XV>7NW;L\8QFO,)/ WAFPU<Z;;V=J\-EI&GZE;7%OIY282L\
M+?:'G8C<CL[)M!(&X +E:YZ2XDA_:O\ 'T<4%U*]P^JV_FV2AY[</'(#-&I9
M2S(,G:IW'&!S5+"T9WY9ST3>LGY?YD2QM>GRJ<*>LDM(+SO^1[?K?Q._9D\-
M7[V.K_#&ZTJ]0!FMKWP]Y,B@]"59@>:M_P##0?[,GBF6SL-2T"0VR$+$VI:<
MSPP]NFYMHQZ"OE7XR6.GZ3\/OAC907<M]>K8W<SSS0M$Q@>X/D@ \A<B7 /K
MGN*\EKLI952K04W4G?7[3Z.QYU?/*^'J."I4[:/X5U2=M.U['Z]V/[.'P@U*
MS@N[3P/X?N;6=!)%-%;*R.I&0P(Z@BI_^&8_A1_T(&A?^ BUD?L>7,MU^S;X
M(>5R[+;21@GLJS2*H_  "O9:^!KUL11JSI>T?NMK=]&?J>&P^%Q%"%;V,5S)
M/9=5?L>8_P##,?PH_P"A T+_ ,!%H_X9C^%(_P"9 T/_ ,!%KTZBL/K6(_Y^
M/[V=/U+"_P#/J/\ X"O\C,\/>&M)\)Z9'IVBZ=;:78QY*V]K$(T!/4X%:=%%
M<S;D[LZXQ45RQ5D%4-!LI-.T>TMI9A<211A6E!)#'UYJ_6;X=M(K#0[*WAN%
MNXHXPJSIC#CU&":!]32HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBOS^_;V^.'BO2?B5%X0T;6+K1]+M+..>5;*0Q--))DY9@<
MX P /K7H8'!3Q];V,';J>5F>8T\LP[Q%17UM9=V?H#17Y&_"#7];\9^)+^VU
MKQ9XI:PL]+N]09+#67AE=HHRX4.X< $CGY36W;0>)?B%X9MM9\#>(O%EO(-3
M32KO3M5U\W!C+QO*DXF58@(]L<F[<OR[<Y(/'NSR!PERRJI6ZVTU^9\S3XI5
M6"E"@W>]E?5VM?IYGZ5^,/A1X.^($\<_B/PUINLSQC:DMW;J[ >F>N*YW_AF
M/X4?]"!H7_@(M?G';Z#\3KR-+JU\;W5UHYM9[Q]7BUJ<VT4<+*LN[^,,&DC&
MW;D^8I'!S4<&D_$>8WDI^()33K>>&U34_P#A()7MKB:5=R1Q,A)9L Y&!MP=
MV,&NF.458+ECBK)>O^9QSSZC4ES3P5V^KM_E^)^D'_#,?PH_Z$#0O_ 1:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^#'BOQS\6/'%WXQFD;2/ WEM;66G2IDW SP_P!<CEOP%?&W[?O_ "<9J/\
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M3PY<K>QZC!=:N);BY2X\IB5E$"K&R/ A4[",#!!.2="3]JG^SK'3[70/"_\
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MV7[ZIK_>_KR^\GFQ%VEAZ.E[^[M9V_S^YG4>9^R!_P \_$'YW7^-'F?L@?\
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MCG_#6_PR_P"@W/\ ^ $__P 11_PUO\,O^@W/_P" $_\ \11[&I_*P_MC+?\
MH(A_X$O\SV.BO'H_VL_AE+(J#7)@6( +6,P'XG;7K=G=PW]K#<V\BS03('CD
M0Y#*1D$5$H2C\2L=F'QN&Q=UAZD9VWLT_P B:BBBH.P**** "O)OVK_^3=?'
M?_8//_H:UZS7E'[5<;2_L[^.U12[?V>3@#T92:Z\'_O-/_$OS.#'_P"Z5O\
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M8+-.S8[#[/+S77CO]UJ_X9?DSARW_?J'^./YH_6>BBBOQ<_HD**** "BBB@
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MJ-W2OLS_ (8M^#'_ $),/_@?=?\ QVC_ (8M^#'_ $),/_@?=?\ QVN'^UL
MK+EGI?\ EZJSZ]?^&L>F\BS1MOFIZVO\71W73I_P]S\X_ 'C73-#\!_$[3[R
MY:WOM<L;>&RC5&;S&6Z21U) P/E!ZXS7LVC_ !Q\-/\ $WQE?VDT^J?VK%X<
MATRV2!P]Q);26AF1=P 4CRY,;L GH>:^MO\ ABWX,?\ 0DP_^!]U_P#':!^Q
M=\& <CP3$#_U_P!W_P#':NKG& JMR<9Z^G]WS_NK\3.CP_FE",8QG"R_Q?WO
M+^^_P/ACXJ^'8?!7P5_LV35Y+VYOO%4M[!;S6<]JRPB$KNV3(K9)9=V 5!P
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MGH C,$;*%,:E1T!48%/ P,#I2T4 %%%% !1110 4444 %%%% !1110 4444
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MA&74;F[T368IU:UGE+I%)'"\JNH)^4_NR#CKGVK]*:_*/]B#_DZ'P7_V^_\
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M-+78'WQ>/K.-\$;DL) ?_0ZSYOVZ_B?IWB[5/#^K3^"='FTZXFMIKNYL;Z2
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M>'?L@T.R^P%C9^6/*W_>V^]/H+J:-%%%(84444 %%%% !1110 4444 %%%%
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M_P CI;K^>D,KJS@^;#--?W5K[MK?^!:WZ:=+V_/2BOJ7_AW+\4/^@CX:_P#
MV;_XS1_P[E^*'_01\-?^!LW_ ,9KV?[5P/\ S]1\]_8F9?\ /B7W''?L0?\
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M=R;Q\C#.>*L:=^SAJVH"QE7Q!HK6FH:?+J-G<0M/()XT8J?E$6Y3N&,$!B2
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M0PHHHH **** "BBB@ HKSGPS\=?#.L:?KU]JM]:>&+72=;NM#,NKWD4*320
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M_P E_P#MC\9?":^'8=-$/B#0M9^VQ7B7$=_IA^>2( !H&1_E7D9#@$@DY##
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M#@9!Q0!'^SIX9O/#?PFTB35$9-;UAI=:U(2#YQ<W3F9U;W7>$]@H':O2Z0#
MP.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5#0_MG]D6G]H?\ '[L'F]/O?AQ5^J&AP75M
MI%I%>OYEVB 2/G.6^M,74OT444AA1110 4444 %%%% !14<\\=K!)-,ZQ11J
M7=W. H'))-<UX#^)GA_XE6]_/H%Z+R.RN&MY3C'(Z,/53U![T[-JYE*K3C-4
MY22D]EU=MSJ&8*,L0![FF^='_P ]%_.OS)_;T^(>M:S\<M7\-27TZZ-I$=O'
M#9JY$99X4E9R!P3E\9/I7F'PVT/1IOA]\0/$.I:1;ZS=Z+'8FTANY9DB!EN/
M+<L(I$8_+TYZU]92R!SP\*\ZEN:VB5][6ZKN?$U^*%3Q<\-3HWY>;5RM\*;>
MBB^S/V%\Z/\ YZ+^=<'XE^!OPX\8ZI+J6M>$M'U"_E.9+B6!=[GU)'4^]?FB
MWPDL/'GA.P\8Z"(?#.D);7!UI+F:26WLI8#&N8B=TA$OFQ;4)8AF(W$#BG+^
MSWJ%IH3^(;G6K*/POY5M/'K,4,TL3).[HK,%0M&%=&1MP&&P.I%;4\FA3=XX
MEQ>WPZW[:2W\OF<]7B&I65IX12CO\2M:U[ZQV\WZ;GZ2?\,Q_"+_ *$70_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *SO#T-M;:)9Q6<IGM5C CD;JP]:T:SO#PM!HEG]@
M+&S\L>47SG;[YI]!=31HHHI#"BBB@ HHHH ***\A_:$_:4\/_L]Z59R:C:SZ
MKJM]N^R:=;L$+A<;F9SG:HR!G!.>W6MJ-&I7FJ=)7;.>OB*6%INM6E:*W9Z]
M17Q3X>_X*,:EXKU6/3=)^%;WM[(KNL2:^ =JJ68Y-N  %!))]*MZ_P#\%!-<
M\,V<%YJ/PG:*SG<QQW,?B%)8F<#)7>EN5W8YQG->H\FQRERN&O\ BC_F>(N(
M<M<>=5';ORSM_P"DD?[6W[&WB7XG_$"7QCX/>UN9[Z*-+RRN9A$P=$"*ZL>"
M"JJ""1TKP7_A@KXP_P#0%L?_  90_P#Q5>P_\/._^J:_^5[_ .YJ/^'G?_5-
M?_*]_P#<U?2T'G>'I1I1I)I:*[7_ ,D?'XJ/#>*K2KRK23D[NRE:_P XL\>_
MX8*^,/\ T!;'_P &4/\ \5777'[,/[0]YI%CIEU8Z/>6=C;"SM4NC82M#".B
M*[*6 Y/0]>>M>@Z%_P %'M0\3:K!IFE_"N2]OYR1%!%KOS/@%CC_ $;T!/X5
M2;_@IR48J?AI@@X(_M[_ .YJTE5SF;M*C%M>G_R1E&AP[35XXB:3T^UK_P"2
M'":C^RO^T3JV@Q:-=B";3XUB0(=1MP[+&28U9Q\S!"?E#$@=L5#XF_9+_:!\
M8VT5OK%O:7D,<K7&S[?;H'E8!6E?;C>Y"J"[9;CK7H'_  \[_P"J:_\ E>_^
MYJT-)_X*.:CKL=\]A\*I+I;&W:[N3'KO^JB7 9S_ *-T&1^=3[3.(>][""MZ
M?_)%>RX?J>[]9J._^+I_VX>81_LF_M"116T216RQVVFRZ1$O]HV_R6DN[S(A
MST;>_OSUKI/!7[-OQK\/PO!JVA?VK;I9Q6-LEMKMI#Y,,<KRJA62*:-UW.Q&
MY-P/(85WGAG]OKQ#XQA>;1_A#+>0K,EOY@U]44RM]V-2UN-SGLHR?:L0_P#!
M3,V]X8+OX:2VYC<I*IUKYT(."-IMQR/0D5$IYM4O!T(>>J_^2-8T\BI6J+$S
M79M2M^,+'GOQ(_9$^-GQ*\:ZIXCOM!T^&>^DW>4-4B;8H 51N)RQP!D]SS7-
M?\,%?&'_ * MC_X,H?\ XJOT7^$OQ4T7XR^";3Q-H9D%I,QCDAG $D,JXW(V
M"1D9'3L1795Y;S[&T/W3A%<NEK/2WS/97#&78I>W4Y2YM;W6M^NQ^8.E?\$_
M_BS?7\,-W9Z;IUNS /<RWR.J#N=J9)_ 5^C/PU\#6OPT\!Z'X7LI6GM],ME@
M$S@ R'JS$#IEB3CWKI:*\O'9IB,>E&K:R['M9;DN%RN4IT+MO2[=]/P"BBBO
M)/>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-T""UM[&5;.8SQ&[N79
MF[2-.YD7\'+#\*TJS= %F+&7["6,/VNYW;\Y\SSW\S\-^_'M6E3>XEL%%%%(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9WAZ6UGT2SDL8FAM&C!BC?JJ^AY/\ZT:S?#MW%?:'
M97$%NMI#)&&6!.B#T& *?074TJ***0PIKNL:EF(50,DDX %.JKJNF6VM:;=:
M?>Q">TNHFAFB;HR,,$?D:!.]M-Q-+U:RUNQBO=/NHKRTER4F@<,C<XX(KE_B
MK\4](^$WAB75M4D#2'*VUHI^>XDQ]T>WJ>U?/S:SK7['WBBXL[B"ZUKX>:B7
MEL]ARUO+@G9D\ YQGU'/4$5N?"WX;ZQ\:O%,7Q(^(,6VT0@Z/HK@E$3.0S _
MP]"/[QY/:NKV48^\W[OYGRO]K5JZ^J4:=L1LT]H_WK]5_+W.M_9_M?'7B"]U
M3QKXMOYK6VU=5^QZ'_RSAC!RKX/W>#CU.<GM7RQ_P4J8GXH^%ER=HT;(&>,^
M?)_A7Z)=*_.S_@I5_P E3\+?]@;_ -KR5[>12YLPB_)_D<.?8?ZKDSI<SD[J
M[>[;>K_X!XA^SC!)=?%"*&&-YII-,U)$CC4LS,;*8  #J37H7P1\)VVA^%K[
M2OB)8OIVGZUKNF)I]AJJ-"9)HS*9) K8*IL;RV?@'?MS7S@K%3D$@^HH:1G(
M+,6(]3FOT*OAG6;M*U[>NC;[GYAAL9'#J-X7:<NNGO))W5O(^G]!T9+>"UO/
M%GP^@EU_^U+RV@TW3=)MX+@V?D'=.EH4$<_DOM*!P=V2,G&1L3_#K1=+M-4O
M5ACU'Q)<6VF2I9V'@VUGO;2V=6W&;3'F6**0LL2NZ$\." /,)KP/X5?"N_\
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M;JZLY'NX_*E%S<1JNW&8UF=8S^*!3GOFM"FQ+8****0PHHHH **** "BBB@
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MW-PZL6W8C:9VC&?9"HQVQBM"FQ+8****0PHHHH **** "BBB@ HHHH ****
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M!^%:%4-&TPZ39R0&3S=]S<3[L8QYDSR8_#?C\*OTV);!1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %1W$AB@D<8)52PS["I*AO?^/.?_ *YM_*@#
MG?\ A*+K_GG#_P!\G_&C_A*+K_GG#_WR?\:QZ*TLC.[-C_A*+K_GG#_WR?\
M&C_A*+K_ )YP_P#?)_QK'HHL@NS8_P"$HNO^></_ 'R?\:/^$HNO^></_?)_
MQK'HHL@NS8_X2BZ_YYP_]\G_ !H_X2BZ_P"></\ WR?\:QZ*+(+LV/\ A*+K
M_GG#_P!\G_&C_A*+K_GG#_WR?\:QZ*+(+LV/^$HNO^></_?)_P :/^$HNO\
MGG#_ -\G_&L>BBR"[-C_ (2BZ_YYP_\ ?)_QH_X2BZ_YYP_]\G_&L>OFCXS_
M +3>N_#?QOXDTNW?P]9C1[:TGL=%U6.9M1\1F8D%+)DD500PV?<D.[J *+(+
ML^K_ /A*+K_GG#_WR?\ &C_A*+K_ )YP_P#?)_QKA_&?C?3O /A>;7=8\Z*V
MC,:>3"GF2O)(P1(U4=6+,%'N:Y>Q^/&A7%JSW>G:QI%Y'JEMI$VGZA:".>*:
MXQY1.&*LA!SN5F'7N,46079[!_PE%U_SSA_[Y/\ C1_PE%U_SSA_[Y/^->!_
M&#]H.W^'EI?_ -GVLMY>:3K.EV&H0FT>8M'=N!^Y5&#,^T\=LXX-3:A\?[.Y
MTLFQMKG1=7M=<T_2K_3->L6$\*W,J*I"H^#N5CM<,R@@Y!P119!=GNW_  E%
MU_SSA_[Y/^-'_"477_/.'_OD_P"->*1?M'^$YM;2T2'56TI]4.BKXB%D3IAO
M1(8C#YV<_P"L!CW[=F_Y=V>*B'[2?A>;639VMAKM_8G49-&BUJVT]FL)KY"R
MM;I+D9;>C)O($>X8WYHL@NSW#_A*+K_GG#_WR?\ &C_A*+K_ )YP_P#?)_QK
MYM^'G[4\7B?P-X>U/4O">N+X@U=+F>+1]-M4ED>"%PKS+F7&P;D4DD$MD!>E
M>HK\2-(F^&\OCBW%U<Z*FGOJ6U("L[1(A9AY;8(? (VG'/%%D%V>@_\ "477
M_/.'_OD_XT?\)1=?\\X?^^3_ (UY WQ_\')XHET$WS_;8O#@\4NX0>6MB2PW
M;L_>PA.WTP>]>:ZW^U7?V%]=-IN@3ZU:MXCT728;6"S,=S;P7MI!<'S=TP5Y
M3YIV;=JC(#9P22R"[/JG_A*+K_GG#_WR?\:/^$HNO^></_?)_P :^:_#'[5%
MFVI^([7Q)I&I6=KIOBF3P\=6M=.?[#:EI$2W6XE+GYV,B!F0%5W+G;FO5?'W
MQ"TWX=Z;:75_#=WD][=)96=C81"2>YG8$A$!('16)+$  $DBBR"[._\ ^$HN
MO^></_?)_P :/^$HNO\ GG#_ -\G_&OGW7?VCQ#=>"DT?POK-Z-:UR?1;^WF
MM1'<:?)%$SLK*S@;NA!!92H8@GC.U!^T-X>F\066GMIFN0V%[J3:1;:[+8%;
M":[5F7RP^[=RRLH8J%)'!/%%D%V>T?\ "477_/.'_OD_XT?\)1=?\\X?^^3_
M (U\Y_#S]IZTUZZN+/7]*U"PQXDOO#T.KQ:>Z::TT=U)%#$9&8G>RHH+8V%S
M@$$[:OZ)^T+!#H^[6;*:^UV[\0:OI.FZ/H5N9+BYBL[J2,R;6? "HB%W9E4%
MATW 46079[[_ ,)1=?\ /.'_ +Y/^-'_  E%U_SSA_[Y/^-<+X$\>:5\1?#X
MU?2FG2)9I+:>WNX3#/;3QL5DBE1N5=6!!'XC((->5ZC^U#8:IK/@JV\,6-W/
MIWB#Q"FE1:Q?V,BV=] $E\U[64, 2&C7:6&&7<5# $@L@NSZ._X2BZ_YYP_]
M\G_&C_A*+K_GG#_WR?\ &OG7PQ^TYI]SX1T:[O;&_P!?UB[L[G4;B'PYIS%8
M+6*X>'S61Y"0,IC 9F8AB!CITOB#]H+PYHSVZV=EK/B%I--BUB8:-8F8VMG(
M"4FE!*D;@"0@RYP<+Q19!=GLO_"477_/.'_OD_XT?\)1=?\ /.'_ +Y/^->,
MZ_\ M!>'M(B@ET_3M:\40/ID>LR3:%9>>D-G("4F8LR@A@K$*NYL \5#K'[1
M_A;3#"]I:ZOKMJ=+@UJXNM)LO.CM+.8$QS2\AL$*QPH9L G%%D%V>V?\)1=?
M\\X?^^3_ (T?\)1=?\\X?^^3_C7C'BG]H?PQX6U._M/LNKZM%I<$5UJU[I5D
M9X-,BD7>C3G((^0ARJAF"$,0 0:Z[Q3X[T;P?X-N?%%_<LVCPPI,)+6-IFE#
ME5C6-5!+,[,JJ!U+"BR"[.Y_X2BZ_P"></\ WR?\:/\ A*+K_GG#_P!\G_&O
M"KW]ISPMHFF>)+K7M.UWPW/X?MK>^O+#5+'9<&VGE\J.>,*S!TWA@<'(*D8S
MQ4\7[2GA*WMO$4FM0ZOX8FT.RAU*XM=9L&BGEMIG:.&2) 6+[Y%*!1\V_"E0
M>*+(+L]N_P"$HNO^></_ 'R?\:/^$HNO^></_?)_QKPKP-\<+GQQ\9;_ ,)K
MHUWHMG:>'X=4DMM7LVM[Y)GN'09^<H8R@4C;GYMP)R"HRM6_:87PO\2_B/HN
MN>'M0@\/>$M,TZ^.IV\2N7-P\ZMN'F?=/EH$P,_+)G'RT6079]%?\)1=?\\X
M?^^3_C1_PE%U_P \X?\ OD_XUY1X[^-OAOX=7^LVNL&[1])T-O$-T\,(=1:B
M4Q''/+;AT].]<M+^U7X:BO+^Q_X1[Q8VIVEBNK'3QH[">33VW?Z6JEAB,%2"
M&(?) V9XHL@NSZ _X2BZ_P"></\ WR?\:/\ A*+K_GG#_P!\G_&O$M5_:0\*
MVBVSZ9::SXGBDTJ#6YY="T]KA;2RF4O%-*<C&]0Q"+N<A20N!5W3OCUX;U_Q
M3IVA:#!J7B*6^L+;5$O-,MA):I9W&[RIWD+ !3MZ?>YX!PV"R"[/8/\ A*+K
M_GG#_P!\G_&C_A*+K_GG#_WR?\:\J\>_&/2? 6MP:/)IVKZWJTEE)J+66C6H
MGDBM48*TKY91C<<  EC@X!P:XF\_:<MK+QS=V<&CZEK_ (??PY9^(+.71=-D
MEN!#*TOF22[F554*L6$(#DE@ V" 6079]%_\)1=?\\X?^^3_ (T?\)1=?\\X
M?^^3_C7BUU^T%H%QJ%AI^B6>J:[<:AI$.MP7%C:;[>.SF!\N>1BRX7@9'WN>
M <'&-IO[3&F1^'_#9NM+U?7M<U#PY:^(KB+P_IC-&EO)&"TN'?Y%!SA&8MR
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MA>DZ7H<OB"X^S0A_]%CE6-MO(R^YAQZ=Z+(+L]:_X2BZ_P"></\ WR?\:/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#>_P#'G/\
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MHN@LSX^^)?P=^)GQ;O/B#J-]I>D:*=:\"-X;T^Q34?/*W1N&E+2/Y8^4[L9
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MA(+9I!,L3^>FR4KY;<_,*U_AW^TSX7^)/@3Q;XFTIH[J'PP'-]'87UO>HVV
M3@1SPNT;Y4XX;A@0<8J'QS\,OA?I5SJ>H^*[QC -/NYO[/O]1EEBM+9UCCN)
M8("Q*#[@)084L,8R*[/2?AEH]EX4U?0VN=3U2QUB-H[J74M0EN)71HA'@.[$
MJ-@ PN.YZDF@#SZP_:CM]0U&WT5/!VKCQ1>"VDL=&,UN7N89[>:X67S-^Q (
M[>7(8@Y '.X5=^%7QWOOBE\1];TVUT;[/X:@\/Z=J]E<RD+<22SO<)(CC>0
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MGMX=?U:+39)[:XO(ED5CNA@\OS7^4'A?-CS_ +PQ0!TU%-1Q(BLIRI&0:=0
M453U#6+#27M%OKVVLVO)Q:VRW$JQF>8@D1ID_,Q"L=HYPI]*N4 %%%% !116
M58>*=*U37]6T2UO$FU72EA>]M@#NA$H8Q$DC!W!6/!/2@#5HHKDM3^+'A#1;
M?6YK_P 06=HNBF<7RROM>(PVXN)L+C+[(65SL!P#0!UM%0VEW%?VD-S XD@F
M19(W'1E(R#^1J:@ HHK,UWQ+IGAI+%M3NTM%OKN*PMRX)\R>0XC08!Y)]>*
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M GJ16)XP^,?A?P)J=I8:Q/J45Q>,J6WV71KVZCG=@6"(\,+JS85CM!S@$XH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^50J,=S$#H.I /&Q_M,>!YKZWABN;^6UE2Q<ZDEA*;.+[9&LEJ'EQM4R!T
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M:/<>"?B-XQO+S0?$6B:;XB32;731K\[7-Q)+#;SF?<S2.P4-GDG'(QP17?\
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M\TWQ!>G3M7N[C3GAEN+9K83:%+ KQQR7D\B*+H(&W2MRS-A5<J.^/@[XL?\
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MED9%+$ Y. K 5]=:II=EK>G7%AJ-I!?V-RACFM;J)9(I4/565@0P/H:L@!0
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M8\98QKN^]@9^M.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGBW4M,LI7\$:?XA\%>'+FUU;4=,6UTTG^U-8:Y5D)C97,<4Q>60*PCW%G;C
M) .A^'?[*_\ Q0'@:'Q?K.HS:]HNGZ-&L*F#98FSEAN3;HR)\Z&6)5+$D[5&
M#WKI[O\ 9CT*[O\ 5&.L:K%I=U-J=W;Z9$\:QV5SJ",EU-&P7>2WF2D*Q*J9
M&P.F/*EU;XL:WXS>.XU_Q'I5I=:[JUA)!:640BM[:'3H[B!HV:$XS<!D#DD,
M"5'/3'\*_%SXCZOXPBA&KZW=>(+:[\.J_AP:<JVK6L]C!)J3RMY7R.H>609=
M2'"@ YVD ]3\%_L?:%\.F%SX:UZ]T/4X[E;JWN+"RLX(8&^S-;N%MTA$6'1M
MS?+]\;NI.=FV_9AT);R[N;[6=5U2:\\0+XBNGN6C!FG&F+IS(=J#Y6C7><8.
MXG! XKP'0_B?\7_$>HQVBW.NZ;9:EJ.A1M+&C7<UI'-?F.\!=[&!8W$3+N0+
M(L>T,)&R<=MI?C7XFI<^!M!EU+4S=>)=4O=*-[=6J![6'3]6G=YV^0#=/I\9
M0,1M+>6P'/(!TF@_L2^"_#7AC4-"L#9Q65XD$,L1\.Z68YHH2Y19T^S8N#E@
M=\FYLHI!!!SZ"_P/TQ?A]X2\*6^I7UO!X9N[6\LKO*/+O@)*A@RE=I!*X
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M"Q;RT ;YMH! I&\0?$?3?'6M-(=5D@L;>73FU]M)C>]6R76@I=91%EB+<E@
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M;3K'4[74)K72_$FA7,DESI",MU#>ZG:3QL@:,[3:P^<C, &C*AB00#7"^%]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>apre-20251231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &= Z8# 2(  A$! Q$!_\0
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M*_"K_HH/A[_P81_XU^+-%']D4_YF']D4_P"9G[3?\-*_"K_HH/A[_P &$?\
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MXLT4?V13_F8?V13_ )F?M-_PTK\*O^B@^'O_  81_P"-'_#2OPJ_Z*#X>_\
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M_P -*_"K_HH/A[_P81_XT?\ #2OPJ_Z*#X>_\&$?^-?BS11_9%/^9A_9%/\
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M,K_DN6N_]B_-_P"E$%<]?+84:4JBD]#GQ&64Z-*512>A^FM%%%?/GSI^=O\
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M4OY1)7<,'CN,BM_PY^TW\.O@+X<\<3?"J.]GU_6]12>RBU:Q M[6#@F,X?)
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M^'M?\3ZEK=I)X@G,5E!H.D/J"PIG:)9W7A$SW].1FM3QS\:O@3\2_%EQX_\
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MXO[<ZE9LT^)6W?-B0 ?2L8_6FDKN]D^BUU\F8Q6*:2N[V3Z+77R9S>M#X8_
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M  );_&C_ &OO'[F'^U_S1^YGRI_P[Z^,7_0*T_\ \#E_PH_X=]?&+_H%:?\
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M_"?^)?\ H/:A_P"!+?XT?\)_XE_Z#VH?^!+?XT?[7WC]S#_:_P":/W,^5/\
MAWU\8O\ H%:?_P"!R_X4?\.^OC%_T"M/_P# Y?\ "OJO_A/_ !+_ -![4/\
MP);_ !H_X3_Q+_T'M0_\"6_QH_VOO'[F'^U_S1^YGRI_P[Z^,7_0*T__ ,#E
M_P */^'?7QB_Z!6G_P#@<O\ A7U7_P )_P")?^@]J'_@2W^-'_"?^)?^@]J'
M_@2W^-'^U]X_<P_VO^:/W,^5/^'?7QB_Z!6G_P#@<O\ A1_P[Z^,7_0*T_\
M\#E_PKZK_P"$_P#$O_0>U#_P);_&C_A/_$O_ $'M0_\  EO\:/\ :^\?N8?[
M7_-'[F?*G_#OKXQ?] K3_P#P.7_"C_AWU\8O^@5I_P#X'+_A7U7_ ,)_XE_Z
M#VH?^!+?XT?\)_XE_P"@]J'_ ($M_C1_M?>/W,/]K_FC]S/E3_AWU\8O^@5I
M_P#X'+_A1_P[Z^,7_0*T_P#\#E_PKZK_ .$_\2_]![4/_ EO\:/^$_\ $O\
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M  G_ (E_Z#VH?^!+?XT?[7WC]S#_ &O^:/W,^5/^'?7QB_Z!6G_^!R_X4?\
M#OKXQ?\ 0*T__P #E_PKZK_X3_Q+_P!![4/_  );_&C_ (3_ ,2_]![4/_ E
MO\:/]K[Q^YA_M?\ -'[F?*G_  [Z^,7_ $"M/_\  Y?\*/\ AWU\8O\ H%:?
M_P"!R_X5]5_\)_XE_P"@]J'_ ($M_C1_PG_B7_H/:A_X$M_C1_M?>/W,/]K_
M )H_<SY4_P"'?7QB_P"@5I__ ('+_A1_P[Z^,7_0*T__ ,#E_P *^J_^$_\
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M_P#@<O\ A7U#J/Q4UC2(HY;_ ,57-E%)*D*/<7IC5I&.%0$D98D@ =2:M?\
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M^@5I_P#X'+_A1_P[Z^,7_0*T_P#\#E_PKZK_ .$_\2_]![4/_ EO\:/^$_\
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M\7P?LS6_@[0%MAXJ&@6VD,[S[(XV\E(IF5\=AOP?7!KQ?6/V![/P?X>T[6O
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M;+5O%%_<VOHT?FD!A[&O>:WHR<J<6S>A)RIQ<@HHHK8W"BBB@ HHHH ****
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ME_YX0?\ ?X5] 45K_:5;LC7^U:_9?U\SY_\ ^%-^)?\ GA!_W^%'_"F_$O\
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M\2_\\(/^_P */^%-^)?^>$'_ '^%?0%%']I5NR#^U:_9?U\SY_\ ^%-^)?\
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MWXE_YX0?]_A7T!13_M*MV0_[5K]E_7S/G_\ X4WXE_YX0?\ ?X4?\*;\2_\
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MH [^BBBF 4444 %%%% !1110 4444 %%%% !1110 5)+_!_NBHZDE_@_W12
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M_5K6ZM=*N);6^G20>7;RQ#,BLW0%>_ISZ46"YVO]H6W]]_\ OFC^T+;^^_\
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MLQ7RVD !^0,6X/'!KH?$7B/3/">E2:EJ]Y'8V4;)&99,G+NP1% &2S,S*H4
MDD@"BP7.K_M"V_OO_P!\T?VA;?WW_P"^:\VE^+W@^'Q<GAE]<@767G%JL11_
M+\\J6$/F[?+\PJ"1'NW>U=-JFIVFB:9=ZCJ%S%9V%I"\]Q<SN%CBC4%F=B>
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M?]]FO,_&'[0FD>!=3M;/5_#GBB$7FHQZ5:W":87BN;B1MJ+&0V6!Y.<< $G
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M.V;R\QDX0 ?,:6I)?X/]T4 5?L%K_P \F_[[-'V"U_YY-_WV:FHH A^P6O\
MSR;_ +[-'V"U_P">3?\ ?9J:B@"'[!:_\\F_[[-'V"U_YY-_WV:FHH A^P6O
M_/)O^^S1]@M?^>3?]]FIJ* (?L%K_P \F_[[-'V"U_YY-_WV:FHH A^P6O\
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MO((8ACEAP<5]-5%!:06H(@ACA!P"(U"YQTZ5+3 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH D@^^?]T_RJ.I(/OG_
M '3_ "J.@84444""BBB@ HHHH **** "BBB@ HHHH **** "OAOXY-J-KH/Q
MB^'7A36-*:^\5ZK&D&FW:3)JXN;D1*P@AQB6$XW&<,!&H<D';7W)4+65NURM
MRT$1N%&!*4&\#V/6D!X]^T:7_M?X0I.?^)._C>S%XI&59Q#.UL&]OM AQ_M!
M.^*X3XL?$WPE\8_&5U\+F\3:)H7AC2]1MY?$]Y>:C#;S7<D4B3+8P*S!CN=$
M\R3LN5')X^@_'G@G3OB+X4O] U3SDM;H*RSVSA)K>5'#Q31,00LD<BHZD@@,
MHR#TJ]'X?L J&:T@NIP!ON)H(]\C=V;"@9/7@ >U 'DLZ-XX_:LB@N&WZ=X)
MT,74-NPROVV\9E\W_>6&-E'M(WK77^/OB9X7T#3[>/4/$(T:+4)YM,BU^V\I
MX]-N?+/+RR*\43@\+YJE2V%(.<'N5B19&D"*)& #,!R<=,FHY+&VFA>*2WB>
M)SN9&0%6/J1W-,#XPU25T_9T\2PZ/</JDMM\0M-/AWQ&QS/J]R^J6A^T;AA6
M8LTJ%HPJ%%.U5%?:U<UKO@'3?$.L^'+^[:80Z#</=VFGQ[%MFG*%%E==N2R!
MGVX( +$X)"D=+2 ****8!1110 4444 %%%% !1110 4444 %%%% !4DO\'^Z
M*CJ27^#_ '12 CHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% 'E'[
M5NB:AXB_9S\?V.EPR7-X^F/(MO"NYYE0AWC5>Y959<=\U@^$_%FC_$O]HZUU
M[PKJ$&LZ-8^$FM[J]LW#Q)+-<))%$S#C>%1B4ZKGD#->Z]:AMK*WLE9;>"*!
M6.2(D"@GUXI ?)GQ2T35?%.D_M3Z=;K+/KTFFVZV<*+NDDM%M-XC0=]Q$JX'
M4M7;:1XKT#XH?'6UUKPW>6VK^']/\%W%O?W%LP>&%[B:%XH7(X#A(Y"4/*@\
M@9KV%_ ]C_PG<?BR*:XMM1-B=/N(HF40W<6[='YH*DEHR7VD$?ZQ@<\8=XJ\
M%V7BCPIJV@":XT>UU.%H+B?2]D4VQN'"L5.TLN5W ;@&)4JP! !PW[*+7+?L
M\>!S=,6/V(B$GO!YC^3^'E[,>U>LU7T[3K;2-/MK&R@2VL[:)8888QA8T485
M0/0  58H ****8!1110 4444 %%%% !1110 4444 %%%% !5K3O]<?\ =JK5
MK3O]<?\ =I,9HT445)1EZQ=Q6TD8D#DD'&W%9_\ :EM_=E_(?XT_Q/\ ZZ#_
M '36+6B6A#>IK_VI;?W9?R'^-']J6W]V7\A_C6113L3<U_[4MO[LOY#_ !H_
MM2V_NR_D/\:R**+!<U_[4MO[LOY#_&C^U+;^[+^0_P :X3Q9\0-'\$ZEX=LM
M6DE@?7KX:=9RB(M'YY1F5';HN[:0,]3Q3];\>:3H'BGP_P"';J24ZKKAF%I#
M%&7^6)-SNY'W5' R>Y [TK#N=Q_:EM_=E_(?XT?VI;?W9?R'^-9%%.PKFO\
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M_(?XT?VI;?W9?R'^-9%%%@N:_P#:EM_=E_(?XT?VI;?W9?R'^-9%%%@N:_\
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MV[N&%SO;3RSS6O0F5KC[^SD\!OEK[;^%;M)\,/![,2S'1[,DDY)/D)7+^/\
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MLZQH%]*KQ0Z+<O>V^GP*B6SW!0HLLB[<LR!GV\@ L202%(Z>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *L7G2#_KF/ZU7JQ>=(/\ KF/ZT 5Z***
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MD&GZ;9ZJTZ7=NK 30F0PKLG0D#;M*$LOSX)(0'L?V:V_Y]D_-O\ &C[-;?\
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MW_.C^TKK_GN_YU6HHL%RS_:5U_SW?\Z/[2NO^>[_ )U6HHL%RS_:5U_SW?\
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M(IY-ZJV0/F ZXX]S7=U9_LVY_P">+4?V;<_\\6IB*U%6?[-N?^>+4?V;<_\
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MU%6?[-N?^>+4?V;<_P#/%J+A8K459_LVY_YXM1_9MS_SQ:BX6*U%6?[-N?\
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M4"O5:L_V;<_\\6H_LVY_YXM3 K459_LVY_YXM1_9MS_SQ:BX6*U%6?[-N?\
MGBU']FW/_/%J+A8K459_LVY_YXM1_9MS_P \6HN%BM15G^S;G_GBU']FW/\
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M'9KB V$UYO$BEL0B78KHC!!(%)1=P:O7OM-O_P ]T_7_  H^TV__ #W3]?\
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M1_:;?_GNGZ_X4?:;?_GNGZ_X4 245']IM_\ GNGZ_P"%'VFW_P">Z?K_ (4
M245']IM_^>Z?K_A1]IM_^>Z?K_A0!)14?VFW_P">Z?K_ (4?:;?_ )[I^O\
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M-O\ \]T_7_"C[3;_ //=/U_PH DHJ/[3;_\ /=/U_P */M-O_P ]T_7_  H
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M %%%% !5B\Z0?]<Q_6J]6+SI!_US']: *]%%% !1110 4444 %%%% !1110
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M?Q/?^,?@KX4U34Y&FU![4PS3/]Z5HG:+>?=MF[\:]&I@%%%% !1110 4444
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M%%QV/&+;]FSP';Z9J.G-IUW<V%YIMQHXM[K4;B9+6SG4K+#;AG/D*5.,1[<
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M^8_PH_LNU_O3?F/\*+A8R**U_P"R[7^]-^8_PH_LNU_O3?F/\*+BL9%%:_\
M9=K_ 'IOS'^%']EVO]Z;\Q_A1<+&116O_9=K_>F_,?X4?V7:_P!Z;\Q_A1<+
M&116O_9=K_>F_,?X4?V7:_WIOS'^%%PL9%%:_P#9=K_>F_,?X4?V7:_WIOS'
M^%%PL9%%:_\ 9=K_ 'IOS'^%']EVO]Z;\Q_A1<+&116O_9=K_>F_,?X4?V7:
M_P!Z;\Q_A1<+&16MX:_X_9/^N9_F*7^R[7^]-^8_PJ]I-G#;7#-&7)*X^;'J
M*3>@TM36HHHJ#0H:E]]/I5.KFI??3Z53JD2PHHHIB"BBB@##\7>-=(\#65C=
M:S<M;07NH6VF0,L;/NN+B58H5PH.,NRC)X&<D@4:SXUTC0/$>@Z%>W+1:GKC
M3+8Q"-F$IB0/)E@,+A2.I&>U>5?M>6TM[X \*V\%W+I\\WC7P_''=P*C20,=
M1A =0ZLI*GD!E(R.01Q7&_%/X:7]U\9/A?I'B#QMKGB>PU:'6K)TO(K.W:!7
MM K-&UM;Q,&P>I)Q@8I#/J.BOSR\3^+_ !'XN^#?BZ\\0ZMJ6FW?P\TNP\+:
MG>VLCQ,^H#4H4N;A6'))BBC<$9XE_"NK^)MY8^%O$]QI/@+5YHOAC=1:,GBF
MYTV^>2&U@DO0DK^<"3&7A.)&!!V$DXZT ?9?B;Q7I7@^SM;K5[Q+."ZO;?3X
M6<$[YYY5BB0 =V=U'Z]!6O7PC\8]!\.3^);G1=&\J\^'=CXC\+7-PJW)DLK2
MYDU%(YPC[B%W1%=X!P,@\9J'5]<\33^(O%^JQKX<T_Q38>,([/2=1OO$MZNH
M0VJSQK;00Z=#8R"2&6$G.)"&$KL2-O !]Z5'<3BVMY9F5W6-2Y6-"[$ 9P%'
M)/L*^*[6Q73+6?QDEQ>/XAC^,B:5'=M=R$QVDNHI \ 7./+*2O\ +C'/L,5=
M&U ^ ]?N;6>XTKQC+KD&NK8^,O#NN3_;F ADFVZC8N"HVE702I(0"J (N[@
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M!9V//"@G )Z"NAKA?C'\4/#/PA\*Q>(?$J&XV74=OI]I#&CW%S>292.* ,0
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MW]YMH&3[F@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;N.VNE>ZDCBM47S4"!OWD["5P<&/.:^G(OVCO TT^F6R7FI-J.H7<MC#IO\
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M#<3:3=?8KS]VRB.;8KE 2 &PKJ>,]:UZ "BBB@ HHHH **** "BBB@ HHHH
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MY,=\N<<94D)QQ\@Q7I=%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>apre-20251231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '1 X$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBOFGXR^(=;NO$OQ:O+?Q)J.A-\/_  O9ZUH]O8W30Q27+?:IY'N(P=MQ')]E
MCAV2 @#S-H#-NH ^EJ*^6;3Q9K^J7X\;RZ[J]O>O\01X7.@)>,MI_9[2"U\G
MR =HDY^U>< )<\;@GRUU?@#3K'1/B=XW\2GQ)KUMX0\-*NBK::EXAOK^VFNB
M(Y9[AUN)9.4WQQ(%P 3+D$[=H![W17RW\3/'5_XEN_BKXET?Q9?Z?;>!- L=
M6T*+3KMHK>XE*S7$C3Q@[;A)O)6WVRJ0H5R@5VW56US]H:_U7]I;PKI]IJ<N
MF>'K4ZIISZ)(#')J5W':AO-8=?+$G[N/.-Q5V'RE&(!]6TA(4$DX Y)-?-'P
M,\2:XNM_"/4+KQ)J&N-\0O!]QKFL6UW=--!'=J+299;:-B1;HOVN2+RX\*1Y
M>1N7)]]\;_\ (EZ__P!@^X_]%M0!M*P90000>01WI:_'OP_^W'\;=/T'3;6W
M\:^7!!;111I_95B=JJ@ &3#D\"M#_AN[XY_]#Q_Y2;'_ .,5T^PD?-O/L,G;
MEE]R_P S]=**_(O_ (;N^.?_ $/'_E)L?_C%'_#=WQS_ .AX_P#*38__ !BC
MZO(7]OX7^67W+_,_72BOR+_X;N^.?_0\?^4FQ_\ C%'_  W=\<_^AX_\I-C_
M /&*/J\@_M_"_P LON7^9^NE%?D7_P -W?'/_H>/_*38_P#QBC_AN[XY_P#0
M\?\ E)L?_C%'U>0?V_A?Y9?<O\S]=**_(O\ X;N^.?\ T/'_ )2;'_XQ1_PW
M=\<_^AX_\I-C_P#&*/J\@_M_"_RR^Y?YGZZ45^1?_#=WQS_Z'C_RDV/_ ,8H
M_P"&[OCG_P!#Q_Y2;'_XQ1]7D']OX7^67W+_ #/USSS2U^1 _;J^. D,G_";
M_.0%)_LFQZ#./^6'N:?_ ,-W?'/_ *'C_P I-C_\8H^KR#^W\+_++[E_F?KI
M17Y%_P##=WQS_P"AX_\ *38__&*/^&[OCG_T/'_E)L?_ (Q1]7D']OX7^67W
M+_,_72BOR+_X;N^.?_0\?^4FQ_\ C%'_  W=\<_^AX_\I-C_ /&*/J\@_M_"
M_P LON7^9^NE%?D7_P -W?'/_H>/_*38_P#QBC_AN[XY_P#0\?\ E)L?_C%'
MU>0?V_A?Y9?<O\S]=**_(O\ X;N^.?\ T/'_ )2;'_XQ7>_#']H3]I7XKRR?
MV1XZL(+:)@LMQ>6>GKL/M$L#2O\ \ 1JB=/V47.<DDMVS6EG5&O-4Z5.4I/9
M))O\S]-Z*^,K[XC_ !3OM!32]*\>+;>+4BA235I])C,$[*7+@Q"!M@.\ ,(\
M_(,UX%\0?VH_VCOAEJJ6&M^-;022 M&]I::9.KKZ_)$2OT8*?:O%RO,\)G$9
MO"5%+E;35^SM?T>Z9[V;*MDKA]<HS2DDT[*VJO9Z[K9H_4DG R>E+7Y$3?MT
M_'"XADBD\;;HW4JP_LFQ&0>#_P L*?\ \-W?'/\ Z'C_ ,I-C_\ &*]WZO(^
M<_M_"_RR^Y?YGZZ45^1?_#=WQS_Z'C_RDV/_ ,8H_P"&[OCG_P!#Q_Y2;'_X
MQ1]7D']OX7^67W+_ #/UTHK\B_\ AN[XY_\ 0\?^4FQ_^,4?\-W?'/\ Z'C_
M ,I-C_\ &*/J\@_M_"_RR^Y?YGZZ45^1?_#=WQS_ .AX_P#*38__ !BC_AN[
MXY_]#Q_Y2;'_ .,4?5Y!_;^%_EE]R_S/UTHK\B_^&[OCG_T/'_E)L?\ XQ1_
MPW=\<_\ H>/_ "DV/_QBCZO(/[?PO\LON7^9^NE%?D7_ ,-W?'/_ *'C_P I
M-C_\8H_X;N^.?_0\?^4FQ_\ C%'U>0?V_A?Y9?<O\S]=*2OR,_X;N^.?_0\?
M^4FQ_P#C%,'[=7QP$K2#QO\ .P"D_P!DV/09Q_RP]S1]7D']OX7^67W+_,_7
M>BOR+_X;N^.?_0\?^4FQ_P#C%'_#=WQS_P"AX_\ *38__&*/J\@_M_"_RR^Y
M?YGZZ45^1?\ PW=\<_\ H>/_ "DV/_QBC_AN[XY_]#Q_Y2;'_P",4?5Y!_;^
M%_EE]R_S/UTHK\B_^&[OCG_T/'_E)L?_ (Q5O2?VV/C]KFHP6-AXQ:YNYVVQ
MQ)I-AEC^,-'L)=QK/L,]%&7W+_,_6FBOB'X8_%+XX:%<RWGQ,\50F&6-$M](
MAM+,S@EU)F9X8=H 0, I<DEAE>*\W^(/QG_:@\ VD^IOXP@U3P^K$1ZI9Z=I
MY1E]3&T D7C'5?Q->+0S+!8G%SP-*M%U(6NKKK?;TMKVNCZ#$?6<+@X8^MAZ
MBISOKR[6MJ]=$[Z=[,_2:BOR+_X;N^.?_0\?^4FQ_P#C%'_#=WQS_P"AX_\
M*38__&*]KZO(^>_M_"_RR^Y?YGZZ4G2OR,_X;N^.?_0\?^4FQ_\ C%,D_;J^
M.$R%'\;Y4]1_9-C_ /&*/J\@_M_"_P LON7^9^N]%?D7_P -W?'/_H>/_*38
M_P#QBC_AN[XY_P#0\?\ E)L?_C%'U>0?V_A?Y9?<O\S]=**_(O\ X;N^.?\
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MW?'/_H>/_*38_P#QBCZO(/[?PO\ ++[E_F?KI17Y%_\ #=WQS_Z'C_RDV/\
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M8)2U6N_]=:?]=?\ V1JLT %%%% !1110 4444 %%%% !1110 4@.:6J6D_\
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M:3_P96?_ ,>H_P"&&?CA_P!"-)_X,K/_ ./4<L?Y_P 0]OB/^@-?^ ,^HO\
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M[D>%?\,._!#_ *$6+_P8WG_QZC_AAWX(?]"+%_X,;S_X]7NM%'/+N'U/#?\
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MB7\7_%>AZS\0)M CTI='\!:7;:IJ,-]!))/J =9)IHXW611"4@BRK%7W.X!
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MX=@>!?\ H;/$/_D#_P"-T?\ #L#P+_T-GB'_ ,@?_&Z.:CV#ZMG'\_XH\/\
M^'F/Q4_Z!/A7_P  KC_X_1_P\Q^*G_0)\*_^ 5Q_\?KW#_AV!X%_Z&SQ#_Y
M_P#C='_#L#P+_P!#9XA_\@?_ !NCFH]@^K9Q_/\ BCP__AYC\5/^@3X5_P#
M*X_^/T?\/,?BI_T"?"O_ (!7'_Q^O</^'8'@7_H;/$/_ ) _^-T?\.P/ O\
MT-GB'_R!_P#&Z.:CV#ZMG'\_XH\/_P"'F/Q4_P"@3X5_\ KC_P"/T?\ #S'X
MJ?\ 0)\*_P#@%<?_ !^O</\ AV!X%_Z&SQ#_ .0/_C='_#L#P+_T-GB'_P @
M?_&Z.:CV#ZMG'\_XH\,'_!2OXIB9I?[)\*[F4*?]"N,8!/\ TW]Z?_P\Q^*G
M_0)\*_\ @%<?_'Z]K7_@F-X&-T\7_"5^(<*BMG]QW)'_ #S]JE_X=@>!?^AL
M\0_^0/\ XW1S4>P?5LX_G_%'A_\ P\Q^*G_0)\*_^ 5Q_P#'Z/\ AYC\5/\
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M)BQ/F,N"8MV=@4!=N * /L6TU"WOS.+>593!)Y4FW^%MH;'Y,#^-6*^.M2^
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M/0_$UU<^$O$GVFZUBTU/3X+=?#@GC<6302,]B7^Q-&'X,9EW[61A*[@D;/\
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M)]8\,7]]KNI3ZY%J=IK%Q$]IMOK8QRN%B9YI=AVQ960+L^7Y?I'QO_R)>O\
M_8/N/_1;4 ?!GA+_ ()?_P!K^%=%O_\ A9?E?:K*&?R_[!W;=T:MC/VD9QFM
M;_AU=_U4_P#\M_\ ^ZJ^5M"_:O\ B[9:)I]O!X]U:.&*WCC1%=<*H4  <>E7
MO^&N/C%_T4#5_P#OM?\ XFN_EJ_S'P$L1E5W>B_O?_R1]-_\.KO^JG_^6_\
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M_P"*KZOV&&_G_%'G>PPW\_XH^_-3_P""AO[/UQIMW%'X^W2/$ZJ/[&U 9)!
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M?\4'L,-_/^*/T%_X>)_L]_\ 10/_ "BZA_\ (]'_  \3_9[_ .B@?^474/\
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M 4444 %%%% !1110!6M?^/B[_P"N@_\ 0%JS5:U_X^+O_KH/_0%JS0 4444
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M-2V0+H8YSQBMG_AD?]D/_GR\/?\ A77/_P E5ZRK4/Y/P1ZRK4/Y/P1\-?\
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MEADL&@O[2$Q[C.2^]+G.1MVE2.0> #[7JEI/_'J__7>;_P!&M7DOQZ^+>O\
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M1_P^ N_^B5P_^#\__(U/VF(_D_$?M,1_)^)\7?\ #.7Q8_Z)?XS_ /"?N_\
MXW1_PSE\6/\ HE_C/_PG[O\ ^-U]H_\ #X"[_P"B5P_^#\__ "-1_P /@+O_
M *)7#_X/S_\ (U'M,1_)^(>TQ'\GXGQ=_P ,Y?%C_HE_C/\ \)^[_P#C='_#
M.7Q8_P"B7^,__"?N_P#XW7VC_P /@+O_ *)7#_X/S_\ (U'_  ^ N_\ HE</
M_@_/_P C4>TQ'\GXA[3$?R?B?%W_  SE\6/^B7^,_P#PG[O_ .-T?\,Y?%C_
M *)?XS_\)^[_ /C=?:/_  ^ N_\ HE</_@_/_P C4?\ #X"[_P"B5P_^#\__
M "-1[3$?R?B'M,1_)^)\7?\ #.7Q8_Z)?XS_ /"?N_\ XW1_PSE\6/\ HE_C
M/_PG[O\ ^-U]H_\ #X"[_P"B5P_^#\__ "-1_P /@+O_ *)7#_X/S_\ (U'M
M,1_)^(>TQ'\GXGQ;_P ,Z?%?<5_X5CXRW 9(_L"[SC_OW2_\,Y?%C_HE_C/_
M ,)^[_\ C=?9H_X*]78N7E_X59#\R!<?V\>Q)_Y]_>I/^'P%W_T2N'_P?G_Y
M&H]IB/Y/Q#VF(_D_$^+O^&<OBQ_T2_QG_P"$_=__ !NC_AG+XL?]$O\ &?\
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MPGN?V@OAG\'/@)X?\)>&-3LK!KV_77+:[T7,T :?47 E625&52OEN-PB&X1
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M6L;WT20-8Q%%2>5_M"A=N ),G>/XL\YKPOQA^TKXNUKPC>7WA?PT_A]M+OM
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M110 4444 %%%% !5;4O^/*7Z#^=6:K:E_P >4OT'\Z +-%%% !1110 4444
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MOC'_ -#Q=?\ @-;_ /QNOT5_X9;^$W_0A:-_WX_^O1_PRW\)O^A"T;_OQ_\
M7H]O2_D_(/95/YC\ZO\ AL;XQ_\ 0\77_@-;_P#QNC_AL;XQ_P#0\77_ (#6
M_P#\;K]%?^&6_A-_T(6C?]^/_KT?\,M_";_H0M&_[\?_ %Z/;TOY/R#V53^8
M^1OA[^U#\1-:\&6NGS>,;N'Q1JD]X;.XO-"CEMGCCA4@>?N0)A@^2J28)&[
MK;^(_P 4_C1\/?@1I^I7VK:W:^(TU=$O[^?3D6)8I+?>L:$Q;2JL54L."^X
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MI?H/YU9JMJ7_ !Y2_0?SH LT444 %%%% !1110 4444 %%%% !1110!6M?\
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MMBT*G>T?F)+M!RHWY R?E /U?KYZ^+?P^\93^)?B+!X>T$:Y8?$30+;0S?\
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M#K&@7&LSVXME@BL9H[J.-([&;/\ IUN4E8&="Z@QH=Z^:$'NWC?_ )$O7_\
ML'W'_HMJ /RS\.?L3_&/4/#VEW4'A1'@GM8I8V_M.T&5* @X,OH:T?\ AASX
MT?\ 0I1_^#2T_P#CM=7X5_X*+^/-+\,:/91^'?#K1VUG#"K/'/DA4 !/[WKQ
M6I_P\F\?_P#0N>&_^_5Q_P#':]=.O;9'G6H]V<!_PPY\:/\ H4H__!I:?_':
M/^&'/C1_T*4?_@TM/_CM=_\ \/)O'_\ T+GAO_OU<?\ QVC_ (>3>/\ _H7/
M#?\ WZN/_CM%\1V0K4>[. _X8<^-'_0I1_\ @TM/_CM'_##GQH_Z%*/_ ,&E
MI_\ ':[_ /X>3>/_ /H7/#?_ 'ZN/_CM'_#R;Q__ -"YX;_[]7'_ ,=HOB.R
M"U'NS@/^&'/C1_T*4?\ X-+3_P".T?\ ##GQH_Z%*/\ \&EI_P#':[__ (>3
M>/\ _H7/#?\ WZN/_CM'_#R;Q_\ ]"YX;_[]7'_QVB^([(+4>[. _P"&'/C1
M_P!"E'_X-+3_ ..T?\,.?&C_ *%*/_P:6G_QVN__ .'DWC__ *%SPW_WZN/_
M ([1_P /)O'_ /T+GAO_ +]7'_QVB^([(+4>[. _X8<^-'_0I1_^#2T_^.UT
M7A#]BOXQZ>NJR2Z-%9J+96_L^;4HC!J@65&-M(8IPR@XW#.!E!RIP:]G^$O[
M<VN^/_-TZ\TO2$UV?SS!';)(JVZ1PLZN4:0O<L[X00Q88 %LG( L^*_VT_%&
MD^'-<-AH>D/K/A^WT^ZOY;@2_9[A+I4XB0.&0HTJ+\S-N&X_+P*ASK7Y;(M0
MI6O=E#5/V:_B!/\ $^ZU)[5-2TG4H[A9TDO%#Z9YMG&DS6R^8$/F/OB7>A(6
M)2V.&KSSX"_L??%+PK\5-(U'7=!32]*6*[AFO!J$#F+S+66-6Q%,'^\Z_=(/
MH1U';^#?^"@MW;?#?X@>-_&.A:?Y>@QVD5I::;*;?[3-*MRRHS2NQY,0'R*Q
M&2=I ./J_P"$WQ.TOXP^ ].\5Z.K)87N\(KNC,"K%6!VDXY!X.&'1@IR!SRJ
MU(7@S:-.$[21Y?\ LH?LX:]^S_:>($UWQ5)XFEU&[FDAWSW$HBC-Q+(O^L?
M+"0%OE+;BV9'&W'T!117&=(4444 %%%% !1110 4444 4]9_Y ]]_P!<)/\
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M>76E^&GB@B@M9+DL9/,E1!+<*#(Y1968(2" "!7T+10 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !5;4O\ CRE^@_G5FJVI?\>4OT'\Z +-%%%
M!1110 4444 %%%% !1110 4444 5K7_CXN_^N@_] 6K-5K7_ (^+O_KH/_0%
MJS0 4444 %%%% !1110 4444 %%%% %:[_UUI_UU_P#9&JS5:[_UUI_UU_\
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M2[2SGG'Q8O&,4;/M_L)!G SC_CXJ;_ARCI?_ $5J\_\ !"G_ ,D47X3[?^G
M_?\ ]6,__A]K_P!49_\ +I_^XZ/^'VO_ %1G_P NG_[CK0_X<HZ7_P!%:O/_
M  0I_P#)%'_#E'2_^BM7G_@A3_Y(HOPGV_\ 3@?O_P"K&?\ \/M?^J,_^73_
M /<==U\)_P#@K+'\5M?AT6+X>:?HFHSN1&E_XCN&38J%WE9X].<(B*K,Q8C
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M_P -=?L+?]$U\/\ _A!6W_QNC_AKK]A;_HFOA_\ \(*V_P#C=']HO_H6R_\
M 5_D')_?/SG_ .&KOC7_ -%=\<_^%'=__'*/^&KOC7_T5WQS_P"%'=__ !RO
MT8_X:Z_86_Z)KX?_ /""MO\ XW1_PUU^PM_T37P__P"$%;?_ !NC^T7_ -"V
M7_@*_P @Y/[Y^<__  U=\:_^BN^.?_"CN_\ XY1_PU=\:_\ HKOCG_PH[O\
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MH **** "BBB@ JK'_P A*X_ZY1_S>K558_\ D)7'_7*/^;T 6J*** "BBB@
MHHHH **** "BBB@ JMJ7_'E+]!_.K-5M2_X\I?H/YT 6:*** "BBB@ HHHH
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M,(< T ?454M)_P"/5_\ KO-_Z-:KM4M)_P"/5_\ KO-_Z-:@"[1110 4444
M%%%% !1110 4444 %5KO_7V7_74_^BWJS5:[_P!?9?\ 74_^BWH LT444 %%
M%% 'PU_P43O]/T7XH_ G5?'EOJEW\(;"]U"YUF'38Y74WJ11M9><L?S$;P<8
M_P!K-?+FE^!+B77_ ('^+/[,U%?CKX_^($WBQI&AD^T6VA^84"RG&%3:JO@]
M%=LX'%?L'<VL-Y$8KB&.>(G)210P_(TS^S[7[6EU]FA^U(GEK/Y8WJG]T-UQ
M[4 6*\+^)_PE\7:QK_Q _P"$=_LR;3?'FA6VB7LU].\<FF,@GB>=%"L)LPW)
M(3*X:(9.&./=*^9/C5K6K7WBGXL7R>)=5T*3X>^%[/6]$MM/OY+:%[EQ=S/)
M<Q*P2ZC<VL</ES!E $FT!F+4 :Z? WQ5!=-X7@DL(?!Q\6CQ2-62X;[:B[Q<
M>0(2A7?]I .\L1L_ASQ4'P[_ &6]<^'/C_6KS3OB5XE_L6ZT"WTVWNY4TN2^
M%PMS<322.38;7.9MV]PS,TLA?=\N.>M/%6MW6J#X@3>(=7M=5'C\>%SH;:@_
M]GKIYE%OY1M2WE;PI^U>=M\WMOV?+6WX+U^X^&_QC\C4O%&N:GX6UCPY)J::
MCJMXVHPZY>":)WNK&.-Y!:0Q1SJIB18D?SD*(1$7(!<\8?!'QLQ\<Z7I6K6_
MB"Q\<Z/;:3J.LZY(D-Y:%5DAFF\N"%8Y2T$ORJJQ@/'SPV1Z9-X(O?\ A<6A
M^)HFA&DV/AV\TEU9SYOFRW%I(A Q@KM@?)SUQQSQX?\ $_QE>>)[_P"*?B?3
MO%.L:2O@+0++5M MK*[FLX)I62>=VN;?*K<+,T"P;)U8*%<H%9BU=OK6O^+=
M$^/TL]QK37&A/X)U+4;+P]%!Y<<4T4UB-\K;B99"7D / 56P!DL6 .]^''@V
M]\,W_C#4=3>&6_US6IKT/"2<6ZJL5NA) Y$<:Y'8L:VO&_\ R)>O_P#8/N/_
M $6U?.W[->O^)HO$_A.X\5W>MFZ\;>%SK2/<ZV=1M+Z9# \DGV8@)IK(+D!(
MK8M$Z/\ .V^)<_1/C?\ Y$O7_P#L'W'_ *+:@#\:]$_X)(_&S6]%L-1M]0\(
MB"[MX[B,/J,P;:ZAAD>1UP:N_P##G[XY?]!'P?\ ^#*?_P",5YKI7_!27]HW
M2M+L[*U^(OE6MM"D,4?]AZ:=J*H"C)M\G  ZU:_X>:_M*?\ 12/_ "A:;_\
M(U?M\*7$7*K5*5O^WO\ (\V]'LST#_AS]\<O^@CX/_\ !E/_ /&*/^'/WQR_
MZ"/@_P#\&4__ ,8KS_\ X>:_M*?]%(_\H6F__(U'_#S7]I3_ **1_P"4+3?_
M )&J_9<1_P#/RE_Y-_D*]'LST#_AS]\<O^@CX/\ _!E/_P#&*/\ AS]\<O\
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M444 %%%% !1110 4444 %5M2_P"/*7Z#^=6:K:E_QY2_0?SH LT444 %%%%
M!1110 4444 %%%% !1110!6M?^/B[_ZZ#_T!:LU6M?\ CXN_^N@_] 6K- !1
M110 4444 %%%% !1110 4444 5KO_76G_77_ -D:K-5KO_76G_77_P!D:K-
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M)JY5/6?^0/??]<)/_035R@ HHHH **** "BBB@ HHHH **** "JL?_(2N/\
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MWF_]&M5VJ6D_\>K_ /7>;_T:U %VBBB@ HHHH **** "BBB@ HHHH *K7?\
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M]"/H/_?^;_&O8/\ AUA\)?\ H;?%?_@9:?\ R/1_PZP^$O\ T-OBO_P,M/\
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MB@ JMJ7_ !Y2_0?SJS5;4O\ CRE^@_G0!9HHHH **** "BBB@ HHHH ****
M"BBB@"M:_P#'Q=_]=!_Z M6:K6O_ !\7?_70?^@+5F@ HHHH **** "BBB@
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M(&:S=4^'DEA\1_V7-;U#3[B3Q-923Z??W3M(_D(-!OMRD9*IF3:"0 6(4$G
MKT+XB?'>Z\%^(-;MM/\ #+:WI'ABSMM1\2W_ -M\B2SMYF;!MXC&PN&2..2:
M12\>U NTNS;1M0_&.TN_C'+X M](U%Y8=&GU:357A*6S&-[9?)B)'[UB+E6+
M+\JXQDG(4 YSX0>#++P=\:?BX-.LI;:VOGTR[>:5Y)#/,T4ID<NY)8Y([\#
MX  KTKQO_P B7K__ &#[C_T6U<+X&^,NL:WX]LO"WB?P>?"M[JVD3:[I2+J
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M'"<N6-2[]/\ @GXX45_04GA?1O[1E']DV./*3_EV3U;VJQ_PB^C?] BP_P#
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MNI'$2]V*KDG'H*/[)J+[2_$/[(J?S+\3]E&8*,DX%+7P7\//&>N1Z5=7=O\
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M^A=\-?\ A&C_ .,5\C_\,1_&W_H1+C_P.M?_ ([1_P ,1_&W_H1+C_P.M?\
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M9"_Z%WPU_P"$:/\ XQ1_POS]D+_H7?#7_A&C_P",5\C_ /#$?QM_Z$2X_P#
MZU_^.T?\,1_&W_H1+C_P.M?_ ([1]7PO_/Y_^!(/JV%_Y_/_ ,"1]<?\+\_9
M"_Z%WPU_X1H_^,4?\+\_9"_Z%WPU_P"$:/\ XQ7R/_PQ'\;?^A$N/_ ZU_\
MCM'_  Q'\;?^A$N/_ ZU_P#CM'U?"_\ /Y_^!(/JV%_Y_/\ \"1]<?\ "_/V
M0O\ H7?#7_A&C_XQ1_POS]D+_H7?#7_A&C_XQ7R/_P ,1_&W_H1+C_P.M?\
MX[1_PQ'\;?\ H1+C_P #K7_X[1]7PO\ S^?_ ($@^K87_G\__ D?8NC?&/\
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M_P"9_>'M:G\S^\X'_AG[X7?]$V\(?^"*U_\ C='_  S]\+O^B;>$/_!%:_\
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M5+2?^/5_^N\W_HUJ/:S_ )G]X>UJ?S/[SCO^&?OA=_T3;PA_X(K7_P"-T?\
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M_P 4?^@#X0_\ [K_ .2:]Q_X8B_9Y_Z&:?\ \'\'_P 31_PQ%^SS_P!#-/\
M^#^#_P")HYL'_P ^G]P<V"_Y]/[CP[_AYO\ %'_H ^$/_ .Z_P#DFC_AYO\
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M)H_X>;_%'_H ^$/_  #NO_DFO<?^&(OV>?\ H9I__!_!_P#$T?\ #$7[//\
MT,T__@_@_P#B:.;!_P#/I_<'-@O^?3^X\._X>;_%'_H ^$/_  #NO_DFC_AY
MO\4?^@#X0_\  .Z_^2:]Q_X8B_9Y_P"AFG_\'\'_ ,31_P ,1?L\_P#0S3_^
M#^#_ .)HYL'_ ,^G]P<V"_Y]/[CP[_AYO\4?^@#X0_\  .Z_^2:/^'F_Q1_Z
M /A#_P  [K_Y)KW'_AB+]GG_ *&:?_P?P?\ Q-'_  Q%^SS_ -#-/_X/X/\
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M444 %%%% !1110 4444 %58_^0E<?]<H_P";U:JK'_R$KC_KE'_-Z +5%%%
M!1110 4444 %%%% !1110 56U+_CRE^@_G5FJVI?\>4OT'\Z +-%%% !1110
M 4444 %%%% !1110 4444 5K7_CXN_\ KH/_ $!:LU6M?^/B[_ZZ#_T!:LT
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M"AKW_@LF_P#B:]K_ .&T]0_Z%:V_\#&_^)H_X;3U#_H5K;_P,;_XFJ]OF/\
MSY7WK_,KZQF7_/A?^!+_ #/%/^%6>-/^A0U[_P %DW_Q-'_"K/&G_0H:]_X+
M)O\ XFO:_P#AM/4/^A6MO_ QO_B:/^&T]0_Z%:V_\#&_^)H]OF/_ #Y7WK_,
M/K&9?\^%_P"!+_,\4_X59XT_Z%#7O_!9-_\ $T?\*L\:?]"AKW_@LF_^)KVO
M_AM/4/\ H5K;_P #&_\ B:/^&T]0_P"A6MO_  ,;_P")H]OF/_/E?>O\P^L9
ME_SX7_@2_P SQ3_A5GC3_H4->_\ !9-_\31_PJSQI_T*&O?^"R;_ .)KVO\
MX;3U#_H5K;_P,;_XFC_AM/4/^A6MO_ QO_B:/;YC_P ^5]Z_S#ZQF7_/A?\
M@2_S/%/^%6>-/^A0U[_P63?_ !-'_"K/&G_0H:]_X+)O_B:]K_X;3U#_ *%:
MV_\  QO_ (FC_AM/4/\ H5K;_P #&_\ B:/;YC_SY7WK_,/K&9?\^%_X$O\
M,\3_ .%7^,BQ7_A$M=W 9(_LV;./^^:7_A5GC3_H4->_\%DW_P 37LX_;-U
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M*#7'W?[+NNZ]J%]K*ZII5E=ZF[1WMI%&Y@B\J"V$+*< R,EW91L"0G[IB,9
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MR(ZD ]=^$/[.^J?#KQ1IVKW-QHBF*_UJ\N(](MGMXW%Z;;RU1#G:$%OC:6.
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M_KDG\VJS1_:^-_G_  7^0?VSCO\ GY^"_P CY>_X8H?_ *'%?_!9_P#;:/\
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MYZSN]OZL%%%%<QS!1110!3UG_D#WW_7"3_T$U<JGK/\ R![[_KA)_P"@FKE
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M^(['I?\ PUAX/_Y\M9_[\1?_ !RC_AK#P?\ \^6L_P#?B+_XY7FG_#)GB_\
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M_P#CE'_#6'@__GRUG_OQ%_\ '*\T_P"&3/%__01T3_O_ #?_ !JC_ADSQ?\
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M4 %%%% %:[_UUI_UU_\ 9&JS5:[_ -=:?]=?_9&JS0 4444 %%%% '@_QI^
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MN_QU_P!#)=_^._X4?\+O\=?]#)=_^._X5[C_ ,(?\"O^?C2O_!O-_P#':/\
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M_AG;X>_]"_\ ^3MQ_P#'*/K.'_D_!!["M_-^+/G?PM\:/%-QKMLFJ^*+J.P
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M^0/??]<)/_035RN8W"BBB@ HHHH **** "BBB@ HHHH *JQ_\A*X_P"N4?\
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MANM'DMIK:"22V>/S(/,"L6,'F %975D5U0YW;0_ST >Y4444 %%%% !1110
M4444 %5KO_7V7_74_P#HMZLU6N_]?9?]=3_Z+>@"S1110 4444 %%%% !7SC
M\7_"7B9/$?Q9M=.\-W6NQ^/_  Q::-IMW;;3%;7"BZ@D%R3CRXU%TDN[G($H
M'S  _1U% 'S'8> _%-A>Q^"FT*^FQX_3Q,?$7R?9?L(E%T6,F<^9N'V?R\9[
M_=YKT/PGX$U+PW\1/B7/H-C8^'K;48=-.G7$EEOM6D59C,3%&\9;E^?F7);.
M37K-% 'S'\1O!OC:&X^*>E2:(WB:]\?:!9Z99:KI=OY-I;W 2:WE\Y7D=H$C
M69)P2S[OWFWY@%+M(\">*+#4['P:VA7T@MOB#/XH?Q"VS[*U@TTMTK;\Y,I,
MBVYCQGJ?NC-?35% 'F/PY\$/X4^*WQ%N[;2(M*T74$TTVAMXECBE=8Y?-*JO
M?<W)QR379^-_^1+U_P#[!]Q_Z+:MNHKFVBO;:6WG02PRH8W1NC*1@@_A0!\$
M>$/@MXWN/">B2Q^'+MXWL8&5AMY!C4@]:UO^%(^.O^A;O/\ QW_&OJ>'X%^$
M+>%(H8-7ABC4*D<>OZ@JJHX  $^ !Z"G_P#"D?"O]W6O_"AU#_X_7H_79]D<
M7U6/<^5?^%(^.O\ H6[S_P =_P :/^%(^.O^A;O/_'?\:^JO^%(^%?[NM?\
MA0ZA_P#'Z/\ A2/A7^[K7_A0ZA_\?H^O3[(/JL>Y\J_\*1\=?]"W>?\ CO\
MC1_PI'QU_P!"W>?^._XU]5?\*1\*_P!W6O\ PH=0_P#C]'_"D?"O]W6O_"AU
M#_X_1]>GV0?58]SY5_X4CXZ_Z%N\_P#'?\:/^%(^.O\ H6[S_P =_P :^JO^
M%(^%?[NM?^%#J'_Q^C_A2/A7^[K7_A0ZA_\ 'Z/KT^R#ZK'N>'^'?@WXVTKP
MVE\MA+/J9CGM[>UFN5"V,+@K(P0M@N^YL <#J>2,2^./A1XLU31YY9]#@O\
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MP?\ PI'PK_=UK_PH=0_^/T?\*1\*_P!W6O\ PH=0_P#C] '>45P?_"D?"O\
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M (4.H?\ Q^@#O**X/_A2/A7^[K7_ (4.H?\ Q^C_ (4CX5_NZU_X4.H?_'Z
M.\HK@_\ A2/A7^[K7_A0ZA_\?H_X4CX5_NZU_P"%#J'_ ,?H [.[_P!=:?\
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MRRKM&S':5=4_@R?H[_A2/A7^[K7_ (4.H?\ Q^C_ (4CX5_NZU_X4.H?_'Z
M/*?'WPN\8_%G3_#Z-IVHZ?-X7EDUBVN/%<MBUWJ=V.(K-VLG9$MF&?,R/FQ%
MP=I->D>&_#6LR_&S5/&-YIK:=IVH^$]+L!#--&\L-U'<WLLL3!&8947$8W E
M2<X)Q5[_ (4CX5_NZU_X4.H?_'Z/^%(^%?[NM?\ A0ZA_P#'Z /*]?\ AMXQ
MUU?%?A>'PY);6^J>-K7Q)#XBN+NW%K%;P2VL^%5)3.)F:U,8_=@#?NW<8/DW
MBS]FWXD>+;(&VT*V@+/9/-&+V(!IXM'U*TF8DN6<B6XMXP[DL0.NU :^K?\
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M&^'7B'PU\.?%GAF2XL+6ZO+W59]-OX)&G 6ZFEFC>6-HU"LIEP5!<';G/.
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M>SVNL:F?#^F:OH^DV>G6%G9WLTUO=O%?6UW(\TC0*T08VB(JJK[0['+=*O\
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M')[5Z[7SWX*^"WCG1?%_PK_M(^'SX?\  MOJ%H+RVNYFN[Y)8?*A?RC"J1D
M+N7>W.2#VKZ$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>apre-20251231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 apre-20251231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '! [D# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /SC_:#_;9^*GP]^-7B_P -Z+J>GP:5IM[Y%O'+IZ2,
M%V*>6/)Y)KSW_AX5\:/^@QI?_@KCKB?VN?\ DY?XA_\ 83/_ *+2O(Z^SH86
MA*E%N"O9'VM#"4)4HMP5[(^DO^'A7QH_Z#&E_P#@KCH_X>%?&C_H,:7_ ."N
M.OFVBM_J>'_D1O\ 4\/_ "(^DO\ AX5\:/\ H,:7_P""N.C_ (>%?&C_ *#&
ME_\ @KCKYMHH^IX?^1!]3P_\B/I+_AX5\:/^@QI?_@KCH_X>%?&C_H,:7_X*
MXZ^;:*/J>'_D0?4\/_(CZ2_X>%?&C_H,:7_X*XZ/^'A7QH_Z#&E_^"N.OFVB
MCZGA_P"1!]3P_P#(CZ2_X>%?&C_H,:7_ ."N.C_AX5\:/^@QI?\ X*XZ^;:*
M/J>'_D0?4\/_ "(^DO\ AX5\:/\ H,:7_P""N.C_ (>%?&C_ *#&E_\ @KCK
MK_V2_P!ESP9\1?AS<^(_'IEC;5]0_LS0@EPT69%5MS87[V6XP?\ GF?6N+^#
MWA?X1Z/XQU/P+\3O#WB'4/%)UPZ=:3:9*$@C3(0"3]ZASNR<A3P17(X87GE3
M5.[CY?EZ7U.'_8_?M3OR[Z>NOIHR7_AX5\:/^@QI?_@KCH_X>%?&C_H,:7_X
M*XZZG]HKP1\!?AKXEU#P%H_AOQ)#XRAFM42]>Y\RR DV.>3-N^X^/N=?SKOO
MB1\&?V>?A;XWT[PKJ7@3QMJ5]>10R+=Z5(\UNOF,5 +&8-D$9("GC&,UDGA9
M*,E2^+;1:[>?F2WA%:]'=7V6W?<\8_X>%?&C_H,:7_X*XZ/^'A7QH_Z#&E_^
M"N.O4-"_8_\  5K^U9JW@6_>ZU+PVNB_VG%#]I9);=BP&QF7!..3SV(KGO G
M[)6@1_M2:EX+U^*;4_",^ESZKI-Q!<,GG0Y0QG>IYQN(/KC/>A2P35^3[/-M
MT5_QT8<V!][W-DGMT=O\T<A_P\*^-'_08TO_ ,%<='_#PKXT?]!C2_\ P5QU
M\\:Q;)9ZO?6\0(CBG=%!.< ,0*^E_A;^RUX8\0?!CQMXPU/Q;IFN:IIVCM?6
MVF:'=EWLGV,R_:<@88E<;<8X/)KHJ4L+2I^TE!6]#KJT,+1:4H+5VV\[&?\
M\/"OC1_T&-+_ /!7'1_P\*^-'_08TO\ \%<=-_91_9G\._&;4H[GQ#XNTJ.
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M"1I^U<5RVO<52AA:4.>4%;T[[6.C_P"'A7QH_P"@QI?_ (*XZ/\ AX5\:/\
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MA*\W,,/2IT'*$4GH>;F&'HTZ#E"*3T/M:BBBOESY4*\[_:&\:ZI\.O@IXO\
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MZGA_Y$'U/#_R(^DO^'A7QH_Z#&E_^"N.C_AX5\:/^@QI?_@KCKYMHH^IX?\
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MMY98?:05&U@1@J,CWK>=/"4Z7M905O0ZJM#"T;<T%J[;%+_AX5\:/^@QI?\
MX*XZ/^'A7QH_Z#&E_P#@KCJ+]DO]FOP]\:]<AE\0^+-+M[7]Z!X?MKHC4YBH
M'S;,85.<Y!)..@J'X(_ WPQXF\0?$O5_$XO;CPKX)AN;E[&RD"SW0C9\)N[<
M)UXYJ9PP=.4HN"T5WH9..#3DN3X;+;J]%8M_\/"OC1_T&-+_ /!7'1_P\*^-
M'_08TO\ \%<=97Q>^%?A&Z^"_A[XI>!].OM"TV\OGTV]TF^NOM/DR@$JR2$
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M+X?\<:?X0O?"]TFOZ@N^UMHV219E[LLBL4('<YX[U-X__9M^(GPRT)]9\0:
M+?2TE$,EU;7D%TD3DX"N8G;:<\<XH]E@]-(Z[;:E*C@VU%*-WZ'HO_#PKXT?
M]!C2_P#P5QT?\/"OC1_T&-+_ /!7'7%ZA^RM\2_#FC'7]7\+21:#!%!=3W*W
MENP\F1E"XQ)R3N' Y&><5[UX7_9@\$>(OC[XO\*S>$]9T;3[#PTNH6FFWU^C
MW N"4 8O#+(I!W' W?@*RJ1P<%?E3WVMTW,)K!17,HIKRL^J7ZH\Y_X>%?&C
M_H,:7_X*XZ/^'A7QH_Z#&E_^"N.O.O'W[-OQ&^&GAQ/$'B#PU+9Z.SA#<QSQ
M3",GH)!&S%#V^8#GBKW[+WP?TWXW?%:U\/:O?266FI;RW<_D?ZV54 .Q/<Y_
M(&M?8X1P<U%-+?Y&LZ6#A3=7E32[:G;_ /#PKXT?]!C2_P#P5QT?\/"OC1_T
M&-+_ /!7'77Z_P#"7X#>/- \4V'@XZ]X+\5Z'#)/#_PDC&.*_P!G4)N=NOI\
MK<CC%8%I^RM_PFW[,G@7Q1X0T:2\\7ZG?7$=]++?+%#Y22S(O^L947[B#KR?
MK6"^J<O,Z=M4M5WO9^FABE@].:%KNVJM;2_Y&?\ \/"OC1_T&-+_ /!7'1_P
M\*^-'_08TO\ \%<=>3ZI\#?'6C_$&/P1=>&[M?%$N#'8)M<NIZ.K*2I7@_,#
MC@\UJ^.OV:?B-\.-%?5]=\/>1ID<@BENK:\@N4A8G&)#$[;.?[V*Z/8X/32.
MNVVOH='L,'=1M&[]#T/_ (>%?&C_ *#&E_\ @KCH_P"'A7QH_P"@QI?_ (*X
MZX5/V5_B=)XW@\(IX;#Z]/9?VC';K?6Y1K?(&_S/,V=2.-V?:L'_ (4AXT_X
M1>^\0_V,3I5GJ7]D2R"XBWF[W[/*6/=O<[N/E!%)4<&]E'\.]OST]1*C@GLH
M_AUU1ZQ_P\*^-'_08TO_ ,%<='_#PKXT?]!C2_\ P5QUQ'B#]E#XJ>&/#MWK
M>H>%72QLXA-<B&[@FF@3&=SPHY=0!URO'>O)*J&'PD[\D4[%PPV%J*\(IKR/
MI+_AX5\:/^@QI?\ X*XZ/^'A7QH_Z#&E_P#@KCKYMHK3ZGA_Y$7]3P_\B/I+
M_AX5\:/^@QI?_@KCH_X>%?&C_H,:7_X*XZ^;:*/J>'_D0?4\/_(CZ2_X>%?&
MC_H,:7_X*XZ/^'A7QH_Z#&E_^"N.OFVBCZGA_P"1!]3P_P#(CZ2_X>%?&C_H
M,:7_ ."N.C_AX5\:/^@QI?\ X*XZ^;:*/J>'_D0?4\/_ "(^DO\ AX5\:/\
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M;^?E_&OSVHJ7@TW>_;\(N/ZA4P:J2E+FM>_XQY?^"?H5X5M;KX5_%+XM^/\
MQ/XNTJ]\&W]I=QV<<6JI.UX[ME$$08E2N"IR!UXR.:X+QSXCTN3]G3]GK%]:
MHUOKJS3PB92T"><YRPSD #UKXRHHA@^5Q;E\/+T_EO\ Y[B^I)SYW+77IY6/
MT/UZXU#P_P#ME:UXETKQ)X8M;+7]*C2R75+A98-0$<$2/"S1OF%MPX+#\#7#
M_M.6_ABV_9^MTFTNR\">)#J0:'PSHFN)?VLZX^:8K'\JYY/3(]3FOBBBIC@N
M7D][X;?@_7\[^5APPG+.,^;:WSLK=_\ @^=@HHHKTST0HHHH **** "BBB@
MHHHH *_1K_@EU_R3GQM_V&(__1"5^<M?HU_P2Z_Y)SXV_P"PQ'_Z(2O*S/\
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M_P#V%?JI15?VIB/+[C3^U<1Y?<?E7_P[I^,?_/KH?_@S_P#L*/\ AW3\8_\
MGUT/_P &?_V%?JI11_:F(\ON#^U<1Y?<?E7_ ,.Z?C'_ ,^NA_\ @S_^PH_X
M=T_&/_GUT/\ \&?_ -A7ZJ44?VIB/+[@_M7$>7W'Y5_\.Z?C'_SZZ'_X,_\
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MZJ44?VIB/+[@_M7$>7W'Y5_\.Z?C'_SZZ'_X,_\ ["C_ (=T_&/_ )]=#_\
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M9_\ V%?JI11_:F(\ON#^U<1Y?<?E7_P[I^,?_/KH?_@S_P#L*/\ AW3\8_\
MGUT/_P &?_V%?JI11_:F(\ON#^U<1Y?<?E7_ ,.Z?C'_ ,^NA_\ @S_^PH_X
M=T_&/_GUT/\ \&?_ -A7ZJ44?VIB/+[@_M7$>7W'Y5_\.Z?C'_SZZ'_X,_\
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M_P#V%?JI11_:F(\ON#^U<1Y?<?E7_P .Z?C'_P ^NA_^#/\ ^PH_X=T_&/\
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MJ44?VIB/+[@_M7$>7W'Y5_\ #NGXQ_\ /KH?_@S_ /L*/^'=/QC_ .?70_\
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M7M]9"[MQY422R,S[]^QL!EX5B>>E7_&WP-\;ZOI_[04=GHHED\4SV;Z.#=0
M700IO/+_ "8P?O[<]JZ*L:'/*46MWU5OBCM\F_DO4<(T/:)W5KKJOYK?=;7T
M\CTGX<?M.^'/%NKZ%X<OK;6M(UK4[-9;.YU;3)+6VU)@@,AMW;[X'/8 ]LUY
MEXQ_:;O_  3\)KO6O#USK_BF\;Q/)IQO-0TF-DM565 \)\I@ "&*QD\L:TH/
MAK\2OB/\0?A@WBCPM8^%M$\"_P"D/J$.HQW#7\NQ558D3YD7*#(8#V)K!F^
MOCY?V>?%.@1:"LGB";Q>=:M;!KV!?M%N+A) 0^\HI(4\,0?6A1H1FFVMUI=-
M6YO\M6B*<*,7&]NEU==I=?\ P%]KNS/6M)^+-C?_ !C@L[K5]=TD/X636)="
MU*RB@MK>,NV99')\Q91@@H?E 'K46A_M>>!M<UJPM%MM?LM,U&X^R6'B"^TJ
M2+3+R7. L<YX))R.0.E<EK7P>\7_ !!^,]]KVHZ,=!TG5? ?]C33-=PS&UO&
MD9C$0K;FP"/F VGUKFG^%'Q6\7?#WPA\*M6\(V&C:+H-S:F?Q3'JD4J7$,#
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M^B598BC&CR\M]=?^!ZKJ8XFBJ$_9K7^OZ3\[A1117&<H4444 %%%% !1110
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M#.T;_E^_Z^G_ *5HUG:-_P OW_7T_P#2M&FQ+8****0PHHHH **** "BBB@
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MNW_3T?X![2;=[_U>_P">OJ>3Z?\ LN_#K2SI)M](N%_LB\6^T\-?SL+60-N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@:_\0?"WA.\2TUOQ
M+I&C7;QB58-0OXH'9"2 P5V!(RI&?8^E;]<AXR_Y&[P%_P!A2?\ ](+F@#K8
MY$FC62-E=& 964Y!!Z$&G444 %%%% !6=8_\A;4_K'_Z!6C6=8_\A;4_K'_Z
M!30C1HHHI#"LWQ#_ ,@B;ZI_Z&*TJS?$/_((F^J?^ABFMQ/8TJ***0PHHHH
M**** "BF2RK#&\CL%1 69CT '4UYM9?M >'9Y'>]LM5T:P>SGO[/4;^W58+Z
M"$CS7BVNS#&Y2 ZH2&& >:5QV;/3**XSP+\4].\=:C>::FGZEHVJ6MO#>FQU
M6%(Y'MI2PBF78[*58HXQG<"N& XSV=4TUN(\]^&/_([?%S_L:(/_ $RZ97H5
M>>_#'_D=OBY_V-$'_IETRO0J0!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %35_P#D$WO_ %P?_P!!-267_'G!_P!<U_E4>K_\@F]_
MZX/_ .@FI++_ (\X/^N:_P J?074GHHHI#"BBB@#.T;_ )?O^OI_Z5HUG:-_
MR_?]?3_TK1IL2V"BH+V^M]-M);J[GCM;:)2\DTSA411U))X KRVV_:O^$5WK
M?]E1>/-*-WNV!F9UA)SC F*^6?P:DM79;CZ7/6:YWXC>))O!W@'Q%KMLD$EQ
MINGSW427,@CC9T0L S$@ 9 ZD5OPS1W,*2Q2++$X#*Z'(8'H0:H>(_#VG^+-
M!O\ 1M5MEN]-OH6M[B!^CHPP12DG9I;E1:4DWL?-V@_M!^)=8OK?0K._FEN]
M5N;""VU+6-!ETR6V\])7D*VTP4RHHBPKXVDMU-;&@?%7QMXM\>ZI\/K;5;2P
MU31)+K[3K;6*N+I(UB,0$1.%)\WYL?W>.M>A?\*$\-S6;1W=SJNH7@,7D:E=
MWK/=6OE',?E28^7:2>W.><TDGP \,&U@$,VJ6=^CS/)JMM>LEY<&;'F^9)_$
M&VK],#&,54K.]O/]+?=U_4E;*_E^M_O_ *L;7P@\;S?$CX8^&O$UQ;BUN=2L
MDGEA7.U7Z-MSVR#CVQ7E_P"Q7_R3KQ=_V.VN_P#I8]>XZ#H=CX9T6QTG3+=;
M33[*%;>W@3HB*, ?D*\._8K_ .2=>+O^QVUW_P!+'IR:<FUL"V/H"BBBI **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Y#QE_R-W@+_L*3_\ I!<UU]<A
MXR_Y&[P%_P!A2?\ ](+F@#KZ*** "BBB@ K.L?\ D+:G]8__ $"M&LZQ_P"0
MMJ?UC_\ 0*:$:-%%%(85F^(?^01-]4_]#%:59OB'_D$3?5/_ $,4UN)[&E11
M12&%%%,EE2%=TCK&OJQP* 'T4R.5)E#(ZNI[J<BGT -D#&-@AVL0<$C.#7SK
MXD^ WB[XA>([C4=:ET_2[K^R[S39+^UOY[E;[S0GEG[,ZA+8*8T8B,DL1R:^
MC**5NHT[;'EGPZ\ ^(H/B#?^,?%$6G6=ZVBVNA6]IIMP\ZF.*221I6=D3!9I
M!A0. O4YKU.BBJ;O_7S_ #)MU_K167X)'GOPQ_Y';XN?]C1!_P"F73*]"KSW
MX8_\CM\7/^QH@_\ 3+IE>A4AA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %35_^03>_P#7!_\ T$U)9?\ 'G!_US7^51ZO_P @F]_Z
MX/\ ^@FI++_CS@_ZYK_*GT%U)Z***0PHHHH SM&_Y?O^OI_Z5HUG:-_R_?\
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M0\<T+AD=3T((X-.SM<=G:Y8HHHI""BBB@ HHHH **** "BBB@ HHHH ****
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M^MP;C_A);;2[IK@.3GS5@+@"3//,A&?6E'2HG_7]?-%/6#7];/\ K9GU;2$
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M56*GWVNIX]:^>]+FN/#'PA\1_#^_\.ZK>>++M[Z.-(M,EDM[YII'*3&X"F(
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M>JKH.A2/JFL06UG:)/,NR-XO.)=_48DSQ_=->K>*O'MU<:NWAKPI&E_KV/\
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M+:-IUE=37#17'VB>5B\D@._B5<OD9(/RCBC1>=O\K_GI\M=RM+?=_P"E)/\
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M-S\ G)  KM*)))Z @HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110
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MSI]AAU=R9@<'>0#R%Z5Z]\?]>U?0_A9JT?A^W:Z\0:F8]*TY &VK/<.(E=B
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MM=_]+'JI)*32$M4?0%%%%2 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%<_P"*/'FB>$%4:C>JEP_^KM8P7FD/HJ#DTTK[";2U
M9T%8_B/Q?H_A.V$VJW\-H#]U&;YW/HJCDFO$O'/[1BV\GV1M4M?"*29"QNGV
MS591Z1VR9VD]MWZ5C^&W\8:Q-]J\&_#^0WL@/_%5?$*X8/D_Q+;K\^/8;3]:
MW5&5KRT1<:<YJZ5EW>B_X)WGC;Q?XD\9^#M=71M&32M#-A<>?J6M$QL\7EMN
M\N/JN1GYFX'<5\N_LK_M ^"-+\>ZE=ZIJ/V"-+!XH1/$2\SF1"!&J@DG:K5]
M(/\ LW:CXX,DOQ.\=:OXNB?_ )@E@YTW3%'93'$=[X]6;ZUS/[+'[-6@?"[Q
M+XNUI-*A6]^UR:?;NU\UV((P59D0-$F!G;\Q)8X[=^B,J$*<HR=WTM_F_P#(
MUC2PR3E4DW);6T7]?([,?M+VVL*/^$7\#>+O$I+;0\.FFVC^I:8IQ[\U')XN
M^.'B96&D>!_#GA.,G"7'B'5'NFQZF*!1@^VZO:0 H  P!V%+7-SQ7PQ^_4/:
M07PQ^_4\3'PD^*7B5F/B7XP7%A XP;/PII,-GL]2)I/,<_EQBK-G^REX&:9)
M];;6O%MVHQY^O:M-<;OJ@94_\=KV.BCVT^CMZ:?D'MI]';TT_(Y?P]\+O!_A
M.)8]&\,:3IJ+]T6]FBX_2N#L-/\ #</[0WVRV\)RVFK2Z;-')J7]F;-[K*H\
MSS,<J0" W?(]:]DKCY64?%J)B0 FAR;CGI^_3K^1_*LG.75F7/+N=A17$ZK\
M5-.BNWL-$@F\2:FO!@T\;D0_[<GW5J@WA+Q3XV8/XDU4Z-IIP?[)T=\,P]))
MNI^@P/I7*ZR;M37,_P /O_IF7/\ RZFQK_Q-T;1;K[% TNKZH>%L=/3S9,^^
M.%_$UCMI7C3QRV=1O!X1TAAS9V)$EY(/]J4C"?\  178:!X6TGPO:BWTJPAL
MX^_EK\S'U+'DGW)K5J?9SJ?Q'IV7^>[_  %RM_$S!\-^!]$\*(?[.L4CF;[]
MQ)\\KGU9SR:SO&7_ "-W@+_L*3_^D%S77UR'C+_D;O 7_84G_P#2"YKHC&,%
M:*LBTDM$=?1115#"BBB@ K.L?^0MJ?UC_P#0*T:SK'_D+:G]8_\ T"FA&C11
M12&%9OB'_D$3?5/_ $,5I5F^(?\ D$3?5/\ T,4UN)[&E1112&%?"'QA^)?Q
M'OO%WBZYTSXG)X;TV/Q9:>#HM$%I"XAMYQ&KW89OF\Q2Y8'H,5]WUY)XH_9-
M^$?C37[[6];\#:?J.JWTOGW-S*TFZ23 &XX8#/ I6]Y-ZK_@K\U=?,J^C2W_
M . _UL_D<S^RWJ6N:9K7C[P3JOB^X\<V?AV\@6PUB\*-<-%+$'*.R\,0<\U]
M UQGPX^#G@SX107L/@_0+;0H[UUDN%MRY\Q@, G<3VKLZMN]O1$)6N%%%>6+
M\=8HG^(3WF@:AIUOX2AAE)NP$DO/,60@HO9?D !)YR>!CF&[#W:7<]3HKSCX
M?_%#4_$'B^]\+^(=&MM'UF+3+?685L[LW,4EM,[H 6*(0ZM&01@CD8)KT>J:
ML*_3^N_Y'GOPQ_Y';XN?]C1!_P"F73*]"KSWX8_\CM\7/^QH@_\ 3+IE>A4A
MA1110 4444 %%%% !1110 445SGQ!\3W'@[PG?:K:V#ZC/ N5A3H/]IN^T=3
MBIG)0BY2V0F[*[.CHKR/X"?%#6/']G?0:O;&22V;<+Z- J-DYV$#N/;M6C^T
M'XKU7PGX @;1[IM-O-3U;3](.I*@8V4=S<QQ/, P(RJL<9! 8C-94*T<1",Z
M?VK)>K=OS%"2FN9;?Y'I=%?,'QPN-4^"KP67AOQ+KUQ#KFC:J;BWU'5)[R6W
MD@M_-2[BEE9GB(;"%5(3]XN%!%;]O\:_$T&NZ<D*VFHZ"]W%ICR#3)^)"GS,
M;PS!6<,.8Q%Z_/Q6_P#7XM?FOQ]2GHN9^?X)/]?P/H"BOGZV^-GC'2?#FD:G
MKLWAQCK^G3W5@EG:7 ^RRQE $<>:YG#"0?=\LA@%YSD5H/C;X^N8X]*6VTFW
MUP^(K;2#=:AI4]NGDS6PFWFV^T,RLN<8,I#8S\N>';7EZ[?C85TX\W3?Y6N?
M15%?*G@_X@^/]?\ %T0TC5-+M#;V_B!KFWU+[7<VT_V;5#$A5&N=R,57&=Q5
M Q"KM 6OI#P/XD_X3'P9H.O>0;7^U+""]\@G)C\R-7VY]LXJN7W>;^MVOT8-
MVDXOS_"U_P T;=%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"IJ_P#R";W_ *X/_P"@FI++_CS@_P"N:_RJ/5_^03>_
M]<'_ /034EE_QYP?]<U_E3Z"ZD]%%%(84444 9VC?\OW_7T_]*T:SM&_Y?O^
MOI_Z5HTV);",H<$, 0>QI:**0PHHJAKNK#0M%OM1:VN;T6L+3?9[.(RS2X&=
MJ*.68] * W+]%>-WG[0[Z-K1\/ZKX5NK/Q1<" Z?IB7<<HN?.9@H,@&(R-C%
M@0< '&:DMOV@VU34'T/2_"]S?>++62X2_P!'^UQH+40A"S>:1A@WF)MP!G/;
M%'G_ %IO]W7L']?Y??T/8*^?_P!BO_DG7B[_ +';7?\ TL>O9?!/B^P\?>$M
M)\1:6S-8:E;)<P^8,, PZ,.Q!R#[BO&OV*_^2=>+O^QVUW_TL>FTT[,%JCZ
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MVNK7EN6^TS&>X5O+F7>DDA)*-E<';C;Q7HMM;16=O%;P1K#!$@2.-!A54#
M'8 5PMI\:-'O/$WBC1UL-95O#UM%<W,K:7< S;W=0((]F^49C/S("I[$UF:?
M\=8O$/A/PSJNB:#>7M_XBDN%L=,N7%M(%A9@YD+#Y#A<[2,Y.*E-M:;?\/\
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M]<U_E4>K_P#()O?^N#_^@FI++_CS@_ZYK_*GT%U)Z***0PHHHH SM&_Y?O\
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MW;Q3Q-NBE0.C>H(R#7@G[%?_ "3KQ=_V.VN_^ECT;:"335T?0%%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5_X8/^"W_0N:I_X4NJ?_ "31_P ,'_!;_H7-4_\ "EU3_P"2:^@**!W/G_\
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M_P  D_PH_P"&?OAM_P!"/H?_ (!)_A7H%% 'G_\ PS]\-O\ H1]#_P# )/\
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M_P!"/H?_ (!)_A7H%(2 "2< 4 <!_P ,_?#;_H1]#_\  )/\*/\ AG[X;?\
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MT/\ \ D_PH_X9^^&W_0CZ'_X!)_A7H%%(9Y__P ,_?#;_H1]#_\  )/\*/\
MAG[X;?\ 0CZ'_P" 2?X5Z!7%?&7XA-\+/AQJ_B2.U^V3VJHD,!!(>21UC3..
M2,L"0.>.*3=AI7=BI_PS]\-O^A'T/_P"3_"C_AG[X;?]"/H?_@$G^%5?@YXY
MUOQ6=7L_$,UL=2LC"Q@33)=/FC61207B>67*G!VL'YP<@$5Z55-6)3N>?_\
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MHN%C-_L^^_Z"LO\ WYC_ ,*/[/OO^@K+_P!^8_\ "M*BBX6,W^S[[_H*R_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>29
<FILENAME>apre-20251231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/14/2026 1:08:35 AM-->
<!--Modified on: 3/14/2026 1:08:35 AM-->
<xsd:schema targetNamespace="http://aprea.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:apre="http://aprea.com/20251231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2025" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" id="StatementCondensedConsolidatedStatementsOfCashFlowsCalc2">
        <link:definition>00405 - Statement - Condensed Consolidated Statements of Cash Flows (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>99940301 - Disclosure - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940501 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" id="DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails">
        <link:definition>99940602 - Disclosure - Income taxes - Income Taxes Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" id="DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails">
        <link:definition>99940603 - Disclosure - Income taxes - Components of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>995200300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>99930203 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>99930303 - Disclosure - Property and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930503 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanTables" id="DisclosureEquityIncentivePlanTables">
        <link:definition>99930803 - Disclosure - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationDetails">
        <link:definition>99940101 - Disclosure - Nature of business and basis of presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails">
        <link:definition>99940201 - Disclosure - Summary of significant accounting policies - Restricted cash and Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails">
        <link:definition>99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureLeasesSummaryDetails" id="DisclosureLeasesSummaryDetails">
        <link:definition>99940401 - Disclosure - Leases - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails">
        <link:definition>99940601 - Disclosure - Income taxes - Components of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>99940604 - Disclosure - Income taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>99940701 - Disclosure - Stockholders' equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" id="DisclosureStockholdersEquityWarrantsOutstandingDetails">
        <link:definition>99940702 - Disclosure - Stockholders' equity - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails" id="DisclosureEquityIncentivePlanSummaryDetails">
        <link:definition>99940801 - Disclosure - Equity Incentive Plan - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails" id="DisclosureEquityIncentivePlanValuationAssumptionsDetails">
        <link:definition>99940802 - Disclosure - Equity Incentive Plan - Valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" id="DisclosureEquityIncentivePlanStockOptionActivityDetails">
        <link:definition>99940803 - Disclosure - Equity Incentive Plan - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" id="DisclosureEquityIncentivePlanRestrictedStockUnitsDetails">
        <link:definition>99940804 - Disclosure - Equity Incentive Plan - Restricted stock units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941001 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>995210101 - Disclosure - Nature of business and basis of presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>995210301 - Disclosure - Property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995210401 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210501 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995210601 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995210701 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureEquityIncentivePlan" id="DisclosureEquityIncentivePlan">
        <link:definition>995210801 - Disclosure - Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995210901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211001 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99930603 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>99930703 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99940901 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd" />
  <xsd:element id="apre_ConvertiblePreferredStockSeriesaMember" name="ConvertiblePreferredStockSeriesaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_TemporaryEquityPolicyTextBlock" name="TemporaryEquityPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_CommonStockNumberOfVotingRightsPerShare" name="CommonStockNumberOfVotingRightsPerShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" name="ResearchAndDevelopmentRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" name="AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="apre_LesseeOperatingLeaseNumberOfOperatingLeases" name="LesseeOperatingLeaseNumberOfOperatingLeases" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="apre_LesseeOperatingLeaseAnnualBaseRent" name="LesseeOperatingLeaseAnnualBaseRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="apre_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" name="ScheduleOfEarningsPerShareBasicAndDilutedTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" name="ScheduleOfEarningsPerShareBasicAndDilutedLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_OfficeFurnitureAndLaboratoryEquipmentMember" name="OfficeFurnitureAndLaboratoryEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_PercentageOfOutstandingShares" name="PercentageOfOutstandingShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="apre_CommonStockTextBlock" name="CommonStockTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_StockSharesAuthorized" name="StockSharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="apre_ShelfRegistrationStatementAbstract" name="ShelfRegistrationStatementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" name="UniversalShelfRegistrationMaximumAmountToBeIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" name="AtMarketOfferingProgramMaximumAmountToBeIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element name="VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" id="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityConversionOfStockAmountConverted" id="apre_TemporaryEquityConversionOfStockAmountConverted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityConversionOfStockSharesConverted" id="apre_TemporaryEquityConversionOfStockSharesConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="VestingOnOneYearAnniversaryOfGrantDateMember" id="apre_VestingOnOneYearAnniversaryOfGrantDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VestingOnTwoYearAnniversaryOfGrantDateMember" id="apre_VestingOnTwoYearAnniversaryOfGrantDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VestingOnThreeYearAnniversaryOfGrantDateMember" id="apre_VestingOnThreeYearAnniversaryOfGrantDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityRemainingSharesToBeConverted" id="apre_TemporaryEquityRemainingSharesToBeConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AtMarketOfferingMember" id="apre_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsAmortization" id="apre_DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedPaymentArrangementExecutiveOfficersMember" id="apre_ShareBasedPaymentArrangementExecutiveOfficersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShelfRegistrationStatementMember" id="apre_ShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShelfRegistrationStatement2024Member" id="apre_ShelfRegistrationStatement2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" id="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="HCWainrightCoLlcMember" id="apre_HCWainrightCoLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarket2024OfferingMember" id="apre_AtMarket2024OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsMember" id="apre_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsExercisePrice7.29PerShareMember" id="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsExercisePrice9.1125PerShareMember" id="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecuritiesPurchaseAgreementMember" id="apre_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CertainPurchasersMember" id="apre_CertainPurchasersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" id="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtEventOfElectionOfHolderMember" id="apre_AtEventOfElectionOfHolderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuanceAnniversaryPeriod" id="apre_StockIssuanceAnniversaryPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" id="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharesIssuedVolumeWeightedAveragePricePerShare" id="apre_SharesIssuedVolumeWeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfConsecutiveTradingDays" id="apre_NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PrivatePlacementAbstract" id="apre_PrivatePlacementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NoncashConsultingFees" id="apre_NoncashConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="apre_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="apre_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="January2026PrivatePlacementMember" id="apre_January2026PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="January2026WarrantsMember" id="apre_January2026WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2024PrivatePlacementMember" id="apre_March2024PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="December2025PrivatePlacementMember" id="apre_December2025PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="December2025WarrantsMember" id="apre_December2025WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PlacementAgentMember" id="apre_PlacementAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsExercised" id="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="March2024TrancheaWarrantsAndTrancheBWarrantsMember" id="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2024TrancheaWarrantsMember" id="apre_March2024TrancheaWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2024TrancheBWarrantsMember" id="apre_March2024TrancheBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2024PreFundedWarrantsMember" id="apre_March2024PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="December2025PreFundedWarrantsMember" id="apre_December2025PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetResearchAndDevelopmentCredits" id="apre_DeferredTaxAssetResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" id="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>30
<FILENAME>apre-20251231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/14/2026 1:08:35 AM-->
<!--Modified on: 3/14/2026 1:08:35 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://aprea.com/role/DisclosureAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://aprea.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639090473146406104" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_639090473146406104" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473146406104" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639090473146406104" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473146406104" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639090473146406104" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639090473146406104" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639090473146406104" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639090473146406104" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639090473146406104" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_639090473146406104" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_639090473146406104" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639090473146406104" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_639090473146406104" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639090473146411882" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent_639090473146411882" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639090473146411882" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639090473146411882" xlink:to="us-gaap_AccountsPayableCurrent_639090473146411882" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_639090473146411882" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639090473146411882" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_639090473146411882" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639090473146411882" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_639090473146411882" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_639090473146411882" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_639090473146411882" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639090473146417669" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639090473146417669" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639090473146417669" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639090473146417669" xlink:to="us-gaap_CommonStockValue_639090473146417669" order="1" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639090473146417669" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639090473146417669" xlink:to="us-gaap_AdditionalPaidInCapital_639090473146417669" order="2" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639090473146417669" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639090473146417669" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639090473146417669" order="3" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639090473146417669" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639090473146417669" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639090473146417669" order="4" use="optional" weight="1" priority="3" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639090473146423455" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_639090473146423455" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639090473146423455" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_639090473146423455" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639090473146423455" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_639090473146423455" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_639090473146423455" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_639090473146423455" order="1" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_639090473146423455" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_639090473146423455" xlink:to="us-gaap_OtherNonoperatingIncome_639090473146423455" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473146423455" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_639090473146423455" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473146423455" order="3" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639090473146428668" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_639090473146423455" xlink:to="us-gaap_OperatingIncomeLoss_639090473146428668" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_639090473146429187" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639090473146428668" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_639090473146429187" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639090473146429187" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639090473146428668" xlink:to="us-gaap_OperatingExpenses_639090473146429187" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_639090473146429187" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639090473146429187" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_639090473146429187" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639090473146429187" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639090473146429187" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639090473146429187" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639090473146429187" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639090473146429187" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639090473146434898" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_ProfitLoss_639090473146434898" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_639090473146434898" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_DepreciationDepletionAndAmortization_639090473146434898" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_639090473146434898" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_639090473146434898" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NoncashConsultingFees" xlink:label="apre_NoncashConsultingFees_639090473146434898" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="apre_NoncashConsultingFees_639090473146434898" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473146440676" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473146440676" order="5" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639090473146441774" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639090473146441774" order="6" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639090473146442267" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639090473146442267" order="7" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_639090473146442267" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_639090473146442267" order="8" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_639090473146442267" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473146434898" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_639090473146442267" order="9" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639090473146442267" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639090473146442267" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639090473146442267" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639090473146442267" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639090473146442267" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473146447481" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473146447481" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639090473146447979" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473146447481" xlink:to="us-gaap_ProceedsFromWarrantExercises_639090473146447979" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639090473146447979" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473146447481" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639090473146447979" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639090473146447979" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473146447481" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639090473146447979" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" xlink:type="extended" xlink:title="00405 - Statement - Condensed Consolidated Statements of Cash Flows (Calc2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473146453184" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473146453184" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_639090473146453680" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash_639090473146453680" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Property and equipment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639090473146453680" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639090473146453680" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639090473146453680" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639090473146453680" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639090473146458900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639090473146458900" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639090473146459384" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639090473146459384" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_639090473146459384" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_639090473146459384" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639090473146459384" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639090473146459384" order="4" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Income taxes - Income Taxes Rate Reconciliation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639090473146459384" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639090473146459384" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_639090473146459384" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_639090473146459384" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639090473146464592" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639090473146464592" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_639090473146465086" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_639090473146465086" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473146465086" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473146465086" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639090473146465086" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639090473146465086" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_639090473146465086" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_639090473146465086" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639090473146465086" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639090473146465086" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639090473146471312" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639090473146471312" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_639090473146471312" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_639090473146471312" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639090473146471312" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639090473146471312" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473146471312" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473146471312" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639090473146471312" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639090473146471312" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_639090473146471312" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_639090473146471312" order="6" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Income taxes - Components of Deferred Taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639090473146477529" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_639090473146477529" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639090473146477529" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639090473146477529" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639090473146477529" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsGross_639090473146477529" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639090473146477529" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639090473146477529" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_639090473146482736" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_639090473146482736" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetResearchAndDevelopmentCredits" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits_639090473146483227" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="apre_DeferredTaxAssetResearchAndDevelopmentCredits_639090473146483227" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetsAmortization" xlink:label="apre_DeferredTaxAssetsAmortization_639090473146483227" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="apre_DeferredTaxAssetsAmortization_639090473146483227" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639090473146483227" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639090473146483227" order="5" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639090473146483227" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639090473146483227" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639090473146483227" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639090473146477529" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639090473146483227" order="7" use="optional" weight="1" priority="2" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>31
<FILENAME>apre-20251231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/14/2026 1:08:35 AM-->
<!--Modified on: 3/14/2026 1:08:35 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationDetails" roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureLeasesSummaryDetails" roleURI="http://aprea.com/role/DisclosureLeasesSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aprea.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureStockholdersEquityWarrantsOutstandingDetails" roleURI="http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanSummaryDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanValuationAssumptionsDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanStockOptionActivityDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://aprea.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://aprea.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="apre-20251231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://aprea.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473146488929" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_639090473146488929" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473146529906" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_639090473146529906" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639090473146581005" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_639090473146581005" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473146587077" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_639090473146587077" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146592796" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146592796" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockAmountConverted" xlink:label="apre_TemporaryEquityConversionOfStockAmountConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="apre_TemporaryEquityConversionOfStockAmountConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockSharesConverted" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_TemporaryEquityConversionOfStockAmountConverted" xlink:to="apre_TemporaryEquityConversionOfStockSharesConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="apre_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="apre_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="apre_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="apre_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of business and basis of presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639090473146628760" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_639090473146628760" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146634443" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146634443" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026PrivatePlacementMember" xlink:label="apre_January2026PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_January2026PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of significant accounting policies - Restricted cash and Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473146647076" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473146647076" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_TechnologyEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_OfficeFurnitureAndLaboratoryEquipmentMember" xlink:label="apre_OfficeFurnitureAndLaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="apre_OfficeFurnitureAndLaboratoryEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639090473146653427" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639090473146653427" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146659785" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146659785" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473146666690" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473146666690" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473146678257" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473146678257" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LaboratoryEquipmentMember" xlink:label="apre_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="apre_LaboratoryEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureLeasesSummaryDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Leases - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639090473146689819" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_639090473146689819" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="apre_LesseeOperatingLeaseNumberOfOperatingLeases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LesseeOperatingLeaseAnnualBaseRent" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Income taxes - Components of Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_IncomeTaxesTable" xlink:label="apre_IncomeTaxesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="apre_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639090473146695608" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639090473146695608" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DomesticCountryMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_IncomeTaxesLineItems" xlink:label="apre_IncomeTaxesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="apre_IncomeTaxesLineItems" xlink:to="apre_IncomeTaxesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_IncomeTaxesLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - Income taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639090473146706968" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639090473146706968" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DomesticCountryMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetResearchAndDevelopmentCredits" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="apre_DeferredTaxAssetResearchAndDevelopmentCredits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Stockholders' equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146718416" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146718416" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024PrivatePlacementMember" xlink:label="apre_March2024PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_March2024PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025PrivatePlacementMember" xlink:label="apre_December2025PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_December2025PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatementMember" xlink:label="apre_ShelfRegistrationStatementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_ShelfRegistrationStatementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShelfRegistrationStatementMember" xlink:to="apre_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatement2024Member" xlink:label="apre_ShelfRegistrationStatement2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_ShelfRegistrationStatement2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarket2024OfferingMember" xlink:label="apre_AtMarket2024OfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShelfRegistrationStatement2024Member" xlink:to="apre_AtMarket2024OfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639090473146729100" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639090473146729100" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_HCWainrightCoLlcMember" xlink:label="apre_HCWainrightCoLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="apre_HCWainrightCoLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="apre_CertainPurchasersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PlacementAgentMember" xlink:label="apre_PlacementAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="apre_PlacementAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473146729100" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_639090473146729100" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473146744981" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473146744981" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="apre_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473146744981" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473146744981" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025WarrantsMember" xlink:label="apre_December2025WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_December2025WarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" xlink:label="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639090473146744981" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_639090473146744981" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="apre_AtEventOfElectionOfHolderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockSharesAuthorized" xlink:label="apre_StockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_StockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockSharesConverted" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_TemporaryEquityConversionOfStockSharesConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityRemainingSharesToBeConverted" xlink:label="apre_TemporaryEquityRemainingSharesToBeConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_TemporaryEquityRemainingSharesToBeConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CommonStockNumberOfVotingRightsPerShare" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_CommonStockNumberOfVotingRightsPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatementAbstract" xlink:label="apre_ShelfRegistrationStatementAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_ShelfRegistrationStatementAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PrivatePlacementAbstract" xlink:label="apre_PrivatePlacementAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_PrivatePlacementAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_StockIssuanceAnniversaryPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_NumberOfConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_PercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Stockholders' equity - Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473146831494" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473146831494" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheaWarrantsMember" xlink:label="apre_March2024TrancheaWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_March2024TrancheaWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheBWarrantsMember" xlink:label="apre_March2024TrancheBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_March2024TrancheBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024PreFundedWarrantsMember" xlink:label="apre_March2024PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_March2024PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025PreFundedWarrantsMember" xlink:label="apre_December2025PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_December2025PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025WarrantsMember" xlink:label="apre_December2025WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_December2025WarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Equity Incentive Plan - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639090473146831494" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_639090473146831494" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Equity Incentive Plan - Valuation assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639090473146831494" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_639090473146831494" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639090473146831494" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_639090473146831494" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Equity Incentive Plan - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639090473146831494" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_639090473146831494" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Equity Incentive Plan - Restricted stock units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639090473146831494" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639090473146831494" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_639090473146901757" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_639090473146901757" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:label="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnOneYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnOneYearAnniversaryOfGrantDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:to="apre_VestingOnOneYearAnniversaryOfGrantDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnTwoYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnTwoYearAnniversaryOfGrantDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:to="apre_VestingOnTwoYearAnniversaryOfGrantDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnThreeYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnThreeYearAnniversaryOfGrantDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:to="apre_VestingOnThreeYearAnniversaryOfGrantDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_639090473146901757" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_639090473146901757" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedPaymentArrangementExecutiveOfficersMember" xlink:label="apre_ShareBasedPaymentArrangementExecutiveOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="apre_ShareBasedPaymentArrangementExecutiveOfficersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639090473146932041" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_639090473146932041" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473146932677" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473146932677" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="apre_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146932677" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473146932677" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026PrivatePlacementMember" xlink:label="apre_January2026PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_January2026PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639090473146940073" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639090473146940073" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="apre_CertainPurchasersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473146946417" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473146946417" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026WarrantsMember" xlink:label="apre_January2026WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_January2026WarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639090473146952077" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_639090473146952077" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="apre_AtEventOfElectionOfHolderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apre_StockIssuanceAnniversaryPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apre_NumberOfConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apre_PercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>32
<FILENAME>apre-20251231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/14/2026 1:08:35 AM-->
<!--Modified on: 3/14/2026 1:08:35 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock (as converted)</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ConvertiblePreferredStockSeriesaMember" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of Series A Preferred may be converted at any time, at the option of the holder, into a share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment-net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other noncurrent assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 and 56,227 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency loss (gain)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency (loss) gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingMember" xlink:to="apre_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to ATM offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockAmountConverted" xlink:label="apre_TemporaryEquityConversionOfStockAmountConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_TemporaryEquityConversionOfStockAmountConverted" xlink:to="apre_TemporaryEquityConversionOfStockAmountConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_TemporaryEquityConversionOfStockAmountConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock classified as temporary equity converted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_TemporaryEquityConversionOfStockAmountConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apre_TemporaryEquityConversionOfStockAmountConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockSharesConverted" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_TemporaryEquityConversionOfStockSharesConverted" xlink:to="apre_TemporaryEquityConversionOfStockSharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of temporary equity converted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and pre-funded warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and pre-funded warrants, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to consultants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to consultants (in shares)</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="apre_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="apre_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="apre_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="apre_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of pre-funded warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit and Share-based Payment Arrangement, Noncash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockbased compensation</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NoncashConsultingFees" xlink:label="apre_NoncashConsultingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_NoncashConsultingFees" xlink:to="apre_NoncashConsultingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_NoncashConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consulting fees included in net income that result in no cash flow.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_NoncashConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_NoncashConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to consultants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current and noncurrent assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash-end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash-beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A convertible preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LeaseDisclosureTextBlock" xlink:label="apre_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LeaseDisclosureTextBlock" xlink:to="apre_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CommonStockTextBlock" xlink:label="apre_CommonStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_CommonStockTextBlock" xlink:to="apre_CommonStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="apre_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency and currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityPolicyTextBlock" xlink:label="apre_TemporaryEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_TemporaryEquityPolicyTextBlock" xlink:to="apre_TemporaryEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting for leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued and adopted accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of useful lives of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation of the effect of applying federal statutory rate to the net loss and the effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant components of deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in valuation of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of restricted stock units activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026PrivatePlacementMember" xlink:label="apre_January2026PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_January2026PrivatePlacementMember" xlink:to="apre_January2026PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_January2026PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to January 2026 Private Placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_January2026PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_January2026PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock in a private placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_OfficeFurnitureAndLaboratoryEquipmentMember" xlink:label="apre_OfficeFurnitureAndLaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_OfficeFurnitureAndLaboratoryEquipmentMember" xlink:to="apre_OfficeFurnitureAndLaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_OfficeFurnitureAndLaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tangible personal property used in an office setting or in a laboratory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_OfficeFurnitureAndLaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment and office furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The table contains disclosure pertaining to an entity's basic and diluted earnings per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Pre-funded warrants exercise price of 7.29 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants Exercise Price 7.29 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Pre-funded warrants exercise price of 9.1125  per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants Exercise Price 9.1125 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares of common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LaboratoryEquipmentMember" xlink:label="apre_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LaboratoryEquipmentMember" xlink:to="apre_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tangible personal property used in a laboratory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, at cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:to="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of operating leases held by the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Number of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LesseeOperatingLeaseAnnualBaseRent" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LesseeOperatingLeaseAnnualBaseRent" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of base rent due annually.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Annual Base Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual base rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation, severance and benefits</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:to="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_IncomeTaxesTable" xlink:label="apre_IncomeTaxesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_IncomeTaxesTable" xlink:to="apre_IncomeTaxesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_IncomeTaxesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of income tax disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_IncomeTaxesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_IncomeTaxesLineItems" xlink:label="apre_IncomeTaxesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_IncomeTaxesLineItems" xlink:to="apre_IncomeTaxesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_IncomeTaxesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_IncomeTaxesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_IncomeTaxesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation, amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at U.S. statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others, Foreign tax effects</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits, Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nontaxable and nondeductible items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustments, Changes in unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of effect of applying the federal statutory rate to the net loss and the effective income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at U.S. statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others, Foreign tax effects</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits, Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Deduction, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nontaxable and nondeductible items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustments, Changes in unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Jurisdiction of Domicile [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant components of deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetsAmortization" xlink:label="apre_DeferredTaxAssetsAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_DeferredTaxAssetsAmortization" xlink:to="apre_DeferredTaxAssetsAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetResearchAndDevelopmentCredits" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_DeferredTaxAssetResearchAndDevelopmentCredits" xlink:to="apre_DeferredTaxAssetResearchAndDevelopmentCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from research and development credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, Research And Development Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets (liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertainty in Income Taxes, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024PrivatePlacementMember" xlink:label="apre_March2024PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_March2024PrivatePlacementMember" xlink:to="apre_March2024PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_March2024PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to March 2024 Private Placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_March2024PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_March2024PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Private Placement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025PrivatePlacementMember" xlink:label="apre_December2025PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_December2025PrivatePlacementMember" xlink:to="apre_December2025PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_December2025PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to December 2025 Private Placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_December2025PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2025 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_December2025PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2025 Private Placement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatementMember" xlink:label="apre_ShelfRegistrationStatementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShelfRegistrationStatementMember" xlink:to="apre_ShelfRegistrationStatementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to a Shelf Registration Statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Shelf Registration Statement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatement2024Member" xlink:label="apre_ShelfRegistrationStatement2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShelfRegistrationStatement2024Member" xlink:to="apre_ShelfRegistrationStatement2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to a 2024 Shelf Registration Statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Shelf Registration Statement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarket2024OfferingMember" xlink:label="apre_AtMarket2024OfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarket2024OfferingMember" xlink:to="apre_AtMarket2024OfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarket2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the 2024 ATM offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarket2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market 2024 Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarket2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 ATM offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_HCWainrightCoLlcMember" xlink:label="apre_HCWainrightCoLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_HCWainrightCoLlcMember" xlink:to="apre_HCWainrightCoLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_HCWainrightCoLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to H.C Wainright &amp; Co, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_HCWainrightCoLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HC Wainright Co Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_HCWainrightCoLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HCW</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_CertainPurchasersMember" xlink:to="apre_CertainPurchasersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_CertainPurchasersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain purchaser with whom company entered into securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_CertainPurchasersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain Purchasers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_CertainPurchasersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchasers</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PlacementAgentMember" xlink:label="apre_PlacementAgentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PlacementAgentMember" xlink:to="apre_PlacementAgentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PlacementAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to placement agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PlacementAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PlacementAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_SecuritiesPurchaseAgreementMember" xlink:to="apre_SecuritiesPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities purchase agreement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025WarrantsMember" xlink:label="apre_December2025WarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_December2025WarrantsMember" xlink:to="apre_December2025WarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_December2025WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to December 2025 Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_December2025WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2025 Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_December2025WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2025 Warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" xlink:label="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" xlink:to="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to March 2024 Tranche A warrants and Tranche B warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 TrancheA Warrants And Tranche B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Tranche A Warrants And Tranche B Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtEventOfElectionOfHolderMember" xlink:to="apre_AtEventOfElectionOfHolderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtEventOfElectionOfHolderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents scenario or event of election of holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtEventOfElectionOfHolderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Event of Election of Holder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtEventOfElectionOfHolderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the election of holder</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockSharesAuthorized" xlink:label="apre_StockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_StockSharesAuthorized" xlink:to="apre_StockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_StockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of shares permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_StockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_StockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityRemainingSharesToBeConverted" xlink:label="apre_TemporaryEquityRemainingSharesToBeConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_TemporaryEquityRemainingSharesToBeConverted" xlink:to="apre_TemporaryEquityRemainingSharesToBeConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_TemporaryEquityRemainingSharesToBeConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares remained to be converted into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_TemporaryEquityRemainingSharesToBeConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Remaining Shares to be Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_TemporaryEquityRemainingSharesToBeConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares remained to be converted into common stock</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CommonStockNumberOfVotingRightsPerShare" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_CommonStockNumberOfVotingRightsPerShare" xlink:to="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of voting rights per share of common stock owned.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Voting Rights Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of voting rights per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatementAbstract" xlink:label="apre_ShelfRegistrationStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_ShelfRegistrationStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShelfRegistrationStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShelfRegistrationStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShelfRegistrationStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:to="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock, preferred stock, warrants, rights and debt securities and units that can be issued under a universal shelf registration statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Universal Shelf Registration Maximum Amount To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be issued under universal shelf registration statement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock to be issued under an at-the-market offering program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering Program Maximum Amount To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be issued under at-the-market offering program</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock to be issued under a supplemental at-the-market offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering Program Maximum Amount To Be Issued, Supplement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be issued under at-the-market offering program, supplement</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PrivatePlacementAbstract" xlink:label="apre_PrivatePlacementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_PrivatePlacementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock with an exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_StockIssuanceAnniversaryPeriod" xlink:to="apre_StockIssuanceAnniversaryPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_StockIssuanceAnniversaryPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of anniversary of issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_StockIssuanceAnniversaryPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Anniversary Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_StockIssuanceAnniversaryPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance anniversary period</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days after the Company announces the recommended Phase 2 dose for ATRN-119.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Days after Company Announces Recommended Phase 2 Dose for ATRN 119</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days after announcement of Phase 2 dose for ATRN-119</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volume weighted average price per share of common stock after announcement of recommended Phase 2 dose for ATRN-119.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Volume Weighted Average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volume weighted average price</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_NumberOfConsecutiveTradingDays" xlink:to="apre_NumberOfConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive trading days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PercentageOfOutstandingShares" xlink:to="apre_PercentageOfOutstandingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding shares</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expected gross proceeds from potential future warrant cash exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Gross Proceeds from Potential Future Warrant Cash Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected gross proceeds from potential future warrants cash exercise</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheaWarrantsMember" xlink:label="apre_March2024TrancheaWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_March2024TrancheaWarrantsMember" xlink:to="apre_March2024TrancheaWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_March2024TrancheaWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to March 2024 Tranche A warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_March2024TrancheaWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 TrancheA Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_March2024TrancheaWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Tranche A Warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheBWarrantsMember" xlink:label="apre_March2024TrancheBWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_March2024TrancheBWarrantsMember" xlink:to="apre_March2024TrancheBWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_March2024TrancheBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to March 2024 Tranche B warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_March2024TrancheBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Tranche B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_March2024TrancheBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Tranche B Warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024PreFundedWarrantsMember" xlink:label="apre_March2024PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_March2024PreFundedWarrantsMember" xlink:to="apre_March2024PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_March2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to March 2024 pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_March2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Pre-Funded warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_March2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025PreFundedWarrantsMember" xlink:label="apre_December2025PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_December2025PreFundedWarrantsMember" xlink:to="apre_December2025PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_December2025PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to December 2025 pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_December2025PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2025 Pre-Funded warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_December2025PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2025 pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Two Thousand Nineteen Equity Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for grant</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:to="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in number of shares available for future grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, increase in number of shares available for grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition period for unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term in years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled/Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average exercise price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled/Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:label="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:to="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to vesting on one year, two year and three year anniversaries of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting On One Year, Two Year and Three Year Anniversaries Of Grant Date</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnOneYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnOneYearAnniversaryOfGrantDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_VestingOnOneYearAnniversaryOfGrantDateMember" xlink:to="apre_VestingOnOneYearAnniversaryOfGrantDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_VestingOnOneYearAnniversaryOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to vesting on one year anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_VestingOnOneYearAnniversaryOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting On One Year Anniversary Of Grant Date</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnTwoYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnTwoYearAnniversaryOfGrantDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_VestingOnTwoYearAnniversaryOfGrantDateMember" xlink:to="apre_VestingOnTwoYearAnniversaryOfGrantDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_VestingOnTwoYearAnniversaryOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to vesting on two year anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_VestingOnTwoYearAnniversaryOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting On Two Year Anniversary Of Grant Date</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnThreeYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnThreeYearAnniversaryOfGrantDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_VestingOnThreeYearAnniversaryOfGrantDateMember" xlink:to="apre_VestingOnThreeYearAnniversaryOfGrantDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_VestingOnThreeYearAnniversaryOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to vesting on three year anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_VestingOnThreeYearAnniversaryOfGrantDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting On Three Year Anniversary Of Grant Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedPaymentArrangementExecutiveOfficersMember" xlink:label="apre_ShareBasedPaymentArrangementExecutiveOfficersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShareBasedPaymentArrangementExecutiveOfficersMember" xlink:to="apre_ShareBasedPaymentArrangementExecutiveOfficersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShareBasedPaymentArrangementExecutiveOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShareBasedPaymentArrangementExecutiveOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive officers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non employee directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units, Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled/Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance, Weighted average grant date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled/Forfeited, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualProvision" xlink:to="us-gaap_LossContingencyAccrualProvision_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual, Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for contingent losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026WarrantsMember" xlink:label="apre_January2026WarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_January2026WarrantsMember" xlink:to="apre_January2026WarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_January2026WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to January 2026 warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_January2026WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_January2026WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>33
<FILENAME>apre-20251231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/14/2026 1:08:35 AM-->
<!--Modified on: 3/14/2026 1:08:35 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://aprea.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation" roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosurePropertyAndEquipment" roleURI="http://aprea.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureLeases" roleURI="http://aprea.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureAccruedExpenses" roleURI="http://aprea.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxes" roleURI="http://aprea.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureStockholdersEquity" roleURI="http://aprea.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlan" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSubsequentEvents" roleURI="http://aprea.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://aprea.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureAccruedExpensesTables" roleURI="http://aprea.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesTables" roleURI="http://aprea.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureStockholdersEquityTables" roleURI="http://aprea.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanTables" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationDetails" roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureLeasesSummaryDetails" roleURI="http://aprea.com/role/DisclosureLeasesSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://aprea.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aprea.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureStockholdersEquityWarrantsOutstandingDetails" roleURI="http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanSummaryDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanValuationAssumptionsDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanStockOptionActivityDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" roleURI="http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://aprea.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://aprea.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639090473146981418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_639090473146981418" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_639090473146981418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_639090473146981418" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639090473146981418" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639090473146981418" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_639090473146986664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_639090473146986664" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_639090473146987208" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_639090473146987208" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639090473146987208" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639090473146987208" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639090473146987208" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639090473146987208" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639090473146987208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639090473146987208" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639090473146992419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639090473146992419" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639090473146992941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_639090473146992941" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639090473146992941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_639090473146992941" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639090473146992941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_639090473146992941" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639090473146992941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_639090473146992941" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639090473146992941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_639090473146992941" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_639090473146992941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_639090473146992941" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_639090473146998222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_639090473146998222" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_639090473146998867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_639090473146998867" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_639090473146998867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_639090473146998867" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639090473146998867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_639090473146998867" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639090473146998867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_639090473146998867" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639090473146998867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639090473146998867" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_639090473146998867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_639090473146998867" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_639090473147004559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_639090473147004559" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_639090473147004559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_639090473147004559" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_639090473147004559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_639090473147004559" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_639090473147004559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_639090473147004559" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_639090473147004559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_639090473147004559" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639090473147004559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639090473147004559" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_639090473147010316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_639090473147010316" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_639090473147010316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_639090473147010316" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_639090473147010316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_639090473147010316" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639090473147010316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_639090473147010316" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName_639090473147010316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_639090473147010316" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_639090473147016025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_639090473147016025" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_639090473147016025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_639090473147016025" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639090473147016025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_639090473147016025" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639090473147016025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147016025" xlink:to="us-gaap_StatementClassOfStockAxis_639090473147016025" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639090473147016025" xlink:to="us-gaap_ClassOfStockDomain_639090473147021734" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639090473147021734" xlink:to="us-gaap_ConvertiblePreferredStockMember_639090473147021734" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_639090473147021734" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_639090473147021734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147016025" xlink:to="us-gaap_StatementLineItems_639090473147021734" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147021734" xlink:to="us-gaap_AssetsAbstract_639090473147021734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639090473147021734" xlink:to="us-gaap_AssetsCurrentAbstract_639090473147021734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473147021734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639090473147021734" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473147021734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639090473147026971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639090473147021734" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639090473147026971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639090473147027513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639090473147021734" xlink:to="us-gaap_AssetsCurrent_639090473147027513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639090473147027513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639090473147021734" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639090473147027513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_639090473147027513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639090473147021734" xlink:to="us-gaap_RestrictedCashNoncurrent_639090473147027513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639090473147027513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639090473147021734" xlink:to="us-gaap_OtherAssetsNoncurrent_639090473147027513" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639090473147027513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639090473147021734" xlink:to="us-gaap_Assets_639090473147027513" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147021734" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639090473147032741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639090473147032741" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639090473147033253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639090473147032741" xlink:to="us-gaap_AccountsPayableCurrent_639090473147033253" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_639090473147033253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639090473147032741" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_639090473147033253" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639090473147033253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639090473147032741" xlink:to="us-gaap_LiabilitiesCurrent_639090473147033253" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639090473147033253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" xlink:to="us-gaap_CommitmentsAndContingencies_639090473147033253" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_639090473147033253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" xlink:to="us-gaap_TemporaryEquityAbstract_639090473147033253" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_639090473147038465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_639090473147033253" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_639090473147038465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639090473147038920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" xlink:to="us-gaap_CommonStockValue_639090473147038920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639090473147146644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" xlink:to="us-gaap_AdditionalPaidInCapital_639090473147146644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639090473147146644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639090473147146644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639090473147146644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639090473147146644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639090473147146644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_639090473147038920" xlink:to="us-gaap_StockholdersEquity_639090473147146644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639090473147151851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639090473147027513" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639090473147151851" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639090473147152385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_639090473147152385" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639090473147152385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147152385" xlink:to="us-gaap_StatementClassOfStockAxis_639090473147152385" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473147152385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639090473147152385" xlink:to="us-gaap_ClassOfStockDomain_639090473147152385" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_639090473147152385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639090473147152385" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_639090473147152385" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639090473147157609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147152385" xlink:to="us-gaap_StatementLineItems_639090473147157609" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_639090473147158749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_639090473147158749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_639090473147159176" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_TemporaryEquitySharesIssued_639090473147159176" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_639090473147159176" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639090473147159176" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_CommonStockSharesAuthorized_639090473147159176" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_CommonStockSharesIssued_639090473147159176" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639090473147159176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147157609" xlink:to="us-gaap_CommonStockSharesOutstanding_639090473147159176" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_639090473147164957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_639090473147164957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_639090473147164957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_639090473147164957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_639090473147164957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639090473147164957" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_639090473147164957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639090473147164957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639090473147164957" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639090473147164957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639090473147164957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639090473147164957" xlink:to="us-gaap_OperatingExpenses_639090473147164957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639090473147164957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_639090473147164957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_639090473147170165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_639090473147170165" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639090473147170165" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_639090473147170688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639090473147170165" xlink:to="us-gaap_OtherNonoperatingIncome_639090473147170688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639090473147170165" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473147170688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639090473147170165" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639090473147170688" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_639090473147170688" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_639090473147170688" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639090473147170688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_639090473147170688" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639090473147170688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_639090473147176432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_639090473147176432" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639090473147176432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_639090473147176432" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639090473147176432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_639090473147176432" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639090473147176432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639090473147176432" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639090473147176432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639090473147176432" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639090473147182184" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147182184" xlink:to="us-gaap_StatementClassOfStockAxis_639090473147182184" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639090473147182184" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_639090473147182184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639090473147182184" xlink:to="us-gaap_ClassOfStockDomain_639090473147182184" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147182184" xlink:to="us-gaap_StatementEquityComponentsAxis_639090473147182184" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639090473147182184" xlink:to="us-gaap_PreferredStockMember_639090473147182184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639090473147182184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639090473147182184" xlink:to="us-gaap_CommonStockMember_639090473147182184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639090473147187396" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639090473147182184" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639090473147187396" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639090473147182184" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639090473147187910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639090473147182184" xlink:to="us-gaap_RetainedEarningsMember_639090473147187910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639090473147182184" xlink:to="us-gaap_EquityComponentDomain_639090473147187910" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147182184" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639090473147187910" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639090473147187910" xlink:to="apre_AtMarketOfferingMember_639090473147187910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639090473147187910" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147187910" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639090473147187910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639090473147182184" xlink:to="us-gaap_StatementLineItems_639090473147187910" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147187910" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_639090473147193664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_639090473147193664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_639090473147193664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_639090473147193664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockAmountConverted" xlink:label="apre_TemporaryEquityConversionOfStockAmountConverted_639090473147193664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" xlink:to="apre_TemporaryEquityConversionOfStockAmountConverted_639090473147193664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockSharesConverted" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted_639090473147193664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_TemporaryEquityConversionOfStockAmountConverted_639090473147193664" xlink:to="apre_TemporaryEquityConversionOfStockSharesConverted_639090473147193664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_6390904731471936641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_6390904731471936641" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6390904731471936641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_639090473147193133" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6390904731471936641" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639090473147187910" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639090473147199419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockholdersEquity_639090473147199419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_639090473147199419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_SharesOutstanding_639090473147199419" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_639090473147199419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_639090473147199419" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_639090473147199419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_639090473147199419" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639090473147199419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639090473147199419" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639090473147204646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_639090473147199419" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639090473147204646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_639090473147205150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_639090473147205150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_639090473147205150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_639090473147205150" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_639090473147205150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="apre_StockIssuedDuringPeriodValueWarrantsExercised_639090473147205150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="apre_StockIssuedDuringPeriodValueWarrantsExercised_639090473147205150" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="apre_StockIssuedDuringPeriodSharesWarrantsExercised_639090473147205150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_StockIssuedDuringPeriodValueWarrantsExercised_639090473147205150" xlink:to="apre_StockIssuedDuringPeriodSharesWarrantsExercised_639090473147205150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639090473147205150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639090473147205150" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639090473147210357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639090473147210357" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639090473147211820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639090473147211820" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639090473147212320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639090473147211820" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639090473147212320" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639090473147212320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_NetIncomeLoss_639090473147212320" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639090473147212320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_StockholdersEquity_639090473147212320" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_639090473147212320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639090473147198890" xlink:to="us-gaap_SharesOutstanding_639090473147212320" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639090473147218043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_ProfitLoss_639090473147218043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_639090473147218043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_DepreciationDepletionAndAmortization_639090473147218043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_639090473147218043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_639090473147218043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NoncashConsultingFees" xlink:label="apre_NoncashConsultingFees_639090473147218043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="apre_NoncashConsultingFees_639090473147218043" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639090473147223766" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639090473147223766" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639090473147223766" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639090473147223766" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639090473147223766" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639090473147223766" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639090473147223766" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_639090473147223766" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639090473147223766" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_639090473147223766" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473147223766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639090473147218043" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639090473147223766" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639090473147228972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639090473147228972" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639090473147229492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639090473147228972" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639090473147229492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639090473147229492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639090473147228972" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639090473147229492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639090473147229492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639090473147229492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639090473147229492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639090473147229492" xlink:to="us-gaap_ProceedsFromWarrantExercises_639090473147229492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639090473147229492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639090473147229492" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639090473147229492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639090473147229492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639090473147229492" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639090473147229492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473147235221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639090473147229492" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639090473147235221" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_639090473147235221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_639090473147235221" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639090473147235221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_639090473147235221" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639090473147235221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639090473147235221" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6390904731472352211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6390904731472352211" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639090473147235221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639090473147235221" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473147240427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639090473147235221" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473147240427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_639090473147240945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639090473147235221" xlink:to="us-gaap_RestrictedCash_639090473147240945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639090473147240945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639090473147235221" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639090473147240945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639090473147240945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639090473147240945" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_639090473147240945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639090473147240945" xlink:to="us-gaap_ConversionOfStockAmountIssued1_639090473147240945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of business and basis of presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639090473147246663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639090473147246663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_639090473147246663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_639090473147246663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="995210301 - Disclosure - Property and equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_639090473147251943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_639090473147251943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995210401 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LeaseDisclosureTextBlock" xlink:label="apre_LeaseDisclosureTextBlock_639090473147252474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="apre_LeaseDisclosureTextBlock_639090473147252474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210501 - Disclosure - Accrued expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_639090473147252474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_639090473147252474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995210601 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639090473147258204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639090473147258204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="995210701 - Disclosure - Stockholders' equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CommonStockTextBlock" xlink:label="apre_CommonStockTextBlock_639090473147258204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="apre_CommonStockTextBlock_639090473147258204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlan" xlink:type="extended" xlink:title="995210801 - Disclosure - Equity Incentive Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639090473147258204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639090473147258204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995210901 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639090473147263925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639090473147263925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211001 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639090473147263925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_639090473147263925" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_639090473147269132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_639090473147269132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639090473147269658" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_639090473147269658" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_639090473147269658" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_639090473147269658" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639090473147269658" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_639090473147269658" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_639090473147269658" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityPolicyTextBlock" xlink:label="apre_TemporaryEquityPolicyTextBlock_639090473147269658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apre_TemporaryEquityPolicyTextBlock_639090473147269658" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_639090473147275380" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_639090473147275380" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639090473147275380" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_639090473147275380" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639090473147275380" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_639090473147275380" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639090473147275380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639090473147275380" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639090473147281115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639090473147281115" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Summary of significant accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_639090473147281115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_639090473147281115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639090473147281115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639090473147281115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Property and equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_639090473147281115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_639090473147281115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Accrued expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639090473147286910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639090473147286910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_639090473147286910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_639090473147286910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639090473147286910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639090473147286910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639090473147286910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639090473147286910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Stockholders' equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_639090473147292585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_639090473147292585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Equity Incentive Plan (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639090473147292585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639090473147292585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639090473147292585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639090473147292585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_639090473147292585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_639090473147292585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of business and basis of presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_639090473147298259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639090473147298259" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639090473147298259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639090473147298259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147298259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026PrivatePlacementMember" xlink:label="apre_January2026PrivatePlacementMember_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147298259" xlink:to="apre_January2026PrivatePlacementMember_639090473147298259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639090473147298259" xlink:to="us-gaap_SubsequentEventTypeAxis_639090473147298259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639090473147298259" xlink:to="us-gaap_SubsequentEventTypeDomain_639090473147298259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639090473147298259" xlink:to="us-gaap_SubsequentEventMember_639090473147298259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639090473147298259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639090473147298259" xlink:to="us-gaap_ClassOfStockLineItems_639090473147298259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473147303933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639090473147298259" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639090473147303933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639090473147303933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639090473147298259" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639090473147303933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639090473147303933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639090473147298259" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639090473147303933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639090473147303933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639090473147298259" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639090473147303933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of significant accounting policies - Restricted cash and Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147303933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147303933" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639090473147309127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147303933" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639090473147309127" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639090473147309127" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147309610" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147309610" xlink:to="us-gaap_TechnologyEquipmentMember_639090473147309610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_OfficeFurnitureAndLaboratoryEquipmentMember" xlink:label="apre_OfficeFurnitureAndLaboratoryEquipmentMember_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147309610" xlink:to="apre_OfficeFurnitureAndLaboratoryEquipmentMember_639090473147309610" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147303933" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147309610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147309610" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_639090473147309610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147309610" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract_639090473147309610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_639090473147309610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract_639090473147309610" xlink:to="us-gaap_RestrictedCashNoncurrent_639090473147309610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_639090473147315281" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_639090473147315281" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639090473147315281" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639090473147315281" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639090473147315281" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639090473147315281" xlink:to="us-gaap_ConvertiblePreferredStockMember_639090473147315281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639090473147315281" xlink:to="us-gaap_EmployeeStockOptionMember_639090473147315281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639090473147315281" xlink:to="us-gaap_WarrantMember_639090473147315281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639090473147315281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639090473147315281" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639090473147315281" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639090473147320470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_639090473147315281" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639090473147320470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639090473147320470" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147320952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147320952" xlink:to="us-gaap_PrivatePlacementMember_639090473147320952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_639090473147315281" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639090473147320952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639090473147320952" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473147320952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147320952" xlink:to="apre_PreFundedWarrantsMember_639090473147320952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_639090473147320952" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_639090473147320952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_639090473147320952" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_639090473147320952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_639090473147320952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_639090473147315281" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_639090473147320952" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_639090473147326654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_639090473147320952" xlink:to="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_639090473147326654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639090473147326654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_639090473147326654" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639090473147326654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639090473147326654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_639090473147326654" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639090473147326654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147326654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147326654" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639090473147326654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147326654" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639090473147326654" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147326654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639090473147326654" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147326654" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LaboratoryEquipmentMember" xlink:label="apre_LaboratoryEquipmentMember_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147326654" xlink:to="apre_LaboratoryEquipmentMember_639090473147332318" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639090473147326654" xlink:to="us-gaap_ComputerEquipmentMember_639090473147332318" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639090473147326654" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147332318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147332318" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639090473147332318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147332318" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639090473147332318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147332318" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639090473147332318" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_639090473147332318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639090473147332318" xlink:to="us-gaap_DepreciationDepletionAndAmortization_639090473147332318" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureLeasesSummaryDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Leases - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_639090473147338005" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639090473147338005" xlink:to="us-gaap_IncomeStatementLocationAxis_639090473147338005" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639090473147338005" xlink:to="us-gaap_IncomeStatementLocationDomain_639090473147338005" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639090473147338005" xlink:to="us-gaap_OperatingExpenseMember_639090473147338005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639090473147338005" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_639090473147338005" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639090473147338005" xlink:to="apre_LesseeOperatingLeaseNumberOfOperatingLeases_639090473147338005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_639090473147338005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639090473147338005" xlink:to="us-gaap_OperatingLeaseExpense_639090473147338005" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_LesseeOperatingLeaseAnnualBaseRent" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_639090473147343410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639090473147338005" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRent_639090473147343410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639090473147343410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639090473147343410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639090473147345642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639090473147345642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_639090473147345642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_639090473147345642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639090473147345642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639090473147345642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_639090473147345642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_639090473147345642" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Income taxes - Components of Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_IncomeTaxesTable" xlink:label="apre_IncomeTaxesTable_639090473147345642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="apre_IncomeTaxesTable_639090473147345642" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639090473147345642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_IncomeTaxesTable_639090473147345642" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639090473147345642" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639090473147350860" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639090473147345642" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639090473147350860" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639090473147350860" xlink:to="us-gaap_ForeignCountryMember_639090473147351920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639090473147350860" xlink:to="us-gaap_DomesticCountryMember_639090473147351920" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DomesticCountryMember_639090473147351920" xlink:to="country_US_639090473147351920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_IncomeTaxesLineItems" xlink:label="apre_IncomeTaxesLineItems_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_IncomeTaxesTable_639090473147345642" xlink:to="apre_IncomeTaxesLineItems_639090473147351920" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_IncomeTaxesLineItems_639090473147351920" xlink:to="us-gaap_NetIncomeLoss_639090473147351920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Income taxes - Income Taxes Rate Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639090473147351920" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639090473147351920" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_639090473147357577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639090473147357577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473147357577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639090473147357577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_639090473147357577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639090473147351920" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639090473147357577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639090473147362766" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639090473147362766" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_639090473147363543" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639090473147363543" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_639090473147363543" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639090473147363543" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639090473147363543" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther_639090473147363543" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639090473147363543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639090473147363543" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639090473147369286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639090473147369286" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_639090473147369286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639090473147357577" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_639090473147369286" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Income taxes - Components of Deferred Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639090473147369286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639090473147369286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639090473147369286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639090473147369286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetsAmortization" xlink:label="apre_DeferredTaxAssetsAmortization_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="apre_DeferredTaxAssetsAmortization_639090473147374927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639090473147374927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_639090473147374927" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetResearchAndDevelopmentCredits" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="apre_DeferredTaxAssetResearchAndDevelopmentCredits_639090473147374927" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639090473147374927" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsGross_639090473147374927" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639090473147374927" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639090473147374927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639090473147369286" xlink:to="us-gaap_DeferredTaxAssetsNet_639090473147374927" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_639090473147380836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_639090473147380836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - Income taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_639090473147380836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_639090473147380836" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639090473147380836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_639090473147380836" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639090473147380836" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639090473147380836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639090473147380836" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639090473147380836" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_639090473147380836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639090473147380836" xlink:to="us-gaap_ForeignCountryMember_639090473147380836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639090473147380836" xlink:to="us-gaap_DomesticCountryMember_639090473147386682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DomesticCountryMember_639090473147386682" xlink:to="country_US_639090473147386682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639090473147380836" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639090473147386682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_639090473147380836" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639090473147386682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" xlink:to="us-gaap_OperatingLossCarryforwards_639090473147386682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_DeferredTaxAssetResearchAndDevelopmentCredits" xlink:label="apre_DeferredTaxAssetResearchAndDevelopmentCredits_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" xlink:to="apre_DeferredTaxAssetResearchAndDevelopmentCredits_639090473147386682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639090473147386682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639090473147386682" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_639090473147392904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639090473147386682" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_639090473147392904" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Stockholders' equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639090473147393337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639090473147393337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639090473147393337" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639090473147393337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" xlink:to="us-gaap_PrivatePlacementMember_639090473147393337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024PrivatePlacementMember" xlink:label="apre_March2024PrivatePlacementMember_639090473147399179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" xlink:to="apre_March2024PrivatePlacementMember_639090473147399179" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025PrivatePlacementMember" xlink:label="apre_December2025PrivatePlacementMember_639090473147418366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" xlink:to="apre_December2025PrivatePlacementMember_639090473147418366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatementMember" xlink:label="apre_ShelfRegistrationStatementMember_639090473147418366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" xlink:to="apre_ShelfRegistrationStatementMember_639090473147418366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember_639090473147418366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementMember_639090473147418366" xlink:to="apre_AtMarketOfferingMember_639090473147418366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatement2024Member" xlink:label="apre_ShelfRegistrationStatement2024Member_639090473147418366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147393337" xlink:to="apre_ShelfRegistrationStatement2024Member_639090473147418366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarket2024OfferingMember" xlink:label="apre_AtMarket2024OfferingMember_639090473147418366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatement2024Member_639090473147418366" xlink:to="apre_AtMarket2024OfferingMember_639090473147418366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639090473147418366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="srt_CounterpartyNameAxis_639090473147418366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639090473147418366" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147424267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_HCWainrightCoLlcMember" xlink:label="apre_HCWainrightCoLlcMember_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147424267" xlink:to="apre_HCWainrightCoLlcMember_639090473147424267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147424267" xlink:to="apre_CertainPurchasersMember_639090473147424267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PlacementAgentMember" xlink:label="apre_PlacementAgentMember_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147424267" xlink:to="apre_PlacementAgentMember_639090473147424267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="us-gaap_StatementClassOfStockAxis_639090473147424267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639090473147424267" xlink:to="us-gaap_ClassOfStockDomain_639090473147424267" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639090473147424267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639090473147424267" xlink:to="us-gaap_CommonStockMember_639090473147424267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_639090473147429989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639090473147424267" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_639090473147429989" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639090473147431552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="us-gaap_TypeOfArrangementAxis_639090473147431552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473147431552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639090473147431552" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473147431552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember_639090473147431552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473147431552" xlink:to="apre_SecuritiesPurchaseAgreementMember_639090473147431552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639090473147431552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639090473147431552" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473147431552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639090473147431552" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473147431552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember_639090473147431552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147431552" xlink:to="apre_PreFundedWarrantsMember_639090473147431552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_639090473147436871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_639090473147431552" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_639090473147436871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_639090473147438021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_639090473147431552" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_639090473147438021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025WarrantsMember" xlink:label="apre_December2025WarrantsMember_639090473147438021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147431552" xlink:to="apre_December2025WarrantsMember_639090473147438021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember" xlink:label="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_639090473147438021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147431552" xlink:to="apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_639090473147438021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639090473147438021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="srt_StatementScenarioAxis_639090473147438021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639090473147438021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639090473147438021" xlink:to="srt_ScenarioUnspecifiedDomain_639090473147438021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember_639090473147438021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639090473147438021" xlink:to="apre_AtEventOfElectionOfHolderMember_639090473147438021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639090473147393337" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockSharesAuthorized" xlink:label="apre_StockSharesAuthorized_639090473147443906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="apre_StockSharesAuthorized_639090473147443906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639090473147443906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_CommonStockSharesAuthorized_639090473147443906" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639090473147443906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639090473147443906" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639090473147443906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_PreferredStockSharesAuthorized_639090473147443906" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639090473147449479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639090473147449479" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityConversionOfStockSharesConverted" xlink:label="apre_TemporaryEquityConversionOfStockSharesConverted_639090473147449782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="apre_TemporaryEquityConversionOfStockSharesConverted_639090473147449782" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639090473147449782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639090473147449782" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_639090473147449782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_639090473147449782" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TemporaryEquityRemainingSharesToBeConverted" xlink:label="apre_TemporaryEquityRemainingSharesToBeConverted_639090473147449782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="apre_TemporaryEquityRemainingSharesToBeConverted_639090473147449782" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CommonStockNumberOfVotingRightsPerShare" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_639090473147455394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="apre_CommonStockNumberOfVotingRightsPerShare_639090473147455394" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639090473147455675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639090473147455675" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShelfRegistrationStatementAbstract" xlink:label="apre_ShelfRegistrationStatementAbstract_639090473147455675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="apre_ShelfRegistrationStatementAbstract_639090473147455675" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_639090473147455675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_639090473147455675" xlink:to="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_639090473147455675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_639090473147455675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_639090473147455675" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_639090473147455675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_639090473147460938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_639090473147455675" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_639090473147460938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639090473147462303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_639090473147455675" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639090473147462303" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639090473147462303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_639090473147455675" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639090473147462303" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639090473147462303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_639090473147455675" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639090473147462303" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PrivatePlacementAbstract" xlink:label="apre_PrivatePlacementAbstract_639090473147462303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639090473147443906" xlink:to="apre_PrivatePlacementAbstract_639090473147462303" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639090473147462303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="us-gaap_SharesIssuedPricePerShare_639090473147462303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639090473147468330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639090473147468330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639090473147468330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639090473147468330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod_639090473147468330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_StockIssuanceAnniversaryPeriod_639090473147468330" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_639090473147468330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_639090473147468330" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_639090473147468330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare_639090473147468330" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays_639090473147474194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_NumberOfConsecutiveTradingDays_639090473147474194" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares_639090473147474194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_PercentageOfOutstandingShares_639090473147474194" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639090473147474194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639090473147474194" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_639090473147474194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_639090473147474194" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639090473147479723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="us-gaap_ProceedsFromWarrantExercises_639090473147479723" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised_639090473147480132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_639090473147462303" xlink:to="apre_ClassOfWarrantOrRightNumberOfWarrantsExercised_639090473147480132" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Stockholders' equity - Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639090473147485719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639090473147485719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639090473147485719" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639090473147486032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639090473147486032" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheaWarrantsMember" xlink:label="apre_March2024TrancheaWarrantsMember_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" xlink:to="apre_March2024TrancheaWarrantsMember_639090473147486032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024TrancheBWarrantsMember" xlink:label="apre_March2024TrancheBWarrantsMember_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" xlink:to="apre_March2024TrancheBWarrantsMember_639090473147486032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_March2024PreFundedWarrantsMember" xlink:label="apre_March2024PreFundedWarrantsMember_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" xlink:to="apre_March2024PreFundedWarrantsMember_639090473147486032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025PreFundedWarrantsMember" xlink:label="apre_December2025PreFundedWarrantsMember_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" xlink:to="apre_December2025PreFundedWarrantsMember_639090473147486032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_December2025WarrantsMember" xlink:label="apre_December2025WarrantsMember_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147486032" xlink:to="apre_December2025WarrantsMember_639090473147486032" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639090473147486032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639090473147485719" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639090473147486032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639090473147492190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639090473147486032" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639090473147492190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639090473147492190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639090473147486032" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639090473147492190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Equity Incentive Plan - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147492190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147492190" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639090473147492190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147492190" xlink:to="us-gaap_PlanNameAxis_639090473147492190" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639090473147492190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639090473147492190" xlink:to="us-gaap_PlanNameDomain_639090473147492190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember_639090473147497771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639090473147492190" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember_639090473147497771" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147492190" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639090473147498564" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639090473147498564" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_639090473147498564" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" xlink:to="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_639090473147498564" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639090473147498564" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639090473147498564" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639090473147498564" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639090473147498564" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639090473147498564" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147498564" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639090473147498564" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Equity Incentive Plan - Valuation assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147504274" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147504274" xlink:to="us-gaap_PlanNameAxis_639090473147504274" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639090473147504274" xlink:to="us-gaap_PlanNameDomain_639090473147504274" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639090473147504274" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember_639090473147504274" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147504274" xlink:to="srt_RangeAxis_639090473147504274" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639090473147504274" xlink:to="srt_RangeMember_639090473147504274" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639090473147504274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639090473147504274" xlink:to="srt_MinimumMember_639090473147504274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639090473147509514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639090473147504274" xlink:to="srt_MaximumMember_639090473147509514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147504274" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_639090473147509962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_639090473147509962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_639090473147509962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_639090473147509962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_639090473147509962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_639090473147509962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_639090473147509962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_639090473147509962" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639090473147509962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639090473147509962" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639090473147515210" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147509962" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639090473147515210" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Equity Incentive Plan - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147517255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147517255" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639090473147517255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147517255" xlink:to="us-gaap_PlanNameAxis_639090473147517255" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639090473147517255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639090473147517255" xlink:to="us-gaap_PlanNameDomain_639090473147517255" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="apre_TwoThousandNineteenEquityIncentivePlanMember_639090473147517255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639090473147517255" xlink:to="apre_TwoThousandNineteenEquityIncentivePlanMember_639090473147517255" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147517255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147517255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639090473147522567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639090473147522567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639090473147523745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_639090473147523745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639090473147523745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_639090473147523745" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_639090473147523745" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639090473147523745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639090473147523745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639090473147529718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639090473147529718" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_639090473147531278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_639090473147531278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639090473147532652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639090473147532652" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639090473147534561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639090473147534561" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_639090473147535852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639090473147523745" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_639090473147535852" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639090473147535852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147517255" xlink:to="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639090473147535852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639090473147535852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639090473147535852" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639090473147535852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_639090473147535852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639090473147535852" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_639090473147535852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_639090473147535852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639090473147535852" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_639090473147535852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639090473147535852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147517255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639090473147535852" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639090473147541099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639090473147535852" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639090473147541099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Equity Incentive Plan - Restricted stock units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147542240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147542240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639090473147542240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147542240" xlink:to="us-gaap_AwardTypeAxis_639090473147542240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639090473147542240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639090473147542240" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639090473147542240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639090473147547480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639090473147542240" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639090473147547480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147542240" xlink:to="us-gaap_VestingAxis_639090473147548561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_639090473147548561" xlink:to="us-gaap_VestingDomain_639090473147548561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember" xlink:label="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639090473147548561" xlink:to="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_639090473147548561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnOneYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnOneYearAnniversaryOfGrantDateMember_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_639090473147548561" xlink:to="apre_VestingOnOneYearAnniversaryOfGrantDateMember_639090473147548561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnTwoYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnTwoYearAnniversaryOfGrantDateMember_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_639090473147548561" xlink:to="apre_VestingOnTwoYearAnniversaryOfGrantDateMember_639090473147548561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_VestingOnThreeYearAnniversaryOfGrantDateMember" xlink:label="apre_VestingOnThreeYearAnniversaryOfGrantDateMember_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember_639090473147548561" xlink:to="apre_VestingOnThreeYearAnniversaryOfGrantDateMember_639090473147548561" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147542240" xlink:to="us-gaap_GranteeStatusAxis_639090473147548561" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_639090473147548561" xlink:to="us-gaap_GranteeStatusDomain_639090473147548561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ShareBasedPaymentArrangementExecutiveOfficersMember" xlink:label="apre_ShareBasedPaymentArrangementExecutiveOfficersMember_639090473147548561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639090473147548561" xlink:to="apre_ShareBasedPaymentArrangementExecutiveOfficersMember_639090473147548561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_639090473147554461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639090473147548561" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_639090473147554461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147554956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639090473147542240" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147554956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_639090473147554956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147554956" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_639090473147554956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639090473147554956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147554956" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639090473147554956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639090473147554956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639090473147554956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639090473147554956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639090473147554956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639090473147561026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639090473147561026" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639090473147561432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639090473147561432" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639090473147561432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639090473147561432" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639090473147561432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639090473147561432" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639090473147554956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639090473147561432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639090473147561432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639090473147567152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639090473147567152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_639090473147567152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_639090473147567152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_639090473147567152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_639090473147567152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639090473147567152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639090473147561432" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639090473147567152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision_639090473147572873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyAccrualProvision_639090473147572873" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_639090473147572873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_639090473147572873" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639090473147572873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="us-gaap_SubsequentEventTypeAxis_639090473147572873" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639090473147572873" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639090473147572873" xlink:to="us-gaap_SubsequentEventTypeDomain_639090473147572873" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639090473147572873" xlink:to="us-gaap_SubsequentEventMember_639090473147578597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="us-gaap_TypeOfArrangementAxis_639090473147578597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639090473147578597" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473147578597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639090473147578597" xlink:to="apre_SecuritiesPurchaseAgreementMember_639090473147578597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639090473147578597" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639090473147578597" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147578597" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026PrivatePlacementMember" xlink:label="apre_January2026PrivatePlacementMember_639090473147578597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639090473147578597" xlink:to="apre_January2026PrivatePlacementMember_639090473147578597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639090473147583819" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="srt_CounterpartyNameAxis_639090473147583819" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147585229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639090473147583819" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147585229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember_639090473147586406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639090473147585229" xlink:to="apre_CertainPurchasersMember_639090473147586406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639090473147587696" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639090473147587696" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639090473147587696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147587696" xlink:to="apre_PreFundedWarrantsMember_639090473147587696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_639090473147587696" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_639090473147587696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_639090473147587696" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_639090473147587696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_January2026WarrantsMember" xlink:label="apre_January2026WarrantsMember_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639090473147587696" xlink:to="apre_January2026WarrantsMember_639090473147587696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639090473147587696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="srt_StatementScenarioAxis_639090473147587696" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639090473147592971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639090473147587696" xlink:to="srt_ScenarioUnspecifiedDomain_639090473147592971" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember_639090473147593439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639090473147592971" xlink:to="apre_AtEventOfElectionOfHolderMember_639090473147593439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_639090473147593439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639090473147572873" xlink:to="us-gaap_SubsequentEventLineItems_639090473147593439" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639090473147593439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639090473147593439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639090473147593439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_SharesIssuedPricePerShare_639090473147593439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639090473147593439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639090473147593439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639090473147598696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639090473147598696" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod_639090473147599113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="apre_StockIssuanceAnniversaryPeriod_639090473147599113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_639090473147599113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_639090473147599113" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_639090473147599113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare_639090473147599113" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays_639090473147599113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="apre_NumberOfConsecutiveTradingDays_639090473147599113" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares_639090473147599113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="apre_PercentageOfOutstandingShares_639090473147599113" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639090473147604336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639090473147604336" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639090473147605393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639090473147605393" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639090473147605393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639090473147605393" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20251231.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_639090473147605393" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639090473147593439" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_639090473147605393" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 16, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aprea Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-2246769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3805 Old Easton Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Doylestown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">948-4119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APRE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,452,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed within 120 days of the registrant&#8217;s fiscal year ended December&#160;31,&#160;2025, are incorporated by reference in Part III of this Annual Report on Form 10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001781983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,599,347<span></span>
</td>
<td class="nump">$ 22,849,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">961,899<span></span>
</td>
<td class="nump">726,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">15,561,246<span></span>
</td>
<td class="nump">23,576,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">59,807<span></span>
</td>
<td class="nump">81,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">41,186<span></span>
</td>
<td class="nump">40,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">271,162<span></span>
</td>
<td class="nump">281,662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,933,401<span></span>
</td>
<td class="nump">23,979,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">713,668<span></span>
</td>
<td class="nump">1,352,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,050,690<span></span>
</td>
<td class="nump">2,008,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,764,358<span></span>
</td>
<td class="nump">3,360,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">8,192<span></span>
</td>
<td class="nump">5,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">356,709,645<span></span>
</td>
<td class="nump">350,971,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(10,634,714)<span></span>
</td>
<td class="num">(10,627,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(333,641,441)<span></span>
</td>
<td class="num">(321,041,872)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">12,441,682<span></span>
</td>
<td class="nump">19,307,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">15,933,401<span></span>
</td>
<td class="nump">23,979,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 and 56,227 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">$ 727,361<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,192,538<span></span>
</td>
<td class="nump">5,481,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,192,538<span></span>
</td>
<td class="nump">5,481,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">31,194<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">31,194<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">$ 285,759<span></span>
</td>
<td class="nump">$ 1,502,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">7,043,035<span></span>
</td>
<td class="nump">9,363,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,476,560<span></span>
</td>
<td class="nump">6,458,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,519,595<span></span>
</td>
<td class="nump">15,822,236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,233,836)<span></span>
</td>
<td class="num">(14,319,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">652,086<span></span>
</td>
<td class="nump">1,289,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">77,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (loss) gain</a></td>
<td class="num">(95,319)<span></span>
</td>
<td class="nump">71,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">634,267<span></span>
</td>
<td class="nump">1,360,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,599,569)<span></span>
</td>
<td class="num">(12,958,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(7,335)<span></span>
</td>
<td class="num">(16,106)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (12,606,904)<span></span>
</td>
<td class="num">$ (12,974,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (2.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (2.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">6,538,722<span></span>
</td>
<td class="nump">5,509,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">6,538,722<span></span>
</td>
<td class="nump">5,509,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in capital </div>
<div>ATM offering</div>
</th>
<th class="th"><div>Additional Paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>ATM offering</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,644,204<span></span>
</td>
<td class="num">$ (10,611,273)<span></span>
</td>
<td class="num">$ (308,083,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,953,506<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and pre-funded warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 1,688<span></span>
</td>
<td class="nump">$ 134,364<span></span>
</td>
<td class="nump">14,685,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,405<span></span>
</td>
<td class="nump">14,687,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and pre-funded warrants, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,152<span></span>
</td>
<td class="nump">1,687,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to consultants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,958,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,958,711)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,971,225<span></span>
</td>
<td class="num">(10,627,379)<span></span>
</td>
<td class="num">(321,041,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,307,455<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,481,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_TemporaryEquityConversionOfStockAmountConverted', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (583,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_TemporaryEquityConversionOfStockSharesConverted', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(25,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">31,194<span></span>
</td>
<td class="nump">31,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 727,361<span></span>
</td>
<td class="nump">$ 727,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and pre-funded warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 1,913,887<span></span>
</td>
<td class="nump">2,724,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,915,225<span></span>
</td>
<td class="nump">2,724,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and pre-funded warrants, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,948<span></span>
</td>
<td class="nump">26,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to consultants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,599,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,599,569)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,709,645<span></span>
</td>
<td class="num">$ (10,634,714)<span></span>
</td>
<td class="num">$ (333,641,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,441,682<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,192,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_TemporaryEquityConversionOfStockAmountConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock classified as temporary equity converted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_TemporaryEquityConversionOfStockAmountConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_TemporaryEquityConversionOfStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of temporary equity converted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_TemporaryEquityConversionOfStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (12,599,569)<span></span>
</td>
<td class="num">$ (12,958,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">21,715<span></span>
</td>
<td class="nump">22,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stockbased compensation</a></td>
<td class="nump">478,141<span></span>
</td>
<td class="nump">489,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NoncashConsultingFees', window );">Issuance of common stock to consultants</a></td>
<td class="nump">39,050<span></span>
</td>
<td class="nump">17,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency loss (gain)</a></td>
<td class="nump">95,319<span></span>
</td>
<td class="num">(71,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and noncurrent assets</a></td>
<td class="num">(217,906)<span></span>
</td>
<td class="num">(96,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(646,701)<span></span>
</td>
<td class="num">(314,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(64,488)<span></span>
</td>
<td class="num">(115,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(528,974)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,894,439)<span></span>
</td>
<td class="num">(13,556,718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,478)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,047,606<span></span>
</td>
<td class="nump">16,140,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="num">(407,459)<span></span>
</td>
<td class="num">(1,318,461)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,640,238<span></span>
</td>
<td class="nump">14,821,895<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(8,254,201)<span></span>
</td>
<td class="nump">1,249,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,679<span></span>
</td>
<td class="num">(7,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash-beginning of year</a></td>
<td class="nump">22,890,055<span></span>
</td>
<td class="nump">21,647,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash-end of period</a></td>
<td class="nump">14,640,533<span></span>
</td>
<td class="nump">22,890,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">14,599,347<span></span>
</td>
<td class="nump">22,849,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">41,186<span></span>
</td>
<td class="nump">40,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">14,640,533<span></span>
</td>
<td class="nump">$ 22,890,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Series A convertible preferred stock to common stock</a></td>
<td class="nump">$ 583,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_NoncashConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consulting fees included in net income that result in no cash flow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_NoncashConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business and basis of presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of business and basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business and basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nature of business</b>&#8212; Aprea Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-<span style="white-space:pre-wrap;">stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania.  The Company&#8217;s two clinical programs are a next-generation oral inhibitor of the WEE1 kinase, APR-1051, and our novel oral macrocyclic ATR inhibitor, ATRN-119. We have voluntarily paused further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and started the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation and management plans</b>&#8212;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S.&#160;GAAP&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management and technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company believes that the December&#160;31,&#160;2025 cash balance of approximately $14.6 million and the gross proceeds of approximately $5.6 million received from our private placement of our common stock and warrants in January 2026, before deducting placement agent fees and offering costs of approximately $0.4 million, will not be sufficient to meet our currently projected operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these consolidated financial statements. Therefore, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these audited consolidated financial statements. The Company is in the process of seeking additional equity financing. In the event that additional funds are not available, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principles of consolidation</b>&#8212;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>&#8212;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions include, but not limited to, stock-based compensation and accounting for research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign currency and currency translation</b>&#8212;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#8217; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk</b>&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents&#8212; </b>The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted cash&#8212; </b>The Company has restricted cash of approximately $41,186 and $40,170 as of December&#160;31,&#160;2025 and 2024, respectively, that is securing the Company&#8217;s credit card program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Property and equipment</b>&#8212;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 years</p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment and office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of long-lived assets</b>&#8212;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b>&#8212;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Series A Convertible Preferred Stock</b>&#8212;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#8217; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounting for leases</b>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b>&#8212; The Company&#8217;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expense. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i><i style="font-style:italic;">Not</i><i style="font-style:italic;">-</i>for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development costs</b>&#8212;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.<span style="background:#ffffff;"> Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b>&#8212;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC&#160;718.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company also awards restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes</b>&#8212;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes (&#8220;ASC 740-10&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b>&#8212;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Included within weighted average common shares outstanding for the year ended December&#160;31,&#160;2025 are&#160;1,813,734&#160;common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,112</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 715,620</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,075,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,194,788</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,712</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,968,232</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Segment Information</b>&#8212;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment at the consolidated level considering the nature of the Company&#8217;s product candidates and services, class of customers and the regulatory environment in which the Company operates. Accordingly, the Company&#8217;s CODM manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s long-term strategic goals. In making these decisions, the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, and allocating resources. The CODM performs this assessment based on the Company&#8217;s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual net loss versus the budget and then decides how to allocate resources to invest in the Company&#8217;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets. Other segment items included in consolidated net loss are interest income and foreign currency gain (loss), which are reflected in the consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recently issued accounting pronouncements</b>&#8212;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses,&#8221; which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In January 2025, the FASB issued ASU 2025-10, &#8220;Government Grants (Topic 832),&#8221; which establishes a new Topic 832, <i style="font-style:italic;">Government Grants</i>, and provides comprehensive recognition, measurement, and disclosure guidance for government assistance arrangements. The ASU requires entities to recognize government grants when the grant agreement is legally enforceable and all eligibility requirements have been met, and to present grant income separately from revenue. The guidance also introduces expanded qualitative and quantitative disclosures related to the nature, terms, and financial statement effects of government grants. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2025, the FASB issued ASU 2025-11, &#8220;Interim Reporting (Topic 270): Narrow-Scope Improvements,&#8221; which amends Topic 270 to enhance interim reporting requirements. The amendments require additional disaggregation of certain expense categories, expanded interim disclosures for significant events or transactions, and alignment of certain interim disclosure requirements with annual reporting requirements. ASU 2025-11 is effective for interim periods beginning after December 15, 2027, and for fiscal years beginning after the same date. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recently adopted accounting pronouncements</b>&#8212;In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#8221;, which requires disaggregated information about a reporting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted this standard prospectively on January 1, 2025, which expanded the Company&#8217;s disclosures beginning with its annual consolidated financial statements for the year ended December 31, 2025, but did not have an impact on the consolidated financial results.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Property and equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148,704</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,258</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, at cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,962</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72,440)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment&#8212;net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,522</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the years ended December&#160;31,&#160;2025 and 2024 was $21,715 and $22,318, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LeaseDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is party to one<span style="white-space:pre-wrap;"> operating lease for office and laboratory space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less.  Rent expense for years ended December&#160;31,&#160;2025 and 2024 was </span>$93,366 and $91,179, respectively, which is included in operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was amended in October 2025 and is currently set to expire on October 31, 2026. Rent expense under this lease is $115,000 annually and the Company has applied the short-term exception to this lease. The Company has no lease obligations beyond October 2026.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Accrued expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional&#160;fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,765</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation, severance&#160;and&#160;benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 770,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 465,015</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research&#160;and&#160;development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 870,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,243,975</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,980</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total&#160;accrued&#160;expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,050,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,008,735</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Income taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of net loss are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256,019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (218,261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,343,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,740,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,599,569)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,958,711)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effective tax rate varies from the federal statutory tax rate as a result of the following differences:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at U.S. statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,646,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax effects </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GAiVwh82eUmdKx4UoyCRCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,220)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,592,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nontaxable and nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in unrecognized tax benefits </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eE2fcbd4R0eebi4itMmEZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Effective tax rate</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As the Company did not recognize any state tax expense for the year ended December 31, 2025 there are no states making up greater than 50% of the tax effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 162(m) limitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred taxes as of December&#160;31,&#160;2025 and 2024 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,568,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,058,034</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,130,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,051,018</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,412</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,386,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,850,529</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 981</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165,558</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,349,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,165,532</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,349,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,165,532)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has no income tax expense due to operating losses incurred for the years ended December&#160;31,&#160;2025 and 2024. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December&#160;31,&#160;2025, the Company has $143.3 million, $85.4 million, and $91.8 million of foreign, federal and state net operating loss carryforwards, respectively, that expire at various dates through 2037. Certain of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section 382 or similar provisions, which impose limitations on their utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company amended its Federal income tax return for year ended December 31, 2023, to claim Research and Development credits of $42,220 and reducing NOL carryforward. Certain of these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section 382 or similar provisions, which impose limitations on their utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The valuation allowance increased in 2025 and 2024 by $6.2 million and $0.7 million, respectively, due to an increase in the deferred tax assets by the same amounts, primarily due to the increase in net operating loss generation. Realization of the future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company&#8217;s formation due to the complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future. For Swedish income tax purposes, the Company&#8217;s net operating losses may be subject to limitations in accordance with the country&#8217;s group contribution restriction laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2022 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2019 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company&#8217;s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company&#8217;s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company&#8217;s effective income tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025 and 2024, the Company had approximately $0.1 million of liabilities, respectively, related to uncertain tax positions. As the Company&#8217;s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has not made payments or received refunds for income taxes for the years ended December&#160;31,&#160;2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; (OBBBA) was enacted into law. The legislation made several changes to the U.S. tax code, including the return of 100% bonus depreciation, the ability to immediately deduct domestic research and development costs, a more favorable rule for deducting interest expenses, and updates to international tax rules around global intangible low-taxed income and foreign-derived intangible income. The Company has evaluated the impact of the new tax provision and determined it to have an immaterial impact on the consolidated financial results. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_CommonStockTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Stockholders&#8217; equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of all classes of capital stock that the Company is authorized to issue is 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share and 40,000,000 shares of preferred stock, par value $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Series A Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December&#160;31,&#160;2025, a total of 31,194 shares of Series A Preferred Stock remained outstanding, which are convertible into 15,596 shares of common stock. In April 2025, a total of 25,033 shares of Series A Preferred stock were converted into 12,516 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Shelf Registration Statement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 26, 2024, the Company filed a shelf registration statement (the &#8220;2024 Shelf Registration Statement&#8221;) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $150.0 million, including a prospectus for the sale of $1.0<span style="white-space:pre-wrap;"> million of shares of common stock under the ATM Agreement, as discussed below, which was declared effective on February 2, 2024.  The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to </span>$2.0<span style="white-space:pre-wrap;"> million of shares of common stock pursuant to the ATM Agreement.  On January 26, 2024, the Company entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainright &amp; Co., LLC (&#8220;HCW&#8221;).  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to </span>$2.0<span style="white-space:pre-wrap;"> million of shares of common stock.  The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On November 8, 2024, the Company filed a prospectus supplement to the 2024 Shelf Registration Statement with the SEC for the sale of up to $3.0<span style="white-space:pre-wrap;"> million pursuant to the 2024 ATM Agreement, as discussed below. On November 8, 2024, the Company entered into an At the Market Offering Agreement (the &#8220;2024 ATM Agreement&#8221;) with HCW.  Pursuant to the 2024 ATM Agreement and the prospectus supplement filed in connection therewith, the Company may, from time to time, in its sole discretion, issue and sell through HCW, acting as sales agent and/or principal, up to </span>$3.0<span style="white-space:pre-wrap;"> million of shares of common stock.  During the year ended December&#160;31,&#160;2024, the Company issued and sold </span>41,152 shares of common stock under the 2024 ATM Agreement resulting in net proceeds to the Company of approximately $0.1 million after deducting approximately $6,000 in issuance costs. During the year ended December&#160;31,&#160;2025, the Company issued and sold 1,337,948 shares of common stock under the 2024 ATM Agreement resulting in net proceeds to the Company of approximately $1.9 million after deducting approximately $76,000 in issuance costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">March 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;March Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the March Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the March Purchasers agreed to purchase from the Company (i)&#160;1,687,712&#160;shares of the Company&#8217;s common stock at a purchase price of $7.29&#160;per share (the &#8220;March 2024 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $7.289&#160;to purchase an aggregate of up to&#160;507,076&#160;shares of the Company&#8217;s common stock at an exercise price of $0.001&#160;per share (the &#8220;March 2024 Pre-Funded Shares&#8221;), (iii) tranche A common stock purchase warrants to purchase up to&#160;1,097,394&#160;shares of the Company&#8217;s common stock at an exercise price of $7.29&#160;per share (the &#8220;Tranche A Warrants&#8221;), and (iv) tranche B common stock purchase warrants to purchase up to&#160;1,097,394&#160;shares of the Company&#8217;s common stock at an exercise price of $9.1125 per share (the &#8220;Tranche B Warrants&#8221;). The Tranche A Warrants will be exercisable until the earlier of (i) the&#160;three-year anniversary of issuance and (ii)&#160;30 days&#160;after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $14.58&#160;for&#160;30&#160;consecutive trading days. The Tranche B Warrants will be </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">exercisable until the earlier of (i) the five-year&#160;anniversary of issuance and (ii)&#160;30 days&#160;after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $18.225&#160;for&#160;30&#160;consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $16.0&#160;million, before deducting placement agent fees and offering costs of approximately $1.3 million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $18.0 million, before deducting placement agent fees. In April 2024, the Company registered on Form S-3 the resale of the March 2024 Shares, the March 2024 Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">December 2025 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On December 8, 2025, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i)&#160;26,459&#160;shares of the Company&#8217;s common stock at a purchase price of $1.165&#160;per share (the &#8220;December 2025 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $1.164&#160;to purchase an aggregate of up to&#160;2,596,564&#160;shares of the Company&#8217;s common stock at an exercise price of $0.001&#160;per share (the &#8220;December 2025 Pre-Funded Shares&#8221;), (iii) common stock purchase warrants to purchase up to&#160;2,880,533&#160;shares of the Company&#8217;s common stock at an exercise price of $1.04&#160;per share, including this issuance of a warrant to purchase up to 257,510 shares of the Company&#8217;s common stock to the placement agent (the &#8220;December 2025 Warrants&#8221;). The December 2025 Warrants will be exercisable until the&#160;five-year anniversary of issuance. To the extent that the exercise of a December 2025 Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $3.1&#160;million, before deducting placement agent fees and offering costs of approximately $0.4 million. In December 2025, the Company registered on Form S-3 the resale of the December 2025 Shares, the December 2025 Pre-Funded Shares and the shares underlying the December 2025 Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company evaluated the terms of the warrants issued in the March 2024 and December 2025 Private Placements and determined that they should be classified as equity instruments within additional paid-in capital. As of December&#160;31,&#160;2025 and 2024,&#160;none&#160;of the Tranche A Warrants or Tranche B Warrants have been exercised. During 2025, 91,206 warrants to purchase March 2024 Pre-Funded Shares were exercised for proceeds of $91 and 1,198,700 warrants to purchase December 2025 Pre-Funded Shares were exercised for no proceeds. No warrants to purchase March 2024 Pre-Funded Shares were exercised during 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A summary of warrants outstanding as of December&#160;31,&#160;2025 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 Tranche A Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,097,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/11/2027</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 Tranche B Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,097,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.1125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/11/2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2025 pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,397,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2025 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,880,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/10/2030</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,889,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company&#8217;s Board of Directors approved the 2019 Equity Incentive Plan (the &#8220;2019 Plan) and each outstanding option to purchase Aprea AB ordinary shares pursuant to a previous plan was cancelled and the Company issued to each holder of such Aprea AB option, a substitute option to purchase, on the same terms and conditions as were applicable to such Aprea AB option, shares of the Company&#8217;s common stock pursuant to the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors has the discretion to provide for accelerated vesting under the 2019 Plan. At December&#160;31,&#160;2025, there were 180,880 shares available for future grant under the 2019 Plan. Effective January 1, 2026, the number of shares available for future grant under the 2019 Plan was increased by 327,701 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense of $0.5 million and $0.5 million during the years ended December&#160;31,&#160;2025 and 2024, respectively. As of December&#160;31,&#160;2025, there was $0.5 million of unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the 2019 Plan, which is expected to be recognized over a weighted-average period of approximately 2.1 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option award is estimated on the date of grant using Black-Scholes, with the assumptions noted in the table below. Expected volatility for the Company&#8217;s common stock was determined based on an average of the historical volatility of a peer group of similar public companies. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employee. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the implied yield on a U.S. Treasury security in effect at the time of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in Black-Scholes are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.0%-83.6%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.8%-92.3%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.99%-4.38%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.18%-4.64%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-10.0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of option activity under the Plan during the years ended December&#160;31,&#160;2025 and 2024 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term&#160;(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,186)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 715,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,539)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 624,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted during the years ended December&#160;31,&#160;2025 and 2024, was $1.57 and $4.53, per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock</i> <i style="font-style:italic;">Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2025, the Company granted the following RSU&#8217;s:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,090</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to executive officers of the Company which vest ratably on the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">st</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">nd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">rd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversaries of the grant date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,360</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to non-employee directors of the Company which vest on the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary of the grant date.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2024, the Company granted the following RSU&#8217;s:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16,820</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to executive officers of the Company which vest ratably on the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">st</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">nd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">rd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversaries of the grant date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6,270</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs to non-employee directors of the Company which vest on the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary of the grant date. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2025, there was $0.1 million of unrecognized compensation cost related to RSUs granted under the 2019 Plan, which is expected to be recognized over a weighted-average period of approximately 1.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table shows restricted stock unit activity during the year ended December&#160;31,&#160;2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.56</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.42</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,730)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.25</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.83</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.02</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.94</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">9. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time to time, the Company may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the years ended December&#160;31,&#160;<span style="white-space:pre-wrap;">2025 and 2024, and, to its knowledge, no material legal proceedings are currently pending or threatened. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.  As of December&#160;31,&#160;2025, the Company has </span>not recorded a provision for any contingent losses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">10. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 28, 2026, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;January Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the January Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the January Purchasers agreed to purchase from the Company (i)&#160;1,877,677&#160;shares of the Company&#8217;s common stock at a purchase price of $0.8891&#160;per share (the &#8220;January 2026 Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $0.8890&#160;to purchase an aggregate of up to&#160;4,411,180&#160;shares of the Company&#8217;s common stock at an exercise price of $0.001&#160;per share (the &#8220;January 2026 Pre-Funded Shares&#8221;), (iii) common stock purchase warrants to purchase up to&#160;6,288,857&#160;shares of the Company&#8217;s common stock at an exercise price of $0.765&#160;per share (the &#8220;January 2026 Warrants&#8221;). The January 2026 Warrants will be exercisable until the&#160;two-year anniversary of issuance. To the extent that the exercise of a January 2026 Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $5.6&#160;million, before deducting placement agent fees and offering costs of approximately $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (12,599,569)<span></span>
</td>
<td class="num">$ (12,958,711)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We are a clinical-stage biopharmaceutical company and we are solely focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response pathways. Therefore, we do not consider that we face significant cybersecurity risk and have not adopted a formal cybersecurity risk management program or process for assessing cybersecurity risk currently. We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized access to or occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. To this end, we utilize an outsourced information technology consultant, who we believe has sufficient experience and expertise with regard to cybersecurity matters, to implement systems and procedures designed to reduce, respond to and monitor for cybersecurity threats and vulnerabilities. Our outsourced information technology consultant conducts proactive patching and monitoring of all of our existing systems and has implemented systems and procedures to mitigate cybersecurity risks that we believe are appropriate for a company of our size, stage of growth and financial condition. In addition, we carry insurance with coverage for cyber events that we believe is suitable for a company of our size, stage of growth and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of the date of this Annual Report on Form 10-K, we are not aware of any cybersecurity threats, <span style="white-space:pre-wrap;">including as a result of any previous cybersecurity incidents, that have materially affected us, including our business strategy, results of operations or financial condition. However, as discussed under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition.  For additional information concerning risks related to cybersecurity, </span><i style="font-style:italic;">see</i> Item 1.A.&#160;<i style="font-style:italic;">Risk Factors: &#8220;Our business and operations would suffer in the event of IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in our or our third-party vendors&#8217; information security program or defenses.</i>&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized access to or occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. To this end, we utilize an outsourced information technology consultant, who we believe has sufficient experience and expertise with regard to cybersecurity matters, to implement systems and procedures designed to reduce, respond to and monitor for cybersecurity threats and vulnerabilities. Our outsourced information technology consultant conducts proactive patching and monitoring of all of our existing systems and has implemented systems and procedures to mitigate cybersecurity risks that we believe are appropriate for a company of our size, stage of growth and financial condition. In addition, we carry insurance with coverage for cyber events that we believe is suitable for a company of our size, stage of growth and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">while our Board of Directors as a whole has responsibility for the oversight of risk management, including as to material risks from cybersecurity threats.In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed.  The Board of Directors has delegated to the Audit Committee of the Board of Directors the responsibility for the oversight of information technology (including cybersecurity) risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Audit Committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed.The Board of Directors has delegated to the Audit Committee of the Board of Directors the responsibility for the oversight of information technology (including cybersecurity) risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Management is responsible for the day-to-day management of the risks we face, while our Board of Directors as a whole has responsibility for the oversight of risk management, including as to material risks from cybersecurity threats.In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, integrity, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principles of consolidation</b>&#8212;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>&#8212;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions include, but not limited to, stock-based compensation and accounting for research and development costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency and currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign currency and currency translation</b>&#8212;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#8217; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk</b>&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents&#8212; </b>The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted cash&#8212; </b>The Company has restricted cash of approximately $41,186 and $40,170 as of December&#160;31,&#160;2025 and 2024, respectively, that is securing the Company&#8217;s credit card program.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Property and equipment</b>&#8212;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 years</p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment and office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of long-lived assets</b>&#8212;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b>&#8212;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_TemporaryEquityPolicyTextBlock', window );">Series A Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Series A Convertible Preferred Stock</b>&#8212;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#8217; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Accounting for leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounting for leases</b>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b>&#8212; The Company&#8217;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expense. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i><i style="font-style:italic;">Not</i><i style="font-style:italic;">-</i>for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development costs</b>&#8212;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.<span style="background:#ffffff;"> Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b>&#8212;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC&#160;718.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company also awards restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes</b>&#8212;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes (&#8220;ASC 740-10&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b>&#8212;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Included within weighted average common shares outstanding for the year ended December&#160;31,&#160;2025 are&#160;1,813,734&#160;common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,112</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 715,620</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,075,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,194,788</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,712</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,968,232</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Segment Information</b>&#8212;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, manages the Company&#8217;s business activities as a single operating and reportable segment at the consolidated level considering the nature of the Company&#8217;s product candidates and services, class of customers and the regulatory environment in which the Company operates. Accordingly, the Company&#8217;s CODM manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#8217;s long-term strategic goals. In making these decisions, the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, and allocating resources. The CODM performs this assessment based on the Company&#8217;s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual net loss versus the budget and then decides how to allocate resources to invest in the Company&#8217;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets. Other segment items included in consolidated net loss are interest income and foreign currency gain (loss), which are reflected in the consolidated statements of operations and comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued and adopted accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recently issued accounting pronouncements</b>&#8212;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses,&#8221; which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In January 2025, the FASB issued ASU 2025-10, &#8220;Government Grants (Topic 832),&#8221; which establishes a new Topic 832, <i style="font-style:italic;">Government Grants</i>, and provides comprehensive recognition, measurement, and disclosure guidance for government assistance arrangements. The ASU requires entities to recognize government grants when the grant agreement is legally enforceable and all eligibility requirements have been met, and to present grant income separately from revenue. The guidance also introduces expanded qualitative and quantitative disclosures related to the nature, terms, and financial statement effects of government grants. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2025, the FASB issued ASU 2025-11, &#8220;Interim Reporting (Topic 270): Narrow-Scope Improvements,&#8221; which amends Topic 270 to enhance interim reporting requirements. The amendments require additional disaggregation of certain expense categories, expanded interim disclosures for significant events or transactions, and alignment of certain interim disclosure requirements with annual reporting requirements. ASU 2025-11 is effective for interim periods beginning after December 15, 2027, and for fiscal years beginning after the same date. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recently adopted accounting pronouncements</b>&#8212;In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#8221;, which requires disaggregated information about a reporting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted this standard prospectively on January 1, 2025, which expanded the Company&#8217;s disclosures beginning with its annual consolidated financial statements for the year ended December 31, 2025, but did not have an impact on the consolidated financial results.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Summary of useful lives of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 years</p></td></tr><tr style=""><td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment and office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7 years</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,112</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 715,620</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,075,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,194,788</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,712</p></td></tr><tr style=""><td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,968,232</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148,704</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,258</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, at cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,962</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72,440)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment&#8212;net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,522</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional&#160;fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,765</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation, severance&#160;and&#160;benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 770,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 465,015</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research&#160;and&#160;development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 870,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,243,975</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,980</p></td></tr><tr style=""><td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total&#160;accrued&#160;expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,050,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,008,735</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of net loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256,019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (218,261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,343,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,740,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,599,569)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,958,711)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of the effect of applying federal statutory rate to the net loss and the effective income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at U.S. statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,646,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax effects </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GAiVwh82eUmdKx4UoyCRCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,220)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,592,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nontaxable and nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in unrecognized tax benefits </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eE2fcbd4R0eebi4itMmEZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Effective tax rate</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 162(m) limitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of significant components of deferred taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,568,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,058,034</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,130,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,051,018</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,412</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,386,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,850,529</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 981</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165,558</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,349,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,165,532</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,349,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,165,532)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 Tranche A Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,097,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/11/2027</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 Tranche B Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,097,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.1125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/11/2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 2024 pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2025 pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,397,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2025 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,880,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/10/2030</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,889,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in valuation of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.0%-83.6%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.8%-92.3%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.99%-4.38%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.18%-4.64%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-10.0</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term&#160;(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,186)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 715,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,539)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 624,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 811,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of restricted stock units activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.56</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.42</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,730)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.25</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.83</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.02</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.94</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business and basis of presentation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,599,347<span></span>
</td>
<td class="nump">$ 22,849,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407,459<span></span>
</td>
<td class="nump">$ 1,318,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_January2026PrivatePlacementMember', window );">January 2026 Private Placement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of gross proceeds</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_January2026PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_January2026PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Restricted cash and Property and equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract', window );"><strong>Restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 41,186<span></span>
</td>
<td class="nump">$ 40,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apre_OfficeFurnitureAndLaboratoryEquipmentMember', window );">Laboratory equipment and office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apre_OfficeFurnitureAndLaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apre_OfficeFurnitureAndLaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Potentially dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">5,933,046<span></span>
</td>
<td class="nump">2,968,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">1,813,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">28,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">811,121<span></span>
</td>
<td class="nump">715,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">5,075,321<span></span>
</td>
<td class="nump">2,194,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">31,008<span></span>
</td>
<td class="nump">29,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 153,962<span></span>
</td>
<td class="nump">$ 153,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(94,155)<span></span>
</td>
<td class="num">(72,440)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment-net</a></td>
<td class="nump">59,807<span></span>
</td>
<td class="nump">81,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">21,715<span></span>
</td>
<td class="nump">22,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apre_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">148,704<span></span>
</td>
<td class="nump">148,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 5,258<span></span>
</td>
<td class="nump">$ 5,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apre_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apre_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LesseeOperatingLeaseNumberOfOperatingLeases', window );">Number of operating leases | lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LesseeOperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 93,366<span></span>
</td>
<td class="nump">$ 91,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LesseeOperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of base rent due annually.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LesseeOperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LesseeOperatingLeaseNumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of operating leases held by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LesseeOperatingLeaseNumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 248,591<span></span>
</td>
<td class="nump">$ 143,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation, severance and benefits</a></td>
<td class="nump">770,562<span></span>
</td>
<td class="nump">465,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent', window );">Research and development</a></td>
<td class="nump">870,165<span></span>
</td>
<td class="nump">1,243,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">161,372<span></span>
</td>
<td class="nump">155,980<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,050,690<span></span>
</td>
<td class="nump">$ 2,008,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Components of Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_IncomeTaxesLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,599,569)<span></span>
</td>
<td class="num">$ (12,958,711)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_IncomeTaxesLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(256,019)<span></span>
</td>
<td class="num">(218,261)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_IncomeTaxesLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,343,550)<span></span>
</td>
<td class="num">$ (12,740,450)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Income Taxes Rate Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation, amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at U.S. statutory rate</a></td>
<td class="num">$ (2,646,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Others, Foreign tax effects</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits, Tax credits</a></td>
<td class="num">(42,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">2,592,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nontaxable and nondeductible items</a></td>
<td class="nump">20,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Other adjustments, Changes in unrecognized tax benefits</a></td>
<td class="nump">73,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation, percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Others, Foreign tax effects</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits, Tax credits</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(20.60%)<span></span>
</td>
<td class="num">(19.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nontaxable and nondeductible items</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther', window );">Other adjustments, Changes in unrecognized tax benefits</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration', window );">Tax Jurisdiction of Domicile [Extensible Enumeration]</a></td>
<td class="text">UNITED STATES<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates tax jurisdiction of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Components of Deferred Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 48,568,167<span></span>
</td>
<td class="nump">$ 41,058,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">4,130,337<span></span>
</td>
<td class="nump">4,051,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">21,883<span></span>
</td>
<td class="nump">39,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research and development costs</a></td>
<td class="nump">3,386,699<span></span>
</td>
<td class="nump">4,850,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_DeferredTaxAssetResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">42,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="nump">199,095<span></span>
</td>
<td class="nump">165,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">56,349,279<span></span>
</td>
<td class="nump">50,165,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (56,349,279)<span></span>
</td>
<td class="num">$ (50,165,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_DeferredTaxAssetResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_DeferredTaxAssetResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_DeferredTaxAssetResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">42,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Uncertain tax positions</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">143,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">85,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 91,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_DeferredTaxAssetResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_DeferredTaxAssetResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 08, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockSharesAuthorized', window );">Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_CommonStockNumberOfVotingRightsPerShare', window );">Number of voting rights per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,047,606<span></span>
</td>
<td class="nump">$ 16,140,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,459<span></span>
</td>
<td class="nump">$ 1,318,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=apre_December2025WarrantsMember', window );">December 2025 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_TemporaryEquityConversionOfStockSharesConverted', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,194<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_TemporaryEquityRemainingSharesToBeConverted', window );">Number of shares remained to be converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Class of warrant or right, number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | March 2024 Tranche A Warrants And Tranche B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Class of warrant or right, number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of common stock in a private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise', window );">Expected gross proceeds from potential future warrants cash exercise | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | At the election of holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,097,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuanceAnniversaryPeriod', window );">Stock issuance anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119', window );">Number of days after announcement of Phase 2 dose for ATRN-119</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_SharesIssuedVolumeWeightedAveragePricePerShare', window );">Volume weighted average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,097,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.1125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuanceAnniversaryPeriod', window );">Stock issuance anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119', window );">Number of days after announcement of Phase 2 dose for ATRN-119</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_SharesIssuedVolumeWeightedAveragePricePerShare', window );">Volume weighted average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember', window );">December 2025 Private Placement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Class of warrant or right, number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember', window );">December 2025 Private Placement | Purchasers | Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">26,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs | $</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 1.165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuanceAnniversaryPeriod', window );">Stock issuance anniversary period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of common stock in a private placement | $</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember', window );">December 2025 Private Placement | Purchasers | Securities purchase agreement | At the election of holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember', window );">December 2025 Private Placement | Purchasers | Securities purchase agreement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 1.164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">2,596,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember', window );">December 2025 Private Placement | Purchasers | Securities purchase agreement | December 2025 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">2,880,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember', window );">December 2025 Private Placement | Placement Agent | Securities purchase agreement | December 2025 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">257,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member', window );">2024 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_UniversalShelfRegistrationMaximumAmountToBeIssued', window );">Maximum amount to be issued under universal shelf registration statement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued', window );">Maximum amount to be issued under at-the-market offering program | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement', window );">Maximum amount to be issued under at-the-market offering program, supplement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member', window );">2024 Shelf Registration Statement | HCW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued', window );">Maximum amount to be issued under at-the-market offering program | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember', window );">2024 ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,948<span></span>
</td>
<td class="nump">41,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember', window );">2024 ATM offering | HCW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued', window );">Maximum amount to be issued under at-the-market offering program | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock to be issued under an at-the-market offering program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AtMarketOfferingProgramMaximumAmountToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock to be issued under a supplemental at-the-market offering program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_CommonStockNumberOfVotingRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of voting rights per share of common stock owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_CommonStockNumberOfVotingRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected gross proceeds from potential future warrant cash exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days after the Company announces the recommended Phase 2 dose for ATRN-119.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_PrivatePlacementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_PrivatePlacementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_SharesIssuedVolumeWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price per share of common stock after announcement of recommended Phase 2 dose for ATRN-119.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_SharesIssuedVolumeWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ShelfRegistrationStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ShelfRegistrationStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockIssuanceAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of anniversary of issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockIssuanceAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_TemporaryEquityConversionOfStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of temporary equity converted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_TemporaryEquityConversionOfStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_TemporaryEquityRemainingSharesToBeConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares remained to be converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_TemporaryEquityRemainingSharesToBeConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_UniversalShelfRegistrationMaximumAmountToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock, preferred stock, warrants, rights and debt securities and units that can be issued under a universal shelf registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_UniversalShelfRegistrationMaximumAmountToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_December2025WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_December2025WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_March2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=apre_CertainPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=apre_CertainPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=apre_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=apre_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=apre_AtEventOfElectionOfHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=apre_AtEventOfElectionOfHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice7.29PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice7.29PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice9.1125PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice9.1125PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_December2025PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=apre_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=apre_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=apre_HCWainrightCoLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=apre_HCWainrightCoLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Warrants Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">6,889,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheaWarrantsMember', window );">March 2024 Tranche A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">1,097,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 7.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheBWarrantsMember', window );">March 2024 Tranche B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">1,097,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 9.1125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024PreFundedWarrantsMember', window );">March 2024 pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">415,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=apre_December2025PreFundedWarrantsMember', window );">December 2025 pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">1,397,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=apre_December2025WarrantsMember', window );">December 2025 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">2,880,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheaWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheaWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_March2024TrancheBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_March2024PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_March2024PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_December2025PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_December2025PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_December2025WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_December2025WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Summary (Details) - 2019 Equity Incentive Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">180,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, increase in number of shares available for grant</a></td>
<td class="nump">327,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for unrecognized compensation cost</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in number of shares available for future grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Valuation assumptions (Details) - 2019 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">83.60%<span></span>
</td>
<td class="nump">92.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate, minimum</a></td>
<td class="nump">3.99%<span></span>
</td>
<td class="nump">4.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate, maximum</a></td>
<td class="nump">4.38%<span></span>
</td>
<td class="nump">4.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Stock option activity (Details) - 2019 Equity Incentive Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period</a></td>
<td class="nump">715,620<span></span>
</td>
<td class="nump">596,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">116,040<span></span>
</td>
<td class="nump">147,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled/Forfeited</a></td>
<td class="num">(20,539)<span></span>
</td>
<td class="num">(28,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period</a></td>
<td class="nump">811,121<span></span>
</td>
<td class="nump">715,620<span></span>
</td>
<td class="nump">596,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">624,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest</a></td>
<td class="nump">811,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 61.79<span></span>
</td>
<td class="nump">$ 72.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.09<span></span>
</td>
<td class="nump">5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/Forfeited (in dollars per share)</a></td>
<td class="nump">7.24<span></span>
</td>
<td class="nump">5.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">54.63<span></span>
</td>
<td class="nump">$ 61.79<span></span>
</td>
<td class="nump">$ 72.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">69.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest (in dollars per share)</a></td>
<td class="nump">$ 54.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apre_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Restricted stock units (Details) - Restricted stock unit - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to RSU</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for unrecognized compensation cost</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">29,712<span></span>
</td>
<td class="nump">23,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">18,450<span></span>
</td>
<td class="nump">23,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(17,154)<span></span>
</td>
<td class="num">(10,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled/Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">31,008<span></span>
</td>
<td class="nump">29,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, Weighted average grant date fair value</a></td>
<td class="nump">$ 7.83<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value</a></td>
<td class="nump">2.02<span></span>
</td>
<td class="nump">5.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value</a></td>
<td class="nump">7.94<span></span>
</td>
<td class="nump">9.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled/Forfeited, Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, Weighted average grant date fair value</a></td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="nump">$ 7.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">10,090<span></span>
</td>
<td class="nump">16,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Non employee directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">8,360<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Vesting On One Year Anniversary Of Grant Date | Executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Vesting On One Year Anniversary Of Grant Date | Non employee directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Vesting On Two Year Anniversary Of Grant Date | Executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Vesting On Three Year Anniversary Of Grant Date | Executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock units, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=apre_ShareBasedPaymentArrangementExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=apre_ShareBasedPaymentArrangementExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=apre_VestingOnOneYearAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=apre_VestingOnOneYearAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=apre_VestingOnTwoYearAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=apre_VestingOnTwoYearAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=apre_VestingOnThreeYearAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=apre_VestingOnThreeYearAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Provision for contingent losses</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407,459<span></span>
</td>
<td class="nump">$ 1,318,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | January 2026 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of gross proceeds</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities purchase agreement | January 2026 Private Placement | Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,877,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 0.8891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of gross proceeds</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities purchase agreement | January 2026 Private Placement | Purchasers | At the election of holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities purchase agreement | January 2026 Private Placement | Purchasers | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 0.889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">4,411,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities purchase agreement | January 2026 Private Placement | Purchasers | January 2026 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">6,288,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price</a></td>
<td class="nump">$ 0.765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuanceAnniversaryPeriod', window );">Stock Issuance Anniversary Period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockIssuanceAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of anniversary of issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockIssuanceAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_January2026PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_January2026PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=apre_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=apre_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=apre_CertainPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=apre_CertainPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=apre_AtEventOfElectionOfHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=apre_AtEventOfElectionOfHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_January2026WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_January2026WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>130</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of business and basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of business and basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureEquityIncentivePlan</Role>
      <ShortName>Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Property and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureEquityIncentivePlanTables</Role>
      <ShortName>Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureEquityIncentivePlan</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of business and basis of presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>Nature of business and basis of presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of significant accounting policies - Restricted cash and Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of significant accounting policies - Restricted cash and Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of significant accounting policies - Potentially dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Leases - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureLeasesSummaryDetails</Role>
      <ShortName>Leases - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Income taxes - Components of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Components of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - Income taxes - Income Taxes Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails</Role>
      <ShortName>Income taxes - Income Taxes Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - Income taxes - Components of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails</Role>
      <ShortName>Income taxes - Components of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940604 - Disclosure - Income taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Stockholders' equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - Stockholders' equity - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' equity - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Equity Incentive Plan - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails</Role>
      <ShortName>Equity Incentive Plan - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Equity Incentive Plan - Valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails</Role>
      <ShortName>Equity Incentive Plan - Valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Equity Incentive Plan - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plan - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Equity Incentive Plan - Restricted stock units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plan - Restricted stock units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="apre-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>apre-20251231.xsd</File>
    <File>apre-20251231_cal.xml</File>
    <File>apre-20251231_def.xml</File>
    <File>apre-20251231_lab.xml</File>
    <File>apre-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="apre-20251231x10k.htm">apre-20251231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apre-20251231x10k001.jpg</File>
    <File>apre-20251231x10k002.jpg</File>
    <File>apre-20251231x10k003.jpg</File>
    <File>apre-20251231x10k004.jpg</File>
    <File>apre-20251231x10k005.jpg</File>
    <File>apre-20251231x10k006.jpg</File>
    <File>apre-20251231x10k007.jpg</File>
    <File>apre-20251231x10k008.jpg</File>
    <File>apre-20251231x10k009.jpg</File>
    <File>apre-20251231x10k010.jpg</File>
    <File>apre-20251231x10k011.jpg</File>
    <File>apre-20251231x10k012.jpg</File>
    <File>apre-20251231x10k013.jpg</File>
    <File>apre-20251231x10k014.jpg</File>
    <File>apre-20251231x10k015.jpg</File>
    <File>apre-20251231x10k016.jpg</File>
    <File>apre-20251231x10k017.jpg</File>
    <File>apre-20251231x10k018.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="446">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "apre-20251231x10k.htm": {
   "nsprefix": "apre",
   "nsuri": "http://aprea.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "apre-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "apre-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apre-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "apre-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apre-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "apre-20251231x10k.htm"
     ]
    }
   },
   "keyStandard": 239,
   "keyCustom": 29,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 20,
   "memberCustom": 29,
   "hidden": {
    "total": 23,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 12,
    "http://aprea.com/20251231": 2,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "contextCount": 130,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 530,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 446,
    "http://xbrl.sec.gov/dei/2025": 38,
    "http://xbrl.sec.gov/cyd/2025": 14,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://aprea.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aprea.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
     "longName": "995200300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "longName": "995210101 - Disclosure - Nature of business and basis of presentation",
     "shortName": "Nature of business and basis of presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aprea.com/role/DisclosurePropertyAndEquipment",
     "longName": "995210301 - Disclosure - Property and equipment",
     "shortName": "Property and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aprea.com/role/DisclosureLeases",
     "longName": "995210401 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "apre:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "apre:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aprea.com/role/DisclosureAccruedExpenses",
     "longName": "995210501 - Disclosure - Accrued expenses",
     "shortName": "Accrued expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxes",
     "longName": "995210601 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aprea.com/role/DisclosureStockholdersEquity",
     "longName": "995210701 - Disclosure - Stockholders' equity",
     "shortName": "Stockholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "apre:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "apre:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aprea.com/role/DisclosureEquityIncentivePlan",
     "longName": "995210801 - Disclosure - Equity Incentive Plan",
     "shortName": "Equity Incentive Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aprea.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995210901 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aprea.com/role/DisclosureSubsequentEvents",
     "longName": "995211001 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "99930203 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "apre:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "apre:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aprea.com/role/DisclosurePropertyAndEquipmentTables",
     "longName": "99930303 - Disclosure - Property and equipment (Tables)",
     "shortName": "Property and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aprea.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930503 - Disclosure - Accrued expenses (Tables)",
     "shortName": "Accrued expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxesTables",
     "longName": "99930603 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aprea.com/role/DisclosureStockholdersEquityTables",
     "longName": "99930703 - Disclosure - Stockholders' equity (Tables)",
     "shortName": "Stockholders' equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aprea.com/role/DisclosureEquityIncentivePlanTables",
     "longName": "99930803 - Disclosure - Equity Incentive Plan (Tables)",
     "shortName": "Equity Incentive Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
     "longName": "99940101 - Disclosure - Nature of business and basis of presentation (Details)",
     "shortName": "Nature of business and basis of presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails",
     "longName": "99940201 - Disclosure - Summary of significant accounting policies - Restricted cash and Property and equipment (Details)",
     "shortName": "Summary of significant accounting policies - Restricted cash and Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_CGXEBDoB80uMJgtwrAZVgw",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "apre:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
     "longName": "99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)",
     "shortName": "Summary of significant accounting policies - Potentially dilutive securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
     "longName": "99940301 - Disclosure - Property and equipment (Details)",
     "shortName": "Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aprea.com/role/DisclosureLeasesSummaryDetails",
     "longName": "99940401 - Disclosure - Leases - Summary (Details)",
     "shortName": "Leases - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "apre:LesseeOperatingLeaseNumberOfOperatingLeases",
      "unitRef": "Unit_Standard_lease_QaFYmEckJU-MqyGJp97u6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "apre:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "apre:LesseeOperatingLeaseNumberOfOperatingLeases",
      "unitRef": "Unit_Standard_lease_QaFYmEckJU-MqyGJp97u6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "apre:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aprea.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940501 - Disclosure - Accrued expenses (Details)",
     "shortName": "Accrued expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
     "longName": "99940601 - Disclosure - Income taxes - Components of Income Taxes (Details)",
     "shortName": "Income taxes - Components of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_x2waWdI6y06iIcRFhALG5Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails",
     "longName": "99940602 - Disclosure - Income taxes - Income Taxes Rate Reconciliation (Details)",
     "shortName": "Income taxes - Income Taxes Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails",
     "longName": "99940603 - Disclosure - Income taxes - Components of Deferred Taxes (Details)",
     "shortName": "Income taxes - Components of Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "99940604 - Disclosure - Income taxes - Narrative (Details)",
     "shortName": "Income taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://aprea.com/role/DisclosureStockholdersEquityDetails",
     "longName": "99940701 - Disclosure - Stockholders' equity (Details)",
     "shortName": "Stockholders' equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "apre:StockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "apre:StockSharesAuthorized",
       "p",
       "apre:CommonStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "apre:StockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "apre:StockSharesAuthorized",
       "p",
       "apre:CommonStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails",
     "longName": "99940702 - Disclosure - Stockholders' equity - Warrants Outstanding (Details)",
     "shortName": "Stockholders' equity - Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
     "longName": "99940801 - Disclosure - Equity Incentive Plan - Summary (Details)",
     "shortName": "Equity Incentive Plan - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails",
     "longName": "99940802 - Disclosure - Equity Incentive Plan - Valuation assumptions (Details)",
     "shortName": "Equity Incentive Plan - Valuation assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
     "longName": "99940803 - Disclosure - Equity Incentive Plan - Stock option activity (Details)",
     "shortName": "Equity Incentive Plan - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
     "longName": "99940804 - Disclosure - Equity Incentive Plan - Restricted stock units (Details)",
     "shortName": "Equity Incentive Plan - Restricted stock units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99940901 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://aprea.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941001 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20251231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r36",
      "r760"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r558"
     ]
    },
    "apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aprea.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities and Employee-related Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r95",
      "r404"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r46",
      "r101",
      "r400",
      "r421",
      "r422",
      "r774"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r14",
      "r338",
      "r341",
      "r378",
      "r417",
      "r418",
      "r702",
      "r703",
      "r704",
      "r714",
      "r715",
      "r716",
      "r717"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r558",
      "r793"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r714",
      "r715",
      "r716",
      "r717",
      "r775",
      "r795"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r648"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r643",
      "r652",
      "r656",
      "r664"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r270",
      "r280"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total shares of common stock equivalents",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r72",
      "r97",
      "r122",
      "r123",
      "r124",
      "r158",
      "r166",
      "r176",
      "r177",
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r326",
      "r330",
      "r356",
      "r390",
      "r391",
      "r396",
      "r470",
      "r534",
      "r535",
      "r538",
      "r558",
      "r560",
      "r561",
      "r572",
      "r729",
      "r730",
      "r781"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r102",
      "r122",
      "r123",
      "r124",
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r326",
      "r330",
      "r356",
      "r558",
      "r729",
      "r730",
      "r781"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtEventOfElectionOfHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AtEventOfElectionOfHolderMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents scenario or event of election of holder.",
        "label": "At Event of Election of Holder [Member]",
        "terseLabel": "At the election of holder"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarket2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AtMarket2024OfferingMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the 2024 ATM offering.",
        "label": "At Market 2024 Offering [Member]",
        "terseLabel": "2024 ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to ATM offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingProgramMaximumAmountToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AtMarketOfferingProgramMaximumAmountToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock to be issued under an at-the-market offering program",
        "label": "At The Market Offering Program Maximum Amount To Be Issued",
        "terseLabel": "Maximum amount to be issued under at-the-market offering program"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock to be issued under a supplemental at-the-market offering program.",
        "label": "At The Market Offering Program Maximum Amount To Be Issued, Supplement",
        "terseLabel": "Maximum amount to be issued under at-the-market offering program, supplement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r601"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r601"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r601"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash balance",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r93",
      "r520"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents and restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r66"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash-end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash-beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r51",
      "r119"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r51"
     ]
    },
    "apre_CertainPurchasersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "CertainPurchasersMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain purchaser with whom company entered into securities purchase agreement.",
        "label": "Certain Purchasers [Member]",
        "terseLabel": "Purchasers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r98",
      "r99",
      "r100",
      "r122",
      "r124",
      "r149",
      "r150",
      "r152",
      "r154",
      "r160",
      "r161",
      "r181",
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r207",
      "r208",
      "r210",
      "r211",
      "r213",
      "r216",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r356",
      "r429",
      "r430",
      "r431",
      "r432",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r458",
      "r478",
      "r497",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r686",
      "r709",
      "r710",
      "r718"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "verboseLabel": "Nature of business and basis of presentation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r160",
      "r210",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r336",
      "r429",
      "r430",
      "r431",
      "r432",
      "r539",
      "r686",
      "r708",
      "r709"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Common stock with an exercise price",
        "verboseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r225"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Stockholders' equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase of shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "apre_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the period.",
        "label": "Class of Warrant or Right, Number of Warrants Exercised",
        "terseLabel": "Class of warrant or right, number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r68",
      "r397",
      "r457"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r188",
      "r189",
      "r514",
      "r725",
      "r727"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r714",
      "r715",
      "r717",
      "r775",
      "r792",
      "r795"
     ]
    },
    "apre_CommonStockNumberOfVotingRightsPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "CommonStockNumberOfVotingRightsPerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of voting rights per share of common stock owned.",
        "label": "Common Stock, Number of Voting Rights Per Share",
        "terseLabel": "Number of voting rights per common share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r458"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r458",
      "r476",
      "r795",
      "r796"
     ]
    },
    "apre_CommonStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "CommonStockTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.",
        "label": "Common Stock [Text Block]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r208",
      "r215",
      "r398",
      "r558"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant components of deferred taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r104",
      "r106",
      "r111",
      "r388",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r528"
     ]
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of Series A convertible preferred stock to common stock",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock (as converted)",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r221",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "apre_ConvertiblePreferredStockSeriesaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ConvertiblePreferredStockSeriesaMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of Series A Preferred may be converted at any time, at the option of the holder, into a share of common stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r203",
      "r220",
      "r379",
      "r385",
      "r395",
      "r521",
      "r522",
      "r523",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r675"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r675"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r677"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r677"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r679"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r677"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r670"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r671"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r671"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r669"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r669"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r669"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r672"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r675"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r678"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r676"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r673"
     ]
    },
    "apre_December2025PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "December2025PreFundedWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to December 2025 pre-funded warrants.",
        "label": "December 2025 Pre-Funded warrants [Member]",
        "terseLabel": "December 2025 pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_December2025PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "December2025PrivatePlacementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to December 2025 Private Placement.",
        "label": "December 2025 Private Placement [Member]",
        "terseLabel": "December 2025 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_December2025WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "December2025WarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to December 2025 Warrants.",
        "label": "December 2025 Warrants [Member]",
        "terseLabel": "December 2025 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_DeferredTaxAssetResearchAndDevelopmentCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "DeferredTaxAssetResearchAndDevelopmentCredits",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from research and development credits.",
        "label": "Deferred Tax Asset, Research And Development Credits",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "auth_ref": []
    },
    "apre_DeferredTaxAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "DeferredTaxAssetsAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to amortization.",
        "label": "Deferred Tax Assets, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued Expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r115",
      "r158",
      "r167",
      "r177",
      "r524",
      "r534",
      "r535"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plan",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r234",
      "r265",
      "r266",
      "r268",
      "r541"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r601"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r601",
      "r644"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "verboseLabel": "Domestic",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r112",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r147",
      "r149",
      "r152",
      "r153",
      "r154",
      "r157",
      "r206",
      "r269",
      "r320",
      "r323",
      "r348",
      "r349",
      "r389",
      "r411",
      "r529"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r112",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r149",
      "r152",
      "r153",
      "r154",
      "r157",
      "r206",
      "r269",
      "r320",
      "r323",
      "r348",
      "r349",
      "r389",
      "r411",
      "r529"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r156"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r542"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of effect of applying the federal statutory rate to the net loss and the effective income tax rate",
        "terseLabel": "Reconciliation, percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at U.S. statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r125",
      "r288",
      "r311",
      "r542"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r542",
      "r708",
      "r713",
      "r762"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "negatedLabel": "Permanent differences",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r713",
      "r762",
      "r763"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Others, Foreign tax effects",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r542",
      "r708",
      "r713",
      "r762"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Nontaxable and nondeductible items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r708",
      "r713",
      "r762"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other adjustments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r708",
      "r713",
      "r762",
      "r763"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesOther",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Percent",
        "verboseLabel": "Other adjustments, Changes in unrecognized tax benefits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax contingencies."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r713",
      "r762"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development credits, Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r708",
      "r713",
      "r762",
      "r764"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit and Share-based Payment Arrangement, Noncash",
        "terseLabel": "Stockbased compensation",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation, severance and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognition period for unrecognized compensation cost",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to RSU",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r83",
      "r84",
      "r108",
      "r109",
      "r110",
      "r130",
      "r131",
      "r132",
      "r134",
      "r141",
      "r143",
      "r145",
      "r159",
      "r182",
      "r183",
      "r184",
      "r205",
      "r226",
      "r269",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r378",
      "r408",
      "r417",
      "r418",
      "r419",
      "r436",
      "r497"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r648"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r645"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected gross proceeds from potential future warrant cash exercises.",
        "label": "Expected Gross Proceeds from Potential Future Warrant Cash Exercise",
        "terseLabel": "Expected gross proceeds from potential future warrants cash exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Foreign",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign currency loss (gain)",
        "terseLabel": "Foreign currency (loss) gain",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r361",
      "r362",
      "r363",
      "r364",
      "r494"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency and currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r480"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "apre_HCWainrightCoLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "HCWainrightCoLlcMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to H.C Wainright &amp; Co, LLC.",
        "label": "HC Wainright Co Llc [Member]",
        "terseLabel": "HCW"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r601"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r57"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r332",
      "r333",
      "r334",
      "r335",
      "r351",
      "r352",
      "r353",
      "r357",
      "r358",
      "r359",
      "r414",
      "r416",
      "r481",
      "r517",
      "r519",
      "r543",
      "r544",
      "r550",
      "r551",
      "r552",
      "r557",
      "r768",
      "r769",
      "r791"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r332",
      "r333",
      "r334",
      "r335",
      "r351",
      "r352",
      "r353",
      "r357",
      "r358",
      "r359",
      "r414",
      "r416",
      "r481",
      "r517",
      "r519",
      "r543",
      "r544",
      "r550",
      "r551",
      "r552",
      "r557",
      "r768",
      "r769",
      "r791"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r288",
      "r289",
      "r298",
      "r306",
      "r542",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r288",
      "r289",
      "r298",
      "r306",
      "r542",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r125",
      "r284",
      "r288",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r312",
      "r314",
      "r315",
      "r316",
      "r394",
      "r424",
      "r434",
      "r542"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Effective tax rate",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r80",
      "r122",
      "r144",
      "r145",
      "r158",
      "r168",
      "r177",
      "r287",
      "r288",
      "r313",
      "r412",
      "r525",
      "r526",
      "r527",
      "r542"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r285",
      "r286",
      "r299",
      "r300",
      "r304",
      "r308",
      "r428"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r542",
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Others, Foreign tax effects",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r542",
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at U.S. statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r542"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Nontaxable and nondeductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingenciesOther",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount",
        "verboseLabel": "Other adjustments, Changes in unrecognized tax benefits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits, Tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r762",
      "r764"
     ]
    },
    "apre_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "apre_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of income tax disclosures.",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred grant revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current and noncurrent assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r643",
      "r652",
      "r656",
      "r664"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "verboseLabel": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r549",
      "r705",
      "r720"
     ]
    },
    "apre_January2026PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "January2026PrivatePlacementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to January 2026 Private Placement.",
        "label": "January 2026 Private Placement [Member]",
        "terseLabel": "January 2026 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_January2026WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "January2026WarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to January 2026 warrants.",
        "label": "January 2026 Warrants [Member]",
        "terseLabel": "January 2026 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in a laboratory.",
        "label": "Lab equipment"
       }
      }
     },
     "auth_ref": []
    },
    "apre_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Accounting for leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "apre_LesseeOperatingLeaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "LesseeOperatingLeaseAnnualBaseRent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of base rent due annually.",
        "label": "Lessee, Operating Lease, Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "auth_ref": []
    },
    "apre_LesseeOperatingLeaseNumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "LesseeOperatingLeaseNumberOfOperatingLeases",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of operating leases held by the Company.",
        "label": "Lessee, Operating Lease, Number of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r69",
      "r402",
      "r558",
      "r560",
      "r561",
      "r708",
      "r711",
      "r724",
      "r778"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r92",
      "r122",
      "r123",
      "r124",
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r327",
      "r330",
      "r331",
      "r356",
      "r558",
      "r729",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Provision for contingent losses",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "apre_March2024PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "March2024PreFundedWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to March 2024 pre-funded warrants",
        "label": "March 2024 Pre-Funded warrants [Member]",
        "terseLabel": "March 2024 pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_March2024PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "March2024PrivatePlacementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to March 2024 Private Placement.",
        "label": "March 2024 Private Placement [Member]",
        "terseLabel": "March 2024 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_March2024TrancheBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "March2024TrancheBWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to March 2024 Tranche B warrants.",
        "label": "March 2024 Tranche B Warrants [Member]",
        "terseLabel": "March 2024 Tranche B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "March2024TrancheaWarrantsAndTrancheBWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to March 2024 Tranche A warrants and Tranche B warrants.",
        "label": "March 2024 TrancheA Warrants And Tranche B Warrants [Member]",
        "terseLabel": "March 2024 Tranche A Warrants And Tranche B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_March2024TrancheaWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "March2024TrancheaWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to March 2024 Tranche A warrants.",
        "label": "March 2024 TrancheA Warrants [Member]",
        "terseLabel": "March 2024 Tranche A Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r190",
      "r191",
      "r192",
      "r193",
      "r228",
      "r260",
      "r261",
      "r262",
      "r282",
      "r350",
      "r386",
      "r413",
      "r415",
      "r423",
      "r449",
      "r450",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r537",
      "r539",
      "r540",
      "r543",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r731",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r190",
      "r191",
      "r192",
      "r193",
      "r228",
      "r260",
      "r261",
      "r262",
      "r282",
      "r350",
      "r386",
      "r413",
      "r415",
      "r423",
      "r449",
      "r450",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r537",
      "r539",
      "r540",
      "r543",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555",
      "r559",
      "r731",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r53",
      "r70",
      "r84",
      "r90",
      "r103",
      "r105",
      "r110",
      "r122",
      "r123",
      "r124",
      "r127",
      "r133",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r151",
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r206",
      "r209",
      "r212",
      "r217",
      "r269",
      "r320",
      "r323",
      "r349",
      "r356",
      "r407",
      "r477",
      "r495",
      "r496",
      "r525",
      "r526",
      "r527",
      "r570",
      "r729"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued and adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r643",
      "r652"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "apre_NoncashConsultingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "NoncashConsultingFees",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consulting fees included in net income that result in no cash flow.",
        "label": "Noncash Consulting Fees",
        "terseLabel": "Issuance of common stock to consultants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "apre_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days.",
        "label": "Number of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after the Company announces the recommended Phase 2 dose for ATRN-119.",
        "label": "Number of Days after Company Announces Recommended Phase 2 Dose for ATRN 119",
        "terseLabel": "Number of days after announcement of Phase 2 dose for ATRN-119"
       }
      }
     },
     "auth_ref": []
    },
    "apre_OfficeFurnitureAndLaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "OfficeFurnitureAndLaboratoryEquipmentMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting or in a laboratory.",
        "label": "Laboratory equipment and office furniture"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expenses",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r525",
      "r527",
      "r531",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of business and basis of presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of business and basis of presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r85",
      "r86",
      "r88",
      "r425",
      "r426"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r408"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r549"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r650"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r610",
      "r620",
      "r653"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r610",
      "r620",
      "r653"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Common stock issuance costs",
        "terseLabel": "Common stock issuance costs",
        "verboseLabel": "Common stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "apre_PercentageOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "PercentageOfOutstandingShares",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of outstanding shares.",
        "label": "Percentage of Outstanding Shares",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "auth_ref": []
    },
    "apre_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to placement agent.",
        "label": "Placement Agent [Member]",
        "terseLabel": "Placement Agent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "apre_PreFundedWarrantsExercisePrice7.29PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "PreFundedWarrantsExercisePrice7.29PerShareMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre-funded warrants exercise price of 7.29 per share.",
        "label": "Pre-funded Warrants Exercise Price 7.29 Per Share [Member]",
        "terseLabel": "Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)"
       }
      }
     },
     "auth_ref": []
    },
    "apre_PreFundedWarrantsExercisePrice9.1125PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "PreFundedWarrantsExercisePrice9.1125PerShareMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre-funded warrants exercise price of 9.1125  per share.",
        "label": "Pre-funded Warrants Exercise Price 9.1125 Per Share [Member]",
        "terseLabel": "Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)"
       }
      }
     },
     "auth_ref": []
    },
    "apre_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to pre-funded warrants.",
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r792",
      "r795"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r218"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r458"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "apre_PrivatePlacementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "PrivatePlacementAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Private Placement [Abstract]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Issuance of gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from sale of common stock in a private placement",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r429"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercises",
        "verboseLabel": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r90",
      "r103",
      "r105",
      "r116",
      "r122",
      "r123",
      "r124",
      "r127",
      "r133",
      "r141",
      "r144",
      "r145",
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r206",
      "r269",
      "r320",
      "r323",
      "r325",
      "r328",
      "r329",
      "r349",
      "r356",
      "r390",
      "r392",
      "r406",
      "r435",
      "r477",
      "r495",
      "r496",
      "r547",
      "r548",
      "r571",
      "r704",
      "r729"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r376"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r94",
      "r405"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment-net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r376",
      "r393",
      "r405",
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r77",
      "r78",
      "r403"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r376"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r190",
      "r191",
      "r192",
      "r193",
      "r227",
      "r228",
      "r260",
      "r261",
      "r262",
      "r268",
      "r282",
      "r350",
      "r383",
      "r384",
      "r386",
      "r413",
      "r415",
      "r423",
      "r449",
      "r450",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r537",
      "r539",
      "r540",
      "r543",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r564",
      "r726",
      "r731",
      "r776",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r190",
      "r191",
      "r192",
      "r193",
      "r227",
      "r228",
      "r260",
      "r261",
      "r262",
      "r268",
      "r282",
      "r350",
      "r383",
      "r384",
      "r386",
      "r413",
      "r415",
      "r423",
      "r449",
      "r450",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r537",
      "r539",
      "r540",
      "r543",
      "r545",
      "r546",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r564",
      "r726",
      "r731",
      "r776",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r645"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r203",
      "r220",
      "r379",
      "r385",
      "r395",
      "r521",
      "r522",
      "r523",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ResearchAndDevelopmentRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Research and Development Related Liabilities, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r613",
      "r646"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r647"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r600",
      "r611",
      "r621",
      "r654"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r707",
      "r789",
      "r790"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrentAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Noncurrent [Abstract]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r691",
      "r707"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted stock unit",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r61",
      "r401",
      "r420",
      "r422",
      "r433",
      "r459",
      "r558"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r130",
      "r131",
      "r132",
      "r134",
      "r141",
      "r143",
      "r145",
      "r182",
      "r183",
      "r184",
      "r205",
      "r269",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r337",
      "r339",
      "r340",
      "r342",
      "r347",
      "r372",
      "r373",
      "r417",
      "r419",
      "r436",
      "r795"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Grant revenue",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89",
      "r146",
      "r229",
      "r687"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of significant components of deferred taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "apre_ScheduleOfEarningsPerShareBasicAndDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTable",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic and diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of reconciliation of the effect of applying federal statutory rate to the net loss and the effective income tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r542",
      "r762"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of net loss",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r712"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://aprea.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r376"
     ]
    },
    "apre_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Summary of useful lives of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r268"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of restricted stock units activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in valuation of stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r59",
      "r60",
      "r61",
      "r98",
      "r99",
      "r100",
      "r160",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r336",
      "r429",
      "r430",
      "r431",
      "r432",
      "r539",
      "r686",
      "r708",
      "r709"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "apre_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r532",
      "r533",
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled/Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled/Forfeited, Weighted average grant date fair value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted average grant date fair value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted stock units, Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance, Weighted average grant date fair value",
        "periodStartLabel": "Beginning balance, Weighted average grant date fair value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted average grant date fair value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in number of shares available for future grant.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, increase in number of shares available for grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity Incentive Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled/Forfeited",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/Forfeited (in dollars per share)",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period",
        "periodStartLabel": "Outstanding, beginning of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "apre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r238",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "apre_ShareBasedPaymentArrangementExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ShareBasedPaymentArrangementExecutiveOfficersMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes executive officers.",
        "label": "Executive officers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non employee directors",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested or expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "apre_SharesIssuedVolumeWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "SharesIssuedVolumeWeightedAveragePricePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Volume weighted average price per share of common stock after announcement of recommended Phase 2 dose for ATRN-119.",
        "label": "Shares Issued, Volume Weighted Average Price Per Share",
        "terseLabel": "Volume weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "apre_ShelfRegistrationStatement2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ShelfRegistrationStatement2024Member",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to a 2024 Shelf Registration Statement.",
        "label": "Shelf Registration Statement 2024 [Member]",
        "terseLabel": "2024 Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_ShelfRegistrationStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ShelfRegistrationStatementAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Shelf Registration Statement Abstract",
        "terseLabel": "Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "ShelfRegistrationStatementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to a Shelf Registration Statement.",
        "label": "Shelf Registration Statement [Member]",
        "terseLabel": "2020 Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r98",
      "r99",
      "r100",
      "r122",
      "r124",
      "r149",
      "r150",
      "r152",
      "r154",
      "r160",
      "r161",
      "r181",
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r207",
      "r208",
      "r210",
      "r211",
      "r213",
      "r216",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r356",
      "r429",
      "r430",
      "r431",
      "r432",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r458",
      "r478",
      "r497",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r686",
      "r709",
      "r710",
      "r718"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r43",
      "r44",
      "r82",
      "r83",
      "r84",
      "r108",
      "r109",
      "r110",
      "r130",
      "r131",
      "r132",
      "r134",
      "r141",
      "r143",
      "r145",
      "r159",
      "r182",
      "r183",
      "r184",
      "r205",
      "r226",
      "r269",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r378",
      "r408",
      "r417",
      "r418",
      "r419",
      "r436",
      "r497"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r159",
      "r207",
      "r208",
      "r210",
      "r213",
      "r373",
      "r387",
      "r427",
      "r437",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r526",
      "r527",
      "r565",
      "r794"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89",
      "r146",
      "r229",
      "r687",
      "r688"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r159",
      "r180",
      "r207",
      "r208",
      "r210",
      "r213",
      "r373",
      "r387",
      "r427",
      "r437",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r497",
      "r526",
      "r527",
      "r565",
      "r794"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "apre_StockIssuanceAnniversaryPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "StockIssuanceAnniversaryPeriod",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of anniversary of issuance of common stock.",
        "label": "Stock Issuance Anniversary Period",
        "terseLabel": "Stock issuance anniversary period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r40",
      "r43",
      "r61",
      "r204"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock to consultants (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock and pre-funded warrants, net (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r40",
      "r61",
      "r429",
      "r497",
      "r506"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61"
     ]
    },
    "apre_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r43",
      "r44",
      "r61"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock to consultants",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock and pre-funded warrants, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r40",
      "r61",
      "r436",
      "r497",
      "r506",
      "r571"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r40",
      "r61"
     ]
    },
    "apre_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apre_StockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "StockSharesAuthorized",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Stock Shares Authorized",
        "terseLabel": "Stock, shares authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r54",
      "r460",
      "r476",
      "r498",
      "r499",
      "r558",
      "r572",
      "r708",
      "r710",
      "r711",
      "r724",
      "r778",
      "r795"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r382"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Common stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesIncomeTaxesRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]",
        "documentation": "Indicates tax jurisdiction of domicile."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r542"
     ]
    },
    "us-gaap_TechnologyEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TechnologyEquipmentMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashAndPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Equipment [Member]",
        "terseLabel": "Computer equipment and software",
        "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://aprea.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, ending balance",
        "periodStartLabel": "Temporary equity, beginning balance",
        "verboseLabel": "Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 and 56,227 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r207",
      "r208",
      "r210",
      "r214",
      "r279",
      "r281",
      "r399"
     ]
    },
    "apre_TemporaryEquityConversionOfStockAmountConverted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "TemporaryEquityConversionOfStockAmountConverted",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock classified as temporary equity converted during the period.",
        "label": "Temporary Equity, Conversion of Stock, Amount Converted",
        "negatedLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "apre_TemporaryEquityConversionOfStockSharesConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "TemporaryEquityConversionOfStockSharesConverted",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of temporary equity converted during the period.",
        "label": "Temporary Equity, Conversion of Stock, Shares Converted",
        "negatedLabel": "Conversion of preferred stock to common stock (in shares)",
        "terseLabel": "Conversion of preferred stock into common stock (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "apre_TemporaryEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "TemporaryEquityPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for temporary equity.",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "apre_TemporaryEquityRemainingSharesToBeConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "TemporaryEquityRemainingSharesToBeConverted",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares remained to be converted into common stock.",
        "label": "Temporary Equity, Remaining Shares to be Converted",
        "terseLabel": "Number of shares remained to be converted into common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r210"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Convertible preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r210"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, ending balance (in shares)",
        "periodStartLabel": "Temporary equity, beginning balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r210"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "apre_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanStockOptionActivityDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanSummaryDetails",
      "http://aprea.com/role/DisclosureEquityIncentivePlanValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Two Thousand Nineteen Equity Incentive Plan",
        "label": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxesDetails",
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "apre_UniversalShelfRegistrationMaximumAmountToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "UniversalShelfRegistrationMaximumAmountToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock, preferred stock, warrants, rights and debt securities and units that can be issued under a universal shelf registration statement.",
        "label": "Universal Shelf Registration Maximum Amount To Be Issued",
        "terseLabel": "Maximum amount to be issued under universal shelf registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r162",
      "r163",
      "r164",
      "r165",
      "r390",
      "r392",
      "r530"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "apre_VestingOnOneYearAnniversaryOfGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "VestingOnOneYearAnniversaryOfGrantDateMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to vesting on one year anniversary of grant date.",
        "label": "Vesting On One Year Anniversary Of Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "apre_VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "VestingOnOneYearTwoYearAndThreeYearAnniversariesOfGrantDateMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to vesting on one year, two year and three year anniversaries of grant date.",
        "label": "Vesting On One Year, Two Year and Three Year Anniversaries Of Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "apre_VestingOnThreeYearAnniversaryOfGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "VestingOnThreeYearAnniversaryOfGrantDateMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to vesting on three year anniversary of grant date.",
        "label": "Vesting On Three Year Anniversary Of Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "apre_VestingOnTwoYearAnniversaryOfGrantDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20251231",
     "localname": "VestingOnTwoYearAnniversaryOfGrantDateMember",
     "presentation": [
      "http://aprea.com/role/DisclosureEquityIncentivePlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to vesting on two year anniversary of grant date.",
        "label": "Vesting On Two Year Anniversary Of Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r154"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aprea.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001104659-26-028068-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-028068-xbrl.zip
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M"38N&KZ,>U?&@SI:KZ'#X]M\W\%VZ%,GL V*1O1X+JY1;;M+S]&J".O@N3^
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M6;S@.\7+ONA')F5(-7I4E/@*CG 9ZPMN!"I>%;4(+ DA?<&IR9LIE1K BQP
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MPZ.CC_#\Y:TXQ,30=K4'U>);8"MN"06O5L^AXTI;75I\DLIG:^T >%J5*<\
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MHB =#$#,1W^R(,4>O#"DTGR'?J2_-%D&2GT!1)'TK/8E9,%S-I/-AJQ=ZPS
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MXO@7Y*^'=?>5<B\ ?HLN=*:.EO'3;K:K/CGO].79V3P,LL+XI:^UC\"?UH_
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M^JV]\S9'PI]):LVMM\+IM_;NW!P)MU1JBQWFRGOS)BB84)Q-F@?5>;?VDMP
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M%.+QM&0/";8;3ELXI5L4-QL.'E;Y4$[<& 438O\ZJV^>R%_8<5.S4Z@HVJ/
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MU/W4W*_"P<$\S?/IOP=XCEQOZJ$)]WPN:&O?<2(4GB75^1AL)N6KAMS'XR,
MWO?VW&!BU<.:/\H4=#R]]E'J@AY/_Q;Z!"?^RB_M8MD5(I6JY<HOQ<3Z'7!I
M#;V5E9_E-K=75%:"@2@6<%.KOJ87.U\Q3HC4)=$R_3^UW? =^I'^Q.6A8F<
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MY#K=TMBGB=,:M<-ZXHQ<#>TA>@=TLQO!^;O@;1M0.DKH.O5UPY'31R<E6^=
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M9WX=Q;R:;_.ID4MFY"A,F9P!-#L/62S1I'D789XH-6P+6^^&U+9-8<\S=/V
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MEU+'L+IFX-IEDZ>^N5NC+4[L4]*P=<%0;8AW*M(M[OB)=!:F&6&[BP6C*M[
M@IVVJF5XMK$.P[T3O&<_W1R?5ZKWPAE? [7NG%+4NRQP)B%18,P$PN'YG3!.
MP.\(?Q?+V[/?<U8!@BF#8:6E,P7!!RZY4G)C^G13>WY@6/M,R>);6\K,B/?4
MNXZC#5/8A]S+#Y0F)^*M,_FA;W<GG/ U3.=&;D1'#[P3!D6Y1^0Q 'E2I4^
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MGD[P89_N8YJ=X9PXR6-^^-)FEG'D$(.8 3L5$#>"%G( -*'9F#*V-.-/'D
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M.1=6#;Y?$(AW67[R_98JTR\$MCM51XC7Q>9 +C"'Z^6C]"3?H3"6EQOKX-/
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M%YBG@/<G&M]'MI9 AK],]>W3%XGGHOZ1-3P_8O^EXGG[=Y@'S^N\OT0\EU@
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M(">I!.4$/&Z2'5NO)F"ZA$8%U ^1@/##2<#+PS.<^,,=_N'!</_XIEE:J('
M<02NY<#N<&)CB=BHDD!L]G)9P0CDC1')-BJ;?1&VR@([Y#%RIST#\Q,5C-FR
M3,=)%86<#Q?(^7 P#?!,UU"[I4\(1/'-3583MODU87"\@W5$-:&R:GH:)J0
M[QZP-F!S_-;P4/&+Q00VL[_H]S[WXL*2'^&:M!>6W*OFQ(@D1'JQ]51S3.2:
M:CL4?6D#C+ OP0^GO@3_^/W2?@/.\AE.M9KNQ269"-F?/Q7\_E5@4V*\GF")
M!2U)_OS[=+2 >(]GH\%XNI@/QH/YJ6U)*BR==#LU1X^+AA]3[,CC'Z7X^AKX
M+W[67PSSJ/JM8^\+$8IJLRD;;3MPL/WYT^!3SW=A6^Q@K:>9S2"]M"Q?,Q_
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MG^^7MY9N^N%[@TZ@W!0TR'X(1V<H!&S%+@@O!MRRK33?2K)Z6:!H<MT9Z!H
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ML50JWG$7$[- )3WB]4%0(I5TG.PGM0/YR(QMH)*FJ9168"NCDU"BME6X-Z^
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M(@;^MA.5O_"<XGOF _V?F98%^V-3[<2UNL$:L]?#6\2T$G,SE[(_]!A'!$%
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MKJ:ND]YKB-W^K7DZ<.X3K*ID9BA(K1PCN,P+M()RV@G+F17R<I(G UQZY2C
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M'06%M3;4$9;K%]OX 11JW=JQM[ 7! 2^ <<FXH4D9%)MA."EZ<RY$2L"K=^
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M]:&(*@JO-L3USH.)?U:M/$,:AMEX,93KH<6#-A6E;B2<M]3A+#QV3@WL)3X
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M1H6SM=SE&MS9VK&^GG:J\'S2=CYI$V3$FO3'PYG<H;$M)VTQ5"J?PE0Y:5.
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M^5QEE4/.ZD@+.[AD6OF>ZVD6DBDD?.'Y)RE#EQ3.+FBD[X42^JZ]:5D[M@[
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MZITJ"R"(J^NEZF/!XJ]?PT$K^NYO_Q]02P,$%     @ ST-P7$(X,)J)^0,
M_JT@ !4   !A<')E+3(P,C4Q,C,Q>#$P:RYH=&WLO7=SZLCV*/K__11Z>^[O
MG+WK&;9$,GC/S"U,L'$"$XSM5Z^H1FI 1DBR L&?_J[5+0F!P<89VSIU9L:
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M9;_:W%M5IWUBX:+*A@4R0C]R+=565/DE8J40#[G#A& &P9M"\.?@E\P[ ^*
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M>'%,-%;2XO\  %EE"^P4@<-8%4S-]":6*@NVD% O%2J-IC"6XE+0?Q4#7MC
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ME\F[:D*=V$68IQPW1=^&/^V=_$V 5-U/''2[A&=UW;+)P:?D9H4A3,JA&07
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M=4[[H]T[#A.UR=N&WCZ(V-L(VTHPZU'2,%>J4,4\0<-?.A8L=@$%R@KF /<
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MS/JB+8%Z$,@OB.?^39IH>UL3;6NB?::)=K3'2O7^6&GN.CFU5?W<J$>?#>T
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MY_9PV+!;-A_F-[3>>_NA<M?%^D/5'D?[R=]%U^A7K2CIB<%'M:"_0))?=$^
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M"$Y !86OA079=U,A@&_4N[%AFT7Z=W+PH]T>\%XYO^CF_7* A&F!B?HTH+-
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M2 TAD6!3BXF#\C*#$"7S\A4UG#]&TK6I4%L8,DV(&:ZH _J6<_BME8$<;LM
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MDG(I.#K+QG3?UI&GHMUGZ#B)^^'KU8PAAIKY3;#-*0) KDL3L(^O,AE2" D
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MD!@:[>E,P7!/?95<P@]4G^04]N2MVV:*\"KR&Y?$2>8L=MP\( UMZT8C(WE
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M1<-M,1$@DE;!8=OQ;*%#A69N_4U\_=D+SSH;;DE7>J^RJ>@.9,/\RVDXH&Q
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MJ_P\VG4'^.R4;KX1EHR+1X1,QFR ,L-$1$ZAQTD !-0\H18.O=!1"Q(![K?
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MSWV[<> 9DQ+"3K^YO.9E!3R:[\ORK5^35TJM*L "E\Y]2B<YM7XS@;0TNK8
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MLH+6"K4-FD1X\UX!@N#>=DW'=9=KJBU%Z?0$_C1(.*Z8$;,G>Z*EF5\+;SI
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M9C(.G_7KD%:]D;!,?BFT2G81WCYEI0M5&]F:V$:RCUO+I+-V  WPH@;:L6[
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M$U ?F6*,V&T&Z3BFDYO:NS>3/YV>9M^</*!!_>GL0?;PY&OZ8O>!XV0MS"-
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M94EE;*1]1*=\< R4?AD;@_*MYM[PKO*:/?O5:,8H>Y!\UAZ.\19$+AE2D6!
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MS:!P3&\=+2YYB"S]8T]BBG>#O4ZIH5358CZ0#?ODG4['E_(%YNTV=G&X&(N
MR@K!?W3)E071%1(%N%-56!L)H?<P<:P_"XH$%IHE6*3T4 2?]J)45733^^Z"
M,;S[.J1NXEDNVB'>/I.MRB\D=@]OF"9NGN97Y/YH.MQN3%I.\S7<],: DI@>
MLNJ4E]L5(B\:@^1/EZ0B2+A*<NWA=1?@'><AANWG8@!]!*4ZZ7A);SS-6O?B
M<]:23CS/O!3W4:MW=2'+N44A#[X\^3Y&>H@3^4L"NMU#&A\);O9*&@)1MT&V
M!!9,,*R$_&=H?CZI5%T:KT!D!*VM,89>+TE_!J&5F)K;RG?3S7YC!33F2X/K
M8@]G"X<<9.+?41)*]R#V;N'V<H(IO)Q;  GN'N;E](!Y.6!>W@[S\JZEN/^U
M#1NZ:( =F"*_P+K$U%B\"5%LI'?*A[>GFDIG_WG'QJJR'CL@"C(;'0V#<**B
M2<SLZBK?,!YN$2[$4?&;CF"Q;2IT%=#US?A8H,UT M(YW5$'(^(APSKNN;=_
M5-, ?D[$Q-\?3WXA?$?Z14E0T$00(GMDZ)-[CYX])BZTC:,2$C4&E0;AC#L?
M(<CD@S8]/+"D-W"=\"0$E[@J<_PN/5TT\SBY]]/CY_<G[:X-7FA/%BL]7 :1
M'Y%CLM! >?28RXQ'#0\NN38Y25X4;3B;U7.PT^3<,:]1<^6/+UZ>WW\'KTZ.
MZ=Y[_+NMY'V/U7G/]-Y(B?>",@WL>E@W*RZCB-*BC((U7AB$&T='EK8F99C\
M0-J#"":C(M##?&4#;VJM[@?,53XIY__?O_USMOXG'7#_//WGZ=>G_\;6[%U;
MHL1C<X7%Z/;0(V3O[;TGU3YA@_6SKFZLI6A<"HVUF L4Y?P>'IC_U*7Z!\D0
M4V;X?$&MLJUUY/W#VO$,:O%RBTKIRUFP<-24JA]]\O*E?58MA+WE5\D@NNHQ
M>5,D.SMQ)"?APA;T^0QMY,,PS_$?YRHO5,8F/$E@VG9J/9=&=RB8-$9?]R_B
MWK0$*O+LWY<7DR?!AMA&ZKP<23W(&+.!-_"X6! XVV;S<?TXUG^!#^/DMI@L
M,5*3>VER^6DXY(@+(/G0_=B)^:C.P^/]E6@B94CYQEZ6,OG.0EQ"&#)J:,Y5
MM3+V AK#CK<@FB[)5(I<.J0?/:<KVME.'?[DR5",([XXL8_;=,GO$I,FU]=*
M_;YU(W41W"AZ&!&J2 ,I+<C\Q[GKC/9/.]#M+P=&>"MI*>FE5)Z_/GF@T<3/
M&N7H*SU/&"NIWY76Z).RI7/N?PD1>'9R\DUO(8:H(]T' Y&2WD()3FFY[2;W
M'O\8#BHV-3QMZ"G ][F7,3B28TM75\/(/G)R33EG]]?<5!"N^^K%TT?G+WYP
MH7+)_?7Z!^26B%UJ<UTWKS6>9#'F];LW]>>I>$.:M1^RDFV1:K!IF(V,U=YH
MF,_A?$DMDQNEUDB JEU%MU5!A1Q;G+[\9Y3D>[;'E)2^Y&?]'"I?]DNP1=YF
MK_'6U<%S+8'EO5"A*W[C'67X!I<VLPY87NND&.&GQ2<NF:3!\8TD!QDC/X@U
M['CR5_\=^Y0UC#('I,B><Z.X:#_XL8#[)+YO4?F)%+6+E+*<H#I<"-J'8,5Q
MOZ+,)4US<44I0Y+E:#?E"H4NN KE_'AR3AG=L/:E.ZC/EM1=#KQBD"$QT=[8
M9"XL41$/GDFYIX*PPU6Q3)7>RRJO4%5COE2",X]1XLNKQJ6I4M:-P!*B5$Q)
MY+2/@H;(8 -MI46ZA.JTN\)O<1?PF>:$A$S%16(MSU0OF$QC<!>0@]N[%[T8
M;L'G6,<9A[F,'Z$.SI7P:FEV<9(<!V=HQOD_Q$;<M"YE-\ZM\"*A:(@>NVC
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M7. EVBJ!QQA?E!5=@?-IY"Z4"Z7\*/*9A(W1/@J@^/13AW5\6,>\CA/(NA6
M#$R8H(U5X;GC+O6Y@)W6RJ# "DJX'>KSG@:(BVAOD*/YCJYPAU;T(5;XH*58
M=-D-KNM40ETA.7S" U[1]LJS CCP+#_FT).;87HVGI7^[I'O4#?5(L1!!9K>
M],P"4B+!9Q2,_4><), 8"MZA\0Y%9(> RAS\29')"9)S3O6Q>NTHZ0"TFET2
MBA?X$"&6,YP(II@G%BC=;26O3@OG@J-FR)+T<"^"N4B!2A\E\//! ?AY '[>
M3:84;48@7@_B0@W/<=$HG1D!RP<UF[G%L"DNJ?@";& PR@4QG:KMR9(O\*XN
M$QB7\:41@A\U%;(-) Z3-IUK)P':)F._0R)9?/IM9FG),*G<$ [PRUSENQ6&
M8+IO*\9Q"G*.QU17PPB"RQI=?-S(43(_Y[^VI$.Z@V.C1%V..0QJKHUU!.<0
M9]$^\Q*"CJNZPLPMBD8ZS*5%34JLKNDGO&1"@9HLV],J*B*'Q_^&F#H4P\ '
M&F*+;0/TXZOBMW!EXI.;LZVU)[8>B/Z]F'^<I( ]K2=#'_,V:? 8?RGTR6#I
MZZC:(JU/TD_*S2+@>Z62A;9?8&S'D_-X5F6Q9]<>I! -7:&"Z-"-\AN]+I3;
MI:RNP@L3JL$GY8)PDL0T7V["HM_R6SI?K\&5&]9KV:SD)NE\VHR%41BMP082
MJMT9''QZU@(N-Q@[*O!X,&IP S6_@!@[+W&!9KF&6]_"57;4#(D6I$+0,H7=
M-3*S#DZKB@7XKW*+CDX9KT)@;F7NN@]Q_WCRK)K\;1N<]-.OH75]RB\((/&7
MVS7U0<NTAB=9E:#OA?R3N0BVO%0#F[6>>%95A"BYJ[@!<8&,D+M\^XV0NW3^
M]&7XT[?#?SK]Y]G)R7NBA/EA?+O0HWU?HHFO#6?1]]OY1;$!6#<\M^SS 8R4
MK0Q! PM>T+;"RQH1WTM5:J +&LD$84!2Y@)>!MQA!>YC7D%?G?R9?DE9;E@$
MG^F.67EFY-E'7N!Z%*&5+-0A8CO_FJ\GC_5B6MH$WX'SS2TQWJT4C"7*.VGR
M2Q&6YO2.^^8FNXUAGM=56+>7];+(U"#GE5"$A-,4#:UA+S;S! Q'[58XE-QC
M)\/"+#_@63X+GAIPZ^$[W8>D.FV7,AN=S;(,PAG>UDNT#<S)I#7UNBFEF<_6
MTME)UCUY[4CYCW\_?7CR'7V"E^5BN[0C7@Q6>GK(O#S*YV6(N6>35_EO)M(:
MC]3+X#L=81:*L/CJ70C6<337#0:AXJEX/!8]#8<YSDWR%,)N@J6'TQM/OP>R
M>83'1F)$ N?J">]'H-HA=B]KOC,2F00Z>T] 3 6]3M97(V/G.&]2723J9B,L
M.0V\KM"5&B(L8L'MZ"?QE9D\8.R)\(I]3P.WM%C?0]3S4)MJ=+&P!$8]XH[4
MIQLY-+7VU4*IGJ3PT'=Z#:Q M>M):Z/G6Z9+^"&8[:#<F-2?^(H\.;B2- 7H
M9T0IG-\44PBP5\8N 7-FN@X"IJIW]8"D<S"A6GT_;?P_T1B5EIXH6"?GVPLR
M3J</<0R>"4_28JEM%\"+2\<%;[PS](T\?<$G;6</:KM#7[2+OC!2B71YD%@[
MK"[(KA@5C%8>(WFRF95[<7.Q1/S#^R(^PW [B<^9N<-5,%WO9TZT3M_)EFL-
MSS)((3A 2P;:([B8X1T,$^^C=,M4'S*W]X*/%F9^OBUDV _N?Z<@PV"$BM:;
M]_TE9.Z4Q9K7OSE^L?X$?76?W4AZ)VMBW=CPS=Z:6O;>CS^^O)]R/ZT2@@+G
MWRI;=:1'H):I-1N[A%\JLS(X\)O!4L"8<ML1HX*,[XSFFCMSF:6+>[.6A#Q%
MR!J.NVM;A[;AX<IL<]OTN)>TKB_LX]H\-=R8HUWC)%LP+>2PF1?,9D("!L]<
ML'/Z)?;9@RSX!D6+"DOPF.;H[ZMJ2BK-!1"@TR2#R";S^O\*X>(9DP[I,GZM
M\\@@:FR;#0=XO$HOR]<,6QT0M1AV3X-I_Q#<@_R6?9>C=C#&%DEK;N2,'_?5
MM25ZJRY]>""&?J!_35Q62H<T]=*YKJ?#KBM'=PRI;-18,M&28ZRWB7?-\N&J
M?X;JZ8*ISGQ\?2V:K-J_"$,=7MA27.T'++ U5U'8:1M>>L$, GKB9;S*^;1T
M1-.ZKLY.Z* VKC02!EE'5EFBOJ\;L@0@,TB04YJ"L.=ES^^G7"*!LQ.[R4\H
M+[)'$ X7&3![CDTX^Z_*9DL>=0655)+6"<]AG*)X@."+DLS\!0CXDVDX.PLO
MD.Z<_(YN@,CNP4DFQY4.."GK!Q?K*/SB2"OU,V;44=.0SW\-NYNPM=)+":JV
MTS]_YURYFF+(I3[U69;,SOX+G?VYQX8NDW5ZJ@%IUT+(44LW.5\1X#VG [J=
MA4E]'GQ.=T2?NFP4KRA+=["ACWR%@YQ*X3#,G DEE<Z<DJXG?^;509^-]!-[
M>-?@)!+[5;@E*!B$WQ>8"2)_#YNG7,>_:KG.IC@),<^^Q+%%5!X#=B#MF'7N
M9;HO$^!%KU-7Z]+V1[16)EE]''C"ER/-PMH>.]K]G#0;^V]ZAC?KH>8S;]%@
M4\]V2J9!WZ:[H%[>NP?XCQKK 0T7(8CLNW$K@W%^84XD[V;V?9-3)#VFG,($
M5J X7^3[47J3<G]3"<2WT+_0&#-IFS^.&5[]FMA[T5A*+* >Z51;"^_Y5;-=
MK9-2$(V22'WHG##1)GLCW+8-"ZXI"DLI;)P87#AW060B:T-)H)T/F GJ)WB!
ME')8US.*T<!=):(1(:1;F6[5O)"[M$[5>J#?,AB2 09&-T?"N<9EM#DGOAFX
M4580(@.D0QN/>^"BGJQ;9*X5ABS-N^OLV1'<;7F7PXA5KVQ\\%'"?S_*LMB7
MA[+8H2QV-\MBG6K7M$#WJ!4Z,F<AQ$1*$)+:1I8Q)*E7J@[,6)T.>9%-7R*H
M+8K7:=J%J4B^Z!,I12*,F@[JADGWNM9'J/U>C8\N7"!_39Y1(K@700&F]H9!
MD__$V28C0ZV793#?5F  T*USFTZ0H#[?MS=X:7GEAL'4Z RX7M4;9CLK&)1A
MQ]S+"7%<U"LI4HEJ5#R8. 9F^2R9M$%(:)OF8&+DG8FCGXZ*A:3$KTP2 "&F
M1TA/',\H9*DJ(GWR%X+C3'ZLB<],$+1??C69D_BO'SY5P"@A&KXV%D AXRQ'
M)P>FW0?R23/Y(/'&CFN"1EAAE&>4.JH%(#_8/#RC><";?1E"(([3[?72) C+
M=0Z%6*L:L]--=SJ/;^/'8$B<9JQ.1F0I<+R?;IM@(1KM3;I9-G6]E.OT=FW.
ME-84"; ?$XGX-\+]Z_I.F48FCUPL=!DZDC=,DDO4C+7P!PVM5(GJK*8ZZB]D
M(@=&>A*3=E;RT\\,+$V[ZMP<=,E$/BFF#7S],Q].\:;JB$WP3J:H>],Z]X9*
M'^5&F191EJ$$4PCZZO#F+^N-VT,6:I/T)6>7PJY>YMN*F/LY3W;Z$"N';B*6
M19,TS"B)-Y".K*J=C6QA#B_J%#(8QV#*<&X[EQ5>"#MF\54*Z2K4YJ"_.A/W
M*:QA**L6<^(#XL>E#9:OX7>KH KX$CG_%W9R/45!JEQ#C1=KF$8*,2\D+<+K
MV5B@6"B=@*Y8F&YNR-->;1$YI5LDP E5R)3/:W:0/N=)28.AD."6W57*O7C?
MEQU\[GP9\Z'3=/KD:2(#RG$&L8[7@#]PBE*/H2%>0W/^D6=, T")$'&R^3*
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M@?%F$.FC[;*AV)#3>TLB(51_;%Z0=T,W5^VFNA&1A;564)F:49^:X/%AG9$
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M"882\=_<_XZ>%;1' X;03M)3+I^L"E42)MSZ]S5A7:FB96@3O@XU>7/G]8\
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M,,?RD14F2V(76[L#A92;7H[4 VA?,'7?94UU ("DR-6BME:9"WD(DX =7 S
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MGY=+PV'V2&BE=B;B22DXJ&XZM-3!C)=5^$5[J<9?+CD 8/V4T6T,:'M+3+$
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MF)Q.KXIE<'&!(P"M-0V%WF7G:_I>^%1,6-9CJCQFKKA5<P9^G<C&FX"86LI
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MQ.I["C:0)>&LK%EBA6>+XFS'-9T,A?,R'?HTJ7[I!?>PDV!6$<F%4"UOYMG
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M\_ZP5T8$^68;OC ;QB!NK >OM0UPR1]FYTNE4)7..W#ZJ;R;#5#]U+&=:F$
MO$M9WR6O0N7 0-E#*Z6I#Y+U3%\6VQ!W_O6A]=UV!H8KS^9_8>:/Y [ @7-%
M'#B"X!KP7<''"+AER7IM7M[X$S&].Q!_N$Y9C.GR/3BK2S^8PBA0@Z^1ZMI0
MD/ELFA=FFG<N8YJ16V@/V[* CJCP4$-7C<PQ2'#Y_:NOVQ0VRV^/<&%V)8BO
M$$6'(LFAA_2Z^N]!^P $?8G> >"?QI518,O2J=4!0N="5G6*;)PXC>_5\#%Z
MDP,Y'QJV^%[$0V=.$:CI$U>HOTS-P7RD>,DJ9D"J.GM*E[8>B2ND[2+UAW,]
M(N'$G%V.V8ZP#_< GD.-:O.B0#3=1T_;FZ2Y6\/&8R*_!]MD49G4/ :C0COS
M"?7V_&'N[9E[>^;>GGG[#6#T01KM%EA51K)<@8!'XK]4'0%E)U>[^*N6Z[ =
M'/:0VWM"!_Y<<7P$8,V4EA?7O-*G-^49H-TV!'O^J[>.ZX3:[#5U = _A1YN
M9-?$-IZ\)1X)H VIJ;2!Y/#+7BB<23^B/G3%GMGC^Z=>D'QWMC MPC(AS;2_
MM'3'&IE#ZC:(R059.DCJ.!_O8GZST.<)[!V!';$\!KZ:\_VUX:-FS)HZ4 ()
M$L\U?91"6I1 %[(HV-6:V/4C"DKZ\TDQ ]SNZ,Z-4P$P2IJM7%,I=\E<5/UT
M=S-B%^LKP#U4D&@!<K$YAKTP*S!T(D!H<I+2C/FIT_L:<MM-,M7,F>^+M*YI
M@RA8,67E0W9_UK$;!$8$9@@'T[P7S=9BMQ[+VUTW*>&9X/M6>=/4:?+O1;NJ
M#UPQ!E:P"B"F0H7MIW VNMGHR.@,2X?5;^I),',-,@7%D@3AO/ON?UBI<6*I
M3"G9T2RIK.;:6!R+W.Z[O(%#-RJ^+>NW0$S(?YG-\L+,,F:),='O0&1 8EZ;
MMYK!\!=G+EA71UPKX &]'6"+H(IBLL[84&#O%(/SD\P1_=@W8\0C!JY$RXBR
M('X/;5!WF#(X2;9L314U*46)2>6X$UR0.740(.]CX)\73DA_//301D.^QDDV
M2H,44M%)\&$R$BJ!8F,5(9U.,D!A&P-TVSB1:SB@ MY:X$F28)O2:T,(ZZ[P
M6X9(4BN55KO8 FJEXK8*UG8'J,K:\.P&+>O@A&W*'B<$OLY?92R545:Y7OQD
MCLIA^P5-)4XX=1NTN[KI4$GP"%<IZK7T+3#Y%@-Q=:FXMXK715B-4"/>TW.
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M-5FK$2(*-: %MLA7^=KMD1N_]7_O0TP>G!5X(;]*5B*1>.B7);#&(^-^<0M
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MO*G+(M2;@7!W#9L%)6;;GKD!PVP/'P:N<8_!\MW#X_*M=(2CQX\4X"<>.K9
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MLQ% ,-?,'&J&:T#@-*M84>]7'Q+M@*]6?ST\,8SW!\?'#][%@6G*I,\S .6
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M!UUQ/?ZCYEB.SV\ERY63VG28+H^6>A8<V;<*E2GS.T7"NY:8!*4^@+6$AC0
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M9IA1N#'6O,E0D \6^"[H0>@1Y3X$7*.*[JB/C20(VD  A\\1+D"8=/PNLM"
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M6)Z)("V92?(.DE''.I3(+<SV.MLKBW44;4CUD;D.2,]"]B_^+*9\_59X@(H
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MV,F>4D"Q[?7H86*((^LJ0.V,:[LR+&>7U)/5\V2E78NJ5$M_FKCL'Z<0G"-
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M3;V2!EV$;SHX.0V4P*1?ASB"1/97DJVT"?25^,R<>K5@WAA\<$K]FG#JO,E
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M8?F#T;]G\,6505((?,6-MNH+2)4!6D7(25&^ 1F7]W5%R# E5GEPY2&D# (
MF&"Q]'9H0 H([%N735Q.:J<C5K^ST_.A8X/=N]BA-J/#<Q6-4"(3,!4GT .
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M$0FD^F&EUB^<IC8?1.$%+U;45E2#;G^L_2!HRZ-DG&%7^0!9M7V8H(16A[G
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ML9I )S/2<$J"<LS@AU7%,(,BB)9N1[0/6X&Y^$R@H2(GDO^WTD.(^F?A@F@
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MDJO@<O:D?*<0#2V;%=.Y#D)*P4:XA8UNMDL8RK7<K*7H>#-OY>%$U\ ]!QY
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MVQ8&*TD4\OW"!_V&>2>.W+W\[2?8.C,2HG^>O*D[$<J^5:52-7<X58[Y?G^
MJW#VB5\5SZ.$:*G;:6'K*[F?NB&B5P;>M7NYHK!WVVYK1W_BVI ;X)U-F!MK
M5(78PQ+9I\-VTU#]<XGO;1NQN^'\'!*WE]]=/3 X*KN=\!=CH1:7,B)]782.
M7_SU3@TM\9^*M!/Y*BD_36PW?PB=.&"R\\*;=^T:G[I#>*AVK[Z%CPO\9[SQ
M3YP[3*8II!7=5P/N?%M^ %Z>=CI>'>H^! 3!XTA/$UV//A>9NYYN0-[_-$;^
M\/EY<J_#_IR@^+6-,=M?W7'F&6LRMN"H=J2#1MYW-*WLTZIM3>QHAI'UOMFM
M(-8["N_I^Q[9ZJ)V*NO6JV:/G'Q2;,Y\?0T)RQY@*=JCU,BIA;QIZJTS*H25
M]3N9$:/X5IA(1Y+$0-T71(&_O_Y "WQ?G M\YP+?^U3@BQZC,=I]\>AB2660
M%OD2VN75+#AE7+*HMXISWRX)Y*BG+,=OE+*@\A5VJ#E30.L-^Y%1F,9)12D(
M0,-)"\QG1H2(?MBI#H)XM80SY.3#%?D+HQM"UX!)V,8WK=!A,$ZM)/#VL0%L
M,]#RZ/3L1$]A9%@1!B?/V^Z]%&9]THJ:<[1MZ%BM^[ <8%I?TUD%5C->,9P[
MJT80JLN;\) $F,S'WRYR;]?T)S@DC'W+%H4N0QR=8P_0)00L:19.A0NL.;W(
MXKA@%!,=M^LWJNSS.DV2/X J8\3*D\(.Z>"F-B2'[N6$<D[)4E+4B<JL,\J@
M7SQO%\_I5*E&BAA%2+7)9"0U20]Z)#J'036?K7TU4577YE83.ZZD\]5]'!EH
MCO*%2@2-<LHB0M#0NM^(! V N]<,7P;_F>LM;40"Y4'U53X)\X6\$SQV;!#I
MR5NKJ&P,-[,:<&6"BF[50+*CX1:#28&/.,6^BP=2,=HB<4KJV0O4*&*+VA!.
MXW.UEJ+-HOYODB"/X%+J.M,86@&77IQ0LL]Q\%3>$8EA0[1K\EJJ* 1-;OJ^
M7FO.EM.0M/D4$5Y9?TX5T0VNG3D!3Q>V<B4L.F_6-#@,37BEMS)I[AVMZA5;
M[4J3=O<<_1 [,^LP[-NK1J':KS$@7#:2JAB=OXDA@X>Q/GKS^<KV,O:AF HG
MQL44,JF[QD2<DS?D*_E%H EFIVS.FUAZ>KU"5XKH+2642KV]K]Q#Y-J'_BY-
M3O%3OI4(V8H0!-?M6Y+8R\WC-['UT N>)3*EXY6%1<.^G@)WO.Z16QIW+0!\
MES5PTK(Y^CXOPS"3UQB6W] R3CL\W"2^71X$MK?T(CO4I1<N>>Z?6ENU.]M2
M4=NKB#L*1W/->EG1D+E7#[\'#,SIDX.B@22W*&Z5!OVPUFZ\QICD_AF?A3'3
M@D!F*3.1]"@SC.1MN/@A0=A[R4F7Z("[445/I-"]YWP1\S^$A)4*/,&P' 3G
MT X='HV:-,,DH&V1>W<0%I#F)&L>E;I:8M^CHANLB8@>*IX:GNJUX E5'FB6
MJO6&SX;5CEZ.^=K4TW:'?CC06.!X7W3]KD-BG4H!5_"W4<+5TTF1>/&7R,(,
MW"Z9RK!MN^U%KG.?+I&"#ZFG0UB09 AB3!)FY*!*/UV^L(I]/J*%MI[J;A+!
MOCN:RN-5G)A[M,NB778Y,U_+PR?LY:W9BV =&U; XE196#?H1$U4[13X/Z#A
M5)*ZJ:R=VR.C011\8[CRX/"(%&3U]"*"\MEK@YL"5JZH_1EN %<B>$*Y+0YT
MLFBRCAN6AWE1'^Q\#*[?H4^V&'>P4HED.\AISU\+>Z?I>32Y59FF.B*%]WN.
M"6.<9[.MTZ^FS=6X234L.&'A5@P,06/\ZK"&+8K&Q?L!I<XX\QA8,'&O%A8]
MA.%Q;F/K&B@'S,BV@Y@W"=?9Q-VQ"2HJHHBA(LNO!@RM; UUZ*%U<DOD&]RO
MQ(TBX6T73=PRQX*Q4\M614ZAS+ZYX"OZ[6; I/LPVMV+%0$6EB73]3X%STT8
M\.[8V(+;TB:MS:4S/?,-=8Z+;ZGK -GO'1UGUFSCQZ9DU9QGK DOW94^,/+&
MB7=-LE-:M4V.E0C1;<J<^9N.8+G.1<N*_6[#=*F9[$[.+@5/[1Z''/OE-JMQ
MIOUDHN MIZ7H6 ZYD&4&O?:G8/+KU?UUB*M8>%D$@\GGK?7/.QC;2ZD;5\EC
MI]IX<5F*4Q3.FAJ0E_1;KR:6FK-PZ?@4/V!W%OB=A(Z,][O_N[([XTYB/X($
M'P)B4(9W?12:?&@E4PLC7^K?] RQIPYF%_7PF,JMN!6O\D$1 46+ 8*$<&[,
MC 8E2Z4(D<?-Q"@J$@/9,^F$P?!7,TW5#0CN5A?+<+.T385F![ZKNOQ(DT]-
MF+2?&_546)K78>M3_?&6EBA>CWM)T,=9&=\&_C$A)RW#QCMR&+0ECW;;C7.'
MXD,7!_1R]HWL]0^SC/>'<QGO7,9[/\MXSO61<(D VIJ-D$XA=H3(UB-"<086
MB:)(MQ NT?.G,G&\:2J$Z#*I"ZH<"@ RP/,9T89K4@3@/RQ_EQ]Q0'EDO A/
M8<Y"X@%HE+DC/9V#9&,:Y@<@E[XAL6_MB8#Q!7!,CHJCI5 HJK)P#YX^ /.P
MQRK)3<[<5MF8."8C %Q'2K6"K-N)NCA]:^1RXVC+%<_%T$<643+M!ZIY$%G6
MAAV@<)G:RW.7HQ$D'#@.B5Y"ES@W%CYQ<D)G"\>;$9_$\)''UZ7-8R!&#X (
M;2DJS^$(NQ&^BS @DI^@*:?MAE"6#FR]):\BKESDD!7$YMLL>[?5-<=M;"YA
MD#*!I3PU_LI(]KA61%VL[TNX\QV*T#3+N>/:;&_:OI,U5"GW#/88(WHFJGB1
M40%,"\YIL;&PK!@O8 KZD;.<.7HJF26"J??,-2C2])*,2:?J-QW5%+BK,G=P
M>]@T($5ZQ4GSJYDV#)L/B%1J#_0Q;RJ IQI^6,./"T:>#$!'3$>5@Y=)[8#[
M>,/>N*[_'2P$/:K.+%_MEK $4I5Q&5]_H,@Y$J^ VL^ZWFQPF-KUDBKQ=;-A
MAAG?GA4>Q3X]NB4.,L[H->YF>,"4+8,91M8,7T"=N93B5\R9'P7.L)5'(#8!
M6Z(M"6%!T+1I(^R#"*'#]&BFRU\8P0A]69AEI[_-9LX,/^VMT7B[$7:[G-K,
MED@_K"/-6+R<I;VUOSXF*K34OR!X-1_4DI7"*& B^#/CQ"#;BV#TNQ"]T?G!
M=8@1]37;'!S%C@3['6Q27SPWLBOB#0Q63$D-T1X.,AMD]H<0;-*Y"D-\ \^)
M6_/X79G1D!.A$H;SN"R9L1@S*7%HFN?()K>XF=SDPEF)CZ/>BB4=ELW_'6A5
M1J46.;LCE%XGN96YE&JV#42\.I@MO=5R"X1V3O>B783_'V+UQ;IN-QG_'@[]
MQ'L0/VK;+%RG 2T>MDT2R!?LT9NQ)N]D;26(^V0IC,J ,]"M@=8R/=[');M7
M.CLT-S"^W&2V@'F6=,.'J&9Q7>4@,L\!Q]M#B%X)RV\>J7^?Z8(&&Y*,)L^-
MD]3C$J?D/?76_EYZO7A8DWE%#_%6BWKN7)-U K]JS%=)H0Q*OQI!R(1(DL8G
M SG,XBA%J5]+]!LG*-A\=EMJ/W(_I7UDK@\M:!1*80_ X_LT\]*% RPKBI^F
MNJ-9/PQIM=Z\Q8G<X:RI0YSF.4\2. VQ >.,P3,TL>9,M\^1@7-BQNR/%?]K
MT?7]8:<M(>$7J$N%YT ?*RVHW+3,B(;+:IICSLITN1?@"J4J*IJXL+"PEH5K
M1E**O=-Z8&P'$LR52^K20(+3FQ@/F$9EFWE][6"\?.\&C0(D\],?GU26@1U@
M#X"C<EB#SL6W@B\X8I.C-P0_:78;N%DA4P6_ '] D!8$B\7/-_6:N#V7X5T7
M>TZ5T_WX7R"3 *V2).0[4 _0 4,4I<SVS! J,OM)PP=2+(<> "I.(*V)CM7H
M9A=[;?3U),]Z(Q1>C\GY%]R%=A >F_*(M)J;PKO1 :7_B, Q'6D^5P0-(2L-
MG-54Y:7J7!,.15%;H/.06&$MXY6Q)V5GLUC5>J&)<L\JSNM*4P]\5T$DB'<U
M[[KGQMK?44*&.X)B.0/.3CB%UW0HKM9(5ZTIZ58'=U330HI[9%"'YN!=[2MN
M/#I/VR63?$<V_28\,M>;[=$(%J#^HU"SQUV\]F\LR3!V@:=.-9X-;VG\2"FU
M 28+'H[4BG8A/&#@N: -O_[A;WRIG]VDA>?^YH7H#SQUA8CP/#]_\[3BEE?$
MITM-F408H]Q[/!7EYWLW1N)IEKRST:'V L06RDUI)C"S>ZUG6;53(=IU,+GB
M74.L]F\&4X?#8%-J$Z4;$\,84XC$[@?C-K>*V(0X0$5)IAJI!\ .P;9L#*EA
M$^[(P^+M)Z?54F<\9D@KP=LN]HK@%$2'?-\7C)V@1;,<V;2P')^J0\1VDR&Q
M]B"%V"1+>+O[@V3>4\B$A67(-TVN^_MX)+ ^D<  J%#(7\:H^X5:>Q?W0ZN0
M_?%<(3M7R-[/"MG_>F2JV3L"\'FV]@Q-RI"4L6Y;L)[DBO.&1==ZU*JPZVKC
MM-=N7TGND&"<&=K,3@"XB,YXT &\9KLKE19)O3"!.M":RTN:F!L)#\#/<'./
M%Z9&_@M"I5$2)NVR!RN0>PK-J78]G\S<W1RQOJ7/LLL6D>VY! ? ES%_P#32
MQX0SQ(%;>8@1),48^\Z X]:7+U1Q(*LP^71S&:8E.!E#FU+RG9ZZ\-+B! 67
M)&8Z> D P#0/)VKP7 Z$1^3T7U]C4IU_&NZ'1="\4$+'(F(4,QI!EB7O]-WX
M,5(!R2GC^=PL1K5Q FF<I]Q)[^"Z2%9DAB4#BUQDI#:+593@]&R[3;MP)>G.
MNTN<A>X'3+O3B6"8:(0QE?;D1TX,B#9NB/J9.]U15_U ASYLYK?BF#P9!F+C
M>JKL^:MX[:\;\KB\J_JLARC"\>.IV)RKO(O@>G4;"V]C2PFG !='6T7IZ!"A
MKFG%<:\3>R22.:!E&3GCZ%Y:"[',\[9C!BO.DHO"B=&5DF_;(+I)BNKHS=")
M'V%IJ;W%X6D!-Y[J1RL](6=F7(/7";3N^/L3309)1\&HJ=%C^)V[F.(@Z/&7
ME-U4I0OV<E,\=8JND(X^J[26B^+55$4\0NE2,A["H1/8.0S6W]OGS6T[B*Y&
M"EF7]HU80BCAU<<C2/L%ZSFB&KQJ0X2FG'Z[:'BK-_6V[\00_F_-<!=>3#F0
MTA2G. 4BF7!#ZVD=2&JT0Q//UY,Y14G-D"07;8LD94'X9LR'6E?Z? K^"<Y$
M"*17K7 JQ1P"GT='S?FDHH]9IEEJT,WBVE$[\='/2D-<R([UVE$*E2-/LI<G
M7[;=LX7)L]7,9NK[9:QZ.5V:,.B0EBI>+O6.H<]3[Y%]]"63\%5!UH8&)D1,
MM^&IXTY$YE6U<+E)(A9KI-F,/)!5N3+SL@[4=*6FV CNO5UZM.#O,+%-BH,R
M=RE\YWTIY_RL*YZ"SL4UO1<!NVBV&']LQCUL3TFPJ%&C$0YOV"+1N*7XYB:%
M@6,S\ F;@)JZ2(ZO"XX5(*6K7E,L\4KJ]UB?CE5HJ[L[IA(PU0-J19A0O@2]
M*AB2#?*8GC>WC7I*@J*'[(#-,*T+O_K9GP0(1="+#,1P\\>\PKCD@1DXPI=$
M!93^02WY]$0N">Z0FK=;=E 5F\@N:H3>Q34JI0_A8]D"&.!3O^B?BSQ+TN9.
MZSR<46LN-]0)32 -SC:,KN6*68024$A\D1-$XGZNN\/R@@4E_1_Q/'R'!KCY
M/CELV+BM^EH[!)M9V!M+%7W@]^"8P;58T+E#U?^C:;/:R]AMN3!>?N-P\%#>
MGK8%P^0=,X+.PT5I,_JYU^JYP%6C34X^[Q@!DM^G;0A4#RCU0F#T5M >=,3/
MC$/5;(K$IXI!99+$.YY=[1R;'D%EF(D3F_7=LSCOX>%VO%KIV 5\Q5HR#KUT
M&. 94&1);NJ_N>F6EG.(2%[?'S1O&'];"RI8ZQ5$?-.% [0CTISP%KQ!<;VC
M!!=2L0!X![\IC (M#*H.TAW1QK$<M&7'$PKH(N0*Y3QF0U#)I_>/RQ,CGMJ(
MMV9;Z:#'YFF4RP>.B4'_L-V;+0(@C"Z5E*1TPF[(Q.I $'6#A+M,?Y8EL<7*
MY)U71]<UJ^CKJ-)I2S(;&#[QLA:>!4SO:%'E,-\$I+**&HMB214=Z>Y]3\-!
M]$=153NSR\EBWJN6=(B%(UO1K<7)=M?XKOC)[%UX(]Q)?-$3#UBPC!*JWAS6
M6U7 ZR#JN'B.2.PZ_"!]KS=M?Q"(NG@W2P6J&::>/H9E/FOZGK;5IEZOP@RJ
M,HGTWI%7I<RO83.3E[&'@HNS&'A3*R."K5E^9IK8@7N54>OGYS'I$ZU<C?PJ
M&IMMLZ<Z3(2\^L'"X;R4.3$\)"\G/B>3=28'),ZP=G> >U8Q=_1B?;3^LB6\
M0.Z7WW?K9NL>79=J? 7)>8DY3>*LK&>"8W])Y7*G%B$OB=9(D@,&O./,IW;S
M";68A"S(N^A*XRZ(]J9>X.A2;R1=LXH/^>MW/SYY4H7_//OFZ5\KGZ(#O#@F
MN__1[261I8XQ@UCF390L4M'N6,@7YK/@5/>\<23H23-=?XVPMK\>PD2$SZOJ
M9LV=UZUB'ALKM^E=Z7(?9)WLRW.=[%PG>S_K9,A31DN&TTJ]R<YU>I$0.1F2
M[ !CD!"94%1*E,A U3\K2VZ62RP9J0<+=C67LU]*#@);V3Y+EKDD(X/=\_M$
MYW;$.Q+]B]&#1,ZJX.2MCX/T?;- A-3CJ$:TVS6P??J-R:C $Q)(B!FO*,UJ
M.T8X,*2H&!#$YO/$=YM308(>EF3OTJB0V<UP ^7-F)&2L9^$/9]GC5(J"1\5
M7?"VF5,$6$DP*0YODS-1U)QVS0/J=Y.&_=&PPR>95D*0=V0M"0*K,P_2+OGJ
M1 JM]C4)G&)TE/(AAM,4E\ZT$"5MA]0B%Q&HHH.3T6&=5[,#1((^JEG>G;^Z
M_-<!:#7&7JWX=3Z>_>[SSZLO'S^B<SZ^9:5T)=+)@6CK!01&PJ5^%RSM'__K
M/QY_$8Z"=KVF*:=O+TB$;UGWLV-8K-P$4#,,\\;0?/R2*FK%]^.N?^!]- &Z
M:/O%8</C.52%ZKEP$Z 3A%_V=Y]^_J@*!USZ(G3E3[H^H6.ZG/VUNVV$*)5"
MG76CSI<:HJS$O:%6B]VZ<<O TF2^2)\V"<I&2RK^#B]ED-WLWIH-U*M:-VM\
M>2J!O5B(I.9X-D"C#;>-8(LS:CJ%_H_@( <7$>%BZFWE"2=I%_!&(:?GXOE4
M[4/*]:13=8RK\7<R/[2&^3=AZ5Y@K:2SPQ#AT8Q;NKIE'_"V[[97U$"J5E*
M>V'7!>.)3MX]=]9(<8.I/3!1S7I=<1B[8O)?BA/O>O=5RL5HI+95])&OD!3S
M\0T=4N_&8'U[Z,DZ5\@[T:T'*0FHK_Z4H!E=OVTY"_U]/0QAW84WW]/!RTT$
M49'3*#LT%BBW&7J@N+O!4Q?]MKP*OA?EC>_<D#ZA\XJMP0;):"UDD?E/JM%Z
M4PG;78W+98L*D^9.K;O3JB=9,;0@[#F.=\1YMA,(HL1"*;82*B>(M&HZ")?#
M[ H2)[UWB-#I93$/<V7C:I>S?R(0=;$:/09X$?7[-PTRS)B_<95JQN/)]U-
MAS=$L8LWZ:B3":&MVNF>!]TH1.OM#/0/1MX2OR2OF;V E"0I6'I3,D]1B*QI
M^V*XR53>4+=MAS#S!%2RI1;E.\0K\>N5U5%,Y4G=G%7:L+S*CQ!!=5#U#!UX
M,=!G+!9?0=H@V6"QXBJ4BE<%SARK#*:H #KBK8#F]%KG7$P0K\M3I9*@%+M[
M:*( J)I>[H5'*0 ;-'C6*+C@43BML@U$%5\:&2?>B[J0, ^P?HZ60P5D4%G%
M/7KI2;+A<O9N+5X]^*S#JEL< -/1E2##0?G6=GMHE)>.3Q,\>&F_$W.FU#<Y
M)6+;=2(KHI5H)#:Y4Y[U*WF"E(0O%F$YY9X7\[0]%FQ JZ/G==<70G[Q.*<I
MD!3@I,5JZ$SD%A#XVD<;!IE;/[]N"<4&50'0T+-FHFF9S5<58^21:Z3+\ ET
ML*BWM,%6Z;3G_V_U]D#>Z^.*I-<>\5ZB;ZCU]ST8R\YW;<R@/VUWIPJ^LCFE
M-=.KNK=TKR*6R 'S6T![8)@[+!SQT:SH3'.9CE.[X[X. 3XV2YLDL7TB89 $
MAO(G$&6RP,&R69MT(UID*4^X8P->K]7@3MA'.B7:=6.CK2%"1%@T+^B8:E6:
MS@?D[NQ252_YDD6=M&*:%WM)QA'!*]J$AQ$?E%H9AD!P%$H.T9[5P/DJ;HZY
M+Q^&=BB0;F0P*2U:UU1>,=E8MJ_I1IA+RPB#_M+3R!U&[-#Q? ^3X8?TA>D'
M^27;89:PH+,/3P=K:L@E7XFWS3=?PSP(.5^@R0SB=<>H_MCP[5;_DWWX+F'[
M_L($!C+(/_YD6T\'+FY)V:/A??]!VCY4!W1[,'P5*)FPY$.,>263B XQ6LOL
MKCG;D2=Y/.I6I<?NW,4)6-/;)1E[V3BRM@"N,, D;L.U9_QE2S) J.F-I!*O
MPV5PM>&YV]8=DCGR$5T*7/!8Y:4X(ATBKX0)#>#1+8$-OO6SDH])S7*0+@U%
M)Q&=3A$3<]/,<LQ7GO77LVN9' A)%4.W@UL_-*_!T>X/P<.OGPO$=R$<I6&&
M:5K(P*_7"!=YH6 !_6]+)S#-SE-*)=<D]?7+ON9TU%-I?ED<1!Q9!.LU?F!-
M,6.79C0G&FZ&/3IU4)UIKJ51R;PW.4S@- (62H@M#/=5EQPA)-TIIP@]S]\.
MX?IA'7]6J<X(X*GA&(VLT4HT[UI_8$J4I-#=NTT]93Y#G-:GLCR>?@,1K%*_
M<$TI/.#7> ]6D7(I1:9-0=&$G#R>U_%XQQQX=XX*D>N6Z_C)3N!AQ=J":($_
M_:5="TOB;96=\\XU8 QY)7LX6;Z))IRU">+A$7D"V@D\[D^ S1/4Z';>6[^Q
MEH2A_!!>>DL 5?&',U_.^V[L-!BXDGW!&X?UM&WN'PX5<%(^@V[?EA-&WK0*
M",<:!RK'W!A^_R%6ML*=SZ6M<VGK_2QM)?4<*;ADR2A%]+$WC7P)*2.PUZ1\
M\>XZTL;J'5!/U,!H-S'K970*8:C7M9X"^*@D19%;IY1+0[U#0EMH@"2X1Q7G
M-"##>I^&BOO88Z&&XO.5'%Y.NT%%4BMC^76$KL%+]KHGX5@9+K%$M,EA=ADF
MES DUR&.&D04IXEB'CYBFWS^AE@/D*F+$'7$.0V?#I$-PJ!<GO7)#]GD/;RM
M/F1]*9H?(B(E]/I*MMK$ 6@B1K54I8]TC^#.A_N0;2[Z0YBB8R61OD,")V(2
MC*=SM4XZFPVN$TE\""+#&*%C'+8, 9=-R>N?_/'-7+*L%#Q]Y,<C+:5YCC$+
M.C^N+'Q<MUZ,X9.NGTB#\;6U33"%3LO@,=(332@>!G<Y>^H(L6X9,#4QA-CE
M5D!S255=DVD>HD(=4O7U3N^&*D%XY4LV65U.]7#R69&?BP:DLDPZ"R,PS9P6
M]>=-QEH ?0,. *4-A-E"BY'1>$(2^DG!"[S%0O*;D'4F9%A*(1"I;+ST5>\S
M-&MA=6R%%PI.%L=)0KCPS8%0XN%9OM&>QB=ABF<?B633-]\\$>FECS_YY7^D
MX]2K@.$:OVB"8?8U+9P?X\+Q"DY4B_STT>,O/OGB#U_./J(OZDW"][_^\2>]
M$2T,7W*:.[('K](8GBTKGG).QHU&PA^>#8?RL_Q/N35/_I:_T)/PU_ 2?S1(
M2OC,W2]?A??MKAI)EMB+TW?=BS\$*>N)!M]LX&5%Z#D%,]%0>B_8&^HJ[PF<
MS8%L[=FB !D.!@'@"7<B)0=J%_F7*</W47-Y=5GQ\AQV864$._IQ]*4&^G?R
MH:<__4 I)N5+I>,@2?YS*NA;WTI!AQMS+7(*-JM 4>;)D2I#Q];(B8+_T;)Z
MA34[)67!SC(V62X81ORCF*=$PP"G^OA,YW )W%92TON8D[EI0J"S"AF+KC6^
MP#IDQ;MJ-ER3RT@&>HT"(I?5_#,)M($0F"OKF" 3GB?&7(.GE:MDI8R3?"CL
MCRHQDLA+LX:6I]$T;@2X:[4X:\N2#4N9(R0-"):.J1_=3)7J4$.@CX=73&)S
MOF,B*1C7&9,7D>S,DC.NLA.,K%8(OQ2Y$-VBB%O('BAFAH/!Y(->C6G6-$A_
M/VS)58[H6_GTT;'2P,>0 =&6"7UKF4*'#9 V=SMG(K\2R+SY&_;PFX82+^VP
MB=7=X&Q:*$-P/:*L4/Q21=D/D4B>N,ZMP!"^^>7BEY^#=>9'^_FZ;=9+A_FA
M?*'D"!]QDI,JK30R?SL,"E).7N27+;V#'I1/__;-+W: +9O%NA; >'9+XU?G
M;8W-(5VP8Y8[?1VMCH1["/V^E.%77.N,  G9"T+Z:JK:WE,+CX;T]4<_/WT:
M+-='[65S29$9C1!L?3:4)N'V\<Q1$Z1 M97JSVRE&KZH>\)E'T@=Q*YDE5<.
M>"G).0Q,S"1VOE!3X$\U0]Y=*OU$^RY;[7*LAQ72[EIN!^4%+.T7 PMVJ<0W
MA;C"--@?75>)8-]A]O2YHVD:O$7Q/<CT^:6@ZFE\.7'K .;>L8DI6P)*#D.L
MM8>1O2'<W)Z3PE9%2]$AS/4&;$7DFX-7%!.,5'N O)^K.^'!/J*_A/7$JP![
MVE"!LN]4?2?RT)6KPLD1+$5O)7&E;LA#+[P5JQ8L,[$ 1@L:(X3[9T3]L9L.
MRZOOAN&"4W)BU];=[3N"?1JFP#DG.MVR6,)OO^=RF5#])>I)<C:3SD,Q7AUM
MY(@OT(,IC!EAG8,MDD-MWG:;ACXM_RZ?7-E)6.X$=WFG! (BE)G)!L-6CWGU
M+G+Z1_Q$>G:QM1HL4RU\,D;^[ ['N-2\[Y0Y8YX!L1:ZO5@+UXVBX^9TFW"=
MZ5ZN9;-AA=U]4O8PT)2\3^%@ONI95LRH"Y)B?P9O\KYDPMD46R2#>S*,L$_T
M8A]K55^Q75XE"TG%40+-OV_46CCTAA)*.%.K<G5)N5?(DK'E6AW6RM=[' V1
MK]C"TXW9N5%%.^J_<JH@2Z*!" &-.U%N,4]F*'C!"IQFQTMZ%WX/9\)[I4 P
M)G@J__BIUDJ5I)6XM\BO9@Z6@=[H>BTN :\:[B=MGNDVDV222&DH&.W31RG"
MFKP1,Z?[CGHJ;[M^O00"H]Y2BA7VEQM51=22[#Q/C<&1"7 KQH'\(8H3N!R>
M4G-X&GMI35AU7N:4:#ZZ[47\!3HIYL>)-BYCS;+43$&KEK/&GG->>N"2IN:K
MKEO2*BW+(6=,''.%YE'0L-3V"H1!OH"GB/2PF*TT'8GFG6S:AUE0>WPNJ)T+
M:N]G0>TGYC2A"&^58$]^^1_#X-%&7/;U+3'[6XC[BP8T?^Z;%^W^X]1ELZ#2
MN^$I4?/_A#LMP]4^DKA1<G0?\ZDO_YJ!JH+X&:\00-^5+&2ORZ6IC-,G>$17
M:4+2O";*TH:+0B+]69Z549X?>1[RU3ZJ17Z,<B\?A^_U5Z@SD#E0XF(.5"*E
MI'DQ9 &AA'Q=P4+&[A5&OV3NOD^NL?>'RT<;O;+<3R:$:T<9'62???7X#Y>?
MS_0T"Y_^_7\R01A.KGB4Z1EV.7L2B1XK960;X91%#_:VH\(<@58*);+FBM9F
MQ>U()@EN**S!X=]Q:L970Z-,>)BKB7(2CJ#A.G8+SE'90#Z L%8)EWPS<X$8
MLZ%KU!^7=9AF0[YZ=%VW.,282[4>NG[#J-7PK2>4V5T>WE&SR7_/DQND!8R?
M(I6(Q+ZFN$<JWN+FH^^/-CN34_WW)_.WD(=^$_48$I,260V1K9MQ.7U0JCD7
M5#&[/'[[8YA#[B8#3NZZ;5:S;XR^C9D=>ZL*_]QLV[ D_I?<W](WOS5'2[YI
MG.QA3,D_J?3>3&&RYZ*EPR7#Z=PVZP=<?"!/EV@9# T1)O"'/IP2?PFF;UG-
M?KR^_/JR>LG9^UMWO9W]>#G[*SWUNGKEV8S>-UBE.*;OJ2UP!])'2CG8<3
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M=WU?*F0EQ;"H]C!H'*@>+ZN'2;G#(29))K7A< 8A]EQ+^,OB_9HIV0@@')>
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M,3&Q3.@LH+'ISA V*GR.LSOW5K[9W;*$0;/-\7]3! "::E.XC$=BT4SH#X3
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M5S*85;7<KF_]FO\;G":%TW7"C*Y 3^2VX\M9<B";8 $EQXG$<R9?=>+!U['
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M>*P?9. 7]680JXG'-TE]D"EJ]:9),<Z94.$$QQ@UJ>A3P_'D5G!0A,"?TEA
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M>Y_(7_;>2C6J+PZ9"%4K\JZSCYC?S!]U)KAE$[ 8J;?]>N<Q; ]]^Z!CUZ1
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MF_05_.SU^Y$>9^'(?E,XTA2.[&;AB-L ]-D12[YCI.G6CEDM7.NULIY5*.R
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MT2B@3M>9AO8-$YI^Z/3L^(U;#6,R,]H$^.SJ#0AP@GEK>493D.=I."ZX?XY
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MHG""@0(OP8EOWC0MSC3N\>0\3J+D+&PL]B='(E,U4Q@.. L0%9VLH$D4A P
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M(">6<9T\0JE2_D [=DRT]0%4'H:5G*6!J.2QO-H='YB4H_A4<,4420H2%%3
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M5L$^1#?#V,  V4%]TT/!9E#S926;82CL@ZA65V#?F]#!_N=\A\!M:54)\D6
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MQMB48INV\V,/I$?+BHA)0$R=:*F1H\E&2AX';_XAFVMYZ^YO4=QW<G_%_G'
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M4TSW_49S0V0G8AZ,C-%T9VV<ZJ#?UK$E-UIW!@-[FJ^N@Y$Q2FTYDC:?V-S
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MX!_X8I-P;5-7$__ X/\>_F1%_IB8T^IZ''%_%(L\6$B(;@U&/]L\CSC@RW)
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M5@BY#,!LVR^9>WE1**R'M2[?&[,%.#2$7 KS4E)=,R,P5&<'RIG-GK*#!IQ
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MY>Y3G9)YQCE4&L\,9 :HW>!0CV-Q+,'W=TB<"/HZFK"RP'?OAZ#I@_P#US=
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M?ZD']D5JBA.M ;TTHK=EJ#&PLPG-B"4 -B$C!QH_NHT\4]- 1@?2A,2$@F0
MG3F@6RYQ>&87_E!2<0C#5;/$PO;L+:@(-"!8\$5;H&VPIVC/+4+32'JA""*V
M)0,V&?S< C]P)T-L&D3/EX8KLN$U1\+^+IQ#P'[%U1M0$>^0AQ839H9#5D_L
M\[U['83[,"$W]MPI0":,X +J8Z;P%D@S+R[NW.@D"Q0<"7LV/[;0H$WHFGM8
MYEN8-2T %MCUER0<J41' T\#+L?/BWR(5<G7P 8?/+'1_.&RHTO$+$%$(FP$
M54.633QHB6\-1Y/PF1.#-&![0*(QD4P!09+P[]: N0%NA27QILB35'UC(*)
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MOG(IN\+'755V_2*S#4F8#7A+/>,P$@KT WHO\-A%//,T$NE90590;R(C2UB
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M8UPQ!!=K^LB*A7:Q><14Q/A!^(O\#G(!+E5MR[(J A,U4-$%!9Q@S_IOFR$
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ME##P$4II"=R%H10[MP,P>8LG-=P^\/ 5&&W)[6U,5N-O 6ZI 7D4.W4$,E[
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MN/W Y*WJE8.Q:ZV>^5%Z/D@NGYZDA:U\^]?0P:6."FJ*H(T")X(KN)%J/_;
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M^1Y5SDR>.Y54JC9*A(*<CE.[2D>M%:UAGYZ,I<XVD\X\=<- 3BM4[7&[KR8
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M(32Y _T,B0_*"NTDP</]Z-N_N'@/U1P62,V9Y=.V\)ZUR;^35,&M(+'$!G,
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M?;Q/Q=B^G>6C;=;.)2:=VF0XKE@0[\EH)'S</2, ^:P"_PC>'*B" T7X_.%
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M20[@\!W +0+3@K1N.0<"XS&2YR[>N5#;O0.BZ!AN$**3?AJ9]XC2D=HNU4
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M=I>X5:_#S5*/3B1>9^56M;MD=9#L<:@HGJ*#T=A+Y5!WW;[CFV%+)9?ISN:
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M;@RPA1;$%4G$H[<#O  O!BH[2'E8 !//,L9389^=(L!8KTV2PI@*H8I!>\5
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ME,RVA<U'^+NO M^S"OP0,+BP#OP ,+BX$OQ%AG KS/"UX(?2@MTI<(^BZ#P
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M2D &1X>IB\Q?^:&T=!>C\6YB!MP;!_D*'!XFU+(=K($;Z__ZDX/\!!?5/F+
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MRD+5(^IG!?A9 7[TP'<87)(K?="/D,RRH:Y*2A4N5TJI>M$:/.4$!O$J/UG
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M_E&ABCO'Q?/H164NGBJ6%QV6D.9=FLXGAS4C=UHONJ)GAZTN;&F864RY=+]
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M1*W7S,?SK-V9)>C9M$G&R 8J&4P\YX-.D:A36X:^0J"5-)MW50;,7?88D*#
MY:@T>?K,L(@@1K%G-URBFAA5"P+#8U-4=&]RL\.FLB$RZ9P$[QO_]W_VM[\K
MET9FEF[\]FJB]\[E6IP4-BHF(#0R "^'^#%\]6]>6?)KTRO 3H8C.P/)VU8$
MLTXB'(G]-[#W]XY7'[#S56@/9JYY$E+ V/KM_LS[S'#-8.=#W<1W_AO3)90J
MZ.FGQ01%AG%$%O[3/5B4#,=C%[JL5^H*^<#40/3ZGW8M?4H=>%N"MK&Q#'D#
MZK2 5.:MR.3/65SX(L*Y!QD=O,7=Y$A71"0GH2+'!]J04?,S8$,SU@P&"IJ
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MINA<=OW3YN^X7^L"3($*!+(E;Z-[IF9Z%G%=8G\^\(,.<;BK9G.BZESM>5?
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MJY8%0I?<M SX>2Q=%)LGX#X UD*:X@CJXD0C61XF:V9$S1C0#Y./=.LLW'"
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M<Q>'DPWISP9+):Y2C>\2VVH&>]M242NSM4[,$,05:,&+.S H,58H9%O"XL'
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M*6914C^:GP0_2+[1[/2;#E49FZQH(NJB]7NK9WI=4",M"BJ2H:@%# F8MC]
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MQ@!<,0#>9/^M\\=&68CODA=A9X^+?ZB.!]!%WOJ ^X]!_ .K:;>7#=#/ZC&
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MU-*0-85(&6\B\#\/<GQ5LU^FH#QK?D=Q>Z$M5-+3A1+2(0#CRR)#)G6?3T?
MFQXB+*8R3NM>P?@*N.L>Y9N-@/#GDC2XU>8<;=L=5=0>+ ;1!/CQ2'9 "!?
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M+ZII#8RJGB0>N)E)VXL(J;$(I5DW4)!+\HH7,K0A5;6GFG'*MF?D.";V=Y=
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M8,?HWY*TZ:!%QCWC56(*J,T$QHYQEN(&D))5O80<7R*X 6SF@&]Q$IX'%&4
M[=* <-X LJ,065</>VX /<8KP[<R^O_;91KD2-!9"-)/>N9]B"SRK3?'2>VB
M@P4+N;V";Z@(M7@*8-TQP4M4)]!@Z'W1@P=;O*9?79.I>K[7W4\XZEVR7/R
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ME?T!X*<5#\PM_.TUIX$DZDP-R2J<6Y(]+8(6;E-)96!*?'P:]]>!3\:=;>T
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MJ3YY &-#L?^<]&%KC+ZCSG].*OQI5;,IV8%+3K>."7M(N^#G7P._#/?>C-X
M+$@/*:W^%CS+A=U#N1)TEX$/_0W!@?H(B^(_=CX_V _J*R!R,.ND>=48SQYN
MP+/^Q"9RWW4YQ#KR)>$AC!8"FBIC1W\C!'?UG&;RUL[8C4/X"K8N1#0*AKU=
M5YR!UD*U0N2'%?<8=)3BU76$ 7(=V<W:"M,0#91J'X;WIUO-W &AP,<R[QW_
M['%<X'I+?2TU>;_E,TCOMS%*A4<E\=J -[ /92?.VL2.WYUG3N'E511$] LG
MN1PTY6R/J$T.?>T?SB4$:P*<Q_Z3C*(#Z!E$P<<@-FU7TG!1(N(W/(8"V" E
M-K(D23;[_-?RW.M01+(<.71,&OF7+.5\;TQN #'3MZ.8]7EJ9K4A)Z7#0([:
M5+IA#D>K?=(-H(L?PG8#R/:[Q2U7V&;R?Q9-I+2$%QS)-\-<C<^S%OW=KX0W
M.K4O.(-N<5D[>P[FH1>"\_I!&^DMYB>?*=)5K2VZ&CT@_?]F6;&VW39D8GX#
M/F+_K5(](# ,?*ZL?0.XUX!,P(0MA=X D 3.XZY_3-N3,V> L3\+,RJY52)3
M]R?E8_\D.%GX7PO'S!G>[C.!?_[YEH^%F*/5;P#/#KIN &C<FFT#W;UBJ,AE
MU__YQ9V(#F:A"%[?GN3;YU;@&1G!CD'"3(L;8Z[>,)XEW "4*+BGY%.N$7O%
M-P"1RU&)?])>#?US^SOAYCK]8WF^_W?+CVAW@ AEZ)$KP!2( *),0BGIM]+0
MJ?@.G1H^$[FTL:DR95I"0G/&T'QZQMK^?R^I$E_W_XJD2H=EVBM)>8S=[@\V
M.2U^5O-H<IF=8U^^2%TW;?Y55\%;=Q> _U8(6+M$[;*&"KUB)7-L3(+Y.9\Z
MU!#K:]=%FLVI"[MICE7GO\REE$ZDIP;?NQ(GU\8"IVFAZC[Y[!%UFVGFFHW.
M#B4U1D?Q3:A8Q0S26?!G+Y]T@'HKKJR1SR_[+)G'3S3U3<?CG1^7%5#7ON%,
M*.RU<AU^1&WI+]3#W,_UXTKDWN'=F3.MF4!YQJ83\>N)A>.KH(/)R>_HA;SM
M^PL@U6SGI5]D/1YLM"NS!'SE0WPUTV(JCHJ<O@NHPL "1QG[+U-0A\U\L$OU
M@K"%"+ .A9>0MRWE6_%;#05<U&(]HI@;VFJBZR6R-0VRW4H;1DJ;,.!,RI!1
M1XPS$@TXR[;D:N1#<[OIZYB20!+DV;]#IM0&'P/J]#RH3T&^TW.Z4IBLE[0[
MSQLNJ:*RB:3!05V>1]S=P7:_'LD1L']RJ6/Z2$VI:%%WGDP9:NR*L>NMN%3?
M,I*'^_[<-/L^:3U^X",K+EV!JU'8YR+G6;*>PHH+Z1I1&^1B5Y0QA)(&C?D>
M=;A2E>2#B-U6NEZDTE.-3(N(GE$[LN*&87[VJ[#XGO_ U4VR'A$1;9MU+"T8
M[VX\S>0KY14CEHG@NP\<]:W3^93I' 99/^+ TDENQR<^C%PSJ[A.@[G4.-.[
M@(O)8([3%R[BQ@1Y<=ABN5[/-+KMV*?5-EX:2,6J//4E^15@*C]4\JK,YK;9
MYB2L[B?-T&I&%82>[%Q[Z=0W56/Z0FBH5A8#7D?Q>J9PF/3]V.YX__E5OW5<
MYFJG)5<EJB#$>\%/ZT@Y\8I'QEG*)4YQN[3ERZ-@6=4W"%'28$]'2^%Q&5V_
M\NLVP[K&MI86EHE!C11^JW"F^^YR>BK?"P')G T'%M"NMMOVW(FSW"*@< F:
MPW1&9CD<7K6<^[KL#?29^XA]U+9W]X*BH6A\66W;_W:FJDQA_&3DC[G)_K(9
M_2EVSS#PCW%]V-M/!:X";X=8;(RAK.(_3O]C2K3_U(7JCQG$_AZ%5FZ]TA9R
M?$"&?F"BJ?++/ *HOO_J?/:%)Z]FR!VU)P_%)O[^+@;@G*0/W9,]?AT-=QE7
MBD_J=(DA=U=_W4+J7@DI&UJ!SM'9_)71KHN",(Z9<C[;*>\6<135JJ'[+K!(
MSJX^DVN$\2P4$G'F*?R:]'4;<?.KTJT9HU.XC1S)SQ-Y<C-S.!K8?5$H' %V
M!8WHN-JDJ,<;&!_&F[NJ6BFR.R\LHYT1)<[:A$#5/)7O8(,2AX%U^8N']V7K
M^X:/@K9506FR7C.I5:NDN)N+,A/?*J?++%>X.($E_B_KXQ<#_#_?KU06?5&I
MLBQ"W-^.^+2IR23S7)9E:074960AKQ4^!QHC*<J'H]TOG32 #_E9Z@4'O,L+
M;5SSU)7 ^LSZP7ZDANC'*P:HT-LA[(ZS>H!'X76=:G5*^?[JX7K*D$9#AB*3
MD$M"L,H;<D&GUARD0 =M9D3>EI[#L+MS/EO%G&SB7D_I=OSMT&>4^IA*U924
MG_Z3UZ";S(Q]WI;O&XX4QP+'T^^S)F9*2:>GTYODDM8ZE+H&KRD  )RO%%A.
M_T,949R6JFH3BI<LG]X "#@_[<EP0CUG_#"D=0T?')/UJJ@]-93<6%6]&G+"
M;:*B/7-%0B8F,;A@D!D2%B4C7:CJXY</+C_4V.EQ5&I^(,P2\BY1,?);V$-@
M?*E(ZO%S+IPA'^B[7HRS]" I/;A$83J^4U;\!F \85-UJ5)RSW_V]!U?55\S
ME2=;&*M'R_?VER03'9G$8QA&,% 3N?_>CM<[2HZ9N)D.KH2GSIX19F_'5B5"
M/J3.%J]>5OR?3LQA8]T &,MN>T;?D9CL/]*@?E7CR@['^^=N]->N5'L# /G=
M F!\3'"-70D0"FNZ??#O;P"*9E4*L;=X\3^DU>'^8_) LS^:ZNEEL^SPQW\.
M:-0$810EVDYN6\+Q Z/M?-@M04Y;NEB^ 5P0Y-?1SA^Y_SO+-G0#L(6=WQK\
M.[>(*0VZV0=[\;<YNC)G*+DE[$@4=F7ZIFI0CB<#U GO2?[$,NGC7C$ M8O7
M2B9BR,J;X_U4Y3^&/Y1OL8OC[UX7_.*5'TVIZ+5&GR4CBC.,'<51EK>ML[C0
M5<"7,1:]V.-JYZWPBI%M+M*F+;5<S87XZSV?BYG.C >6TVZP_:A9C=F7F:<]
MG"SP/41?TC@GQ%5'@4E0AX;,9%'\.NM*8+7B33*LR RX.,*_S[?K-J1;C>Y(
M5"'ILSTW^6;1%3*BY1.)L$D[G[O M)A6.RD-2, "H*"9$C'> _X@9LCCL1K.
M*7;DSO:;P++KX:F2.^ <&W5V0Z\SX;QDJ.&(*DMSG>),3094;T+4.=!:#X3G
M',21^I=&M>=)-[#[LE)$F*]#SC[IJ+<#Y'N8]M8USWFZ9C0DU3U,CJ%O>4]E
M9=N"[V7(PJ*XR:)!C!N.JTXN_5?*N6!AH7#;I2X>OJ=:-35-DR<:*2[[>OL_
MD$-A8KGAA#&\V0 L(UMN15PA7+U(!,4-H(10Y(,^IFSC.J@@$>AT1BUW=ZJ&
ME +<9 8D)74R*P]UQ4N6!BXZB;#]YE./EY%)P*7#OIYV3^FR:CB_LD;AZV 6
M, M2B2TS'[PUA0.VCM.F:LCFFRU]NC$Z=&XF6.^)7&.<!$$I'P.PT&2(7^6B
MTA'24<\[5U4OG\ZI$_=;V69$:$L?&!'S5+"U6:K1X%/FE$(XQDYF;9+V-W0%
MO-PI\[]:-1S> *JMHL(,TKFP0H?:XX(-PQ.B>4#.FK)MQ#7BAD4%=8C:MC6?
MTP2^X5+A$G=3,A-QH5@5K^@I,3$R:V5#G>(<+(5V[ QS_,Q_V5/^]QN=VJ]*
M\">< ++1E<=+;G4W@,Q;8K"D=#LR8F2!VVU#!NB"G\_D__%#3-TMNAZ]1> '
MW_2M(O6(U8(6W&\ LK?=M?4CXS^*Y??0?!5COO1INSJ-P5Q0!#8N80)4;P"!
MA&D45F\G0_=NR=X17/YR4_=T!WJ^QWA]S.VB&XZCQ_@/[:ISMT/,1C7T[&=1
MA0K7_U@]E'=JU@##*;%V2D%GX^4K7VL>_5?:3=$.^C>*'^/E_MN;TZ&-O?[[
M=<O]HWK-<"$%IZ=_NW"NOU<NSM6#543Z=^TY?[])@U\Y%/]'U).8G?H$1I,3
MBBV44?#G;'S8_W\:V/_=:6#_CN%Z4; 84??01M>RTSJQ;IT%"U5K;+BIMA]O
MU4#&IXK.Z+5TAN!:]S_,PA(@%HR[&^V#RX[?!Q)W6W)_S]1H(O))V;/6N\QC
M3OS,U3_P4F%8[JU/*SDZY993TFZGAJ3DC_HS%!3T/:H3ETK*\'HEI<JQ%W]W
M(^IA[.>7--C"N?9,,_J@1Q UI'%W;!"7XQ%_"0R=N2\KY"*CDNH1/WW0M06&
M>=FQU!V&PBDM-R# J75CNKO]AGG9:$)G>NX?LM8*KL8(:W &9Q.R-VU9ND7X
M9[?HN0'-<0I;IGWHGARP\4N[,*G@8T +D]QD=BL@M),,7850_2 *ON()E/@0
M-+$B'GS[;Q'.[\!PL^#1S&^!7O35O<((?GZR).;ZE^3.[IV@>Q#7%6BHV7Z=
M!V+/2OO3:1:)*)$FQPW ,&S/YRZLVU@#DG3T@Z++NYVE.OQ'>[7-=UQ:P,5H
M=QLUA'WYVN<X$&1TR9$;\7*8=#8/0C277%MSGGCW?#UJ!C8868N%UT2+?FJ,
M]G 4B#P)R II(Q%;(D;;&2.=G[IAZ!LF$,(=I8/L7;FDM)]-?N:H'\*D<Y^0
MMN2B]9%=O7%.0O2O?,HX>_2V&JOE'D\VRR(T,N3UFORM?(Q<+9V[B->"E6+<
MQEAI?KS%Y6EPP-EOY%G>HT9XNR*/S)']R*F1#(2D@'?)Y@F]!&+XI*8V[W4$
MRY<:>NRGC7O&]ZOCVXL?-N=+"L:W#N1L6<I.REMKDSE@:,9(WS?;-=KEV7^%
MSYY/*[S*!3HR1R,B:]_-.+/IB;^:+SG\"  $P"*:@7G@!UUUC?MUWB['36)&
MJ;9AOU\U!!<:*)A^J>(B_!JO!C"*2H0[41F=Z?(6/4*5%E=UCZEA/<2*:[>5
M.2S%P@_&@H7+>"%#GZ+\/C1KV"XOA5!/6Q*+O]'0R-ZV?)0T-SIEA)$7]JE-
M%1Q_4=LS#4S4H]<B:IV(J75U?559&[*X2+.WAU!\Y/'LFR[%O3LZD@ 2  46
MW[^)4B"B,,Y01S6I1R"4-V*BHK8F^ I2%\K>:DM6^[DZJ9U7!&^K;12T43AD
M53.^%?LB8^P)T<_]98JVUI?2RO,+*%2DT!E]UR4$X6)+I*N(CY36P<\>,R\O
M0!EWI,JVIO M17C3V4[IR*5M;,>J"+S;6DMZS39JU5#LR_CPBM3G.A07(X \
MR<\K[<*M?1.P0S7,NVYC'&5%N#$\3__\<__+]LA@+IS:[.^LJ!M "#O*)I-*
MF]R1=,5A]0BD#-R,VL['FG^UT'SOOE>D)P]C+_0! ED77@VZ9[IE;+;QR<?9
M.>(7;UEN.!/3V]Y*M5$>;N2$"G:P^D+ZRP<*]"V4/5D1F8_&(8\+=EIYVMZW
MOUY\<5J"'VX?W=']8R1?:%WPGG;24)[ZO7K;'['.1CLKI!]+:^8"R5>[&Y5;
MJSP8,T@R^*XT/%A<^5JL^>K+IZQCA3YRU@#<Q\QK(U#Z'99L8VM3U3$T#E+E
MB?3C)BTG206X/_FZ/A,0^%AEJPBK8-NS-2Y[/KZX 70?X(/UIM<W@"B[T)RY
M.?.()^N38EPOU0JX'CWK^77',U=\8N2N9,=7DM3P3A1CE'<,$5KIH/O,3TF3
M87'>_/QTJ>5(9]4]N>X@J9\H.C?&K.=G*YLE"!Q,S&F*S(0A>AMK TJ<2W(H
M?DKE2Y0T:W5R8GU&H#)?:TW\Y1GT_;JR1I(49&]+]61%RTCXY6Z5QRTN=90
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M0^TCKL2QV<%X2'?$ %WW*RL]UET8V35@Q(\40QN#%4P+V)17=+T&S)JSWW
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M4\L#(T,[H^9-4?#=G&7*_>,(1PES=9K#&T4DR.I2-/YGQ=L)8=(-R<A'>)M
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M[N.=?EN9=_!P/^Z=%-:NEMM@*5;2VR/NU?5')PUA";_ >TM:5#PE#6SY"T.
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MG")65K</UO=DQ;G3XL]X,=) N97RED-';X*K*/&,"S4?BZB32_8;^!)U#4@
MCLCMVE== \9,YC#7@*L(MQ8"!^.0#HZUJ ?].B-=8;<;!KTHRLLOE3*!3DZ6
M[T2BZ+[4;+3^Y,B\WV*[6K]#FG"I#[-_2INJ<E3$-U%^Y$M]>M:N,1L\ J%#
MM?B?E$B_KD:'Y"]OR9H7>(&:?067S$R-?BS^I%JZG_*<*J 'M1G 1[":O-N
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M73<7U9QY_5F^O/'^-V<J[G*S<J8HY?8HB3;OLXC=4LM1&0'/U<'[B.E7PM3
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MN)>TK<N4&*[<[0^&:-=.&R_1><[JGV/F/LY,*V_+>JQ8[#1I;R\GI/R<O@8
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M_AJ%O%U-BOZED"?^_6U=O/KH\/J+D3=TDVU!G%;X_%(??7D1PT%3V/NH6^!
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MD)?$=PD1QU/P1(Q$OO* R<82NT!!T?N:')]]%&GWNT-$*NB_X[.&Y]<@VR)
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M_$R*DLJ]WJF8WX\K[4J[(/H]BW@K]"JF;8T%F7+='_\6 _CUV?@'WO5C<@S
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MD%$*_P3;>)Y:]ZHA%0,8.0]<V<O^B7)E0W$)?=OFSM \B_X:0PWMZF<[",4
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M&K%8PQ;5$[VRQ+5]ZJ'-/3"GZ.Y(N: ^:..\AD7M2YX\V*XJT%)UMD"-<R0
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M=W18\["G"T2;7RM\0!,GF.'R"0: %%OQ@+\$7)*E_P/Y$R4Z$C^LX9N%:&,
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M[^N>@R#8!V5:H,A1X'2DTG,S<X'5U!,[0-%O>"%]K:Y(3&;$_YL 4$L#!!0
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MD_?.,'=3]^4^+[\:>+CP2\[]IEU&8NZJRI'[A6O^(4@A/R&:I7]\O3D)][J
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M.K%(0<YU>G4;O'OWLA?CJYK($3;DF6H8YK[@(GK&\&U!8//<Y3:Z9(TX:>K
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M^]G5=![?_$*N):?(^3902A@8ZC"RKMW)I"S]=(V:*HQ-C4T "["NPP(RJ+&
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M[1$^2G'GI4RSQ:3?+"D2.G81[A5U?,?]>%6J+G3>X@105DW?O?IDW_]Y:7>
MF3P!D!*;R Q$@7/?WD^W\V:5JJ;5(A_)A8F"YF!+L(IQKO&CCV^Y_"M+22.Y
M/5<+7_ \H/,,.I@*.0&$/T=XHD (V09"5/YSI[$F9?.GTB^&K>MFP(0K%VGF
M^SR*4D6A]A"CZ 6:,('BI.?"+K0M(798EGKH<>"OV9H;YSARHPDB62Z4R%ZE
M=O4L0XIAJ!OE+V+^V .!\'I%.\TKG>J]1(ZWL8A3O+>K!=1-G=P-@[UC[IRL
MNO+32$]##Z-/S=,4-R!&X.?JRP\3QIG$:BON46Y=OX[2A"S:N\$P3LH<X>VB
M-=L:L$-$\M>V1V9B-\;^JSE"U_5_/AY!UT";H&,M<(?,Q;Z%?L_%GQ-[EJUU
MZ?=V;:=]019&T9-QE)GR@865#C5,)/J*+_B*=;T67)E-5%W=L+V( DX+4OER
M47E3/H>47C)!N] 3]ZEDQ'MCD/HIM]B-]P/O>)I;H?6WE+GU&YF*_!>__J#Y
M0A?[%?(TE1R >%BR[S__CK/C"$BQLHVAZNR7:Q^\'FN:"_Q9@.*V.P9B>#&=
M,OQP3=%Q9[?M?9XIBYX?VJN%+6%0 -#]>()V,99HO"DO R1?&7Y:AN@Z(IKM
M:^-.'7U MV&5-_!5"?>*S(UM='?!!>J*/7F1WPUD"YN/&F1$"XZ:D0_H$#A<
M)-W)33/^&%XHV?T2T*,@F0Z]7.02;F8\^SKL3I:!S@_7HKS*;^^5=,^4MQ2_
MBHM==)TL$;/@U^*6/YT2?/,&A_PXE',5(WFE(_' :O E\OT785G]TAX^U<(^
M#AZ&C3OUJ=!OO:*YX>'EKE/-<V'%O]<MV)IKMCZ7R,OFM.J:OM8VS7VU57S3
MV,1(%OJ0VDA]3Y-M)?;A!)+Q"D['R(&J^0YPN!^WUT $>:)X8IF+P@;"MY-]
M\,Y%"UE%WD\P6BLV)0*<R]>SP7.&[02.HQ!8[L)MD%4.3S,)64",YG3<$.XO
MQGUJ[M[6I<@4],PBPK&28(_D! Q1%S\[GN6BDGIWD*=TJPV=KJ=%7:0AD!Q'
M/,=WR"< &D=&ZPF ;6.UU?-QM6/=0!!L"3(ZL1C1V+NYHY*B>^/]Y)\*]930
M'LP0&7X^7^5I_HCVQL31KOK/RL3IXB/75W0&VV-;O4NO%A&@8PWZ@MT-9U3'
M(W&'F.J>]VG2'&/W+C_7O5E99,&>H: GW+1WTR2!X\]FT!C'3#=!MVM[\0F.
M#;=12+GK(%N6^I+G->JRQOF2%DGJ1]IULI!.EL6XNIR?1X$6K1;W? /4^)AH
MO)^I9+P"#7&O$9FZN^8C!5');6;Z?@*H.@$DMPBNKI@/(M2\@PJNF$MSO[(Z
MO\[FS8>]N(1NG1JU%X-=ZODRP-DP$F_\="U6O>TY%X=^C9A>IYZ=5_E<GFF\
MATA%HK8G>:"5=[Y]UM^.KX,7T>"9SQOM>F/]U!_>MC*A&_+Y7+Z]A@J^]+AZ
M-)!S G@*3JA$R)"K6#("5 R9.LYZ>+(F]Z:< /K$-.N%0R\A\R,R*;?"@Z1<
MD@(M/U?<\GW\7(OQVL1FQO=D?ID.U*L6WHFZ<^GXH3/S^T,ZXU1M9&C'-VV>
M;C:.EN2) MPA2./]L+Y^\4;]/#WG$AFC_I?T.YRE:[!;Y&/A PLT<W56RM>;
MTV5F7<ACOR2Y34TB2/]XMQ-YO9: CO*S<]]JL[&TT?,1$F@U0Z_!7LVSJKL$
M$('=O!,QVQ^:N_)\=S^< ,Z++(%>?L>@?]UF2;NAK]:W [8G+-Y, M]*5RUN
M<IV:QX>$]FZ/=ZO1";\3-/I_1T\TGKS)<SM]6WO]^W,PKZ]%ZJ_&O"@]KK%'
M;[1C7QCX:VL;/?.\=U9QYZ_&N?;4AP9N^?[W8V<SBHM3M#F?] O\\7VDQ7CF
M\9#6O[48?X,(1K#DY 4O$#:L1BU%WBZHRI._Q;+\Y4*R87OR=^BZ-@ILK5/D
MD[.>GIGX(?'2;&F)O(E8JX7I:Y0^=8 L03P-BH-=;)+#QSR@4Z^>\$L4\TL/
M;_(M!9**XO5?+ D-'JLHA<#WJ;J7X@K>#UN8RV>0TP>6L4*UF,M4#%(6'8$]
MCRFH>GNSOIC-X4E$;Q4P$T*^^(?J;3\/>X\E/(+%0/#H!&/7VP8-?7?K6)_Q
MJT\<OJ-9<AS\UF1]2O1.:.$H.42U@J^W#I'&4D*D(!F_W_]^/]E8<>-=MMY?
M-]%<K+WF]_\BHS(0"SG$F.A<[Y2WIH@)*;+_(1@^=WM736"L^@3 A##F2H:V
MOG"3[<9;H"0MZT_%3ME@C%YF]H^^LLN"UM#L>E[$^3];$L58CM*KV.0X7L6/
MWJ@@G-M"=;ABNM[#V)?%LA"8_G*3,2&D2X"Y9LA3(?%*B++?Q_#.Z3,/+4]_
M<IAX7IH7FZ/DV@_.O&%>(/4Y239NG8(BU'6"F,I+MRB0?(-\PR">]+-ODS]J
MM:I#Q6SN>A<)N*KECIA '_X;RDR."I+ZDN3JZ/HE,>)SW'/SL!]"1,R$S&_X
MXGGR "'98,SS*O_3T=#D1\83O[02YPG7HRCP'?&6&CJ)^B&T0AGQS@6XH'S!
M":NZ7:&[@;MY*\G%J8?0_I5)[9@VU=B0P8FE"0I--RLY;TNTWD]W=9_=&):&
M%OU/X-?1@:]#?GU DR!L1UQ[=\CY*&OZE<7B3R27T"3#X<3:#:0T<DK@1FH'
M715C$IW]9](G[OZ2!3?RAE%V[3F]C=LO];:,@,T)\V>O6OAM?:XNX)+)JH1E
MJ>O'B6*BP<5MS4PXD>]8=HIS?3,O^V7M)X]SMA7X?K]2)"WLS:PDMS616JK(
MVI]A"&UJ?),33N9\3B/1C'>&Z\""<RMVI48@H@00U%WC]Z2HJW0JX_YLXW3.
M[N&<:CG#)=ZWF48F"4'9Q>)&OR >S2;UBV@VE(L,#T)ZM#K>9N-!C:A?%.O:
M1*9M.)ZO0/A28=_HGR0)S!CJ*3CFR"+,#^DP(NVUN:"DI*K0O*ZQ>3LLQ?KV
M@-'8'$**(!)#.Q](EWMS!401:QL[WE"]S&FMIF\.-\*N1::])D1XFV:J&Q^K
M4FP;R/-$)JMH8W1[,/*X;YDH?"#%7UW[TT \EJL<RB P-O/U:U6&T-QX2XG!
MS*'>RK<TY>&C,?FWMO4S=E]&9X),L$:U+64V]UKW,2]IDH,M'*LG@,L%55#"
M7('$O:M#M=:*S'V[23-%'(.N)X!*3*(?AG^2K'^VTLYD5]?NA9PPSH&SN]ZS
MJZ6$().T9R=$\B%K+21SGL\GU"4\&?4]+HGJ>OS.%B3^./0=K6;2QM4 -S\M
M/?& ]00 ST>W)U?%O-TZ?F"B<VJK$53FJWM*W[;\>&=^K"3;$"GY4RS$5?GS
MXI:M7;7WJWJHW8C1QA#Z,D*'^EY=ES#0-K+1D%3V:<[FGJ#.X-K16Y^?!HI#
MKTQ3>Y;KYUD1K$38*QK?&E)Q;/-25'+13!;<6*E/XG7];/5N]<*N?2=Q7C>E
MN[6_T!)QKH$<. ZMZ+]9+[59=R%Q\KQYUZV?T)T2+)=Z0#E%FYJD+E=*CC=.
M-1D5)LH7+3\ 7,P5/%V< &#\5*XW^/G#<$O<!FI,A RZ%]E?L1O%:^+M[J?B
M2)W.AW]^>T/YL'8));2D*IK;E+<'P 118UJ$P.VH*9%VG^I\R1HE5:<? V<=
M<9"%5GAK,2VLL.<S/#-T4]HA?0ZO8M[]R#RL'ZZ3EV\B9\>SO&SY8)%@_K5J
MRAN^K;MW:KPIA%1'[",S+G#%>3U^W1W@QSAY[<GO_$/4&X6U;+8QJ!VAY4UA
M3N_LE/8M\/8U\'B+*3U<4S<,/0B+[<%/54YO&,NJ'D7>2QZ=V+1RNA'3.1SQ
MNX;F0MBZ:(CG4/%%O3F<RG-_J<HBYIJ+==;LD/!J%6!M(6['[R6SK'WBV]+'
M>>!G!]E&T8]/@2.?0ET(\.[;"'ER$0[-#F'-OJ1(=$I76'\47I:,N V.=++J
M-TTM(%I-3^3(>6A_^QN\7$+0Q7'4YI<%6H-CH/Y(B6'<BXF 07%+ ]G0U7:_
MC<XG9(>%NHAJ8#0O- $I#)\X\N7]62:0Y9!_7SCEOFE46BR-=Q.A1YC&7=J.
MI1@O?G3!<]06X;:TG)NJA^5W>@KY8F7O7M8Y-XSJ*IZ&X,#)Z'-TY3V-X;(,
M5((1<E)F;I:AI4/\59A+&249W0_'K N$0P]W9GW4W*M#W.8F1N[],DW+:-K*
MWYN&&/T1N$#'F] B.E$&9RC2A9YJ.#/EX,YYE/@)IB@WI:*UP#I7[P9V"?+5
MD,!_FBC('C$G/(_-25(0L.MMY"_7HUVYI2.!)0A@"%@<JK/?$\1$#K_WN2#*
M4\IQ3/K/H;2,OL.!K>-I[V1D6A5XBP&'C8'1I6/LI_&_'EO(ZV5O@\T25JZX
MWQ;RC.TN:KUVO#+^Q9SX)O-/8\0?ZQ*%@)+#,M"/#)/*E)JID2^-?WWF1.E5
M%E\@[Z5+"HFF75Q<F4D?.0Y5G3-%8AF2&[^QU#/&+6M>H/77@KD1#D@N:U7H
MJX7ZE*D+TOIE^^V1DJQ/-8@]&F=#,/$T(5MR5'O;2AN(;P]T87+:E6!C.VF;
M OO%L Q^3OI.D?A..T..AQ @6TINA? 6H9J&D:V5!CGW]0XM"?EG2LD'L7M%
M>5 .=0W=7X?#7LYT$KR!RCIO5%(@$NI!I2L&N2Z%K!LC?O$;\D_7O-3?2"B9
M<,3T4(H_N@8F!?Y%W"LV9(L53%F'ZO)S<PGS#F"*DMO*@^,?YY6QFS-3+:@Q
M39XT>?+9O-(=KX;AV4UAX3\X8!^:?($=&GL":%5&&),@EP*G'P:TW0OR>/XI
M>T>HZ 0P]#2.@I)O;["<JH@;/CC>IT*2.DV7,,*-:$GD;,MM%!=MF";&=]#Z
M13[8UY9P6I1>B"7+(<UWJ?Y@GAJ=<9ITX#CUUW+]N->-@8KW,52))$R7-QLI
MK4!DK.HX0+2]]*9== ZHZCRF]2R[L:5 _1JHZIGQ /'@.VMOO+!7Z?0Y79XS
M7E=983D90X;EE#ODZ$_S@7EM2-F12_E3UH$"O[KDL5"FG9L[YWA"7\!W97#;
M"<[DD,5$IH[:<>(L)-^NV_^U_@.HZ(M3W<J83S#2 J>F\"@%DDN1)\R]P4_C
M;FZYRTG\3%ID7N#L@O]N?>IF_&51:6( CK)!OR-J&B;]]'Y3%ADY')EZX)NA
M<+1>O<$?(C!!D- GJM'Z[)EJ"4EUN'EF>!UO_PS+$>5VJN;5,-Z_INF,-1!,
MH$MKMBJU=,]0\QA2.>J'90[TMRD+NE:E2)J8((HYG3K/%WUM)8>;@]B%(4Y;
MC+5P!J):HZ9$SR47&11K%W5MBK@Y"G\@<8O4^-&N43$4O;+ [C:!6]$/*RJ(
MSI'/I$1&\3-&^0*W8]]^$) ;&:^U[%5_$[_61_:BDY!<?U%[4,:X!+3 <3T$
M;O5Y0JEM>LX8;N#%Y>R^<0*H@<:V7".[="%!1*Y7\@.L:U6GQP?.?@JK1BAR
MC+WQ"?M^V'BP!;N#_(%EV4* ""%W:\?5)12KD<+V$+B?;VV7UA.W/Y5Y%=V]
M/#$K,]ECNU@Z>.#86C+4;H@BMZ !;+M"CF"P:/[*/#PC_:)7"?16(#AXG#$)
MZWX"X O,/7Z@JK%'8QOQ;50N71BI+HFV_!JQ+1 DTGS_MOS:P)018DMZ=AZ=
ML9(S$=MS^]N,S"AATB_Z57[ -@P79_"@4:2_/&MGSB8[A*CT?0)U"8'"!#KO
M/T ;-@8JL2:N WOGXQ9H"C^A.93GY'9O8GOG4&#*L7[-B((0G+^YSSI=$/?:
MX:?**J0F:"EPWXQ]_N8L<(@@VV' 9(A/*[;RD=I?IU=5S@'\=:U@3H,%KWCD
ME8DG**G2&E';NF.UEUZ#F=2)<,=O42H.:BG:S 6CK&]@ \UY[\IQWJU0TZ.)
M;=WVCW?66P"$I=\;BF@&]#%)8D-694TY6.YPN_.AJFD;WF)+'^R72?F]"Z&P
MHSK*"BB20[Z^+PH>C3(H@SH*/R_N"F)5X']A9+&T/IXF-B_*-2-Z.)UNX<6L
M,H=?Y#ZO,+Y-!,OTC7W=^/?*?<0V=/&8K_T*.5CFM\3W[@YK:&R-#6K+ ".E
M+J>4(5[W@E821U[)#V9\U0)&W"'<C.9,_D3.7#$:$7S:X\%;9"[\Y\T;>T\U
MH/K]QT5_/Q[ \]:;C=SWEHRE[1..[?D<E+9X"-N60'55J?E(80,#OL]B(5Z\
MNN$WA%,LCS(7OC03?KTYUB0?VY-=J(UX):SSR'Z(A_]!R%K/MV6MRU>3 H7J
MAENL,Q8AB2O$QT3Y%J&F5#M6>:; 329)Q\>%_ "%]SA43+80 49"DZ1+%,+7
MO=]YL=ZR\%7Y\3A0PS#(N-==6Z+'K:] UWD6/9^W7?_C:XI%X]1\A.9;:LX6
M AJ03^$] ;SB\)J_HRK)Y.C;/&<]^\=SMN[E?  &V^Q.82,'X.O!KL KY"J\
MW1::E!'YS,+-R]-%BW'JL^%7QN< /BWA T:.W>@(I%K@ 8Z6,N4<AH?W@R&2
MMC9%S(40DT\1=1CW7C0^(,ZS6LI!-\NF/L-H7(1+]97T[^.'$=PN&A"M0XOY
M1YC-CV?PZ<4G /?^61HH1/ZHV0AZ%AZP4:*91L4TB?G@,5'9'$3*5/K[LG62
MI&^S\[;N.\,+PJELCKY[%&U$M$V#2Y+"+*AM*B-J<Y_GVN#^36A#)8![Z<D@
M^M[W-4L[^'#KHVS>C,K4!L/ID2,*2Z;\K.B.TBH=I@%9D<C7]+RMHJX_5=#&
M#]7WE_3MUTY[$2Q1^!C\$>D%G443'I9\V4'X>:!30YN^';0#UV!JZ%;(*9'?
M!>3I??7--J5VK 3(9TB;XU!OY\G_]$CHGZ<K/=ZZ5V#GC_[<CJPS<+9[7S -
MC4[=5$(9[#7'$92N/"Q&$U! =;;'P"OKE4:ZY9/Z)X#-_<,B&-,'PSZVOM\R
MN^ 2=:5VG22=XK(5,7#C+/4T759<ICX29= 0+;$VQ[L=I97]_"HU^KRW4E[Z
MN3 @HGJQXI-A=9;^RNKV]^2(\4S8]UD@;KP$%UM>KA[RQ1XVNR$XD_8U];'B
M^D#RV]?**X4"-3AT!291W7@A.5D5VK;144WK237-EMBPB5>>[2M6?/Y3Z53:
MN::-+G#-=C+%8/&'^CV'8EM7Q=HND)#NUV]^-=K) .F9'1:5HU%&4GIC,BDJ
M M^/C2Z5JF%/_16JJ82ZJ7O[K:21SR\?^\T*,[.B!H]RG8S2X!. O<N?O<JK
MO\R\GW>VR9&(;\M"=L8F,E WT\;CTT!ZE#/D^F+R(ND+438P78UO5JT]/1C]
M^Y.!<IYYHO!VY$KD.GR"QDZY-4AA)*9V(T52VN8\Y+JX%.<GX<)"SCV/Y7Y
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M%DTI?T!F(/$3@/AAR[7"G+"W(=58V."NSX47@_#FY"]TZ4$I/;SS/V82&'!
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M7)2+A*7J!T2A5\=I($5+=:[C$;]*7#IZ7F@%C-% DLU=T-TU])LR,<9C*\X
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M[[.><][S/,_OG'7>=[WO?^^]]^>OO?>][FOMS_7Y7->][MN_MRL *G45-14
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M]]^"#=H;'P.AQ0!78D89,?,&-[VH_<Q^MO-LN]15ZU<(J@]1S"/&02N^&XW
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M.JYC;?*&$OJWL "Z+>:])P;05:;[#V%HL!E]HBG3P^(3ZEOF>-:\\3-1P[9
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M<M'W@,DQTKDWH[< TEH@ .2_<W.L,I[XIB%;/X&[T9)[E-_-YJ7^\:M?EJJ
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M_P3U'?;.<%".?6@U\F%V]9X/%"$^+*"([=PD9:^I\TP:(<HWOJ/L,BGF\2W
MJ!UU'EX;2'C^-G/_6<I(NB5];=K$>GRZZ(-0+MN%@P_?:OPSMOA^W#.&T(-X
MP%Y+XA9$6WA]KY\L/6"Q <+Q_2"&%'W+HM=O2<[;M_JU'O\$XM^PPW=FG_V4
MQT7UF'P?R>>HD=MQ.-L5:T"GD_M^0(A,%F=8<?-^%&FG_.,)-^ O34\]DD*2
MZCQR),/K@VPS[8XZ:?XMZAV<8U)":(>H9&1\1/D$B9U,0>MI)J]$*!^Y-;A>
MZ6@VTKI*'S]MD=U(W;U+<!C8F>BSZUV&+8": 0R"$#,1PH[/!'RX"_3'1+_5
M48LD]!UL(V.,7_W 'FW]Z\N%]$^^,OS:>7:E^]'=82/S;@+3?HU5PSN&@&WR
MR)!<_S"$Z(XA[_YA2.(=0[YY(6M/A$FV( Q)>DG*X[77G*<R#1WMSF1O@A87
MVB6''^E(#OQE]AF48A8O\7=_OCTLHOP_/%[)SK/O6?$.LT;G'XU->9<R-I1C
MB::C</,FO(<ES1M$MS/"*O( 4B+PU]5%\NEZRD;\#>*U_"GS&7#&HMSHQ!?_
M75<VN=TY# JP CKB%\MRJ*R^G=L)NQ5ES>)SMCQKSI24B+MXR]&K_ \OACG8
MKX,@[(X0)G1X4L6NO#!Z?3.J_'YEXVRK45EFF_H,,9L:OL\QOH6 ZN.RF,Z+
M9/O[!.52MP"K?<+=E5O YW;VW66J&VY0OS;Z5910G0(MZ//RDJDJ:VF)Z47"
MUSS6-.X+VTQW_"]TPF,BZ@E<HI7*NHE_/@**-(^(9/=C2>[M2;'+W(A5Z,4$
ML%$&R^,[ "DAO*#1?A/OC7P)&++%[-G$&6NQM0.7!M_KITPI.D]XM$P]);0U
MV_A_MS^]^<4!P(RN"M,Y-[3SH&$1N>B73Q^VY(("C!G@KOEB:M6L42M/*_UH
MB;N_M^3IO4F\:O^B<>+W^]&"!Z/;QX_:VOFO&Z@KK2I@#15+#LU$# VJ8;O0
M*K?N0QK-589IVQGA/+1*5*&#KZ[<Q/U@@8\NA9]^6B;:OH<U)K8D@QL'),#\
M5X_@(&O$852KH'"O0G3S&ASQ JQ8@NE":FIUVY$&IKZ$)UA6]Z_)'->=%Y'*
MM;W:[_?W%M'FP!!=/05!SZ#M:*%B>R20#C/:8\[IH% K?@M@=LJ&,TXHDZ:$
M4S^<QF'T3.C3.E CS0D,_U\?P, C[/XESS1Q(JCQLAJUD62?Y^0BL^PX]K8G
M]=Q% KPJ8.G3E,3K_M[79E,\P1JEBIA)1[!VW/E9HJZS+,;61D;?9]PLXM7&
MVE)S4>: 3.;^- ZFS]B84=P6$SZ\;U/RK"!5P\995^%6P=RE4=CSU.;:!A8O
M$8D\4EP:F1 CD=R0YT8# /0;<8N06P"E]^(+UFN-7UG,4\(YDR-)],,S\6X"
M57-T-A*__WR*5)>!I<J_DR%_G[%WIP6T-A&\P3"NEKC5SBR.[T(GF)/,L"3U
MX$\SNK> TOJ/^AMA 2H0W;\&AYCGX*?7,(;26P#Q1M)U,4/V=1+[^5^KXXDA
MZ2N^P)9/TIM#(PMGY3M\>,DHX2XH'E;XRA?+V4Z!N@5\:E^LV8?^-7G'8.$P
MUV*?OO[@8+X-_6W5T[JXHN+_Y'Q+8S8'UAH%ZX[\ZP2/KMN0-V6UW- "C2X"
M?7=Z2%'+5)"YM,170SD8?S[K41J+ ;/(4W@CX.9A7:STD(T?Z-LH21BXCA=F
M6XJE+.&#)7R ?LBF47KH>J+Y;$/AH,]<]&+M%O#XU +W9BJ+#FTS#E^^R*#8
M_?[#C,K2>O[>,\A]_13F_IQ8ME4"\W<E/A!_Z"^YU.@/'MSC90F57N^9C;44
MB7((6R57(_;9/5$-O:G^0M_S.XL'UT@./D_0SS=^+WDZMF+/*Z=*WVM2RZ>:
ME5<MWR TY"Y=[AW>I9IAZ.95:_[A7)V_RTL;?@OH8FRV27(R;+BTW>%TJX[$
MCG/>[-SQ?"YDIK^+\K/)+2#NH([9>Y12*#:_IGBR\%VX+7<(V].U$YD@/'AK
MF:%OZHHU,]*YCU1KL,$EP,E?'.,KVC59;$2MUJG4HGX+0-RXI8R:YT;S+\A_
M^%>^@3]"@;65M+EN*9,W:L^RI<XGSB#]LQ,3&Q5[D'Z(#*V) A78-Q]#UNT[
M>WY>:?KGBXPBW@!^DOR]:8,=-:EMBZQZPX<KZ04R:Q[&7T^YSV%<['$@1Y4G
M:@U-E[QDJ#;9HQ23O^GJU+'))O4PTX.Z^DQ?^6A,QY616=VD8SN>=YS4"/=T
M_B=ISVT6*2Z./>D](OU%+.]U?BV0!N-(%'7*:L9H6L_*2]N0QG83%U$H-ULD
M_Q>6^(=JON]/KRZ=30T;0&Y8Y4QGX8<7?*>;,WF->L^Y)\XR,E95MV6Y4.F4
M98$]V:"SGX2XL7%WI/S/U>*I=OU0?OP8D!*K@NJ/SFU-4IO9.TS\8[?2SWM9
MM>,Y'SJJ/EB%GH[_'+;>'EO4O#SW;H_O[$\+NP>X?M2LTU0VCK(<[()*,ZI!
M-<0AS+2,WT^X(0,TTCF3^P:_B3SY\)GZ0<Z@%)/TJOB)AY/)2!T20_,;"6H5
M=6%19O^;?#&AUD)$[%&Q\F4^'A6BI4J_.];WNY76V70N_]H!XI[QL4V@E)KO
MA6;?PGARN9O8R?GW2WY'E]&WC=.6FL]<7O:*[3O3U3!9$0D8?.STMT$]'Q8L
M[_%0I%]3'YG%>4LH#;"675G]O#KYH(E=Y=!X4MSLJ=?579?A0!XY>#,TZ],E
M2O?A!\:\MX\C&>Q[G!8!UBC:,DIE>+9?D;L+F@#6FZODXT5P/L#EX>)104PJ
MQ/I>O<FW Y<,K3]^-P5W"[ P=<YO+8=F'!86S/TY5FX*[K=2$3V,FW[/MC)#
M&6'38%$KP)ADQLF9*&U#41/WAG94!R3'[ZXJ?3C1G'M0 3+(&92(&%>F5\%1
MIM,AVDC;=T1##=!$_6UN+YL;$^5$7R2XN A*6C*N&3H^7?R:U>8>#/^.RD1F
MY:_$NLX:3FSR/Z!Z&-0PZ [TLER <@W =*[;%.QBRFT&T4I=8\QNY;EO9@2L
MS&UC/:.F?&V9R.4 <K'@P)5#.FO[T<O9+>9 $X/*W]]KZS(4E(9*)LK#W^SG
MEXU?7JVXL6PO*: 6"VH*U)J9D]T^9V?PWG"[?72&M ,P!.@": 3+T9^18X=9
MD,;0>\]X-3HH")+'-=%^-NG-;V:MW=!>_5W(18A*C:[J6^FC+65P@65PZKV"
M;+*YFXA!.RGF]R6.9>:C)P)WN-<Y7OV[ML5)*?\[Z,N35^SVF%?P06E"ZWOT
M9T13O\GH^.&'NL"GA-]]VY>D._QM6=\^L3)[*\G%>[+]5H%1_L$\1E0KA$_X
MI%'<S_1)1?[3M[_8-0AD6M"=6\[)DQ#A;9:E?/;O[7GV<GNOR1:4GST8C&-Z
MD'",ETB$#C 2V,B3X5@G%]M!3&MLM<Y$R9EJYR\F=0Q^7_^^7[=X5E:E*OY]
MS]./X*#=0I0)ON.A2"XB(G-/661BXUAMEJ)HTM5\7L?MR0[G%R57W,=%7-);
M[=]2*U1UVJ;J8G7>.34\<XFJ;[K22EL?%)JMORJ; /BDLH:+/(M+L3)-]Q(F
M6%XT=W:!*=*][[+Z]/(=_<"2W^(W82["RK/LX)U K4'^@G5;%W-8C8F,C -\
M9M>4XV?BI[2D(#7=QO=5N_V[&NY0%P<=;5F=FF]\"5V)@346]'?^E+;5TKXH
MBM4H)6%-2'F>YLO3 29VG'>W (&,.G?D(ZR!3]+RCJ21;^0J;0BS3F7_;Y(1
MT!Z15(5MNB+,YUG6_$H)*F5G^EW]XL/1VB)8%I@37=/#HI+M8ELTI^AC@/T*
MMQH?4-'Z99JP)1KW8[8"JX )M423:38UU:B&.QO'MO70>,?^&A%=")C-T:#5
M*D_TS^:*'W3W\T_>44&9&98.'3[+X,MMCB?^7^[6%"V!D/=EHS\=A[]_M!(B
M<D\9(/COIZ[^MP$^OU*"C DC'.U0LQ&V?:6?S<Q@IA]5%U]0+I_*M;?)*:T2
MQ?5W=P!V3)K?+X8=N;PY3C<-DSI;NZ%'D0T+GOYI$&W1$*LP6VP24!OD15>4
MT$VU;8 +_+X.W4OEB*G-.JR^!830B,TFR<[2M!Y++TR\ZDV/+^8M+B0.*L2)
MSBG;06^=95E3'#WMXBV^,[B'"]AK^..]EO7HN%<X]#WQ]$XOW#E3U#>OS<<;
MMLT"X\HI#K+2E-:)0MJZ?>D*IJ6:U.8>5'[)DJ_]B $U:6D-\OC,[\7-=W6P
MRKHA-!]KLJK-F),))43$VCA$2!._9<^#5U5D'1I/\4Z)RQ2[P0I=)D9E&.P4
M]&] 9<./%20,DS^[2E=X(AE[G;7Q7]<_F6?=5_NBD-;BI$+YHG]Y#))RX<I/
M+:!LK*[7W-*PG7,3B3K35N4=JL3XOWGSF$]9"][N+.0\Y%M^.5]UFMTM#,#H
MBGT]#7AY V\Q6'C]6U)EQ=[AQ4?*J1OQ?M#NJD*4^?7^R=1--\.11T7P.C<0
MN4",?7HQ.PPD[7" 1HYAFN$*E YCNS2O5]0*YA4YC_7E2/#W;P&@$UB=K-_*
M6UE'Q%]QYZ^TBC.?2(]X>HI>L-GT<A4__@A:H-RV&/G[6^I=?.2JD5S:#*<1
MQB.II>"P)GQF;PH\TR#+IOG8#V*3GZ[@S(P5;&F\D-IWDZ&X4[**F-*^=JG0
M[HPUAMG*8;(..")F*%&D1,L4^(B(:4N::]M"8W:S(1@,]485]GUTGJD?7R)0
M"7%@K^2.K?K"Y"6+2RG'?[",#VH>[<^BGZS;Q4^5,?T[5/*ZT?M^RGO()^JL
MTVO]5*O ,C9>_D&(ZB]TNR8;X4.F;^+TI")JC@T2#9,%V8)RFK_Y<MORCI_\
M9VF,$(;S=_F'!Z,#]#-N'(7*3Q]>F95-L-WL)1T%?)#6D0.<5JAP$P>1GBC
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M4:[E,*NW7K&6XZOI;ZM4   /U3]$2A>?9T/!TJA0C&>GX=+[^\IB)3GJ(4]
MH\!8'[A=C&>1$X.AA:4A(XTJSO4VOD!9::MWW^3NKC+S5*$X3S-Y/]FG/L2F
MEMN"X_)Z^4Q+H?5!]&,9D'(K=4_3XV@Z^S'R-REG$<<RI'RYP?]1?A@1H=.0
M@1U=A\2#X.=INM^^?D H]#Z41Y^Q:R-V-7EY;6P-R_CTO1_+<$LB(_H"B1 N
M18PCLR;),<VLQ)"K@*JMO(4;P.P01/PZO]49N;VF(3.ZQRZ;R$!&F3*PWZS=
MEETPOF_N5K+3T,X][>HMJ.+3U-KHR9VHX*G[&,<\F:^/=6=TN"J]G8OQX8\+
MRSFW8^@$NV?1#N-D[3EC ^V??IZU+S6TNTDF&8SQ8&V$8ZJF\+OVVOEQ!KM'
MF.*5DP-^#L>\AL^M%54_;AY*T<T'% G3U8K\+'F6+-WKTKZ%ILMG-A>I.9VZ
MM$#$[W^8?*=4B/F-_WR-;VH_#2? [N7)]N\KM(7ZG/G\CN&719,_:0R3?*#U
MV ;^1UN*L&%I3G+^N0Y[BU@C#K*9%=1-N8Q:COD -8M2=G73")/_(V[[X],*
M]63]=^/R#0(CA<PE4H5>9X%&L+3T,Q<ZW7>\2_\[S0<4O8&SE):GA=?^@OH<
M:7SL7GQQ1ZXM30O1ET_J3BGW,W]HR,<@KAWIQ PGU5P>';3\LE703JC!& U5
MUANV/5/H5EV_F$CL'\W\O>S!72':%[>I'Z;E0US=D3[LXYU9OE6U^P1@.I0N
MK=J_%5@*:A']54XD)1:O4 'K,BQ8U6BDZ$KWB%@@+:0,.631J1ZB45U,7KO!
M;9Z7>;7GDA="/\]"3@GU-\@CK?1:JT@WM@5K6407?L[A)>DL9-R(JHV2"&7]
M^/NCTWIAYR@)5A^MF0B*/EC5].XJ._OYZ"O>37'4 . X]//,XV&>\OF:1W M
M3WA;)J*C*P9&H\116$HT>5)U7.26JO9\D^LJ;ZD#'_G!CO51Y\SEL+VR4QY_
MP.SV[ZS#R^:%6\!+QTTZ=VEE6:_=7O6/,:X4,FJ]$JG7_JP0X8S9,S=4>7Y\
M$)@X+<F,/=M)1.!C#A-KX9?LIU&[07)^].OG$ $T;^2^M1NU$]2EF3>@'_?B
M(Z="5]26G#8OS/]4.PI*[S5>,(2XYN%JCW\?KA$%\=8AE']WJK!O]%F)?:04
MZE*XC9);W!^*S E_FNHC1P#FQ5D;267<Q6#EJFA<)S-=/;3M[7TY9A:_S=TC
M2XWIM2J&Y[5L)$U7'-P"2,:QO*CP=#0>TC4M=V=2S$?/+2%/*52B5W ]=%YJ
M=_N;9_352%?7O'IUR,@(\7[Y>T4VG9X< SIR &"+?^T6\.D64 .-$\OFV,HX
M*$J%&Y1_WI6-=J5??__L!TG"J%+BLW-8!?\E)7_^8Z^U35:)6P#>\;UG?_A6
MW9/SPBL*B?MM#I):VN%FI1Q0-&QU.5C!WHT4CDE",K3<M=.;&&__#+"D@G76
MIM=>XJOB>CH?YK<_I;F PN\2LNEO 1%Y-W\L3O2A1\$ET"/Q0 /E -4-^]\=
MJ!/H7,Q-M-N-CKCVC4K>#4?\U5/H^%VO^4UXYQH&ID\-Z'".8%@YX)G5+2 W
M\Q:03*%_"T@H^A<3 L"EMP!*U>NO'5L%MX!UO#>W@#6GO(I;0*<>U/[EN%NF
M*B;%Y6%9I71MW/F+:4.B-,>_U?1UW(^D\(->L:V<W$%7L!B?[6%AO_EZ;B2A
MN_3\;-_=EC=-S.E7B"[ZJ)Z27)I=50SG.'XOYQ9 @(OQO3(<:-9*)[A;2:MY
MPD620P.:F1% \]KSQ]^A?O0'ZVOXI7_C+2#<@EB6&>7\7).QTYRM$G60)6U3
M$TF4?.3[:E-@,VF(QJ^B*TA6OQ]871C6:HDD6W04=CLI;6EP+'C+S"*1T"08
M_N[(X]4H9/I(;D(BJFQY._%UC7A^3^J-DU=@F1'7;O3I*%P!J1TK>,.Y8\[!
M$M:7GM='.Q ]]K5GO/K1T)/UIH&3U7Q0XUBJ*@V),<X. !;3KY5<(C41EN%Z
MV'0MV?7U0R ;G=,JF@WUS6JE8=V\/</40O^5-EO,YQ!*'4?NIE>S14P52B9H
M^?@\B^LO.^IICWV2%23EU^Y1SM1ZJ977]3@2+.C'!5M]H3V5@DD<6N_[/4@3
M/Q$[V>KK0)H):\I@,TN3HU640HJT_RQ2*F9-G_*&M3,Y0(#A?%Z2$ADUZN.#
M4E$9BN/!W4< CD(WV5 +064;L;FPWI;FWX4>57VJ$^V9&&5TG 4P8N*0?4]\
MX+Z=I'IFKC>P[\W[.-.$[-?^1N5IO[_9K(H?RL6/-K:'2^0S37>K7?'!_"":
M%44M CZ:L*XO>VWA,YT_;Z8B]]_HJ3^10FA((&HYO@.XJ<L=(MXT-4],K]5E
M77I'_0P7B!?HFX-CD\'A3+QQ 0F&6%O2MDP31?>KJ_3H?O8BXY<M6NJ64;_T
MWJ[8Q$-2]+LN><ISU;S&>FW.19\^S?W"Z:'%Q/<!\$>#^HOH?%M 6FW3!XCA
M]K'N6<.1V37D:K_@^^AS4][J(&[+ST=Y_)KGD@,]M,'+'9O]TJ4W'(&*K$-3
MG+%LL56M@FWJPJ^K=/R3.DO@+K6^7P2[*:JK'KK3N=!*OXN+2!J!-%T:]J6(
M33X?EM7&.[RORA4AHZJ4L"-]:#:^<*$.5RXLO>F 83Q.085]'?.B*X=[^\A2
M"PKL"W0$ENMR>CK1B6H>:F?^[B XZ]7TN1)9T9#R_4[I"__WGZ_,Z*LVLQ_?
M KK';P%VPI>/.BZ>3RM<L,1C_!7V>F\!RI*W #Z6PEL E]'T&QVB_Y?IJX%6
MNB$=12EU7>*SI(5B7V:)MT7OB#>-&VEW5#>F+K8;@KA3%Y3;2 SA>SG)3\A9
M =>T5_(W$Q#"ZX+6^V#EE9C=S!B'OSR]=?NEG>(MW[!EE+_[0W^+"K=Y >D@
MM"#/5:%0PE#DO+&X'(&0WDZ@P&\]LOK7R<8A*\V$W2XC9(\3[Q%X^3\,*\ X
M:S1,>L60N0AK-9A]@1MW52DSG1CH +!\N*<VH!8#%\JNYKX?V9"9">.TG:)7
MU\[F-6"-GY14(-\WDV3X5[9EJ5=?;2A^&W'[[FJZ%7_7<E4=:HL?7O/)<.3V
M,)Z+89!3&Q9*#;'S8SU,^I:P#4_5\"L3YJUK_-SM3A[+EM#PYOU'Q4MJM4)U
M%K6G0?GQ3ALCWI_HKS(Q)E-/0>E23GG @/IF6,9=S6WPH>WQU=G.>#=+2Q_'
ME.;+)2T7Q-'4Z]>3D>A$$])0K<E?\?!][QNV;RON"6-&>9C2;C7D(M/?S*:R
MRLY/">\WV2/EE#U8?+MF)@NB>)KCCF:'YN][/UYO6K,N=#.Y<*(7%#(&CC6-
M$$SGL#3Z5F3[VKH]O-%N*BSH:H"_H7GJDS(Z<D^GP17*:6C>;ZTAVI&$^SD%
M\B+;PCREA4ZWDY@XQX!(UJ>"RW1&R)O"T!97WPW :OT2X;DX.GDT4)$155">
M@UPIF4CF_GD!LU_'[+KNYBTNG(Z&G_L,Y4J4!W+)E>G5-><.5%59D?$3;-WE
MG=3HC_/R?:&9*YTX,QF-)AP6%4E&T31C#H; 7RJ2 $JB O^SAZV;B*F8W&TB
MFRA\S8UG/.VKOJS[\+*O[$]>[2[G!]AEVKHA7!X.U.6O_TWH*67_DT"DI\CD
M<Q_;M)DT=M;G+-4F?I&5XE!PO>B&.IEWV;]DJ<^B_O3V.G5F44?C\8#@6:*(
M*44<I8X":4LAR,1Y7TF[=O)EL2_=C1/?!5,R?R+3"1-SYXGL3'Q83J96G.,I
MB1Z]'\7,EM) 0H&OO8_TX/[!4_/\E9;DNH9)$Z;5(S>>9+'J]CDF#X,@UU=2
M*S@3+<6ZL2JPG",,]G<%@\C:>8O//'I^^EPF9\R^',38"YP?6C'JA+(Y95&B
MT^*@55C5_*]ABVEGRB<W1IDT0\!1.O((OAT0+W-G)[+M++5M]<ASW>*_,%?W
MOS;)RY)HP(71?R;O%/0_58'VDMP@>8/_3%W@?ZP!L)*B'Y01\EQW;?<=A!2D
M=?4BN]ND!G.G#K__F%JIJFRM:ZO1PU%;9:3ZJ?>CF__AZ8=JZH06X%LP%Z83
M81%G3ER-M@^M(YKR<JZ@4;N?2&3XB\>8#9=XU#RB2IRH)SXDBQK34N2@C^E_
MS7&_=MS.N513"-U@?/UCA21+*/%9T(N# 9Q,O"2S_/R?# Q5IB;=['6MCVFD
MK)X711," !\!)W0XXF"YJ]>8=FTZK&Y+K='#436@352 *UL3UC0>0PQK_.=0
MM9[LDOCLSS1Y:XO76MJ!&\VHG:,/%T)<):LOZ&8FH E9,;5ZXVH/_!*J-UF#
MF2LF5T;E9L6-IF'L,4!.->H"4'^Y4OYR>UH V\"K=XA^JSJ*WA:X-K=(2$4$
M/DM@;.8.H[MIG\@?/Z[* V=(1)2?M$7Q=E X("XB(_S]FW!SXC6K @/2'-7G
M3QXE7L-[.29-@-Z0T1L)*!M69-+5E6TPT#Z3/YP[\4^0992<FM[/;#WG\=V-
M[+_-.X:3K=JN:D\$*IM#I,B50N,'("_:4V%")>N9JCMSMHY&G9/%@OMN+=IC
M?+G1 Z?_^K0KWX][ODC*T')LP,J^OE(C/'?G 5="\ -I(KX%_R=$[)=&FWUU
MN18@H[=-$Z=\+/"CN3-95YG+>.M9-&PBXQ@68X%_XA:=:KEQ"U"<1KY3AK*L
M7?''(RVF?"HRQ/W$ H#2F>OQK/1Z:7T=]//8^#"#4+U9RU5H2)8P!BJ:N2BA
M4?H$8CKTQ#8RWH/0"(W;"*VEGJ(^K3BU+U&0+2893^-Y6XL=HJ.-#MV77C%,
MB\"*EH.:,<9;<-N9/.G[]"$BG:)C_YC'+X_VFZA;LP4,YKYSKQ/S3W'P+]=1
MDF*-,84(,W*X2:=U@5E_M<=DY/=??3Q?_EL[Y_74!*"E<92F5$4ZTI$>D"I*
MD]Z$T -$B@)"*-)[:"*]&;J"H!116D0(-03I'81 @-"K=!)$"!!PW3NS#[NS
M=^<^[.-]^/Z",V>^4W[GW&EU#Z#Z<-K?P80F\E]F9^HUQUCBPW1\?//\T;?B
M4X&7LLH<6PJG<L=N?+U)"1\MM*]'1Y%#:[RRG&?;].6DS+-^ZC4RGR8'MK5Y
MH-8QY3M*_$HOM1*"U[.Q!*<:9+XM^S;A1.5Y[HET[@43M)VQ:-^SV>%DJ4GH
M!W0NZO12-+>C:':LYXJ! ']6L>L#[OFTW;$!SI-@P@0*#S*!#NG;"MX\ DUE
MF5>UTK-I^UBZ#U^J/W4I,/\(HK=QTR^&+(IN*W-6>_6N:#&"/D$50%E0)SP\
M1=:+':J$:X\Y]%>6V.V>!M4"(VL@?FXWJ=3<T+2U6GXO??77[A'&]'^''J6G
M%)%ZJ$@1T"L;F-;2K="_-6L]=>5<JH;!-"!G0^B7IXUP4O=6?\_3N+/:%"<G
M_..[J/?X7]:$\-7#NP2O5<!BYNK-8PY:,6,$"I>6JUSW5)GX"ZSF@)EX:J0U
M-$)U%IQ+5W==G5Q@RWT)$1>[0BMDD=M=> =O&5,#:;3Q1"YRO%O$K!D''QZH
MC+G[L,P>""1982U@1@/4,7>NO\5RC$+5+ICG9UU1LCB=F'TE(6?<DN6D)]3Z
M$\0F]=,Q O.\\.$]1.&\5D/838R 62[]+?&DJF@F;Y005'SJBH/ /&<R$<$%
ME2#X5"P2QCH;,,QV# @(LS4%W"N^M14<]AR?XZU4%B/,E*?;<_*!$FD=\>.'
MW>SN&\EH)0>4^/C!OL<!E*\A9V+I#TEI#4&0H<\;4\QLPOOKW3)?WGNVF-1X
M(:/+3QY(M:JMT*>A1M4KJ;9$!R61+UOG4REWQFCZ# O/=-Z2SR8RE6CZB,HN
M+4B]FD,GX1OW3O'\?8T1O'CEW[W)SZIV<]\YL5PQ3A U(B&.(:6S'<%%3KEF
M<61%T@;A L.6\R*W=6Y;DA>,$WPN! FY'5>B=9,Y?1V%=R?0JV0J]]DEXY S
MU1[[<8G*,7.:A>IB"CF:G@0UGL4-1P&=QUQ+.,4U97A?.KDUH<X AVG]Z/H
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M3U^(0 )#!*H]%3*'!4,P0YSU)N!>U8T"74;Z0>25V1[GR_YJ\0I>#RD/NM*
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MG+&BF"MP(L76C/]SEIR7K0\!8"3)^RE;_R^0Y__6O_4OB/O/['\ 4$L#!!0
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M 5@UJ#^_J!V75EAOQ]N[X@PKM6OJCS@N%SZ4DH\:-%RT>;Z=')^N^,/?VN^
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M! M4"F,R8Z:.0.K(U4BI%TAL7[W:^]'-Q?5"<W/%L2J-5(R-Z,1E*!ZE1UR
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MY+-8LU8,U?Q@;13!9IDXF8"<LL]$<DBLU^OQZ4OAR8S;]P(6MC9!O[U(ER?
MBW9^R^)UTY&0+1S640D',#L3;= 7;=9I>XP"8[Y?KQE+5Q)J!DV].K'A^]'!
MC(Z\OT#6)K5+#3M?NI>, X\%K621.(Q P]@EM- J1+(\&*X<?2U%B9 P^BA<
M!WG'9%5AG8HIC''@-I1U:1$5@MV@N5RN(<X:]15KB_.N.*5C?,^1VV7#R<_.
MY:UKS-)#%#6LORKW!+J"Z))!L/YG\*IR1D6LN +[GXP-8]\GB8*"2:"UC $)
M4#OT-I=S/P_=\3:C%JYN,.-]!5NO='47ZOO(N*):%^>X9?/7ZAM5"RL]_]M4
MVI?:P^A"5X('LW*,/Z)><<BZ(7&X+Z''_1WKSHK_&$)%I#<O:&8\>V:F=JFF
M7FEN)@[J4T012Z*PYF4;'L-(J7K]2H:S$A!@T-]%: 92Z(8T5ELMQOLZXJ<)
M=>!:IS8!\%'_QO-+O,>M&.5,G>UD ]X\BC5.WRL60PYK<81HE>LW?)9$R@%9
M4%').D,.=@"Z['FX[*ZO?]#$#[(:<A>&)% LZH]?%.\PF"(.9&4B#<SPWIE9
M7EM:.@DI?S(!'T0&;N-+A),-GK;L4PPZH$P]XA_[/#+ +?JS5QRJZ2/!\;8O
M0VR%?K10>N>+)>D9H$RG1D ZQ)OQHMM!EU"+A\A_DYP' /&7!BWTEUMYD?NR
M<,V8:_4<NWV#AD4J3\<_Y9VBD]"^,OIM"644Y%] A4%I.GA5HO/6J9BKY+-3
M%3K/$?],I@W&$MXE[P'8V"=_,2C2-A@_]U%F!&=$:LCH1.LT73*M)I0XI:H(
MMSNO&?K(/-:F3ABC$J1.>'3*P$BZ$KVDE!;%WN6%>#LY=RZ3[U1YD S!>0)\
M1@;48?NR3;#J3Q4- 3XMEC:4(F1.E+++7/[N21[\@QC%ML"DLQM[#=.N^$<R
MA/+0'U)?6F;88GK5E!VYB7JI,?,$KLHK2\OT$3U)?SRU([8?V?&MMF6B;3_]
MR ;P8H2? /4&$6>2ZJ5"ZY5;;,Q)I/7Z!JV-?LSO$]Y,RCI<R$+V.>?Y[\ K
M@8+PA^@!7J2#8*Y9:"Z.C %8O=FJ966/HTEV195BNU:HJ=SAAO+TL]&1OOYM
M9!'^Q(MY3@Y"7#F.[B0\H3$+1PM8=:/%@3#Y+%;AAJ.P^Z\?#BHX[H38 *W
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MB8.H-CT_&N3BA)\QE"MB/K.16=/R0A<V _?M\]P<3[.;RBT-$9.%A@FUTU?
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M<)$.366B'T5,@+F,C75Y:LW3)RRSUO,39S6#*QG)$PXS1CXCM1@\HT\ 7LG
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M?:0P:C=E>3S_2PW-S9(XH1SIHT%8H$C6XA%KE,TSKY6W74W@4U+\S10Q;\
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M 9VY8/*.7N2D#UQV0.'T/5/Y2Z]$':DBIQQ1$/G% W]' YP4&)^I .%*L_>
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M@;%3^>R]>T M30R_HAFD=K9.Q T'TT?K)T,V>0B?-/;EIWM 8>) PFUUF-D
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MP*0. ]2KV*#QY/YS]P#J\QSLE85]CTM1M4R^3,5C#E<SRZ&UA FO17^Y =H
M&2=YJKEQE\4EN6IE<<UO3>_8/RF%>)4W!0VIKU &8\><XCD!P7@I!Z-ZR^[R
MQC0OYS)J6P[CY[D"I>H:@_TE]R0=PKTNC(P9<=SRC1(:N;T31$6M$&D,<\_9
M9ME.TEXWS_F*5-IXA\4MA&65I>K9<7(03UJ)107C/^9(PMB@39"78%N%WK;X
MBTOSDZ!K-";!\C43E7/I,F39$A:=L,Q=$KCE)5ZR6:AGG)E7;LO:E?XVCDEI
M&Y]I44(69E[\1NPY C*,Y(98%#$9DV5D-97"'[^(2:$++Z$]*WN0Z@?03!Y
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MD38V@.AU,.;KJL$M_\3@>T,<_?(M'?%RY0.L<ODO_O<-.;PUE;"?44/$]"1
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MU4$)!VJ]!<NS4E7Q<J\ZEFQ&"^MB;IA?29Y6W>=?PM4[QW:U&'6*6+DPCL*
M$84QZ7L#%5X0+6R'8$S<C(2\>4!J?UN8;49DNPOO*.PZ <@[#/'!86V#.TRS
MTTFO8XK/B1UV.-CWGG^>2 ,(X+R'$,U_$:995@<//8_]XQ6BR/,D0]]H.$<=
M4.#F_*!IM^^3D>BB%85&_(TAONH4 R:__;-I7@I5A7_7D_?C#[/G,!N%"*%F
MZV+/7U"-VIA&U^J(&J<:0>[$<VF^W^^&!;*![DVHCS9=5)]Y:[M  R0V2Q!4
M^*"G+FP<T^>'ULP=<9C#5G-9B7NS>:&1^89=W8-=5U+4MN!ED2UFD9]M^T&U
MX@BD$\75HWF$*K^6*TP=B'.0?;'%4=%\;LM7[>>4E*"KYMY*_."*^@E\>'=7
M'<0&POB.'XG.O[=L/Y6,53.FI<//ZU59+D[FV?DZUR=FOH/:[M&W!.Z]G!/J
M<F$=X79<#?[L8,@@\O/UUKGD-%59E57_T(HC;%C?QT[C@K^XJ>IAZXDGQ*#D
M3&(X54#-=/\+! +Q40;=D1YHMYN3^_FDC_#38B_""_%MZS7%=#Y[F.<2N@1*
M_6O*JVZ3>_G74(X;9"=B +(S*"WA/ 3=17J?%.21&$[EB>Z-7"'J;^WV.]MC
M-]I:WVE5[KY*U:QR;M-ZMO@=\>=#'R1(R3XVEBKK^1,R%@ ]OA_^\=-2X<U"
MF%:E:K>!2DAFV.D<HA^NMKI+K!U14CZ#X\@#I-A.]!E=QE "%U_+>)A2X;MN
M!?NIVNTSFSR1UDO"TK)UP7N+P-I <;T&LL77VT3,W9$])'^?C G'E\:X_9ZK
M<W>-@ZUE+N&O^GVR,JFMO2RO51I-[-VO):9T#SI:5!/WD_"9KBVN5;CA_ &Q
MKX_.963D)ZL.PVSK;9<$UV?F/I8#/3>X;# ;DFG=M_#&.;5;PBM7IF[,.L;0
MFU>_82\NZ120KH0.1B9/#BI;82QU6I_^HQL8&?D>W/@7LXVX-:GSNWQVD:\I
MW;379Y1.NF3UUI[DDR?'$_&'-?MOB-TG-$"/+P-8DP;@A;0*8;%>(=],OM9.
MN@34U#XQK)HY(R16+,-Y1<\+9(6N^'BD&2%K$"K81BZ./[;::=6@ 3HF?WHE
M1&2%G:2E[<#S\Q'9Q8.]YVTK)S1<+;\_,."+B81$_I+@HMB[DUB/+<A%)+:;
MI+J6W1UO$=^8O;.3[)K[A@^E[)5J]^X\NN8\ZM/'E 8*IG#'8''S7*]<:^N_
M5=>9:?/'X^ZB/K#9C:NP\?F_E"I9%T4X+.I?A F0C.);)6_BT:PP@^RV@]OF
M(D%=]Y<G#Z(6&!)7[0N7HGKIZRU*D:;$GAQX(33<HGHBR'!R3^B"W::&P,M'
M6IQ,*@O(_H;=\Y8Q[P]A-( "]0/F>6[==70EHF+PKES^6T;8 6EXOW$LDHU\
M!&<:++X95#Y8Z+@JXNV$*VJ<-=,80=D9;D*E_:2O">-;7R$_4J]":VPF: #/
M5T1[<M#\:?T=QI@2DX<IJFF-4HNL%FV0GJ$?>/_C=Z'\U%"DMRDA/ER':D:I
M;P"Y6M2AU=&.L&%3L@+)UY(<&X&OX.K2UJA/P%MP.-^&1(@C0O>;;'=<>?.2
MS;X&1$<5GF%&/D!>(RM4DN'V8QKP=16&U=RS?F%C./O5K.MCL^!,_9",:U.J
MLN7Q=N&8@HG6W(3M"T&G KS08P H=JIG..#SL5T;1FW[69"D],&M?2L1SK*O
MCM,:Y35. U+F3YYT?(N[+);W/F=O!5U3W"T6@ ^.QJLB>XN'P_/ :EX26*RV
MMMWJ31ZA069_8T##+2U-8:$G& D2ZP%^%DD:MCSET[# ',Y>XU.&-HY:,G9,
MTK']J!.1KY"0RO(:<_#8VOB:Z^]'G)I =[@P=*HG6(+[$JDR)6+^4$G70J\^
M\PL(*W-V]N=-^LMY!F?NS([RR Y^VB,D%)<[']3 #]4?'FX=-&%_7/;)VLR@
MWITZT0_W&?;+C[\,4/BK$H>CV]NP)0#C@]92HL.XNB* #[)F'?4L[4E,:1K5
MY=X5(G>L7M\PG$\NS#H:M@*_&E/&_O)IY&Z("VOEQ&'XB7L9W8B4U@M5$[(3
MDB3;Z#HDAY=-$N?'7.%D3XV36_8Y8O=>@E03#8'! [6J3Z7Y"LII .1:L5F0
M*!F.7$,Z<WVO_9TH$E3^E+%>GK?TM:A_[PO]^^$O1\LG]*3 94F7^AV77PDB
M6=5)\C],6)/Z]6,U_"L=JZ6)98S0I8T'Q"T[<@81B[DW$GA-UTQ7I*YH':NT
M^/E9Q=;CI&V2J21#NG[NYR!ZIM]KBRK8 CRB&QTK\G-M#LGI?52?$%)8>!_G
MI6T\SI%$<,IOKGRQ=>&Q<MNCRAO#_-FV7J%4!>M#$27$7BNB=)HZ2&5 M&%=
MJOAP[(&^,3&A[UZWII2R=3=TG"Q>,!S5MJVV3:0.9R&20%:D#REX9].')(&T
M(N=NSDRD]Y&_O47PO="/$ /K()LY[1*F=T,*?\KL W=![S[=BI<KD9/+CP?\
MSX:/5*?<39@[Z,#QD(? MR,XDR#[&2@N5%@,8"=Z+3>]APS>[R8;X%LLS<?4
M3T6G##9]I_#^U$G42HCQC&# '<!2@P86YDXLS+U&!N&5.)4TQ5P=IR!O'OL%
M3U8-W3[#7W3_+J?V"_#2:?U''</Q-EN27*;:]B4X LT<1ONM8^TF:Y6\*BO4
M/VL7IGY,9_]. WSP-@U[:2Z^VP!'-E\L#$4CI=?NFM?6OII[2'\JFK'1'6@V
MJA YS4H 3)3N..#YG;VUGL('-5!6\7B_Z7I<$/3#_]JAR5 89ERBQK=KBPOV
M@'Q[ONGDS,Y=Q(^QC;RFNI&HBI;WLP\_O'Y@PBSXV>D37>*D2]ZQ-871L<^U
ME8R8>QET3NBOR1X8LMPV5SKPA#N@.ZPR.N2+=YA995Y!'\3OR^P=%+>3 T3U
M7N+5RL+G-QFXO3J--4:F]F@ 8)ML^=@:<N4$-LAZJ(8?[@3%<)'&NL)P76A!
MSXL^BA --B7MHYV!UEK3YP,R.BP7-MR/?V;[]^I!D>5K"RIQ1QGM-  #)8BD
ML?4&61E4X7T2N%:3WUUH&K(/N<4O-=ZKK3*@_N;@D:*6V[7%(ICI$15=-+D0
MD0EWMMT[L=OE^B-X<ZP6_AH3$J9?5^1]9(,L=_&VJ?*\49$4I?-RW]-JKL2Y
M\.V-3K7G"E/@;AK _9JZ)E&@IL1+)&>_*+1T#971^'V\O+5;KV[GZAO)</CA
M$ZO+'"W4??, EQ$'B^)\2@9N#1,@M[<'SSYNT7X&Q6U($\-\$T1LXA1AH%*H
MY?TQI-O'BMP:O^+N\+/S2[<OO$YO<-IXW%^O\[1>GQ\F0<1T0@SWEVZ3N.*"
M,BM=>?K$:_ Z.6;<])^^#DHSZA/X.Z@8*A=9BR FW?F<8DT2C&W6"/""980Y
M3[8H7GCRNVU H$^(A0>S\'A*<N],[6EYV>3[9Y7#PQIX%M1N5OI1\%1D$!-,
MV?H6? YAPXJY:F,:ZOO!.Y2,O8.#RQ'ZH,S-H%@"2,03R-6L%5))SG@8;3("
MJ7^SI>POG:C*JO7H^=4;%?W;*=A8PU][N*C&!63<GE^^Y_Q<5CA:<BC2Y%T4
M<X_I!TDY *])J7NW<P9,@2@[+_:AP!V/X(2R=7"#U"(JI^S& LO<W]8$+,J4
M-/3U_17?6['>ENU$<,-$?>-%9%H9QBG@^83P@1J6J':?#5V=H A4 -:4H: _
M.7(]KB3@K;F_PEKC2)F,1WA+B*@,6!TB6A+XR#H]YB93B<;AWO'=93B[/@\X
MZVC%A,AU*\V\7I";'.)(##.-W$ %SZQ()5:M;!\@?]D_,78+E7D4]Z)&=1FP
M"NZY=%)&!4P/W4/SP=@4NS8&5O>[W^PNE E4[H9ER;I7]H*)<#Q7+/4B!3@:
M!.?TUA1)SWAW7AGK=5:HR$JTX#X+O1<!\,G6RSIPLB:U7[A<-\WKZALW*.#W
MJN%M]N<W^;WKLYNSJ][SYZ=OPB((6[$2;('P)'$]DF!7BB TC+HQ.V57/>9;
MN1/BR]MV03.M<R?T0_<OXQ)!G9QD;9&]K3\*G9JM@N0+A=UNE2N-)TD;@Y,%
M#%A5X&.427$H8TMK*$]WTR,F!LBRMFT:.<.:#"0>$^#)RD@57Y@1?JW%<.IA
M_6A%H)?*Q>J)U_E=TE%/G'23F-]08GS..@)$]A!_]#L[]T%,2D^(^\B@"H/0
M$I +S@GG</+!O35U'KNH%4W?)R_OOGWLAG:P.E7#VR ,1<)\$V.)/Z2F'*&R
MJ=9P5R3/27XD"[#;V:@#4]^J/@%3T<P._K(]-.S4,#:/KG%[P].<8;G(OFFX
M)Z0KLK]ZB-Q'$7W;A@6\J5P(/#*.HC:_ ;K7(!AL!,KB5MYXV?5+W?\;ER@]
MYFL]\U\;7WS*5RIZ,%@>HF)T F_?#(OM@+_6%R<_/7KWJVXFQ$$K"J@.=CCI
M*5W8F$G*#:C_N7F]1^UE;OIR.D&BI@7=%B?A1 .\5J1R/Y62V "2#=Q?TP#H
MA=!6^VM478_9EMS:=UFKCZ!+O:==!LW_V4/R>7\XTD\2E7DX,_/I3M$/:W:_
M-AF";/P"19HH.*_YLM0>FM8I#B!^0$0"X>"O*V%FM?X<;925R\JA#-M<U\L1
MV&SC7QJ(5R'R>(CCL:@Q"EW3F/KX&89#P4A;NZM*[N*?'ZP AD^[2#FR/1)V
M_I0>U*#T5J2,F U?CW?25;6"-JVBS<W,#HZ6# 4#R4%_:SU+;LLSO360\YY!
MG2BBD63_HD)82L5I;KKQ/_]%A=]E[7Y=%91W<5$T)(=28F-_)E-"&-NP^IR+
M?K3<=A"$8CSYDC*/ WB'S&JDS.]59+QYG&46,:D%?ORW_VJIU-6JI3Q+DR:'
MD]'CF9CT,=13ZD+ BH/" N@/ ;\40W$CB8CIW#OYXD$N"IS<OO9+9DQQCAT@
MG!9X7QJ&WG)M_5KFW:?_MSAX9 #V<(1BBI>(C;PP!A,K[Y[?XG.V[Q/(^7KO
MY>BDJ[X]:_HSPC)X9Z!#_WS-"%43&MH,Q\.9R5/=^]A:S802, '4D*.LV\9<
M;VM=;_1#)[CDP2YRS/OP  ]:/R0)XG5';VIUMWL4*!<(Y#%&D8-G*#5\^7;O
M^YH"&-TM<]62P\=OSWPM7CG</02-EX;_\M./RJ^FJ#XN]0IC3/J"_ J'>/L9
M"H23SK0OH8)_%[X^8AW_&G;UP0YG'HD&P!?'ZSX@S"ATB L39S,>SU<8.NN;
MV7:%6,+SR_W><'01\Z/<WOG?+Q _:Q:&6:<!2)H[!*X.,Z9NU)&_5X;MRB5R
MOJ)K1.I5%E=%.M7O]U>-AR;Y"8UU![U<(M TO#I+F2/Y7&>6^VX]J5]77WG3
MI4\*=WY__6]17]HB>U&D2PX8<TK8<&YH<;<$$TRG%#IL 5$#9<GR=EY$_<DI
MX+W:+7V;!E#,)#!W U_5ZSS@\)K93ZDL@R-\HG/3QIHHVK"FO;'6UA07B^,;
ME&?C5&8O!_UB\-P:FL_K( /LX><'"3K/\F2SOZKV]9&TFEO(#;_<NC7^O^A:
MV02J#%G6>%2%*D$.L" I6@1_.'JO9:HVR.#37W;5B/=#T$.31V=O+%65AB.M
M3Q?@\L.UY4%D#/4Z*39^CZT$9C+'EL+L:,0-K;PT?J'AG*9?+?.0T?F_F,^V
M"(I6-OX9Z@!$S'&$^K"IR(D&Y)NJ&3\9UGGU@MUMM.5,Z:Z:L[D@(>6%<J0<
M18XD^[H\Z6WS>$5SB7F^T%0LNY#PF6U;Z7=#8=P& 1(,%#8"FF4UY"&TQI0<
MZN8SN7;>'ZK=$1Z:V;X$S^S!/;9JU0/C>-;U)6'7QW3I0SC*;7=F<FZX_!&N
M<+>*]9>I/+O<[D,O?WY?[U1VA!)\A<'8BMEL/)IN<+X8E>*_>A_7'>3A'Y!X
M0>AY^/S[",\4F\9TY3<T@*W>F>8=PE9,,QB/>XVMSR0>=XU ;W=M?\P2<W@R
M6V58^>5!4M* I#L#>R(F;^RB#73F0;TJP]F>YQ'>,I7E5LXYPT.^?Y:,?Y7#
M/8&<SN PS"O**77ZB/--!$ELK.6895JCV$(:3SK$&[" WGE00?H.,A[M 7]#
M59S8S9Y")O:7%>)$CZ_9=FJ2332K2V4CS>DED&%'3.91X1!]K$)92MUTH7?U
M]#.6Q2OGZT?:^I;XB[88$+=U'" 'BIA^+6 MHIN+VRM2:6(7PM8Q>YZX'QT2
M<?X(%:<LZ^==G\KO62GE_-KE/KV"_&7^E]>7(RN1[X+T/ CP-^HJ(JO8Y!)=
ML?P55,:?JAHB!KN5W9<FT,=[S;TQ^<GO[HF M/^#L2N/A[+]^C>*DI)]BY%=
M0D0BC)0M:43VF$IEF9!L0QB1?9F0%&5DR6XJNS#9VV2G[#/(SHQU,&;>6\_:
M\_S>]_W]TZ?KGNL^YWN^YUQG,7//A+9>3O3&9>XHKZS.D35N8-W,MD#"I@/$
MB8W-&T)0,)_BV&V=NIQXU(H>JB18MKWH.)DK?DE+W:&R.*,*%3KPJK:(HDH$
M9\ZHXXS)!)G4?;=P;QF$+C;3>;7>$1JNMKALTV-PR<!'(:3&U"'1/X \F._/
M5=$A=X<BX$6(UK@T;_G9P\V'<[^3S".1E0.K%F(QJTQ\<S:8@Q07PA+7L)T>
M 48WA-3F?:2DV)9[[IZ$V#(00XJKZ6-=H"/0@$B[@^4=<OYT^+8S3>8;/-&(
M/-F!K\LV,H_8;^D_?J+E\:[#HX-_A.RFTI3GBH7BU2J($]R#3-_CPL6^-I=\
MI0$G#BG,6#5>61I.UI!UFS.MS5V\L;(PB4:_8%Y9/'8!3"@#%4V!BL2*^LTE
M_[WNRCF1 E>Z70AI!Q2\3:3E10PB8T*2V$HF2 \2XV,>]BMGCGQ>\N;OMAO8
M:>4@ZHTY-$'#K,NC'0)>^2NXL5H:2F[=3LT9*LX5/1-%T.657P$LU_B6X(86
M24B;EE'V0G]#^W1RP?LWPS87F@6:ML17;W=J[5E*X-L7?S+HQ+LJ:*Q?D<UW
MCMY0SLLF)_[U&'/-.,&GY2E5@)RL1:0(L?=3; OF3B4G=PQ.N]Q,NW(*>R>A
M--;+@WYGKE*+V1*3^B!J"H?/\,)MB:1!:<#[(@9P)'E,M\"U E](QF/XR#F7
M.N9K!(@>6N0D#U&U]ORYRS-==4E\+1<51M3"O!="XE2+2ZC\DC8T($-ZG 90
MF#N@FTYZ%*5+%33@O&DK#2!SI:.6N[);4^\EOFD);$$Q72?KN10-TH"&EW5D
M%,H[3[RO)-=9S>M+2N+$I+;5N^,7:K5#S::BMEQKX/^%X-+'514G+[267K:3
MIP$'.8IH0"<GZ"WJ7D<(I33S7P),+A,T)8GA324$%)M*Q*I\5 JU0B+3<TLS
M<VR4?=!J1MKY:^"7.M-+J1=>=8PXG]*7?(2813_T#I3NKN-%V@VV;"C8(:ME
M-3E[)1\&8^]RNJD"#.UW3\ NX%'_(A'5>'X.M:JCCJ(!#ZR9:("L=/-R:W(W
MD09HUC;8K5;5HB!SE_YKX/JLCM@G*&=LY.CA0!YRL<W" 5B/;J3[RT)NGP'-
M!W)YDH-&+6(<OOH+O/JO/U;NN2W&T2)31P/"(OMHP'04D@;0 /I25JKUY7\K
MR^K+HP$VEEGS(!>XF0TNU"TT&[FUR4\O8I*TMZ\BWY%M1+>:NX!@*S63$CID
M9_(LYLGDY>#"U. 2D44&]1B.13/P_!$[U49WV& 0&C!F_H &?+X _2<A2?=\
M;HK;#TAA>?X[6'E\(6"BAK/5V)"Z3>O*2-P5&8YL,X>AX4N>@ZLV C9-MU?&
MWY5)GO1-S11^I&5V/4G#&WIK089PZ06"Q B/?&W@DC>"3$.D[JL;7L_=^S(8
MJ#L[Y*UK=?/HB1,&A%?_'88<GD\IMD7D')2M[,P/]HVZ[9U/H\0 F&/&?Q6;
MCX0JBK*6'?MG7-XMR+H)1U]O=!UP#_GVH\Z5K(QW0X_L(U_'EP?8-395APR&
MX;K4;XE%^KA)7#)SS1BN1-45K14/_A=*0C/=:G$':,!3#3.T?9F3]8"HVK%+
MQGQ<AZZ<4@4V^/)V1]__/S:E& 9D&C3E_)5)N#BJ_/2K=MO^4MA^B6=241MG
M>\Q'YZV#[A0FLT'6IC\OAS;*>3PZK8SZ+[#%[086"JXPJAN%*>F+)1D:D;!-
MJG5B@B0CC0PGC\%A/EDY4?WRFC<ZE9OBJ4\N'@KPZZ_JCZ8!_X+W']QEZKHN
M+B/4J>,QRNJ/0) $ZM54(@M=7 M=O QO5<4-D(73A%&A#2>+\1T+MX4>]I_3
M__615ZX).)__.0("=01YII$*Z1]L['0^E1+;V]9D_FCHS-.#KW7HS:XQ+0T]
M9R%*,=2"$1$\7R>*/&E)_)KI<=_)/M^FK+3;J9]Q!'^Y>O[1O9R1FFA\Z[P+
M'A,*_VY,]FD14BOM]OR^Y]&,@YW;VU.'O$NO ]?NQZW)KZ.:H%O'>$;)$F]H
MP/@5E ,%[ ,S7@: \A$0JK+VAFV'AMFS)4Z+$$$H@9<&I/SYDOZ=P*/HS?P_
M;Z6;5F.JAS.1W9H"C_;=*;WOA;%]X5H\EB#FZ#_V[F)$=J#Y]5AP9O7K=V%1
M&&R*/Q_-J4^?+]R0*P@(%M3'8IH4:("R]C8-V-,'I3@_<"#MHP%M,#!EU"NC
M:0!_9G9(4;M_L1SKPT#!"E)?!:&LPJ='.6*A;Y'/)N"=(>-YTX@/1V\9N]=X
M!&G(?#V8W"3_-ZL.0") /R5@_H"N]]17Z 6Q'Y^62'RG5_NF:^0'?FGI50_6
M3?[6BD-5Y>/@Q8559F":_H&M"U+^F^91\ S^#<D\Y##H^9Q1U%@*&%FQIK7O
M5W&14&:*!LG&Z$U)?]'%5PW+,MN&3U^7V+0),++$G&UQ+XU[R,YJ/>VY<\"H
MRS;M,ZRLQ)OW=L4#X_AI?2X"ZAHYG ;H:/YA>\H=ZM$X#,<2CFAD3P-:\NX4
M"LS>G_1 ':YAR/8W(KZ8"B_+?OIM:.%&WS+O9&QOB&CFH1A>>M8RW],EY C4
MCS^!&1^GBD V\S;^YB!</885X=<:AEUDO\7/->C,9J/=<+I8[E/H]OGW=#_T
M3UR">:0LSM5K-I-8J5$!&]3]A2AR+^3&K_A>K+XNO-_)QZL>A:\1)\+J1YBK
M^[*[E1"WC,Q)V,F*)YS(C*2@(?N]@5I--]$F,+^51B<2*W39] ^#<K<EP9B3
M_A-7>4_ \?L#(BU1$2_-=.ESW]._L&.4U3R:2 /$_]09XD!B\23_Z4 MH?!7
M% 'BCW@"CH,<UL5G0@.:.'1\[A7CQZ-F1)9#OUQXOWGO,7-VN&UP,46![)3E
M+T%\;LT8O1XIV[1BV^;A*_WD?FKD347#XS%^)6?8$9_K/I(X_F;Q37+D+Q[Q
M-M\,>+\VM#$P'GC47YPXVC13*A-[K_U+3:=\HO&;=]'TEEEVS!,AC[W$K?P.
M!R;]:/E,$()._.D)DP/R$>%4YS_$R^6MLXH.KN[PP+H,4P4.($3(H^M(<XUO
M,\\/.2\@);_5_1IPV=M,O_!%-XMA"Q2:@7)0Y$^%%F[..2^WJADAI*,<;\6&
M9$4T9C("?;?SB#Z- Q51_F>*#3GC/[YLEUTHR]JCQS"L_\Z:H .X)>ZML]\A
M(-KK&DD<OWCF5TVRIYB*IVHOV[$<USR*^2N2S(8IS*13!82ET"WSG*)AV?57
MW;;URI^:WOC6F?6\D7&Y"EQ(_WJZ#?#I^?N?$'Y@( N!4J-(9D/XPT1'[S3)
M%#/=ZOZ;GE&\=WT47?0^K[;HRMPGH)KT-7G(%MO. 9*7^PUM!RT;<V;L] 8D
MGO@^D6IXEAVEL'+ZHP/ TK__/_0-O;UA+UY\/;=^AWQV?#1<2+H*1[((K3G>
MG_+PSD!RU'C?HM=!ZUD8WN36 _I6S)@)IS?7:BT2]Z\J@28[%KE1(W) [HDR
M9VG 9+:-SQMIRS4(]W2%D"CQ:T[V@'.RM6SO\+MF[LR;6BG#$?ANX9B0=I$:
M"[S/>U8A)VXUL_X835EDIG&?[.UA][VU/;).]_)I@-S94$M&8\5T4@*=!L*>
MRB]C_5>]0OVL5^9E?R&A 6";ZK@8MF:N\2J*!"<[MMU$M7']9BV44IH-EJ"8
M/M1T%/FW"@2A6ALS'<RC?K0842*I- G"6OG!+9&%98+:-D4J!K;./P0,W]GS
M+KLX1.I;-ETZ?7/N.>;"VNCWI7HA8;(',;R1*D32S:A^4N(@$'G3(.U6I+7N
MS=";J&=-CF8,*F)RB!107^RO^G8;%+Y"T =_H<K0G/<U'PB$]+V4]UW16*.@
M8/++>F46B8$=J(/^"!*#01?D_8@RCO@DV]X;K7ZJJ]#=;K!$*EXPQM4L./C*
M@_Z0^G$HE?_D+C$R?R?&KA3UXX]:"VHV*6^\U&I*',6[OAP3U)Z=W6BU$R7=
M:#\<8S-G>GZ&[:N/7)/=?0^[!W:R($2N(M0?40+]V<K^@W>S^PE)T5"A.G;$
M*%<9=%_S]:*K,]6"+WJP>8T.*-GG34HW=1354;Z9_H=CE]-V9#C&VN>W XB)
MA&)LGN557HJ*>_8Y-W>Q_@281R%\2M'N:]%RYOJGM?9K>YW QD$' ?^C<6#]
M7QJ'RSR?*]90<\OSA9-+CC2@R&T'5>]0:B%.LFA(:8VMV5LPO<44X4J1*8+Q
M;$D4W*KX$J9U#X<\?"4^I%4;\?"? G?9037JS/VB]IAU]>ON21\!8LD8.MI?
M=2<\'YE*<(@L<S'9UXOU_"Y'>/+)2B$,V)1J]O@P8]?_DS8>D#:NO],F_RMM
MYL,?P3FG_Z//Z%MN;/$T]40MR7:"JMBW*+=4K+2C.&=3A895.R1Z/>^20[F+
M'?-&'[_FPI08M8H#CQ?BE^,%(79:]__1K(?L-NMAV$WN%W7;:2%$')C&'M8)
M(MUT^LM.%LZ=XCX\. )/@&&.Y;)\5W^>-I5HJ_//([Q[<, S_.+/,ZRUJ^1J
MUJ2D9,]7:1VQZ%%('3^RG["W_(%\<(U++O+2CY9Y@0^R$I8)R]\C#AW@'0HW
MWF_">/*1WX0KY13Y.FI,H. C5MV=(,]]X.&^-XA[37/[F51M(VHP?I/_FBK^
MW<H>LWCW!C92UNZ(5=EYZ<]*@$7@F-=D61M2,.MV1>I]2Y5#!G<D0R7TGC <
M1ZG?.,^2FAQ?704:\D\#(/\::<PKN\MS!+,#/U6,'"27C,'9D!Z7JYI#OZP@
MK+]FY\,TAIN?12;(*LFP"XG?-F<9PCY12X1?_$_M[+&Z[.V+LWZ77G@%^!#M
M6TG6@^>[#24'/#G*.-E;&:Y\?,^4;9/H)#^W1:VH.@4&6_\:&!]O]2HO7RDU
MLA:\K_.Z9Z&WZ\ @<M'>2HN%J^?$'GK=NP%&MGF\__@2)CH\G)L.6HIIO.--
MQ$1"5TO.%3^I:H_"+=]#':0!\R8D2>H31Z_.CM^[XKZ[I<#LL9(1$2^19SLO
M(1NY])-<^K-L: +DQ?F!4IG>_I7T@\=D-#7,^0XQA*PJ*]3%L"QRTCE'Y>QD
MLU$5]-9CX*.<=/>BO@;8[9D3AL0J>[WS/LV>1W%DN!3U-=4\6&RH"]!H<\#P
M6(:)ME_<<61XF?$:BC_V5E3S'M6+)4WQ];D0-:HG75>G)7>==$DU1.P3BO_6
M4O2=.S2@[U(!N8/I7,K)JRGD):/ 9"D4OP6I[WE(:B@D%O#RS51NS6F2E<4X
M5E_<<9XAN20G_?#]7-&O1-<Y<;G2@L&79*A;>@^+#-IRS0\G+$;YV>;LK&D)
MQ5>:A#'6E,-B!HX;A>T^WD=?9"1/B(O/.RSZ3ANV#?9O\!(HY1%\#PWXIH%Z
MAC7"QE/.DG*LR6S;S$AXBZ80M94_QMA**V&N\].Z>V')0X='YV?)=)%CZ].(
M<&+_PO!X59T@N=NJ"EUO)Q_ /'?14GF4:1!^ZMG=BI.^]P8?/FM\UL%"_+:9
MC#;17''R!(.#:I_@;E"7,\)I\;5\M+PB_&9'69XDZ+D%==BKV3?3,WA5E\/.
M*C[LK3^T18TG[TZKT'\YH4;(18:L+Q+K0O +<A-DPZ829-B*<:)A<J,LYV&[
M@:NZ48L)S\0M5\)-3DQY!U[MKI@A#U+Z1^3G5FB 1,!)G;LD?V?B56YO="$R
M\0*Q=Y4HMO *H?:0N]\XC(^N$R/<;V\?X)+WO=''P9UKN/"3D/38W>E9/Z[K
M]4*$L!2N19@.IPFO1:R_]6ER)W&)6J_63PV_;O?93IX44.Y_F^R-F@7+P;0W
M)UU1=7#OQ6'[,HLGF^$Z$D'R1E(ZDLI)'D7UKG>7@P++/I.WFRRV',*QKK+"
MBD9';B7I>< 3,-S0.ZBHS!;K%^7P"W'[OW-#9$N"W'LZF.9MR&'?6#8_HXN.
M"XF5)I47SL+>8)M\46"H1,F[3 KJN6W;6;59$?46?$@F@TW<=;9#*6F;5WA9
M;DYP=$<!.W6V%T0TR909&C"@8'^F=0J>1A7=R:X3=?(VEV<*_Y'\Q1@.D*S]
M( O*XY$N7,7J9TZ[O4QGK;6X')/&"VG)X7&V4,4^+%T:N-\B:1TV3-$X$3DH
M\!J)S::<&1<TO=*17IW0FQG?+\YJ#:S!2PN$2NMNI*U-<0=*X9BFRD5>!(S?
MCS[,K^^=<Z^5DV[FV/O.RD-K7V;X)RKZ@FV?:N2K*K\+?5S<& 7,\ALS63ND
MG8SI/[XU_S7K&(=92\D]>_O)1P'3#$7W/W0L:V7Q=,:_:%S!AM( 1[>!QF84
MB_]YV>,4J'O (<*!EJP8"ZC]]AUD@@O' @S_KO1&5;VI%B1]=. RPT;XE$ET
MZ=U#*&O*,Q(/A1/:JNUC"#ED(,#8\"RIBK(WH(CH,RZ$);2'^6F^R[>L+1KN
M.3H1CGG<P=2E?6LM)Y)' _&A4#W R\,OML*E?.0LDVK18W(0!A%VE*-\G4&T
M#/#31.9(<ST3))XH.'S7^7R-R4DM?DXS\3J3;\U6BM=/1@$)S]7,KKLG=J7=
MT@@%8'KSW31 [/Y%&H!=,*0!EWBXF%7MN[E4?E[V^>LR)V"X;>PO'M+2/K:I
M>=21C?Q"3O/#@.E(_E<)*MYT=. =YA"R0I?D;]$U79T$)NO8H2<JLG?P#U78
MQOU=IC_'QR_!6<D'UF$D6#-&D'*ANI?BH!*NSB496RPG3MR@B)YJ^;%Z-+9/
M?VE"R%GTL.:8Z.1I]3Z]T#I.9RH_21'9#RLCR59$\! F)W-C8)ZRN));PF<$
M_#=O"0#/3JT\6+&/RG<RT$OU3MP>8J<!71C;)$IDZN2]\H]E&]+0G8H*NW>8
MEST64YC&'8YF"+&TT- :2>TG3*TWKR"Q9B^*;2XD&LJK/!;>L_,BZ!SKDUP5
M>M6"T;=&R=$4E4+DG#;Q4K+F2P+=34MD8\L)A+=W,D_P19?JTLIGO2_"UA5M
M%.,&KWA=MK!8QJU-_E@HCJB2,^]_@1- U:_V;&]%U1-%R"_\Q5^A^>KB)2,I
MN-4?'0EF;^43J;D7#!_$!(P__U&1Z_RU*<?+XQ/*";+)M@K?YEN%[9P^:WH%
M6II,B=B2WXG9DJ0^%\Z9&GG4RIW5IB)L*G0MO8/A(T.10C9#K?N(+#GR%=E:
M<2-Y/_N#W@BNJ>[ +CL^YB9GMFNH<BF&06N\GA]<P[T>^[AL=!!6OW4[O;PH
MK^6F;!!#U)H@$V$MK>QE*^K 2>VY2K89+:&RJ6"GD7MQ:^-$BEV9;X1Q:TK:
M."'BEM"52ZW?C)F*LH+22HGO^<<IXEC#@OK:\9OM&P69QS=GM'@JHHS?]QZI
M6C#5+O3KV+/]_G2.6_Z7V,HQ$\6ZT^D'#DHQ**?Z%#:Z?G.B[TDHV'29B]K<
M)I2G$F;6E%UD(V*$])3H%AOM@E9^Q)BEVEI+#S+C"R:[>6())8#N%_)&<2M>
MFXQ9:-V^+&A:[L@P^K"Q#_-#OL@C;N/"F-099WOWT[!J1P;?JT)AR9IKZ.OJ
M79#G;!;/<<Y 177L4*_7<!0L58D.X24Q&\-0GG&F1(N[@GDJ4*2"8K/$ 189
MN3EP"%9V<3U=C"*(0L@65$D:\-JVGQKE#"PLJ'ME^I\D<[U"9C;QR#IES/B)
MES7WS'!<N+S'(('KK/TJ?:7+@?5Q\CG"08&K/?A^^0675<19E&=*6*P/0CKH
M-5SQ]$2LM<YGX$)(3)1;"X;9>>3T3O2:$=.YMZF7>[$4A3VG^LK)*V(>[-?D
M[O?'4PQVHG]TXAPPO&W7BY"#!"A:&<+:^LI:A^!BY#I9%E/C)L8]"_8;24N)
MRVL99]XMT "P[P4Z=>7C??RVG*AWMB$PDE!2_D";AU/NP- YIJVIN%LB'#'X
MS4U]P;AC"H2%?=.M%OQ]:9[I=]WJ>B&/5%NWOBS,+<$YR*WK]B2A:!3II %1
M\F%*8\-6&.:E;7D20O+[R]X1OFB[P?!V=@/^!;&U=LF4*2_<]_6Y)A2KNA6*
MJ4&>DVS8X*/V(G8D<<Q(1% 3\?1VI*!XFHWJ]Z(!E=$0B ;#7:=W8@/4,D/*
MPDQ13/I@V>ZWZH#(MVI9.PK.# ;H]IU)-2!4523YB'54>KK/[AN+2JF[018E
M3A$FP&U4R.O^^4 .JQD+Q5.9>!L(B_7KGB+_]_86C.;<<<:'&R2N';CIB<UQ
MSN;$8>>VAB[[,$MEI*?O/M]>7R>O;[^3I2EP6!&%YR )TX"/;8?*8P?1^$),
M-(//@CAQE-HLSXZ:N1UNR_I80XH^O<:>HB301YTI"+RPQ7R.?HL9R'+#;+\J
M*=/0G;QNSY[PC5 1^+4N.&4]OS$;0%I$*R]Q%WZ1%3D3F)1T/1_9I2/D)+S-
MO#'C^31+/0/3D%*M?HYJA9W4$CHJEG8\"1G_8,N<^^4K<A\^PO#98<B%+>CV
M,?E%9MC\T\CMX"#U,_753%%'D[V&AV*JEFPG^S!Y-996EA#GQ<SN3C4I2*C!
MNLYJ.JMR1:>75J!36JE]I]LW#QFJU_ !L]6<Z.O@Z?55"9/+_GH+]17CA)<>
M?Z00C^.P"W))[GIL\V @Z/0VR.5GCSOV0WX6:IJ0RGL^*E-VKZYQ8ARL@15/
MXLG\<7?*+%^@X#/8<93:ZE))E.;7NAZZ>B<[IFU>7OO+LU3 ]ISXLY(U['DV
MNK,1_,#R3?+5".3MUKX7DHV<\7>M<&IKIO1= <^-F1ZQ/NPL3 TY%5B6.T('
MO:G =,>>:P;E #][M@(LA.H(R)Z46>]'^IN2?6^SR1"Y(2:WKW5/[XN[]O)U
M/UJ[K 61-R1*.*@.-6VG#!$WZC\62IA_9KG?W^%@! .;2,N,5?J@T]B]_L(A
MX_+SD;O?TJ:B%NT4KR<8.O/L.OOBL@3[G6/Z^/)QU7'EF5&>NH/?_:\0>2@B
M,Y[51R36^XAM;G>*$ED*)$Y-> W&3,7T1R!&V<HPX'SY>BK4WR"]S8MK)W]F
M6B?I[9"1F,N] C$G 8:J9P;&"L_35 M=SJPGD4-)]\=YHDHA>YRJIX*[!NO?
MV'Z?&8%V7GHV.9SZ%NT3;C(?K/E\07Q?J^EYVU6T[FB;V!)9_IF1DT_%YKO
MG$QD^_JY\";J<9)/U!U_>U0Z,MFLYXZ7B[Q)26GLX(6J\O)ENF\3A9\^79J\
MQG1ZHW#!8EVSK[B&SB/SN[])#;K)NFAEEG_]71[9S:C'PBSIT=%A%R4=$3HM
M,[9'P ?58O;V]2 2IE'^^Q0!%KF&$Q@@-WP=65 :W8?$F92&PVRU?;5B/FB'
MQKZ,NWU'G['/\MM$G/-H8WMLH 0)-T\B[;VC>=QQ !/C3^<K]A;9\&W \'J>
M3<N>F1^;SO:6PRJZS2>NQ(3$GS/0M?@NCC*"RGO/%:=^"UQY?+_B%GEPS;"D
MKK4(:;.N0C;(1-KH=I5AZ<D^+18#7OG6+^SAG46NKE,'GKMZGPM2O)L9=(*)
MOC;:H.N.IZ#BX*7NXV/=J]N63<;6 RVB46(,=&97 &"5:PSS!M/LQD[Q(YH7
MD%AM>T4,C<SGF^WQE5RG9J1Y!\P&';WCT5]\C@ 6@$5';U9/8FF%W].6-J=N
MK8PH&<6&&@?"P"+8'\^C>G;_%M(Q+_.]H(6J/+.U"CFLSH%UTN3MH1@YV-_*
M&QAJS:ZM3)!X5L1R,S([YK!_\C3L;#-@=X)A(/'#U7ME7U -< )Z2UQ3@0;4
ME8Y2+V92V9<X49W2)/3.VBMP$+\%W'%6\_<Y\5:1?E_+/JP@"35/ _ 8MA&-
MYKYXQ/'">[8O36 S=M&2434FHRL7_.UI0( 3CO+,#-,D= RUF:UYXG?!Z:S<
MJ>N6Q(=!(1G6J-$D&L#<19R:'\:[T,\XE'<NV#\^$G8X%_JI]OR<YC$H*.CZ
M[X+TE3%<Z,ULNS_E,$>/W6>,O5PD>DW#V"RW9G\.'?JM#GICK[[RZ.[&/Q7F
M631I'H/_'0%C\]A!A5NLZZ??GIGGZK!Q))T['&M/IW=-ALO?D!!/ Y1R6J ;
M?:E@+DT2(1<T,U"=8#&HI2(5&I HQ>"B]#0L\.RFF:Q-@[=U$Z- A%G'>O,5
M(1D2.-NGF(Y#VHUHP,0G*/XX26^''<-+]7,#QR%CQH6T9X*%(DI:G"SVG 8W
M0DM>!YJ!O?5^MRCH]&-R*W6K&[6I&$+ <4) H J4U5V8!SMS]';J-TUM8-I9
M=R!)-U -%K^X*$M3YC<=-&#4^J>6O0?OX[\F%WVN^_%5VJ:W@_^KV\,!Z8>M
MZ_M.C><\D?$D9S8S_<T6:2A>XA>03*PJ[UD/&IV.+TV]\?VK?S;HFT4E[)YO
M,WT*@WKTQ_5/<$J]SZ(!#Y.;^6A  FCK]MQ/8Y$D6!03I>OO0$J)12F'CEY>
MY1*SXRXU8(A(%AW(17.2,ZF1H'J-G]KUHBC&T!^@\2N[M@>IF;W5>N#^/MM&
M2;  I/YA13-D]4*-_>8,Z'L]BG@=V+)D_*42F'G22_=5-6^=Y485E&Q8\YND
MWVA$DPTIEVG ^3^]^)BN=].^*_E:,8P*-L^_1#6$F/P[J#_\6P0PP[_G4/77
MG]$ ^$ R];F<#!@2#W&[</Z,:MO=3W:]G$T3)%_>_3I'SX%+F5,C,/&D1E&#
MPT\6G:XHZ-[ZVG\5'[&1OL\-YRB_WXEZF)03>?L)T2F-K?9)H^FM"O$^R_7%
M;U6;X5]K^H0RMVW\U;NH(E;(4XC:\[,\K'M8[PMA9+X-PA29PO87 ]\2WKY]
ME+7!M>+3!/O6V#QR@CC5\N*&K'W+NEI?'O;J\(P07[>_KG"7EQ0L^<UDQ<$W
M%==+:H*]8_K-BITP;.TMMO(@::$"7M#&!36$X8R\9^JPVK?9E(3ST>OO7M]D
M%6DNTRY6] Z^!'#B'3ZW?8<O]F\MW=R*\E.]-U]5M#&SXV6-T1X,[- \^([<
M[4-\*_,]M=F[+V/V_#+LD>)+RAO)<\+:A:;%?8QO^M=SB3((-L<,&QI UL?8
M:@I1F[:EMYV'Z"JKT.HZ)5,K:BZJV.15Z/>5]8==R@%0@ME[XL[7'/EH2--&
M('\8BW-4R0VF"A5=-[%\FU Z/__,Y_U>;L0<PKG SG/CW63M[W(3-=3WFKPB
M@PMY60RO[?@J7%9*5A9&J=C)N>8K7$-7Z@*K _F7=Y9GKJ6^341_)NWPJ P+
M#K>_R<V(>I!V>=N !GR(S0!;XO8,U$P#L\FK/&JO=1\&/QIF'9A3 !]T2G'!
M1BI9N<K+2UA>#V5\R6@U',',E*?< !9A(W]!, ;?C*$H4J#WR9. G[2V,]^U
MXUFW*QFV__FB$K4;SA0!'A/L7_O=,4>H^PU)QSZFVU2Y5 IS8NE+=L*%I%)4
MO0R?T2TB9I^AG.1#L/T$W(/VG2_>*,J] LR _-C4#I<; YAK]1QH0*L4P^1]
M>;)DX(-3;PXN3)1<G!ZL<[/>*FC ,"N!O<_T":<W.MM/.Z3VF/*LQY!/LU*2
MX'M0>)W=.X^Y;QOX"S%0+^""H<3,$AHP_ICNI1NQVRCTK6P_]$)O!=$VYC0]
M%^]Z\=W +@P3:KI@]YOIF<] J:HP2&E%?2<-4(;70\B7O], TB=@Z4[I](+%
M'4=.U@O5'%$K#[8O^@M!5LPH8+,>*HBA 4>R(:7]]?C=F]Z#QO]^UVI0Y;3T
M>XO4_\"F/$5I]*<2^[_OCS'6\<7MOC*Z)2/$1 ,:XMII0-SN^Q4J1$\:T&9)
MA%(Y=ZD*TN#J%B99K<Q\E/'_Q-I7B2$[84-PJ^;J?P)ZA1EP&%M$310B(;_;
MI26(63\/'X(DP5Q>M>[_8 QEQD/QKS0/T8!.BS_D/H<Z84(RJ<ZM#VC '[1-
M!]/%/7XU#'->P?U+R^Z[.:GD,^"\]8L=.I'V>:>V?S.<LFOX7V$!(7:C0+K_
M!DLH@3NV[,?H/Z_K_8L'8Z:LA:S6LO^5(1]JU-]QSYQ!O"!'84AN-3 :<.T=
M=H>S]POJ=SQ_.>(Z<F,]D:SG.^;&9E-/@M6;MLNEWHMOAD2X\+V(N0@ !@D&
M"UI"S<64LZA0:(DVN>Z,4@]$ESC/<Z-W8KG/Z'7.WM?N:\WN/J/E\+!)$CIL
M%7Y(,W5<O$=)9N$&25TC-WNAK:2>7^V]2+3[[7O-NG?OJ?'/U^@0J6Y1N!))
MBLBIC<M61H7(>P=T*I\=R+KU\I*^H,[=V&W(3-TA4G\HQ8HX:$3,"2ZSA9RK
M[<Y&"/*?<??Q..[XIDWR,0]2U^3N=TDO\3X:T(=>JZ H. _XTP 860+=L#3@
M<+7/5=V&J0G&*/D HMW9W<0R$RB7=.?Y2:G425/.]T?%]YU>4SZ'1RV<)>"B
MH ?\K0J_D_<>KW'*:.6:U^2KQ D/?__,F\+#?@<_HGBW\OWUX/O]!S.I'^#<
MRI#0$1FB2G2@,#)PO;]9Q?ASP9SU;8RZV@L"W]G*%0E?7O9.M*R6<7X-79R,
M">1;13/J4-F"]38>UZSAH;:(WHG-'2)WK=N:S.YA4:^2Q<061MQDS@FR%/I6
M$. R"+-=I %[-][)/:KVFYL!,Y?*ALS&ZA*8/R-0 T)SUCVK;JQMU\<^'Q6L
MK<OS;SNRH8+\0MIW@?@&\[C<]YKN::PCEIO,MGT&_7W)IA<\,2RSOD2NM1J3
MXGA/.X.%I?<'CG^:&+^3[GI]9U'/U*[[TM7J>V#=ZY^XZ%:T^] 7]D7#'X\[
MK< C<?M<*3X$&G (F7R1I#1RI&<5(;"C>L&J]5ZBCI=X%OK1SC[$::)>@;D*
M11K%C^J\E$P#]IB/CE_1A/K#26Y!-5YCHP?)5IZ67TM>S::$-G]]XZ3<TO[V
MLSU_QG$/O=C1.S<,)!</J1:+45S(Y8R!HV-8"MLP6*9= #_Y7R7J_;JTNXL[
M$GC\3>L@A0>S3??SE@N:RO[6HE1M(>;VG'7!4; KZ6!ZB6I()N7L<,Z@B#HN
M5*5?5LI3HN/HYN!M5*D_IT#'M ^*DFK.,R[97,Y'[21:4/<5TX!-M: S2V03
MZDGPO+R0I^XKPK6@?UU6BI*B"=]HP%-T,(ZHXP/V'CVHAG%R!0TX"]E+ \:B
MEL >(Y>A%LP6\N/0+>FNW6N#%,=_K!$AX(5&DALU6/, #:CG M%+FJ :"/^E
M(-A_$L3\JZ 8&N!(E@'9LT!17F@)+OV?]%YEI<C!HU&K;$3X[T0\UU0 V84.
M_,1W<%>L,9,OF*?@+9A5T^Q=517DSG^L^\'L=""<,+JSQY^+!@3+X*B7P%="
M<;OP[)C_DN/S_\EAT92CV AC%N3WHL;"=HG(PQ$K-66GJ-IV?UKY7XF1]P?[
ME/3D8#!%GOO=62,_.9;?Y3CL-XZK_L'IOS@.@_ $RE90FFIVK1( K<J!1,-Y
MF/YV(?W0*)43%PN=SC'<-=R-E/GKLEC,WXI<COHA"0;\X=WH]8(0RS5EP8$.
M5@\G'ZT!.]Y98 &'-R1W4Z,\<621<AK #_UU20AO=HL&SZP"]$]60+-*J7*H
M#M-=(>]^"IG_OX6,X_!.E%U.<L#X_8V23 *ZN1$4"_M#;"[#Z_\OZAZ!%S D
M#VIPW:X_]N[Z8_>G-\X11MQW"G9MM-VU$?!3A].M&F(>JDDV+EC/SIETE];?
M:9C4#[.RX]L3U<K <#Q3V P>"2UQ>U@G/5L]DEU@E#]HA^#G)WO/&FD2&XR>
M/OY<>NT(^Y>S&O7-GG#&&H< $BO>(<S?(*_9C?%EGI782JMCX1LF#6]&L0>M
MVK"^=VKF,SO.A6!I9$RU05F/KO00!1G6)<FH+"<UU_C<$7)B\Y8<QE=PGA\>
M5>;04W1.S(5?,DE*9C*H=:)%D2G;K@]J#PVM3LN\KUP<OO,@9Q9RB]K16:KQ
MQ)RG8>2<&$))(9?E "3UU1B@O,AIMG)FQ4MBP'*<(DO$GB7"HRGG"()"JH7%
MRDO26!?11.XV,43IA3?CS)-W]PMJ"25]NZRC__/WW"IQ$2@>RDEB=8#B03^C
MBT.SVJ8(MZSIBNKG;X_?5V^11K#$Y-?=N/>>]:F';3:RM;D;#9YEL&>9__W]
M,'LJ?\%[S,K,.(JB,K#[48*CN\V V1AL<Y6$HPHLH&C H_P/2D$3'7L@Q%[-
M/30  ]O]J8^Z?O!@,Z/)SAAZ5'O.[N^MC")H "74W.>:B6]&$)@K&J^0.:@!
MZN"$%[8-!\/I&!2?[[^?!FBF@:-38P 6="H7[$?4O0^\A" 9U+]VP\C.V'^(
M%GO$H"\.=.R!_E= ]J2GE19)T?]OLNEH0#OVY_:YW>VF.^FF_LV218 >:+[I
M+^;G@< I8#;2K#L% D?]!&ZI>%>U6?NVR;<V0(7*CWV/6ID;=Z.H;/UDT!@*
MBD][4J<"W8"5T0"J=K:B?)'A@2@@FLJ?\V^R?]667_^8(0IVVN^_Y9O;>'@F
M8>B8\2XK=O_>_@\.#=>31)>N1)ZXH=H&Z/S+T;D@0_E$2<K6[N^^'%S'@>./
MV;7G)HP_@H3_> 7YYRM7</_&E\.D+ Z8_H>]J$8SY*\^>(L\G37D2(^C*%L\
M@$YU[_[$CMM/LK#GB?"854R$)M_;_E75R:JN)8:G66D#-DZ*Q1_J,Y+,.L+,
M]R@&[YNY>FR-2_Z?[]=QTLW^_0&V<QX^>U.8*E-.'W[.&-\0'*":3P,&J]UV
M]LA"ET!?Q2*Q"Q:93@.44>;",EO-?M.WB<TF/.4UH;<C([J4110+]YT6AC34
M+,-"ZQ@,]#49B2/0>3;0A"9CIE[<W^5 _K[PSP1KQ[OW-R'DE_ZJ8,J.1E%%
M4GD:T/27P%K_4* 10Y8"JP9!BF&.=6%8A1K,C=G80;6@__;_.L,:\MDQQ\%)
MHD6X^T+6(#@5<-I0A(DGKU4$^Y\ASX!Q2-$! IQVWKT"L[YV-Q6TG]SYRZK_
MTV<BZKTOA'0>Z0%9W[^K\!@X9X0$,BQ_A.\AN^NO=EW["6)V]'\#H0Y_:+>7
MW9YZ&,<*V0X]"YI])03/\^#T[IO;C:/D8V"W$)'."AZ'"L_1K7W6J-&UW1+Q
M]\6F<B K<I\6BA!)G*$!E5<@%)W+$"8*TW-P\.#"+U&XZG]R^0WROW,9I'F8
MS(HF9]2 X(-SH>2HKNBQI: 8.AQ^/W$*MK6G_O_U1B*D 0H\VP=2+]E8N=&5
MOLN$-_G<&&2+W5\5O;WW[&\2?@V,7T54N!%1^&T]#%E;_11JD6,W DQ1>%-_
MZ(@>19@*AG^]#ACE;%H04Y3K#&[U<"D-P,V!'>/?%LK+@Q0QLC^/Z/N?^XUV
M]QNA\9)!O*@/:#R.POG3R71K*NN+X-AW]@!LFXH;U_O[ BZM AJ2#-WU*-CD
M_XR!@\3[[T^W4XYJ'@%E7H3L!H7-_QD4E_TAQ /@Y@8V_.AO.KE8<$S^>W^
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M[:@)IL0GVVUDX#3V?K%A Y3%$[47F=F<0GW>+['=U']Y!+X_B^5!EP+_/*^
M;J]@.WB\*SQK>49=4.QIB[N_!QAD$>[O4FZ(C:8!A\;CS\FOV[V]BQI]C77'
M,I-W?.7"29#W:I]GU$8R<\[:YP^VR<5FVL[J2L87?F*R<<RZQ2+JSPYLPI2
MG//EPFAIW_57S?AM_8F1HT8CE<4H*G=Y*GB>:0 8F0_[:, F^V-_B^ZSH--0
MK5"R-@(%'C_!A*;<EUJ /9?EM^8?W,?V%U^C6':#5>8#;C<VE7'4\[FP9A=U
M(76-W;47;C=6,US4^/2.'4/8G"\WRF>40=. T+R<*:K.TA',=OSNEIQ6DLTE
M07^-\7@P^\I5_#Q\N%Q'[XU[FVC^-VLBZ2A6Z[<+"L4R_+"H ?<9_)\WYJ82
M7CR8P8\>0?^V3C]8 &49&!R*-%?^,.U^B<04ME"6"I=S;#S4\+J;D!T,RN=<
MB@/ST8W?M,S4';/D:B#?;Y6D3MBZ[:9C.ED*74X]=^\#NE9U<T\,RQWQFCA3
M^D63@[8@ZDQPZM"> MD)W3VWH>3L&ZR4Z+3=!,MC_3/!3KNIJ[CY9FDDICM^
M]Q[K9W(AVE\(]G9[^XK@\=Q"%\?EN?!44XCT%36O\Y->,)F$YERS@1+C?A:$
MWQ P8'H#668J&MT>/=5 %!+U@HLHLC>O!9^('N0RHDH[D<<;?]-HLZOQ"6M4
M]3UT:N.(*F1#9&[700+6X6%CM97L;V-[]XSPAV8,OKY1DDHH3T']@)/:J8=3
M1L'48PIK-CJ-WN3YF>Q^YSLO&^DM(SV@HU6U* -I$0+*2'NBEG4+];!^2')>
M#NMF<LU?FS_62<VT=S=25:&_*^7MI)PHBV(/YFR1KK9HE$'(7G;E%C_XO*^"
M<GR;=8O'_^>M/S-9)$GSO28L7-T#O<WFM9O)#J3)$V,"A;OJ/HN$\8[Q$^YH
MLMH,O(2)NZ\5EZ.BN ]E"@GNXJ[N!W%?@1)+CJ.F;?^\8,QT4J7A@$]E9-.U
MO:KCM7[FR9FR3Z)DS;2,]W%]14>6 VARSE_*D]RHW*]22R!$-'(*NOX;\B/9
M4PU)J68)8RRN-SQ2>D"'W.<+DCMI,4@(?>"V"2+?Q0E&5C:$8Y4&@*;<@R[^
MYKP@,2+Z0:)N'4<H'Y-(K<SZ;1J0H)R-ZE_,I@'9&UQ3A_VO=-O/@>/A;O4^
M4+1;8_P<Y@<17@Y$#UV;SP)M:KYR\CG;IUXBQ$NGT;YG7I&SS#S%K2[Q,K1?
M #8AS:=&F2D6!%Q$G1CYW?B"7@,-8"]E/?S1+5.VO%:Y]D>J,W, 9MX;(6QU
M/F0/1G;CYD0_A(!BH8CT^B.VSY)SFM,D^.%- 9 K5N!L,7(TY1-XM+XUD'B+
MS,W8.?Z'O?<.:VK=WD4G(J(@!)3>@J(" J)(;\$"B*@T :E1$1&0)BU"2%!Z
M%Q!0$*(4:0)*EQ8Z*@)2HR"$T#L)-4!([L2U]UI[K_4[>^US[G/_NN>/\&1^
M&5\;Y?W>P1R9$9^Q>1BG788*<X2QU(B,2;//4H7[D5+I<SX;J31 R#QK"G,8
M9X)?[S0Q_$P#Z(Z7G$$Q4I1J26XDJS9_56E8^.%T]X+V# NYY1<'Z+<F%98
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MDE#):.J->:/>=^L_RJZX_+1(5.#V'=$[I?_55?V&SEC=MO!9X<B /K[)4I=
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M%N_R[C'/5RBUW$>(MIF+-E\_["@$K5$8=$NS<%%L)E%7%,3&6>D(SR/'&<L
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M;$> L.H2^'=%&Y-/)?E!PTOUDTS,/<Y^>8D-%)#)$1&.79.E6]?D#!@O$GB
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M]U/1U_=],?_SS6XPE=M\[LBP)B&%,_;[!Q4](_.H'2&DTK/;Y$?-&Z"':0A
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M,HGGWJ^I$':S;=SLW$DBK<5#EEK?VGD3ZYVU>$2.]ZH^?4 ?2EZU5P6S[XH
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M4)>2[J]^7V^0FZ#K24X:!>=TVX%3E:[@2QD;4W_0@*"DT64*]-?D#N#D+VG
M ^F@DPCRR[UF<[ Y@,J-;\2 T "!;4+!DWL\89V!@VZ%1-XD9M* CFM$-+@F
M-'G2/&+C"=DP/X9LEL:Z5U( AIY 4=;,:\@+B_'-QG3TQ%L$#"3<X.I%D$BR
M(7KJMVNPIQ\,W$T;I U<C!A^Q4@52I[?VW6<2PP-8'JYHGX* ?N'(NI2P<W
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M;K-UJT)1,IFO_Z=*ED5<K1+M-RD]*B?@\GB_H:2S0250>7.%_S^4!1G3L\U
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M?0A[BXXS+B(X,EQ+7/ZJP:'[Q2_!SK 3&\$7])\_?WROAJGF['[%455&]QG
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M>>VX@%/9#I6ZV%>&,9=_9_SHU\X@MUW1F(X- I2P#<U)?.$K0U%OCBDF,\S
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MF>$@GI#-K#MJP]<;9RIU8B=]O?,,T&UHV\VBL^B*>XRB[])^KR4P+*T$D>P
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M!=EKL$I^:8&_:QF^_S[\51ZN,,MX"M+T2'13CS@'97S<477<\+ W>^0!QGQ
M4QVRTH"3]+8R:SGG<I1,;O0(GDDF8/DT1S2:4-B9 IO4L,#:.MVU4L] WW_+
M\+SS)=O18/@3OZQ]Z%4O9C#A_VGO6L.A3MOX7[(.6V$9*>RTTLF0MU<(K9$<
M:IF='15E,)22=1A+C,48RB&]Q2JEG&9I8Y*9:21C<A@BH2TY9-9@QBB3PTXS
M0QC,S']'^_:AWG??Z]K=CZ\/S_/I?G[/]=S7\_O=]Y?[OID9Q($?\#7Z:\?%
MQWU"]?H7<8-[VV:R2FIV*'_A$7ZR4]#6W=.H4UI:9L"V%M8U<KQJEF)F:4_,
M-N;Y4\L3%MXV%N7,[WU05NR@["8K[C?7%SU]/" (*M2GR>[>TLH;G'YI>-??
M=@_%<BZMMD^*$4UA^JU>]$FA,=B$L!//=U(#ZWNQ^B3?7ZJF2[PO:^4^3F1U
MG#EL9NS)1]XA)# )4WA5I/JOKWXBH@6OJKG+[3_>:CHJ=@#V<2F>=P:K5MYZ
M 3/WH\@1RJW[O=N$CE1]$=[.7U;<I.QIN#\9!%YDWW)'->W2OPU3:.X?U>5E
MPD?*U;QYPC1-F4L!"#@WX ((G #<")P3D!33[0*9>SWT<9MSH[QFILY1B<TH
M-2VF 8$+F;-+/81LBTQA[)F;DGC?C[/G]9-Y%FS;O>&W_='[1YZ8?X4(J?>@
MF_;3]1[=8#V)3,)%.BV<X'<T0V:,()>^BD#F[WSV%/_:W.?SW@+T#A@<$;LT
M, M]B-&."QZ]VGA'\_RK?R%[$BW(3T=_,1_;M+YJ2S$ZR*@C4*M)+JZ,%>\L
M$<_P+"Z&A6_8)CXGR8U+1UCYJD<(V-9.QJK"Z],W3W<\WH>Q0QV5><&"V1PO
M^NN3A'UXOVC;<O*;>CJ3BY/$.N1($"):(U1"=V;5!U<XA4N_#(P>-2"K;!TV
MOYY].@5:47FYO3,VYF'A!:$B"RN"OCQ5-"*+&A1$AB:M$WL@OI.]CQQ1[R*'
M[PE5H/A[ZD52N9E] 3_W/OK[4"JG^I^W4^?R(GP:+"*N?=N_P&RAS;9EWY$0
MCHEM'@TBUX1<6[1IM5Z*&AA&G)EQ20@[ECJA?R+M.N7 I)H)H(E1$\VW/(6V
MQ>?:8=,3]YLLLG)G\-E^-/?M94%^'(^O[[DWNF[6J-2"HOSQ+KKC=N[#><Z-
MPEYR0T*1QI5L&S.ZO $9*Y'9=XFXO+[X1Y4^T$R!,8-^Q8F.V6$NP/%M=@7E
MGMIRK_AK2S]Z9K#X)"NE7G>O2JQ.4TM+H!6I9U2-O#J%V>,L#U6949\@7A?3
MK::+=&7IF9A3''9H$M$2?F<"@J?VUC%YSY?H;6SR \WUU;&7OAM1KRX(ZKG%
M[#?>>-SAU?3:PH-*V&KE.E@M06_.T/N@6*?UWL2E\N'3-7H.QGV;Q954HU16
MSKYZ(W.E(%R <E9L<5URTU:F/8F")5'Y\FHN9G/>Y*?#+*S%FT&&D%#-)YKE
MP\_=3Q@^=,S/:=(^-5RYU?.QU>Q9LT(=TV2A@:%@QO9E%JQY>VG=[4-SJ#'&
MQ*$,$UUL@N(+^^1_T*(_GOJK@B[;M$<LEM3+IZW&CDQRJTA= IT1;1! [9:[
MTJC2'?'P]H?O*R"\EHL?LK13(5L2E19$&274Y.4AK_#))"@(L-Q!8$P%+XG?
M*%DOUSB?%B")QP<QY5ZSXV,@(/S'@MSC;91PGJ2(#5L3(2ZZWFQHQ/*TO;^Z
M(!^WG6D)'0*!XRKF2Z@X$TUTE\RXF"%^EXQEA2%%IHI7R.*6T[!O][AJ';XJ
M<FMZYX#@238DBZZ6+G_V:?M^K/:0*Z6$L:%9M1CYVD<7=3<LJIQ'3^\ @1_6
M*10B.0<$Q+L)#VM$7!EPABM=G0T"F92*"Y3@(4H(SA8C\>(8@,"/_\O4EAC)
MSXN^JA"B<!YS$9A@2M05GM-QD\*P:T'@N2H"!)H.@( D?Y)T\\;\NA74%=2_
MA^J]6[AZ//](IR\[1,^:I5Y4]2CL_%3.N;.?N&T@3V[GXUMNS&NM6>/9[7+P
MBV,/&E,"*:XT[@":TY8116YUWZ3:MVIM",JUF=9)3.<8;),[VF'EJ]Q H+4;
M!#0&6PAOE7H)HL_@\JT/*DP9Q"C&K:$Q @\=AY4G_['A\J7Y?L^\Y1!Z.@B,
M*Y<I%,2$($5 1>1Z&Q!P-%)L2IM!8#2THC0K>,AV!7,%\\]B^MP56:>5^[I]
M67,I<+6X\*><0>,JXC>.[92S[WB";U5>=>V"Z4&-GU](;<NF2G>1CJ+]S\_<
M$VA5%D2S-J@:J81TO__T7=+D]RR[^?$U,8>/1#N,1;LS.D'@0T+^%U/4STL9
MN^L*J?]!<_B'KV0=<3'LJET!70']ZZ",,@G,N2?"<[3W *VFUD-P#1;DYGO1
M4,OR>0ZZ;_F4Y9M-^KK5*,\#J'\/(?D_6$K@P&]02P,$%     @ ST-P7,U(
M O[P=P  NZ4  !@   !A<')E+3(P,C4Q,C,Q>#$P:S P-BYJ<&?LNP<X7.^V
M/[Y%1$(0/7H21"<1O4U$]" (8@1IRA!$M%$G(7H+@H0PB5[")'J?Z$$0=1AA
M&$3T&74PY>?[O;][[_F>>__GW'/_YY[G/O__V68]S[Q[O_:LM==ZU_JL]:Y-
MF:#, N<,=/1U *H3 $!U_ =0I@ M@/K$B=\^Q\?)XP_-:1J:DR=IZ&AI3YT^
M2W?V+#T=/3T#(\LY!D9F1GKZ<QSGF%G9V-G9SS)QGN=@.\_"QL[VVTVHJ(__
MYR3-&1J:,VP,] QL?_-!^0(PGS[!=()"374).,%,1<U,1>D !([YI*'Z_0#^
M[T%UXIC'4[2GS]#1'T^H/@><H**F/G&2^C>NCZ\&'U\'3C+3L%R\JGF*U?0!
M[25/-MD721]."][XW,IN-H03NO;P6>@9.@[.\US<PI=%1,7$Y>05%)645;1N
M:NOHZND;F-^QL+2Z:PU^]-C!T<D9XN+E[>/K!_4/"'L9'A$9%1V3G/(Z-2W]
MS=N,G-R\_(+"HN*2BLJJZIK:NOJ&MO:.SJ[NKSV]PR.C8^.HB4GT''9^8?'G
MTJ_E%?S6]L[NWC[AX/ WN:@ :JI_/?Y3N9B/Y3IQ\B3U2=K?Y*(ZX??;!.:3
M-!>OGF+1-*5]X,EZ2?;%:;8;21\^MYX1O&:&8W_X;(B.0TAN3AC_FVB_2_9?
M$RSTOR79OPGV[W*A@;/45,?*HV8&0 #)/"=FL460J#.LP4%XLIJ!0FMT7-:#
M#>7.'&4JS0LFB.5-55PK-F.[OW+'-V8ZRXA]UAXW!6(,EH<1J06(M@)_.G!=
M<X&)S5, =P?D-AGDOUEE]0+6_H2HO#-& 7!G87CO/XX"N>&] E-O/8@4('$F
M</TOW9F_JW K<N^G#04 S>]G'VE#.8D*@^UP(WL* '13 $[=/QM^+B9^(-6G
M48!! FFI9<B.A@(P5.*61JPHP)>K%*!SZ,_'QYR+PO[)]S_Y_B??_^3[GWS_
MD^]_\OVG?***@JX1LG*#K''$AH'PO<3/G4_'R_:*VA1V+1YUF9SW-!?WBFE*
M&HG\AKM;?*3"?B=_\EI93HS$M1$ZT9SG=#C[*2NRWCOX'G,M!9@LG2EMA;G9
M'UQZ!IO0P5  Q[(B"L"B41B=10&^UC*3.8*HM=FL6F JX6RFUVG^JR3I/-R0
MP_"M&V#\F9S%&\\6\\NWX97FCMR732P)'B)HQ**7S30ZR7O*DIE1\U? N$=T
M"#.TKQ7]8-0'P3BS7',QE&OIENBC[SZ('-!CCU@[&3PBL;RJW^->W>B3BR-9
M\Z$6M]G#1&F?JW)OQSMUSP@3,O%W"3(=W.O32Y%.J(P)='QL]<EON2>EH>Q]
M_5;H$A?TZE9SR_:JR/.^D'S>.[R;E[$IBX0R5!]>32-FWYXCB!NW%W^D R&?
MJ3VRWY/<Y&XY>)%^-C.!A[]E[/LRO#(]HAJ6D'T!%_K#S@;BRQ$*?5<'N;;Q
M5*F@M+73L,%C0VE<-]9'V B,SXB@ )"5%MU^.:NQ%CY2=@LG=%4'Y;:C'FAF
M:WXSN#8]I?S2>1&AB]2"BX((ER]XF589P)4"G-HU.4_@-!T53C%(Z:OC;!:Z
M4+YVXI32_79$ODA4Z Q)Q3L0I.74/E'-[R#:S&.9C$K'&C;:FKQS1N0'J>,$
MOO"?Q9U*P0I$9W0NYAV61(:.?WMUF_G5%2JAV3A\ETMA/ 5P,J+7P].^E.=C
M,LTTQX4T/WMUD-G])K.9AX^<&C*N1LSVW4(^HDW"CLFX%O1L86;TU]!K0:O:
MP7SXD5D*T"X3K@#._PAN7B7$Z(WM')U8;#N[]?ABX#:*3V(0YL1$BX;.SY\*
M+[3OJIB44._XK*A[.C\4_O!ZH<%'ET+ABBL=#A:XNJ('ET?>98!5)VL=0C +
M#W_!3A$]L$;J'E6#9UT4?>-DA?7J0%E>*C6)P>\Q^DY%:$,''ZYV;=G4!_;F
M1%U"-Y[5EC"B&-I$_S3CV=UO;K/51E'"$QING77=M E*12#G?M8._HO#31+^
MV$&ZSKR5$S]5#;-NS&R(L+I?8 X72GPR?JY,3$E5PM#]<&W0B3GE0:YQ17NO
M^YTJM^YI-_<4&YMO!\8QA['SM%\&PRD _=K&S</J0Y=TW[<CDHH'<8[=,\\X
M-U)>3*WJP:E:N(+D<3.Q,AUES_88'EEH7II"LYRTIK[P/&_VL4/"*5?MJ)>I
MJ,+2+:6E=D*##Y^R@42J;8N#<YE4"*HE:S"]")'O8S_9WA["32B="Y0HG8K7
M;9VYI',D]4WVI4]P/5!S6K! W0O<0DM*:U(O(4QU-;@CA!=\59Y@,2:35RP=
M'Z3^\!P\G[MZKIJ8>925L7L:MZ=@H9YA0.Q5W4^4#8GWT;!8!6<@PG?=&.F5
MJQDT O40G,&-O6]8$ABM4$7$U:D=4)@=ZW>-\ZO9XOC'X+ADZY5XAY,*E1\=
MQN[)W%!60_D?F?X@V)/9*<!SJ[6 1/1"5=RRS$_IK[D=UJQ,6-6G2ILF4R)*
M72K3^?NEJ;P)GNT6"#L7Z:L_#<DSBR@CM:;!U[N8LRLMY^L2&,!MP1H0UF\W
MLQ32[$T/+!V"Y_%]K3!&HO9\&4# @.NJ&IJJ#0TE5,WNI#01OTTHG:Q1WD&D
MDC6"),/F1!+RAMVDP2N]=].@_"9-;'L@@X&TB\:]AE8P(]J,QQ97>'?%>@R8
MJW?O]:X:EF>L/;/CP2D@YT]O+ QYE\;K2[$&K9]8ZK,WO_OX/K8%3HI'+C#-
M8P[QY(A/1 :<8:L?DM:\.T1DS./)^YCE9._G3@$1@'CB)LOUTE2+,[VRD\*$
M'P-I)I(ZW/%@F1FXJA]$Z(,[4J-P,+6P#&IOB5N9JBDL''Q82]\B*.LVTY+3
M7(K=;T6<AB#/RL'XH9>VMHRD5Q[0MP=,90I]&M0,I7NE'>C4>6Q8!%IP)>[.
MC.JXM.0#5[G:FIKJ@0/>^9]"U,^O+1M8[%6L.C:L>^6D:9H9E!3+9<0Y</KT
MCF8A0KH[&CA>%!$R[T0:#Y<)M[2\P2I=Y'+4&*N$X-H[_?8;RK):POVE!M(4
M[3J*OU%S'30K(0),0BUA#$AG.-TRVKC4GS^KZ$,V?536S:'$_2A!?*<?Z/3.
MK_46(:)#97USQMV7!LFV/UX-NTT\ZW].!0IW4M-M[&=:]+"_G-3"&?FCI$0I
M;60OAK$?/, (%F"QQ$(%[5+::3L,\W_PG06E>822-WT]XTBN4TW"N+"YI<[-
MLZMX@H+;PY$.[IL:]\G#/F+>5YZVZD[30C:3DBSEW.A$00Z>,%B1BYL#?X%9
ML,J9VS=[A2]^HEORL_,"]U;HY^<:>4Q61D08*@>.0#J[GAE+R4,WX(7V7W!2
M6FT-72FN3E[^A?=L;&9@W4W)ET\B3<#I'2WT*#7>\=*RY71N5UO=GU]$[OE'
M=PM.)=E;A PI\K-YO"33VG]>>; 8K_/Z9O%1-F@1@>!/[2=Z$QX%8^%\1!4<
MJ;PP$*:1_QA()HT1P]LX!%T2@)[-X0+Y=WFI99OR^Y<IP-Q G*4^]]7BM<5O
M\]QN-DUH,.G0YF<04CL8(O(%'CJ>+6)RT@1KI$MF:3L9N/]0YDK<BWW?4%AC
MHQI*;-9D,F:  F %8HG7L#S+][G5Z.44K]RGM>PY&_R)JN#S.1>2%,QBP:LO
M$O_Y]?UZ&X]4M#[:LCE_X@ =<^AE3.##]75GG\/30W4M1A?&=YS?YB6O1BU<
M\*&[/CL_WO)(D)8]3URLEGUD5^V'H[T5S7GC7".#/<@TI.'@."2#L^^;:K,!
M?RM9S0A\&B0FK6N1VZ_!?KUQG3T\:M_CH@#)ZD6P"4</$BO#LX?(B&#$:=C7
M?E@X_*:I-CL67O<[!(#*K)=2 "%CDZ/34Q1@;6S38A99@R F*8/6!#TH0*7E
M*"Q:P+SC^(DLV$0=+PP-JF.(@@%EW8@1?7_B;R F/U("T3 /:H.UV!VO++%>
M5N@OU.?N#U1I"X^]#$A>'Z2-F9,*,G3*"7JJLMI[O%Y<![T=HC89!+*-%[M-
M$W144+3:)C*;[':]F/A!P]61P[PKQ1 N9?O^4@$/PG.BY&B+% 3$[$!X<7\+
M+F5N%.,\P"M-K>K>*\JG1348\ V'ZF Z:T,>X9<:<\!SI/*_U<AFD4 UQVD)
M/LII>6KR21Z?Q=[[J4?"_F:&7=S^8D>*EWG\^<*!@K69,@@!?CL(P*>]R&G'
MWW7AGH$_]+@%=S@R&M9=6NB)?PM2-!T9K]1@AU;>'($Y(/D@G &=\36E7M[K
M-'$HT4H#!:W>#\J"8=]]Y;=3V9^]STAN69&@ %1*RTZI8H&JFH'O*(!&,'DC
M<GQ[908@Y9!YH.XCMOAP1-CN-/]5ME#\D$4=,*LJ>O_IZ0OX6_CT#LRI7^D@
MIB"FN>F'?%J&PS*7TE;O^%^/HB)CIO>_*K%OV;*18GXV[S2O_[09+%&!M2=6
M>9H^&]^0R$>X+CL./B"5^JQ?ZX!SNB.\LVZ@S"M=G5_?L_Y6T:4WG52OS]Y)
M%,.OP<\2@_.@T9<4Z2$7MQ_2TLS?MWB^WZJTW_GLCN7K]\6:FOP:(CSFS+%I
M5P,K/#*-XPZ/.OFY"39XF0ZM;FY0Y^DF@6#0IOO#:Q_--[K[JSAUS8(KU,5E
M8F$L:A<1Q&NXL818+'-1<)A5-!=BH]U6+ZI=]M.C1LAJLL2"BX2PIFZJ2!X8
M$J":O4 (-;-0=NXTR'$QLK?9K5YK.LHF'=TC5!XCI XI[GWM,<EJY_N5UX>M
M[PGUGE=X:I!,A=#"/X8S'&.[8,[VAI;\^5B3TRM[YZ+<RSSXY44^.%!-!L9%
M</'N(!*+<N38'IP7P=6,[%[Q_[%D5PU^/9IK(2S:.#5=70W>T8@C'.$C-572
M0ZM,3MORD!3;NA1L.I599-<!:@R5KKHRPHA0C<]M5PE&1%3ST8)'-A >NQ*N
M99I2[DGH*S%4,VP+/NK!$E@7L1*ZH<;F+))/(S$I!\M[(Q4BFC^0K!_\.C6U
MQ0AN2AY'GB.JPM[_RJ -W[7ATQFVB6RI5[B6]\'FT\.\V84E_C':;CZMZWA4
MVR;5BHI]3)4._&9EC&J\_,:71L=+\A<?K;::&7M^Z0_JUF;[5>(BIGZ<#9CT
M::D9^YNSFU6M:(+S[KB5I_DU'*P$RQSI0Y$W4"VRA,M'M\:]23=Z9U0?R'>6
M]>KS0M^DU+]^=47Y9_T@>KLCPR2:?,GZWJ_#K.S2)S6B$:YBXX\9EE.%')ND
M8TS?Y[Q'X&K(VVJ67N9LI<6:,JY],&G[;8T8TFLUJQRHAP'^&,0W)Z3M<]A<
MM.E['?5U0DT:*QN2RDL6'[+9NQ[,YC(N<E<E*N4(M'YF:7W[SE+?P-JC%HFE
M#/%";6-CH\V^8Y_5F**K6*S+Q*L26A&OAR&W@"F 3Y5&Q%B014[/D<"O@$LN
MXU(?NXLJ6[*ESPV4_NQ]]FA@]HKF@&I,]9$AH58+]9,0Y-W_L-V4H^979:;-
MZY1>95Z%85^R_'8P&REY:0F)_DF45%YB%XF$AF@[G6Y?Y R$.Q"0W>3S#81U
M'.9V9 ?X3@U'FH.T=/+>-381ZLC[$^:[N7.%B4&"#G@3;.=X(99!@4^:>"'"
MLBE.JFV]=:M'Z=%.?Q!$VV'7>2J-Q'TT/;#8X9/J8#-9NBWFL\QH&(R&/X3*
MSL^EK^W/P5E6,W3CRX(,8<6M%0/#G%IRKJ&F=!(LC#9I]YM5Z.8>XB/B9=;2
MO?(URAXV?,L(ZR-EN[,.MB8E!#5M=&ND;I>Q3=//;.S7SI5<]=]Y;:%R)_=\
M4;^UO?_&+I%YYSCG5#=I)ZL0%&<SXT&=8$F_ "$7%+=/YX1A@5*K16(QZ)YE
M80<F+H S@BQ&E,<S1.1"/J(A>Y<E6A\\33G?+EY*7?7NRDE<L,1"K_B8<']_
M2!EIN? @27*K-*[^_NN,4"2!&S*U$)SJ-V?_,J"P8Y3P&L,BR4(M:Y\EVG?^
M=6]=:ZO;[&/J6L?@%<0+#7DHK!/$2A9<30_(*DAZY%,H59T^M:1WJ]7B]2-/
M+I&PQ  ".:9OI2\]J5ER>*M^M"[A:5&)>>[Y6FE_,'D;U3CD,IUN_BMQ,K<3
M+/W"#7_2): YX9W[QTFWSK%>W9_OLCD]>1*'6Z#N=TD0T?)P>J/!'IDZG,2\
M@SV3">/8:UXX^>0(49+-5-O9?TZ;[3;5WTKVT)!VT)9N-=/1V7X*D/, $;:Z
MR33A1-;;^T !'KQ%[MR2[XDA<^TU7:0 @O)DCF#FXP0\)F3V^!<!]C_&4*MF
MJU R&KEU<X$"?(I'DOMM3,E"P2:LJA0@R5V0*$DX%2.*""+[_)[W_[\DC2@2
MG,Q*N$<0N$.(GH_J'TA\_.T5F-_RAI)0 A%':[!*Y$,0>0A3)3US#KB;&EQ-
M=6=KTI^*2RAW\Q:=U^B6YVS-%"5+AGQ#=X?*';V91TE=]F?A?.)!LQ^VHRRX
M(D$_R[2V.<] C[5-J$8L(W(A#7<BG#+FGC.]Z,*8;MXS7TS5+TFNL/$>GB(M
M_9H ^T!,6[MI-8W9-12P^65K(\$L=A&%K8@(;IK$Q"8WW&:'BFU";B"OE'#X
M>@?=,$"+2Y9E9(31+<(<0<>I[&"GNB^(>:+=/Y\0<J9EA/W'@UP(]1.>%WL_
M,#ANCV@-2?1$R.A2QQY+Q,A<DZ%?4H :S(<"O$6X$_IH$EL1D9AS\IEB-S#0
MAD7!6K1_NP[U(YQL+5:"UBSO?HGZ$@]L"BU,4"4F9)Q_P@?I[7GVH$0?J61=
MO;JI,Q.W-?@2<[9)9'[:J<M.'26)K<)%O/42F=PY\IGDHD[ZLD9EIYIBH\&'
MUVVUCT7'HR(PK7O9K(XZ1](%9Y]N"'Z0!-#!T?),:[U[QZM1:M[DA/;35ZNL
ME49TJH^@#O<$CI:?AE1W$4&DY";#CZZUIH1R+J)R#CI7+KV_]F>W4?UL8L"P
M@?BSEXL.;&6(-$3_CZ6<534-_G+&ET[K]]Z11G>1;9A)RQVU10W^)@K AFI3
M\+N*V6SA&/IQO75H-"GBZ_P'1'&(,I$=]X0"T.U6X<K3'=S*H*Y]@=%N'RQ2
MV]Y+\B88WTD[C,&"'!(C#^_9LZMIEK?ZNLO),$7JR8@ 'H^2ZN833IG,V77B
M>HBTH'BUVPT>B9?PPDLQ?EQ5XU,OGF/\J-^)"2Z;VSWSC'NX:YBYE(_8NO6K
MI^)08R 7<3K?TIUN'<*6T60SO2U7M:M&OZ>$2PC'#IXCQ,M/\P_>C9@9$DI0
M_6IYO5 J^=I(OJ\= R$2A^AND8]L"YO33DV9-AC'K@C%QR1E/SW'/%(.+16H
MZ XOQ#%U(J/ \FU!>U=I;#$=']X4$W68YL'PT\<!WX1@U"+2.==#%,M?#G5*
MEFNJ//_ZRF!1R;OFCYOL/KW9>QOGN6^W/7 V*Q-M,\[+V:21=I4K"\EN<?I&
M 7C5V!_ACA&_X^><Y6'.BO!VG3,]U_VGX"[+(*=FSE83SW+7&?GD,^MRI3!9
MC-';R,,[;T1X8+%4GHEF$A]13=JSR @!]B:( W;SK/Z\2-HO-=:!%;LK.GK"
M+=4VF@2O]\3@L2;=CU#9R:!KG@6:O&D97!:7'*D20EX^9QHOR=)=L]AT#;)-
M9+DKJBO[NDBTU^59M4A(^JJKC2&:K*L[3P$8H:Q8DR^N@WR_[,Z;G+:[:[(H
M9"JJG?D32  87DU[MIZTZI/?0\24^0PRD_NY%S L<E_EC'0&S(5C;H:>,-;Y
MD8.3-3SKQXOJM+@CT*RT8])\Z'<%2^<"LBKN<Q)UW=BJ&0FHVR$= _KR]H70
MOQ'6_S]2"XX4 5M(=!'8X\JD #?;[6E1?Y:DI+ 3KZU#M<@ZKD3)PTO''I"-
M]$4T)P:0^&.A$Q%0SH/=?UZ%B;;CKOKN8U67T!OXZVW&6!N2ZG.HID ^Q-C@
MFE&VH],-Z$=V,!M9['+2P0OMX$4*<%89MT^&R6\2Z6(I0+SIGY^P*MUM<%JP
M7XEP0H-@1.I9M,2F#.'!8"1R^P !F[UC3W1)_+-AV0C3KM:U=0$DF0KGQKZ?
M3KRRU(XY(**0.'$9LKSNGPW'ER,//[S=2SR6 2 HQ!SUD<][S6T2R:X8 CLG
M!>#._?/QJG<[Z?:W(]U-"O \B.>_(H+I;L,#<I%C<.X^!?BBP9#3LD4!(G@)
M@10 E+%/IM&F %U%__',X?05"G#GFL;0$068%3@U9.\/:V<,4J< \/[C>2=R
M*,#\G?]X)MC]#:R$"^Y,H@ XIC!G1!-R+E*#GP(,_FRF "],8?@2T)^?T*B]
M!1H[.U@50@$(M*U55C/VN'8X$VQIV^Z8W2(D84S@S\<V!0+_U,?_)_2Q]P*K
M;MZ&CK&'<(XL[T.&[PI #@7LNQJR N?AB4%&A<T)^=C8U4RK\\[[XB?4>Y^[
MKO[YW?XXS,>*]F&M#OCD"$XJN9QT7OH:,48"IR(N5C"I>]F*1),%">E= 6[A
M$=4?[[DH^ IR#!G&Z7;-7%&>?91QI/I7-%V E\O^:3IW#WVF2TIH?[]V5X-[
M:+>4 C!AN@,+9HP>^0E,9]"*MS4@SP6YXS$QWN,CNR:L=M/6G]IO6M]AWJPZ
MX;J*^(O,IW0,I:T<HT2#H&OOAF+CE86RE_5+X>=_'6?$AG-E=/LZP[N0CU5]
MWV)CH:'86W&\[YP*FQU^\5\8#9(JG7+),/J1IA)>Z1X#Q=<S7L5,9!S%_A6!
M"G=+K)!F]O2.Z]K*$KH>@1[&W5]O!T'PU37-@67:6/HWNX83XSRQKXH;[I@^
M9^I+D,@:"C(J@?K9Q-X=\1"J&LWQNG2O0/&4NHD@^QX%^(O+2O^A<[<#@5V#
M:Z#$>@ RB;%6/SH\@)\CI'0<%L;N0GS4'ZXC$(N VL9[CNYR(+<]1'2LZ6*)
M;M$OU#8$]1E7>7U":4<]:D]^;_\O_HS10XBPPV>F<"]_$W1-?2U2X5A)2GA8
MIST'86]&29[DNVH6>BTUP>Q$V.IS0+[WKYLV/:N.BI2&IE5X9<#64JFPR'3O
M,7#\ZU[$9-7[&_*?/NW_GS[MG_KX7Z:/X+FCLQ2@AW\4M'9-D1P=D?4?,%Y>
M$!_!*Y\H->3C1J^;_--&:!1\&^7.M_6],_LZ=6W^ [LF<:TTD>''O*#X/L^2
MYL!GDV5\ X?'6%2.=.5W+"IA>X1V(H6(;+F,?2SSVX3 =PGPGN(/ZO%@T9Q7
M;7\OL/R/H(HJ>P)Q'+:Z30&<.\'5J<<:[OY920'LX4<ZXLZV1O\F4$4UIKD
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MZ$7;E4TW3 S.O9Q>VBU4$^WC >50IA.0Y;*\.Z#K]K7)KZ3E*L%I#L$/2><
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M6!'\2YK*[.<OKGFD2B*GJ0?J6PG!+#& '^@I6(USOKD*9/&W4T#+WN%>_8Y
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MIEG3JQGH$C53T06!T/;A>MGF/3X,PS]5^2A7SZT\/%]Q7>9X ZD;"0!F/P+
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MI">K[QZXBLDS!KOS@N;L:WQXT/S_WF4^LMB8WBNT3^0G.MOE(QM<?Q(B.M'
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MG$.%YT_$O@%^ !T];Q,@ ,+\@-B,Y,3_T#3 T8S0E81_QE.#QR30N7BR)0(
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M8RU1\\*T%WJR*_M\_*$?FY@DC6)^Q98R' #OWJ?C9,'R/)M^;OG4B2%I9(P
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ML[; 7[(6^3)_-\+VMSC=C7@11UM2_EZI\ 87 T%CI!:UQ)=Q?EZA/T:6"BL
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M;M):I2FE/,W(]W4/FVV6=Q4/:Y\$V-$B>!B?6Z;U\D 4%3S2OZE"?R#SH9X
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MJ5:6*7D2CU9O55/0H6)#1 <."YQDX.[N7?HW/.8VS)!QWBW!?E?9^IYWA"(
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M#-T10PA>Z@ 2^*<)09@_7OT)%:XU<QL2*@H-PP,OFMA?N6M2/DEWXI@;;SO
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MA.R?F.;4NQIOW**"CD5HBYM;NCG0A,J,%TZK2<(TQVU 8 ]S.0X!G'E'A(1
MY#"9BVD%)GE>9F S8I#ILS1-!DM%E53QLN-I*_MQ0(M=52N1Y"A8"%:+24JP
MEY]08;AGY^;M:B\R47[$J]$-]O+P/XZ6&&!LVQ7:__)#^1EKS,@CWW(Z9HQ)
MHAPPFD8"$<N&(C+E/- *JRBL?Y9?G1@L:ABCDFQ3><0+5=TH' H*")$<Q)U7
ME#18GQ*YB<Z_)RW[+1!U7CT,='@M.I_'374XEI.SZ\4!O 7RX&M=<H48FQB9
MUG3'-]M4 (^E,#L>.!-21&XMZI F[MQ(WLC$/KQ7[K[%-.9OYW'JK_.\<)V'
M_"E^3 %/!@HFB.T>IY%SIT3JM<FGED.@ZRI@C DOP10[G5^Z53RHQC?Y F$2
MR:KG*?36=)_L][!Y]&,]WON\8AO6'L]$%BX!;\&'0NH!_8VG(F<1+*9FC_]=
M TE^PAYC<U.6@>1N%M8+V5ZEL]K<MA7MXUXF\G+B\4^QKSL9<S$=]WV#[YW-
M'0,N<H_&TX0ST8M<,VZ!9:+2^QX99T;C]\)RRI+U=T E;VY#1#6>0V\>5EKV
M$26PQ=]'*.PV<P7;)@ZEZ.<DA5+_BFK="]F=?Z._?=T($.*_N257%2VA)BI;
M XS:PPU[V+KQ<_1(<(U)3*_CB.4#E'\FXE'U(8/':ORXWI$= 0R(;"LFWP::
MW4>[ )S>=4_H;0WP[JLQKDY%OOS$,AR8Y';&=K[LW*VJCE;MB*^$:19H+]F\
MN\8]/7?L3[9TJ_*^^U^//NB&G4AW$C<>A&&(<#]"4&S*6Q=%R*-IST)4OKR-
MM*5_QY<?"\ R4(,7V9%\(>.Y5%B3!)7@0GR_+HXMJ731HVXT(NZ!4%4R^RJ3
MO.9!>XOEY'(A; TG0S1YNU1U$6<O2/0S/WR^H4&CS<]9J8!Q3O14(2_H"O+X
MO,G''R#$R!TL1ZJ73[:K-F]A+JKSWG:MAMC"RM&L+%";U\82,M[20$&PWF.#
M+]V]!' ].#?87#PT)%BI[_R&)P1TS#:9K,+QM!T#VV?I(8-[H-6@:5?P()$7
M9HW$'5?X./LL[8"[!UG47)HF\R@3?1+R%]H5<4"T?037:!5?8! ,M?IF^--7
MY#- "FT$Z9W7)&*Y&H4#1U51'2Y[\4J+70S10+XVFSRI63DQ!@I\@'@^0H+%
M;"C YT9Z9A'[:X>MV/V.61-,8Q\\/--""8!/]\;H04RBSG)KQBO>^QWHOKX!
MF]$<\V?ZT 7PR9K_=2%I<^Z4.<C.R*GD02]S:AY+:,57H$="%\F0?##5:4<^
MM4DY[D%N#X\V'W2.EDVFGX7=EFR"<%=;6I\BZQ%JQQ&7;8.WPXH83JL(W6Z8
M.OIC\FA<0FHWCRE.TW>SR,G^781(XL=;H6HQ T?Y M-(>7Q*)0&$OX,6NY!
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MA[!NN,JAP14Z:W]K)RJ(KI7 ;Z9'>_8R2XB8+/7N#C(\J-N>>DQ@&N98.O-
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M./@'*9NA'>592?_IR02 <, Z)N"'.?]OBFL7L@H527M%P 'O@8,)]:3I<=*
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MK9:E\$&&(C[F:G&I)>C>E[ U]YD=;M@K<PU'ZB7GS.OD7A>SV4O-PTVJ/[G
M5$<,*?MK-8L#HM(!(0TPXE8+ENG:8P*P@03).)IZOBM,>,RM29T>,7>]R;7
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M\9N<'27- 9M^#D&6G\.@^](>+[&@[;%*$MND I^:2]F2F=_>3AI2ILY!D^[
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M.BK3&]8\LW8<TDF"67#(XONPZ,1%/86ST.A5.O%>7#O3HC9O_O6!%/>)'A5
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MH?3P\B'YKO/G%AXU]]>UF0YMJO@P K$ PH9ML=2EVVWR9C)U[A\<(%<S7'&
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M'TJZS3*5B\==;D693^5TZ ?Z96QPE_P)[0<"+'I5?DX=60[EF^FM@]1R]H^
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M"&O%EF/)<O<J0/#8VU@]\9N2,UR&R@#LN<TN+\[7QLOGS(O= ]793TAF$ .
M22ANY<PZ>1\:)+]-R\?%7\FU--@7HGJ4T[$L4>4Y.C/X8YX_IB<]/>CIH8\7
MO!7=4_N+6VBRWSOF!1%20E;O1[.NA%K;M<%I;:>% V2^96G/7=<MZCSI; %=
M=,5J->S$4+$A!_H(L^BV_3/=?L2L:Z@+;"Y]"N[2QY,G?)/Z</V':#J7 T**
MC+C[M?ABE?_Q-+_GT^?.[_#_!GXJ7-G'B0R6T^Q*'5:S"(>L0F=33Y1%3^Q@
MRKQ:NBL#9(>?%<B';%!M-KIHT[_AOSH]S+0ZAK(%KJAKG&Q] 7&G6*70@S&0
M2[_^TMKBVC?#_\/LQC]F.Q0^A)3*OGR87IZ7HJJ;#KAX38\9$)*(W2"T07["
MK*D>E&,P7CN:)R5R."BH\P@RF*2*\TR=>6K^56A\G'_;C4]_,DUC0FI=/WD%
M,?G@@ ?NV45R=)8XPM5ICIDW(LSI/Z-;+8RYT*+S.L^: PZ:S_F3<*\  , ,
MN[U,P;"EQOG@[NZU_O\#'<*-?^QN>TU>H%N(4B3H'0UFAX+;V]A_WCEZT=F#
MXK+SANI"OK;61^A"*@[1U/S@40;B]5-VP^?<V0N9SV]_X#8J6^>AQAF3LQ,"
M2KW.5BZ.!90(7:RK?5(4JY'BU:P GOF(KFK"YFWJ4]2,&N #M>&"\U>H0JUS
M@/Y9B(*96CN&*M,?GWP^<;<% BB3WLN'3?:4O$(I=<THW3B+E*)Y4W9I?,Q=
M-L!3.&YL7S2Y<]0DHS^._1U].&RF!*CSDZMI>=4L#%A5&(%R![*,/Q;C&W)Y
M'LZ-A5R+T![.FAPO[EYU4FLSBP*)4'6)',!3<!NCB#N#W@,7=-G#')C7%8_0
M6$5)F-:)V?45$_+L3B*%'U=#:A_1W5(EC1\RWTTY[MJM5?*>M[LBB'B6QHLA
M*K3 !#VF),E;P0/XRH=DJ<YBV7;N8N,9@M/!#>1@&IIY6]8(3N,M6=X9NO4H
M9-SM\#M<.OP&*(OB;$:$466DHP-,/*<(MN21J20WZ:F&S=N9J)GS?LYNCCT<
M>H6?BS7!>J&=)\+]:#VLGWYJ*66I8@(NU>PZ[VY@^S^7R$99A=\:]ZTF+P .
MO7[WANQ,CB#NN$83">$^VX+[I\RL#COJ#S9\]PDQU*Y.NC8USE=23(K2.]S1
M?>\CW/K:/:$_C@"PCJ-@V2Y'M#T(UA*ZCDKM0YC>-+H86]QN^PVN3/^>WVNU
M;Q$YAW(XM[#JP)59Z/E:%QC9J)V[=,:3^])KH_=&<C.?P" NUF"ZRC"]:[JJ
M%+[@K-%7"IU;O&L@E7ZC53/ -FV\ '69O"Y<D.P>P))5$?G,3;MI;&^S_UR2
M$A'G716T<\YF47JE@P)NH2N2/_Z9XO^$&R(8)=SN?N;Y<*K=M5)[PP_"G_9@
M<?[=\FA:;=;*UM-0@1Y3C(G9#_6";*A9Q-7T0+& PJ@W!<NFG[&&NH9/;^9-
MRU]7"]&VCS4+#-'BT?<Z_J0]7#WW;DG)58 HBZ$N_WX=U;GE_W)/ZHE_Z&K_
M.3'V[P(]&\LFJ*9I7;V!V%Q.?/?OKETTL[K8MF<50I=D(MMJ;[Q?@"UR\ CV
ME[CF./E5(@&9-W!B@="&&2MMAAWX4[NL:AIK:S.M!\O]&TRN0\=7N?T_JU)C
M9\.;^GPA'Y.5M R^-PB&W<GN&L2=(T^'H]Q1;/3AL=W.YQ2.MFSOG8CNRK,&
MUB)1TM_?N=0!F)+N+5O0C!B \ ]4[V7I-CR;EF(QS9R0_N5D&=&UZE;PF=^N
M\8>@:J:=E<T.**^1<@R?Y[6^%3ZF)4-,)-['; RXX]GP ^:/X;5=1/$@W&%0
M.56!'>O6)0<;M_/ JT\ 6MLJ;4OHDR!UY"#;6'0G/DX PHE05.AE -A&8_SC
M+B55$%J6DQP)T<B!Z5-:2F1WJZ$R),NR</!/[8B;)9XVI_-'>MO+>FO3!7W.
MG6Z>":P0IJZH"CF7W\:A<E;FTD%@]8K*G\*F?B'R9TDK>-Z,HY; Z2VJ#$!U
MCUJBEIF6(E7$>#@/Z\5&S5YSLWP:'W*>"Y^.&4-SPT.,R6_C//(6!>XNCD'S
M'EZ2_W"C6#@QC D2 ZY2:%>(0U>MO*V'134:.[0=.\1RE,O(MQC^=K/R?CTD
MSH?DW^J*07GB7Z+YW. ^B >%5 F3ITS8SYQ2S#A'&>G-LF*7MY>7F>\$9- -
M:F!.RJ"F)V(>T=#Y1'5X^5[^,T0.EP>X81[YG$H@=;T B=EK=[W4NNE6>#E^
M)>6N*UA7")R/F)U5H%X22)=<=YLQXW+R(EQW<RCMG[B9/(V1H& R_?'LM,O9
MJQ4($\JQ7:MZK>KB1YN*VW-]X#M;HLR=#$ 5,J*F]S/E"O;:D^.C^>9)!SF?
M[LG5Q%(2AZ_ZO _I0773]45M[U];Z EKMNRTA'B6[BCCS)-4#!$3W)K4%LHF
MJ2LIP\%$QY9G,8U-Y^?C[P)2P F_%A<[X#&D&#7.AE!-R:?>Q/C\UF19RV'O
M\8[.?C+!^0B+U*19D7WR29I@J@Y"YF):87ZEC1$6S@&:_7HW5+'7@BI#^0.7
M[JK779V+[/$@=Z=?J,K6\P;>[N,>K,63Q'SU+I:4QX0_F5H*3)M@ "0(:'Z*
MJ;3,6W.Y@E1A"_N^2(\?:1BYT 6?P==-6%#W -@UKLDCMY;2'R.-OZL^5,:=
M>BS)5''?Y@OU'C$I2NNTQ^_']=K8EYV<+R.>[4X25$B!#$ - ]!V4NB,[7;M
MN?>B.UH*A/GR(C!T/9+7I^^3K\ /])1]97\EIC"G-:#2+$/0SB_(HV:WH6H#
M >8,O>-3]F2U=_WB^[Q#U[6OC3H'PG";]F#L5(YOR5)VP/=>I4<W?DK^WMXG
M!)$S9Q*3R=&K^%]!-347ED5&YXV+NCY@V(?!,[FX4U_JWVI"3UC4QSB6=*<Z
M]637EH>>H+/SDM?-O]2FT(>LAGXGB3RT/5YP<S5<UA,A!#EU;UF9##6JGX:D
M-X'XWXH5CLH0,])"@VG]17\P[^8.FQ# )PW5>"YJG$6?[^?V>/KMT:?T<?NI
MPB<4#^#)1AV_\,#&HJ]LVP?XT2:5Y'F%8.MM#Z3WUJA-?$CK5+E"+]IZ"-$.
M;,=G(= 5R!] 8:S3M45E? 1!X,^/2B6CZUP1HGJ"3V5)<0P /^)NRH9>QGI[
MJ?2[+H_-VNM:-N5AQ-B?'5>"/R4T#N.E<_X\>*KQ+F[3,AXZC_[=_S.LI9X'
M^0:[MWB@X43_43\:B43(%[6_C5$%TL](2=7<#^U=@N_;?': .^SDU]N$8/BH
MP2/=!\GM\> M)D?;]PD/2NZ\_Z2\M1ET4-;G^<L^1^VD352V#P,0D%2@4AYD
M2IZ+F%I*J[2UEY[*(+9>HID\;9N-#A/ZDG36XSH#@$G%O*9K(:Y0*4'D'2M"
M0"F,?ZPZ%G*4"SAG&("0FCM[9G2^M*3"]T7DJ!(1B?/VE<>:WC=$7X67F ;X
MWME=K)E]%*RNE7G*.?,-A6.. 6#M6H'FKS8=5ML(#.EKG2GR?ZO*6<9]Z]0=
MUYLC832OV74FY#?4:1\MD=RXI-C@OJ33ST4.KO-A?G6"YI7&\WU,#@26[<._
M*N#DJ(G068^QMF3GXV1!09,.TBAZ\O4A]T5;8SG7H78%&@OZ;M-JH^VTEB%Z
M79U_ 2($4M(GX]MD2FP]\.04X\&7O=CR5AGSI:=>7[WQ]YW$9#B<J+OMA-)X
M%H^=F<.;%2@2>D6%/SHRE2:D0J\J.\GZ9UM4[[9%UM>63B^$*N_E'?*]]NNR
M#("LT?Q>:L+C@>80VV+K>@;@5-JTO_,1C5W]54)%W\OH,J&Z%T/ZF5G2Y0MM
M%'_/OF??QQLTO;887+TR]R6ES_"CG? 4!"\D(66J&4L%SQ!:P$E %FS3K=V;
M UO-A'$+"';B).N 7XO6+J9ARQT7>K$7*QFK?:.]@"A^_09U+PR4WJNU$\4>
M3ZIT;&P:S@R1'YELC,ZP:+/(L/5ZNJ>)SVCX%!A["?-6Z_R_'J^8]X@M/Z:9
M67)PV*]CX:;DL\YM6711WCJ4-2E]BP$8CS-NHJ9RQ4E'8.-0;(Z>$;=K*!&?
M0U,<>EL03743K"36M=0UI#BU>&;]I'.<-JQ#6"\UT%(]?&-#??I$3LMU3.P1
MI7X.Y)O'#X+X'>'@K^3L+-(PY30E:9RG0Y)#HV?N)?T(GJ>)*D+<J)DS^.>-
M7L%IN//D@M=E4WD/%7V?>7X&_1B7M([1_Z6[?2A7[S^Z_/MV14FW/'X&/]B_
ML %Z0,VDQ#77H+\DM3;=XC[[>/"G_:)]>/_3M$_O9N4>C E5A9ERST%NP2-V
MWE/-B:&738PL*/1(EC?>_/E&V+3C6X+&Z$&<)S7S $13KSJLQ@EX[- Y!\6'
MUK8:]J[(NV#-^<JBY//3<CIG]P@#N N'R70N:JYAF@F>^BQ'I>S%&8EJR_.)
M+T[;-8SK&&Q,3_W</(31V<T/-/\LOJ%&0(O>ST)3&ROTYS_6)CC0V6?)9TT?
M5O:33MW<Z_I5/1&.S.\(44TZ.$-C'_AX&TN%$ =LZ/:&CRJZELSL_\@S (^
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M:NB8E @Z354B.76\H<N01[,J^MW0548A;('1VH'9N<JZ&WU*JW039.[4M:0
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M+M8D7S\&^OB)2>E67NJMR<!P,['MJYY7KGD=,?TOU=.]#7O>"9Z@QWVR& 9
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M;OSJWM_^_G/V_>^]YSGW?\XBDR>9:\XQYBCS'6.L-0D3A'G@@J:JABI 0@H
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M.H!>:<*4NWJBN'H6,"-+9IG.EMKWY_S#K84N6V2Z9Z'ATE,8L\,P5'S/"ZQ
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M@Q2=.H4^9MTJ$E!\D]VZ#.E>U>'*1AKT3P]O#VX'^!,K&(LB>V*=3G($QS+
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MZ\JF$E1Q9[XT\XG],]' M)Q;9#?T56_S/B/?2W W;X94JX4%:M%&?/1;_<*
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M:S/4;>/S4F7XT?57?KU]XWIA\ >)R';^DW3<]S]]@X@B B>/0$!PU#$&\G7
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M;*T SF_YY2'#>0T[K(%W4(,A[U^"Z3>G@J,O]=?*M-8_JLM]EN,P-9C8++N
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MK(<,J-)^<A//^(&7:='4Q3JWW#FIV6GE_AJGL"!$2FKVS?ZD'X_H?,1TX\4
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MA+I &ZYR;0T,D;K+ZU!EG!J9UWO'!+#E$^4#CY][54^U?YZ0<04W?7Z/HSY
MUN/^CL#U+WH%6C&Q@L<.JR>*/=GIM=XK;T;3B:EH3G$=#1)PMO:)EG/U=70J
M\UI1FYBUQ#H?,]O/51^MX&Y\_*Y>=5\(>KIEX@A>(F1RX$THRK;1?T&\I#0+
MD7YDX^H[:D_CV L?+J2_7##@62XC-GJ_L&N<)H'#ZW*28?VZ9$#$?H.A-.$
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MV9_E9?04XS.L2D18BMU*$MVOTG)F$:BY4DIWDS'1K%<E(G6_'HV"+16:#W7
MB5P\O9H/0(?KO0J).@2S-]!(RW(]T?VO+VO;<TV,RCZ]?\,_90N8O(,;-[1>
M<\EY;7/]Q2K+[LH^10QV/L!K'WA2Y-%5;5"FW/_29@<UQ  -U]5.1R&G08QX
M^(&@]DMC31\TK1J758 N7D7>.NR9Y_B)H7OA=A*"WU1[,%H?V=CO8<_$1;?
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MHS\T^-R(O3*8T:HF@-=LA*O&?N-7D&JN,LY1SVZ?^09A]J5V[W&W:\*1"LD
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M08*=LC:OX%F5,9;$ZE/Q 2?S/>)/OWZGAC8WUD0@MPZ<^)=]S9&8:&?944-
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MC@@UC_04XY-;D\VM-0]F2N*OFOC[.WK>OQ(\%=PTS7G _ /X^=9GD@5%T@:
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MO=_MUF[Z2B//F2BQ02TR?;]-D;$V"@A^-5$FL99ISFP7QQ3EP_P!<&*?[/;
MYHFFDJ15FL].L\OFSMB>NO:.=,#T^O3T^MHEX$;>IEZE,VI*?& 9,V/A[S"G
M)56BV#9!N1GOFM+G9Z*/%XC= 1F,E!Z<U1V8K8SF-4"5>IU8>"HU%WR5OQC>
M7A4WX8I99MF#3:/GTV*"F8E3^N.'#>PLG9V7 !U-D=?:V8I03'?_F/@)I,'-
MM53GSMODR;H+LB/5<0E+/=/:ZJKA@ZIGA14,I360BL0=;\8LI?HHDR?0F 0/
M.1I ;H_W/](%'/&M, YXJ"OZYO@,J1BF1T[D?\1G-RQ!'@;=Y ;)7.]I7&DY
M\9]Y/OA^*7UB]$"7;NA5QJNQ4@FB,',BL*#T405;#'MW'MO'.+7 "=&MJH!%
M2]?!*TRUSK$-(^D=!5HGDR)+%]TA$BIO%0H,!_>XK9%!?U[I^G*2D6[@S@4:
M4TW?CI6&#H5)G%&A*\4N 9KC.0$AO'MNTDF5ZM+97[=;_@E*),&GX'OG^NG8
MW7/#\TS2RT-Y/6H_JS;]>/WJ461TP*9F:*6E*HRN[TX0N?6'7L29;(=5AO:H
M-U]M%DA>/L>3I4LBGDXI/4K+R$:C_QKOA_=V4UT^V97@N/)J$]#VT[8$9Y/%
M[HT$[.Q=E'A+,5^;]L9##FL_U,\Y'9K0"(7WA^@_33Y=\_!XA7L%LUBGURYI
MJ$IGI;<>B2!0#_^_)6;P["?Q?,#S&?=TX(XGV-+KA-00FK*]FK9P^N[]T#F/
M%7/6XNG^F9!64I *#\/,)< QHKK?;\7NG?T4>YR:[68P!S%H88@6/+?!PA%Z
M,Z7P#ZS\^CI!)DKF3<U%U.?,7S1/* \0&0X7\8VJGO.;4%&]FLIA!]"TZ#)U
M\;?PM!5R".>L*EV$JUBDU,\_#UI<77HNLAOU%G^>VU(7A1[$4P]X>A??JG;X
M-KIHE]K_)[5V+WQ'^C?T3\K)32:)]%F!L7.T,6E7TOOF]]R"*A_X5.[!5$^V
MGF+D C3@.7+,?DRB9."!C=;;WUD8J=#[#U0>6H<"O.9M8E5;F^DG9LW/-$=V
MK=YH?ID!J7%[J7XQ2/"@WZ.P!3_;!%?Y1E9SEV"[BOY5X&:Z/#87W3UP[S)Y
MJYV2>J;ZNB.UV'9XJ#+K!AR(NT?6!.AR%F-(VZE>^,/JX8,R.2JS=/!CD/-"
M6E"WBHV-PM!N^:B'K^L0@]T*9&=J*0"=T@SW7I'N\6W*7H<U'^^A9@\X4@J)
M%!U'4G*AA6FY8!!6HL8GJ<>668P^H:2+V?[&<WL%&IJGYCA\E)\#I$$077&0
M5C]V3&6FV'<OX-W>G%GG:QPS(MWK$C =;36F.R.X($JE1;XM(?5.X-XEP+[!
M<D :NV! >[JJ9:MR<Y)#Y9PH0S/9?!M" N M=/)!PB3Y<05+7T]8@"U4N 38
M-)(D+2W^R^;);TV0B,I.['/>Q)313?A$0S *CE^R@D^F_=?(O>M=PW)A9?-#
MX>\GOY=!G0M=FA\UG?'>;--S3#T**EVNBZ3\8V1CB?]%P6M<T!5^_M3?:7BH
M</TI9E'SI8?R?7Y>V40W=44;<8U 3RM; M/\=6(J9[@4YIWQ[4!AE$'!X;AU
M84A0S.\N7D?R'3JDJS^G[[/GY31C1]83DD*7 )JFJ?# 9SGKC"SEV>X!>6:#
M#I_PH-*6'0M_%Q83<7[5ZYJ<3UF<A?9PO\XR4 OHH8E(;7.TT/DVO N&[N%4
M ?G9MIJ_SS<^?17]KD([Z9<:]#9YXLWQMX"%+VZT!IB,LBOX ^?')P+!<(BU
M+;"ZJB?@5\%/2+P@DZ=]HLYO@->#4Y,!U"6@ IEV5)_<E^_TU$4Z-9VT&4EC
M5N[JZ"^<#ZR2C7G"79\SB#//;L^NVFT/\F$':>T=P+;6[<=W<IL#UL0'^";2
MVW_UK)PW6+!]_Q[#YI/[>-=D[+"Z>3MX23TI!64"64X9.VE2W/\W:[C9>NKS
M+: 4I_$V=81K?$? B4RI.^3^W6LV+?0 ]^^ &XY.QED4XUO>S!(7K*^B6K66
MTI>U"H*RJ+Z9,;Y(8(HUM@T#9_J^_41YYQ:GM%_RD25A**+1L=A%F@46MA*V
MJM/-5_\T>&]C%*1Z1XM+C/&AU"WMU,=Z7$#S,24'SOOKIX4%/RW\0*VG6=^\
M;$T#124GL3J^I*$J%-/MP,R&Q0!_GP\AD>*WTYV%K"Z4"BX"MR22M7<MX8C^
MTQ!]_'&X9*PA9O'LY>BN-_/MKWRUJ#BM/*&D BWR&%=>V\*E3;WXY\,2%X8;
M!(E9*:PAVA)UO_1>Z135O^V8VM/59E]\UQ:JY)]Y__OQI9<-!'+%QV.',H=A
M-JYJ,<85J@K6O3N6'<SO*.Z():^/G>L0!4N)#5UI4P3G=+53<%.)^>94,D/C
M<"JP87+6AVVWS?'.AQUY%,UC<W.S2X"QWB&JYVNQ=$!9VL8$FNI\\+@%,_1!
M1$'2MY08/*5WI3R1Y2_2#)P+)Q]9*41.BT<GMEU?3W#SEQS"!8*))L7G$OC5
M?&Y%+GQXQ$V)AF?2;;[O$VJIDIXCPRB\L2&9W6)Q[A:EN*K!*J:M,^DV*->Z
M.6#B4.L24"TBO,A*UPE*2]+]24_A$__.3X;9=H@A^P=I($MTS!NDJ[C4X<$?
MZ5AFL5%SFOK%<'!#3 '<&&N[-\T0V/\=CG26*-]>.07OCU5GK58B[>UG+S#8
MO:F)=SXF2@^:&91]\UP2G5&G845 9(D3!ASBS8K%FN99LR5V)V ::["FVX)<
M*K3,Y;LZ2#P\\ES4^:?YWW7?]_23]MS^P+OJP![R'&.#:H^\1\];K-35_,>"
M!V'0Q5G%)1V"5$.^\[#SL<&,U?3<CZ:&NG3OE"S#D83I-K88SS@A\()O2\_Y
ML_DF3FT"P\'Q)L26/]L[7Z)8,=-'H4O1*V)D)=^M)4/@@4"(*C'P$K!P"4!\
MS4HRQI*80TP)V2W;0JUR_(AGJ2F^N9:Z0LZY;2H!K?V-.KQN;52U^DRK"2+#
M/^B>KQ;])H;BT1:$[<X0ZR)J/<O&3S(BY5OGDM[/JEX0*.ED$89D ,/05U,)
MWF1L42M7?!BB*(@'AS6RU5.G)GI>\82+N46ZYPQK@%?8Q@M[O[_<+7K 8,L\
MKL1$LW3.+:QW#C'M!6/6 _SAEU14:AHJ2ZPF\Q* =#7D->"K4%?Q49S]#)M&
M7LSLOY)R'8*M!YN3J SM=[ITMR\!U,?H_6=IK15$'HMQ;]8AVNEU)J8:&J^&
MDA*=-[0/])]2NC5^>/*$DJS Y5\Z;7B@]-''O'6,0\J<M2VYV]DY]OGA,T@Z
M$81?"&;G9&AQM"U:KV&)*P%N%]1D,\=)J!NQY7ZXULV[V Q+.[(@1HM4%<\%
MA;1%4A^!]&NBUI.>@>SW+&ZMM8.B=.XZQ>VM*)/X9(JC&Z+>6PJ=./L2SSLG
M8T](->?-&I-R G%(SGN6+C6GP07T^\Z^8-L&<O%;JW\12$: =.^&1QW;X8!%
M1KO4$[ Y1B))(4W^2$&_H;U!'10857 ?Z_Y@.YUX<@FPU?4TK29LH10Y\9-)
MIV5E9T[IWF4M?A*;D=:1UO:*YJ&/1I(>O(%N_# >BE.RL_34G_2FQQ_6Q!8Y
M^3*61CLE(776GE5J\&R_^2/<DS2K]WK 4+NG&1>+[G\=B)B= N]= I3^G!;"
M[YIBY\RP#W@3=Z)+87=H>;6-?*5.&+2[NG27[?#B+H*-)OG83;G@+\<C06C]
M.#-HK@7J:P5TGV;A3^?AAO_0@Q;$MT/8M(Y9?&<Z\E0R*]%^(;+<OA8U]C:S
M;-P_W<YG=R_76J>_5.M!MZPL;U0)[ SHEX(,L+X9O3! 94#V^A,&P@26UHE;
M9&;@D+[[ 10H3G=/W\9BS^-E4WD#>.TOQ"O[]29#<XW]'9&'CT%.W)V4!Z>C
M%Y4X.DY%!8WC0<+>19#0,H(RN#N].2M0V+&JLO)35SN%43TRB6CY\,98.734
M=.)MK/2WPE@"TJO'1D-"X=G90[\BM3%85D  \!5^R.4XU1>3=0:[F^_IGT05
M:DK/3XA'KV8]T;)ZG*Z%N01,G5^3W\,A8!EC^'.]HO ./2I.6LC[M:/**\UW
MJNJ!PCV7>R+L7KI:0/MLW5:4*11,]-C'Q7LJ^&-QK#4EU]TWKYRQZD66MQ/<
M$1'!0=4T?' +(=FWV8!E?RB]+VP]9Y0;DQK_H< ]H='M^;8)B?6<;K)1>BF#
M^M72E9O)KK*8F=4I-=6KW]@0]/7W>9DK>3'#]0O1K\[#;#0@+X2Y8%I&@Y)]
M2_8OP.LP].1<A^U2&:T!@;$B!SN7.NX5&C%7HOJP@_:K],.3 A5&GLR<2$#,
MQT3S*;F4@GPH[]2]W%\/:$P=G1[PTASN%[7CIJ>,IP(U%H-4M88#I0-@Y1M'
M*%\#J]R2(7J?5G&P6&4%G?WOEJH-6LE>HN>1%>&S/E$."-$:%MV5N)#"ZC5.
MB+@.]#U4L3>LR'O!2L<CXE,?U\_Z0+:D%ER>G7(%W]AWB)+A4X0Z@?_;(K5(
ME\'OQK@ ^;_M-7L>S399G\E"3HT@V:Q.J5G"8XV2?*?4,'U4U@9FQ.!KH]O7
M]E)3ZA)D'^<=9?E:"@K.1Z);'Q=!9;9M>WJ.UK:V]D48#*BMT$7HNK.X*F^8
M%O=UG*<_-B6N,V;Y;D>84 51Z^P9,;D%S=PHORB_S:E<A1H]:#+L/#:NK'-L
MG%BI39]=RC*ZDI+[9'5?XYZX_YE6%P&M(^8SFX]A8WV/ZCS.^D"B:,3AA=*;
M4;B3$CG$2@A,"P*[0(*/DYQ'ACQSP"WVP-[KYO0-23<^XE9@*7:\\TLRY2@+
M0G#\0C=P=5PTB7FM/JY7/&K4P9EF7(6>S>Y8X2KC5M_.9/UJICJ2K%0+3)V/
M$_V2=%UP[;0("PO1I$&=%\)FY$Y#K!+V+=TSFK*EV==(_<%*PX=$$=>M VK%
M22VOL^CVW_5<6@I,=_:TW[R0?EKB9IJZ="/>O,.R1;$>C$=ODE23(>FSHK N
MTK4#/#%QH6U>G9"TX3+'!KI6S-H1V<.X(AV^U[K;8T@SV]!@JV!\6'; ]+/L
M3LY>SM'!VUO=O5D:PU.]<%JX XS!"6,2=A!=QMI&XOA=C:RHF,P?+9_%&=^M
M[!ZMW9L2-I?4RQ!P=GV^V,0TCVH%@OXH"DVX'NK>5W_:F!8SQ_]I50,]/@D)
M2Q43AP+>J5/N,W6.H)P6JY.B8&E#>.SNV7E4:ES?Z24@[*QQR($T7#UCLOUD
MF<VVG\&\#5PY;INRY/_0=(?C[\4O2F"?'!M[KIIAV[,''J6RY%$G7L%=AH^=
MK^C,SDG7+YTCYT;_EL>>B[AE?LT8XW22K3+7'?^7"WX29_#IO Z?-+S%AMRK
MCXM8G\8)7M+0^"ZO9AG'ZH9L7J/*W>3'O\2_0ZT;PA_(?BW!7,!.T(.XJ'W6
MRE=SX%2T[V'QH8V%&F\92V_LPXOE.Y2<!H8F _ ;2H[4GG^4&,L5]$JU1>R-
MZJF+"W/J$)]+I83:N8U;'_W9YTUF9G4?"!+4R;4[='J4&Z7Z?RSH_!^.IU?N
MT-\QQ^7^>A\96(,,>7W]2*V11AIE/_3:RAT?TMG\B'#=+P;"Y&.^$OI%ORFK
MSMIA<MA"NW?5*=$LH]^TMY"7@AH=%]8D8#6\=:Z3.[<N]QD&C-T"DJ^S(>Z+
M/VFY-AQF)?^)VG..G&B4$RA3U8 <69WBKZE[$9L[J:#ZTR4JZL<'GK,W>R>J
MY&L.,X3O\]9>:>G#')OC>T#:)8J8<\D??M(=5@(37@..:@3V\9IX6\A;X96J
MAZR1!JGJ*2$?N-I<J3YX8K*MSUZ[< @%B0.IVC11/);5O\>YTTG2:C7I%"EV
M6@#,*WHVGY8'L@.^<GI;(_AC#;,E2R']<>!*&,2[9N*P[T*%RNL+0P*HPUT^
MGS7EFU8$=PM/$7V?Z'3\PFHV.4&MT,5NB \Y.B""_MGSM/'!WM?NL33>FX_]
M3[YLOT,P0$LN)L\.K=X'!ZMHCU3-#01NH].*4DX3SWDN?KP+%B*&OQY9',7J
MU5;7@/Z:6G:Y)3\?["ZKDZ$0&KY_B%#$4VR_+M?S+%->1-SYXL<_(6(;0)E0
M*C4Y%38I$R_KSZ(<@Y<]0)CAF?[ ;P2*3X05+<S*[8T>F%/=W=^82E.&MKF:
M?AH0^JFFY'4ME$V$@N$9HH63W%S/_[&36)65JC=,)M7?SHRG-K/H.X,#SVI*
MM->2##/@=O#&639NA 2.="XWSCHV/MB(HP)=%,*0U(;LMS?_I&7COZ!W65_&
MZT<F6C_I>]RS9LO\D(FY4YEA-%"0N*S(;V&I*A .DS!CTJZ>W#8V2[+U=)9-
M,6@&UT^'?GR](;N*1,(^D&X/]]/29/AZ>E)U;_K_W$#YHH2MGMZCEAAMC+LN
M9F1L0\_YY38&O]L&HR8:.JV,'HR\6R]4SBMW2%(^TM1!NEM_#0GAV0NVS=+Z
MD[_M"-N$3^+B$S*1J(,=-!5X#2;E?V-H6ZS<Q7,:NZY(*W4,QAP9CV%Q8/6D
M:+,YM3E;+@78U^XV$=GY[W>E8' 7:G&<[JA#M&I#;=-$&2-$B.\;F8[0'%^^
M.Z."R)J;+P?@9KV0WO34'Y\G,UTTWX(5SB)$ KLF$5F:YDRB="JK-L.=I?TO
M#%+TOIXWIA?1;M7A1V^,IP0JR9X%6KT,/81T/BGZ+G#]N@,_[MTOWM<TK66]
M\^D,2+WFYM3JY@OXJ\]:\BA.T2%PF]Z$JULST\6O7>A0# _!]<.D=+WWQ/C[
MH,S&7P-N(Q(&9;_?+>0[IC]A_> ;)U/>L'C<%49\O0BEZS@HB=7?$'M1; ^K
M,.T#]NN+[C(30AX-L=^0NZK2UE067-CJV,*98F+>!JQ<,K,_>7;(.]C$98"O
M?>SI71F/?+9Z'CN&M2H"K!5!Y;=Y97B?>>J<>1]EC50CT4ZI2L+YQ>)N,=?:
M$_,\:%]R4-)?8%O/!! %:"4B;1"%?+,K. U' F> V-K!'*5ES0Q$="?+8!:&
M+8LI:0.K7Y&^P$LIP<5>PM7Z&]H3TC57KG$4?%%8U@B99\V(9W!)]\E9I)8W
M@HH?P:F4@8=Y3W^F,KZ^E>QRXIKS+8Z,9SG&Y-=,H""^;"[[I^E  >6[0^J7
M$"9]Y%Y*ZI;X[X3S6?$(GXLY.>/,\! OJ%![>EB3HTTJINRBT7CJ=6<_>46[
M1>=M1U>-KSBIIR$Q\[>_G!WJ[(YNOV] Z"AQ34YNX08@=A<,V1EC_2=GNA>_
M[(@?EW!TZQQWIQKY+C)@>9*#F<#)'%9MOKBEOE3G%/#R\[JWX7>>]W1"5(Z[
MT/<*\3<FRR"+0E0!$=Z<6]OB"P<W>2S%_6T8-3'V8M1;F]]_<_NZ"4T&@O$A
MK<%R$-3$P30'J$'IMXYDYM91DK_BVV271I&8(C\*CX0Y8N$_\"T%Z84SJ-0M
M=(WDC?_:>U4&-I_:/11\F-WKA**HRU)_? ][Z]7PJWDR3VTI+4&XU>$EX"!3
M*9_F?*"L'CXOA<*1 F86%!7.M0E3K=ED?HQ+FJC?4PI:\%*LJ<L3YBB^_N 7
MHX._8W$\G(]">;/T)%N<KBX9BFQ^B"W-8JRM@LHMF31]E*22OQ?PK FI=2^F
M&I%>VN99V1!?_YQYM?D+@>*S5S:#7K[N+_.@7[K\A]ZL/*MR_B:WXSZ2#*4#
M*V7:[#S'/EKH! _ :49[=2#/;D,Y@PY.(^I&O'6:%%=E5[GZ#?WXM.Y9?#!C
M^/3=0[#CW&+6*@M,>Z*T7HD#YJ:I(4BZ),BIYF(C!<&Q,YMY<FY(>1P)I5D=
MTP.58'N$E^NT5L1[.%,KJM1'/JYD8IOM!9@7Z^%A8/IJ-#VQSVSTT'[,G)6=
M2F]<:=%(-)M55_"K3J6^V_I9!2IJHODBJY$BP+X0*Y+H653P&7K'T-F\8#9F
MB%7,5\O^TQO_E*^I]@F_;;2XDES4B13S2():'-K1L?C?:6@FDM%=(P^2=AI4
M_(GMQ* )>9]7_/$.%X7*$S>_0LPD;O(2@)>@J]0; >V"L^I/OG=]"'1?BJ=?
M5V0D9'86Y*@M[-YM?)?.5G'R%*0J,-/1 I_3B;&7HO&XMH@\AQ-(0PN[[;I*
MK=(8X,R4>4J)U?1,QT-_CQ9&W3&VO3LZR,1S4*?\Y&0T7OH_ VS%IMY)-$2X
MMB/<&4I<3 Q-L;UKHKQ24&Y4Z-\DG2Z6)+,X?]FZLO.'^+1(R1/O)CVM,X<2
M@412"E]_0X):;6[14,346E!O+6WM#G6Z88#')0"LB)[J'@-EJ162IHTQ'7EZ
MCO/08.5G*REE(0/DJ?C9Z&^?#1*%*W(_4=YYXWKB/_!N.GB<PG!LMQP:R!D@
M-F*=M&058]E.DQ7)DP=5VOM+6A]D8J-]OXE$3*_],7]R':>>>32+G>LXRGRU
ML]3MQ[O/;=K8 ^J-Y%R]6_AW3Z]O@&]M:W>>=3/'[52"()NR^@U:+5]KN!OP
M[8'(/3XJ=XY%O91'=@]D#)*-=J9]K_H]U&90O4O$<5TC>F'W% 17_4#0V ZQ
M7\B@5C56O(]N&'Y8-;ZS[7UKQY;3Y>Q.P(I^^)>>^?OKH/==VZ(<X5?=IDH#
M?JG+\V=0NJ#8S]8!V+,__(]Z[R3)M-A^>-H)H:/].]0VE24_>1@;8)AA-B+)
M+%K6&=;LW>B4]E9X25"JHS?&@7G1]GN%;8A52#EI*.L&02 BS0(]6HXU,(/N
MD"F76"ES9ESK%S\QZ"UN<H\]\[V7POM)[=7WBMVIPQ/2#1V'O.::<^#IS/PE
MP $1,Z=(S @2]T.I5/Y&)NM9JE!N"Q@^]R\P4OF1Y/;S9I#R,X)^UQEH2$B9
M"T_S RA0F6T8Y=#\F1'YR9U\E&%+53RAR91C8C/X =%D(9L"C)ESFGQJ.@"U
MO\AF*3O8YDQLK#6._5YRM[_]Z?4V7K*0-UTMHC<B@ NDCHO9YFRI-):+7[!4
MC!FC&<_9^<K$*ST>9G(:09&T_0OH*7B5UD3(NQI-12IB^!4\SB@'3-Z4GN-H
M"F^M'')WM"^)3(P=:%<^%D@Y3KC/&FKCW_5NBC7@#+P1S$APC)#(ODM4V9$_
M2!UD%U6OI/9^>I*ZJU"^IQ*?P*"N^(JRJ^G]_$5V([DW%18UPF'MD\0S/0#W
MY$MZ<)/7;]M<]8ZAC(!78FZ#W4J<KKWJF?"Y%.K3 L^H)'UMEE\YV("%E'.T
MP.N.=#+>'-I/.W;M5JF]4^3<O1B^<@&Y@*<9^Y":E!!$&]CG2P"3:S"/BR)O
M5@#E09-<+ZO6]C:L##.WRLTK/Z/-2<ZV]H L:EEB"+.(,XU^HZ-$.3L+-H_V
MMP[#;//'+GR;933CC7D2JZR:O'\M<5 683FLR$J$M1+ '07K!I@..+V;12?[
MM-T+W:A;-L]/_&0VQY>G[D'.!,\E*V(GL5H37 EM[/46&HM +<<PF;](&T&U
M3F(-G<J7QT9:!J&\KWU6??["'8>N#,PG\W&2+#"M;?<.,0FKDDI:LASG'K,>
MFV^,./%HD$NR)R_6UU^."_JX6%NG]"X(>)CIBNEKE3O**7(>G<&6%U#GYU(Z
M?'I-']V4=^_G'+/@G&?<IR97W (L#.A%?5\M_B7/JY'RI-->J=J4;P*&[=J#
M(*\8G0J^/D9A';LIH46]:42+^?+[S19;R=BY<LM"I7>UJ1BIQ+:7!)!$UAL]
M?IJC6*.O25J\P]N^T&K43!D11[H%3#D>V_<]!Q*_@)9(.1>_YCC!-RS1T<G'
MH\X/3X'1T"J_C,'.L<3.&4=?CL.!#<YJCISROQM51(W644OEPJ$"WJM.3XM%
MIN%>G9%5W1O/Y#&93<O1X$$.,EUVKTO ;Q>[R($^\"7 %7?1-/-3A65_:']:
M"I!EEE XS,3,7&:F>-M/[&#;JD/"$PK]55TU6U8V@V>$>+WYG,<3\L!(C9/;
M8NG[]Q'<RB6 XC_^4,O_/SN2#V?VFH2.AD:K_1$*\;<@G5-.EHH'F-[4XV0)
MPI^$;U:2+QR2C+!A;Y_;8JJ]LN/>GZ-IFH%^X>:C4^H-^"]I.M3? QSM3,O:
MOV>VV,D*G-4=E9?33C<LK#3*?>=13=>$+3I9R1[*UQG/4I7& $.TU<HM[PTE
M5@G_FGTNF9-W3HVW"KU"_%T_FRGM3"3L+J52-4_]N*LK7X,X?Y>H1))$1A0>
MY!.P)N$,DP^6!A=< GJ\\Z<40-//@N39LD.4G%8(>C'"2#,%25]G>U^X>X'J
MKZ9V>[NZL'M"M,(>].5NGN,V^82BB$ (18<04*B-)#"6K:>25I_Y&:-X":@P
MHVTT=W]R@B-_-+WQ_O;6 ?JS(MV(ZU9YZ4$V?X#\B;<,Y_93J;YO/'N9>(N0
M+TL4'\<!_J5%Q&L+-PDINU$\\'M8%Q1*T->K)DMHXFUUEAJ ^JC8@]N^]<.;
MPE$9KN6Q9(N>KJ*U=<Q5ML,,#*L,2>A\_ZSH,^>_?E'=5LYSMPCD1[[J,^LH
M<5 /N31$(BHBL(?GS>M]L@^@F.\3:Q=%DE+HJKI+P&<+\W6?D8W?&P0].%T/
MS-M17*W"(J$T'V6EB#\HW]6ZR%3D_/?Y(OG%5ZYTV9PHJ/:&Z;:/TM=(UWA!
MTX?4(2LO&&0X@?(6%UD*9(OR_ES-(T5.RPWUS>XWBWRO.9>;2O2_]"B6_WJ3
M+#?A]H?GQ<'@R<D+.)FNZ$K1;-DE0*^K>R\6=E1;6S=BHC]V0"C,D(\^>Z8]
M&S4KWD.-?-UIZV9DRO!-ZUS#Y0 7AF-E[6H6:AQ>&Q;Q<N9&!418[7C1]4=L
MQ+P4H,D3OL7CD?!^3[P//AVRT-0H/0*WGGV%&MR;R2BS.?))U8BT]N5;%0AX
MR.6P@57FS8+\P*>U#%$26=NES>=BBV:4?UJH#^]DZ]?51MV:#I%3IJ\4?U[:
M6_!9.R>J6/9/22-L!=:)6R/>0_#5X_!C>K4+R%T.(LZJNI8 +<_+^>OG@S62
M$E ??RBFB2]=9/3T %-R+_]ZQY69IS"A"S_Z&=_VGJV^&O<9-I#9'^R36+DA
MCHD*RGU$V75>)?OM%O6XB:_HGZ$;NHN%!++UIZR=M4SQD(L<SR.*6G*&S-+&
MH2KDCP\OPL3G/WBF_U)RS 8L&9B,%*4+K6GX\8_O+$>Q5Y:VO(TM$')MMA%B
MB'A8P1;RFB/RO_"WXCH%A9M? M)PRY[I:=N/LCAJ)QTF&T7]B_ZE2XY4H,<G
M5V5?>$;;9[O\6$F[8^*V(^=IL*&$C)V,]"UTQF1_0@ E8PU7)X6$N /NGR0,
MM@N7+H4*Q7^3BW\-FH17H3\/Q53CZ#9J]C:EZPLV9R^R5E?AE?S_Z.BH45^M
M?3"EY#$9'SRN=5SQ#,"/5?T)4LYRMCW!LB/@#NJT;&4F4<%_;X+#V2R5=P9K
M0ZXN[E:MD[J9T7L)0!SN[5-BC6B5B)Q3YV(KS4(7Y2*)WF5*S_'+GBYX-=XC
M6OX<^@H+7A.Q%C'H=^Z;RA^3LVW$+#5"X,Z;2@\"-?5N8XA@LR<9D5M@D[A)
MQYJHQ;MS-E4GUM=OJNLO#+ZZ>1-B +>'AT7RU([ 6IS60BF.=G)JF L?CZK=
MW2?0!Z28&4C]>C*3HR>)_A%(A_<-"S2X!%#>S"ZRZ"IV=:;7+9[5=4VJW/9/
MFEUQ2G5\0/WXAT_/3)< KX6AU@GN@*T,YNN9.=ZHMZ1'#R$)7@',TWCTX)E\
MV^N+;_/-%=)T5MT/M4# 5=$OM>^NDUU1M1_\Z,^(J)<?_X1$1@:U,D_6ZM&D
M+'F66JE4MG- 3IRYN-1C0I(E9.3<#*_7RB$Q.5A6/&U5MA0*BM^Z,-_I%)H
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M(G<&]AU:-?8:OW-_4+&^]%G-L4D''/7SB_CXT!K'C]4&6WMMY^8D<;JL0,2
MAO7\06S-%K NRC+B5TOSI[!'Z^,5!LSN5\?S 0?Y)/1OUNMQKNM7D>[@:*N
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M\GY]$P8U6I6SH?(Z0/A&7S9^N.,:%9A$P=]TOQ;7M+'S@2SV-GT(^CB9(IS
M9B>5=.S>I5F+-#BTRPZ+!HU]^- DVTJ.11]93/O"Z2FGB0%0 D,[OR*:S26
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M,YA7.\(VB_?K\%.?Y(3I[M!?KWL'-"H_I:5V%ZEG)+INCL&"0\OJ#'YA!+_
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M*!!)V:N08M'634G15]SVIP(2!Z#[?:3'X'>;ZN!"Y8@-LD2A)3&!)0"'"DV
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M$)NS^O?Y E<_1_<1KU&&:%A*>8Z&[HB\D:1UBH@[Z)@-1],'FC*I2U9%@8]
M4U2 'GE<&8<35MZ!,8/_/Y?".ILHL6L^&.$)4J$?O:: (=_GHP2'C"#_L\KS
MG]\J\[)__T4,]G8"WJ;,I3=4HR%%X0I/)%G:0Y0W^+?)=9R^Z'ZOR/Z_\62J
M>ZWCXO%6V_X=7;G__H?NMVH+-/1OVO@+5TEPU W/);( '/40ND0&'8).#D+#
M_L;IWT4_S@NG>+9%["?S'2(9*/]S&A_@SAAD.O[Q<<%;VCPJ$(^7YCD8_ZO&
M_V*^?V.)'^[R&)Z.AR^$,FF'[?U=W7^UWGZLT"'R-.C_B0Q__87D;^SEC8'G
M4@:A1 LS_'S@X:"?SQG2S>&7<H<09%%J?["%#DBAW:3LS ^KBUD#>;LWO"90
M/%^'B\[\-_;> ZC);]L;CHH@"J+T)D&ZTA2I@B B74 !06I41)H0Z:%&1'KO
M"@HBO886.HET 0'I$DH@])Y00H"4E_\Y[WGO.>>>^[_?_>:=;^Y\<V=8S.S9
MS]ZS][/W7NOW6WNM)U;PR:S84=-U Z*"X00Y\C.:( PD>L41W/)@)!8%)%9?
MA; 5L',\E$P!#**)J:!%?^&*HM_$VF](0^A\;RIRWWCY=+KR%,!"#;0]11RZ
M6M1_.E]7"J#[]%V;2V4=G9SBQ3YB\&_CS4"+)Z B%>R2+NCXICMT[C,4AU+Y
MYR[*. R(I%/S94M6W;SII2)>"!O-^H>Q /^Q_7AT 3F0 EBLH@!X\2R*P-3_
M9"K #0TC"D %NFL&C?>[^"6NSU'T0)C,7>1$ :CK@XE,<61%S7]L?I!SX]2"
M(8_$D#_NA>AW+\%9CD\MS&5C. 7PK4".3-M- 5S+^:<>_NYU\;05V.RB(DG:
MIXM[\Q0B#QEE4 !4"Q1 [-"_ZX5DWPM=V2'K2NXRO#"J/')6#SREXO_NI?YS
M-^0:6Y6]0PI ,.V(YO]/2S,\PT:^CP<>M*F0J)ZB\KZ=*AZ>=G+]Z0'Y&MD$
M"L[\^D2=&?"OY.D]"[*2P#&,_.'FDM$8<J'-H/CTV#]X)_$?-?A+(\4=PO$(
M!;#Q1_ =V/3FET-BP*F*._C#ZU'W]5+R/Q&AOQ=-5_(W@T.#W<+]G2.:*>B$
M(/E!;CT%\$3XI.#(V->;&+R%W$BD *[?9_TS?U[!Z2"[3V7"'KK_<JSWGXI_
MZ@HL.,5)0#SH%,S\<EPR.@7-<2>2):?CEG%[]\],___('VVN7_K?CQ7-0'\\
MZ%NG ([I 99_1!#^%^5L:M3I(OLQ',\#R>]O;AD.01<97E  EORG(U*W^GHV
M4N1?2]$Z&C<O/ ;=OVYZ,[., N!A##B=Q /F,V[_48N_M$)#N\>S3I'>(#G*
MM\%X![FP84 !E*^<'L"6/QW^6<6X T9H(S1%LP#Z0WF*W""YRR+8?1RA,J/2
MFS."7 2>@EO+M*.+@,H_<4J=OV=*/OUK4J, <EC+G_Y#Z4^]6><58813F'N,
M) >?;J\)(G0R $0!J)8D_\F>A!U=,/OK4RGZ&^0'K']98_NS2\Q/[I__+PIS
M#>CHW&_HQ(4_/H!HZOB/*P: =+=E75UOS.J&11T[+^=X>A:L[:YAAL?-S'+J
MZ&G%*[7;%G==QXN)KT@Y, 3;>OHB*X*CNK'JUZ;1X^:6<7AP?EG;K9>&/R\(
M[LT\B)G<'65]TJ30$8&M[B:S$DH6#%@@%B;8J4E"_-2=*4=\';V D$COVZ%Z
M*NZ5/'?$+5(ZT0@#O$I F\ GI$5<E&SS6^T"/+T+E XY_;IIDDWZH_PK;Q_5
MUOH('$CG3D4[#P7*BKOM*6Y2 '-T8-2$Q80 [N$L,R& I[(  E6OF2AWD817
MOMZ=ZC_SL9OS@L#/WC-GGA5G[92YSBH0UA9 3.N!-T>ES[&$!9<'<L5=<1@N
M+Q PC9<N:1#:':>C/7/==7GN3+R;JW4P=@=O,ZK$E@,9'EBPKFU*ZN#AAO\:
M6JBSO5(C6T;S454IN$F^=)R4*K-A1=VM4X43?/>!P*A"/5LS'JLK;7]VD(<K
M*-ZM0.EIOWJ#V];("@>L=?=4@7JH-VF038_D5<A:H%!HC5UXS6]_IFS"2!N3
MFFS3_"=X@!2^W>ANR-AD;:1LN@+FMG":*"U+FM,/6@%&!@LR$ZG0DX&1L**#
M34&'U?1+&D[L-T61A#?3T5.V$3F/_9M^-(=WB*<"/OA0JW(4^8-/;EE!?D)8
M[V"NOP"&-<L4K3)I@YEH;9U*(-\8N]QWMW9[6@?<S0(Y21^;#6PP@^<=TS)Y
MAZ2;#.C6TNY:FB!X1LQ_UZ?>>O_V9S?CV895#<>"/H6^6N2))P+*<.#V_/,+
MGF/H%I)4=V SV,RR<!!V<G:PBRR-0[:#HG8M-=*&"?%6/3F@1]RT?._/8GYT
M\\[3^5F>O>S^^20FJXL"8"3D=![WIWWPIP>&>] S&%F)&HZ"S'0MDB1Y;"R^
MXY(3;*;O(.Q[6E'L"]*>.\&!\KB5D(E6A"1.**X48G?KJ&[MY5K1 /_-[Y4S
M2R6,S56%^*)]<+"U!!88J:0J'.ROG;\V"YPXN%HTHQGP:F3&XL>#""KAMP^X
M[$^^+PA]&/$].O8XRG-:97@]3@%@*0"_*?>L)#P,6175;7YJF(/+MOS%YP,<
MK<YMY3P3]_3SNGBA[?[SB\5=ZN?306F9])QA6\&V<S439?Y..69KC;-9>9TE
MYJA5W\;UQR!U@0V7RM(ND5H=0<A82MJYGU1WZ!*RO4\DVLL@-!BV4+B>X8V1
MCEF!M [9W;)ZV]J7-J\T-7[XLQ]MJI9R#?X^4@)E0V('.PPAX$<!#[JX%.V5
M;F=W.H.9.N\.5/]@9TWHZ_IDZ#5GPSVJ,1XG9PNU?NKGLP?J1?NX3 ],69&F
M4?X-@= $< <0_G.6=HCXE *@90@58P,-[4.W?DB3N*S8*JRF=BZ8#MZZKLV<
M:9S-$ZTI\QLBNO :7DS4J\&"(I4$:<)@,O>N'?1+^8F;;O4)7%B-33I'%VA<
MLGP=E:^N(.\>.2\#GE0QQ $_^(,*IF<(H <MXQZPS7JV]D8^\RGA ?9^(64O
MF^CGM\X-M]PC,UG*=8'I(.@3#4E^3>S!0"0^TVR&7U= 0H#^,T#IV^W8 ]>E
M1F36DFB@4KX+WHN, ))_[Z<7E$"[/V2=COY7B&6Q;QT1HGT (ETPL4W[F^7#
MHE$K7>EQ[X@,\V6Z^BVC;WIP$EG,"SJ,TB,/AE\LT/*8M5^6?>>^9DD!Q 0J
M=1?YVQ+T[ J$(_?OR>KVZ^CIW#-21XP\;XR\IVSW5-G#OLK9EHXM\<*@XP%#
M#/#2"J$H9]7$Y!"WMI6_89)>HI20=KD"@0FF>IYE#NY AM!@@-'^]"7W,*H.
M\R=1DQ+BD[1.'^JK$]&.GXFY/I]6[HG$C(+\D"1!"QQW*8H"8-B0'.ZF*2"/
M-+8LI\T/7M&;*WS3+(C)R+;)7C=<7QS8DP?S3K?QDGZZL<PG++U(2+DF&DJP
M.=$C]*D3M.<:B'JY:W?3PHFZ)8ZRJ6D3J+VIWQ\B?2+DF$CQ1YI+M[^)@>MO
M?B[7LD8_(&5X3ODQT$! )CC!O)7W2H+0:^0O5+*E:4GL=3XW[J2*PN6@%ZCF
M7F?-#P;QW,%FM8<3KU.7S3L[/:I%-J6*ZCEI.<S7UZ;;)8NU>WD7Q4>7GP&X
M&F_"7(Y]'9"99!-A:UN2$VRN9J\!;'IJT3 ;8&:":!L*VM[G!+L*26S;W<_K
M#G\B+M;9I$'K@ DUQ%4DA1K/?/GZM4>4.NOD\30D8O_+I8?8M*R%J;ZIODLQ
MC">&5RS,M)WB%'(;M'*%E*121#G$N/US/OM\R?J.YO*_1>C&#D^TF<9K81T:
MIP_EO$WN**?1?)%INO2B9EEF;I.K>M?W=0N3/NF3C,&EV35KD5]$-9=9Q3I$
M"[*Y&5GWNJ;9J=0G(=F0X\F#KY;<Q!P9DY@D/T42L5\RI6[C=UJ (7J_;B4
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MN'J)?VMX@=>]P57:Z?5^CKSEP[W ,X(;;#W,O(KMCB!:>9XRLJM3+3&?WQ+
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M.58Z/G;B]/HX?MR>Z\)MH91=^W%JNXX[KLQO[ &!Y9 "> <G[I_^E\,U.5,
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M\TC!^]G]\],F"M<>5 >-N2<$6R O^D.]%T2:50L<<5.ML%7.Y'3/?:^OX5,
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MGHCC33RTCU  ;42'EY/&C_?\RYP"#J&N+>K,QLQ_(R'_E+I0;"Y)#-I4V?@
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MJJ@[AJWCBV9;(-W$P;5+K2AT^('SW0OI$[JU<!&7V4?.QL+OV524E;?IWU(
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MDX""PUG;I9:!] 5];$TE31H2GL.W8[30=]N(5D[:JOE]M'D ?5%P1JIKZG'
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M%/I^(O>AXK=>504+PLW':M(E N_SJ"/E=XR>?IR#7^BK*,<.FJ^?,,Q*7B'
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M_W<+YI4%TJ3"7W/'KF@/KV?LL2+(N2]H#2KM__LG]O_Q9\AO?OL'4$L#!!0
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MP2?75I=<>);;J8<YELUO3-?'?^:[2MJ3)?:M:S8E![R<^0U<4^2VLJ*6NG
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M@7K@KUF$ 2)0,Q!I "'FY016V"EM?2BBV9DY]/!$OKX4VWTW/W391=Z:>H.
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M!^>Z*&1DV[58HNHZP>08C:!)<;JMVL;&V0;(;2_Y%;Y7^Z]46-G9.37,MDM
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MY?Y499&"Y<!YQW_8L1'I@+V[,?&TK'904-5.H\@'N9Z"#YRI3NX /[%GPI]
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M)S+N"%12S]L(?*[6')>N&97(HV*Q]#OP8X:%M^Z.O$))AR=169HETE132IG
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M[H;8;01+$?.?!<T?(QUXP"G;!!#U'(C^,_+7QPXTV')B%=[]W[)R<0^!U'C
MJ.>[6_[=>^LK(Q3;#HHASZ^'TH18_GM>#.8=%H@'*"V*X0$$W'@ \Y-KXII\
M[,"1I$V)D7]MH5U75]0-=$>K27C34/+&&5Q:'47[*Q%Y2*MG_=-7/0^C_BY!
M>QHN9"K8KLB,/-2-(J[1<.8[S\6H4 %7OX!];@M-P-JMD0X8E*:K9&R5Z5@7
MS?0MHSX,/=[[<)-].G>08VM>@29J'NK@'TEF"D0J],R[_00RG^$!&#O@#\BI
MMJ\"'O"]#R?QRNPFQY\4G*O2-.[NQ HV?S_AQ/UTP6@$'!G_:)=DR&U,5^!C
ME*9J8=S$2PF;R?]ZPJPJ^UWXH5C.51H;XVUP7*I6T6KWE<I[*A1"ULUCBB6(
ML6)'^XEX@+)$*\J'& ]@@15>88%)()<S("CT>.!0D1QF4G.3\WC4HJ4%-1+B
M-D)I+QM9$[]D:K#QF8O8\.XKDO;.Z.VR?P\S/GW2G^! C;16ZM_03N,!;?L<
M6,<8C/7RG! NW!ZR<DZ-D])^8BJ ?9^\\+KB5R'Z)<A5T3KF/#!9O<[ #41E
MN&-$.S.C?Q42_]B+YF K*L=]N4,EXF$#IYD*4LT\4& )^RVUB:,(;-2A'-+S
MNF["?"+GQ_"X/*>)UY' 5\#P09LT*T!.?S+[_[T&.F=I''VB]7'_9Y1U9S4&
M8:U=@[D%AL=RIO?W=&Q+);9^S:A;U72I' EQ]I81#]83$ZYEZ&I%M(BAOH(H
MJF.(P&^,3'Y,.TJD1T!ERM,(J9F[X^[51\LP!9CYO[OSU_&;0<R?UM5LB 7L
M2@"*!P3- C&+;OY4-[>^U)KZIY2HTVHK$\C>DT1*7,]H\+DT>]V#S1RDC7+Q
M<9_QP/JKSM65R4L+Z,8Q4)8?-@G">,RT@RXQ: X<<<]M/RW" T(=?'GQ@.R8
M!WC BB\$:P>[UJ'>NF"X*0T]N8X9*+E1Q ,";6V392'_*#7M?QKQ'\DKN;C<
M^1RUS5D;XWR^R$+=7H\'4."Z((02D)\,1G0)]HCL<U]VOXZ^(EC\2!.UZ,8+
M+;,W7"UMJ*-0MQ%2FR1OQ1A+JLP"PVZNP&DB1%S1/K"GN)S"7Y+.]EJZ<%EG
ML'N3MD*\7L!3W.9/.(J:Y'\W[R74A9/!?HMI^SOPQR:>U+V/-NRQF=XDQTWV
MJ =4*Z:5YDPT%,<1)MZHYC_AT_ ,4OML'@\XMX:#13O>/&Y!)4?"2?9/A]3U
MH^U%!1VLI"W(F_.73S3^\1&T2M,MOPROK<[JX34JQ\8MG(M^SV;3Z4)WY>Q5
MD9SEO7]4]Y6H@> 2> +["@M7Y#,NC[/^[5<PW?,._89:N'?\ =?/UV^>9B]B
MTW'H_O-N'_URW\<W?Z)S<^'9/]VR[YLN(HBTBVW3*#=.Q6)4;+B<6<WCE+T%
M1.TI Q/UEGEJ%0Z;;MM 'YM0U+K/5P+9:4?&8$P1Q#=WFS[?8I'';=OW3A'O
M7X+38MKGY8J2/D8[O/H0IP=.$P!(71#>4[WSZZ27\\%HY,R=:6\%WS8\@(B!
M$#?,P(@'_(;"3NRN_&_;B1ULW-'R' 7%)2)+U8V'R"SP@#?1!S6_"3+G*R7C
M)N\KL<.;24O<S:7&TD>+BG4CEU7\&<9 )2#4 +"*&(NQ:<7HF$".-3C^6]H/
M>)XINI&\T#IXE7WP%C0@6@])O30&V?A2W>0TD:\NA^"8JR;ES3U7/<?%H[3>
M-:$0LUH\S%&=<S;E YUEF><;(2NN8UY )4C'$]P@Q\GJ'SQ@5<,%#^@3_Q\6
MB1%CEI?57I9,?KU;T.@<,_G*R)9UWSFD*(*OS1-(?HB->6 &(E^\.Z$*1Q$B
M[,G]!'<?L\ (LA=J^2V(-(]-E;H5-1,^W.3Z,\6P^\JC)?.1Z7C 0SOZ9+%,
M)0?S2>Z*2AI$]1?+FLQ9E1UN@@C7@!*/P#;[V_ZSF@2QHKY$C4%0!75XP'H:
M\+\;.N97&]5AC@T04-C( 6IY0*2Y8>?&G^_6A<!!76SD2(9H-V,8Q7)/\>/4
M+TEX  +5XQ:OV18ALB-B,+B?VKTE<SIBU(^91[-HH+<"%1GFYW<K=].Z$_.&
M[I5,E*6/>V1F;WH2>'$&Q6I-M]PB>8CA30IPJT,9#VA/6[MUEC;_TV0/7K-1
M4N8?6#P&;;JILKTD$U Q.XK' \2.:\)O/OQ_*R+W6C/Y%K5O"X#8?< 9^@U@
M1_H1_YF34^*H'/G^G5'1= :7.&32CAL 59%\4LG^DY %1.;7 0L10MNM5#8-
MUJ%N0FQ2RC6!(V]K@LUK F?O,*L0WW%!- WZ/V<,MWN@8>^G)<81%<*5]N/+
M=.WD.$P.<XM$7"J%MV1(Z^>M^[WP,0LS8T%E(T,25ENI[,X9]-BYLVRPVD@N
MD!9J*<>+=!CN#4YB9*)> </NHV*^P0:<(IJP!NC"FY CR*G/S!2( >BH(+0J
MVJE%;#..4>U$#"<CGST!;5_1'<!OJHOTM^Z/T)#F/KJ<]11@HU+VS4%K;H@J
M\H%;P!TEZF5FLF$/X@+$ZIGT $'[+[B:*3@Z1X;JYF^68DJQT6;-HAV@JM!.
M$,.VGG=WW.HR?*?6=E-):MXAP7L]\L#V#FO0I'Z:_DS-]!+1)([6EW7"U]ZO
M=*?@>&E73@BJ:!E.Z_1<8<E%AI-&A_ N\5"&OI]AG5'//TMI0>F^C^?#_0(2
M1_R[ZTG08F/_GA%[E&KWP9HN*FXT3^N^^.-5!YXLWD7&80,9OQ_.WNS=4$SC
MN2_F^XHIO:FQ$6H_J<'7X(1//<6*-"$RCJ6"8"%2?P*AF.N_#$^*R36U'?EL
MG;L=CYCM>])M71_J^#I_A$]!9OW35AIZZ-6::D"3&.JD,XL#91H:5M P\^5:
M?GSOI'NL,Z5-L&@KX^&L1]\*6;>$G5I>LODL--$2X^V:^#;*<$BHT5? >'&C
M<6INCTU"FA1W%WR^K.RGIT757Q-&C$CUQ42VBQZE>%ZF7,SKR\M<2_FJH!U#
MK<ML%=FNS3(]LBS$_!KFI&#ET[$/,.%GK22JKBA@>S+' ZQKR:*=HLC4?MJ,
MVOCAEJTE_XN.-P8) 4]=9GTR]$"=\\)V)RM\[:+[!J(%F5R_$KZ4&VH-5&<V
MR^QH(88:A;SC;A)_!$M]L//4WG1IV)S6?HO;@T\X3C=4SNC\:])>50"U&0TB
M].H_BZ07*0>.#MYS]KZO2LCQ_DU9VA7Q>?ZU$=AG]8?W&%]G7V[M?&?A\S6!
M*HA_SM7%D.^-*>W&".W<27T(L[3\NZ*V1B&GEF(YH(2/V+[3["WL=A9V0\Z6
M;K6L4E++7U@"'O#)Z9(0,X)K1. !V\]GING6OD#"1^;K[''*XOZ0*QTR_C_U
M,85B9S#,>0RN 6H]'?*_IDZO\BLR:LGXBZR: I=L'B6!UY*^Z?$O_K,E87JD
MZ@O0HNWT8F^\YL1RH$5C-M %A2L^<JWWA[XEN[Z=&.9,LR"@YJUS(<^Z(Q>[
M?OS-"_:9@( @W\KHEO:U3CNZ13B8M:_IU; 4_@W?8 :'LE9_.C3++3HR^O6?
M$QMW0M<@A-NM#[!\Q1CK3KU7VF,2TN\8/ I48X9>*G6O/PI5&@V?F*B^]N/3
M@E=4Q_3#:\(^A\LGP&D!N7P) <1&?),.PN7FM6F[C.4\*G%<7G>K!-=< 5Z<
M%A;G0[SEQ=9^XJ/SIFTNXH^8#9!QAK%/^Y, Z+C>$>T7]$5_4I\4$VKQ1%=T
M!U3)L1(1%//]_4T\IFULTN'C1-?55"Q/4P3>" L2*F8B?-!&Z%EL\U^;:<J)
MN[.I1'RUD2J3?YK"2>;5D[5F=]46+CO\9,HW=W=96&P=1:RBEY9X17DJ_WY4
M)N")!P.H3K?SU9!JW.[Q4G<21]>?*I H=(DCIFC&O<5^.(4R/![XAR+OK5H]
MUQ%R #:W$UWZR7J6[4%^),?Z2E>CEN=7Q#I\:ZW\0FWO7)BSN9IE?P293I@W
M2D85&4%'XSX_99H$IO0;ZCBZUA7Q4.7=M:N?K7\0LW)$IKZ:WGI?X\F.]"2<
MN.E%0%1 @&2VOU#Y6.O:U1&NO@N[5+4^Z?"E):3O\+-Z7UQ>^&+>755E3C'!
M,TY'D[@)YS,H)0L.6(X'[&6 AG99ZEWT)&^I4=#[__];3/@P2N4[[$R8S-5F
M';.8P7$')QJUX_3VZ&'].KV.3Z['Z+2K?[X6J(V8B.J:>K1BJ/.8:I$6W1!\
M<6@DGNT9<_5$19MYS.+W8.YH(229T"F%F:D6DX1,'U3X$@](1=6]:R^@88U5
MVX,,8&/*?<G10:J336RK A(C=&W$D7GC<!^Z:5&>9>$?XV^67O4ZOV'1=?8+
M.#+2P;X;_5PY)I[:Y%.X ,[#6.UIQG3NB?6QP><L96S?+#4&K/;V=7LC6\3+
MTU=' EM7@6C3\NB9G0)EKL8^M]'J+KJ/"7"&)//1.WN3^FPF!3]D2OHU>#TK
M)SSG'3QV/3X,V0\D97Q)]S!N]C"]F'#=&;)>8P\K .N;UE2AW9NW(J"^"O;6
M(O7VCU2:ZVC6+[_=9^HO!DJUEKMX&F*F5DU?Z:.-[*YN6J"_A<L3))J34WC4
M+-5TMV8SR==9LPI99U)V\8!*\*B3.W<1ID5(^/& >H2N_=SI'!VV)C:W5+GQ
M6^4:IVO\BS4XI?JY5:A2T]2ANQ,C8A9CU3\^OJL VO\@IW$>5"-QK-1_S,+'
M!R#8BY$4?[YC5R)YPP$^*+@2XBVIW^ZO^<RVDW\"6EHVK9W:WO=1S$>W*DU@
M[5?KM<+=BI]8S/#6/9]=,ET0UXNB")>?2:R@2;+I"U89_?A@O.Y %9DS^AOC
MEY_-WE64<G8==I:>+JRTKO9)3$C%TC6PKSHN9"WFLXEU)R0$QSH*M %18NRU
M*I5R%BF!P\&\L65+5E*97;642SV1,_JW6GMN60N.!G:F2D1)MONQ#[,DCW\.
M^FAH$1#6HM''&MS],";#SRNO^%/Q2SJ>I0H-/OO&1=&T3>R]W37!86<UFX/\
M?:@53NO7OC\[5AF5E%"T9 :,K,8<B$@LFADW"J7W/6*QC.L4974I,NR@_%$]
MJ*MT^8*K*09IF9G<V2S:'K>=-IQV;*-(^]"TAP>:T?UMK'P**$TL+<WJ#E-&
MUW90 \#&'] ?90N#3TWY7D[LT_BP8.!]S.?V415/(^<ORUY\&9;1[B;9I?RR
MRT':I/ ;'-K5PE4;J(SQQS&%:L,KU8MIY,*L21Z%I8-%_BB+!BZ^_- Q0DUZ
M[>VH[V,V[6^D<'/0@IX)]NJ8U5 9\#&[A>[F1=S:,([>7E:D"C70E44X"?<!
M49OMZM-?U-SJT=6O0TR7N7&_:#*HJ*A!)@0S&&Y=%*R=4JZ[YCR+=]Q7QT_R
M.UE*^>^3KP4-RTDA3S$G[^_*4?_>EH$\\!]."PE%-0QT=A^.P>]E?79UE!"R
M"N;2[4^9!0XOE9 J3JTE'JI$L5K+%7Y .^D6["XKAD8(3OWU#<^74Q-F;Y3#
M-F3K9D?X/YQRQ(H506^R@G.6=QC2V*;#K.^JB!N'!1[6&8S>':O73ICU<S'C
M70/=M6&G0C57J:YI #MEL3-\DD:2E]#<4*=E6R9]RECI'LC7&0)EIU=W_QXW
MRU0WVI;CS"! XQ2][J:7\#<%UWL%$2,#&]MT5]K7@K?<'8 *O7&YI=NJ?:"T
ML_]A,R.FA31T8$&Y"N7,>(!/-@:T&1.,$WI#W(D',+CB <]\6F]8I^JM4:^,
M&T<?OL>-C:TTQ_?!&:L-R\^7U1WO*'[2:'3^2 _XRT.5*92 @;O7(K,C[WG;
M,T"N9/;^-F/B5J@?V-8T)#7FV^NS\]:,Z[RC3SI62?H@[G+I,FBQN"E 1IM(
MIB1T!!)<^*4;,V+^\L?>]/GB8OG!U.(B7\DV]"(C""-G&BWE,5Z>2--K]Z1;
MD:A"F@8/:-!B@K:A0#TA-JOLM%/R<_=[P\Y=D]Z_X-M)XLATK^5@]>5P74G_
M:31AI$6CL?H+A7X?FZX\>_TCO?9HZV9)@?(#VKHG4\QX2O&1J6%Y(0F:* J>
MGX3*^?.LVK)C=9CVQ^?C+1DF.ODSEMFYE6\8E>.2Y5S3O&LOWA/I:U@(3J@"
M_K>^;E1T-1!G60N/6WED%1=-]_&"YQ3J)[;B&2W!<=^V00[L?]B]BZV-OZA(
MR26K6^K,ZB?A8U(,R!)J:;DIDE=PS\7X2U</I/OT.HK/3/[PD%SS-JIDS6N[
MJ&_WS0G\GF%-!WI[DU\MI.&JWEP?I)\E!WJP;!=SW&U@K'4G2MN5;XDP7O_[
MD<Z!X+QYCN6E49IFE;WFXM25QW7TPRX.8E^M56'Z$9VF:FH*=!]/&,F7\QS>
M!QSB='>^K=\)]#XOU](?/W*C?&E,J8)0%^JM.0JT1 S$,EKXD0"C_(A1> "R
M)\3W%0SC^CK8L2?DB7BSRHQ>NJ%-#B5Y19+DZO F$:WY)#KM<JL;)PRAQ[0:
M3)M6.CGFI?@(F%?[&T %AC40;Y ]*W^KB[O+V?6;$VL1 GW+4WE-AVYX !F.
MWPY(AC5V*-LY-'MV;#+_\'CDP6[A<IU"E'\,1JZKP2G:5\82:JL3MG\8^SS6
M2V=1*X<X")2P;'\!^WJ3JJC8VC[R\)8V]HZ#73_$/MG+/J-A)PSP?W'M)T2A
MP6%3G]N@L,0T;)FL>P7WO"Z&K,-:<_<N4CE0.D[T=E(<=&[45.+[XJ6FO*(?
M /XZ3^+[RSJ]D1)T*QQ5H0%N,6'+3.) *OL!9X3&I'Z\9DW\SW5%W;P)?@JE
MGB'F\YVT<RV,P+MB8,_BXS>SSX&APJD&;IPC+N$HV'<\@ :)44++O4%;7-G;
MH6;S!YTL$B[O*0DWQ:*NC1E/Q$9/8=94V9/C(>=8K=TGSR$Z;[/.)R9/)U#&
M'1P,BNQVWLL=PMSZ$^Z+''HU$^7B46]O1))V'%E567HX7R/:>GL_1UIL5CI"
M+#@8,XW?5(S#G:C 44YGW'EJ[GF@ZK^SB\'6-EN\M,5DT=\(J'\%J/V3908=
MJ'Y&[6D&#JRV_EA'[7^S&]U%_$C+RC_?$1E4%:!_[?+CW;'S<S];T'GZJ#CX
M4P6JY[OE6'78647Y;M(!=-"R/E$WD$='I:):,/A"Y/FWTG@5)89I<W_=0O6Y
MFZN;Y9\ST^;N=/]7(BP%:*'%N #&<9#-V7G?R^4V5"O2*#9:>C-=4Z$R#QH:
M_*+[*#S2RTON.Q,3=P9:]-^-\>I(%X@:H]6Y].[OKBM"W#/--_A/?6WBI%-4
MJF[H!T5+P@?CS=%:\^6OITXW:U&;N3?I] F*">[R5_-L>FYQ8XE=NZ_+V20!
M94KR%3P):<?4'%@[/.#'!-(C#!E<.:DWHN9C3EE>6#92M" =UB&YL\D3V,G1
M4)(K+VPJ%>:TK*>'?5N %K[>[5\RSDJ&X3IQG#.^[FM"3B0:EK:_=[Q+;=/
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M%*QTUV0W.,\M7U"M91=AU=&B[4L/QJ!P#?U.6=/,?"1]I1?L2Z199F-@NV%
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MV4Z$7(7)GY7EKIUZV)^SUG4W<S:,S37(O+V45DK:F<H3Z:Y,-N^93MX4O]U
MP[1MFUWY.4_"6SJMDS*_P:*D.3""KTC@/X!"_)<'R>]HY?NY4#<!@M UM,39
M"<82U===)\6R,C^_?UK\Y0!8L;\&0;I.::@]N*%2"YXO@=KD8.H4ILK<95^1
M*P@2_5 _.X0+*>EV_$W9BZCI&4Q)[)<9MDK5%SKPJ:). ,^TO[T?]N$LG<)
MH&N\MT#\D';VZO&UWY@.O;YF^?;@ 1@2\'^<O1UN98"-MB#Q "Q1S=\CKG]
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M:-^J6>F\:4H"6,$H]\#=,I9(&K1-A(?9.UFI$=68,\1O#7(Y2MJ6QL3.!S$
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MC"4E1;F*MV BW2$_1QJ1J#[.P>_E)URKHS=_/0RQ[9 W^X 'N-@<NF;(VIT
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MT7Y^GW=R/7/JXVL<<9/KSX@YULQODI1KZS:_[VE.O]-!G_MFQDM ^JK'J-S
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M'3E.:.\&3NQ#","2IU_7MC5+G$]6O&;RW?[,1QE/F2[STM+ @JY TC^G\Z;
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MY+$E@XX8!#B//R:EK^Y!1MXRCAKMEY!0X:<XN;GK>'%K$!K@H7SJ'0!_.S)
M]>%7\:A:CV=U'YUMO@QON0YP65T\"Z]HYUN'),#\UV\4-"8$ZTU%E68/O$:U
MWK:WU"0C$?"A/03BD3"G2;3&P$V'GHGG]JRL%CIY:OMG!^_?0#7R%9U)#B="
MZ$A(=@F*L 92) /&LZ\HK+Y9WW^Y+2V-UZ5% ';6(M:P*?[CP\0\J17Y^T_
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MZ.T;$K^JVWO*M^)_<2QNI\4Q[C431K<S:JL#AA$LM_>!B^]5N+VXD3PPHXT
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M@!=X!R@\-H^</;(1Q&2=JN[1<K"__9+'F)J^%LB(A+Y'EB0HV*WB@Y5ZF9]
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MQ1U@&GZRO@K!5KF:L&FOK 7+]F3XK6U<A3M^P,]!"C;%C_=@_<^7N(P/?9U
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M2?<_<*DDU'^03/_L<%Z[O#R2=H[AL4M3>?Q#3EW,F3[5$T*RF\.<X#G-+W!
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MJ7\O]5VHX;.9I)F%VU6!]7;Z;C[T.+(C;WV<PM'OU>7L4313&5%I35.$7<A
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MG'%3S9)>NM6/KD^@.(R1(+D#[):_7"OLC20.%O]86:UQ(/-T&0#U]O6-T\"
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M%JP"0=ZT<F#>;03I(B3?Z[Q\$]\-\:&],+;Y] !$N8A)#J!]GWY)?4$^>?8
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MN\?S! @4RVVP%P3)"[\#Q.@;W@$(H]<@ESA@R!T XZ^JIR"=EF#X[9=EACO
M[_O'Z%,_0KX#%4W-C<@Z"-IU>_L. -0**!RD<+X#(+>>_6N-6O^I"8>VVI0N
MA<DL35-\!6$\QO#RX.C>K^4*<LDGE>D/7&9*_E-[#L4VL7:O[VW+2UU](1\Y
MAMB+]*SKEZ%=L9=D&_<R39"_KG'^(V]J>RTL$GT/&^@0=X!K[*P[0*QN]I7!
MM;R34"U)MMV6AB$6^[[!XH6<G, 32$;TW!;5,%&!75V0#,,)CKZ0<<=?;6C\
M2YW&C1H=YI&I=#6:\VA[YA>@%^IJB6KTB) %)J=.I*1>2^$!$/7H5B(4.BX(
M#(+&CGS/J:S_0&I%./0&SM&/^2Q&7C8+*A/].N#2^?-@IBPT_0GZ8EH@V5J*
M#5=F;RI<]65F0B'.C7=ZRO]B:.:&UY3H.A *V'FR%.EB#;%;E2CYN/"9U=I0
M([O].MJ;S$O(M=2:JM$U2,>L;=.+S+7YGG%G>CI;<9&%#>D4]56Z V2;F5_C
MU_UU ;=[!P! ;*,AG?Z\=2B*<"8U2<,0?J-P/66J/J[$FC@ UGE%X<]RE?D1
M]A81M;S$ \B)Z-Z60>J?)>$$C=H[P!!'3@12 _"O.5;_E;A.*O3O  %FZ#B'
ME-<JJ)BO;O 7K:-G]?FD0:,#-'8LHG\JQE7DVKWC)%Q-!5\(\9^?@5R+0]@+
MJ&^'85M;.-?B5SU9?T3M9,X/0;?L>77_LZJ6PBB--1X2)FZ1FH]#0SB^#P#/
M4&278F:**-LUMU;JZ;+K9P@:P=EF(%@V9C8Y8HYA[6O BU[1OE.A!=I.,A&K
M.P 69?IQ 6E630D7GYKQ?HK>R+),Z*4DG-CIFJK(F+TLNR"#_KL@A6I2)ED4
M.ZW/EV']<>FG8,7.<0<M0SOA;"$.[-J5^H<0:8:T<T<KGJ\7:1L[_:N-QCCU
M"0,/FZ.9&SD*#%:=!BIB9*5Z'+J]-/0]/L'3=&+&;Q^#15[53)65-LO8/Q5/
M*JIL(J)^S=. 1:ELH?3VQ84"CM3S?3CA-9]+P1[,MY$P"BI^7+R;?"Q'Q?>@
M(X[O&[&)/*V=5)RW;@:PIY$A=&*IHI8RAX+BE_UXT%#HP1/1&%:F5UP-852B
MF UD!:G!I=$"^4/<8W> ,GQ&=IGS%AEJ66N@&?:8Y&M$GR"=HDI=XP3C<7.:
M'A:W@J27->Z&RLK[ -QROU8L7QEQ]HP\XD<[J)U&KZQ]*"K[%67J:]9.QH#7
M3>3O/^&),3>1E!H(M67RE4710"\"=!>RWFY1K;^KA"^H<<<KNCP9I!!@KN?.
MTH)]%GN#%EOY5COO'G;]LK#WIPJ-;Q'Y>')DOPVNM&;/BU^_J!9Z7,P@9;>#
M,T9'72U\YEF:OV+E)OFXA?#5A.F8M ^IN*=P68SSXSC#!$(ZWTR\_TH:)*%8
MLGTK."YTXZD[_N= 3J+EM:H2:W,$?]>;:IP7&7.P^6/X86*4:\3"#R(]\Q!Z
MVMN1B(E)]=BWQ]RVDTZ%50_$G'Y\3\I36LAHL'I]JJ4OJ;'BA-_C;0K-*K>O
M=/"8F> >"S]IY7SZF,[D\<"]O_/XH]*V&DA+]FF-*7EG9ZI:04K^?&?ASDQ\
MV ]HG6Q\3^ /@%NYJQGZU0K\B2%/03[BRCC-?<I8_]U%BM/:0T+1YZ^(/$6D
M-YL><6"&HB =3EQ=;?CNY@]@:^H31RM UP:CE>?5SHXACK\DD1K>H&N..\"#
M#&8IH681FYE^U[/?ZD<O1^8L^39M_3U(6_QW>E4.?_X@8IY=R?K"K3W-T\Q3
M:*P(I(J@1$1:,'MMKMEI]6#EU5.N)$;9).^M%'X!U=)I7ZYU7/J>B^>Y]H(G
M%).^OA4>\MBRXQ6U 3Q)3.POAT4 -D_Y0J6I9M@;DT_D:S.-<QTGE09#7)V5
M/Z^[?N7N\K::,J- FR)DL!U2C))#?\SOI-0]'V\>8\=5\-N/$&=.OH@HQV!T
M^5U>$ $XR7KH2X#<"CH],#=)GH!KS[@3JN]I421T!E)DM&OFA_69E%\_4*03
M+:.C6&G[<BW977-$8']6.!2BRT7O09EWPHR7U5A\!^#7_8U3ZU&C^9 OHIDF
M!PWKX5(#:41J!G!BC8>R"CICT"1]P:(E%97"*\5&TZU@!2I\\67+SZ.6!!)&
M*0/P"!QN+0K&VS7OZ]'KPXE[:3K\%*-OP9<%Z510YE>DB!ADJ%TN[?\X3+_A
MGG+S<>Y3+D3BE[1C^I80L/T.0.0KM(++:X&\C045\(S Q7*PJH--B_._)=8J
M8KA^2?PL ,S+^2R:=J^%6K&G1M+.*O!WCJ/%F;"KOB%+'D/X%61%W8B38?-4
MSV+4@ RAM]3BT+JB#*+NBM,FJ^JI0VHR'J\'G+HQ&D<<>BPXE>4!$8"U&H8@
M>@)D5W*5?29=-31U9MWLM?#$A")'>+8>05<F2_P4P0J.(Y&:A^#_XGKZ_S'I
M#U.?=[51^3Y$%[F+1)6SS323E&LTXM?GK@[% '3I^%\DW3(*B W;XXHM\8Q*
M4$6'8"NXZVPX#_^)33MN#9TX76.@A=B)MM*K$GU!++C-2EIZR'7:_&CL3/QL
MPL=ZR;<*+HV-:JL)L(=;(V<_4]V[T&0.=IFJ,&(A1OVKPAA\RW2/E=19]),K
MF6[DOFH%.L#\ $*YO+'5^/7HL6UQD92Z=QTDWYZ2@]<[B]4+'.5DXJ0?.+@,
M?WJN=6RZ<4'JZ]LTQ0>QY=%>>U=K3*AB4)JZ"A-9K&QH"/T4N-S*6M%X![ _
MNF"Z9;D#>$_> 52R*X*Y#@08SNTAX;=*-Y&A^KRDRDU7\!SID)9)7V,?1%90
M+.*GD$*,!&AYV*9BO<<7$<A"_)7 -GF-JOS>D>J$T=U6N_]$0SJ@]+S4*6%F
MDUH)2K!7UH\?X<GF.6(=@?B1,L\O,GD@[^KJ'LL7F?8":-XH2V!C3E)UO[8O
M,IWCCG1REVKLXU_E?!1"CY:<-?X]?, %@ALW[56HA[K^5CN0^ <S:4:/]D24
M1&/J3#I>BV##I$9R::F'IVSL,E@\</W':9Y@Z)J)_"2L8[SNY$>7W$.>H#^Q
M(2(D"]OLNZ)N=H=KL^^_>*6?U"\*_I;6H#?*9B2)>6%&@[SJ]-Z*%OJ08Z]?
M9H_5/'(D%O-46VXC1,$U#K">6IT/UMO3G"2E&78J=61M$R;_U7H>HQS*FH3S
MZ$=2__KU$K%0U*^)8#6@XR2T;>O&FU*5D./=#'18 G@+F<W>AN#\<9+I8B!R
M<OL?[9UG,!Q<V\=7221Z]!(ET7(K*]%;K! $002K6T&(LKH@RKHC1$V"&T&L
MJ*MD]25$B=[""E%VE;6KEV65L/KKGO?+\SSSOO-\?&?>>3[\9L[_G ]GSCDS
M9Z[_G#/7=6:>%G!T:NI9>U6)7BV3<>:@'Q A_VOCG(=4%OSV85TCJ<Q-9GT[
ML"A*_C7V<Q^_;3GG)V*C+<6R#[<MH34DZN'D\U_ ?0\#C^GL!#WNXCH4.-7I
M%M:R[)A?=ALL;TC3G7RUY5? V3/MBID9VV[IK=K7;?<$@$% ]8()%)PSJSRE
MW -G#,FL(S6/VZ;9V!^_JC1=O4_W'<Y:-8[*43SAP5F.ARD76]OT4[_464+D
M[+ID###"G]UD:OD@:PGBE$M2?$AV(O#:B0\8*DP%O[NJX*>BF+(\FW!G:A.
M5D)S][(O<#;IQLLQ8Y&S<"1BVP$9*N?7^[6J[\JPLB#_*:&ZL*TQ72QN2R1X
M]G12QT\+=!B[%;Z*B$K-*B5ZI;7^]@:MXXVO*,J;8O=$O%NLSV#E<!2IH8N3
M4X!>#588 MZQGEZ34E@E4.K9]A4 9XUH  'L"^.2BJ8VA:5LHSHI%1AVKLB%
MD>/X^!;Q@#3E80.BZCD-PB@>H=P?CH!]/PXZ$ 6U["!&+UVYE\0ZS]&EO@#8
M+$ ./6$'A-;\2O0>[!";*]TOD+,BL#VN#DFAO9/?[-_SCV7K_E?PK7?#5+()
M%F^RC6O'@7))^G,/_-W\J1/SGD.^?>/3W=VXO'7'?(-TY$LZ;QB9E4D@"M2M
MWR^L=-&54Y .^"A-=N[98OM??0^AXQ+8V8%G]L*^X; M0?,K[=E,T<<!#:P#
M@1!6^_/="P X>SE%Y[ZYWN(=4*ZIW?':1'G$9 ?V5O#/V*QYP3U:J@_?FA:$
M=\ >5F9-=>;O)>@R]-.T+5A-?OT5D'0L/6'\)5'@)ODEA",8? '0B]YT2E\R
MDW '5_I[W<6W!H]:9C:]#%RA^>2P=VE]U&_.!=,]&I<2S7T8XC4EHY!0;.B8
ML)N\=]W+53*\'9)7<1S?=8!.VV^+PNY'L)!B4J&D[1.!+A6C@@)U)$'(WP54
MI]V"U9,;K'FZR\C_>(#]W/.*\"?_"#8RS4(E[:K*CP7="?EM5MW"&4Q+?>NQ
MV(%ZR>[CZ%@;2WSCIYIRF8124VJB"V\"4^V=STQ)K:P10W-B->0H*71<F,(>
MV<^;-<E9M"S+\0YDTPG:B(0RI7S]:M91XI24^&-1]A>/V.;/A=@ I!]-=E=U
M<-K^D/X(#NU?H%5L7S>L'QT:S'&@L<!UHN4B8RR5F%MW.0$SF6'>!LT8IDV.
M0UX .J@C!%:Q72I/K3!R$U^>!SMF/O=+'U41I1/<V /PE@J&AO]S7L/_,RSG
M@*28M(4<R@V="2C'5@]>OZ;!_'ZFL:,J#R8_Z^7X#26=0EO1"OCJ;EL4J';R
M[3GC6?'R>/;3<5<7 :^O)DU*>QUWB+VFN/U*L_QXO]3LYD2?*7<E??>D:[O=
M 6H-!Y^>XJA.=0#"R[]VU@Y*RO$J9]*3=08@EA>33?9YS/#A+=$8L_OM?"W7
MUID<)9:3# Z 38HI?*"N$61%Q -_3X,_MQYTAQL9O\^+*1(/S$&US;?UG7AF
MW_U;FO^W/(+''ZN><S5<>J*\OS])4D#^KG_^KQV5L!.+*Q< $(CF7/<R@/>8
M;UM9F;\ ])$NQ]=?8J63 E1/^M6R#3SZBM(-B^I+'/2^4\/O2Q2/HF9Y3<:@
M4MZ!#\=@M;\SY0&C6D)'.^HS;Z80]&K5G0YALSH2HVWXA$#8,?=F&XG]TF.7
M@?Y9=H3$7/7.QEH=@T#2LO#B9Y$E1SDV(-V5I>60B.@%5>$=IG>!JG'6@R?V
M';^E,CQ8G-.UGS\N45I0@RMMV(&3=CAU&B:((J&(IG@0+7:M'!"OU;K$?]N1
MBB_"%#U[6)'];Q?_Q35A<*7%&'V:B$@81/S=>.?42^IUFA=@4W7W#L"^C6,)
M)BXW9'$+'8E*<CTJWZ./?+E(SQA2R559Y-7FA&.&0$^,$P6_8@[#IIP]PV7&
M:4[O>55> +3N9YQ3MEW&'=8C/^X&.(Z5PU(O $+ZW.]H$ZT#O6%B:U-'/?_#
MX11!IAK,9Q2#X6CO,.M6V+[XZOE$.PR-OHP6D\?.*E]? ')SHRX MP\WC1 _
M=O+:VSF$0.0;D">3K*1<O$LN"=&)1F &)BU8V[+] ]8IDJLC[TTQ=FYLV*'"
M@.K-ODJ9XS'H?; ZS=W*FT;B@<]JS]A?Q]^I5-O[M\\:_P CK#=C[M98LUB)
M;;"%411X\B<-1@KH?*-G\Y& +,<3 #6\ ,&MQMW,&X2$D"&&7W?X$JV]&H4%
M9[$:^-$_5*,='@GM(,ON4"T/>1]491B01)$^3?;Y<R*H29Q^7&^,O.+H#R=3
MCN^HJ?=]Z+_\C+, $4H@*:^ADT=SW=!R8"X^3DT+5E1?&1A$;7'=;0F#L5/C
M?KH4-;!D-#X0]5K/2**IF2R?APN^>M(A8QPF-SBDC5+F<X;(Z4_F>@CR?9U>
M]DUT]>9&RR]= -@N *X,]N?<T%/6$'5X(-=OR]]T"^5T5G;2Q;)Z=$PU@ZU\
MFX^F'--\H_]B,02(O06Y)^DL]&3MJ[2]S7_;P;S1I)[D4:;MP_&"]\F8Y):C
ME9#RWJ.L%2>93=J*C_1:9NFX>OOHH(*-IK36;(9]A5?WEU%N5V)*V?:&&!JY
M]7[J2"WZ#)CK>1T)OI8HKSK+/)6_FG5PJ/CJS:[Q%S>>W^U6S!)V;A,'59IL
M;$I)Z<.W!_STI&*XN=(%,&/ZQ@P;ZKP9W?QB3:2AWTD]V= "@Q!.S/ZJJ&=-
M9[T@NF$K+Z?H3@&MQK"&0K/)CL)A1ZL Z4>&"DT. 7(#(IKM5* 5K! R=#,E
M9R^-PN16C*X+K?%@)%=RKBQ)FBA+@#"_4,2YD3R#(H2JFR:*FL>06]U-6 P&
MTN]9WMAPE'K7*,J]&JS\X$_[S@7<VY?\H%%)*2!P^W*O%;94SU3-QC <RP-X
M"O.4^ZNK>N  \=6!@4W:#Q[H_0L !J(Y*F=6/79J2LB6R B] -2O^\[:H,9/
M+3(8?'WIOXRPTSH[:NF4WEXD^J9^N$:$N1OR'W8WO I3\>'1+LJW'PKUA;%Q
MVFM92>&P+*.&E<*"*EUV= *R0EYL5?U59U4!";-4X%\6C^LSB5)0Z6<V?&#5
MCV\L6 NIB#+YA)D>9W#JK=<5!#K'IB&; T_2\+>*M4G%P^.6N6A$30LB1A2N
M.#8?V* PGW<O\V=8[7GI\QL<1_$<RTBW-BJCS,^V;GH+%P#N?JX87JCZR[9H
MB&&\*'T"EZ6FP:%FK:WDCXT/2W\*1EI!$N8@[=^V^8<*CA+<H/+H*;D3,G "
M;Q)K2K]3K6,%H"\D*CUK-%MDE(6<E2)/>7ZNP45'B/M,K#.ST]/6&'OWG\B"
M+_6[PR*A^9]URJH>%T+%7I55$.<GS@M(XCA],B\!1AG\:LL-B(K=6@P].0(K
MIB_C$_J%N$S :K4^M[7- 5"3^!@0IN%QUJA$.8XM.'ZO>V2V/11*Z!>MYXDN
MZ&;5C..RI.:'9 B7F.,="&"IQBH-&F4F(I2QJ,C>7042[=J"&@N00/H_3=M.
M9A%I@+_@5_HH<;U!C=ZDAWTDIF^>3P*&E04G6#?5_#JE ^8P)!X'!-7R/57F
M$6YUJ&+7:).E-/[82 &+SFW05?PNQ7%H-"&%8G"R&Q<;WQ<;D?:NK.2P6HI;
M3-=-%;E;8>WZ_8F0"<J$78,]K_24:P1EIV79G!6*!Y:*Y@CC19Y0U$!'B$?!
M_0(*_O"ISTP,&0>(G:5%ZYR>9/P0Q^XPG90*X0]@A?"?@^AR6RNEY[P]"IT]
M3-3.BPKCF_),TZP=Q\!OY=.X7J\FEPS_\.>!\L4%-P^3#5^DR"TA ?35+MQ/
MU/TL@697^[ 7@!AKTHR"#!:S\8KXYBE&*O5(9KK:B6\QX\/0WG><FM^@Z$S8
M&P4^"!7OC5.JT8C9<F'L\C=__!#8)CL!1]?2I8= W^^HF7DT?=LJ-C4L\6=F
M&'+8QD&0F2*'-$9 QS<_VX'8DI9;\!_#Y)T\\$152U3L#%T<ID*D$<RX_O(T
MG_V*AI+#E LUSTJS[,Y@]YPT>2V/K-_3J1_560FML,/-#E=XV5JYW\#DZ^35
M(V0H+;=FX91.- UD*$FS%]\6)_U[?$<L5DV[Q&ZMODDCW(_ _5"AGBBD&;?4
M]29YN=XJ0=;',KU?0>T>R?@!*3?)<4?[T^%V2;=WJ8VXH3A7_=R<;I B!45?
MBCP=FNZ#7\AG1HNGY),RZV!X.-5C$OK@H!";7N!&FUU4^TZ)>"L&#%Q4-PB9
MXJ+ZY$PQY)_50+2 59*=#":;;^!30_,'89^Q]NO6B>T1PX$T]2Y)STPSG&/6
M96Q\*')\;EZM-$&19?.PP<AFS50<[X)_:""J$"(=_LM75YK7/_+68_]V,65B
MM_5YWSG76, LY^.QY@<$0T7=2R]=,Q>N@EVF8"P PIT4QFR]WM2?:O,TI/?=
MO+W(\CGRNIPWEO/))"H!R:E%JIL3F9!D\9C5O 84JKN+I<,0'7=/>V[KV4X;
M::9KG_T<!"Y=122TN<7M,['AR.X,K(;ASY#;<QVLR$[)N>?-4N+9L4[47>^8
M/P3=6Z1D@ZMP@URE6'CW0HL\SF^1?B\2++VW LJ_$M+/L0:90(;F=XZ2\36&
MP,DWO>+7>3TC/XU#00=.)&),:P81Z=$ ?C)K/SN]NCM$B>TX?+'F.Z!9TV<)
M8I!\-QC)_I<S,Z.TSEG-%Q8&#IQU5;7A0QLW5ZMWDZ8/)&7GM-DB;6RJ]D0?
M6A4$J4'!M\(ZODB4C*BK>L#_(+^?GZ8S9NQUQ3,QBQ:2W/W1R\9WZ[^;5CEH
M?UV*5-UM>0D7OP"\;7,YD^T8LZK/)&RS6W4)UD:9O)[;NF8!/A$OT]C[B ?K
M7DON&:)(^/'0/'S>L8+L?P ;5;NW8*?8Q8'=^B;?FG907?S"WY!F2E*[_T<[
M99>P9W+R\J.3$+I(7PW^?TU"_A_^P_]7:"XP_P502P,$%     @ ST-P7'9L
M;8_8[@  #RH! !@   !A<')E+3(P,C4Q,C,Q>#$P:S Q,BYJ<&?LO =84^VV
M+CII(EVD@Q 5D ZB=(&H2!,!$>E"E"(=I(.4V "E"@@H"$B33E1ZC700D0[2
M2:A2$VJ E#O]UUY[_66M?ZV]SCG[N6??&_E\8)(YOE'?,=[D"Z3OI%G@Q'4-
M;0V C!P R,!_ &D"4 ,HR,E_?H$/2O"+ZC@5%24E%2TU];'C]+3T]'2T='0,
MC"=/,# R,]+1G6 _P<S"RL;&1L_$P<G.RGF2E8WUIQ R"O >2BH:*BH:5@8Z
M!M;_\H/T&6 ^3M9'X4Q!=A8@9R:C8"8CM0(04$\JLE\>P'\\R,A!'8]1'Z>A
MI0.?4'$"(">CH""GI/BI-?C;8/#W "4SU<DSTE>.L1C<HS[KP7KA<5SF<?ZK
M'YO8;O5C!"Y:>SZAH67GX.3B%CPG)"PB*B,K)Z^@J*1V35U#4TO[NN%M(V,3
M4S-S&UN[^_8.CDY>WCZ^?OX!#Y\^"PT+?_XB(C[A56)2\NLW*5G9.;GO\_(+
M"C^5E5=45E77U#:WM+:U=W1V?1D8'!H>&?T^-HY"S\TO+"XM_UC!;FWO[.[M
MXPX.?]I%!E"0_?7Q=^UB!NTBIZ2DH*3^:1<9N=_/)S!34IV1/G;RB@'U/0^6
MLQ<>'V>]&I?YL8F&_^(M#)NU9S\MNX ,2A#[T[1?+/O7#'OR;UGVGX;]S:YQ
M@)Z"# P>!3, !0B&61'"P/_D51S+[H_0P4##=GD#S>LL)"2;V=/1OE25^3L4
M@B\4R"X+Q /S(PT!B'4.5+1)&PDX+EO'P-Z_RZ"G*"&561:=:+ZTMF]PA_-5
MY;$ETXBHEQ<TM-Y1N8^S-!FKTF(Y7NR67-=G,/7W3AQ&C<PZ6T3*?1=0=TA=
M%.Q_]>[.YB3Y/-;R%9_(H" F)X0_,,XUN^+E$/?B+&?K TY\SWI&7>C\4JZ_
M( EXBFCD=X3PU&L+A;JA(\T';2K[7'R<I22WS-;7WE]1:I[SOF'[-HLE[!(-
M)SW-=ZS\(WP@&OXHO&E$VM'7-WF:3NG.A\GR@H?)KK8V-!F[=]W'&0/=WC%.
MM,#YZB%H7B'C(;O&U"N5 ^O60Y(Q#6Y[5!("]-8UK>]"?NPI,*SDG&*.R)9:
MA\P>!,FBIMQO*)4VN"*^JY;8,";D]GI=,I.<&F7@+C4XM@.1HQ$'*$>E9WD9
M-]%"K=&:;=Q5H5+>:=Q2]*8.R+M8JI3LG@#>UF1&8[EO\\]??T[@O-]U]>IB
M-9V*9H<J'2&=R(E7K<!L/M^)G-+4.%*M0I@Y7ICNSFHM"KL6<;YU2G4]WV+^
M!H?KQ-7SU,-*C'7WT-%,^B,R1?F;Y3U7IR\56;R.N66:IL8?:WU<=EMJ_<R1
MW63(-QA'9I]DD"KQS*![N;#4;(Q88I6#X)%NJ^?)-LX/=J8?%-I;1F5W3![)
ME$A=P:@^?K^<9/BC5B7MF=R>KY^!LF<+[>G;FB8'3P'@4DVO.1Y% IZD/($[
MZ#/-VA-%'$C SB=T^?M7.0G*D^WE&)S9T/NU8:3,P^D7)(#J(@EX%FX0T]Z!
M>KLU67W?* %6%:I%(;08QZ:)=MJ,A,YFFTQ3UY97CA!9K4QU_%RJDF97*[=H
M[EE?[2Q^_KE@_('7-['M[:;:^ZE%.*3:IY$-_D_]>8U/+JV^2752=[/E<V:)
M.9]:N-0:R]8UA^!UKOUQY92)GZ0K^MKW#Q.(+DHG9',1=];C";:QM<S@V!BS
M1JFQJ5Z+/=A\2")>D/!I75E-5"JBF 242;A;?*NHB]H\P9_6?:J:XM(5"O]3
M<P*TAV[?MABNCHBEFF575R6J:8K?X#)]^$1I="'OT4[@>J!NO[C,JC;"_5QE
MJ,T32O&OOHS#^["U=4Q"*Y3!^PW$?,3NWH,:;AD7/DZF_4@(F@3X4:S"[#(6
M.$])'+<6T;WJ*N6'3%D_> A1;*K73+W/^08ES9IVW<-]/]7S0+Z,! PTZ-_/
MBA#;'MR[^P\*E[PQ\Z+%F.[94TJE&DX/"XK@G7)SA/%*4]%X/6 ^!3 7O13X
M?.-=C,,=;=8(+EX]-8J^B/AXQY5'PED1=UD-U(%_M"['EUGU<$'/9IT_C!\C
M7LTK_ COU)LCUFCBITMNDJFS_ODR0BP&!AI[GSXOJLB70UMV>]<=AX47DH#E
MJX\D!@9HS0%P^S]=HN6&EZ8G-;2^/SX^-ZI(-+I?T$0"SH@A]VV(&H\D#=19
M@7^RR*P.[S\!.A_XO5OJ^T"](VM=Z)2!78&NYL /N8=K_W,?$:XG(N*7;U[0
M_J%SQ[X]3>C6:",3;DFW/W'&I+X/4;(V(E5_/]#O-L7D1R#8@1R$(.)9G$5'
MWW07JB%0?R2KS(.WZ6.:+7/\A8LQK;9/^V9G4X;Z*@CRK8?JE04YL FGAZY?
M-IYL#!@(W"K5^O)A-NKI0*,KYM@;U$S4M(+I6HDN*/$,AC<IO.CJ$QW_D;EU
M\MME"6Z#C3(GJ2.AP@G.](K4:GN>=5B^A".9(,4!&3B#KF<5MTOEUIV2K\;9
M^H350A:>EZV )WD,^=S (Y6J%LA)9;$Y7IU;@^42<+UA=^\E$3]W^P>?E 6D
MU:HIQA*352X<7Q'55@Y$^>,O^2"Z2G]$9IGK"M8?1M[)&T/'"4HK<7RCH"&[
M>G&_>A5V,8AC<&>3!X87[I-8?S^%FB%?X1:*M(Y1=+4:<&1X!;-+3'86B!;G
M8&0]\?WJW!.:A=W-,&XQ8IN50+DEM37.KS7EZZ%*E./9#J<6TT1^[V>GI&_;
ME"=>\JIY$/".J?IR6Y#\$0Q' E"(QR3 00&)NN=/AO?:0]"-!T?:%F;8300$
M+ 8OWMF8@A"P,,_110X\ZRA1CZ5E9D],DP3D)K.5R ;D! 2D:>K0*';XN X?
M9D%Q,&29/>$$#1)S5HIX21,O-3/V@03T *DD@/PL"9BKV IEFUH;A;?BH(AA
MHBD)F)4F ?P;,"!D*H,NA-.BFRD\A--9[NQ53Q+@6&5/DY%TONT3LP; ]\A>
M*&455'5YFH,$9/)8D8#/J>Y$4:32<F%^0WG-BMQ,JFB8'8R!ZGIH-EN_0/)\
M2 2\I;]>B@1<E6L@ 8_E9O!&$,R..QT)Z(M&P&=UJT@ &RS-VSBD_1@)F%#H
M7<0S'XJ0 "8-#))P?'R?2#D!Q][^@X@0GW[-CX_@+G/05(SF<AY>A:<9!%]^
MYQD<BRL):#/XG0"C@U%UOG8R0ED4T;T)DI7Q>P4T?R_ 9,F2-9"3>N_;Q0,D
MY;]H@L':7<A_CP&9HW",(0F@NV.AS8Q1K96/LE\W;B$!]TNS6Y!5MK"3=#]2
M8"V;S*:1U?-13GZZ'&.S7S+>/%<F4#_$C_3O%DV1'TB)"QVI?/$.CIC))A>;
M4F4C]C>>'JHWS%D>_U%>\ZGN]64W2JL[SRU"E7D;'BCY(:CE36M- ^H%978>
MUEPJ41)SWD\=Z,%>]'U+ BB#G>%'-O#FMP/B,H&;%,[C:^PC<]SIZ?VOM;J:
MTSI.YW]6+/4F 4T&09(TU)_']S0I@]]/Q.(?UG/,V7=,.3=-BU;WR0A6Z)]E
MW2ZUB^I$:W")'O/XS)^_"5/!Q;:9YT6ZZTX7>>T5='U#<9^&/'E\IX:V;;CY
MUF&/3/:7XH.T\<ID8T*(6E$*6D3UNM=$5XC]\K>?W9:Q"GON37#^#QB=LEG^
M]^]/W-PD4JBU/H1^TW++O&)-?9I^)VN.2,MQTM^)UQLOA;W-K=)U.]S0]VFG
MX.O"M(E:=DJ*OL33)E] )P?IOIO$,7U.DD]PE$LZ/)=;J%L\<V>%P3[_N^:%
M(DT/NTIUJ7/#X[ELWVM%3[#5=/6[2>P@PU2%.*;Y!WV8UEVYVWDN[0S=J&KI
MKGV1/3#>_\WF]OC7;ZS"XW(UU-0_;/24NRP*RLO$]<L6]])XQMR=]PX>9F3"
MCD.=>(7:TS62T2SLT:6G3K]\:S$IK_\JHU9_7W_6>8JLLW,1><&;B6$E1'R$
M17= /!?9D!CS/?-.>H/^795>MOWD)@BE?_+G:58=*>;5\-NO9]M<]Y.&;#9H
MF"3P80J(#^@[J=3)2.?P_*R9[P03N]6M8*:4V1#!K]O/:SF_Z!G$XNO-I;3]
M0E+V+?75P;8[JS_Z)$+X'?GO%NVO6J&1*7)>R(,$W,DFNAOG_],IN_!A%=X?
M.0S?.6,BFEY" OBD=F&$XS>I/NIHB3C\\[L?P#NO;Q*^DX"XHD0]I@,:2Q)0
M!]F2(?/\.UK^0>N4//S#V,,?$&)8A=O?;X:B8G75XA+W:VI2+@7ZW^P2^/3A
MMCHX_2L#@-"Y7(0@H4ABL0;'@+:+$1%ZS)!3%:<1VCV6.RGE31MC&B FJ:G(
MQ2E#-B;5QG0L@QYRDHG=(;QEVCZ!4$+(IJF82:L+FIKP2I=.K^@;FYZ8&6OQ
M<U;VDRL[G22"?K"\K*%V[-0)345$<DF]V6R!JJ#_?NO,^+C1^TB_ M.F=[BL
M0 ^?]Q8KJWE:93<$Z,\R+,AXN$N^^[#5XH8NQ,%N8ADZUN#%..>6=/;AC6LI
MC!6N>;@G8[,6@<6R7]J4K@T(K B1V:IK1>0GDL>_XP8.[5NLI/N4[5Q5OCTN
M^7$X57^2TRY9KT[G6?3G+F-A+6I*C]L5\!<A)S#$6+O"E721_O)U21QZ9&_S
M9H2P&^/%9[YW>1X]Y,;$4CFFL^)JL!163Z_8UF/$IZD'RB>V<^ZHU.M>T+_8
MX=++?(OKWB4S,DK^T+L4UM50.OQ53!6(5V,=J&-OV"J?@D5&?0=3]L-<9GPR
M[HKS/8<F]=;MKC-DKGW//T4F)3XY&Y-[6754TXS9DO/"A\Z[GL<1T5#'=?W9
M]VE'5Q.PX7H9-YE0SE)K3>26<I-65@=C6YP^A-'IG;F&8$U,WN4/F+P6*5J'
M%.,\0L7['[5&%6F56;RP=>F.DUE=B0*\35Y-'<HF2_:_[ZFYL@$" 6\2]6U"
MWZZEE62;6&27@@-\QIX0V/; IDC$.V7@+2&8!&(KB-N2,!(P$PU"<B0B/+]T
MTWZ1N(U"EL/P!^%$\F#04AKHFCZ(_@LD@( ;AN)JH2@A HA2RW>0) #)G4<"
M.&!,!IIEVW!_N /R8)L)3WD43CP)_YY!#.TF 4?80CC6&]ZL?\0"MIP:. D(
MD=4G2C;R9<6".V&(_?#M10B.9I\)+T "/D()=,DD8'_N-@E +_]1Y2 5=;[>
M'@**D$4"EKY",2P;$)PV";"&'W* #6JSO0#L/OU_U!CW,$(E(_6HY4B=!/2^
MAL\*34+_8'OV[U3VP>RR!D+E]\/W(DE QGEP5-"OAO_!<LT_:+V*6A'>"W'?
M9%H'9PS5>R3@4<8#$O![\V/_H/9HRY#!&GYF&C(N10P"O4ZFBOH70Y8]=H"L
MA_XU8'5>:/?OQ9_14DRPXM<'6D\-5W%=QA)XLR/V)@_62B)DR*9:DX$GASM3
M]/,\\_;N-S%4X3J1^LO># ?^C =[NH_9^B[GQIF/'![C;^9OU)Z.UT_4MKMC
M7S#KJ2ZD;3;U"?5:45MS3 VVD7%G)42"\%(V6'O#!\ZTRC%>T;\MF.XL82"0
M5E<Y?/>2+V<A ZA)IC9UB]]LS+NFGRYM<30/WKG@I#19@NX,4B_PU]O-[<M#
MQB]9@ASIQ3./\$]^1CZ3-=:Y9,<%/I]^:J5RI-FV$&2#Y3HK$!#T(L>TG9>W
M9.X^"WSP@?YF8$ JCBU1R2#B]IQW_.;WU9(7WJC>M=E=(CC47=P)O$.(A=K'
MTCOX*8U\1#DSB&F7QWY+W]LWKHT0-CSZVG.>5I'7Z9#8DD%A%Z5-_223ZM6%
MZRG1$S;5]XXF^=JKF:+\]LPW7Q!/^ZNZ/Y="!W/<_E 5V<K'E*HC[XC*YQ:$
M.IC=(TMX0!M40"-0.:O!X(<DKW>4CPPYY__8!\ZK@&4H374_10(81EK6/)8=
M$U7MOREW1=HRR? ^DP/:Q=[H.1?L06\U5]A?AWJJF'R&,I1#PL9O?NIW&3G[
M.6!4:EM7<==W<^<48W-MBG!AD7%N0&VB[63Z>DI?RT#S0#0WLT&4K[;9:;"S
M\;_[>Z2KB /_; .Z^@K>LS)L%$F\Z@?9_0)=W'5Z1"N<]><KKPC>$4DP 4N'
MS;-@908+,ETC,&M# 0O6\B=)_\+]U/AG(-!,Q1YPU]R>)0$O$V>./H*C^66.
M?T84?ZZ"0GA'/@DHC0,KS-EXY3U8%7S9Q%H0T3)++'[5!,6B<(.%*P\Y0"IY
MRLE<3,F9_2';;ENJYGZ2;97O59460'/@D5*FJY/K#7+AQF\*TFL\#Y?RKJ?)
MK?.$;+J8='$+A09!'-'KT.;^*37[V2F_9FXCPCIR8IQ35N)*:;/Y06]"0VF(
M=\C[!Z]=O[?Y0"B#P)GVN'YXD 4J8!W!8_8)RTLHJ4B*ON<5_-[L8K%7BSM]
M?_LUC]/IYX-FI)P#GCKE T P%[W'-5[KVU>JDVB!^5W94WO&5<<I^]3/(@ E
M<NHEF% 0^Z"1+-.SI9;:M^,A'^<@Y"L<1/XAB5R6;HEIES?N@DPU5K=3 H8M
MFXZ^5G_^O."SR>2DMB>*Y8IM2SF$6_LGF ;8R5\IE3V=\C6_R$O:<L$K3#34
M[Z[(@6<.Q8;PG&F< >M9X<]&G(!)RTS%3!CQ!.[I7F@DD1T1X0-C.%XOX4A(
M([QA@::E=O?*^YY)X&SU_[$?:S7C\0_IV=MA98%Y=/JX2I4:R)_NA'3"=F[C
M0?QYU$L".D%TKR:\1"X7X$!(),L X[XZGQ(_-7#I>;I6:V=I<;_T:07J1 '/
MBX/\Z<YU8'@OJC*MQOU$U:.,@PR0OS77$%["EPO]\V(/?>%$M5P((]2691"=
M$:$_,$8"#AAK7%WQ.F@$1Y!R->9^\OOEE*3,6:, OH'1[LJ!DJ@J.HGF*@GV
M5H.CR>3Y.?') WC[^L.9UG1H$GJ:[N5',_-Q[8! !U?[(=N(T[%^ M?(WQM3
M??#TB'J[F'GNL*PTU\$P,OE3#"'#'0MY@(,1:18P@>U6IP9EI_A;B2)U Q5B
MWK45&;VARIUO[2R<+9Y<8+I*5@)2',INW%V]8T@T2"-&A\&&P%DJ^D43B;%O
M&2NU7$JLY\TNNU0CD, ROULZ,?M*AZ,MEI&5RG,40,7RKPV,\A?(K'NM%MCA
MM >CIF0+;T!18Q!ZY+(*&H&G!1G9'"N\Y9,J%[POL V&8W,G@:BQ^D4D4'M?
MAM@#IGUO>5 X"6#LQ-F1@"N;;/!9HY_[9Q-YXS#=Q*?3HF"S*H(3I6%6!IKE
M&0_^)]X2$ @&H!=G[^HH7E2*R_D4%35E00*P$1E$WH3?WF?J-+/%4$T"?$LB
M5'*.PO?<F(C!V?-PG"^\Q5V^!VRQL6V-[OB=(Q<>))1?!FR\E)TXV[%O#>@L
M_5MN)0=@>K/M+K""KF=:FX3@CS09L!=1?''@?_L1RB(R9<O]N(C1M:J4I*23
M8I\ 6IX 0[#BNRDZV(;-EY-\DZ6G(OWGD3H^%?*E$?8.39VW<%U<2[P7O$R6
MBWMO_!D8_@\'\925TJAB"A'.TU%/1(87,LH7/P9GXEE&-V2.NLH/<N*_#>C4
M!2C7G ESKK[W9ACY[/F\)Z>GTMX[QJ?Z.)59RTM7A\LCH30.(X=ZQ4V(XKE/
M4>H/-.D:/+[-H(B;+L:;8<IBV?Y2FI'7^[R[+?EUH\IR*]Y>56B1%N]Y/!FO
M+12OIQO4A9YB,1RHE\<>-5N=Q,IEH](XK@V6[-+=+TOXEC+4$#5PYPIE//OY
M3>GV RY16^MJ\>.K>$-L<)#(D:*R'$<R1;OSK$W^F#7-G8.BNY:PKZ(FIPN@
M%VWGIA^I!+; F.HE9@EJMX:\5:CU!MQEJ:4"/.Q=/M9W>-A4/^[]^G7&6*B@
MP X##<O%K(^$GWN1UQ@9()XP:2K[Z?6Y>&WZTJ^OFR3.2&JOZ#T<[9J6 .'@
MF7Q'+=-C&0FUF^#W%UL-<)ZZ=]*N.M)<F)K,KDHQ_90:1^_1>'R:ND!@:<67
MNRI"V<8+<Z3!@HOH5A]6OCS"+;&(4'E+Y_+!]/G\T76Y1>> C=P8A9C+)T]]
MXASJHYYDP_JM:V-B49MMT'$6HA@2HC8+_X S[UT+\9DJASC.! 0NVGQ37O^>
MX7>$WT/DAE X+[5!J)3I"BNS?8JU?;+,M<]E!I^("$S>>B43\^XEU^N3#[2Z
M9M,K#A D@,KQYDRYT+,M,A(08>H#V3E0<;^JO,OJ?J]81=EB3]9HD 2$JUPD
M<O'L!9& K ,0!)ZZRN,=2$"8!B$#NMQH!I^=T"4!W/CQK<&CR -:Y7(BFGBU
MP;T(NF@'+ZJ&+! ;MW>:1_<L<5PVHCJN1QH2Y1_SDN*O($S;O[SYUF?TF"[]
M@<)[*^*7&;+=2T\] H_4V@(5 :[2BCJ:.X_[W.X+L1WD+N3M<VRQ!C@2VO"A
M$"/X5^AN($65U!+1?FTJ+!7#-WJE3V8L1-QA((W_>N7 +5LLP]O[6K.W\K^^
MBZM+>&L\&BJK_SC]!)8A_:,C5E,M:64T(-I-6=.A*TE#[>7Q7OK 4;1)4L8D
MK-/@EWW8DH=L\!UYIRC/OC+LAR!AF'XH+5@K.3@=$D#M._-SQO_]E1#R@U]T
MXS.'>\#/:(+WMQQ&P5\3#D$OO<"!E:XNU S#7:K\"V?Z_:55#$>W_H;4O/!?
M'*B:#5EDRN\XB)U!X!PR0N$[MX)^OB=7Y_Z3E/SN I(LZ!=WQTI JY$OLU>D
MB7?_K]Z85W\O%&<A\6PE@QE_[JO)(]F?>Q63@)9K>#$P^Q)04GC>"9"GX.A^
MDQ(&L=O4/X.V.8J7T6]&'HJHGB0!35-5O_"_WU^!/6K\2YC^$O-=3A)P/E@#
M^C6$ /_]-FEHR+C8YZ[L26AX_;UWSN-9Z])CCH>OY$]^F,Z,:;5^0"8DB_.8
MG:&V\/^$M] M^:'$^4VYY_K51X3SBOBV8 ^,_*Q5,F9Z(]AIQCSV3GWUT\Z3
MGR/.1FM3KI^.]WH,2\>Z!3SK_.!SMU#6LFU+TJ1N;'ID,+@WJPOWT'0<DS"2
M\G"E<MUYQC)V@)V0V<BAT6:+BT29YAB&:8Z4)+[:I^28C;VN_X? B*A*A?34
M7G0:3Z]CBBB640NX>$>V]#T;O[%-/-OC;Q?7G!<;3'0B;S3&3TFZ2@TS*A]I
MS/ $TU <F%3%W?>G)SXI"DUU^[*:6*1:N&Z&3U60'F.X0:7)C=!+A;\YF@$I
M$PL&08S0?X;$^+G^A<O_[LKHK-2OBVF'!(#1X;/_WQ">GVD0) [=OJ4L]+>T
MA(>^[L6+Q]+,C1ZY3?RDVUT9CXG',.V9LW!Z]>(?W#>JIL\UC$AD/2%.Z@06
M'1C7N<Y]?.7AU#_)I_-J^FNU/86=-2ZYQ?Q8"29CC<A#[*T84E9$6<H;C<P.
M*9^7V)3D,[NI*^Z'V*[D\_],9L0MO57FU['RH:'T:V,1W?@:X0T&T:9/A5LA
M6D 8_:O41C>MG_<(-K[);_$XJ_E2/E%#@/[EQ4$!$PVW60[KH1[(^'4NRDMA
M6^]F*Y7F!.A'YZ7P+.:7FK!B:/F]^W7.*,O+_A?F6THL+\>WV38O3KZPY RU
ML\HY214,CDYTM(M0S@G_C6"_IE%5R2H,/IT#QEY<5OKR7@!5TQ#7U1.G3[;'
MO13H>#WA][C'T^1]@7[B*9\?A88+-X[T(A95N5+W,(S/QO->2"C#\F6S9 X7
MHD3H.8H#+IP](\JZUZ0BEE=,_S_[1=>8JJSO_K%:]0.[.@JR#$I;YYZ@1Q8H
M.L1=SG_YXG\ZHL'*Y^@*KNXV1K/9TMZPWYZ]-EO;V<[=TX9IS[>Z)F*F9]Q?
MD#+WD;*=AO\[AA(ZE%]H_264JT[+"+<RLZ/2RU>PJVM;/ AI.<7$J<@:8?*%
MUVGOR!X!)1.6)YM[-<*UPT8$!ZVK+&Y73+QNO>+[;-Q?K"J*;W@[-B)(!TO=
M;,6%ZT7U,N#>2"*"I&V.9=\K6<5&1D::GBM/TM9@-KH?9\XNO3E._9K"5I+)
M \T4I=8,+:N?/NMZ=7RUS9AX0NFK<=F7,+,%BXN2Z*>43SXG/%(X]D@I6'X6
M]F@'P;!BSH8(*T[0&3*7JWFV8=TN'J#@V?9*X[(PZZ-G=KZ#LE*/ILF&@^3S
M'$Q4><J5W-*WNESR!S3/RM1LQZ84GSI(?1'T<5K/XES]9LLH40D#UI@/DO)'
MNC W,=L#Y2SA.7@+*W!O8'QA0R#,TYCM5G_BS54(YUV-649-*<Q@&U$*5_7S
M=3)NALW("A7);4-,:.]S615[O1CAI;J:&*TS5[;Y1=]=O/2*(C[_XB-/LMUS
M&7GC/^381XSE^L;&+#0^-+FZ<\8H9-\DS\I'W08 BD=403I'EB$]Z=R$3*B#
M DAVSV#GK6B(79B&=T][M"S655T7%M<"XH6FMI+?AY  A3FH(9X6F[;?"GW:
MR( ]E\_/G92;V^3A?<\R?R"19TSSKI8 XQBB!X83N^,HM$Z#.K\<0QT:/G,3
MOK %-U]N>;\BD!83I>16J/U]%8J:@#' E^O'2<!,JCX1JHF_Y(Q"$#A284?;
MCB2@8W5[:>T#O+<>NK\.;X[]!#(A5=!?,Q4D@'8O.!%V<(#C']OS@2XMS<;V
MN>-\1UM@AU)RR/U%<,:*!9&4<1SG#+;)Q5$B?AR./<0?'(E#MC>9"$<P3/:O
MY-J9$$-"CJNDZ?^4M\-#Y*W C!(C>Q"$@W*0F.[ 6RH;N4E ?P"X+5(N Q^"
M5 WIIL8?@<PI9!0O_"N98R#MR,AXPF1O^%,@X1@XZ;D&R8(-<!M4(\05BB-
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MQ8*R(7>*)O%98#B?Z ;I5(8NN'/XZSM%O549)0%<!7_<0=Z8!+QT[3BJ<#$
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MERM-!?,1^$3P-K'\F,M>SL?E;A, ;]8?C=%>! !Y46.CE #T,B&V?35&+0E
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M-\%(JVG<B[1P_'EEQ.5(.1BX6..]_RMCS=?.(6;)O$D 7?-Q1 A>IQT1MTP
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M%5W&TY1.?<'OX%W,$.X(.2P(SS+8BMC3W&C<QH%/(K>]#B4!Z.<EDMI&) %
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M2A/CP@-0A,=!L 6*E%8P,]D^"8WDDUX>+MHY63GX **%;I8 ')&L-F+(0 2
M5@-WQ83X\Q-[ @'P=B0NN^21$*U8ZU-K/L87K,7&M,1WW9WGP%:'&=J5ZP0
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M5"//>Y,7EN"9</08?M3#IB/+()=PDI^=62].J5Z::.GB&.52=Y)F=?+/ACW
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MBGG0]UF8 5QK)VNB\Q6ZG$%M)6=;ON$6\=BPW8V5<Y+WUF6Y-CF.IV(,XQD
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M7Y_LQARMBV)!%P@-E).S&A-40>">%( =PT OW% J#>4)O(@J1A%8R+W  (%
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M',\BS$YDUS2,F[O5>CJ/[;^B62/8@=X0R_DBGV'=_(ZBV:=GC6PP<VJ)HU<
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M4D&_.S0)!7HQ=$N57L-">F:^!92F&D&HMY(X&>M;JB==-%66N[[A0&'ZC=7
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M\A^?=NJ= $Y+H35=AQU. +<GBB=L+&^2<;E76$HVG :$<N7%NS?D)6DS[+%
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M>WSR"Q<)@)3DWX[_%!<#$=<Y,C)2,HI?N$C.!?P28" CYY<^SWC#B.*A%Y.
MS'-*YIO)N55M5(*RQF@6.^^A"ZQ"<@O"F%_0_H;LSP$+^S^%[-^!_1/7%("&
ME(2X>*0, "#@E ! %6W)HPF ^9YH]WT0R_KP#U?9*=B25T%M"BF3ZGOEN]KF
MTTFNB]"%5C@-]'LO$ \P(  Z)WJ1:!/HL90*VUG<$^C:_3'(44?E9$8WD!G.
MX3:G_!W>=CDU7U?-[**!JD1'[=T/Y0PW7X::67O+^(!OZ9-&I;&/E5RN"&'A
M/L][S][T0V;CB3 !0+N%ML='ZA( Z'.>^,M)6$_/<+Y]&1 !\(P)BI$_GER
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M\:?/BPAY*:GVP@G9D1"S8ZKE'_>FO)]Z_BKX]@?_J.#;$^E&4ODA %C]-KS
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MD$4J-BFF)Z;N.<KXFE\R5&J:OG>9 *B816P'MX;N\(@6X80S5W&"1=?QDZ/
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M(I/5*OU\E3]+R%Y9HVYYD$I9SWAE#+GMBLQ3*YE?O:H7//65 / Q/6/8!R<
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M6^'Q@R]^,.U.%1B^BDX-=G/]T$)2L,>@6I:5_5!^D)LY+\5[[<1R[ITA9+Z
M.4,1-#R^OQYRO @&N" 8*]382M<S+!\5S"]C[I@V4)5#(#]//@CWGIOV+A6J
M<G)-KLENCF&). 5!'69P<MA4QY %'D>[H0-*_N$Z95\;(*A^9&D&D,AF,6X5
M/1OTPDXV]7E\L#[*,WI.')-W/9L?HU%3\8'"5[]DG7&&<K!TQSY\OQ ;A6*+
M;;%Q='>JP&:8CY=O)3YH&/5<SE;ZU/.UHE.*V\N07;FKJ]$=_Y"&&X6:J2<
M9'_F_ !5=B6=LA3AZ_8-PW.Q9NW9W-B@]RZ\C*,M^@L))AV1V[L\JCH?T\>Q
MK\-UY8XFF+2(5>03=CJOGQ2KO.&H?L]VI!N^:]R/5G#+BUTRM,T7'3B477RJ
M,P/OB6UPQ-!W609$%7QW5S,HM_QI'"8TPH](DWC+VQBM,))3</^Q4*E!KSYT
MM\KO8TJ9HK $ ?"U9PI($BPRCTP()4?7E_E^G^I (ZP^I6!V6$@'"]U=\F3=
MA:3/RW'TLFN37AK/:&^%WIS08(7DH&S?Y,_UHR2<NMS)VYV;)"H*_-P\TW8E
M<&]>"VC=JUBA4/8)'^&C=.$5'6\!.A9/KCWMPF>Y%'?SMS;4-D*(U'PK5/J!
MPA9$F]Q[4(*37LQAA%RV^(#>B98W.*_[V0)\IS7EQQ?5\U<Z!#?TS'7U#C-L
M@ KPQR9M7ZWGCOYV>UIYOVIH2TWY%'0KS]E,@TMK1()S4?>30N?T#/N/3^":
M/@$ Y/'Y+^):YZ5MR)KL@G70XG"^[W+F+1R^V;P:3I'!9@O7Q;^6QL]H![*3
MFQ, 5#)\-F_.(]1@+6XH+C$;TRFD[>A\_1ABB9_&+$74UH\ L":U,RS:<8*!
M@<PXYSD^3@9,:(NO-%_:V6L_97A_32%2S'\FR(Y(P&'P6,H9</XEVGA-PA?W
MZS:[YI328FH6/V++P>::L"S<F>RQ=2FF/GEGO#5GGJ*+1WO!LQV: )?=-5W?
M'>PR';9NNT( 6"8]8718S17=)-GT O/@%#%C1QU GI^A5T?NV^[I-^F_2!A@
MO:ZQR_?(6'O14D,%FQ."<@_J,G'>!6.#.N8NM;IMO#LO=A3D[SV-?W*N_+7'
M#;$>WK2ZQZIEBB'O$!30SKEZGO$L^  RO!7N-(=@J*VD@\@N.#WS ]&X<9J^
M6X!9=<?!)F<W+@;6^\>HUWXSO4?3>-^]@X-]WBFV'1N#X1P^_1QZJ2$.!6UW
M.W:L>L,Z8?A]4M)1F)*:*>3#PN#U)X%;8+(92(=M,WJY(6IU_("CELN%YKN+
ML<V7\2KE 0L[$=><-XVD0.F#\D\B*5/.*Y%:L>8_5'3B[Z<]_W(I\86I].=I
M5!I>YZL25[!Q:XY#2.^"Y[EU<'54!W4.^[J_964T7!R;8>BFSW4E-WU![I/Y
M.4MC$JZHOK?9^<Z+7N6@'\BVT&MHIT0YE[K*"[/J&;%RC1FZF'L!^BIKURC?
MO1N[_X[-:[=;"!#_1%D _L0SB0!@YM%KZ$QBDTD.HVOV"P/N+-NY(!EP%A^<
M97[Z\UX9?UQK<8M*;CKDIO/66\6Y\]?:#(,P9@>N*2]>9;8T($]&,&+K8\)4
M5^4#/0[PM3C0^UH;#24"P &::*JHJ%MJY1)ZN3H5!+^4++[BFZC+G+VB >^9
M@UM5WFC"5FNW44M%F:JX672=E9_ \T,] K)Z%383_-VY6)CI%!5 :KZ5&A6E
MUUXI-S8AAJ2^;^13W<K**CMC/)-D-M+TY2&QS3J5(0!Z/T,H\.W?"0"5/=%]
MY&0&WI#T,_"0->IX_#XB2DK+T0KKO>^TQ<-L!,[)R>;EQ\#[/BORBM5ZLD X
M.SJGHGZ\U [P+;40F,,:WICGZ<&3VP:=9: ]\3&\R01 Z @!$%/1</B" $@>
MZ,.W,!$ 6KJV#\%F$1WM]^Q%H*W$]O+@M;6<B)9,P#2QUY3-P_=A%0F VTDZ
M! #"Y=?;ZM]/YA^[?@(# G^-G#C0"X4&_<E1&F6@P1WH"M^]HM4CQ)Z*U"8B
M'+JOLY]T>IB#,^";A)XG[JS):WQ'6T!LYJIS_GHM#G^$?_B7AK\T_*7A+PW_
M_]60GZ2/56[U0J?J4 A2]!D",5/#&(TL=";HXKH$%-V@U]HJBWCG_3/KP^/=
MGN4=:P?H!MNZF%D7<E?.->> V/T/U$ L@]?<CA!2LHH110/IS1J5?=\:?F=E
M_JG4//*,45T0?U9$ #!9;[$4C;D<G^W@^C5*_F:\+_BW=@*K\;0$P)#@,'!G
M"HJ1'QC2_KM\Q_JK7]8[:?Z1 N80TYP<8G?U[4\JF$@,]CW+X\=*PYQ-2;5"
M'GJ\FG4UUE88W#R5%O)Z\V4J@':8)%&C[NU/HR)>%T5/,_PCGURMMX$?9EO!
MQSDW"0!''!>QI=7^ $76_OHER.^7;2(!TH%J0_=T[I! C"74)5&8F[.(Z> M
M^/4(AD@VE]EF:'&WZ@C^0O!]/E8-5A>X3&.5 8='NEF0EV)F%=DCLAU^G_;5
M F&MN SAV3-P1DXF8_Z-OF1%J-GRZDJ2W1^1I#)%Z*Q,#1Q89(!JY5J0+"H-
M5DE\$@>36)?X-N1QP3%QPN/0.IMR$9"B1:<.,L,>ST/IL2DC'5/I,/F*5M_T
M'=ZWCR5Y'QODB+],?DL31B5RP:N9@R.Z@UZJ%N]>^>W?;PY!_QWU,(-T."B:
M(D[-#L\Z'*Q-NU)?J&ENRF&J?,>)3O#-2VU^WNB>W'WYKY#P0QCZA8;(]WUZ
MNKEI;+A1ZX3[OM4K$R%]RN2O<LF-!C7N@B]?)+X1%"@9Z2@(]<2](0!>SZK)
MF*T0:YV<XQQMZ!^M1;(+F+N%N@*"\J0TQ\;.02_>'HC\(?2<9]1Q2%ALN;FX
M5[1<I\,AN.@BQ/[P.39D48JM;R&!K[/^*'.8X_[#W0*=%><!;DVQ*XG&*@L<
MB22"SW1"NZ/VH$N#N*^'2M"_FY'=^X<A4/F/$ C]ORD$&CY ?.:WBTJF+:7:
MW7D5WK132/.3HJ>MTQY#;N&U0F3QS;#;Z-%1*[-3Y'&RFH0\ZQA1K6-^03 7
M!5[W\G^E%K/N(@K_>T8R&[OZR^"!N-^*:!^"VQ G0D^USTY!^,N-4XL:$CC0
M1ZSV_&3=]+1;PLU;XO[UZ:QQ36[-44HZ+P-$<CYS&G<,QWJ[3X\15[H@LH!Y
M:;JAC)BZQJ"_<9'<[Q;>;97O7+ 'IO4H<7^'%K*X$++Z(NM>Q')U:SW<X";3
M1\=.&'MGB+8)LL"=R KB@ X>XT'CYGK,3?6*=QX3BB9U:>U"KGR/9(:>6=<#
MXAU[!0%+IGK9/&5[\NM3N,F4HBA77/_3>H1"4-%O "7])@@@<TFGUX.!$\%\
MY9"\D<Z74+LU^F4D2$WF,UH:4"RM$W?9ZI(D\[::)(AE &MR^ [=$!=LA-*1
MJ-A:1 _$?>@HZ8,9[M IJI8)=@F(\7/=X%C:9N>.1SA%F1XUX/<( .E3<96&
MEH-?M[(_/?^[^-L#1A&;F18IC%[[RDX'9^FZD96.X#M.CDOIEP4%?;U%/Y'Y
M"CV81[4@>X"UA@7HH,X,:<A&AQA]I'#CQ1]NF9I+/JJ1$E6.]>)"Q@ .44JU
MQ>$8XUSV$H6MN1U<^[UB+5&#YH#FAI60J_\]+VVM,$P]9J&,:+/#\9CW2$CA
MH7^LJC[UE1Q)!T%Z_@MWO(J5'PD^$_OFBYQ2M1XOKZVM1R]_L/R,"41WY[HV
MA(8THZB6I,@6G46DKPB5]'Q36&47UGO!)^:Y8Y<F>C$8UGSRY23\O^-;R]X"
M 1"_!>>'  TPY.6,4]J0%W4MG6P18[$JC%04-.4R2DI?*B)KS5V-S0Q^A:<I
MZZNTD?]\,QY'ALGM1'AAFW7=Q1;2,PI=!1;NL"4+G(\XO;987'&AB2\*L:OZ
M$W&PFS.05\B9^2*[.0"ZHGE'0IY*W7^;&)@G7V.O5"9IR!WO_+:# G/CAX"<
M^$O!W*]=.16?EQ\@+PC=%9\J/XF]V>LE5"C-E_&NTZ%GCR0IJ_(\O/LL%[CD
M4TT 5)(18R'%K(](YJ+G=4G12*H=7_7SDQX'5SW%5\RS[\>S)*XH^C1&<XNF
M@JUT=1?8!&L:;FVL70TQ\%95];V&(S_5"LRH7-B)SG1&9R3$#T7O6[%DW/W&
M2+*LYQ!AP\STB=&*^CDQ\6^J*6.F/V=+8&2=.4'1#YM&,?RW=QUU"G<Q*X'&
MU='+T]G^LG8??3TCITIQCS%PA-^YM@_K4[396>[^U5=#-A#?N&Y\Z;ZWA';K
M"F7$]_.JH1MBY51M]%2C'^,4I(1JQE8QU#.3O6*1#.SB]?@-U>J%3TKJ6,5!
M6UHQ&W!#SL$2N+;R?%I%Y?3@R:[ZAN%9/IYW@\VL?IQSSP;D[NX54"?N<7.0
MFU3FM75/_6.ZH721C_)]6*;#%K1V= M#_D;F\DPV7]-HQ>7ZQ/[-;<=OT;J4
M%0(=*5F@OI<6]4E9L7O@%SGG- 1<@(PX?A0?T\^.+15?L_&GV55>E77[$]EV
MH>N:"7#S/.[2O&"DM+AT;"-Z;QZ1Y#N)9UR;:HB<KZU"VU8^W9V3S&=N1U&1
MQ:>\8!?;4^(*5'.*C3"[N+F%!4IA@5X7ZODG=_'T?7CZF2"ZN%.#8%D,7>Z'
M27-(MO*VO&[HH&OA\ )S7XI:PZ-XRIDM)3-1T,,O,&>\$I87S$$ M%_)W'>'
MG;V?"KQ)%5RI=NZ.1NB@V+=Y7%:#UW +&^@L!^?B-K\EV;GF);S)QT0?O71N
M75)<08G1*<#ZXW'H49WI$/ 1E-T%P60ZCA([K:01B;$"&YC@&17U-4'7ON9O
M IP&:2.0;WE=TUQ/;('A5TT[72!X^I/C;*3(EA1ZBN?!FC<DS1CC=W[XK7S:
MYT35@@>%BJE]/]Z^/==).D#55DH 4,,U7)!,Q!@;Z6 ]3)E"1*V:VZ6A7H7D
M:MUJ%#Y7R 6XJBR8G-P?Z-^*YNLZ0E"T^.3>*&CW<S?KWMTP'3HKY%^Q?)/_
M8+GA 4\I1$1CK+D(QX[QQ:M@:XK4NXXB]_E8;*9=%4*O#LD+QZZS)CV4)N-3
MFMT[-T-S3KE?WA@ATS0R,@'JV^$L ;^Q<5E;VL<W9Q=4X-S0 9$XAVQF^)@P
M^.+'F(AX5C:F^DDJRLX>KBO6\:PBU,DI,K)\41HJ6+8N^%4-GN'@&RPKI<%M
MG)3"YH72BY#81S>X"WR^: GY_'2+PKJ@099HITXD@\TZ9\)A0Y$U]NFT?KCM
M:,7MB=0O0FD?D /;I)>I]GG35I#DP$>5'!#5'@WV^@F);:0F^ML1V[5U3Y1(
MYK!WYXM3]72@MXY/<P %Q=M%^2VWV:!F!'!CM<IVO'6BN7EO!+QADV2"!FZI
M+YQI+Z2'HW)8OC2Q#%1*=#XQGVQ37T2\6C8OO1V_!" 18>?@'LW<(0K"5+OQ
M@*%RBSH)Q:Z[O=Z9;R_>V>!^H)1TH5A70F#KTN(#LH^DF9AFX+,<)M^=J#FR
M[P[#6@6%4Y*Y=+!<S4H>=8Z55Z\+TLVK'6)N]"88AI0%M2/)<8'S9R+S=9U/
MR=B.YMB2C*M&-T>,$J4D5<,%Q(M7^9^9TC\?O/[$)_Z^M6:*6X/V,G2TZWZG
M7*I-$U ,7]3P$\S30H4"L^;0NL#Y(U?-)(1<V"/OQSJ!X,EW[FD+2OEI"3W
MM/7PHY*F\MOKI^!Q!5C7$]JG^#UP_9 36-(9=4,P+2#6^+GP%6U^]H-5EB4D
M#=!QA_VGAMSW_2U7KIKWSHH3BM_7D>CDYJG>UM<]AT$7$4TOCZ.\[,.CE'M)
MRG\"SX>*_)SC0TL]=T2/9RA$+8"8I]>=.AE<K_!NSSYR$O_(D'9)>C:]]S.
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M6P&)O5@W=I#)-P#?J]RX!WP7LDJM&0!&%^ ,"  U=P2:WYD B)!">1XONA,
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MO$7ZY=+(!EN;BA"<$_TH_ -(Y)U"SD-/YUTGU4RE,5V<#JSTMP3$0L>+QM^
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M#6^%[G8$"TZ]Q;1=VCND1M@^Q\0H.\XQLQ><.U%;Y1_5_R!2I.T[NN.>(4G
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MI\<1&= CIR4:">K9-1D#/ND_EIQC$5$GU^_F+VTD\\^",,0]+D552\8.[Y#
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MD*H!#3I?L)R"/040'C6%GK<T_S'I$BB.,<'A(_"5$0N@ZU4L-@U&1ISQ$B\
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M="G;T#%3A8)&4UE1T^?&T&]<N]54XK?H.Y0D:KOTXDX!?B>SVMY_DMX3C_W
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M^G(G<1:O+=L8]U&G@,L;69=R7K#TCD4]PP18^99W/"WFDS%[5Q%C[/'M0M!
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MYA/VW#=-1Z;4Z.ZBT.QF2Y*I!C;P[?J>P,->G?[C%[,NP_S?BM%]!I,-['1
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MLI9NB_M4AY2YEST>;,\#,5>BJC"L)!6*K^995)3:-![Y.:+\%-OHB%D-,$(
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MD5DV_ XR.4KNA,1O_,F==%]Q&5UL3@U<8UZE\Y?B>BH.5R:'*>I4/G:!G2]
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MQU6A3\D?E%>6.K+%Z5MK.2HR).(QJ,N/BF5_F*%7>?_13_ .!5/3S_Y7VV\
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MA>CI_7>,F&<NM>"5/KC%C41N!=OULHD^KCE=SBG&6VK6+A%\6N UV$26+]N
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M$/00;1_?8YK/O0";R$T\%9"B<)60*VW*=]"R@CI)9)A,/:8L,U=;#7_=?\4
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M<H<Z<H_TO@GJ[B1^&8+FMU:]+?7IUIC;TF0>6%;O:&Y?^%T:R$'F".K1%0B
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M;J/%5")T3;2!62VQ*J"J_P_K>^:L:&\S.P1J\]W<L7!AAZU_<6>;.CU0)UJ
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MU^YL"G46H>.NW]W!\:SY0UX7R;LL@57Z'S%FW15Z' JZYYF-.:%#1&V-[LM
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MTT)[L\?8O(>F$O^-"F%;T"CS=XLEAQ'\XDCA2R&8EYZR25"A?FV-]0=7(1;
M]_T_9WMH7S_JI,BJ@G2BS/,()8=BX,U _Z;5D(XFKMS%L150&7X%E;&+.K:9
MNWCL;9"A.7ODW%5W1"_N*;$)R]RD/R.J.DH-Z3K:H[ZLY.'#YNV5E,JRBI!P
MDG^N+8E9&Z9SX1)J\XICB'QZFD(&C"A&S9^=;G56;D9%DMLX%/6!4T(">T]V
MU.1@3/Y&#I9&W^\ 0X/@)$RW9->UQ"1^V3_KY=?OUSC%1FWT^<.^#2=TL_P
M<O^;\U(^/E?(VF7S'F9H?9GN9AHVY^,# CGR8WW=9U07E2Q]2G5F6C+#:[US
MZAR,QNE<.&>OY@ &P_^2"_J1NR90DO7XA[J-2\D!'6OW[.=_/ZLK#H, ?H.1
M\H]%3D2L&9S1,O&L-LVB[^T3MX5"SP%^@TIK=2Z=)&#+FWY:F4)HZK@P3T#+
M!ZZTA!\K]3QXV="945&*CQ>G\><64"JL/<,[ %:[D%-Q4*Y$!^UC08J>$N!R
MPUQ72L4G00^6Y]]E2YBV9?=D8^0S(M%/BU&:+^JG)<IMZW\V:"6_*,CV4.?*
M5>=*4=].43\T]=+!_[=CV'LGW>K,DZ'X-G;^#G!MQ.V? Z#25?[_U:AW_$70
MV;[1=X C;*<[P \M_T(_R[@[ "_S%N@&L'0'^#/SC.7?E0DF/JTCYH=&ABRO
M;8X.Z#/?CUA?_'4?W#-USBFFF_BP\,4AF&"6=2!#RJA)3",16O"&J48P!&F$
MXU5-) Z%_9SYP43#NO188]I7747^YM0Y=4I>4M9MMF16W[MXQ+8HHTW^>4K-
M1*30(+G%P:.D%^VIUZD:$H0_[@!&%0>/,><J]SZD8#A$HDK0KUWWN>X "OK"
M&MH.MX?HJ@^ZQH,:<Z_16<O)=P M9QO7G5BK.J?DI'3,@-7UOGTW)@6BH=!D
M5,4"^<N[_P2INZ\;#-J^K]1S>2$'+=:0+T@&(?459X&?09*IV#>#?AB^QT'!
M6:AOP#N BSI&/>IGADKGY?57"4/I>=>96Y<H'_P*C_X[P(VT1!X\Q1I];5G(
MVK5X!?G#-8.9ZJN.:3BD%QECN^YXE1Z< !JZK_8481!&/(0L@1Q69I>CYS\B
M?!+W\'5"08<_/F# /VXTL0,"[M^@&YKHOH/+KN3;T=_?2Y2K'5+O &6SSO=
M/;Q!\Y6#<I[$/\J3D&K A5<=_%U]6<$)XH^?ZZ+28O@*QI1)5J1$Q)0Y?DTV
M#CW(3ON '8XB-VU1EOBZ\E6J%$B5^0/XG";VY506P/1Q)0??D#5^2\G2&2Y(
M8BJI/#9*>M!'+RZ PY&_W#'=(6?!C=A[- X#9'1J=0PZ?CX77%>":8CKGTP\
MU]R-?;V+C!/1-;D#P#_MFPPB<W(AAZV0!&"[>B';T*RS^S%_UA ,'N=?<Q\.
M,OZF'3G> 01N$O@%<EI1<9M.%,J#T1?-H@MC[0F0S JGI,1UTF-U"O#R<Y);
M:%?"US-\B?0WX:FUE:QH0DCF%#&><'&/BO:T"#KQ)/:LFAPSP_)@LEY(23?<
MF*%\J?M<J"-;K.5SR?ADCV3\=6JH>=?1V(U>4M+5]7R>>_X=X.V:PY\FHAUS
MOZGVE\O/N$K80]$D7OP7A=QTPU?RN,GOK0Q*$])H2F<:EF<@O.\QFDKK]M]C
M5^#/_R4S3>H+Q<C,M%,+1V=]]-6ZK2SI*WJ&A--3\WS>E$KN+95[=STG\@AM
M"%^/:#>PVSS6N/\_72>,10P4AWTL,)P$O$M1^?,C5WR!)#&R#B-\SQD1\2QT
M%O2")O6K_B.O\XZ;R&AL(K5V]#^XILOCN<D?1B(&CV!EX*Z!XU)(KUZ?1GO=
MG)#KVZQY$6FB$CTNX]]LP]^+%&P^ 08\!D)D;B!)N8RM=<2?#I1T4C3!Q_7%
MC<O>'KRJ8&:J1LE654[;+]8J-XUI'&W:1."\5XCT4+N*??W;[P/[1"H[&I\4
M^8>[S^B-J=DNV&(1T9WXX$*T8B&J<>M0W95\'_0F<FWX*1=-79\K[JBPJ5:F
M2NKQJSZ"94F^D7=9EZP1:\09FW> T(M;BJU]5^&W#L6Y]K-E$G4OSQ4F_988
MGN/Y=5-AC2S^)]Z":O: PNJ1B24CX]OO&[=EEU\"!:3Z@7"WKH9'),*RJ;8[
MQUHW&@EMGMD8X#6$-/#S:LZRBN=%_CN2\M^55[_'=IK;!D[9ACO?R_OL 2G!
MX2^U9 *0L\XT ^L\3JDR!#\&+<:RB0.RSJH3UEA;X5?1@2 $;=\U&;*SJ:C-
MV*+'Z0-7<^ZX:UKCQKLCY^J%[WFF9TGD(UM=9&NHJ)Y=_.EZ\%%1SL6--HFV
MNW-9Q:<Z38X)*A6)U#'>4VEI@/.'2<Z#?>\Q&0+!W52=AD3&@1>-R44Z=75!
MW5$@4?F:^9R20TD&Z9#U=3,3PAWCMU*4@L'OHKX+JXVP='M:\:*LMD3BZYVL
M2/_ M<I6S$RUO@]\6K47]*1<3I:S18?6Z*9Y+ [OX98Y^T*O%^(#!=Y(5LDI
MN]_+]K">*HD$I3Z]WG1*[L'1-YEO6=X%/),-=</GCG1_-E'IX-3?B0,>'+#D
M1PAWRFEZ>U,LGR1<?,TAW9HU'>9BHSNQH.9^_F63Z/J$66#9_M%_@F7]SQA6
MZKTDW^\DGA(&.IO:10X#I.B^^16\!3],'J@XZ;\PP,G3V(9L0L#<:*G"P_3K
MM-7+W$*W^<8IXWU?(UHM_A1FAE5.L6_FS,N?G0>EJ^(&%Y:0.9M.0VCQ J7*
M0\?FQOKF-K-W@@&9!-*#EI'M'I"/"YWB<.',0B<(6<5%I;TV<%2FPK3=8V6_
M";<O*/]E=$)+HCHY$L"4&,*J.,B6#G0C(,;""L5'X!?ZN?SK,&B98T><COP$
M%2SRTZ4V-:03?M9C<WEH:?//$J@%[M>?Q)[M6S$&RM^6=W+=!UL6;U;B5? [
M1U,/30G(HH^.H)'D0524F-I!\;H[8"_VA@:QG3C]/LHNBSS6[^/QN/3X4VAP
M4"#[;85KN^Z-ZL2/17#L\)[)G M77?K\":'>[%^_;D.BM %2LN#+*4T\A/J0
M@<[._-CI=B):V#-R^(=>3B#M/+/!<&Y7&P:9MYO[-<_^#M#;@WAP=@<@E7M!
MY<VQIVWSERA+"<%KH)N."MH*P3<G$H.PNQN<-)Q2+3UP 4[@F_!?BF5JGR>[
M&V=T4<WW-*X':J%\K54=F![? 0:K(E1_-E[27IX]Q73=R[=17IC(O-V+8+[5
MT-0-$,T&9*:RY0ZP=$F+%BJ-0O_"B-P!>APAB*6M4P4I>YK#S& @BEYTXEI"
M5Q-=I?4^*2F7(2U:.S[+>>ABYH)3]/[^OE-'M.A;*\\[P+;&]3'K-0X$17L'
M^. OA1:Z5WG/7>_["ZX#096E8FB.NVX?8@3O'\"TOFGITT7O5=HUASJ'&EDA
MR>#R(TG=MPD1%(&OLI1'I2!4IS.8'#3KCMT?RSEWU1JK\\N@"73XX6=6=._(
M'>"!U>[$/=&(Z"J"Y9!! =>L9*MW $0K_H %CG<-@B%W ^6J [L#L"U\+8Z_
ME-T(["""X?:QFLG*ZD!.&U_JQ:W3K)!O@UFW/F:>>F^1B.&"+)I,6-- MBP-
MM"M#UV/X=X G]^[O7K@#<$RHL=*CI?VAU=A_ I^6;$.V'Y(-0!X^Z1LI>WQ2
M_6W]@4)^GZ7])/K9YTT%5E1,Z!T@[Y2UPMR?E:]IW]"H#_+(50<7+E]91YYT
M<0>(7DI-ZE<E+'4KGH?\O7?T!Y"S:N']P\+O'<9OYPJ"YF%I)\M5#;:._5C9
M#E*,+=5""&R&NW-#LU5;&S[6_$3+_73Z!(GL(J]2Q^_#D#0R8V7T9W6L@; 9
M@BWV.5'BL$4SX2XRYX6;RB)'*9Q@GF-(FH<V5EAYY8N\2HD[ !)FOP5CC?R<
M<3MP!SCA50I".&T:1'P^%XD^JLR5>&]P\W)R.S0W'*]=::/I6'73E1S<IU\_
M[^(J82:EDB;,VYQZRWZ/KP@B><02)>>[U>8:TU6WGMBP'KGVN+9NMIT=>#N?
MX4E,8\A"?;:=.?J2FL+!92+=^)/4'8#PZ;$5_SW+^[D'[<(/?#4+)*/?KP5+
M]MV(PB)ON^HNY:<S*;?)6SX_7B)<;6J478B(W1QM(H_Y896^-K:N5E(94'!T
M,6.947.\*1XOSP3T-W [^UR4EM> <KX#N"UL3S3;HGK@>[+6[?/5>27&UK,$
MH.?/6"OU0;1HCK^B?V0N1A9W<Z45T;8M5O/%<4B7Y 7GB:2&!7VT9.O[Y \@
MQ @;Q#0=M)BGM=X*H0</[RW?&+QE_?M0HMKJ1D3H4 6$(H9LY(H-O@(16XU[
M0%)BLNX 5!(QS>&].@%!;?U9@39G9E&@0G$,):2>_?'F*9[I-7 BIK^KP$T4
MG>!:?=2SX<NZK]IOM'B(3*)TE'8MJ]A@'0Z_X4<+^I!(?<QOY_S6T=K<#$*A
M(S.0EO>L38%VE0SS K(DG?@I"O/Z#K!3S.R-(!508768ZZ3;5SB;D!\'/>"\
M'YNUIPK"8 /=SF6$[V9N9B*R54_JD+MGS!^:<;0#;^Q_"XI:8X1<'Q<IBV B
MBYH$%:A0 NJ#OP/9\Q=AF*"+7Y3KM08574)F.E;_&(P<(L=R'L&'87> IOM?
MA>IY\L4#U9&:2;*PW?@]Z8'40I-W02!/=FH)"*T"Y5KC'*IAJT-YPNKHD#X#
MI%VWF#3=F=TP=23HCG22#0CT.OMN@'E>><QR!\C1Z]F P?6:5C%*F)F!CCW6
MSQQ=G+L1"-?>D1)?:M37:I9NAV!VV20T'I=IU75>GZ\S LV 6*M)3#%'N9P\
MA\#9>ZJ+$2JXCB539HKXR%Q0H9_(C=\=(/,\GN4Q_+:QIP@SULF;%L4_D;\_
MF3>NWD/] Q]J1;?,S@ Z.J\VB_@C+.(U8G7[P*@Z:$D>EXXE;8KV%>C=5KD5
MM1FL;+UR?7<B!6(O$@MB\ :%64K$SFSB[H9R99D/-\TOH8VDGCPHH%5[&Y]A
M+7Z6V+#!"M>0/:5KZG>EAY8O.XG\Z,R*&F^-22'8I8A_8$Q<@[-!O&$7>PNT
M_<59%#"O&HF6PH]T/F%OY./,LFNV5=,3[4@TWGPVQ-M2^ME^[%Q:X +3WDK^
M\'>6FY>-[IFF=P"O<_TB&J,"I=+58_N_%MV^J@?4Z^GFVF/9%XP) ?QL,]#9
M Z7WM+FA"Y,V9%EL:6)['PU%RR"_*UWO^\S#J'3R_Z$$(T.(]19^06@@CNN,
M* %D5"/<)>?[DE8!87ZTV1!V W0CT'8J%$;?W2U/ZG38\!20'#M,S:E;W\JR
M]B9UJW;XM<!;(<>IW82<B_/CKLN2^C08:[UJ++!X^@ZPR0)/&/_!&HVC5?+K
M^JE*%AUL1RGLX+GL&^T:X(!J^9\[ $6@$;S-L&&A@:L)H=.6?CV];-6<8/BB
MX4-O*5,^F;"R'-:L9]8L@JSHI_P?:*"O4^6Z?1ZMR(>)Z$MF*:4&A)Z)0IM?
MM;;[0[:F^-M$8_IAWBQUK&6 * R?^D<9*LH,[IS>Y.Q7[FBZ%WJI95%9<9K?
ME:69PW#H?YRPJR[7A[V]D7K&0C8,Q@NRT[3D1=@-^']<)Y8SQTO= N$Q,ZD(
M>6N6-UO3&KMAOT"\.GE]M4:5?5&*5BU?KQY((C4Q/DQ]YMHN[[,U=S+4)!8B
MJ?%VG!#G]L@K7[5VRA+K!G30R=V&R"VUA0#GYBIS<V-*5Q2*1"H+9@/[4HG"
M?&S%-(B=-ZBI3R_^>0;V&OB'LWFJ6N\%:22MM,*PHQ;_FJRSS)JTKDT\6V_)
M/5MW^1?!0YR1\@><*!TQ+F2*]ZEOAS0_]*KUJM)QY#[Z4G.!+@_NJ3O#?.'_
MF3P#-D_26,R,] K!6*#BAA6*>RUBTS5N$CSS&A$'3AERY6[+4&J?^O%HK,MW
M>&PW%TLAI_R$GP][XKC+;B("^?6E%6D@7X4,""E4XSI:Y.0XL9GQ46(#MSC"
M2U-'QD_&ZW'2D%/1]Y#'2_;S-  B)X$ -]#>9_ZN7P8=/]!9IGQ8HI?H/]T*
M%_4Z#YQ9PN+UIOY[(I%;Z)_CO%NYPC-?MUC[3;PT;ZI9]J^=Z]?M-'-(+_9]
M.+2Y;>E3:"F'U7CSF@D&9//4X:X158&<[^:%J@YD=K+.B0[."*ML+O6%L=QG
M&,_Z\KX@DAAO*R^)-!4W?GL3C1"9T5>Y^"986;9-'S.GLQFY-^"I,WG6!TV=
M4PZ97EB%)#GP]@815KS[F3X9$]@T(V+7WL0Y!FFY#]'M[MEGZ#W.?"KBGMOO
M0 'GQ\&LYEHE0:&#<?5S>BZC['.%?6'8 )C#4WR.]IE!TZ9(6AA->R E[#[&
M1F0X%QX0*GS.:D\="7";KYA'ECL:YQO_Y/JE6Q]!SYW569Q"E<$X9<4L1;P5
M$4,=APO(W=#AA-TP:W"6.T@BEQ)&NXB+4M5EQD9G6L*/M9Q\;$W>\>ZLLM6=
M*X("2UQ,RO^ 0A88<M9[<T@M#$YL6Q3 B9JC?ZM=>#^9U=FEO.003QW:R'7J
M.+/A&ZKQD?1HWMBKIKH&G(V(_'V:H(^!.D%N!5(Z7K77CF!>V=P'M1K3]3N
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MY%,2,&:8:XN2 PNOO ?,=32XI?1BG61?!EB1/L]@FY/6GM"RU=2D-I54^A#
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MT,$:K^XE[.11=M_*BUWR3B_T8?NTGTOS10B:F!BAK:/"T\S)6,B)?9*/G;I
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MD/7J%?L0AOO05EO8M."-@_:0[^L!QJ::='S7;OX0.<WI)S[AO?4H#YB=_-D
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MTM\#W@AQQ0BK>5UAGY2_AK?W'#Z&C0<[.=:^SA-H<2"C<&D0^+"I C#NGLX
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MK9D?N=SJ85!25N172/(!]6F\\VK:XK7=-;HDN!<-XGX3!N1\OTI!'@=)T?*
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M&>L**D3!X9/%[0CW.U(UQ+ZN7[OV=(VU97U[]&:<+TNL/%267(_!E-3T"I"
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M'>L3C%K*G'0:-^X!U" N1/%X1U.5W6("FF$:7X;AJ?[(G)>QE5G)UI.T2SQ
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MH?S5 /\QH_^A#/^[ _!UY'=02P,$%     @ ST-P7([MDEO!$@$ SS4! !@
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MBRTX%B'P6E)D[6 Z(9-QS%_VB\ET+A@^2K;J\=8QEHQ!FR#V=P<U#/_;K_?
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M>=THO8OR/..#,Z\_/JU;,&/M+$:FI5E:Z:,0?7NI9P14G/6RZS=.-J HS<J
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M_ZNF8+"9\=O&7<&,H4T24+H[45OHMBWHY[[VTF 7]=^H>\^HIJ)U;70I8D-
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M0'=OM%S9G"3$)&ZBO:+<^)4X;>T[)^%U"<N$=%/-/ ZZG9/ Y))3?,RFQ_H
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M^H$Q:3F!\X2F:1(0/S5HXP7^:"X=C5DR;1R'-PBRX8XX%,TV!P3$-)U<G=\
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M@$8#+X5L$SVC'"0!'^A( );>_Z*SMG.;B]KMYQ?H@C9^T":[T0\T-8C^5OF
MTNVEZ0<*T[YKBUZHLLG9-BB$LK\Q4I*.VV=9]6N/^B,&VL\Y6$&.[P'.;$R>
M844LT_Z2)."NX[WLG]O_U\JT?9<I)%$'U04]I@:=L:)*4=^"QERKD57(F#'Z
M!JA=P@<E%LWR1J[S?A!6M&^AZP(\C/^A"?X@5>/!4,57Q3CIQ7TG?C0WI/=M
M=:V9TU(ZW^?*"G5-AF]1V1GI):SY%5W33B>23YM?KQ1<Z93;_'W9=>OC,-(^
M_KEQ?#TH/>N^NF;'9 8,9H9_\C< G-/E6CHQC0OM7ZJL'!$2X5:O.:B;$%ZZ
M1"_SXX"R5B%F>S3:'TN/^V;_'N)GG.?N3C'9FV_1E'MLH'9)_)>/]'?].U3G
M-1COV[YR>\Z>6Y.P(R7W]N2Y6Y$=^Q"O%SAO\ZH8AE [WA]YB=E@L9_W?ZV^
MJA4C"ZZ]BO/:[^S5:*S TJZSVD5+I3J9/(/7#H]/S4F%+Y#?:M8=9<M]_J4K
MH7%YL5'4\=09S8A*'M3C0PVLC?J3]]N/QNL<!8I"0'O*Z<(V?0&J2[ OS;=&
MGR'.EBQK\K>*6_SK!?_D)I!?^?M4]8IGR[.NZO+91B?@?3TH_$CGJH[:MN@;
M1*#ZN+9@/K.-I+B-'WLPBBP#/H?;-/5HXD*7?Y3JHR[:D-Z7VG[?5UEZU2(_
MD;X^OFZBY^FUJ(6%U::&"XNP2+'984]'%$U6V*!T&QOY;-J_;]T6E_L^G0CB
M=KOVO3MZ.M7+F_U0OKE?33W%^_3=L!67?YIC&/Q;VB:\UT7&FXD?86$^UY I
M"<FD:S18U!$]!QF,K=36V- D+ZO%N[.&1/7>+730*@28A-0%<S"#$<K< 8^P
M(:MED'(6N(75W2<-]<@DR<^F=Z_X+%-)2_J\O/F+.^%ORIF>UEB>7J0U&QS#
M6/;J:A3Q[BA7.^.O.?6O,Q*Z_6SR9.=#RXDT+V^77WWH"TO%7X*634.4)8,?
MU?X-Z9]MC.N&E/'J'1>VM_2T\[U@>6\HS<5"T:E+KB8_5'+#;42K%Y9:4^\
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M$,&E8@;1\QV]#?,XNQWJECGU1#[\@8:M\J\J67>W(9KS(<;6#]@#=D_'?9:
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MM<W:H%%M3I N+"AB[YTP/C(:_"1P%;)"@QZ7<;DG2Q;">]FP1A&Y&,#)%K:
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M@_[T+VJ*YMU=ZQ#,:RZHG>&0-;>,M)IN?N?K[[6&\T)Q80Y^LYH$!UTG#I
M!H]\9 UVE 304R40\I-'WBJP2"D4+L.C9=Z9IGOOZE]=$OHQ<*#"!3-:.0@:
M(MZ0UXN L[%%:U@$M\G_&I+B'3KLC>RV:7@096 332%K<'?EVVTJ-Q]8[ZQ
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MF[@XS'!;FS5;)<JCJ['F$V3R7>X(W"P+DO>;DCVG=\E&Y!%7:V]4C;MU;'D
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MSF =:[Z+RV]3&7*:6CW;5?E 71^)U^VJ_-BM/-9HPQJ$75AT-8UJ56[I6H1
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MZG&<>/&6^>.Z%./*T0V(ABZQ$=N*6Q1WZD_CUY^#+3?\Z5YR&:I?.Z6>L)C
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M_'*%LPQD;_ 4^_Y4@T].?G+'+/2EHV4:M<C[BK!:VT"5.PGWZWGOS'9Y91
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M&R\.VV-GV@8VDU@V[=K#0GQ)>AZX/;AW,FZW6'46+#8<(2DO%MD)LU7[7M!
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MO ?3!>^L? _O[-'F5>&JHS.^= C&7W3) H3;ZM^EIOAG.OX$UQ<SV%$\!/-
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MQLK?!EL.;'U* (S0]Q  )-H$ $9_%_@?R7* RYNP$PW880L!,#=Q7,WF&5;
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M&ZU.#5CC50I(*86=&\6RL[>,R6PGC8"53D,BT?Y/4JX'%BY>)?*\:'"X+)M
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M,FV-54?2JNPC\[[!.T1##ZV"3P AEHO.\FB$[7+]7SX2_L4<,BH).4C"B:U
MZ.4=I"'AT)LT.'M:O63A*#62\J[H!9#5:GRQ@:U1[^W0I19+31R91A$84M,X
MT5]5USCN'6#NJ351>3SLW_,153Y45/(B=V7?0-I,A(=]G9E*Z;-YYMXU@$@)
M@3T*QYW+KZG\1^&@/$L8Y./FS,3X@VG35X':?TJ1#VPTO[J^#..@R/AV#2@C
MD+WT<3WWM8^*")H(HDLW%O>I8]R[BIRR&<^9*8>=.A-5?JZN;5)/@"[%I/^D
MVJ=?3KLQS!G%WR.YN1R>52MCP8V2"*^55>_R1V)"#=53D>/'\WI0E1 ZXB,A
MV][.1II$!<'/=/G^45C5B4<85^$XP9[ID:BT@&U3W=LU,-5/7_V (6R V$)F
M]#_T"_U;_?SPP!"4!RC''']9?MX*M8)6;U#8*(\4D' 97>JZ5S])V.I747^I
MO_S+TEP\/5NKW*0^XMC\$9.1P)"O.,IB3L$-O#AYQT\KS0<XE\LN[J9VH]Q%
MX7]PM/_DHN>5W6RU2NE.01RUZ$<)Q<9S6VV\2=U]!K636;OB^7DOZTTCU;,R
M8B(8/M\W'\QHK-2_8<V"$JM+Z8[>$++%];-Z-5M[ZW>4B0&IOZBI;K%[&7!6
M 0!J#Z/9FZ7_F6_^7O0]C:=<!/&*0DAV)')-$-SCKGN;M50+CH=*]Z3Y^269
MFB@5;/GH0T C4VPPB? "]!UHYIQ=(]FG_;PYI;IFP0^F1!73J> ?E_4> P/T
M1;HJ^/^"ZOC?H@K^C3HZS80A*BH$3J[XM7_T10JWR))7TF9N%<#&%]5HGC P
M1"X-1)%8O_,,5I!VPD5>ON@DCV\VKDZ[-&]&$U3F;37)?7*Q:6B,&ME6'4HW
M1MW.>>!KIW\G7*-#QX;.ONT:T*7C?0V06;T&M&EA_M,^S(0_R/CE@Y50F.GC
M@HR'QGEUF4O[]TA/)WM[;*+T7/2G/^ '<;"'6A@6X:;$&0MJ5DI=28T61PM!
MH7#>?*4RRU\_ZWS'\%.& XP5 :H.",=W8>8]-U?_L*OTW]H5T<T&V\SR7&5A
MW#_MO098S@CM[GLS18"?%3XQ$K1J (%G5#Y_?OJUP\[N003]U@0F]#0$M1ES
MNF-O6X;YE#=I-?.(42SRZ]SL3R*U?/QBIF!.]L%OS,(TQG=F=]O_/?I%(?]1
M:T3,SDT"HPN'162G:$W65M(\O[#Q'TIR,+#P5[1GYWID-90=1@SGVW^/UZ-8
M%C2.HYTD%79T+MVI*U0/-6EHFGC?\F=/8!._3[0EK).XCYCA!]&_I![[OTL]
M:ZR\5]^Q3U:!FKC)W::V<MH4?$.3VOUD&_O0UU%*2['/?G*L/Q@HLKNK2'F+
MH.F !G.@C(*$NH!U(![#N=W$KSEK8PL<%9.-9L2TU45J^(I8U(EO0-V'_$=7
M=?A/";N2N/6J4$8PQS&3LPD!V_/M]L0$S2U='';K5<VZ 0M3!N) 736$&JL?
M.G_R*8OT:-'M\:[R![A2J94KEF*L@.0#+*^0".,?#H70.7N'U43..]$'":_N
ML(EC>;5!-^5CU.5ORT,+?\<RLQ#8'0V]\33G7/,_=3Z9;.%ZB?.&-<X!ZZG[
M+ 1!'F%//ZC.9Z6[<;,7#4RW.WY"M</;(RZ$&E?W7E!0@-1?3U;&%;I2-WJZ
M'96ZL-HORIG@=XP./G(_'+]QX''+O[7J%]#!FFL8CL5R1[RILUEEPDL<33;9
M?=>;-N<-59],W>KD9*O'!&XZB#'J$->'HSJ@%2]TM&JJFNR-Z_(3/5W$04N,
MK![KA="']^/9_8N6V?+_!&'J:8@C!?&<8,T6-&TT$IGT*M0TTYQ$R_D3K#I5
MO4>TD(-IZLG=YF^?.(7NF$^VR8)<+=&:&=\='CM9/(1>=,WKJ0\__:7F!/5E
M:BE>>M%Q1]H_<!]$2!9R(_;MWX-;VM=.?YQUR]G-X=!QKJV^5,WV4<Z,B5A1
MIFJY3@BL$JH3VP>X;;2RPLR(=)5W''069EZ<[<S=-KFA?,O=T"#VFA2E21OH
MBB*_^J::T*:^/G'5N[OD:F_QW@;?!,RQY=\Y,!)A":/]X%YDY'C!E5E<L>#$
M^%)J@8Y6/'UOK>8KFY ???4JB($M(/-69Z]X^N5KQP0,I-MN1WWZ9,]3&[51
M&5'Q$(7[.LQHVD\O*,2"4R*45+9:"):@=+BA!G^$_TGVG5^>,U2:E'F!N+?0
MR?UQ'RQM7>98W4E2NW&,$)%2(E7+ROAV9^Z#9Z*:)#,0U'P:,@YF<H?<'PE'
M\G?FS_9 2OO?%4:^48^<^B'"TLW)(V @NW[KF_4_<L,>V]]Z43AF\!2*R@HU
MU7DT;XP0A)7+R;YYTS3^GG%34&[II3#3:P5\VN>F#OB?SB-(AN6-K_)DGN0U
M& EXE]OW3[Z=/AA)MK)G!)8-6$AD$8;QE<W3>:[8N]SEO-%T_I_%JS3:%[Y'
MTME.=M#B[2V]B/&?^.E$$,!%+?KY\UT;!H:?["=E69%LS"T2J*H3[YE/6U(6
MX<(10G+#=R''1AM&\ZX<PHWAK!E_;L3,M/\3,3PH[MYRBKXF;!.GN$E;;$FT
MV%1V[4R9R?3^'D-=)++_F=D*I=M@HR_/SPI+@ZN<[ZB^GE%ZC*?%1(7H*"G(
M4Z%NAAN1@??P/%Y2.MAC7BOQ_NUB.V W7@ST)OU= _[.?398[V)&<S$(N'"V
M>$89QM?LDG[JP63M#@=0L*=NI<#H_$&PU?<P1=YWC<I*MF -M!9<D'K'K&6<
M [49N9I!IT%760**M/EJT1]N'XFO^_V3]L.-!7'U&-[.?P3I^[^-EK:WZ/H]
M8:2Y\.IHL(Q:#H;Z-XY/];@T?2=6K6[>T7UQF,9.?,-$#>+O5B+98=>QL@]6
MP8Q7@-21G&D:W_QU'>L47XN86J@\:)Z20[BALFJJ?]X^#_#PB,_,$C;Y1U&C
M^+NB=B0<UB:=CL0W*2BFK],@VC>1??#E<=KFHIQRP_M,G84G+P #P/<97<TF
M_[V)_O_1_?M[MB)SW1P AK$G?9I*ZOK'!^>$\Q $%^Y%F8'=_SI&[__3TEZZ
M!O3=\.:3X?9D#9U1!B@1)3.M;J,<,EA2BM\91^5X#?@-@Y2SH:*UK@&RN5?.
MZKG2(K11<S<*FD#.]]AV5+ /)Z\!HS<A82(4,M234]>^2IN%"U"YN&%!=V'7
M@*,Y^9GH[)HG#N65&*7"&SW'<3!(EZ \]C3^).>/P)#)7TEQ:"+Y9T(JO[4]
M -.A+;Y[HU6T)KTTZ,QJT'. M+9<SXWA_"27'T#>'RE& ^>1L/C4>,W:$_E_
MOUO^7S?G16N?")KON/ATT$6#&BZOR$ V-P"!>WGA<*66THWXMQZ[+:4_=!4]
MP]A7$ E&8!)T>7RXM^4/TSYK?*FEU-(M5OKVF?Q6U:"AC<+;JYV\FS;OE/5]
M*-[$5\C_I?IRK]"$79#(H(>-:(.F.;M8UQ)+3+C2]'NOW^V"C)T.AD-JG$1G
M<43T^!ZR?/'P4?(=\8L<4"X<;>PHU1[1HK,ZSR_(./-'LXO)N7P^^JVKAXW/
M ^7;'PXLW]WP@?^)98DAA+Q<C.S%"&Y[IG?S8NBFT4H#'"HTO*M[PF 6U["C
M-&:<]1 C?&H]#::?N;B%\OU4.ZCJO>6*@%]DP,NN 3;.=0W:,Z7U$B0-/,!.
M#SSF-4(8QF^%(M*20G18HE/*><L'QU*-<!%.A\N]]=N<W&B"KL]??2O +QPZ
M'/P-L T?ME3[M\WD_IM)Z13LP!_L4=(].F Y5'NX6-8=AR#V^!<2T"T9*7B=
M;RXX'9E)\A'0>Y=3U,:>G7+A[:5KUP'A#B-%5P9_=QO_%'E-27YIIZ_'(8,Z
MO\@[DGKA6H8W[AMUZR>5NG_C'1@YQ.D+S$V'=7?JL5;1UC5@#B$UL&4X6=87
M3TH" L:\<D]Z$,<=V"KQRJ]2%:W5<7"?C0;3;3HA^)Y;/9[>08Y]LFSI]\ 1
M<+=<<!7ZU.=S[-<L5YU@*;NVHK\2:'(G]>A1/<H0/E?8!6%QX&7YYI]9OX:/
M (Z-'I*X0X#/%GZMUKW$^J_---_D[S:*%G3])\%=0;!\'BB-JSG.-%9:/WE%
MF'YTF'005Z'MIDBI@N_^+=[LKT3YWD!9N3H:NB0Y)EI)IJDC3)Z,[!=S!K*>
M&0:D5$\N376NDZ3>>GK?SN\9#C<&NA_.W3$:T537O#K?:D5_PJ*H@98Q*5^J
M\:X<?JCUO@9*<J=@G/GE \L4O/UOU)K.NUI_%9ZC7XZS/K93"ATO8UYZRTJK
MP<948@K1##/L;<+\IF0*%<@(Q9I(HE]$B\$B2]6U\;,I)BDF8RU*XLD%H$2@
MB"&:-/&/KZ\R3>:D=LL1,H$+;SU9_)$"_8.O-M99/R!_&2DRT:O<P?FH^@^5
MHO-7]U10Z_5G$O?ZWV6G/.FM9B:;>#:4N-?[^Y:"+(UA$@:R<@V  [E5,6HK
M_>]%[5 ''\0BA#AG#%#GB+JQ;E&=^^'V/R]M=#NJUMT[*\O_6IZ<6.BI+UHV
M)1@KG+L,TE)&N(K.\S<DXB:-TC6G! H3M]7TRN$0_X<5>16W2*4WRQ:"1C)Y
M)FM!M8%O5,;;'CFE9++^F'05$C/MJW6H!(XGYW/R'G$$SG*$#21AS0)#_UU6
M_+_A:WXG]= P*N@N:&E3$I8>P,342BQ/8;I5QQB47F;FZ.^3[E7497 I99L?
MD]BL*$))QUI0<P/M-:"GGO4>:B131BQOM-RQC:%F8J]%H7!'9 M11^>NK!_=
MY"[ZX,=  P[%OMG6^W?!<:!WE79R)=W#*C3%UIW)AOD@'YE;^V5YQU?7]"IQ
M2]"Z/F4XEO# RI5'DEAA(T5VYU<;-T:^1V*9T+(;1]Q:/U[[<ZTVDG%\N)I>
M5Q6+R0$_"P>_^E/>;][Q.P91!?G+\']3'C2<*8K@1)>-.?JDF4G-1!9NG=8A
M3-811T1OV^_]G!CFX=Y\X4;'L<'27ZF 0:#XS3$):QJ&!I,5@H+!XZ*87=;5
M2(,VV)0&,B^* %QW2R_A9_]:U(7A7]>-#AF255=F2ZS/M(P[,I!#8UQT%OR,
M(!;HZ!AX6@R&-R8:V .C'H-'GFQM:WA:WL<18"I[61]A?GAUOA60L5U=?#HP
MMX_T*)C;'E!/N?N'X)5\9JZ;S%N4\_9?!TA\&Q>6!9.*=CE"DN<&YF\Q\LZT
MW%UBFMQ]HW,TL,@4]@46OQ'_9;_W^0K/&B>BR/D:0.8=J()$1(&5 /6XD2DP
M'6NH:]-K^3F#@%1R94GS&FYY"\E*][^QW[G*:F579<3RG>-HAV,-816$D#<%
MR9\+6^2BY5>EV).,PMG9MC6_'_6$>(0;,N %K^6:]HX,Q97D!:CG8D^1D<)J
M+)URV%Z0(=3YC8^=5597WLC7=5SRL<I?5\A12Y8V^NT@*01LODB&*Q\4-4?R
M[&'4GK<:K%5SQ*,C)(7J).+#P ISD<QQ41L#F!,-":L08\"JE2A6.$G(44T>
M.XI1_P:?Z3 E<8@KNU].G<=SXR=8*OVUFZRADE9^1\@P )W2(FH7Z8)A\>1L
M?.;+6S[H@>K3RU3OSH,M38P6*L 2Y7"S5YA2Q5L4;>KJS&'^(B[Y]D_./C;/
M37K9*_X_HW]IIEC;JR3O8<W!KK.)8=="3&'7$L7D>R]S9::PAPC].H^A5VMD
M]R@6$Q4&FC_$3(]&+M]MXP&KIO1T:]?6MY@[JT4MOPK&A#D["[*^<:+V!G'H
MG,8,V;@-?PLI/?Q@:?G7"G$C?=LQTKG@MY-EPF!Y7]]2D/^$AN;RFRF-ECG@
MP):S\^&#UPN].]1??@7AUM?JIN-WU\J,MPUQ[.%=C,+1Z? FUB\%9"[H/=/7
MS?75<;/)7<5'#_DBX'@-E&NM@0'%8+Z)VHQ7")TIT6&A2^V;)!,?T)RNEV@4
M@(W32\:2.?U;,<Z_L60D5@VCX;O&-HLPP@2^]=I[BMM1PHU^-'TY/MO#KA!<
MHOZT+^%#/[L_(@0W:4&/WB]>R8J2$T?+I10X-%EA91K&D=6P-HFG)*%NB370
M7[F.>'B3KNULGO^J>,E%_ >.Z5W[ZO:XF=,1;U[!5KB5ZOJ;J:>?%5A[,\:,
M,[E7LX@P?7#(?=@R/:BZ6V/\P;AH=.S3B5&M)@E!=X'#EQ,#0_H^V93L^NM8
M^#=#;G3HBF$DV&\-PCA:*/;-WS<"^^R=-=GZ)/.<A;&YECLKINJH=U.?D) =
MK^_51>A?)X).&,5=S&!/%IV7/".F4G.R19;@0][B3>JA-;3;VW_4"#(Q9CCE
MT=-Q^6[(P!4IN66&Z(TGP*J@1^'IJJ/A[V644 BM#X_BE8%&)A '"WOI_1HF
MVC@9LJHX(LXZMSN!LG^3VI$0.AFZ2NQKC&'!UH]9DZVYT=.PE$#97#.7*"JR
M*9%7T>PZS<0QA'@R7N6544MWDWJ;! SJQ*&*VFGZ=8&:7I9R(].C!W.TO8I?
M!F*H!O'F6M7_6KU-(-Z*9M5WL%/US.Y>V7M14Y97ICU3["EG1\;BF8)6DS$!
MH%C.VPHCRY_?WO:0Q?W?X.7_=>0_0/,:\#FP_LK#<IVO1\F9*F2.OA\_YPYG
M #&T1O2__#_LU5KTVC4 8^S/Y$B]9=TIIRB4DS0/;3PBL;GO^MC]4Y]"O8]J
MDF3\CREO?@W6KLT+W#83$[_#G/&^BPU5'S7/H,@3=AZ\1*W;C8),:_;!8 5(
M@;'CDO"$T($W#W;0U&%_<LC],X#_6REUQYWW3SH[SC4!SRJCYD8C'F&J4+^[
M_%4BA5M$K,L52D;]W LZG3GW@1-X] 1(!CW2G[-=ZQ<(WM6#.<TSA8F30&Z+
M21<9K4J0"_"UD^&<E=+M?FO[IWVG=<IO97J-[WDY8IV%QK(!4J.Q;AAF4%(7
MG1S7E/>P/)PRNC,WBX)K;5&JNN_T&U>U]'V 2J+R'5JV6RUX2&$21V?;=\7&
MLTP!$;-#*>(I$@EF@YL+@F.!U?+I[$M(A41XYO&M2/=+2XQ<GQ&Z/&/]Z6S?
MJBF1-U-!0V-]W.KJRT\?0V;S[@EH_2[H?W4.'!WBMUQ=WA-9A43*X:-=(V$%
M<=MLI(02X[\L39=R@<&:^)Y=>TP;FI(N])3N4>%]\J1M=%N&4IFYR.;>QV1R
M^ZZ[EU?*QE:P.N\XZ<BWP54\<BM<!#0_>I_RUTP$,3B<6M!,'XLW3IVHLUB)
MQVV;JVM#D8;*$2K!^_"B7X"NM<9MM6P*N1]717LG9,K+2EJ$3FL]="%SZBST
MPRX6FPQ[FPW&X.%+RKM[&S^MR)\S[]_W737L"SB(LJ0Z:15'*%_*AV6C<!FE
MLV8#+Q;4! [<$CEBUP'E!!WB<3HCJK;EPUJG8%10(3CE&F#?6C.%#)NX*[Q[
M8!,&HEUZ9A4_Z.91.)BIYWI ^*P\BPC+@UK^<.)02T8[OFNG(43&9O6Z5[S^
MTSKHC%=2@-&1?*U_P<,!KP\K>&DNB1*LJT):DIKE+[9^:ZJH]NJ-Z2G\1=(/
M3/1@?#&,*U'FRZOC\(P+J>:^JL/*HD9?U%JR6#Z_^%:S[4M-VU0'LZT)P9EZ
M/^GC^)[YO!CN3N#S"]3/<"(=/YO546\P-J]F"P)2RNB:1L_B^SX6ZVP0/ZR
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M&GD!AP^OT,W%SV;KKKYZ<;4T-[;->)OK.H]2"D=49&[D$CCV?FWR?# 7NN&
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M/P2DZ#3^/'7?@(/BC3W_?3[%Y&[)IX%T3N/IQI]HRIYP*1^ZX'#AAL..*1U
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M,KK-C31'A&IJ:^/J@D7WA5,K+@49VTR<G=J"$5QZ01(MXLL@-ET9]Q;!070
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MKEH>W/V/,G$L[S=HE<S^IN)_.2K^G?/^)MK?1/M_E&AIF-D\L# $1#PWG&0
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M9?L3HZ[>E4X5R^;OZ;Z.19$G22$1G2UL!--$3SQ[,^@6(;8VU61T'6=X+T7
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M5K1+</GL)W;6KU<R'V7YCG@TKQ3N)_YX[,>]X5.U0EY?U \K-M9YKT.UE^D
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MF[^4H]L_6!#\MBUJUU!C-[WJYG-GD=JI(63&ZMZ+MU\4$B8]E+/VP= 1DJ?
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MM.7ELR^M1IU9]ZX'^S+859QG%Z31H%F<H^3AQD6HPGU>AJ IU1FVMZ=7&"\
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M4.@TVE_B_ BHJ7>Z\?6MMWJ:\A&!];?5I>.9_&VJMH.!MKT:?=V[M^5M(!>
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MLOKI78'.&MLW-(C/F7$]B,JPNU>HT)S SMR<-^'*\A06 Z6!@=KH5#'K)^W
M.MO-\C5!6=N)0;F2^X$%,[D6=A3XW]J.;DPR#"'5U!/TQO>^+DA8Q3^<4(0
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M*MR+RRW^9?G(4EX,KXA21/[QQ(;!P1]'@H)%5"BZ:?-%=15PG8;]C'?BAB\
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MWUJR,-CW! ;2:\\O)C@!IL^BA3Y_.5J)75.PM)7XR;>\UFH<K3$01?B):!=
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M2K.HY_4;_&D?)&=-N]>TCVJ B0=',B"R.JNI$"TA)ER'3+46Q@X*<81[<G<
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MP9-6X!ZI8B-%;?6*K.OG&-,!$LKWV/;C9N>^5RH!TC4)FDG;!LTQXD,S.DS
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M1X>=E#?E%QRK]\Y L#/+;D-E1/5-3M&*T;?%.D?^O%7F&6AJGM!G'W+Q^'X
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M/^>LFAPP?$D.R1OEV!3@)OB)K,N]P>7\!!\WFTN9@K8[.[)C +]&7)=N.>X
M6.,%X]5&P!7(1!F/BZN .F]EOK]]Y/%/\FXS(//-#N=1QXY'Q9MWX?CZ@G>
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MCYV?^OH'!H>&1T;'</B9;[/?Y^87?A!7U]8W-K=(VSN_]*(#Z.G^]?A'O;A
MO?8Q,- S,/W2BVZ?[Z\;N!@8#Y_<SWW>F.G6?9XCIQXS\UZ(SRQI8A$_?8W
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MXJA$&KF[_Y',C,Q*! W@72GC[5O'B,E51E\[>LW ,D#J-,-23E?(@<<5]+5
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M$XE?J>9**+1]VV0 Z? /4[[N_\(D^7_CO)C3MXMG \/ZOLY#,94FKV0:$&F
MDCY( ]+%!FC ?WL6;LB@CJ.%E6+MA[[.X0TJXCUE\/J+7X[TM+'.2#Z7+#VY
MT'M>8MIX24()?2NM4K8!L@:S<,9TL]F-0?%9"+M!!(\O49FR7%BJNL@UG^I]
M7\OU*4M.NK:S'IVY!. W[:/8M3+&A)_NE9=X3T+#=]X2%N'Y4X+KHF?ME>VO
M9:G<XCIB)^LY[=[=E;ZAT;EU#EG^UNVGOO[FPAKL8A[F*V8T=W.0%/H6'M)F
M7J\R\%/-(MOE'!M6/LW%Y8Z[C-YF@?-C'3:Q[VPR.#9$Z_2^^W8V@5U8,<BR
M("&]JVTYJS/SRJH?]UCG\4ML$3,/[S3)'DB9/F-V:/\8/?O<T2K5TPUL46&G
MT.5O4FV=BGJU^9AN/BNW7*'XY%)\:,"H4&$/G3:OT6_M$J>+:W(B#1##T ";
M[S2@MTA3P#DK"CBZIQT[YEJ.W=E5V/F!7+?J84P]FA7$^J^-"(U)@;*,MR>_
MAW]JQV^9]LL5_52X4R8@Q>:O\^%+C2L;&P.<H;<F_ZLH[^L80#C6WP>Q1KS=
M&"B?U@KCG>Y%G-M9SD61E=RRQJ<ZO-CO+_0?GV@1MV81M?K$\N ]1/:LJL-!
MAI@@MS(L2]K,@RD:X#2A$A66NZFP#%1*&PAEE"_$4-#+2*=MM<EZ1^SD"E5H
MB2H,QS2.O:F<$:5O&MX<3JG6>+-2K.LF<_EPW:L7W\SL+V&KE+\Q?1/WV'_2
MUO@6H:MM4R">!-ME=?$N)_;!LZG<MWTAB9OG3U0?JT2F?=\.Z1PO]9CR?5B\
MID7@K\L@S>#5A\,S^Q'J_#F>;]XD^GHYRKO3M[_?;BO")TL=$EBH.V5U5JUG
MOV[; I6G<Z;+ F%WZWY P<*[T2Y_I8P/RD,$I:_NG!DE)V+Q/-FU]O=^A#K<
M$_CN.EY+BB1LV9#2LL9MRC#%+K[#CVS3WG;ROG56"/QJB1^4Q*L\NQAW^>5,
MUSV-.T=J5SJ@G-3#-*#M4Q_V<@719AA5)F.@L.MI<+VDK.2EQ-":VE,#U8_Q
MA0\*\[ER) KB.$]G$Q6:Q.1)L?ANR+A"V(IW9YGZY3N50Y(#F55]8YW+.4\F
M_"0B&;LDVC2Y@I]42,B\:A2&,OX,Y$$)?%$)+I2_NR%JV:[?Q19=7LT_;'8D
MH._5F2M7[C=]_Q37"5S4<+AR/?A-G2%8RE8E%VG )J0*#"9W6W$"#VXN6HT/
M [_ZI:SHMF:?(HJ#!CBZ(<?.54]9NJJX?,NI&6N7"(AZ+*U:H;7Z,;J,!D J
MX5CJQ3HDM6D+NB.71X]O8"(A-Y4]69S#J#;0Y?9V>HW%70*B6\[7"1+W8<$*
M2HBCMJ'7AG5H0%-8)FB1X<YZ*"4R4,E5B#/-QW/ZA42POW-.+ THN]L^>X=!
M1+"T9RB<?**[ [+#!5;=IB0T&/_%/V_0 !@><1H344,#;MN1Z#6R:, 3WTU9
M,'=5JU#9E2!4>11)%VG?O;V8C9QN,:(!^,59+.D6.@ZZ+JY' T)D8%1UW;W]
M9B?#NDF)RT3H^OX&POX L#(SKRQ9T !U;T_R05<HV>9WZ;L:""TP$=B\#C@O
M]YLAR8]0>P>11:*)$$\0_64HT8"@TS\4]L@U_YOD]39@I1 DX6C !44TZ50I
MF,@'D"WLY'M@(A<R) N"$A%_G+U-I@$1_@A="AV&3(<V1C:K[O(CNVV$03F$
MPFF @"Y9O*'$B;S1VT"XE8<D^JRN_*8N]:#33#B%N0\Y_:F;!J",NZ!S9*UQ
M/&R> SG-OA--Y<*.E%(?S6-))P9@I&H83I02#9LK!IT3PJ%% Z(Q*4A<6. 9
M9$^L-)6]$*P8&] ]QHC[PT]B6"X:H.E& P"G_@+<RDC+\E7V:EA2R7T:P,-&
M_7"6"LO1_\W4B#+8K978=BTH^="J)W 2.F86P D^(%<7"_O?+_: W5[']_XN
M,!B*[*>)+=0G+C#"'2<:T)'WNQL?=&S3@ .;)-0._7]MU(97MB)[A&A H^"&
MP![']XZ3I2B)/%=*!@\9"-K7=HSRJSNN+//<^7R[*\+@N_*- R?JM!$^>X4O
M6%!X@BU%MZ(8K>&^YD2!<-GR<77YOB]RBGF'WH?M?)V5YQLE]Y!N1G]_->5H
M!_\4\O)*@I4^\9SS]8)K9NE\"KOW-I!"XV0V0IF[$QYY8*PE$]M8831. UPF
M2IPJ[25U4E7D+_^,.77:X<"I<R9DR5UI:C?T  +FAIG7X*\8+$O[0C7X9AG[
M<U2Y1OSVJ9 6&4ASO27I[2XO0J^NSSNYGRQPRQ</*YM4FOT:[LNK''OW\C9K
MLXN68F9MWPU(]4<61X;AS!L(=DI&&204N]_;CFW2&NY3YK^8,K1T9# #==,/
M8R,2+QRL?"GD[#./A%.W)-DXS]UX=..2DI9^!;; O7(KO?4^7RF[H?RIJ#+[
M!'=O,SV;31O( Q 8V2L$/]QQGR@AB4G&'WYH0LGT;0)FJ):#:-(M;#!T_4@;
MZ"CA;JJZ[9?\_4*BTQXWK#0>>'WM-_^Q/3OQ<R==F!J@^U,W%-G"23X 3FA^
M!?+!*23Q!PP7'LB,[(D6H+)[PD@;_D6\7EU5 89@ M;(WA)O;OC[93!B&QA@
M\]H@IMRO@B8_JAN*.CL[H9$;1@/0QKOQ.+L]UU%[95O4%EG]"35I07;G43X2
M,'LN@S&VT@3&F#T88[%SOQ"'3U:<GR_D+:YA;B#P&]Q\[W4PE?A.@W.R!#G=
MO@;.2?/J7EVUFO ! G;M!^R!FLR>R]=9=@^0N57Z=1 <_&VQ!R'+;/6O*Y"S
MF'<81#Z(6S]>GJ%^T"5/_77(W/_%(4& RJY*T*(^N=% N.WW*\ GG;/3;5I^
MP#VW-Z ?Q/CV7L^#OEMI.H#\IO,_L/%LM><2;AK%L6 WNL/_2N.5J\>15YG^
MNVD15)VO^_3%CW_C9@%$A#+Q"J/".-UH'T',!H9=/]_V<ENZ6Y'E1J?&:-KC
MI3-\2XKFBD>;7UF81Y7-.F#-W<;7G*QGA)[=ON!R1F=91D9FQ;/JW^6=:K_9
MB6__P^ *WMH\3)+D*XQ+WQ]Q8AY9)D]!+A;YSYH--,Q\LLN@>O\UU%I!)O3_
MI5C[CSL>3-NB)!"M79"U(YVL!=/VX,\RXVYYW(::"GD'-8&B#P&M*;%F_9:@
M>%$\J(%XHF;:G8GJ[P_FAKVF>C],U9"G 8L9(+'D+^S]2R>LOXTRL-=K6Y9'
MYU+N_2<S1A<XK",D3*4ZKARI$MJ+44J[[Q)PHK;*+%4A\1O>\)EH%.>$ [M(
ML)<"^;1NBYVL-%F<:UGH?(_NCDV[=J1]N\AV^FLRUE_$2<0\UU@_U>:+!D9W
M6V "I4CRVE5!J)#TBZQ=J;R$SY97,^_?'4KX+)^;YJW=^VDY?B1@OF=.$%\S
MR:/5CU#*L5Q(U4&[Y;A4E$04+2UEWK@5"C1>UP:. C>!XQN\:9Y>ETQ"E;H8
M$E9[0.JB$^K6L#&$WABF 0ZNI:;%-&#8$CEL1XG/_P+P&FL#?-LIN_ID5@(D
M".F"/FBW$"@*.A@:NH.)$Z],,ZYU1IM'+;^0OC5''X.J8K[R$--_>89L2 AO
MJE<<\O1Q]VS93(W+\<ONPNU&1X9X)!HF1>MYW N<X=9;6=&$\L'3-E^3YG 4
M'MS&$Y7D5&P$PA#W 7%;Z2L*E^>@KV\L8B4791C FF1V2BU%>#7S*3.!Y=@,
M=CP1KYZS^;C &3OJDCN.@F@7.R>GNM3I^VW0\51_"72\B)I]YG>!\>6[)O<@
MXL96+-()$F;'15;/< Z4(I@E%;E8[I.UM"D?T [-8C1E#3_+%FJD<^]AS'I^
MX&%*L@87J:!UIM42T[+,N69E!7<WVR@*BA</]WPF<'#,Z C0PL!(?P8?I'&6
MX-3J&3/%062*6))5\WUC:TM"SXAV/&G[6I"EUOQ%XXMJV<<W,Y*:<:)/@S,O
MPB?#9FZW("M4VKHA4 ZW>ID/!&IEIO5BX"'"E_:T-RX/SJNM+KRSOE09K"5S
M5Y[(>"+TT-&O>"NVC4^!7Z'L>&);1XQ)4_7=0*FJ@2.#=P:,+1S\JWK[SL9Q
MJC FGW^)%.R6*AXCLQ 8TUS>0-EN*&QZY'@56G*\CL#(T[-\!]"UN/&S,]_5
MC)A:4NV6FX@E&B*DZ!MU?4M#/V9:S-*/]/[TX3@WU7<FW:K+&5$>I]J9CI],
MGL;CDL6?S=*=X0KLHP'\&O(3SE#>0-%%6X5^SDS<I%6+N?&/,>4DR;S4L1US
M#@_B]MSQN/B7R=OMY^G5 EYD!GZ",2-.YBQ6/TPDT #M_J7RX=B-@T73Q^59
MS\33G?U(UW@SFUX\YRZI8!K:@A7NPELHK; L[&23$H3= BR*#R0^?,I]DZ.;
MP'T_QB<#<I:22Q5'Z) L"%M-0U,\U24#9/.WK@=&IFQT;_-6<N?%IEK(R4I\
MB+C<6HPHD;^0V-F&^(##Q$TI$X?;ND.F3GP@UB>ZN=S&=7--_JCH7=C2L^^W
MO+IX%O[M.%$UXPI:+@:IW'OH2/U/HF<C%B"M-9K9LA(AH=X4N^8A&>ZQA4KC
MY$L,MUG>S3V89G<0>R'*X?40_7ZEV6T9TO((0:7KM>UJ.34I%<\T2JC(7ZT@
M ##E):^:LW/J!D @ G&#4A2H@- DZ1-/MZ2&U7GR%74'+ZD9NN>[5,M6N_C[
M86Y%77+O?-DIP9EX4_^(SN>\QE9ZA]TZ&K!L2(3@L,$:&I8_SDW%(O,1JN\(
MJPOFN8;\"VJ5]R[<41",+TU.9*VI^B@RW/L(NN1+L&JQ?)A]*X=\IF>I2$GX
MF.+BQ^PG>/SDA*K.W-E;'ZX'^S'J,+=IY5'!0D"_X7+W=2W)*6-"[\YML5<>
M*W2RR0M;/&?GG*=/;@<!3@ K0-A%CA7@U2N7N6Z]<4UY))D;)(\XO_\Q5USC
MA-77;@\6N\KS$F'")<? A."7&7M/>.O%0=C=X52]726R? KX' K=.*8*;\>Z
M1)OOPE:2DA[*/.)G:[0_W3CWV#9%DY'7^-^:&8CD[>[0 !M#:O2C/[/0*'+8
MA 9D307)]FKS L;_TLS#$0:D.OP7'ALB@;#TZ-I"/4//<GD-J9S9(<%&%YYN
M'JQL;LQR8/SE64ZVRQ^ 8]U5P]$(2Y(_CL.\'2)6-)-$2!J.O8OO6?'V\F,P
MP)QGC[EX4A:ML62M)WRPWK[T=MXUX-1RX!E2ZNXUNP.:J<8$$W@5W,A"D9NM
M_P5CU8>URF7H@@1$H6OWY<]NOLII6*2&+'J&@<I,E)GW3>3@*W<+ZYU)5NI_
ML]8K7HZ5<9Q[H*KR/#\-@7DA\/G\]>X6V'Y(%&RD8.:QR)RQF Q(1005;EH$
M]O%XCNV#8",J'TO1C7]GGRO7GNX.FV(B%C?<]T3.I"&C88082X/,BL2WUF,_
M]C=)QOOFS!M96NB5:T]J6)T\.1LM!-A%(@7(YIF+L -2/>)]*;H$_A3W?-<3
MV/,2B3_HAO3>Q*E8\%ZXQOR^T'1+-4B3[?-.>$?T+A9E*TAP"E\J4E!3]Q%=
ML@Q[>_)N]$A1:Y<G%Y.@YO6/]^[7'OVF? R^.+W5,@FS";]@R#M*VC?<EOS4
MY33<[).;U<6AFY5/WT4Q/]]O4N$42W[*8@&<.7QI>!CIA ECPH>'J1ER1N.6
MZ=N2UZ8F+<N+7[GPM5%:X\EKRB8(E*#&38]+TE)!$ ;X;GLV?L*6G2B1*E:\
MDJE1D*<1XJGHDFWXO;W$JE,B;LHYR?9";(7RD<GQFQRAZYX@W_Z8@J$!(QHS
M8&8IO]? 1!52:)X$B>(EL3,IK2G]QP84< U1V.5A[LNM;"\F-;T28@H:C7A<
M@WCI)O^^=K)VN@5&N*80)60>MEYPU!O#]MR]Z$@HV^C7&_D9]+"&Q3879,OG
MP./('NGF!A(C2(8[%H?4P/$9>@@Z13@.SAU#/OACB0\EP8ZFJR?8=%X_7O4?
MZB"KTC<VK"O#PVG (22Q>NE[]@AI./S+"D@?>>%(LEH'/I>R#P%Z/\@<2@Y$
MD?Q0;88[#"1SD/86PT@4__ ]'<!P(V*,( HI;85MT]. V'ZP0W2!$[2;E-T"
M(L?O,#[8/ _.CKRO"H0TZ[\)/+'W>9!(<S82%"@<Z2 6^@@E>\2YJH?\&.U8
MHQX%4_5><:"$-6@4>IV%@*'262.).UL0TD.FQ\CYNT0(51,<T!O9\DZ-C09H
M.44@5YEH@'!V*NKF3L5],@V(4H-1Q6X33:B/-4#(URB#HL)T]ZI?UT(5?3QM
MMR.LID4#GL)(DU#"$F0?B-U&\5#R8QK0/@]JJU'T$@G#HR T(/PY^3H-R# ,
M11)80>^C0%T@)TEO:8 F&H1WTWP=- "*N0?>=Q,N0 WK!L';-PA517>/1<_F
M;4+^Q8!,9%X,_OF+'&HGH?B[42Z%=>8@ PWH1S[ZS5%U1<CIYU/[50P%R)*!
MAYNS*I#W)^)I@!HEWVZ/1;R,EZ!F7V%HHBXXWAYWS/^NPW#5;R;<8Q.1 7^F
MP5+4'-D8!P+>O_L#MB< -G[^9L'?S*$DUK1Q=V8;C$>_[A8[TE&!U@8A4I2^
M<!>,U6)<VT6]_^,M9Z_9S)LUL]77K5^REZS8ACKM6B%T)M_0 %=+YU3CH8W7
M/655;='6]N;!@OQ^HO(5:A<GM#X[O'H=_Q)X2#X)SI!)$C+#KDOI:TF!&W^_
M)D'/'?Z4*PSJ=T/JVSW-P\]"QC,/[4C8O3<,?6KQ.F5KK2UGLB7@M<[LR5MJ
M1A(GJQHI<UP76S7.'U7EYO2XOI*EFM?S^3K23R[ \$6]"+))DWK$K8'/VY 3
M'G*5,%N?IIQ5D=(W.FHMR$5_ZU/@]OM[G!HFZTJ;TDV@=:<X2=^56G"J"PK[
M40^'*AEGFBL$DVQN<+-6]&E*G#@X41"/YB-TD'D*FFQ%B0%Q#2H1Y75F5O[Q
M7I+EV,39"9'9I,V,,V?/-HFZ36CP(9@(L"87I4@U:*:5\TK^E^\3S[G,#YT^
MI9,![)/:9%7E/'5/YER<W&YN=DI_F\F3Y&.36 //S'D02#L\RE%WHFIN83>:
M#2D,@Y]R"\&Y)[9+K=(#0R'UP]_+X;\V4Q3U@CETXQ/L^X9K/AC:AV50.[/0
MM4= ^3^]K# M5R"MILS#7EGDCZ60_?37H5__7CS_TN@L_T:3!MWL2"2P!A>'
M@#/)LO0?I>'[*S?X5;!M7,"&W-0I4/RS-)]40*TOPO@-,J9X7$[E'\Q]BI*_
MT*+J-4*!*_4/1\(7FW=04?42=F,C5I%,*9 7BAD1V8R/2J@AB=;/4Q-S>!<*
M:EY\O7KLQN:+N;@A%JFD8&VAE(?J +W$L"0.'2/&3DPNE4K,@D=U71O(EE O
M8]?/'(.RGVP:.]^T='[%:DJX%]VRHU0>,F40>,NFWGONNP;V_#AFJ-:N'0;9
M6#;7(E'<.%\]L&I5.2&JTAF >A!RI30TZL2A8+&S F>99&R,W5^/E3AO5><6
MNO%K0/M^;LA=_B$CJM&GG.K_8N3XQ2"'4IX>.KM3>H3SZ^A8KB^>F=@%,^5'
M<:_D0^[C)J6ZES8?ZI6_";K29CEV6CK]3NS)[[*M04LC8CYXZ.-S-" :$CUF
M!S"DF1*^8SAF,_JRX@0Q[.\Z73&*";4I"3]C7SD^G>99O;MPQ6GR9A@0\M1O
M?W(]S&ZTQQ5[P+O(<K&)>5/%]MR+E60\+_,8=//8)5R"VO0X)><(I9/1-T\2
M_L6+RD"2G#D:'MH1+5M[N3H.?>NU5M;4B.6X37<N,Z=DA/75[8JS@D^#&4K>
M7;,3UF0:VTG.=LM>V%(9+NUP<W(7-E!<K1B(Y;WS/+T1,-#*NIPXXE?R#CYE
M86%Q]?Q^G29,X@9T].=VF7ZO0$A6^JYU']EP?XE$KZ[XE%IB^#N+%Y'8V(+9
MD*=!-]TQ%XBHX'%3@D*+L!FA-A4=7-:UNH,-M2\WJ9^PLI9@'JJ5C>1=IC_X
M <BX*_J,;J7<Q&RP<%WNU*+Q@(?]^W?ED6_2\8ZL\4=B2D^J WRK;1W-DQ<7
M3U0D3=<Y=EG$;6DC67_LQ&0Y]I1]O'(!/_K]U,=><H%7_0G#5"EMR9+0UL$&
M)]4Y G^N$S3XUH>ZH5H53$<!R\TX/06/+WB#FU*RAL^[@NTG7SW6M*G:%Z31
M5C8@M_(9/V7ZK$DZ20J+<\\LV3X!B[V!B2M7"!*8.D'<&!VL%1G6X#M "M;7
M5\T;L"K0OY6MZZQ6.'V@Q_HN Z*(7X?9Q$Q-%8>,B%](%4,7.0L-#GU %I),
M+&L'#A;&ZQRJ*-5O40Q=%74(N]85?/6\8&<CTW"9>8<M/TDF7SL+'NM3 .%_
M\\'WC?7XHB?(V(]6/RMZ$.-PJC2L5D*&#XN>5(NX=^/P)@T8+6W90876BW7G
M3,WW.%?TN/)0HF3\I=Y99+D7]E&>=AVJF)2YC"B[V=#*YVL?I&X9=31CWZ]6
M8$,#,._!B9T+0J4ZB_QAY.)2PR)8+WL]-?G_^B93YAN8*Q-&7:9D26VWBJW*
MQM!1"/'<$;B.5$3-U&3VY/&FNZI=HI^'5BLF^-CC[@G<VVFN=</KMD^Z->^L
M1.-Z%:T,M*X2S.(]BQ8?V%SME.B]Y.@8-7%4_/,E]V](=+"ETL'.0_0=K<F;
MJ5TD-U--+%<BWFA84FK_6MBKLM.V/W\<V@7<D*=5?0,75>LML20EO"$K?*4C
MF2I#N%A]! 3P+0GS&D*$T+AL!O/^T=J>VM*)CJJRR^Q<S#/WDR8/WQ-LM/V!
MG9G*]</(D85,$TD'22_A)LMO<*&C+^,/5K'%UMN-,8=[^"+YD6'E9'KB)X4(
MV$&$'4Z8 T:5V.&++6\]UTXN6L(HM9HP0"=T@][\7!(6806(GC'FBV*YQ(?=
MK3OZEJ3<MD"1ON5::7MDGT15M>XK^ZC1E'"X@D24[SA*]MRE$>,JJZ$RC)C6
M[@T2I%5H,T1T(%:^X/8;I?*=;:X;17E--W6Y57_&1XH.[G_HX7F5%$VLL2"T
M5\XP]JY;Z2]#FRQ]BG.+]7U4)=YW*#Q?E:PRTIG/B'RM2K*?SQ9Y5UE ]HN"
MQ 4*DP)R%AK&[F'')[H"WKX.DBPL:92*F^!</76@E5NYX# ,;L3T@MJ] XOQ
M1H_=;J],5^AM%?J)P;TZMWBM)HR@[Y$0D+_E8!3CU*7=ZI9^7^S[[.)\PQY$
M[0>BEH;H:AH0$2AA@(,<F$^V?)A)B5-Z>[-_A?%SZM6%8,D<G'7&B\'*8Q=,
M:]^6/,U,ZU';L\V/9)/C_"C1Y:&#R];%@T;!AST"C9?-&M[YP':8P)#$AM$
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M-#KK[[N9!N=H +,W+/2<><0&U[1.5,#E@[,5-RM]54Z.-B?&2]95);V0PUO
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M'2\&M,B>* ]DP(Y!%'P+ZS(7#+GFK<<O?7^=H7_ FCF0OH!XE'Z>YN-T(T7
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MKI<?G<C.5)'SJ;72B=78IYU3T%B?_3!IQ9Z.0;?R&:I'B6:VY0_J=EQ-MF<
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MDR[E[.%%OMC_V1_=/Y@XL9H$K!9IY\YRC6T]X?E09OPL\0$-'>7" 46M/@%
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ME[>&ZL@Y_GKD1NO;OP3W*7GV,G]27[24_TV"F,[_9:#S'])./^Q4#"+[74,
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M@ /0XQ9ZA=38 HYQ@8F=Y>\!X?86]6-NV2$9'B1IEQX/I'='5W*(.(D]>0
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M]'48+ET7IZQK0 "\^16N\@D+48 G2+>'M^PO1!  )Y4P H">V+H/1((Y1@2
MW_ ?^?'8OY4&(;^JV)^QE@[B&(C]%32)8-XB (I)CPB ,2*CL.'P,Q,8K@%Z
MFI+ZE^^:/TO]R:E$-,SW["JP!5_F1@#\QO3?AB#@]9\%4[$/4W*(&Z;G'A%N
M7B8 >EGLHTZA:ZUGQ,W660+:!L8\W"7BW=S3+Z6IV)OJ5*"]GSMW?J?I#5U(
M.+'\%-R"])J#E)3#-EFV]8@8/=4SY\\A8$=JS)\\ $'/+ :)7)XB=IDXH'W$
M#M6O_I'?T/JS+!"]S"N-3QC[B:>\2P!DB+90'1( HY&G!,!Z-Q2G,8$O&<3;
M@LYZ=/_R;?5GH3_&5OO_CBEQ?X[(0W#$A)L:$/WN,*2RRN?7*>;5+]W0Q8%W
M?S!^?6P'Q^AF4%-=X(=QPB295&_AVS5?TBSB-<1\_[.I L(#P40Y1YQ]4C#\
M8N%ON7+ZOY7\?:V^P8E,$P"W*?[%$@^RIR( %LHJ<683R&$GHMQ=S4W:ON$!
M1:G&&"9$SYD%[_^DC/OPK2NN]?Q^A?F?DR802 ]:R AUZYB&LC[7$)RQG0=;
MR4^IL?N^^9#'*)'^0NB:2*\SESZ[26?Y1)&S);KZW5G&40.4^8#K\&AB7Q 3
MA&.UA'"^[@H+6U#GK=CV9C>N'BW$J/?D^WONLB9HB]S^T?@])-+RJ1=_&CUK
MXZD:L=H[39*8""-F ]0\W31.9;0F[%Z!ZON#UX$^2TX_HEG:V'BB5'5N+SY6
MOE1S ,2*J$WU1!G%^N+%/(-"K;!.]'3:SL(O:=\:,K].67/<\ULY?TWE9^#M
M34BMU@(4QS31#J66@-@6;S1+-&$"\U#<K-7!9,^KK\AFF&G&\]H\F;RP;L[/
M1$<6<C4G78U76SOB:!,7/A&NV+P,!W^#5QX<138%O8+<1'<5QT'D/EAOJ"@,
M!R3LCAT)L#Q,(3ET<<2:G3D$L[=Q&76D7O# \PRALFFENBYH\E3+E[VJ]/)Q
MNBU[&X#4 0  Y&<0QY'_;B&KB(F"&]26&GMD)\PGD-?:S)77>0GITPT73O>9
M< K@+VOV,#QM \0,:)+FKDJI*;^;Q<;TV&2/V9M5(7)'YI8RGZ.R"CU8:!97
MKG2' -O5-Q:-&"*&@&Q$+<6SODG$.^R!&C_$P-O)B>N>=L2W49T*M7GI0,7L
M8\3]T E=%)QA?1CB][W6@/>V9@!%HL,H_VCN0==I]Z.A)RRU%,Y6-:D_7U!*
M1ONGD$I51Q7ZN-[R],>E%@6DQLQQ8<A2X\H.:(6Y2Z$,T?A17=>SXWOW=+XH
MFQF7UN:0W7Q"R<_5^PD+7.C[3#=Q,_/F<TUO?\FE(*H2FZ+)7%.7%W-+>L+^
MEZK%M_WK'TP"S+^J*"6Z)5Y'W\CF$VRI'SE(O;!F'J'6E(&_?GC$Y&DFTR^X
M:7W&.BOTW>R6UU0E8G:W6WT>V=P84(0%HC9S31<-"U<;/J]C(Y:+E"[P&U"'
M< A4>J\C)!\6*I/ZS#VI$CW(&Z1P1TSIY!<9%FN=Y1<;^"H459V+IV[].I1%
MG>0M5L][M4(<1=]J2]K-QP&[_;&V:A3>/*&.8S</W+7IX?E_V'OOL*:Z-E]X
M"PHH M([H8I*$P&I$E$1$1%1*=(B2D= 12! (-([$510$")-$(1(1T B7:1W
M 2FA5TFH 5+.]IGW>U_U><[,G/GFS,R9:_X(ESMFK777=?_NM=>ZUWK'T90O
MTH5EEJ%>XN&?[W_^?%8)=X-T@8C&Y9^B B9/FQ-W24E6SU\O2;W13+3FLVKU
ME1(?:+L.3 JS;_L>^IP5NR#.0_N>G.)_C!C52-$L*NPC>=-'K7A Z$?@H9,]
M_'H.%U.\%4>L]LL?L^9#/;]^O>>PX'(S#[ )"Z0"AT2)6CB]?&D8T^6U78K?
MU;6%ZQ=N23Z+:336E4!8W[2=]E01+SQ:)?C3]O""_I\WBS^6[?ZKQ/]?7%<6
MD&SVZ(),-,<D-IJ8A22&=L0]5.)/D8(Z1XZWJ@_+O$Z9L.?9/U?J;[8 @ER]
M3B$BG5RPIABQ>!+&A6;[RI[MY \OC_]Z^7#C4/JUM)NNG6=.7CPHMN&^514V
M&8S=OYF!CZ=T-#>*\)ZMM!:(OW@S4/C)^X.G+S^7?I#*A-C$C8P/)S?6*.#'
M TCZ!%I<6<@#-Z74M+=?YW>C9*NV3$<%:\/E[P@PY<>5?->8Z*(?[5]#-R>6
M80DF37KM=EMZ+CIU8ZR]FY!#RJ_N^JJ_\2V[M4((FM5UYZS6CTXX%/X0XKA;
M5&T^.1Y;S9(-;[0;U#A4(XO%Z[\S&^UX_VC/>Z2^2U]LWWW4<69^KK5+8U=-
MI56A]4]8CH<9CKP#H8>EES0:7]@[>;M'(SS;3>/KA.37.N;WY"AE(:O3J^2Y
ML9U<<-9%1_"UCZ\<F,JW;^32E"C]4(-O2H%7,CHJWU/\W-@__.Y0.C1E:V5L
MX<GJK(MT7M*&$8$*!&01RRKKX(+BH%[ :,H.!D6\J;DK-[\R.;&C$SWS75TA
M)M5Z9*#2[3!"%X^.J%$@EM>K688_;1@60MMYR!BY=-''ZB2WEJ_[K_-\^2#5
M?24ULXL^!&$U((W0RR'!!C?YHUJ9S.O]!7I62:*)=\SUHE2'LN&IQ[Y*Y75Z
M"=RO:+(T%+OW=MA/;MFGX.6>T2TGD^&Q+*2SUT3[.=,2[4,R^1I5*1JL?,<.
M3-O)ZA5*SAXZ>4"?8-)L1=^+N)=H-AY@TF@R=BB0Z?*<E8OFL!V>Y,7&R=:T
M]F1BDBN.].I)7" R6"AR?!(5O.D64R[$4O0^G@HT5GJBSK15QM]"R3($#2>6
M<N_?][%ZS_&PTR5:ZWN(#\ :R]!>DP^8%SFZ\5D2(T<L>MU*88<7RAW3Q[]V
M<JA=9TSN>N]J>PAF-]JA:>*WIW> KB;JU]R"%0<)CW,>Y_8XPPP#QAQV-_AN
M*HPOG3KS*EWE,&H++AY_G'>MH6WQA3 P%QV]1?EM-P3%^Q[6R2UZP/.^>2W!
MOJFKEL,IKA$2[MIO>/83<% %\'R+Q>75*($QWI+02>'P0I(>8K4TI/9,_1M.
M6_%TKVRRA*GM+\</U0LVQ$R8V\L(G^5)D%]_FNH[D$U2&ER6H0(7!NM!3*5E
MCB14DE-Y@PQA^!0YT@%DW-Q#)((T1P5""XB#(%3Q:H82#4>I .$+]$\#7H3B
M"K#6;KM':R"@?1X:^=M&:(\]1F2W$IX*4(X8CY-<,7O:5*"K#$8\1 5$_KT[
M1ZUP4X%S0\@)*5+0T[VY.2A)R:L)!%0UJF"CV-4?[XC 1I8$#"5R-1:)S_A1
M4>SYKOQ?=$1TQGPUIT1@PD#<%5CV1^$Q!^PN5RL5V >;%D"/0\$>?R<2171:
MC4%NF"#<J4"(( B?!3#=?]51O:5_W?B&/@(*NA9G^8\27#_)1'B:LK/3^2<J
MGR'K31 @>$ROFD*3COVH>S;C'_T7/5'XEK:XP)\YXZ@ 23@?2QR%#,M10HJH
MP">3'7K)[<X.-Z)39XQ6%++N&Z%I\J0!2=S$NYE,ROH++9#98</C6[S<5YMQ
MY6&DHD@ '(5YI. J?(W<J/<_PO\W"#]2D\:_GPIP91#S,CKS$%K$L$D]1M."
M@O$KQ0-'*[VO&!=]SFQ43#5/+\I[?_]BO]OSFH5=<] Q2R&-_#PB@]\1SE,K
MEY'\FD%NV19:;Q:^)YUHE^AS$TA83KVXDW224/3IS4VMQ'/.0Q1^_SYLX9O"
MJ1C1D7HAVJZ-]D>7[4IKHFKOFY<6QEP)-11M_G ZM]CFH7RCCU7(GH5_V_6E
M5%F"'=HOW=PBW=QL25/2\F"&+U8#^ISVB^BZ[>=RMV>!0+2/241L8^53M[TS
M^5P$2[(:MF:@6"GZ7HW"NC,.TTP%HHUA99(A"*EWB%L$JX_V+"B91ZV?FXKO
MER46QFC=?>*MOL7PS7ZZZ9O 7<[=B#U-_X'K"'=BVB0(,)2#,8]X2FS6K2LK
M'XGT2>]+#%5?6RN6$AZ9698\4&@E ]K&5@HYNA0=D<K?72TS(4/#PC;JM#60
M9+2""5R9..[9>^*\Z&6Q R=G+ODS3! B]TPNN#&?+I^DS4B17J*;A*X\O3M#
MSN@\TCQ#SG9KQ[:LE:W.V;4]B-SI$"Y8NOI\7LW8\KK)>M=P?)'/-RP87C\+
M[5$J=*G ZZ0/-W^^KU9JNKWNKU99<T'N1:10NS.0=9_2GW>A V:_UT[^HW[R
M<"+)6V\#TO&N___;@OYKW=1?SCB"E@?A1FYV(><9C9U*,:0?=1$'M4#B9&[]
M]2G*0>12/G0)0_G<_\<A^8(2\(/=$S/ZQQE*J1>5!+D@%X0S7?*#W/EKQ$K3
MNGI[F08I_WDMX1/LLZR/#6@':F@()O6PX73D2"R3LT$UX37QFH:U_?UN[<G3
MYBS+.(V+AEM(#1:YVX@W'1<O,CLO,MTYXWZ1V(*4#.-N@@U7HL-EQ&O*/[PW
M[K;I;<Q\T"KM12,3%8+:9V:@W [QNNN^</?D@[H3KDH<.\\W%J9)GZ,_8-(6
MDV!1"-H<9)T6<\H[XL.YY5;QRC;/<N/5F7T5EP9%#+ZHW$O<4%TU]Q>LZE;R
MHQESH7/1W+[PDN7IT5<M$L4%E]0OVU[J\/$=;#%6DXN0T9#/FO<Q?CGE!_M4
MJ920XIV_D'JL)[R:?631N$>#:['P6*7F.8M$4T3#DTQK1NZ=CUZ?C'TJB<I3
M='GVMF\7NIW-/GY/2S-O=9;)_WK>VDV(P)C;PG^FS;UB/YU$_=U9C&+Q5_L>
MZ>^W$R3+HL7#Q>X$W76!/*+C$1,,UQ!Z42")P]3JB^'>9'F\U7KK5#F;=R;3
M&.(V(!&KFS!VJBW'3*77E\O.+D&_YT.MU[W#<(FY0 0R8X$O90"%G,J+N3.H
M@R</I,IYN)QS2"+/6GM_%/Q2,<S=%A-P4V#%XJDYLMB_,%>78#Q^Y>-'0EH%
M[("YQ>*6OU3"ZNV^]J:AS A)]?N7;O.QSAPY&09TT?<9Z8&VC#(!S6 =.3^0
M5_K+XVO&DK]ZR?8O7ZU*7P_#&ZJ3H=K$#+RD$6&FYJT7/K1N^]J' >O>N\_[
MQC(-2Q-?%9(:W.AYJ("STMILXH1>!)AZ!E"D*6U])E,8%$58?[(I+NWI"M<P
MY,4UZ6R>F\.YQ#.<(RH")LN"[>^4XW@*1&+A$2VZ'"=),0I[FH,KCAY;#OY]
M$3/O**9C;\E=HP]6SG))U5$D21($ST(,Z2PX%WOMG7)1;D[B+(OP5=I8%4BZ
M*YPJF<(A=;"8J47D5(5#Z%6>J5&I68,8LX%\OTET%'?+I*7)N:>XU9#ES8]L
M(P;8^&'N#P^\%%K<V=[KY7P;;F9)/&D+Z);0W>G;5X"F11@=Z(5;'906P3\@
M.! N]<?C:H:CJBV\:=A"O,B9M-6%_- PC9L09BI@^]$=UXG:S&M7GS2)0!:Z
MEC#ZG1[[?K-GNH:;T?V!8KSJ:7Z+69>1;PH*>B)^X[*J2P:<SEYFKXD!RN$>
MOI8WX22XQ;Q+#G3+9V'6T&V&__J8,3Y[Q<IS7+F,C)9Q(<K!*HAN!-3GOFK#
M B=_K@$-U:-ODF+SX,/1:C,329*^>3Q3W@<RY774WD9PB2-5#XFP<@MS:UCC
M=9K:$.Y9"V:EV'!IA'O&B*-:+.@Y3\;,.&^))+G),ABKZFG)?<DM?$Q8K[?Q
ML1EC^ @&U,8T8M+18,?3FH+5/9:W.I-G6Q\XBAZ1#ZRZC7BUV2Q   ,>.\G6
M>]*7"D3Z2_96WWCG* 5.TJW&73+O"F:+ QUO2:8,SXZ?*&=4./O^7HKI,9-C
MG"]*/7<'L).C[%,;Q=^<]1^D00,]9"ZVUG=KS31S=.O?4?XR$I%PSNHLRSZC
M]W1Z7,"JOP#\]':],N5DGX=RJ#G9W2QI0T/\E7GN.^-Y7=HX >>XKX7YF-^V
M7B!6]I26*$>C&BCL%03+L3+7:A><>[[8MR5[PY*:EX=9Q-%VPD>3/LN>O90?
M=6&>"JB[1;AO&/SI0"7?A@%1'-74[J;]OL]EDX4A7'9EJB):,^.D2T%:J$[<
M(-V/.T30-:K(+IU:$!Z<0H/!T"1I 8:_#AM6OMRSO)SO+[IC7-8%ZH,<]B8E
M)Y<F.AGQ"E#KQQ"],2L_JFJ)48%C9FY40,QD!9_58)';?]R<,@8^MG\4:MM@
M(;IO-\OM,A!!K$%W \1FD5!<Y[@ =EYL D0:O 94H$D*A"VX66Q)-ID#14IS
MQ/XH+:PQN/4,I#^."CR3^9%1Y)(36:E YQ?8CO+.H0U?A:X_]?)C*1B*> C&
M%E00B)ELP?%X\N6&T%L;Q$&"WI1RJ(;<Y&J464QH2BYL9"C=,96_9\P\0OSY
MD:-;CQD2#^LBY/?=YWAJ%4"_8DF@L(3LTF711Q>0="9E? WZE10##W3+2)0%
M#CNFG^>L,E/X=OOL6@TT+"#P8,&ABNC=:/*KW!LU*1#S34?9Z)*W2KX*K<A_
M#7UYX\5A) ZIJ=4832E31[.Y&%S_HQV9@A<C!AFW1+E-!=*.'HLCWF:F/3Q%
M'[FW78?E1OA0-/ %Z+=.NRY;*6^=(#:IQS8ZCV_MG*HX,69=^X5YK'1VEK?,
M*Z%OR\.6;L6/?7W5M?F A>NA$">X3\S;FYZ1Q8.['W86J "S/W&&"FA!Z*G
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MY.P?F/!7\GWI26KU.#DR4\T/<V@UH.AD_%G+Y"Q<-ID&2Z)#DIX\O M-7M-
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MQ_'_7![^'S26._,_;K*SH0)'G#QW_=$X&+.EU=61NQ$: OON1J=>X0$ 7<F
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M^,JZZ5/SQJ^#2M8I!?F@CT(1LB T<L&QD%C-?ES@MUSZ\X'^Y.'.'?28=\U
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MV?95#'JIX^K<!> /2K)_?"MS_H #\(FG94? 7?ID#/J_A.B#%DM<\&6PU#H
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MU15&4=F:,E^>5X"7Q-.U1+SN\'HZTTD;XBMW+%=*AF%8[58'+;53Y\TGJLU
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MNK4Y&$D)W4XN_[L*-?X/4F&BF_+Y%QG1,GO/$QICSTJ! 40U;5\H:0IG@A
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M\*FBW%PWMGL*1&D.,4Z:+2Y^B2H>[WLVC<CMKU"+J5Q?H?6SB+<Y)!(..9+
M[\;[1.J\LI^&PX;4@H(8@=)=XYZWQX,BCJ(ZDQY1C]4ZIZHMI$2XW@G/M#PU
MFE(.9:=YSV:QB&GI^2,GM%04YA2&K%1%D=;F@F\,*]=,8*0K.I[6CB5<Z:WC
M?.1R&'CHFAT7+5<Z?*ECJ1PK&5A^53,*@>'YK,@:6CHF5OY63VD)$"7'#+3
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M+GE5ZICJ\HHK1O=#P?M5BL"-PQX._++?C>)($,A3;- % )->]SM6R6 /&.U
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M+/U[HWIZC_Q%(Y,X\0LNVX-2LM721CB4!,*%4BJ#$8Y_GMH3^[F?G:9#,JK
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MY%7E-LVHDU8RD.1.JF8TP@-!>FH\YJ%)O%U<*]S\.21IN5=!AWNM[RFMRRN
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MI'/="F9 >9/GPTU/RS!67F/P:9DBG?OYY?ESJP63T/(AW[-E'%8WXSQ^HDI
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MC'O^Y$C ^PXD/T/_&GYP_U/)77,$H0XWL^JBKJ26B>STRD[^AG2?B<&OT
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M!O'F,+\!LSW=)_ 1)$(=B3<HCGC ;C6320-<@>82NUN].2;Z9#:TB!0;+NZ
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M!Z]J(\?K>+I[T0K]>//P)I? 0JSDC&^.\C7SA?G 46"X!Q)V(.RQTH",ND@
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MW6_>1BC]-/X-]GJN-QT$/T%)GVESQG6F@!NMFGY+B<8.HN]7ULLJU*#X>3]
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M0VBT)06%XCZ49W3?Y?O"EV"9.?I8G,[:L*+?-S4U(;#"JA-4Y17OC?>X3XK
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MAZL]-YZR =2R\TM701?"QC29&RA%9" N$U@#;6-RR^\KG+Q6(['4-XDZ0M
MFJC1ZBZS8E58XWAYJ', @HB>O*XK45+UCMW-!J20!Y(W)$ABF;82JF'AR%/5
M'+65(Z=3_$/-5V\#=.MUY#1/S]5=!VR]=?">0XVM';&T.%PD *,@!H$5XM$P
MZA5%3%*\=-8$PW0*V_KM.-5YYU<VA<3&KT- CQ!4S&\;5"@V/>+HIK+V@:]4
MQ0C_.Z$$GJ?"D<+L86I@32@]*:/W+F&K \BS:M-[T];&O2&QLSD[X5[88[^=
M,Q\ =UIYU'T2AKO79!=\+!='5D+MX$^7FS6T4SH&WUW;'3ST#G4)7%O:?FI
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M;!RN'Z7_YMNY$KHH'9^CO+4TR)&E*.B;5;34'@O]"J:P [5.,>PD&O@48F@
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MQDP5$OVJ/'94(W@8"??1UZW;EHQ(@*@<M^Z3RCT^$L!0^Q)AH%DQK&?KS-P
M2+EQ"H^O\9C6[4F+B"H8*6\Q 2\H%+P#TK;T7#:TR"._1X=4&')/0KMF,Q&T
M6#N&IC![:M=M*@K@:$N! J%/'BV:T>(\XS<FF^R8:[G-6Q%'*T3-B7NS\+E
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M<ES?ZYB5G>_YI0D%-WA7P8WN[UKCHH33&^]:+ 738&C.G;IY&, 2@ONP@\Q
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M=-OEQ14)#Q??7G8(N2]SXQ>\/T1WW$CCRK^D->9,."1>%UN7A9KNR0$76I8
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M'=DSGEB'R"VQ'14[8H^2/!WI,IH<,Y)??WI9'^0CV:/UL"R&OJ-&Z-ME@!"
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M\FG028<A&K_54/'K#YK!0VNW12MOO8L$&$K.&K4G$F5E@E5P_,-W2  ,18E
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M;*$"O64&BV?1(;ZR!>&KF*$'30V-04"1?D:N1WP!$GO9=R1KM17(5V6]XD5
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M"S-W=9^B3FMG NJ;WL_V*6>/:+V8AHFX_@#7.ZBU$:EJL79IN/SX@&(;^?0
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M@Z_\KX;^!%0SW])0:0!6$@!&?'Y84PQ,%9LCCZ!+:'.+]9BX<%Y3Q@E3O%7
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M2O#03K*:MX;704E='V]@Y9?^EEFIYD&E:TG$8^@)_T*L\9);Z?*<<NOTW'K
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MVXLM:$9B,_1'76]@'A1E-*6\^*KX.B[KAC\+:>" WU-554;'Y$8BP*'I*QK
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MO>F]#?LN!</=/.[S/J$[4,41&:++?H>*1;'1;2[0/^ C2%"?2"R0H#XJ">>
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M:R)-UQ=9_V)Z"_H+"V7XP;"LIL[ FZM(KTF1S*)$&!DWH<5?G5=D*1U5 _P
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MGO I]D> ,5\RY:*.Z\F^@V\F8W#H\:W1.) VO=$Q1-Q\Y3H240<A=A7:C=F
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M\* 52.\1T-X#)%!5ZG_"MZ^$;]^.U28<S>,>J-8V?V'4UG^@]#]02P,$%
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M-7FJJFI?LQ/;9I572#JPBD55>UX"M'-UJV+0M?+YNNIH.3]1-:MK"8H2E!S
M$0B\H!DW!B4&?!*%T<#00+&W8X*HC8MRU:IW_MA6[EIU0QS!>"H%[#)%COPE
M7=DE\\*"1:,Z8Y?&NVN5%5:^2I++<5PT]N%!Q<9_-@'#48,"(.N"0 6\EN9M
M%=58)0TJ2? Q1["HV0S6>CQJY0WRL\?(E1\3&_\WD#[?C;@Y_3[$S0><IT+;
M4+)>O&B-W3VQ9,MZF">CZ@E\&4VW.D4N4@BD^]+H&YVJ.1L@Q3)7IEKH<M!D
MZ0P57_WO:_+,99CS$HL"+J#3B/Y:Y,!7[', 3%@,& Q-O'!#3P&XF1(W8 S
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MOVR.?'I'Z[]HFM1E./$E'=V7KJ(2H( ]<N![6#]=JTD5$MWC-2X(%PE0$U<
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M'P <@8=XQCA600/MRH@@Q1P7;#8O.:))"$E0S&H'+&;<>V?KSV#Y;DQ3XN5
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M"]J(-HU6WCO$KB(?;P 5I0Y[YEYZ>40 @VF3#,-<(;XK.<H]HXZE-M".C[;
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M(HO<J<_^+J7Z2Q+'=CLU6Y=2'4C)*%4BD#3H0(*.-B(!B/(RWEFF-N? KRB
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M/<;><XT;8.=9D]'[8O5EVP#V9X=?+FAE'/DU<Z>)[/?0_6W9]+1->^-%AM6
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M,2YX<V102P$"% ,4    " #/0W!<2IE5A=L,  "PLP  %0
M@ &9#P  87!R92TR,#(U,3(S,5]C86PN>&UL4$L! A0#%     @ ST-P7,$Y
MT\C#+@  I"(# !4              ( !IQP  &%P<F4M,C R-3$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( ,]#<%QJ,E:JR6$  -*(!@ 5              "
M 9U+  !A<')E+3(P,C4Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #/0W!<2 U^
MO85$  #@[@0 %0              @ &9K0  87!R92TR,#(U,3(S,5]P<F4N
M>&UL4$L! A0#%     @ ST-P7$(X,)J)^0, _JT@ !4              ( !
M4?(  &%P<F4M,C R-3$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( ,]#<%P*3Q)$
MG@@! /<_ 0 8              "  0WL! !A<')E+3(P,C4Q,C,Q>#$P:S P
M,2YJ<&=02P$"% ,4    " #/0W!<:E>F6U.U   /Q   &
M@ 'A] 4 87!R92TR,#(U,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ ST-P
M7'%>! :Z5P  ;5X  !@              ( !:JH& &%P<F4M,C R-3$R,S%X
M,3!K,# S+FIP9U!+ 0(4 Q0    ( ,]#<%RBYLQB)](  *C@   8
M      "  5H"!P!A<')E+3(P,C4Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4
M" #/0W!<10(4EMH. 0 7-0$ &               @ &WU < 87!R92TR,#(U
M,3(S,7@Q,&LP,#4N:G!G4$L! A0#%     @ ST-P7,U( O[P=P  NZ4  !@
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M,"YJ<&=02P$"% ,4    " #/0W!<:*6.(CU4 0"W;@$ &
M@ %X=@L 87!R92TR,#(U,3(S,7@Q,&LP,3$N:G!G4$L! A0#%     @ ST-P
M7'9L;8_8[@  #RH! !@              ( !Z\H, &%P<F4M,C R-3$R,S%X
M,3!K,#$R+FIP9U!+ 0(4 Q0    ( ,]#<%ST*E0USNL  )@Z 0 8
M      "  ?FY#0!A<')E+3(P,C4Q,C,Q>#$P:S Q,RYJ<&=02P$"% ,4
M" #/0W!<G:O"!W*)  #TGP  &               @ ']I0X 87!R92TR,#(U
M,3(S,7@Q,&LP,30N:G!G4$L! A0#%     @ ST-P7([MDEO!$@$ SS4! !@
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M,RYH=&U02P$"% ,4    " #/0W!<;,Z(V3X)   @-0  &
M@ %>&1, 87!R92TR,#(U,3(S,7AE>#$P9#0N:'1M4$L! A0#%     @ ST-P
M7)P,NM93'   SJ@  !@              ( !TB(3 &%P<F4M,C R-3$R,S%X
M97@Q,&0U+FAT;5!+ 0(4 Q0    ( ,]#<%S)]CV000D   8\   8
M      "  5L_$P!A<')E+3(P,C4Q,C,Q>&5X,3!D-BYH=&U02P$"% ,4
M" #/0W!<64T\I,@#   U"P  &               @ '22!, 87!R92TR,#(U
M,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ ST-P7!SU/BJ'"0  #40  !@
M             ( !T$P3 &%P<F4M,C R-3$R,S%X97@S,60Q+FAT;5!+ 0(4
M Q0    ( ,]#<%P/A/_(" D  $ _   8              "  8U6$P!A<')E
M+3(P,C4Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " #/0W!<'/F=3((%   ?
M%0  &               @ '+7Q, 87!R92TR,#(U,3(S,7AE>#,R9#$N:'1M
M4$L! A0#%     @ ST-P7!8O_%)_!0  3!8  !@              ( !@V43
M &%P<F4M,C R-3$R,S%X97@S,F0R+FAT;5!+!08     (0 A / (   X:Q,
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>apre-20251231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apre="http://aprea.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="apre-20251231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UTwtKV-qkEOxVLKfaZVgbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IJ8zJ18I4EClq_KQWPYSqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_X9yxNCi1eUiwkdxf-fOimw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_tzboIpMCLE6jmiSEJoPsxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember__-_le6ti2UOYE_b8iPNg5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_0OTUY_lcakyo9dePfZ4fUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_ukSBibSsYkOC0ffd9tzE2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_3j5lWFF8JEWOa1ah--AL8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-QRsPFW0-E--PaKIJUY7Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAL2DshPD0OdJw_EpkpGGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J9HtUxOqeEaXcgWIs4717Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PilxZKpEyEi9WNFYDfCOhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F_cddC-SRkOjmWWwt-fqVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T49vl6RPsU-nKirVaTJE3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7S-nLeE1P0KWLPTOkK9J0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W8VMjZfm3kqAuG4zdxRBGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uxcYngPZ4Ueh1LhH_AOjNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HdVMa0DdwEmc14llqTxLvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtIejotXFUSQPrZvskRYfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K43Lpib1Z0SaiG-7BlUL6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8TENrsfRpEip6COKOMdc6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_EQUr4jqfV0eUSMk3W0IsWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_VhYbqu6uqEa_Z5RqOOudRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_svVivUO6SEy1bko-xpnpmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_vo0Rp1fMEEe6cXCjrjqRkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_uALQGM6dfkS0eVFcd0iIJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_RiL5VScdAUCDUTJd-n0MRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_evHTOe8x2keNSJoG80M35Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vI7qdqQk_0OgoyeWE7tHaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_S_ge6OQffkO1GwngF7q5dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_76awlW8Ih02pce5XsSRECw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_c5rmFiY3ek-6CbIN1sUk5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_KhoEA3ZPM0CBUJFvhI2tBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_K66RcqO0CUSYIecB3rtHQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_ObCThvYr3EuNhTdvZHWN5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnTwoYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_51RPXCrdCEOuPhYMJBeuWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnThreeYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_ppTWFla4xU-u0Ra-s34Jfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LrUkAv7nCEugy4KCFPIs0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_XAXHtIodGE2ofHLJnzdW0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnTwoYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_kvlb4D8nYUSyelfb-KCo2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnThreeYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LU7BJLvVE0iqW66H9_OrGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">apre:ShareBasedPaymentArrangementExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">apre:VestingOnOneYearAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_CGXEBDoB80uMJgtwrAZVgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_OfficeFurnitureAndLaboratoryEquipmentMember_N7HQnrCgnk6dOXicETh-5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apre:OfficeFurnitureAndLaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ZLW0Hz7D7kWIA9AazR-fdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_sUM0Rd5XwUaQcZ4Pzaib0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apre:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajl5U0Fik0WBAVlJp8BOHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_uJ12jSW3IE2IlsnxHNVHYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apre:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-28</startDate>
            <endDate>2026-01-28</endDate>
        </period>
    </context>
    <context id="Duration_1_28_2026_To_1_28_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_dtwms4JdkkCkrALAA9rEeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-28</startDate>
            <endDate>2026-01-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rw7WXSTzPUS_r8Ou3XFKVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rfpje9runUCtL_Q69zMdAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_sq6NeJo7pkSi5n0W2_R52w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_-mt0Lba2K0O1my_pp5wpyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_ZoIolndLmUyXsd1mQPpAUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_OyQ7wp2wFUSYaMzly9YdTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_kq5Z_aQ4GkOW-yWNsb-P5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mRdeq00MTEmoRCUVaSWaIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_x2waWdI6y06iIcRFhALG5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_mZZT_4w8FUqzJrb9O-iaKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7BZm_z9xCkSv0FQpO74xqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_iTqHbEL2pkeKPob89U4UMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_gXVMK2ewSUubD_HBDBGCyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6EMQYsKTe06p12xtaqpj7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_PlacementAgentMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_nCqKvJ6VqEOdmrCe-eB1xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JlhBUytMKkeo3cvNZE4vVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_12HariDjbkGdtP5EmFWGYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:January2026WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheBWarrantsMember_fQ1ml1hVHU6nU0Lh1uc_aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsMember_HnwiahFpV0Kqxh7uoQXQfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheaWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024PreFundedWarrantsMember_a-axkHFuHU6wmJ8RwuZaXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_IWhpmSyLkkquMghWrBhMLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025PreFundedWarrantsMember_-GQYBDW1ekGtGJann-TV6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JysbG2LVi0WviMI_bz_gpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:December2025WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_CJR1S7G5HUqhj3cWK_5B4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Pk_DcJsgPU6S0cEiZFfnSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_REODE2xYG0ygbK6Gt1iCwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oq3hsrqBykm0qXaMoCxjKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7byEi2lE20ibECXouEsanw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_hqbRhvOLLEi90FCZNRS2RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_05GUoR4aq0ubc6DwiLlP2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_yFpzhwTg9Ea949XNcHNkug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_kKVKD6hRDEiYuHXysXTBig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2026_c8x7vDEpiEe3RndPj6R4hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2026-03-16</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_0jPUe0y1K0OJ53mzIl5oew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BAoeaXQje0CtAvGY50doJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lqTYSTP7MUWrNQSGACl75w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:January2026WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-28</startDate>
            <endDate>2026-01-28</endDate>
        </period>
    </context>
    <context id="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-08</startDate>
            <endDate>2025-12-08</endDate>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apre:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_dYgdlu90I0-v-bYG_Tb6iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_X3e_9uk1uEKJQCgyQcQNiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:January2026PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Vm4iVeX890G-C4Gmcq830Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MGDWpqe1Kkq0c-y3kaCxwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zk8TLXVZiU-91j2mSRo40Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_jtkh2IFT8EeIdDld8qFq5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_lILoXMI7xUCZVU-gQHudoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:December2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_Pm5taDx8J0uJMmRJ6og-yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheaWarrantsAndTrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_R5lNv0SMpkG5QNmfjLhHmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_7wfplDUgUEm3Te5ScBml_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:March2024TrancheaWarrantsAndTrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:March2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_8_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_1IwBxFQ5D06BZajC8QiMmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-08</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_wfZiBhJ28kKlJpaYLmFFOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:HCWainrightCoLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-08</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_e9RDxBm4kkmD7GckPR-Osw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:HCWainrightCoLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_Vote_xL2dOMznHEmc_uWBXbUEqA">
        <measure>apre:Vote</measure>
    </unit>
    <unit id="Unit_Standard_lease_QaFYmEckJU-MqyGJp97u6A">
        <measure>apre:lease</measure>
    </unit>
    <unit id="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      id="Hidden_9oFZihkkQECVl5y8JTh2kw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      id="Hidden_qhPKQOZ9VEe6KfkyUEYQWA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Hidden_rkBjBNAGOE6odzFkepIi6w"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">6538722</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Hidden_2bIqUQ7Wo0WN9XrI5UPgUQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5509921</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_5jDj1vEUukmMZAgR8urGxQ_1_1">0001781983</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_kJCYyi2-kUqsQAJR4mixjw_2_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_JOTNd_e--0qn9EYECguCJw_3_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_8y9pwbBXWU-0j5Gv6PNeaQ_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_ML03aarikkO8ANbVPu4kXQ_5_1">false</dei:AmendmentFlag>
    <apre:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_7wfplDUgUEm3Te5ScBml_w"
      decimals="INF"
      id="Hidden_P05V6E5pREuHn9AeSp3VTQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">0</apre:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <apre:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsAndTrancheBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_Pm5taDx8J0uJMmRJ6og-yg"
      decimals="INF"
      id="Hidden_kQnMjb4IG0CtJN1L8Njr2Q"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">0</apre:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w"
      decimals="INF"
      id="Hidden_f-pPCqIy8E-ac35O2X99gw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">56227</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="INF"
      id="Hidden_Wt4Cqy-K_0eS7ycaDAWEUA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">31194</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Hidden_T-uNdx4YOk20X25X5TdsLg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5481055</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Hidden_VO-coJ2sxUK7ihYecHFhqA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">8192538</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="2"
      id="Hidden_UtaHMkDmT0ap2lFEPXUUqA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">-1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="2"
      id="Hidden_rVAU4-Gn2EmhmVcPiU32CQ"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">-2.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Hidden_GAiVwh82eUmdKx4UoyCRCA"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw"
      xsi:nil="true"/>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Hidden_eE2fcbd4R0eebi4itMmEZg">http://xbrl.sec.gov/country/2025#US</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ"
      id="Hidden_qn32aboQakGIBXr3nC5CDw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ"
      id="Hidden_cLaLWqpS3UqfFJPfyGBgqw">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ"
      id="Hidden_qPJf3vDE6U6wN26nyYncQQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_smtUrJvby0KY0TlrmRWVYQ"
      id="Hidden_otCW9f-QjESf3tKfAs3j6w">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_gwfw0YKNLkKIZKeLnXH1Hg">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_FNF8hA31h0qGXAfVPPQP2w">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_-Z9t7E250UWn-6ROqhOJYg">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_EJL1RSj9rk2FjUA2HFUd-g">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_kcBep-XPNESx2hmtOOej1A">001-39069</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_zYReueof-0mqF9FuC0Q3sw">Aprea Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_LuH8CSiO80SoV6iGA22e1g_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_sNQSyn0GsUKFajCblGKUpg_1_1">84-2246769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_VGaKVaG_wUy5-b4Bx-UuGA_4_0">3805 Old Easton Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_Rv5-yM2C40yS9-KmCF-0Kw_4_1">18902</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_xC0voTpWp0qgzJ1toNQlyQ">Doylestown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_jN2XHmiatUCYu7-_6Ty8AQ">PA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_3cpjoolZQkeDcRUCvptTLg">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_YfWyrKTPBUK65_0QgKflqQ">948-4119</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_48JDFbcMq0yAG4cBGdjm2Q_3_0">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_LUG_NkoiEUmMKgsdnE3JeA_3_2">APRE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tc_Bs6ypfV8Z0OPXmvY_eh8OQ_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_yRG1u1oWok2FQkxlBNR6cg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_8mAdtvcQN0ymcy5ALrcTzQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_k3RJfIWxlkCyDLFXIr-OAA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_XqeL8TZ-8EmG4XsT_JTMDg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_hlO-eZ84AUCvOjNvAHqmDg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_q_Y4-JQ7wUGByCVj-0yJpA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_Ol5QUaxU4UiA9XLYSrbAIw">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_sBQtnNgWO0S29YCVNtTYRQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_Qwn7avrb8EWPgtz9P4YRyQ">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_dIz1Iry5IUOtb6YoBS4-gA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2025_kKVKD6hRDEiYuHXysXTBig"
      decimals="-5"
      id="Narr_UNj8PE1pGU-VNRF1nu9_bw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">8600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_16_2026_c8x7vDEpiEe3RndPj6R4hA"
      decimals="INF"
      id="Narr_CggGJvZwYEGl3FiRIGW7zw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">11452452</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_M_fJjvH4Ck6ffjKitQWK4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;), to be filed within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31,&#160;2025, are incorporated by reference in Part III of this Annual Report on Form 10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_unU2dLPsR0y7qoTx9g8Kxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;font-weight:bold;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;We are a clinical-stage biopharmaceutical company and we are solely focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response pathways. Therefore, we do not consider that we face significant cybersecurity risk and have not adopted a formal cybersecurity risk management program or process for assessing cybersecurity risk currently. We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized access to or occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. To this end, we utilize an outsourced information technology consultant, who we believe has sufficient experience and expertise with regard to cybersecurity matters, to implement systems and procedures designed to reduce, respond to and monitor for cybersecurity threats and vulnerabilities. Our outsourced information technology consultant conducts proactive patching and monitoring of all of our existing systems and has implemented systems and procedures to mitigate cybersecurity risks that we believe are appropriate for a company of our size, stage of growth and financial condition. In addition, we carry insurance with coverage for cyber events that we believe is suitable for a company of our size, stage of growth and financial condition. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;As of the date of this Annual Report on Form 10-K, we are not aware of any cybersecurity threats, &lt;span style="white-space:pre-wrap;"&gt;including as a result of any previous cybersecurity incidents, that have materially affected us, including our business strategy, results of operations or financial condition. However, as discussed under &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition.  For additional information concerning risks related to cybersecurity, &lt;/span&gt;&lt;i style="font-style:italic;"&gt;see&lt;/i&gt; Item 1.A.&#160;&lt;i style="font-style:italic;"&gt;Risk Factors: &#x201c;Our business and operations would suffer in the event of IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in our or our third-party vendors&#x2019; information security program or defenses.&lt;/i&gt;&#x201d;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_4iXDy739FESH0o5W7r86Ew">We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized access to or occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. To this end, we utilize an outsourced information technology consultant, who we believe has sufficient experience and expertise with regard to cybersecurity matters, to implement systems and procedures designed to reduce, respond to and monitor for cybersecurity threats and vulnerabilities. Our outsourced information technology consultant conducts proactive patching and monitoring of all of our existing systems and has implemented systems and procedures to mitigate cybersecurity risks that we believe are appropriate for a company of our size, stage of growth and financial condition. In addition, we carry insurance with coverage for cyber events that we believe is suitable for a company of our size, stage of growth and financial condition.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_6HPX-q5LRkiPT1QF_Ojlsw">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_N-lteahHREa-lflYIW8R_g">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_Wlsk0DN9R068yCnsgYqt4w">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_5a0PP8WLPk-DEJ4MiBSOxA">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Group_E__SEL-s2UOeDD7mC5ghAQ">Management is responsible for the day-to-day management of the risks we face, while our Board of Directors as a whole has responsibility for the oversight of risk management, including as to material risks from cybersecurity threats.In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed. </cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_MFgVXvEEfUyeucIxpkczww">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Group_uEt2JygDxk2NtN8jsEzbSQ">while our Board of Directors as a whole has responsibility for the oversight of risk management, including as to material risks from cybersecurity threats.In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed.  The Board of Directors has delegated to the Audit Committee of the Board of Directors the responsibility for the oversight of information technology (including cybersecurity) risks.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_nhDR7EY7kUaavTPctkV5qw">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_uBJKJE_4-ku_fM9LwXgFXQ">Board of Directors</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Group_EuZPP_x9aU6MY04_T8Dbcg">In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed.The Board of Directors has delegated to the Audit Committee of the Board of Directors the responsibility for the oversight of information technology (including cybersecurity) risks.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_TxG8ZdmZ4UWBXct20B8Xbw">Audit Committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_TkEVlNlGY0OaC3zEDZrMZw">In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, integrity, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_qxFEa0uezkWQ2yU4OoY9vg">274</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_sLGkZC8dpkOE47FrxQFNpw">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_bro0QsOvZkO7D7qfz53VKw">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_WH4kw_yB1Uu_iqJSFRP72w_5_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14599347</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_Vw3Kt42_b0y-g-UnrJu-8w_5_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22849885</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_Xkk7m7WwMU-3rReRONsb1Q_6_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">961899</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_0nMVAQCD90mEBFjVTNMJ_w_6_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">726254</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_zysOtpyKu0qH6NDGzrRMrA_7_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">15561246</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_muDAIicf00WyfuwHABa9fw_7_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">23576139</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_xGIB1O5YE0qyneRaYYzrkA_8_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">59807</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_Ae1u05TZiUygyI1A1S578Q_8_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">81522</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_1nz5a065KkmYZRGaZyzzuQ_9_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">41186</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_PDWwMooQtU6LVopTKpYu2w_9_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">40170</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_ND4tW0z2oU-v0FOZCyV5QA_10_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">271162</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_zOWDU1p2qkyu1scWNlrIEw_10_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">281662</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_2iftL89HlEesf7vasEEwvQ_11_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">15933401</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_FxnvGAQPbk-QN1D_FoiOZQ_11_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">23979493</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_RMBaN6_y8kW63ToJ_80jAw_14_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">713668</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_rFinBbH_oUCvEqYDPmyQag_14_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1352240</us-gaap:AccountsPayableCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_yFRS6KIUgES5dbBjPKdO4A_15_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2050690</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_ga-y0TED1kqC1ju0eYS1Tg_15_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2008735</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_1sFdAX2leEKa38oiMd4nZg_16_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2764358</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_4PLtS-kw802ttYZkWCTbIw_16_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">3360975</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w"
      decimals="INF"
      id="Narr_IqJ6BLiOP0GbkNjfTG1rXw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="INF"
      id="Narr_dwII8s4ICUaxs9kyMHMjwQ"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w"
      decimals="INF"
      id="Narr_AlFrP1vyfEuDAb7xbKAo1g"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">40000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="INF"
      id="Narr_ikiJ5NJMHEOGwLHrsZFnow"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">40000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="INF"
      id="Narr_bLLfu64C_UqFMMrFSm-XWA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">31194</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w"
      decimals="INF"
      id="Narr_jPoDLkuP9E6HZC_LJ65ORg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="0"
      id="Tc_PX5_uJFl7E62IMVcvzPZSA_18_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">727361</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_RYCYAZK_pEWprwjh9kla6w"
      decimals="0"
      id="Tc_AsXw5-PGHkmviFfMGuW-Pg_18_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_NpeZImQCWku5w7MGerAulw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_7D-W8TrOPEyOwldZFCLjsw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_GrRbU7DE6EiyC8act_e-Og"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_bCKlwD_c3kiiO3-z1HHtTg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_iaH-4tdqJE2z9N-qQAaY9A"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">8192538</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_lAvkuqlHpEeXndczZt2VZQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5481055</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_mHzdgiq4X0afInPFmmQEDA_20_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">8192</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_oQGUjjZMd0SmozgHjGqAUQ_20_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5481</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_80vrbRSz3UW80RTZd5xwUw_21_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">356709645</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_QQjX-cmme0yg0IsQRJ4PdQ_21_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">350971225</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_rfjQ7aO-W0q85IuSPAaUsw_22_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-10634714</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_5elbOoIc80S6RxijAvbHTQ_22_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-10627379</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_2ZZP2fLs6k2kz-UL3PmSMQ_23_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-333641441</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_SrNzXnsVbkWMev3VjDFK5A_23_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-321041872</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_8zSLGN8S6UyWJ9N7Ny9Xvg_24_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">12441682</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_FY42SZuqsk-LIieNK0576g_24_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">19307455</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_C-az3pPIxEmC0g9FuydMaw_25_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">15933401</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_yVb0bf550EiLG_xW5uCrPw_25_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">23979493</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_XQVUQPgy5UmEFfZl6_W4Sg_3_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">285759</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_S4be3dchUEOFgCEfAu0E5w_3_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1502581</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_0h42JqRxxEaGRMuX90gkRQ_5_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">7043035</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_zYa1hx9QU0GLuhAkS6jn2w_5_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">9363537</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_f4UMm83Bz0CIeloWHypZqA_6_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">6476560</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_bjY2Tm59xUyFQ3QmhK57Eg_6_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">6458699</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_QUzfox4yM0-kgWy4-Duyng_7_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">13519595</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_zBGHx3RkWEifwRNayvVYrA_7_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">15822236</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_67jdReUGgk-XIfps8O8-fA_8_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-13233836</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_IWwpZrIaEUC0GSTTAh6YPQ_8_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-14319655</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_x_yx5gYG4UCCb_Bqhqp8aA_10_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">652086</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_Sw_3m9kvb0KdOF5xGhIYeA_10_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1289144</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_gUjG6t6s1ES8T9XOEQauoA_11_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">77500</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_XAx3tbcHh0y0Pu0e5T1AJQ_12_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-95319</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_i5Orm--gkE-lptrIS2knaQ_12_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">71800</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_LLJFjp2dN0-1MvLzc2AT1Q_13_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">634267</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_v_5SiMkBDkayga76EqiUew_13_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1360944</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_CL4lvuO1xUaI_ZFbOyx16w_14_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12599569</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_I8VLKocUmk-j-syDbZZDlw_14_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12958711</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_tl41kbCtOk-WRyWBvGJ68g_16_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-7335</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_D965BVoa1E2fKMm01ofYMg_16_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-16106</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_J0lcz_nBSkiJFI2eDn_lkw_17_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12606904</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_choOLT4pd06BQPY2EDnDbg_17_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12974817</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="2"
      id="Tc_uBrdFnNaP02BXg-hZCjE8A_18_3"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="2"
      id="Tc_NJkTqWRXCkKNopYEZ0Zu2A_18_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">-2.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_hnEjoz-6S0GJodnX01PpbQ_19_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">6538722</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_uo63NEJL9Em8OFAxWTV5QQ_19_6"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5509921</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg"
      decimals="INF"
      id="Tc_8Ws7dVYx6Uqf69viL-JZRw_4_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7xgFWSFRdUezv37296CiJg"
      decimals="0"
      id="Tc_nN0JDZuCJ0uN6Xm8hK7mTw_4_5"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8TENrsfRpEip6COKOMdc6g"
      decimals="INF"
      id="Tc_c-qD3vGhZEOw6KojnMPmPQ_4_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">3736673</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8TENrsfRpEip6COKOMdc6g"
      decimals="0"
      id="Tc_ckkPIu-pHEmTx8GqgsVUEA_4_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">3736</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uxcYngPZ4Ueh1LhH_AOjNw"
      decimals="0"
      id="Tc_dvMYorMrAEmBFAu1k_H3gQ_4_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">335644204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HdVMa0DdwEmc14llqTxLvA"
      decimals="0"
      id="Tc_Sarlsf6vnUOrXNJPZiH_rA_4_16"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-10611273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W8VMjZfm3kqAuG4zdxRBGg"
      decimals="0"
      id="Tc_rJjQ7igR1U2jE8mP8VdzTA_4_19"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-308083161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ"
      decimals="0"
      id="Tc_u-klsmDGyUiLo2nwvg6xwA_4_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">16953506</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"
      decimals="INF"
      id="Tc_hsDIZixODk-nEmWp-57o9w_5_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">10518</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"
      decimals="0"
      id="Tc_kt06ERe6cUinrCnhTeoIFg_5_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">11</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ"
      decimals="0"
      id="Tc_82VZs14Nk0ONh4SdrA0Nlg_5_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-11</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"
      decimals="INF"
      id="Tc_osfMVAXMfkGIj-zduuAjSA_6_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1687712</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"
      decimals="0"
      id="Tc_F3kuEBpfVkOaXyj1p-Oamw_6_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1688</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ"
      decimals="0"
      id="Tc_31qY-_bfpU2Ki-IGygsvpA_6_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14685802</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_zgmcxKSiXESqquhtjPlE-w_6_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14687490</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_3j5lWFF8JEWOa1ah--AL8A"
      decimals="INF"
      id="Tc_HkQpgUUpqE2nttuKyrcnFA_7_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">41152</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_3j5lWFF8JEWOa1ah--AL8A"
      decimals="0"
      id="Tc_eykU_eobrEikptvqQDB7gA_7_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">41</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember__-_le6ti2UOYE_b8iPNg5g"
      decimals="0"
      id="Tc_2xzJmlI3oEKKX_9puFDuLQ_7_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">134364</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_0OTUY_lcakyo9dePfZ4fUw"
      decimals="0"
      id="Tc_BCZlPjFsuU6EVBmjslgG9g_7_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">134405</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"
      decimals="INF"
      id="Tc_TT13S4P6J0ukgjkzaQR_NQ_8_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Sr22jtcaU0mj1r8rUogxdg"
      decimals="0"
      id="Tc_PPYCSbQAmUOnSu9srVdSRg_8_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ"
      decimals="0"
      id="Tc_7etNWwg5UUKCIwC5F2q-GQ_8_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">17430</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_WZujxwp5QE-CCqDk4JY_dA_8_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">17435</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XxNyFVraWk6u5UXWuEJ4xQ"
      decimals="0"
      id="Tc_J44a7fOKWECwbntivlVquQ_9_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">489436</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_sWDEFjVCckKm0vsK7aI9pw_9_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">489436</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rfpje9runUCtL_Q69zMdAA"
      decimals="0"
      id="Tc_p_TLWjjQDkuXRew_gBjMzQ_10_16"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-16106</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_8iFkoDViskunRHc_ug-9Qg_10_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-16106</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7BZm_z9xCkSv0FQpO74xqQ"
      decimals="0"
      id="Tc_RiIbtuHZLEaP8muV1zc4fA_11_19"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12958711</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_W6F9j7tp5ECrA6VdIKHsFg_11_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12958711</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IJ8zJ18I4EClq_KQWPYSqw"
      decimals="INF"
      id="Tc_Y7iSv2ZZUUSO9Vz2C7nuAA_12_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IJ8zJ18I4EClq_KQWPYSqw"
      decimals="0"
      id="Tc_CQmv_61wvEKs94TBuFgJ6A_12_5"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K43Lpib1Z0SaiG-7BlUL6g"
      decimals="INF"
      id="Tc_WrearMmAwkSiDIj85b06Ig_12_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5481055</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K43Lpib1Z0SaiG-7BlUL6g"
      decimals="0"
      id="Tc_rs3m6SwqD0C60VIUz-Lf7Q_12_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5481</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T49vl6RPsU-nKirVaTJE3A"
      decimals="0"
      id="Tc_-P0SSQyaNUOVq496epfjcA_12_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">350971225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7S-nLeE1P0KWLPTOkK9J0Q"
      decimals="0"
      id="Tc_2MonwH2kWUy3U0f0YT4Uhg_12_16"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-10627379</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F_cddC-SRkOjmWWwt-fqVg"
      decimals="0"
      id="Tc_X2FU_AZw1UGamaZvExtHWg_12_19"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-321041872</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_mALnVDEh6UaxUj_ccVn_uA_12_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">19307455</us-gaap:StockholdersEquity>
    <apre:TemporaryEquityConversionOfStockSharesConverted
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BAoeaXQje0CtAvGY50doJg"
      decimals="INF"
      id="Tc_38-3p78ik06RiPCGQAsRYQ_13_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">25033</apre:TemporaryEquityConversionOfStockSharesConverted>
    <apre:TemporaryEquityConversionOfStockAmountConverted
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BAoeaXQje0CtAvGY50doJg"
      decimals="0"
      id="Tc__IfxYTwQK0irS2hA4XQkFw_13_5"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">583702</apre:TemporaryEquityConversionOfStockAmountConverted>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="INF"
      id="Tc_5zZFaPgozE6pQ25HhLSHJA_13_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">12516</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="0"
      id="Tc_BpPRnZpz4EK1uFQd9f2SVA_13_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">12</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"
      decimals="0"
      id="Tc_jrZKjI57r0KNSErXAaDbow_13_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">583690</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_6clkwkQC70O9xU_bLN_DXQ_13_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">583702</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="INF"
      id="Tc_7pSGlW5j9UWzOci5vYwY0w_14_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">17154</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="0"
      id="Tc_Wr7zKGkDkUK1NcZYUtoA0g_14_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">17</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"
      decimals="0"
      id="Tc_un9amfXwzkS7hf1aCYfFlQ_14_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-17</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="INF"
      id="Tc_tRVpbnz5_06cGJ1BHnzhNA_15_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">26459</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="0"
      id="Tc_L1GDsPY59UKVRpnISr525A_15_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">26</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"
      decimals="0"
      id="Tc_9cZremIV6UySkPyksP2oDg_15_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2724896</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_rIm9aVZ4N0-NWL-e3wk2OQ_15_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2724922</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_ukSBibSsYkOC0ffd9tzE2w"
      decimals="INF"
      id="Tc_PNCtVVOCJUe4g2EbWlVX2w_16_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1337948</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_ukSBibSsYkOC0ffd9tzE2w"
      decimals="0"
      id="Tc_wpkU-wMLBE-dF36-DCcImQ_16_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1338</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_X9yxNCi1eUiwkdxf-fOimw"
      decimals="0"
      id="Tc_EOQ9oBSuvkaAaAvnzfcmcQ_16_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1913887</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_tzboIpMCLE6jmiSEJoPsxg"
      decimals="0"
      id="Tc_vq5PQTtMM0yzBTTbOpsG6Q_16_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1915225</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="INF"
      id="Tc_65GHa0Yxzk6jvNBJG7rWmg_17_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">27500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="0"
      id="Tc_OcJCDvc270aQfa91Xcgdew_17_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">28</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"
      decimals="0"
      id="Tc_sW7z2gZ0NkmW7t43GQPquw_17_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">39022</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_No2vYpCcf0SNmB9aN0CXTA_17_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">39050</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <apre:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="INF"
      id="Tc_qpvQHiWHt0WVRQI5ccUhkQ_18_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1289906</apre:StockIssuedDuringPeriodSharesWarrantsExercised>
    <apre:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LCttbcd8DkCWA3dovZ5sLw"
      decimals="0"
      id="Tc_UScn8lC5xUSbiSf107VzBA_18_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1290</apre:StockIssuedDuringPeriodValueWarrantsExercised>
    <apre:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"
      decimals="0"
      id="Tc_fevU9B_sCk2ylqQkwup2hg_18_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-1199</apre:StockIssuedDuringPeriodValueWarrantsExercised>
    <apre:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_nsHI97AmIUi_OkOgQ5JaZA_18_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">91</apre:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_giu9FVM0AEihDy8qpDcRUw"
      decimals="0"
      id="Tc_PlEG9mSHQUagFpeJNPD3Rw_19_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">478141</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_Y5yrOIX0NEeISbS9KqkEKw_19_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">478141</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rw7WXSTzPUS_r8Ou3XFKVg"
      decimals="0"
      id="Tc_7b9DdsYGCkqEvDDeA2ED1Q_20_16"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-7335</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_sA94sZAHq0KGcFqEskj8_g_20_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-7335</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mRdeq00MTEmoRCUVaSWaIg"
      decimals="0"
      id="Tc_yYlF5fh-b02fR0W_63FP9A_21_19"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12599569</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_uhu1DNPfqU6CRr_6k3xTDQ_21_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12599569</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UTwtKV-qkEOxVLKfaZVgbg"
      decimals="INF"
      id="Tc_V0mY4N0UJ0ymrpjG0mwdZg_22_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">31194</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UTwtKV-qkEOxVLKfaZVgbg"
      decimals="0"
      id="Tc_uurZgqVhb0uRXkhW-_HrUw_22_5"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">727361</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtIejotXFUSQPrZvskRYfw"
      decimals="INF"
      id="Tc_LqKy6gJL8EKCoLKLDKkuGQ_22_7"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">8192538</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtIejotXFUSQPrZvskRYfw"
      decimals="0"
      id="Tc_H0JFcdIpG02pzScTUh2epw_22_10"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">8192</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J9HtUxOqeEaXcgWIs4717Q"
      decimals="0"
      id="Tc_EXH_CttqT0eLZDQJ-aIvWQ_22_13"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">356709645</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PilxZKpEyEi9WNFYDfCOhA"
      decimals="0"
      id="Tc_chn_GeV77UCW40cBkTd-8w_22_16"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-10634714</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAL2DshPD0OdJw_EpkpGGg"
      decimals="0"
      id="Tc_oZY7DrtaR0Sq3zLoAJ3x0w_22_19"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-333641441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_py0XfPoJ5UaMpADTNjiatA_22_22"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">12441682</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_phKZIxvKZki5dNYyz4xJRQ_4_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12599569</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_4OdbiXkUhEG4J4HgWE4neQ_4_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12958711</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_LIo4yw6-hEGgT8wPeAfbUA_6_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">21715</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_IbdhY3DK_EmvhJQFREneeQ_6_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22318</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_mPjhEP-x2EqIcqKxzDIwgg_7_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">478141</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_PozDa3PoC0S_5KagLKWUZw_7_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">489436</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <apre:NoncashConsultingFees
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_aSN8N4qZqEqxPpVn3dgUjg_8_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">39050</apre:NoncashConsultingFees>
    <apre:NoncashConsultingFees
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_Mah4rp5wMUqUIbGbn8-SyQ_8_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">17435</apre:NoncashConsultingFees>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_Zj4s0rHaTkC_r5udofMA1g_9_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-95319</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_lXXAbTHP9EOUuKhJdRJhGA_9_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">71800</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_DH-QQrRH2UueEPTR-kYJXw_11_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">217906</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc__lYowyhgkE2NLd4geCjzjg_11_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">96674</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_vwNM9qE_j0SATsOOpGDcLQ_12_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-646701</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_YMEpaFMBKkaUbDvfVpp6bA_12_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-314207</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_2gWDaCTsTkWJLONyiyZ8KQ_13_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-64488</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_khAthY-cT0qoM_ue9G4TNA_13_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-115541</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_2bmEiSkLgk6mqsW7W9YRPA_14_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-528974</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_xX2rV8apgkW8Lm1xiscqjQ_15_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12894439</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_JUYAJPBz5UacpuvjD9oUbA_15_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-13556718</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_kLSWQ1CCn0SOdvnFD5j1mg_17_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">15478</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_4DUHAwMfykChKvhmt6OkBg_18_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-15478</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_yeCY05szxEubHSeQqn4srg_20_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">91</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_sIRy3tqS-EizkNA8XXY6SQ_21_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5047606</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_HfiOlvCT_EmhVVPKIFSu3w_21_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">16140356</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_iT-AX_1osUusr4ZEuT4XTA_22_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">407459</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_N-27zl60OEienk4XxMhBjQ_22_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1318461</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_Z3X-Q7NfeEmgKdYtXUO4lQ_23_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">4640238</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_mJQsioGwJUydFmCjRNRCIQ_23_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14821895</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_wr9JjcU3eEu9CJAHQKUj1A_24_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-8254201</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_2lZ6adbUBEip6lzHaWB_Nw_24_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1249699</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_YAsiRHFKDEiKmQOFRnSOvQ_25_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">4679</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_y2oAI1NbM0-BGCc2qKBH_w_25_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-7181</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_x2AgZaPJk06N71wtBS0OYQ_26_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22890055</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ"
      decimals="0"
      id="Tc_hydXrsU8mU2Y1LMrlvqyAg_26_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">21647537</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_onwvAvS6sUeek-DBNS_1og_27_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14640533</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_n7wZxwJZK0ytffzSH-pNsg_27_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22890055</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_TI2ZfbaSBE-AyCFrlGkdgg_30_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14599347</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_a-D3ZmTQqEiJFymzBBvpYA_30_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22849885</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_rJZArZ_8VEuvJd08z9e8og_31_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">41186</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_Rr8_l_wREEqGAuDogI8dPA_31_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">40170</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_o475PSFCbkGu_Rn2yBzffA_32_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14640533</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_nD6vMBMEaUaPBl1uKBJU7A_32_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22890055</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_OBSc3gUdfU-ASI1Nt3agNg_35_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">583702</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_4FMynduzZkSeC97h5YUEkQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Nature of business and basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nature of business&lt;/b&gt;&#x2014; Aprea Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical-&lt;span style="white-space:pre-wrap;"&gt;stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania.  The Company&#x2019;s two clinical programs are a next-generation oral inhibitor of the WEE1 kinase, APR-1051, and our novel oral macrocyclic ATR inhibitor, ATRN-119. We have voluntarily paused further patient enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119 and started the orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of presentation and management plans&lt;/b&gt;&#x2014;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S.&#160;GAAP&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management and technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company believes that the December&#160;31,&#160;2025 cash balance of approximately $14.6 million and the gross proceeds of approximately $5.6 million received from our private placement of our common stock and warrants in January 2026, before deducting placement agent fees and offering costs of approximately $0.4 million, will not be sufficient to meet our currently projected operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these consolidated financial statements. Therefore, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these audited consolidated financial statements. The Company is in the process of seeking additional equity financing. In the event that additional funds are not available, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="-5"
      id="Narr__5YX357FnEOOPlZfKlLlTg"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">14600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_28_2026_To_1_28_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_dtwms4JdkkCkrALAA9rEeA"
      decimals="-5"
      id="Narr_fmkrvxQ46kqbsWnJBuc_pw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_28_2026_To_1_28_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_dtwms4JdkkCkrALAA9rEeA"
      decimals="-5"
      id="Narr_z_YMm5QrG0WzGkSbeQwOXQ"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_nsX7oikbxE2dXRdF0vsNgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of significant accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principles of consolidation&lt;/b&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&#x2014;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions include, but not limited to, stock-based compensation and accounting for research and development costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign currency and currency translation&lt;/b&gt;&#x2014;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#x2019; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Concentrations of credit risk&lt;/b&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&#x2014; &lt;/b&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted cash&#x2014; &lt;/b&gt;The Company has restricted cash of approximately $41,186 and $40,170 as of December&#160;31,&#160;2025 and 2024, respectively, that is securing the Company&#x2019;s credit card program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment&lt;/b&gt;&#x2014;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment and office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment of long-lived assets&lt;/b&gt;&#x2014;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&#x2014;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A Convertible Preferred Stock&lt;/b&gt;&#x2014;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#x2019; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting for leases&lt;/b&gt;&#x2014;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&#x2014; The Company&#x2019;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expense. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;&lt;i style="font-style:italic;"&gt;958,&lt;/i&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;i style="font-style:italic;"&gt;Not&lt;/i&gt;&lt;i style="font-style:italic;"&gt;-&lt;/i&gt;for-Profit Entities, and that the grants are&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;within the scope of ASC&#160;&lt;i style="font-style:italic;"&gt;606,&lt;/i&gt;&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;meet the definition of a customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&#x2014;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.&lt;span style="background:#ffffff;"&gt; Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&#x2014;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC&#160;718.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#x2019;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also awards restricted stock units (&#x201c;RSUs&#x201d;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&#x2014;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share&lt;/b&gt;&#x2014;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Included within weighted average common shares outstanding for the year ended December&#160;31,&#160;2025 are&#160;1,813,734&#160;common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 715,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,075,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,194,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,933,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,968,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&#x2014;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, manages the Company&#x2019;s business activities as a single operating and reportable segment at the consolidated level considering the nature of the Company&#x2019;s product candidates and services, class of customers and the regulatory environment in which the Company operates. Accordingly, the Company&#x2019;s CODM manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#x2019;s long-term strategic goals. In making these decisions, the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, and allocating resources. The CODM performs this assessment based on the Company&#x2019;s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual net loss versus the budget and then decides how to allocate resources to invest in the Company&#x2019;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets. Other segment items included in consolidated net loss are interest income and foreign currency gain (loss), which are reflected in the consolidated statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently issued accounting pronouncements&lt;/b&gt;&#x2014;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In January 2025, the FASB issued ASU 2025-10, &#x201c;Government Grants (Topic 832),&#x201d; which establishes a new Topic 832, &lt;i style="font-style:italic;"&gt;Government Grants&lt;/i&gt;, and provides comprehensive recognition, measurement, and disclosure guidance for government assistance arrangements. The ASU requires entities to recognize government grants when the grant agreement is legally enforceable and all eligibility requirements have been met, and to present grant income separately from revenue. The guidance also introduces expanded qualitative and quantitative disclosures related to the nature, terms, and financial statement effects of government grants. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February 2025, the FASB issued ASU 2025-11, &#x201c;Interim Reporting (Topic 270): Narrow-Scope Improvements,&#x201d; which amends Topic 270 to enhance interim reporting requirements. The amendments require additional disaggregation of certain expense categories, expanded interim disclosures for significant events or transactions, and alignment of certain interim disclosure requirements with annual reporting requirements. ASU 2025-11 is effective for interim periods beginning after December 15, 2027, and for fiscal years beginning after the same date. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently adopted accounting pronouncements&lt;/b&gt;&#x2014;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#x201d;, which requires disaggregated information about a reporting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted this standard prospectively on January 1, 2025, which expanded the Company&#x2019;s disclosures beginning with its annual consolidated financial statements for the year ended December 31, 2025, but did not have an impact on the consolidated financial results.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_OA-vMj0f_0KE_5qEVM2m0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principles of consolidation&lt;/b&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_cuvV8Qc2kEGQuHVZmRBTSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&#x2014;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions include, but not limited to, stock-based compensation and accounting for research and development costs.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_sW_KehfiB0ictIiA01X6SQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign currency and currency translation&lt;/b&gt;&#x2014;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#x2019; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss as incurred.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_OaEjHakQ8EiuHozl-uVpQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Concentrations of credit risk&lt;/b&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_4sWRw4_qIk2gOWtSqz0Exw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&#x2014; &lt;/b&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted cash&#x2014; &lt;/b&gt;The Company has restricted cash of approximately $41,186 and $40,170 as of December&#160;31,&#160;2025 and 2024, respectively, that is securing the Company&#x2019;s credit card program.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Narr_K6FWRfHjSkeUVGyR7i7Sog"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">41186</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Narr_hxI0lPkOrUCFNIPhQsrGgw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">40170</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_wIebo9UGFEidykq3h9E4Mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment&lt;/b&gt;&#x2014;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment and office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <apre:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_u0jC7xfaq0i7-lRT2AvsPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:78.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment and office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</apre:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_CGXEBDoB80uMJgtwrAZVgw"
      id="Tc_3CtQVUR160SZlRwSjhJQ-w_2_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_OfficeFurnitureAndLaboratoryEquipmentMember_N7HQnrCgnk6dOXicETh-5w"
      id="Tc_l8_2qYJ_Z0aaHSzGIeNMLw_3_2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_TjO__aRXhkOIFaXo3HS1eQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment of long-lived assets&lt;/b&gt;&#x2014;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_bC-TSWnxu0mbQkWtyzJw0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&#x2014;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <apre:TemporaryEquityPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_r-7LgWd9E06EWy20TrsZZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A Convertible Preferred Stock&lt;/b&gt;&#x2014;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#x2019; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;&lt;/p&gt;</apre:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_wudcW2zq306UVJVc581EPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting for leases&lt;/b&gt;&#x2014;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_MmhwbVqo5UunafekePRqMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&#x2014; The Company&#x2019;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expense. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;&lt;i style="font-style:italic;"&gt;958,&lt;/i&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;i style="font-style:italic;"&gt;Not&lt;/i&gt;&lt;i style="font-style:italic;"&gt;-&lt;/i&gt;for-Profit Entities, and that the grants are&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;within the scope of ASC&#160;&lt;i style="font-style:italic;"&gt;606,&lt;/i&gt;&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;meet the definition of a customer.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_XKCswMNODECG_VsovjCXRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&#x2014;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.&lt;span style="background:#ffffff;"&gt; Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_HlXg3-M4FUqlW6PiGDgPjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&#x2014;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC&#160;718.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#x2019;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also awards restricted stock units (&#x201c;RSUs&#x201d;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_4n46abSfXUK8D6gH-C_XDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&#x2014;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_ulxJHbNHc0-FZ605HYIy2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share&lt;/b&gt;&#x2014;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Included within weighted average common shares outstanding for the year ended December&#160;31,&#160;2025 are&#160;1,813,734&#160;common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 715,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,075,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,194,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,933,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,968,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6EMQYsKTe06p12xtaqpj7A"
      decimals="INF"
      id="Narr_xiQSwU_2lkePwv9d3n1ngg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1813734</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_S1lG8LydLkKPYINNj8Bbyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 715,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,075,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,194,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:74.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,933,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,968,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oq3hsrqBykm0qXaMoCxjKQ"
      decimals="INF"
      id="Tc_L_2rGOqpxUKJ_eX9iybtmg_3_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">15596</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_yFpzhwTg9Ea949XNcHNkug"
      decimals="INF"
      id="Tc_EMhwiOlti0CWDVDIAM82BA_3_4"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">28112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_REODE2xYG0ygbK6Gt1iCwQ"
      decimals="INF"
      id="Tc_IkZoIIfR1EeVx8DOfKVzMQ_4_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">811121</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_05GUoR4aq0ubc6DwiLlP2g"
      decimals="INF"
      id="Tc_eNciHTGj2E-S9kXngZIVsA_4_4"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">715620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_CJR1S7G5HUqhj3cWK_5B4Q"
      decimals="INF"
      id="Tc_8Pt6BaAXe0eol09nXzZ6tg_5_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5075321</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7byEi2lE20ibECXouEsanw"
      decimals="INF"
      id="Tc_gHE4GgX7T0OP-ebmsKFxEg_5_4"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">2194788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Pk_DcJsgPU6S0cEiZFfnSw"
      decimals="INF"
      id="Tc_jzfsKVZXjEOS04Cwdr8YMg_6_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">31008</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_hqbRhvOLLEi90FCZNRS2RA"
      decimals="INF"
      id="Tc_P3YABIdQBECRK8OCoqgTjg_6_4"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">29712</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="INF"
      id="Tc_X0FYkAEykkCkRLp9cqubLA_7_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">5933046</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="INF"
      id="Tc_L6IAwy73bEKTz0d3bX7dHw_7_4"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">2968232</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_DTNZGLX3qEe9hJVOBB1UNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&#x2014;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, manages the Company&#x2019;s business activities as a single operating and reportable segment at the consolidated level considering the nature of the Company&#x2019;s product candidates and services, class of customers and the regulatory environment in which the Company operates. Accordingly, the Company&#x2019;s CODM manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company&#x2019;s long-term strategic goals. In making these decisions, the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, and allocating resources. The CODM performs this assessment based on the Company&#x2019;s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual net loss versus the budget and then decides how to allocate resources to invest in the Company&#x2019;s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets. Other segment items included in consolidated net loss are interest income and foreign currency gain (loss), which are reflected in the consolidated statements of operations and comprehensive loss. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_gJmNm3cVbUOL8slkDuEBhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently issued accounting pronouncements&lt;/b&gt;&#x2014;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In January 2025, the FASB issued ASU 2025-10, &#x201c;Government Grants (Topic 832),&#x201d; which establishes a new Topic 832, &lt;i style="font-style:italic;"&gt;Government Grants&lt;/i&gt;, and provides comprehensive recognition, measurement, and disclosure guidance for government assistance arrangements. The ASU requires entities to recognize government grants when the grant agreement is legally enforceable and all eligibility requirements have been met, and to present grant income separately from revenue. The guidance also introduces expanded qualitative and quantitative disclosures related to the nature, terms, and financial statement effects of government grants. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February 2025, the FASB issued ASU 2025-11, &#x201c;Interim Reporting (Topic 270): Narrow-Scope Improvements,&#x201d; which amends Topic 270 to enhance interim reporting requirements. The amendments require additional disaggregation of certain expense categories, expanded interim disclosures for significant events or transactions, and alignment of certain interim disclosure requirements with annual reporting requirements. ASU 2025-11 is effective for interim periods beginning after December 15, 2027, and for fiscal years beginning after the same date. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently adopted accounting pronouncements&lt;/b&gt;&#x2014;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (ASC 740): Improvements to Income Tax Disclosures&#x201d;, which requires disaggregated information about a reporting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted this standard prospectively on January 1, 2025, which expanded the Company&#x2019;s disclosures beginning with its annual consolidated financial statements for the year ended December 31, 2025, but did not have an impact on the consolidated financial results.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_hqcCK8OM6k2GLQxcmWZ54Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Property and equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148,704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (94,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72,440)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Property and equipment&#x2014;net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense for the years ended December&#160;31,&#160;2025 and 2024 was $21,715 and $22,318, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_UNS6ampgqUWTwjtB1jtlJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148,704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (94,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72,440)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Property and equipment&#x2014;net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_sUM0Rd5XwUaQcZ4Pzaib0Q"
      decimals="0"
      id="Tc_Q-4ha_y54US2uCaT-Y8jmA_3_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">148704</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_apre_LaboratoryEquipmentMember_uJ12jSW3IE2IlsnxHNVHYg"
      decimals="0"
      id="Tc_GlaDAcZPOUybyrMDqD5kZg_3_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">148704</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ZLW0Hz7D7kWIA9AazR-fdg"
      decimals="0"
      id="Tc_N3MV9w5Wm0SfvMlS6o1eNw_4_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5258</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajl5U0Fik0WBAVlJp8BOHA"
      decimals="0"
      id="Tc_xV3SGfFBW0aUZ_Z7zpiVvA_4_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5258</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_IWY62v9fwEeI9r9wrx8WNw_5_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">153962</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_I00OHUnhx0ufZgxtkKooDQ_5_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">153962</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_KfAfDDX7iE6IlQ9omkAxwQ_6_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">94155</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_0vSlbg-oqUWxStLUplaOjw_6_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">72440</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_cpq7S-t_mkCcJfR13NBAqA_7_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">59807</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_NPbyuH1URUSwmy5I94QcoA_7_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">81522</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Narr_LcaaX25gKE2PtxE6XcgyUA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">21715</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Narr_oHSVaDDuXUWmqt5XjAPixQ"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">22318</us-gaap:DepreciationDepletionAndAmortization>
    <apre:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_JtqBdbDzMkSRPpB2Y_ntAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is party to one&lt;span style="white-space:pre-wrap;"&gt; operating lease for office and laboratory space. The Company&#x2019;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less.  Rent expense for years ended December&#160;31,&#160;2025 and 2024 was &lt;/span&gt;$93,366 and $91,179, respectively, which is included in operating expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was amended in October 2025 and is currently set to expire on October 31, 2026. Rent expense under this lease is $115,000 annually and the Company has applied the short-term exception to this lease. The Company has no lease obligations beyond October 2026.&lt;/p&gt;</apre:LeaseDisclosureTextBlock>
    <apre:LesseeOperatingLeaseNumberOfOperatingLeases
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_inHzoxNpjEW6hT3mYYdktg"
      unitRef="Unit_Standard_lease_QaFYmEckJU-MqyGJp97u6A">1</apre:LesseeOperatingLeaseNumberOfOperatingLeases>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_OyQ7wp2wFUSYaMzly9YdTg"
      decimals="0"
      id="Narr_c3GbCkY_2kGJy2Fxy0fMCw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">93366</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember_kq5Z_aQ4GkOW-yWNsb-P5Q"
      decimals="0"
      id="Narr_gzQfsyTWtEG-P6ulw088yg"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">91179</us-gaap:OperatingLeaseExpense>
    <apre:LesseeOperatingLeaseAnnualBaseRent
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Narr_fOxsWzU71kmjb9y0QkJCOQ"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">115000</apre:LesseeOperatingLeaseAnnualBaseRent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_lByz84FpaECIUz1rGIyS9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Accrued expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional&#160;fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,765&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation, severance&#160;and&#160;benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 770,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 465,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research&#160;and&#160;development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 870,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,243,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 161,372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&#160;accrued&#160;expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,050,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,008,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_ynxeQrGBJEqsQCAxKo_DPQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional&#160;fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,765&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation, severance&#160;and&#160;benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 770,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 465,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research&#160;and&#160;development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 870,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,243,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 161,372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&#160;accrued&#160;expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,050,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,008,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_m1Dd-XHGqkmmq3JLY2QvCA_3_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">248591</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_xFefa-lat0m7gre3dkx-UA_3_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">143765</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_1kOY8AG2AUCiBPO94BI0rA_4_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">770562</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_B-Zf4oiWwU2O9AJ8X8ktlA_4_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">465015</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_paHCRBAFXEamJ4aEzVrUFg_5_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">870165</apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
    <apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_ou2hqranEkeCTRxJ6_pcgw_5_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1243975</apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_ho-nQ5iHIU6M2O-m-tdJjw_6_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">161372</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_b56lyBseEkW4XTwWxyLKxA_6_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">155980</us-gaap:OtherAccruedLiabilitiesCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_dkPU7pdZLUKmGQRKA1jahQ_7_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2050690</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_ldhoQWm50EOPzESPFxuSjg_7_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2008735</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_5HOxAcLi2U2yIzNg4GaEtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Income taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of net loss are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (256,019)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (218,261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,343,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,740,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,599,569)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,958,711)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The effective tax rate varies from the federal statutory tax rate as a result of the following differences:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at U.S. statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,646,101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign tax effects &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_GAiVwh82eUmdKx4UoyCRCA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,220)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,592,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nontaxable and nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in unrecognized tax benefits &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_eE2fcbd4R0eebi4itMmEZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Effective tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company did not recognize any state tax expense for the year ended December 31, 2025 there are no states making up greater than 50% of the tax effect.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Section 162(m) limitation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred taxes as of December&#160;31,&#160;2025 and 2024 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,568,167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,058,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,130,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,051,018&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,386,699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,850,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Accrued Expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 199,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 165,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,349,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,165,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,349,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,165,532)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company has no income tax expense due to operating losses incurred for the years ended December&#160;31,&#160;2025 and 2024. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December&#160;31,&#160;2025, the Company has $143.3 million, $85.4 million, and $91.8 million of foreign, federal and state net operating loss carryforwards, respectively, that expire at various dates through 2037. Certain of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section 382 or similar provisions, which impose limitations on their utilization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company amended its Federal income tax return for year ended December 31, 2023, to claim Research and Development credits of $42,220 and reducing NOL carryforward. Certain of these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section 382 or similar provisions, which impose limitations on their utilization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation allowance increased in 2025 and 2024 by $6.2 million and $0.7 million, respectively, due to an increase in the deferred tax assets by the same amounts, primarily due to the increase in net operating loss generation. Realization of the future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain changes in the Company&#x2019;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company&#x2019;s formation due to the complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#x2019;s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future. For Swedish income tax purposes, the Company&#x2019;s net operating losses may be subject to limitations in accordance with the country&#x2019;s group contribution restriction laws.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2022 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2019 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company&#x2019;s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company&#x2019;s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company&#x2019;s effective income tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2025 and 2024, the Company had approximately $0.1 million of liabilities, respectively, related to uncertain tax positions. As the Company&#x2019;s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has not made payments or received refunds for income taxes for the years ended December&#160;31,&#160;2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 4, 2025, the &#x201c;One Big Beautiful Bill Act&#x201d; (OBBBA) was enacted into law. The legislation made several changes to the U.S. tax code, including the return of 100% bonus depreciation, the ability to immediately deduct domestic research and development costs, a more favorable rule for deducting interest expenses, and updates to international tax rules around global intangible low-taxed income and foreign-derived intangible income. The Company has evaluated the impact of the new tax provision and determined it to have an immaterial impact on the consolidated financial results. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_fs316a8JSUqtdLE_HzM09Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (256,019)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (218,261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,343,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,740,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,599,569)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,958,711)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_x2waWdI6y06iIcRFhALG5Q"
      decimals="0"
      id="Tc_7ch0_pMKX0C-4lFjkC7RmQ_3_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-256019</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_iTqHbEL2pkeKPob89U4UMA"
      decimals="0"
      id="Tc_QqafQSYGsECwgV2U7BZWDg_3_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-218261</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_mZZT_4w8FUqzJrb9O-iaKQ"
      decimals="0"
      id="Tc_MNxXDlDabkenYTn7VSffeg_4_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12343550</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_gXVMK2ewSUubD_HBDBGCyA"
      decimals="0"
      id="Tc_159z8I5adky0DYpJ7jiL9w_4_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12740450</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_EBqGlsaNjUqe5G1X1xEBKQ_5_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12599569</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="0"
      id="Tc_H8CnzAgMtUOfplwMSkTeNg_5_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-12958711</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Group_Tb3OY83dh0GT2MZSQ1uujA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at U.S. statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,646,101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign tax effects &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_GAiVwh82eUmdKx4UoyCRCA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,220)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,592,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nontaxable and nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in unrecognized tax benefits &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_eE2fcbd4R0eebi4itMmEZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Effective tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Section 162(m) limitation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_D_AZWUBKM0Od5B51H0GytA_3_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">-2646101</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="3"
      id="Tc_i_VXJvI2JEqAWIXBFH7lQw_3_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_S4dRfsWTs0adMLI9QTUkTg_5_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1024</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_C1geEHpPIkCyj6RAlcmqEQ_7_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">42220</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="3"
      id="Tc_HrhczReTbk-gLlvH2HFa7Q_7_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_AzeK96mY5Em10wWbhKO-0w_8_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2592855</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="3"
      id="Tc_2m2ui5cjPUmBoAdtHTPMTg_8_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">-0.206</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_FRc_wc4IPkGb392BEn92mg_9_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">20946</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="3"
      id="Tc_XaDlyEFMQUafJ_u3XkC3Sw_9_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_5dLVuKMC0EuarmSvi-TFvA_11_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">73496</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesOther
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="3"
      id="Tc_6VRHKWzRpkqqay6Q4eahWA_11_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Tc_3152p6KFFUCBvYHawMKlLQ_12_2"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="3"
      id="Tc_M7VCAWDZdEm62KWsUvwUEA_12_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="3"
      id="Tc_yYaKlAg5DUS1yGNYqEjEWA_3_2"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="3"
      id="Tc_8eFi7I2QM0m2UTNRLOLpzA_4_2"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="3"
      id="Tc_isoW3wvcv0ue8yP_11fgng_6_2"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">-0.197</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="3"
      id="Tc_502ClfJV-UGozJUHfPmC_g_7_2"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="3"
      id="Tc_2L9hDC3srUW_LDrSLlssTw_8_2"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_dCrULkWFJkKJHiFwtGu6Mg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,568,167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,058,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,130,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,051,018&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,386,699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,850,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Accrued Expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 199,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 165,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,349,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,165,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,349,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,165,532)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_4xIRbYOo-kCNBdSGp2Ze-w_4_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">48568167</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_ZbCXES4ctEmVYlNHSVptqQ_4_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">41058034</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_nTXYIkMnJEeRMME23V-KLw_5_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">4130337</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_m43CozsFCUq8TzCWzUhNQw_5_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">4051018</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <apre:DeferredTaxAssetsAmortization
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_4ri0Lr0Nsk-d_0NwwNqJvA_6_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">21883</apre:DeferredTaxAssetsAmortization>
    <apre:DeferredTaxAssetsAmortization
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_vzSuXRoE7EaZyyjuLCFTEg_6_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">39412</apre:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_fXI7e8hM2UePEjE1sDn-Hw_7_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">3386699</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_4s2UO_ZK3UqjsDDcYzP3zQ_7_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">4850529</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_qfN34OUtJkmzctymGZRkaw_8_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">878</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_lUkuyPBA0kCSdO04zqsHEA_8_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">981</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <apre:DeferredTaxAssetResearchAndDevelopmentCredits
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_p_o8OoEUl0O2RygMU3chqw_9_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">42220</apre:DeferredTaxAssetResearchAndDevelopmentCredits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_64N_qP2zZ0CWfePBdNj3eQ_10_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">199095</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_sIGlktZ1E0eMlnR4hSRjLg_10_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">165558</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_wPLvxw36w06ImTSArXftSQ_11_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">56349279</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_9-pyxXIgiEykRW3N2w5imA_11_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">50165532</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="0"
      id="Tc_LM_cUmmDZE-EFH8sOns0Ng_12_3"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">56349279</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="0"
      id="Tc_e4CmsBAnIU2klsAShxw7yg_12_6"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">50165532</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="-5"
      id="Narr_qAYIyUobPUCbcZZXwvT9kQ"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="-5"
      id="Narr_eAcHp2RtcUee0EON7zQXDg"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_-mt0Lba2K0O1my_pp5wpyg"
      decimals="-5"
      id="Narr_B5EYuFa4TEuG8gVOg_fMtg"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">143300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_ZoIolndLmUyXsd1mQPpAUQ"
      decimals="-5"
      id="Narr_lGpTadA0jkiIea2Ru41lAA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">85400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_sq6NeJo7pkSi5n0W2_R52w"
      decimals="-5"
      id="Narr_mYTEApUTkUu0PI2gq5xoOQ"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">91800000</us-gaap:OperatingLossCarryforwards>
    <apre:DeferredTaxAssetResearchAndDevelopmentCredits
      contextRef="As_Of_12_31_2023_pWaew3NZG0-gfpa7CpZbxQ"
      decimals="0"
      id="Narr_K-9FDj8Ft0S8wJ-8bQR3ig"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">42220</apre:DeferredTaxAssetResearchAndDevelopmentCredits>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="-5"
      id="Narr_5Q9Z9MP8DkGbYKX6yB_Dow"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">6200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_ebRTEUE0rkqiPqOiJr_BKQ"
      decimals="-5"
      id="Narr_hMtUET0ADkSXlDqPkB-Rww"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="-5"
      id="Narr_TwR0hlaDvUSSZesa2Xkj9A"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">100000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="-5"
      id="Narr_cn02YIgTkk-UFg3sfRhUOw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">100000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <apre:CommonStockTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_jpKoo_mt_0upKYTLhxaI7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Stockholders&#x2019; equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The total number of shares of all classes of capital stock that the Company is authorized to issue is 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share and 40,000,000 shares of preferred stock, par value $0.001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series A Preferred Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December&#160;31,&#160;2025, a total of 31,194 shares of Series A Preferred Stock remained outstanding, which are convertible into 15,596 shares of common stock. In April 2025, a total of 25,033 shares of Series A Preferred stock were converted into 12,516 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Common Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Shelf Registration Statement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;On January 26, 2024, the Company filed a shelf registration statement (the &#x201c;2024 Shelf Registration Statement&#x201d;) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $150.0 million, including a prospectus for the sale of $1.0&lt;span style="white-space:pre-wrap;"&gt; million of shares of common stock under the ATM Agreement, as discussed below, which was declared effective on February 2, 2024.  The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to &lt;/span&gt;$2.0&lt;span style="white-space:pre-wrap;"&gt; million of shares of common stock pursuant to the ATM Agreement.  On January 26, 2024, the Company entered into an At the Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainright &amp;amp; Co., LLC (&#x201c;HCW&#x201d;).  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to &lt;/span&gt;$2.0&lt;span style="white-space:pre-wrap;"&gt; million of shares of common stock.  The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;On November 8, 2024, the Company filed a prospectus supplement to the 2024 Shelf Registration Statement with the SEC for the sale of up to $3.0&lt;span style="white-space:pre-wrap;"&gt; million pursuant to the 2024 ATM Agreement, as discussed below. On November 8, 2024, the Company entered into an At the Market Offering Agreement (the &#x201c;2024 ATM Agreement&#x201d;) with HCW.  Pursuant to the 2024 ATM Agreement and the prospectus supplement filed in connection therewith, the Company may, from time to time, in its sole discretion, issue and sell through HCW, acting as sales agent and/or principal, up to &lt;/span&gt;$3.0&lt;span style="white-space:pre-wrap;"&gt; million of shares of common stock.  During the year ended December&#160;31,&#160;2024, the Company issued and sold &lt;/span&gt;41,152 shares of common stock under the 2024 ATM Agreement resulting in net proceeds to the Company of approximately $0.1 million after deducting approximately $6,000 in issuance costs. During the year ended December&#160;31,&#160;2025, the Company issued and sold 1,337,948 shares of common stock under the 2024 ATM Agreement resulting in net proceeds to the Company of approximately $1.9 million after deducting approximately $76,000 in issuance costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;March 2024 Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the &#x201c;March Purchasers&#x201d;) pursuant to which the Company agreed to issue and sell to the March Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the March Purchasers agreed to purchase from the Company (i)&#160;1,687,712&#160;shares of the Company&#x2019;s common stock at a purchase price of $7.29&#160;per share (the &#x201c;March 2024 Shares&#x201d;), (ii) pre-funded common stock purchase warrants at a purchase price of $7.289&#160;to purchase an aggregate of up to&#160;507,076&#160;shares of the Company&#x2019;s common stock at an exercise price of $0.001&#160;per share (the &#x201c;March 2024 Pre-Funded Shares&#x201d;), (iii) tranche A common stock purchase warrants to purchase up to&#160;1,097,394&#160;shares of the Company&#x2019;s common stock at an exercise price of $7.29&#160;per share (the &#x201c;Tranche A Warrants&#x201d;), and (iv) tranche B common stock purchase warrants to purchase up to&#160;1,097,394&#160;shares of the Company&#x2019;s common stock at an exercise price of $9.1125 per share (the &#x201c;Tranche B Warrants&#x201d;). The Tranche A Warrants will be exercisable until the earlier of (i) the&#160;three-year anniversary of issuance and (ii)&#160;30 days&#160;after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company&#x2019;s common stock equals or exceeds $14.58&#160;for&#160;30&#160;consecutive trading days. The Tranche B Warrants will be &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;exercisable until the earlier of (i) the five-year&#160;anniversary of issuance and (ii)&#160;30 days&#160;after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company&#x2019;s common stock equals or exceeds $18.225&#160;for&#160;30&#160;consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of the Company&#x2019;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $16.0&#160;million, before deducting placement agent fees and offering costs of approximately $1.3 million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $18.0 million, before deducting placement agent fees. In April 2024, the Company registered on Form S-3 the resale of the March 2024 Shares, the March 2024 Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;December 2025 Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 8, 2025, the Company entered into a securities purchase agreement with certain purchasers (the &#x201c;Purchasers&#x201d;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i)&#160;26,459&#160;shares of the Company&#x2019;s common stock at a purchase price of $1.165&#160;per share (the &#x201c;December 2025 Shares&#x201d;), (ii) pre-funded common stock purchase warrants at a purchase price of $1.164&#160;to purchase an aggregate of up to&#160;2,596,564&#160;shares of the Company&#x2019;s common stock at an exercise price of $0.001&#160;per share (the &#x201c;December 2025 Pre-Funded Shares&#x201d;), (iii) common stock purchase warrants to purchase up to&#160;2,880,533&#160;shares of the Company&#x2019;s common stock at an exercise price of $1.04&#160;per share, including this issuance of a warrant to purchase up to 257,510 shares of the Company&#x2019;s common stock to the placement agent (the &#x201c;December 2025 Warrants&#x201d;). The December 2025 Warrants will be exercisable until the&#160;five-year anniversary of issuance. To the extent that the exercise of a December 2025 Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of the Company&#x2019;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $3.1&#160;million, before deducting placement agent fees and offering costs of approximately $0.4 million. In December 2025, the Company registered on Form S-3 the resale of the December 2025 Shares, the December 2025 Pre-Funded Shares and the shares underlying the December 2025 Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company evaluated the terms of the warrants issued in the March 2024 and December 2025 Private Placements and determined that they should be classified as equity instruments within additional paid-in capital. As of December&#160;31,&#160;2025 and 2024,&#160;none&#160;of the Tranche A Warrants or Tranche B Warrants have been exercised. During 2025, 91,206 warrants to purchase March 2024 Pre-Funded Shares were exercised for proceeds of $91 and 1,198,700 warrants to purchase December 2025 Pre-Funded Shares were exercised for no proceeds. No warrants to purchase March 2024 Pre-Funded Shares were exercised during 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;A summary of warrants outstanding as of December&#160;31,&#160;2025 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 2024 Tranche A Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,097,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.2900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/11/2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 2024 Tranche B Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,097,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.1125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/11/2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 2024 pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 2025 pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,397,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 2025 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,880,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/10/2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,889,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</apre:CommonStockTextBlock>
    <apre:StockSharesAuthorized
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_4TYbdS6R4UitZ0U4ea8JaA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">440000000</apre:StockSharesAuthorized>
    <apre:StockSharesAuthorized
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_7rQMRLmEGk-sA69T_0_JLw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">440000000</apre:StockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_LQJQODyO6E24dRMOu_Etww"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_7K6WoDXDH0el8BoX5s7Yhg"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_veNjMYaaiEC6KzmLqJbLkA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_CYOhz1KtJUepG4vgLt39CQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_DQY0mHjVSUm6LhDm1EcJwQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_6fdIQxwT9UajU_jL-0xx-A"
      decimals="INF"
      id="Narr_eLa8s0KM7EO-_i4WnX8qPg"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Narr_t1RvY7k8x0K1oOLY11FevA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="INF"
      id="Narr_l2H1ORwuzUeRmNZ3Wdbo9A"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">31194</us-gaap:TemporaryEquitySharesOutstanding>
    <apre:TemporaryEquityRemainingSharesToBeConverted
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_gj5F-jtTh06UBlJ6bkbJow"
      decimals="INF"
      id="Narr_R9kdy8OvQEyn4N8dafTKJg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">15596</apre:TemporaryEquityRemainingSharesToBeConverted>
    <apre:TemporaryEquityConversionOfStockSharesConverted
      contextRef="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_0jPUe0y1K0OJ53mzIl5oew"
      decimals="INF"
      id="Narr_4IAF-ETGl0Knz4eFSLN4cw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">25033</apre:TemporaryEquityConversionOfStockSharesConverted>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2025_To_4_30_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-QRsPFW0-E--PaKIJUY7Ag"
      decimals="INF"
      id="Narr_kVT-Yb0ncEq6IvDFPFHO5A"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">12516</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <apre:CommonStockNumberOfVotingRightsPerShare
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="INF"
      id="Narr_B-Ub5dcHLECwYnJV2CJU2Q"
      unitRef="Unit_Standard_Vote_xL2dOMznHEmc_uWBXbUEqA">1</apre:CommonStockNumberOfVotingRightsPerShare>
    <apre:UniversalShelfRegistrationMaximumAmountToBeIssued
      contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ"
      decimals="-5"
      id="Narr_VfCM9ge48EisMx-_1BYy2Q"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">150000000</apre:UniversalShelfRegistrationMaximumAmountToBeIssued>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssued
      contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ"
      decimals="-5"
      id="Narr_1swmd1PV60-R1yy6KXK-Ig"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssued>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement
      contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_zkxigKIPKk6jqUpiwqYDXQ"
      decimals="-5"
      id="Narr_Hanb7k3cGEaQVQEkJsgLbw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssued
      contextRef="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_e9RDxBm4kkmD7GckPR-Osw"
      decimals="-5"
      id="Narr_fBwzTTBiI0yJXcddeLTTmw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">2000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssued>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement
      contextRef="As_Of_11_8_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_1IwBxFQ5D06BZajC8QiMmQ"
      decimals="-5"
      id="Narr_YC3zFmdHbUOUlxN5JTKxVA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">3000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssued
      contextRef="As_Of_11_8_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_wfZiBhJ28kKlJpaYLmFFOw"
      decimals="-5"
      id="Narr_5KEpeTuqu0i0ESc8CvwNGw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">3000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA"
      decimals="INF"
      id="Narr_SoCfpnLnY0mMCdXRyNqU9Q"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">41152</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA"
      decimals="-5"
      id="Narr_zTrsMMEn-UOwdGQZ1udYOg"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_VVcBquPyRE-Uo4rbFHhZmA"
      decimals="0"
      id="Narr_6GY15NcDJU6s6cmx6BPohw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">6000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q"
      decimals="INF"
      id="Narr_VaaXhK0mzkCWmTEn4YhyBA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1337948</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q"
      decimals="-5"
      id="Narr_wfYFM2-__UOpnXNN9QAhLA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_fsx_YlFZsES7S_dYKh8V8Q"
      decimals="0"
      id="Narr_HkJRDxuE3U6vztP8AVKh_g"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">76000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg"
      decimals="INF"
      id="Narr_4M3WWqsLMUuCAFh35_4-rA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1687712</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ"
      decimals="2"
      id="Narr_SUay5q6g3UuXMsBzy7wIMA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.29</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JlhBUytMKkeo3cvNZE4vVg"
      decimals="3"
      id="Narr_qObnA8VIF0CgnQO0s65xCg"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.289</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JlhBUytMKkeo3cvNZE4vVg"
      decimals="INF"
      id="Narr_sPXOoO-kMkOUsYSJ_DkFGw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">507076</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ"
      decimals="3"
      id="Narr_0ilofRNh_USHz8XrPNgeuQ"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ"
      decimals="INF"
      id="Narr_JCtfMhV7qEK9Dz5QrKqeEQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1097394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ"
      decimals="2"
      id="Narr_lr4BUAGLJ0ex_JUNgG5sPQ"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ"
      decimals="INF"
      id="Narr_lKdx8wZkg0CpjaoZE4OJHA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1097394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ"
      decimals="4"
      id="Narr_BoXqU_p1VEGjo7sPu7LmJw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">9.1125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <apre:StockIssuanceAnniversaryPeriod
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q"
      id="Narr_5x8tUjdlmUigB9nb7Qx9Ug">P3Y</apre:StockIssuanceAnniversaryPeriod>
    <apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q"
      id="Narr_5hPaiM0AM0Oenm9uRFkDuA">P30D</apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119>
    <apre:SharesIssuedVolumeWeightedAveragePricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_i331foXmLUu8WORUyTr1UQ"
      decimals="2"
      id="Narr_7RPEJYmsz0OEmi1gemkYMw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">14.58</apre:SharesIssuedVolumeWeightedAveragePricePerShare>
    <apre:NumberOfConsecutiveTradingDays
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice729PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_IMuDhNFgkkOXmfhiH9ia1Q"
      id="Narr_dOz9KXotu0uUtMzR0jQ1mw">P30D</apre:NumberOfConsecutiveTradingDays>
    <apre:StockIssuanceAnniversaryPeriod
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ"
      id="Narr_GPu8On5mzEqeHV4RbqI74A">P5Y</apre:StockIssuanceAnniversaryPeriod>
    <apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ"
      id="Narr_5mNx8YKIo0i2CfK_9wu-MQ">P30D</apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119>
    <apre:SharesIssuedVolumeWeightedAveragePricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_sVooaPtYr0WGa9H0mHaWaQ"
      decimals="3"
      id="Narr_1RqbMcUfuUuYPLVxUaaB0A"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">18.225</apre:SharesIssuedVolumeWeightedAveragePricePerShare>
    <apre:NumberOfConsecutiveTradingDays
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice91125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zA1CohxthkW1no8SwkPHCQ"
      id="Narr_RKeDPpLNYEKopVNQ-82Vpg">P30D</apre:NumberOfConsecutiveTradingDays>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_czSUUBGEZEeGpiS6JzjgAQ"
      decimals="4"
      id="Narr_4LzVi2SgW0uFWZty0nu_AQ"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0499</apre:PercentageOfOutstandingShares>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zk8TLXVZiU-91j2mSRo40Q"
      decimals="4"
      id="Narr_UvZUAA2U5kmARNMq5NnVYg"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0999</apre:PercentageOfOutstandingShares>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg"
      decimals="-5"
      id="Narr_bkViGh8Wkkymwkx1fVEUfA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">16000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg"
      decimals="-5"
      id="Narr_u8kaEAhI4E-D7EtBM6toIQ"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">1300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <apre:ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MEs9PZKuskq6TqCWBungqg"
      decimals="-5"
      id="Narr_uX02co_MYUy_-RzVUGCWfA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">18000000</apre:ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A"
      decimals="INF"
      id="Narr_zwo4giaoEkSNWwEoe9XUCg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">26459</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MGDWpqe1Kkq0c-y3kaCxwg"
      decimals="3"
      id="Narr_Ms8YyZ5VG0O4WBHpw5wrIA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">1.165</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w"
      decimals="3"
      id="Narr_8h4a3ebVSkCHonNIO6L0-g"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">1.164</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w"
      decimals="INF"
      id="Narr_xtmeugomiEq_n3aTXb7hvg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">2596564</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_FsI2OEjG2E-NuKDw-fmb9w"
      decimals="3"
      id="Narr_21MipUxIlkWseqhVGxI2IA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JysbG2LVi0WviMI_bz_gpw"
      decimals="INF"
      id="Narr_HfCN6JHUmUuu0zJmE43gsw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">2880533</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_JysbG2LVi0WviMI_bz_gpw"
      decimals="2"
      id="Narr_DSU71B4WVkaY05TJQvrVcw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_PlacementAgentMember_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_nCqKvJ6VqEOdmrCe-eB1xw"
      decimals="INF"
      id="Narr_CMAxsO4DAEOwiRiHn_cVMw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">257510</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <apre:StockIssuanceAnniversaryPeriod
      contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A"
      id="Narr_3xODfYiJ2kyMjWcGbo6OXw">P5Y</apre:StockIssuanceAnniversaryPeriod>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_MGDWpqe1Kkq0c-y3kaCxwg"
      decimals="4"
      id="Narr_mHiTl6tG2EWmFsUCDvbhrA"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0499</apre:PercentageOfOutstandingShares>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Vm4iVeX890G-C4Gmcq830Q"
      decimals="4"
      id="Narr_sLzyngdyW0CsnSlwI37sLA"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0999</apre:PercentageOfOutstandingShares>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A"
      decimals="-5"
      id="Narr_ol8hzVEyK0eNK32nBkUVMw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">3100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_8_2025_To_12_8_2025_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_hi2NahI6s02Ji9Nki9uW0A"
      decimals="-5"
      id="Narr_H9lFmKYNJEe94IUxylo35g"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <apre:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_jtkh2IFT8EeIdDld8qFq5w"
      decimals="INF"
      id="Narr_CCT03FBjtk2cm3yHUuplbw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">91206</apre:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_jtkh2IFT8EeIdDld8qFq5w"
      decimals="0"
      id="Narr_XzldKfUnpUWVhqA07vcHgg"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">91</us-gaap:ProceedsFromWarrantExercises>
    <apre:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_lILoXMI7xUCZVU-gQHudoA"
      decimals="INF"
      id="Narr_JpJvIAS0NEytjUSv35EBhg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1198700</apre:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_December2025PrivatePlacementMember_lILoXMI7xUCZVU-gQHudoA"
      decimals="0"
      id="Narr_ouahwI6DsEymQ526U1o63g"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">0</us-gaap:ProceedsFromWarrantExercises>
    <apre:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_apre_March2024PrivatePlacementMember_R5lNv0SMpkG5QNmfjLhHmw"
      decimals="INF"
      id="Narr_OFUkBKuaakC-yv4_b0MoGw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">0</apre:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_ZALsErMLbEi0BAK48kT9EA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:65.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 2024 Tranche A Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,097,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.2900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/11/2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 2024 Tranche B Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,097,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.1125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/11/2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 2024 pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 2025 pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,397,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 2025 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,880,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/10/2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,889,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsMember_HnwiahFpV0Kqxh7uoQXQfw"
      decimals="INF"
      id="Tc_cj-YYpBIakC77lAHymG-8Q_4_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1097394</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheaWarrantsMember_HnwiahFpV0Kqxh7uoQXQfw"
      decimals="4"
      id="Tc_mFQeldk4SUGSSgbqC3w53g_4_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheBWarrantsMember_fQ1ml1hVHU6nU0Lh1uc_aA"
      decimals="INF"
      id="Tc_TNQYQ9PdMUa95Wj-lxPAWg_5_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1097394</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024TrancheBWarrantsMember_fQ1ml1hVHU6nU0Lh1uc_aA"
      decimals="4"
      id="Tc_x8i_T0ZuN0WQqsObc85VaA_5_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">9.1125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024PreFundedWarrantsMember_a-axkHFuHU6wmJ8RwuZaXA"
      decimals="INF"
      id="Tc_B0H9KY0ZZUu9f5YW_ANPNA_6_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">415870</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_March2024PreFundedWarrantsMember_a-axkHFuHU6wmJ8RwuZaXA"
      decimals="4"
      id="Tc_XItOxzg7EkmhRUFGeVy0bA_6_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025PreFundedWarrantsMember_-GQYBDW1ekGtGJann-TV6A"
      decimals="INF"
      id="Tc_l8_HYDetsUewSAIoyS7sqw_7_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1397864</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025PreFundedWarrantsMember_-GQYBDW1ekGtGJann-TV6A"
      decimals="4"
      id="Tc_J1aDzvWG8EGfsaezMiq4RQ_7_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_IWhpmSyLkkquMghWrBhMLg"
      decimals="INF"
      id="Tc_AZHSFHSGa0GXlPi7jAH9dw_8_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">2880533</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_apre_December2025WarrantsMember_IWhpmSyLkkquMghWrBhMLg"
      decimals="4"
      id="Tc_Xx4RfrDX2EeNidqFZRxnTA_8_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_DlsZiLzd602yHKstWXDVMg"
      decimals="INF"
      id="Tc_NtrgUORAgEmeTDRhyvBEpg_9_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">6889055</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_xIvXIL6vTkuHzGjyQe74yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2019, the Company&#x2019;s Board of Directors approved the 2019 Equity Incentive Plan (the &#x201c;2019 Plan) and each outstanding option to purchase Aprea AB ordinary shares pursuant to a previous plan was cancelled and the Company issued to each holder of such Aprea AB option, a substitute option to purchase, on the same terms and conditions as were applicable to such Aprea AB option, shares of the Company&#x2019;s common stock pursuant to the 2019 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Board of Directors has the discretion to provide for accelerated vesting under the 2019 Plan. At December&#160;31,&#160;2025, there were 180,880 shares available for future grant under the 2019 Plan. Effective January 1, 2026, the number of shares available for future grant under the 2019 Plan was increased by 327,701 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense of $0.5 million and $0.5 million during the years ended December&#160;31,&#160;2025 and 2024, respectively. As of December&#160;31,&#160;2025, there was $0.5 million of unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the 2019 Plan, which is expected to be recognized over a weighted-average period of approximately 2.1 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each option award is estimated on the date of grant using Black-Scholes, with the assumptions noted in the table below. Expected volatility for the Company&#x2019;s common stock was determined based on an average of the historical volatility of a peer group of similar public companies. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employee. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the implied yield on a U.S. Treasury security in effect at the time of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in Black-Scholes are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.0%-83.6%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.8%-92.3%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk&#x2011;free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.99%-4.38%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.18%-4.64%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-10.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-10.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of option activity under the Plan during the years ended December&#160;31,&#160;2025 and 2024 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.7%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term&#160;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 596,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,186)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 715,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,040&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,539)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 624,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of options granted during the years ended December&#160;31,&#160;2025 and 2024, was $1.57 and $4.53, per share, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Stock&lt;/i&gt; &lt;i style="font-style:italic;"&gt;Units&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December&#160;31,&#160;2025, the Company granted the following RSU&#x2019;s:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10,090&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; RSUs to executive officers of the Company which vest ratably on the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;nd&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;rd&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; anniversaries of the grant date. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8,360&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; RSUs to non-employee directors of the Company which vest on the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; anniversary of the grant date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December&#160;31,&#160;2024, the Company granted the following RSU&#x2019;s:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;16,820&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; RSUs to executive officers of the Company which vest ratably on the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;nd&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;rd&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; anniversaries of the grant date. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6,270&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; RSUs to non-employee directors of the Company which vest on the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; anniversary of the grant date. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2025, there was $0.1 million of unrecognized compensation cost related to RSUs granted under the 2019 Plan, which is expected to be recognized over a weighted-average period of approximately 1.8 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table shows restricted stock unit activity during the year ended December&#160;31,&#160;2025:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,730)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,154)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.94&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="INF"
      id="Narr_jPMoEwg9gUiVCVvIlI1JQw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">180880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <apre:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="INF"
      id="Narr_q7Mb8ySOmEC8u5UcygsBnw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">327701</apre:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="-5"
      id="Narr_WE2Yaoqsn0O-fiiukhXDhA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="-5"
      id="Narr_vmewpsxCXUeBYlvoZMAuNA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="-5"
      id="Narr_P7V8qUEam0qTi62gWaCZAw"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      id="Narr_dhDmZ6lYikyy0nCnG_ehpg">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_GO_3XJpAW06_IGmivtId2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.0%-83.6%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.8%-92.3%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk&#x2011;free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.99%-4.38%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.18%-4.64%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-10.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-10.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="3"
      id="Narr_lG2LXxfIBU-RkesygO0z-Q"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="3"
      id="Narr_iDfDpbedJEK3qfU1roFS2Q"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="3"
      id="Narr_qPJJRpu0_kmi4KOL-IEI9g"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="3"
      id="Narr_3DyDFeHhWkSjss7rKi8FjA"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="4"
      id="Narr_QAQJpHR5n0Kje7cKnrSQaQ"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="4"
      id="Narr_2ybM4SMIAkmWxpr7QWwGGw"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="4"
      id="Narr_-d22Yp9T_k6gLcxPXi9ddw"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="4"
      id="Narr_aglhZ6Xrv0uX48PhEc3_SQ"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="2"
      id="Tc_qPkrs1Znnka5Km6rXeMcfQ_5_2"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="2"
      id="Tc_xpklrCwCfUCb0IyJPLdy3Q_5_4"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_svVivUO6SEy1bko-xpnpmw"
      id="Narr_JUStlXN5GEeDZBg07mFP4g">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_vo0Rp1fMEEe6cXCjrjqRkQ"
      id="Narr_7nVCxegYSEOM2ia4M_QDfw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_uALQGM6dfkS0eVFcd0iIJg"
      id="Narr_Ilv3emo7c0SwFvok26CKuA">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_RiL5VScdAUCDUTJd-n0MRQ"
      id="Narr_8ehnQWLarU-iXsD70rnmcQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_jrR20ui8J06atBk9L5dznA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.7%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term&#160;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 596,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,186)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 715,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,040&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,539)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 624,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 811,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_VhYbqu6uqEa_Z5RqOOudRA"
      decimals="INF"
      id="Tc_W7txncZ2uU-OsWpqqObCdQ_6_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">596466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_VhYbqu6uqEa_Z5RqOOudRA"
      decimals="2"
      id="Tc_VBxCTTvypUm1gjQjYHDUvg_6_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">72.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_EQUr4jqfV0eUSMk3W0IsWQ"
      id="Tc_iplY3rNWi0qQVlTBXqAR-w_6_8">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="INF"
      id="Tc_5FXM6rY-YUqQlPbUeoOHVQ_7_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">147340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="2"
      id="Tc_giivbmDiP0eEF6OnbECYHQ_7_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">5.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="INF"
      id="Tc_A6VCfIgca0a7H0FRiJuBVQ_8_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">28186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="2"
      id="Tc_OIS3mywfJUGVWzP5FyYkaA_8_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">5.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ"
      decimals="INF"
      id="Tc_u0-Ar2Tqm0KjjxiVQ0T_mg_9_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">715620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_1KMgxKqBqEuBh8h9u5uccQ"
      decimals="2"
      id="Tc_I5IBwco6E06rN3mKcDF23g_9_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">61.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      id="Tc_9Caj6B-zfEagQDSmVAOrzg_9_8">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="INF"
      id="Tc_eGQGspjSL0-MK6F8DwGqGg_10_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">116040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="2"
      id="Tc_8hzORMPVl0OshOO0AZuLRQ_10_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">2.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="INF"
      id="Tc_P69_8qc_Mka1fpJIjal9aA_11_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">20539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="2"
      id="Tc_QS6Q-WL0_Um_ExSMSFDHRA_11_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="INF"
      id="Tc_mLohVKtxYk6iTA_VWgei2A_12_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">811121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="2"
      id="Tc_5R1KTg0Ql0OkiOJeLlLqzg_12_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">54.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      id="Tc_XtkVaIrILEuTQ7vIWvRUgg_12_8">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="INF"
      id="Tc_adXO11SU9UGngK5T4dEp2A_13_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">624537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="2"
      id="Tc_GhxjTFxkpESEnnyxnUreow_13_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">69.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      id="Tc_fPWtC6qYfEenT6erKr1G_Q_13_8">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="INF"
      id="Tc_RNdE1s_LyESHLxT_gGQ4EQ_14_3"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">811121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_gfgMv9P4906OHAW-fyCk0A"
      decimals="2"
      id="Tc_9FE-Wm1iMUGKBmoJtZjGcA_14_6"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">54.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      id="Tc_P7CeC6XgKkaNC9eHS97s5Q_14_8">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_4nFBwt6L-kOfZ0SVHpayiA"
      decimals="2"
      id="Narr_0k0aCHFJM02yL7-iWC_i4w"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_apre_TwoThousandNineteenEquityIncentivePlanMember_Mv9TG5E8m0qXxPWEeJIP4w"
      decimals="2"
      id="Narr_0Y3qb4QAYUql7SYkrtAv8A"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_76awlW8Ih02pce5XsSRECw"
      decimals="INF"
      id="Narr_H2D9KB5X0EKqXZF8NlgJHg"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">10090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_ppTWFla4xU-u0Ra-s34Jfw"
      id="Narr_pRl61QhGSkKeyDSESJz3nw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_ObCThvYr3EuNhTdvZHWN5Q"
      id="Narr_NbdAuIBDc0uaW_XI5ct56A">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_51RPXCrdCEOuPhYMJBeuWw"
      id="Narr_Aams-Ds29EWsx0Up1BCe4w">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_S_ge6OQffkO1GwngF7q5dg"
      decimals="INF"
      id="Narr_Zxip6_-rB0-SUnaRF2qmYQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">8360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_K66RcqO0CUSYIecB3rtHQg"
      id="Narr_lxBrN0nRlEOLJk-x8OVjiA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_KhoEA3ZPM0CBUJFvhI2tBA"
      decimals="INF"
      id="Narr__Rbzi04H5kG1s8EfPJ4UvA"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">16820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LU7BJLvVE0iqW66H9_OrGg"
      id="Narr_ENvui_DvhUCYI1bwIz0Fyw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnTwoYearAnniversaryOfGrantDateMember_XAXHtIodGE2ofHLJnzdW0g"
      id="Narr_23S2sDipC0SBm0m6AQcMtA">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_apre_ShareBasedPaymentArrangementExecutiveOfficersMember_us-gaap_VestingAxis_apre_VestingOnThreeYearAnniversaryOfGrantDateMember_kvlb4D8nYUSyelfb-KCo2w"
      id="Narr_c6NykJbsQ0mTsCO27qAnnQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_c5rmFiY3ek-6CbIN1sUk5g"
      decimals="INF"
      id="Narr_T6Bil0R_FEupy5HmQy6gTQ"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">6270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_VestingAxis_apre_VestingOnOneYearAnniversaryOfGrantDateMember_LrUkAv7nCEugy4KCFPIs0A"
      id="Narr_ASOvmybBfkuMVWZIAJQu3g">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw"
      decimals="-5"
      id="Narr_d3Eisifw3Ey5Cxr1wbNYew"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA"
      id="Narr_eX8OXRH7HEuVp86phR151Q">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_A0aTbvLOr0CIJVzTKoYZog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,730)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,154)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.94&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vI7qdqQk_0OgoyeWE7tHaQ"
      decimals="INF"
      id="Tc_bHcZcMuWpUuWhZlw9Bgocg_5_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">23870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vI7qdqQk_0OgoyeWE7tHaQ"
      decimals="2"
      id="Tc_7vyr5tpgd0es4-nwfYw_bQ_5_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"
      decimals="INF"
      id="Tc_MQ4ilclP0UCB1w_tcFSH4g_6_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">23090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"
      decimals="2"
      id="Tc_26PQOB66z0-Hu2Z5GnxB1Q_6_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"
      decimals="INF"
      id="Tc_0qcSlGpUnUOCVlBJpV_uZQ_7_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">10518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"
      decimals="2"
      id="Tc_ESuCe1tZsk-iTgoNSjumCg_7_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">9.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"
      decimals="INF"
      id="Tc_4vd7cWqRkU25MqihdmEB9Q_8_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">6730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JSuZfRwpykmD4UA-4GuQ2w"
      decimals="2"
      id="Tc_CEy_YdsCUUOQ8vmrpoxejg_8_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_evHTOe8x2keNSJoG80M35Q"
      decimals="INF"
      id="Tc_-y6g8vomak2Xrbim6e7B5w_9_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">29712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_evHTOe8x2keNSJoG80M35Q"
      decimals="2"
      id="Tc_UHnz98wobEepLM6PjxRwCw_9_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA"
      decimals="INF"
      id="Tc_a4DlDWpsdkuA2C34UtdXDg_10_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">18450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA"
      decimals="2"
      id="Tc_QpgxvakRSEqDfMB9-LshFA_10_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA"
      decimals="INF"
      id="Tc_3nk069he-0W59USWLh6n6g_11_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">17154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Z4pgDmeHm0CwBtgiwYzLhA"
      decimals="2"
      id="Tc_MBBYWE_A_02GBUf3WXiFIQ_11_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw"
      decimals="INF"
      id="Tc_joQ6-cKN3keWCq_ienLkMQ_13_2"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">31008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JqvORmDFnk-wPwGTNUK7mw"
      decimals="2"
      id="Tc_Fsj8PyYxkkOncgKYOjX8Yg_13_5"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_05G77KkcSUi6u7OEBtSaLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;From time to time, the Company may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the years ended December&#160;31,&#160;&lt;span style="white-space:pre-wrap;"&gt;2025 and 2024, and, to its knowledge, no material legal proceedings are currently pending or threatened. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.  As of December&#160;31,&#160;2025, the Company has &lt;/span&gt;not recorded a provision for any contingent losses.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      decimals="0"
      id="Narr_3tzaCfBd60yP9qViCpJW0Q"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Tb_uvBmRoLDE0WpF6SqWhPwig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;On January 28, 2026, the Company entered into a securities purchase agreement with certain purchasers (the &#x201c;January Purchasers&#x201d;) pursuant to which the Company agreed to issue and sell to the January Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the January Purchasers agreed to purchase from the Company (i)&#160;1,877,677&#160;shares of the Company&#x2019;s common stock at a purchase price of $0.8891&#160;per share (the &#x201c;January 2026 Shares&#x201d;), (ii) pre-funded common stock purchase warrants at a purchase price of $0.8890&#160;to purchase an aggregate of up to&#160;4,411,180&#160;shares of the Company&#x2019;s common stock at an exercise price of $0.001&#160;per share (the &#x201c;January 2026 Pre-Funded Shares&#x201d;), (iii) common stock purchase warrants to purchase up to&#160;6,288,857&#160;shares of the Company&#x2019;s common stock at an exercise price of $0.765&#160;per share (the &#x201c;January 2026 Warrants&#x201d;). The January 2026 Warrants will be exercisable until the&#160;two-year anniversary of issuance. To the extent that the exercise of a January 2026 Warrant would result in the holder beneficially owning greater than&#160;4.99% (or, at the election of the holder, greater than&#160;9.99%) of the Company&#x2019;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $5.6&#160;million, before deducting placement agent fees and offering costs of approximately $0.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A"
      decimals="INF"
      id="Narr_YxQxhu00KECPiD_8anDHtw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">1877677</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_X3e_9uk1uEKJQCgyQcQNiA"
      decimals="4"
      id="Narr_gdxjZMnGRE2zKgKL6SqAeQ"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.8891</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA"
      decimals="4"
      id="Narr_sVJjCN2Uv0qull_ZDw0TnQ"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.889</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA"
      decimals="INF"
      id="Narr_aRQKTzTG-UyxCw4SI5GqTw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">4411180</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zta_ZzMcFUmbIMHjaDg1jA"
      decimals="3"
      id="Narr_Tzst32cPJ0eCLDfZeYNBgw"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_12HariDjbkGdtP5EmFWGYA"
      decimals="INF"
      id="Narr_BYJpI3rZL0qh5GLVkmtEQw"
      unitRef="Unit_Standard_shares_FzZuVmF4Y0e-ska611lDsA">6288857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_12HariDjbkGdtP5EmFWGYA"
      decimals="3"
      id="Narr_benDwa52WEiBemXelpzjjA"
      unitRef="Unit_Divide_USD_shares_6fwzjygHk0qOrP_fAMhglQ">0.765</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <apre:StockIssuanceAnniversaryPeriod
      contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_January2026WarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lqTYSTP7MUWrNQSGACl75w"
      id="Narr_30RlMolsBEK7ap3jyoYUeg">P2Y</apre:StockIssuanceAnniversaryPeriod>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_X3e_9uk1uEKJQCgyQcQNiA"
      decimals="4"
      id="Narr_pFN_Qql5G0aZ7kMBUMRXHw"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0499</apre:PercentageOfOutstandingShares>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_dYgdlu90I0-v-bYG_Tb6iQ"
      decimals="4"
      id="Narr_tWMLp1aG3UGnZLkrjdiA9g"
      unitRef="Unit_Standard_pure_WcktkD_WgkO6nCuxzXVpQw">0.0999</apre:PercentageOfOutstandingShares>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A"
      decimals="-5"
      id="Narr_og8pm1DYH0OWAVHjOmFBlA"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">5600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_28_2026_To_1_28_2026_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_apre_January2026PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_vYUi2QokK0Cjfci18sAL6A"
      decimals="-5"
      id="Narr_BrneuhuJFUuiWCMmBRr80A"
      unitRef="Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_qFPRpKlT5kKlLPLALp_JRA"
      id="Narr_8oe8PRUQLEO1i-oIZC4UqQ">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
